{"title": "PDF", "author": "PDF", "url": "https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Melanom/Melanom_2/S3_LL_Melanom-OL-Evidenztabellen_2.0.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n   \nEvidenz tabellen  \nzur S3-Leitlinie Diagnostik, Ther apie \nund Nachsorge des Melanoms  \n \nVersion 2.0 \u2013 Juli 2016  \nAWMF -Register -Nummer : 032/ 024OL  \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 2 von 817 \n1. Informationen zum \nDokument  \n1.1. Autoren  \nDr. Annette Pflugfelder,  Universit\u00e4ts -Hautklinik T\u00fcbin gen \nDr. Corinna K ochs, Klinik f\u00fcr Dermatologie,  \nUniversit\u00e4tskli nikum Essen  \nDr. Corinna M\u00fchlenbein, Klinik f\u00fcr Dermatologie, \nUniversit\u00e4tsklinikum Essen  \nDr. Christina Czeschik, Klinik f\u00fcr Dermatologie, \nUnivers it\u00e4tsklinikum Essen  \nPD. Dr. Thomas Eigentler, Universit\u00e4ts -Hautkl inik T\u00fcbingen  \nDr. Markus Follmann, MPH, MSc, Office des Leitlinienprogramms Onkologie \u2013 DKG e.V. \nProf. Dr. Claus Garbe, Universit\u00e4ts -Hautklinik T\u00fcbingen  \nProf. Dr. Dirk Schadendorf, Klinik f\u00fcr Dermatologie, \nUniversit\u00e4tsklin ikum Essen  \n1.2. Herausgeber  \nLeitlinienp rogramm Onkologie der Arbeitsgemeinschaft  der \nWissenschaftlichen Med izinischen Fachgesellschaften e.V. (AWMF) , \nDeutschen Krebsgesellschaft e.V.  (DKG) und Deutschen Krebshilfe \n(DKH).  1.3. Kontakt  \nOffice: c/o Deutsch e Krebsgesellschaft e.V. \nKuno -Fischer -Str. 8 14 057 Berlin  \nleitlinienprogramm@krebsgesellschaft.de  \nwww.leitlinienprogramm -onkologie.de  \n1.4. Finanzierung  der Leitlinie  \nDie Entwicklung der  Leitlinie wurde von der Deutschen Krebshilfe \nim Rahmen des Onkologischen Leitlinienprogramms gef\u00f6rdert.  \n1.5. Federf\u00fchrende \nFachgesellschaften  \nDeutsche  Dermatologische  Gesellschaft (DDG)  \nArbeitsgemeinschaft Dermat ologische Onkologie (ADO)  der \nDeutschen Krebsgesellschaft (DKG) und der Deutsche  \nDermatologische  Gesellschaft (DDG)  \n \n \n  \n \n \n \n1.6. Zitierweise  \nLeitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, \nDeutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge \ndes Melanoms,  Evidenztabellen 2.0., [2016],  AWMF \nRegisternummer: 032/ 024OL , http://leitlinienprogramm -\nonkologie.de/Melanom.65.0.html , (Zugriff am TT.MM.JJJJ)  \n \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 3 von 817 \n \nInhaltsverzeichnis  \n1. Informationen zum Dokument  ................................ ................................ ................................ ..... 2 \n1.1. Autoren ............................................................................................................................................................................................. 2 \n1.2. Herausgeber  ..................................................................................................................................................................................... 2 \n1.3. Kontakt ............................................................................................................................................................................................. 2 \n1.4. Finanzierung der Leitlinie  .................................................................................................................................................................. 2 \n1.5. Federf\u00fchrende Fachgesellschaften  ..................................................................................................................................................... 2 \n1.6. Zitierweise  ........................................................................................................................................................................................ 2 \n2. AG Diagnostik  ................................ ................................ ................................ ..........................  14 \n2.1. Frage I.2. und I.3. Apparative Verfahren zur klinischen Diagnostik des malignen Melanoms -  Adaptation  ......................................... 14 \n2.1.1.  Synopse Quelleitlinien (kurz)  ..................................................................................................................................................... 14 \n2.1.2.  Empfehlung, Hintergrundstext und Literatur Australische Quell -Leitlinie  ................................................................................... 15 \n2.2. Frage I.3. Konfokale Laserscan -Mikroskopie und optische Koh\u00e4renztomographie -  De-novo- Recherche  .......................................... 26 \n2.2.1.  PICO, Suchw\u00f6rter  ...................................................................................................................................................................... 26 \n2.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  .............................................................................................................................. 27 \n2.2.3.  Auswahlkriterien  ....................................................................................................................................................................... 28 \n2.2.4.  Evidenztabelle ........................................................................................................................................................................... 28 \n2.2.5.  Literatur  ................................................................................................................................................................................... 35  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 4 von 817 \n2.3. Frage I.6., I.7., I.8., VII.6. Ausbreitungsdiagnostik bei Patienten mit malignem Melanom \u2013  De-novo-Reche rche ................................ 37 \n2.3.1.  PICO, Suchw\u00f6rter  ...................................................................................................................................................................... 37 \n2.3.2.  Datenbanken, Suchstrategie, Trefferzahlen ................................................................................................................................ 38 \n2.3.2.1.  Prim\u00e4rrecherche 2012  ....................................................................................................................................................... 38 \n2.3.2.2.  Aktualisierungsrecherche 2015 f\u00fcr I.7. und I.8  .................................................................................................................. 41 \n2.3.3.  Auswah lkriterien  ....................................................................................................................................................................... 43 \n2.3.3.1.  Prim\u00e4rrecherche 2012  ....................................................................................................................................................... 43 \n2.3.3.2.  Aktualisierungsrecherche 2015  ......................................................................................................................................... 43 \n2.3.4.  Evidenztabelle (zusammengefa\u00dft f\u00fcr I.6., I.7., I.8., VII.6.)  ........................................................................................................... 44 \n2.3.4.1.  Prim\u00e4rrecherche 2012  ....................................................................................................................................................... 44 \n2.3.4.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 149 \n2.3.5.  Literatur  ................................................................................................................................................................................. 153 \n2.4. Frage I.9. Ausbreitungsdiagnostik beim metastasierten okku lten Melanom -  Adaptation  ................................................................ 166 \n2.4.1.  Synopse Quellleitlinien (kurz)  .................................................................................................................................................. 167 \n2.4.2.  Empfehlung, Hintergrundstext und Literatur Austra lische Quell -Leitlinie  ................................................................................. 167 \n2.4.3.  Erg\u00e4nzende Recherche, Datenbanken, Suchstrategien, Trefferzahlen  ....................................................................................... 169 \n2.4.4.  Evidenztabelle ......................................................................................................................................................................... 171 \n2.4.5.  Literatur:  ................................................................................................................................................................................ 173 \n3. AG Sentinel Node Biopsie  ................................ ................................ ................................ ........  174  \n3.1. Frage II.1. Sentinel -Node -Biopsie \u2013 De-novo- Recherche  ................................................................................................................ 174 \n3.1.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 174 \n3.1.2.  Datenbanken, Suchstrategien, Trefferzah len ............................................................................................................................ 174 \n3.1.3.  Auswahlkriterien  ..................................................................................................................................................................... 176 \n3.1.4.  Evidenztabelle ......................................................................................................................................................................... 176  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 5 von 817 \n3.1.5. Literatur  ................................................................................................................................................................................. 219 \n3.2. Frage II.5. und III.4. Tumorlast am Sentinel -Node und komplettierende Lymphadenektomie \u2013 De-novo- Recherche  ......................... 221 \n3.2.1.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 221 \n3.2.1.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 221 \n3.2.1.2.  Aktualisierungsrecherche  2015  ....................................................................................................................................... 222 \n3.2.2.  Auswahlkriterien  ..................................................................................................................................................................... 222 \n3.2.2.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 222 \n3.2.2.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 223 \n3.2.3.  Evidenztabelle# ....................................................................................................................................................................... 223 \n3.2.3.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 223 \n3.2.3.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 249 \n3.2.4.  Literatur  ................................................................................................................................................................................. 265 \n4. AG Chirurgisc he Therapie  ................................ ................................ ................................ ........  267  \n4.1. Frage III.1. Sicherheitsabst\u00e4nde bei Prim\u00e4rexzision \u2013  De-novo- Recherche  ...................................................................................... 267 \n4.1.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 267 \n4.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 267 \n4.1.3.  Auswahlkriterien  ..................................................................................................................................................................... 268 \n4.1.4.  Evidenztabelle ......................................................................................................................................................................... 269 \n4.1.5.  Literatur  ................................................................................................................................................................................. 278 \n4.2. Frage III.2. Prophylaktische Lymphadenektomie -  Adaptation  ......................................................................................................... 279 \n4.2.1.  Synopse Quellleitlinien (kurz)  .................................................................................................................................................. 279 \n4.2.2.  Empfehlung,  Hintergrundstext und Literatur Australische  Quell Leitlinie  ................................................................................. 279 \n4.3. Frage III.3. Therapeutische Lymphadenektomie \u2013 De-novo-Recherche  ........................................................................................... 288  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 6 von 817 \n4.3.1.  PICO-Unterfragen  ................................................................................................................................................................... 288 \n4.3.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 288 \n4.3.3.  Auswahlkriterien  ..................................................................................................................................................................... 290 \n4.3.4.  Evidenztabelle ......................................................................................................................................................................... 290 \n4.3.5.  Literatur  ................................................................................................................................................................................. 318 \n4.4. Frage III.7. Operative Therapie bei Fernmetastasen \u2013  De-novo- Recherche  ...................................................................................... 319 \n4.4.1.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 319 \n4.4.2.  Auswahlkriterien  ..................................................................................................................................................................... 320 \n4.4.3.  Evidenztabelle ......................................................................................................................................................................... 320 \n4.4.4.  Literatur  ................................................................................................................................................................................. 359 \n5. AG Adjuvante Therapie ................................ ................................ ................................ ............  361  \n5.1. Frage IV.1. Adjuvante Chemotherapie -  Adaptation  ........................................................................................................................ 361 \n5.1.1.  Synopse Quellleitlinien  ............................................................................................................................................................ 361 \n5.1.2.  Empfehl ung und Hintergrundstext franz\u00f6sische Quell Leitlinie  ................................................................................................ 362 \n5.1.3.  Empfehlung und Hintergrundstext kanadische Quell Leitlinie  ................................................................................................... 363 \n5.2. Frage IV.2. Adjuvante Vakzinierung \u2013  Adaptation  ........................................................................................................................... 364 \n5.2.1.  Synopse Quellleitlinien  ............................................................................................................................................................ 364 \n5.2.2.  Empfehlung und Hintergrundste xt franz\u00f6sische Quell Leitlinie  ................................................................................................ 367 \n5.2.3.  Empfehlung und Hintergrundstext kanadische Quell Leitlinie  ................................................................................................... 373 \n5.3. Frage IV.3. Adjuv ante Extremit\u00e4tenperfusion - Adaptation  ............................................................................................................. 375 \n5.3.1.  Synopse Quellleitlinien  ............................................................................................................................................................ 375 \n5.3.2.  Empfehlung und Hintergrundstext franz\u00f6sisc he Quell Leitlinie  ................................................................................................ 376 \n5.4. Frage IV.4. Adjuvante Immunstimulation -  Adaptation  ................................................................................................................... 378  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 7 von 817 \n5.4.1.  Synopse Quelleitlinien  ............................................................................................................................................................. 378 \n5.4.2.  Empfehlung und Hintergrundstext franz\u00f6sische Quell Leitlinie  ................................................................................................ 380 \n5.4.3.  Empfehlung und Hintergrundstext kanadische Quell Leitlinie  ................................................................................................... 381 \n5.5. Frage IV.5. und IV.6. Adjuvante Interferon alpha Therapie \u2013  De novo Recherche  ............................................................................. 384 \n5.5.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 384 \n5.5.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 385 \n5.5.3.  Auswahlkriterien  ..................................................................................................................................................................... 386 \n5.5.4.  Evidenztabelle - Kurzfassung  .................................................................................................................................................. 387 \n5.5.5.  Hochdosis versus Niedrigdosis Interferon alpha ....................................................................................................................... 388 \n5.5.6.  Evidenztabelle n \u2013 Langfassung  ................................................................................................................................................ 390 \n5.5.6.1.  Evidenztabelle \u2013 Systematische Reviews and Metaanalysen  .............................................................................................. 390 \n5.5.6.2.  Evidenztabelle \u2013 Niedrigdosis IFN alpha  ........................................................................................................................... 398 \n5.5.6.3.  Evidenztabelle - Mittlere Dosis IFN alpha ......................................................................................................................... 402 \n5.5.6.4.  Evidenztabelle - Hochdosis IFN alpha  .............................................................................................................................. 403 \n5.5.6.5.  Evidenztabelle - Pegyliertes IFN alpha  ............................................................................................................................. 408 \n5.5.7.  Subgruppenanalysen  ............................................................................................................................................................... 409 \n5.5.8.  Toxizit\u00e4t  ................................................................................................................................................................................. 412 \n5.5.9.  Metaanalysen  .......................................................................................................................................................................... 416 \n5.5.10.  Literatur  ................................................................................................................................................................................. 420 \n6. AG Medikament\u00f6se Therapie bei Metastasierung  ................................ ................................ ...... 421  \n6.1. Frage V.1. Lokale medikament\u00f6se Therapie Intransitmetastasen \u2013  De novo Recherche  .................................................................... 421 \n6.1.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 421 \n6.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 422 \n6.1.2.1.  Prim\u00e4rreche rche 2012  ..................................................................................................................................................... 422  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 8 von 817 \n6.1.2.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 423 \n6.1.3.  Auswahlkriterien  ..................................................................................................................................................................... 424 \n6.1.3.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 424 \n6.1.3.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 425 \n6.1.4.  Evidenztabelle ......................................................................................................................................................................... 426 \n6.1.4.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 426 \n6.1.4.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 443 \n6.1.5.  Literatur  ................................................................................................................................................................................. 449 \n6.2. Frage V.2. und V.3. Systemtherapie Einzelsubstanzen \u2013 De novo Recherche  ................................................................................... 451 \n6.2.1.  PICO, Such w\u00f6rter  .................................................................................................................................................................... 451 \n6.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 452 \n6.2.2.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 452 \n6.2.2.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 453 \n6.2.3.  Auswahlkriterien  ..................................................................................................................................................................... 454 \n6.2.3.1.  Prim\u00e4rrecherc he 2012  ..................................................................................................................................................... 454 \n6.2.3.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 455 \n6.2.4.  Evidenztabelle ......................................................................................................................................................................... 456 \n6.2.4.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 456 \n6.2.4.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 479 \n6.2.4.2.1.  RCTs - Chemotherapy/Chem osensitizer  ...................................................................................................................... 479 \n6.2.4.2.2.  RCTs - Immuntherapie/Immunmodulation  .................................................................................................................. 484 \n6.2.4.2.3.  Zielgerichtete Therapien /small molecules  .................................................................................................................. 500 \n6.2.4.2.4.  Reviews  ..................................................................................................................................................................... 523 \n6.2.5.  Literatur  ................................................................................................................................................................................. 536 \n6.3. Frage V.4. Biochemo therapie - Adaptation  ..................................................................................................................................... 540  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 9 von 817 \n6.3.1.  Synopse Quellleitlinien  ............................................................................................................................................................ 540 \n6.3.2.  Empfehlung,  Hintergrundstext und Literatur Kanadische Quell  Leitlinie  ................................................................................... 541 \n6.4. Frage V.5. Polychemotherapie \u2013  De novo Recherche  ....................................................................................................................... 544 \n6.4.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 544 \n6.4.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 545 \n6.4.3.  Auswahlkriterien  ..................................................................................................................................................................... 545 \n6.4.4.  Evidenztabelle ......................................................................................................................................................................... 546 \n6.4.5.  Literatur  ................................................................................................................................................................................. 548 \n6.5. Frage V.7. Lebermetastasen \u2013  De novo Recherche  .......................................................................................................................... 550 \n6.5.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 550 \n6.5.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 551 \n6.5.3.  Auswahlkr iterien  ..................................................................................................................................................................... 552 \n6.5.4.  Evidenztabelle ......................................................................................................................................................................... 553 \n6.5.5.  Literatur  ................................................................................................................................................................................. 567 \n6.6. Frage V.8. Lebensqualit\u00e4t \u2013  De novo Recherche  .............................................................................................................................. 570 \n6.6.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 570 \n6.6.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 570 \n6.6.2.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 570 \n6.6.2.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 571 \n6.6.3.  Auswahlkriterien  ..................................................................................................................................................................... 572 \n6.6.3.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 572 \n6.6.3.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 573 \n6.6.4.  Evidenztabelle ......................................................................................................................................................................... 574 \n6.6.4.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 574 \n6.6.4.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 590  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 10 von 817 \n6.6.5.  Literatur  ................................................................................................................................................................................. 602 \n6.6.6.  \u00dcbersicht Frageb\u00f6gen zur Erhebung der Lebensqualit\u00e4t ........................................................................................................... 603 \n6.7. Frage V.9. Medikament\u00f6se Therapie Hirnmetastasen \u2013  De novo Recherche  ..................................................................................... 607 \n6.7.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 607 \n6.7.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 607 \n6.7.2.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 607 \n6.7.2.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 608 \n6.7.3.  Auswahlkriterien  ..................................................................................................................................................................... 609 \n6.7.4.  Evidenztabelle ......................................................................................................................................................................... 610 \n6.7.4.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 610 \n6.7.4.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 616 \n6.7.5.  Literatur  ................................................................................................................................................................................. 623 \n7. AG Radiotherapie  ................................ ................................ ................................ ....................  624  \n7.1. Frage VI.1. Radiotherapie Prim\u00e4rtumor  .......................................................................................................................................... 624 \n7.1.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 624 \n7.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 625 \n7.1.3.  Auswahlkriterien  ..................................................................................................................................................................... 626 \n7.1.4.  Evidenztabelle ......................................................................................................................................................................... 626 \n7.1.5.  Literatur  ................................................................................................................................................................................. 637 \n7.2. Frage VI.2. und VI.3. Radiot herapie Intransit - und Fernmetastasen .................................................................................................  638 \n7.2.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 638 \n7.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 640 \n7.2.3.  Auswahlkriterien  ..................................................................................................................................................................... 643 \n7.2.4.  Evidenztabelle ......................................................................................................................................................................... 643  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 11 von 817 \n7.2.5.  Literat ur ................................................................................................................................................................................. 653 \n7.3. Frage VI.4. Radiotherapie und Chirurgie Hirnmetastasen  ................................................................................................................ 654 \n7.3.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 654 \n7.3.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 655 \n7.3.2.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 655 \n7.3.2 .2. Aktualisierungsrecherche 2015  ....................................................................................................................................... 656 \n7.3.3.  Auswahlkriterien  ..................................................................................................................................................................... 656 \n7.3.3.1.  Prim\u00e4rrecherche 2012  ..................................................................................................................................................... 656 \n7.3.3.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 657 \n7.3.4.  Evidenztabelle ......................................................................................................................................................................... 658 \n7.3.4.1.  Prim\u00e4rrecherch e 2012  ..................................................................................................................................................... 658 \n7.3.4.2.  Aktualisierungsrecherche 2015  ....................................................................................................................................... 686 \n7.3.5.  Literatur  ................................................................................................................................................................................. 689 \n7.4. Frage VI.5. Adjuvante Radiotherapie Regionale Lymphknotenstation  .............................................................................................. 691 \n7.4.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 691 \n7.4.2.  Datenban ken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 692 \n7.4.3.  Auswahlkriterien  ..................................................................................................................................................................... 693 \n7.4.4.  Evidenztabelle ......................................................................................................................................................................... 693 \n7.4.5.  Literatur  ................................................................................................................................................................................. 703 \n7.5. Frage VI.6. Fraktionierung  ............................................................................................................................................................. 703 \n7.5.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 703 \n7.5.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 704 \n7.5.3.  Auswahlkriterien  ..................................................................................................................................................................... 705 \n7.5.4.  Evidenztabelle ......................................................................................................................................................................... 706 \n7.5.5.  Literatur  ................................................................................................................................................................................. 707  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 12 von 817 \n8. AG Nachsorge  ................................ ................................ ................................ .........................  707  \n8.1. Frage VII.3. Selbstuntersuchung im Rahmen der Nachsorge -  Adaptation  ....................................................................................... 707 \n8.1.1.  Synopse (kurz) ........................................................................................................................................................................ 707 \n8.1.2.  Empfehlung , Hintergrundstext und Literatur australischen und franz\u00f6sischen Quell -Leitlinien  ................................................. 708 \n8.2. Frage VII.4., VII.5. und VII.6. Nachsorge -Dauer und - Intervalle \u2013 De-novo- Recherche  .................................................................... 719 \n8.2.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 719 \n8.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 719 \n8.2.3.  Auswahlkriterien  ..................................................................................................................................................................... 720 \n8.2.4.  Evidenztabelle ......................................................................................................................................................................... 721 \n8.2.5.  Literatur  ................................................................................................................................................................................. 792 \n9. AG Begleittherapie  ................................ ................................ ................................ ..................  799  \n9.1. Frage VIII.1. Misteltherapie  ............................................................................................................................................................ 799 \n9.1.1.  PICO, Suchw\u00f6rter  .................................................................................................................................................................... 799 \n9.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  ............................................................................................................................ 800 \n9.1.3.  Auswahlkriterien  ..................................................................................................................................................................... 800 \n9.1.4. Evidenztabelle ......................................................................................................................................................................... 801 \n9.1.5.  Literatur  ................................................................................................................................................................................. 807 \n10.  AG Versorgungsqualit\u00e4t und Qualit\u00e4tsindikatoren  ................................ ................................ ..... 808  \n10.1.  Frage IX.1. Klinische Studien -  Adaptation  ..................................................................................................................................... 808 \n10.1.1.  Synopse Quellleitlinien (kurz)  .................................................................................................................................................. 808 \n10.1.2.  Empfehlung, Hintergrundstext und Literatur australischen und franz\u00f6sischen Quell -Leitlinien  ................................................. 809  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 13 von 817 \n11.  Abk\u00fcrzungsverzeichnis  ................................ ................................ ................................ ...........  814 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 14 von 817 \n2. AG Diagnostik  \n2.1. Frage  I.2. und I.3. Apparative Verfahren zur klinischen Diagnostik des malignen \nMelanoms  - Adaptation  \nFrage I.2. Welche diagnostischen Verfahren sind geeignet, die klinische Diagnose des MM zu verbessern? \nFrage I .3. Welche Hilfsmittel oder apparativen Verfahren  k\u00f6nnen die klinische Diagnostik des MM ggf. weiter verbessern ? \n2.1.1.  Synopse Quelleitlinien  (kurz)  \n Thema/Fragestellung  LL Austr alien  \nNew Zealand Guidelines Group \n2008 LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005)  LL Kanada  \nCancer C are O ntario 2007  \n2. Welche diagnostischen \nVerfa hren/Hilfsmittel \nk\u00f6nnen helfen, die klinische \nDiagnose des MM zu \nsichern?  Klinische Unters uchung, \nAnamnese mit Konzentration auf \nVer\u00e4nd erungen von Hautl\u00e4sionen;  \nDermatoskopie wird empfo hlen \n(A); \nBeobachtungsp eriode m\u00f6glich;  \nEinsatz von \u201eSequential digital \ndermoscopy imaging\u201c und/oder \n\u201eTotal body photography\u201c kann in \nZweifelsf\u00e4llen in Erw\u00e4gung \ngezogen we rden (B)  Klinische \nUntersuchung, \nDermat oskopie  Klinische Untersuchung, \nDermat oskopie  (nur relevant f\u00fcr \nmedik ament\u00f6se Therapie n) \n3. Erh\u00f6ht der Einsatz der \nDermatoskopie (mit/ohne \nSchulung der anwendenden \n\u00c4rzte) die diagnost ische \nGenauigkeit?  Training in Derm atoskopie wird \nempfohlen f\u00fcr \u00c4rzte, die \nregelm\u00e4\u00dfig pigmentierte HV \nunters uchen (A)  Empfohlen  Keine Erw\u00e4 hnung   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 15 von 817 \n2.1.2.  Empfehlung, Hintergr unds text und Literatur Australische Quell -Leitlinie  \n (mit Seitenangaben der Quellleitlinie)  \n LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005)  \nSchl\u00fcsselempfe hlungen  S. 31  \n \n1. Training and utilisation of \ndermo scopy is recommended for \nclinicians routinely examining \npigmented skin lesions  \nGrade of Recommendation: A  \n \n2. Consider the use of s equential digital \ndermoscopy imaging to d etect \nmelanomas that lack dermosc opic \nfeatures of mel anoma  \nGrade of Recommendation: B  \n \n3. Consider the use of bas eline total \nbody photography as a tool for  \nthe early detection of mel anoma in \npatients who are at high risk for  \ndeveloping primary melan oma \nGrade of Recommendation: C  S. 84  \n \nA. Recommend ations  \n \nInvestigation and dia gnosis  \n \nGPs should receive training as \nrecommended in the NICE Referral  \nguidelines for suspected ca ncer [44] on \nthe diagnosis of precanc erous and \ncancerous lesions, and should receive \nfeedback through audit on their \ndiagnostic accuracy.  \nGPs should refer certain groups of skin \nlesions as d escribed in Box 1 and Figure \n14 directly to an LSMDT without biopsy. \nThis practice should be subject to audit.  \n \nAll excised skin specimens should be \nsent for histopathological exami nation \nas recommended in the NICE Referral \nguidelines for su spected cancer . [45]  \n \nDermatoscopy should be ava ilable in all \nMDTs, but its use requires train ing. \n Die franz\u00f6sische LL gibt keine \nEmpfehlungen zur klinischen \nErstdiagnose eines Melanoms; \ndie Dermatoskopie wird jedoch \nim Abs chnitt \u00fcber Unte rsuchung \nund Nachsorge von R0 -\nresezierten Patienten (N0, M0) \nkurz bespr ochen sowie auf \nGutachten der Haute Autorit\u00e9 de \nSant\u00e9 (HAS) und der Agency for \nHealthcare Research and Quality \n(AHRQ) ve rwiesen:  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 16 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005)  \nThere should be equity of a ccess so that \nall tissue samples are reviewed in high -\nquality histopatho logy se rvices. \nAccurate diagnosis in derma topathology \ndepends on clinicopatholog ical \ncorrelation, involving input from both \nclinician and p athologist. Although this \ncan be achieved in difficult cases by \ninterspecialist discussion or seeing the \npatient re cords, in some instances (such \nas cutaneous ly mphoma) it may be \nessential for the patient to be seen \njointly. Accordingly, for good clinical \ngovernance, it is recommended that the \nhistopathology r eporting of any \nspecimens likely to be consid ered by a \nskin ca ncer MDT should be unde rtaken \nin a laboratory having easy access to \nrelevant clin icians, patient records and \nthe a ttending patient.  \nHintergrundtexte  S. 29 - 30 \n \n5.6 Evide nce-based a ssessment of aids \nto the clinical diagnosis  \nof melanoma  \n \n5.6.1 Dermoscopy  \nDermoscopy (surface m icroscopy, oil S. 90  \n \nE. Evidence  \n \nDermatoscopy  \nOne RCT found that, followi ng a brief \ntraining intervention for GPs in the use \nof dermatoscopy, th ere was a significant S. 44  \n \nEXAMEN CLINIQUE, \nDERMOSCOPIE  \nLes performances diagnostiques \nde l\u2019examen clinique et de la \ndermoscopie dans le diagnostic \ndes t umeurs cutan\u00e9es font  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 17 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005)  \nepiluminescence microscopy, \ndermatoscopy) is a technique that uses \na hand -held magnifying device \ncombined with either the application o f \na liquid between the tran sparent plate \nof the device and the skin, or the use of \ncross -polarised light. This tec hnique \nallows the visualisation of diagnostic \nfeatures of pi gmented skin lesions that \nare not seen with the n aked eye. [15 \u2013\n18]  \nMeta-analyses performed on stu dies in a \nvariety of clinical and experi mental \nsettings have shown that using \ndermoscopy improves diagnostic \naccuracy for melan oma.[19,20]  \nFrom a meta -analysis of nine level II \ndiagnostic studies su bject to varying \ndegrees of verification bias  performed \nprospectively in a clinical setting [21 \u2013\n31] the diagnostic acc uracy for \nmelanoma, as expressed by the relative \ndiagnostic odds r atio, was 15.6 (95% CI \n2.9\u201383.7) times higher for dermoscopy \ncompared with naked eye examination. \nImportantly th e meta -analysis was \nrestricted to studies that directly \ncompared the two methods within each \nstudy. Sensitivity of derm oscopy was improvement in the accuracy of clinical \ndiagnosis of melan oma and in the \ndiagnosis of melan oma using \ndermatoscopy. The improvement was \nsignificantly greater for th e use of \ndermatoscopy than for clinical \ndiagn osis.  \n \nThree systematic reviews and one case \nseries provide ev idence that hand -held \ndermatoscopy i mproves diagnostic \naccuracy as compared with unaided \nexamination. There is evidence from \none systematic review t hat the \ndiagnostic accuracy of dermatoscopy \ndepends on the degree of experience of \nthe exa miner. \n \nTeledermatology  \nOne RCT compared telede rmatology \nwith face -to-face consultation as a \nmethod of examining p atients with skin \nlesions at a dermatology departmen t. \nAll patients re ceived a further, \nindependent face -to-face skin \nexamination with a co nsultant \ndermatologist. For each randomised \ngroup, concordance between the two \nconsultations for each patient was actuellement l\u2019objet d\u2019une \nexpertise par la Haute Autorit\u00e9 \nde Sant\u00e9 (HAS) et ne seront donc \nici qu\u2019\u00e9voqu\u00e9es. Ces \nperfo rmances ont surtout \u00e9t\u00e9 \n\u00e9tudi\u00e9es pour le diagnostic initial \ndu m\u00e9lan ome, et non dans la \nsituation sp\u00e9cif ique du patient \nayant d\u00e9j\u00e0 eu un m\u00e9lanome. Pour \nces derniers, la probabilit\u00e9 de \nsurvenue d\u2019un autre m\u00e9lanome \nest beaucoup plus \u00e9lev\u00e9e que \ndans la population g \u00e9n\u00e9rale.  \nUne revue syst\u00e9matique publi\u00e9e \npar l\u2019Agency for healthcare \nresearch and quality (AHRQ) a \nr\u00e9cemment revu les \nperformances de l\u2019examen \nclinique pour \u00e9tablir une \n\u00e9ventuelle str at\u00e9gie de d\u00e9pistage \nsyst\u00e9matique des cancers de la \npeau et a montr\u00e9 que les \nperformances dia gnostiques (en \ntermes de sensibilit\u00e9 et de \nsp\u00e9cificit\u00e9) des derm atologues \n\u00e9taient sup\u00e9rieures \u00e0 celles des \nnon-dermatologues [17]. \u00c0 noter \ncepen dant que cette revue  \nsyst\u00e9matique a \u00e9t\u00e9 faite avant  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 18 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005)  \n18% (95% CI 9% \u201327%; P=0.002) higher \nthan for eye exam ination, but there was \nno evidence of an effect on specificity \n[31] (see Appendix 4). Specificity can \nalso be exa mined by its effect on \nexcision rates of benign lesions, which \nwas not a ddressed in the meta -analysis. \nTwo such stu dies suggest reduced rates \nof excision of benign lesions using \nderm oscopy (reduced benign to \nmalignan t ratio of excised lesions and \nreduction of patients referred to biopsy) \nand provide indirect evidence for \nimproved specificity in a specialist \nsetting. [22,23]  \nWhile there are fewer studies on \ndermoscopy in general pra ctice, all \nthree that were unde rtaken  in this \ncontext (one study with both general \npractitioners and inexperienced \nspecialists or trainees) [32] show a \nconsistently improved sensitiv ity for the \ndiagnosis of melanoma or the \nidentification of suspicious lesions \nrequir ing biopsy. [21,32,33] It s hould \nbe noted that all the stu dies cited were \nundertaken by clin icians with some \ntraining in dermoscopy (restricted to \nlectures or reading material in some measured, prima rily for management \nplan and secondarily  for diagnosis. \nThere was significantly greater \nconcordance between consultations for \nmanagement plan and for dia gnosis in \npatients randomised to face -to-face skin \nexamination than in those randomised \nto teledermatology. No difference was \ndetected between randomised groups \nfor patient sati sfaction. \n \nOne RCT compared two types of \nteledermatology (by live \nvideoco nference and by sending still \nphotographic images) with traditional \noutpatient consult ation, as methods for \nGPs to refer patients to dermatologists. \nThe de rmatologist requested a \nsubsequent hospital appointment for \n69% of p atients examined by the still \nimage method, compared to 46% of \npatients examined by videoconferencing \nand 45% of patients exa mined in \nperson.  \n \nOne RCT compared telede rmatology \nwith s tandard referral and found that \npatients in the telederm atology group \nreceived definitive treatment que la dermoscopie, une \ntechnique initialement mise au \npoint en Europe et en Australie, \nsoit largement diff us\u00e9e aux \n\u00c9tats-Unis.  \nDeux m\u00e9ta -analyses r\u00e9centes ont \nmontr\u00e9 que pour les \ndermatologues exp\u00e9riment\u00e9s, la \ndermoscopie am\u00e9liorait les \nperformances diagno stiques \n[160, 161]. Dans l\u2019\u00e9tude de \nBafounta et al. , le rapport de \nvraisemblance positif estim\u00e9 de \nla dermoscopie et de l\u2019examen \nclinique ont \u00e9t\u00e9 respe ctivement \nde 9,0 [IC95 : 5,9- 19,0] et 3,7 \n[IC95 : 2,8 -5,3] [160]. La m\u00e9 ta-\nanalyse de Kittler et al. a \nconfirm\u00e9 ces donn\u00e9es, montrant \nclairement que seuls les \nop\u00e9rateurs exp\u00e9riment\u00e9s \nam\u00e9lioraient leurs performances \ndiagnostiques [161].  \n \nKLINISCHE UNTERSUCHUNG, \nDERMATOSKOPIE  \nDie diagnostische \nLeistungsf\u00e4higkeit der klinischen \nUntersuchung und der  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 19 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005)  \nstudies). For this reason, and based on \nother ev idence [34], some formal \ntraining in dermoscopy is required to \nachieve improvement in diagnostic \naccuracy.  \n \n5.6.2 Sequential digital ima ging \nSequential digital dermoscopy ima ging \n(SDDI) involves the capture and \nassessment of successive derm oscopic \nimages, separated by an i nterval of \ntime, of one or many me lanocytic \nlesions to detect suspicious change. \nThis is pe rformed in two settings: short -\nterm digital mon itoring (over a period of \n1.5\u20134.5 months) for susp icious \nmelanocytic lesions, and long -term \nmonitoring for surveillance (usually at \nintervals of 6 \u201312 mo nths). [35]  \nFour level II studies that were conducted \nin a specialist se tting show consistently \nthat SDDI allows the detection of \nmelanoma that lack dermoscopic \nevidence of maligna ncy. [35 \u201338]  \nIn one prospective study of melan omas \ndiagnosed by a variety o f clin ical means, \n34% were detected using the changes \ndetected by SDDI e xclusively and were \nwithout dermoscopic features of signif icantly more quickly than patients \nin the standard referral group. \nTeledermatology patients were \nsignif icantly more likely to avoid the \nneed for a fur ther clinic visit compared \nwith co ntrol patients.  \n \nOne RCT compared telede rmatology \nconsultation using a videolink with \noutpatient consultation and found no \ndifference b etween the groups in the \nreported clinical dia gnoses.  \n \nOne RCT of teledermatology com pared \nto traditional consultation found no \nsignificant difference b etween groups \nfor patient satisfaction  \nwith either their care or the \nmanagement of their skin pro blems, \nand \n85% of the telemedicine p atients \nreported that they would use the system \nagain.  \n \nTwo systematic reviews suggest that \nthere is no conse nsus from primary \nstudies on whether telede rmatology is \nmore cost -effective than traditional \nmanagement of dermatology p atients.  Dermatoskopie in der Diagnostik \nvon Hauttumoren ist zur Zeit \nGegenstand eines Gutachtens der \nHaute Autorit\u00e9 de Sant\u00e9 (HAS) \nund wird hier daher nur \nerw\u00e4hnt. Die Wirksamkeit dieser \nVerfahren ist vor allem f\u00fcr die \nPrim\u00e4rdiagnostik des Melanoms \nuntersucht worden, nicht f\u00fcr die \nspezielle Situation der Patienten, \ndie bereits ein Melanom gehabt \nhaben. F\u00fcr letztere ist die \nWahrscheinlichkeit, ein weit eres \nMelanom zu \u00fcberleben, sehr viel \nh\u00f6her als in der \nAllgemeinbev\u00f6lk erung.  \nEin systematisches R eview der \nAgency for Healthcare Research \nand Quality (AHRQ) hat unl\u00e4ngst \ndie Wirksamkeit der klinischen \nUntersuchung untersucht, um \nm\u00f6glicherweise eine Strategie \nzum systemat ischen Screening \nvon Hauttumoren zu eta blieren \nund um zu zeigen, dass die \ndiagnost ische Wirksamkeit der \nklinischen Untersuchung \n(Sensitivit\u00e4t und Spezifit\u00e4t) bei \nDermatol ogen der von Nicht - \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 20 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005)  \nmelanoma. [36] Long -term digital \nmonitoring is generally used in the \nsurvei llance of high -risk patients, \nusually with multiple dysplastic naevi. In \ncontrast, short -term digital monitoring \nof individual su spicious naevi can be \nused in any patient setting. At this time \ndiagnostic acc uracy of the technique \nwas not able to be as sessed.  \n \n5.6.3 Automated instr uments for the \ndiagnosis of primary melan oma \nAn automated diagnostic i nstrument is \ndefined as one that requires min imal or \nno input from the clinician to achieve a \ndiagnosis. Each automa ted instrument \noffers different tec hnology with \ndiffering diagnostic abil ity. Guidelines \nfor assessin g such i nstruments have \nbeen published. [39] To date, only three \ninstruments have had their diagnostic \naccuracy compared with a human \ndiagnosis in the clinical field with a \nsample size that could allow some \nassessment of their a pplication to the \nwider clin ical arena. [25,40,41] The \ninstruments  \nshowed a significantly inf erior [25,41] \nor equivalent [40] specificity for the  \nAudit data from the UK ind icates that \nGPs report quicker referral of  \ndermat ology patients through \nteledermatology.  \n \nS. 99 \n \nE. Resource impl ications  \n \nInvestigation and dia gnosis  \nThe main resource implication of the \nrecommendations co ncerning the \ninvestigation and diagnosis concerns \nthe additional role for histopathologists. \nThe in creased workload has been \ncalculated taking a ccount of LSMDT and \nSSMDT working, i mplementation of the \nminimum dataset, doubling the \nreporting of s everely atypical naevi, and \nMM and SSMDT mandatory review. \nApprox imately two -thirds of the \nadditional workload  relates to SSMDT \nand tertiary review. \n \nIt is estimated that approx imately 1.75 \nadditional consultant \nhistopathologists/dermatopathologists \nwould be required per network to Dermatologen \u00fcberlegen ist. [17]  \nEs ist allerdings zu bemerken, \ndass dieses systematische Review \ndurchgef\u00fchrt wurde, bevor die \nDermato skopie, eine Technik, die \nzuerst in Europa und Australien \nentwickelt wurde, gr\u00f6\u00dfere \nVerbreitung in den USA fand.  \nZwei aktuelle Meta -Analysen \nhaben gezeigt, dass die \nDermatoskopie bei erfahrenen \nDermatologen die dia gnostische \nLeistung verbessert [160, 161]. \nIn der Studie von Bafounta et al. \nist der gesch\u00e4tzte positive \npr\u00e4di ktive Wert der \nDermatoskopie und der \nklinischen Untersuchung 9,0 \n[IC95 : 5,9 -19,0] bzw. 3,7 [IC95 : \n2,8-5,3] [160]. Die Meta -Analyse \nvon Kittler et al. hat diese Daten \nbest\u00e4tigt und klar gezeigt, dass \nnur erfahrene Anwender der \nDermatoskopie ihre \ndiagnostische Leistung damit \nverbe ssern [161].  \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 21 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005)  \ndiagnosis of mel anoma compared with \nspecialists. In all stu dies sample sizes \nwere not large enough to be able to \ndetect pote ntial differen ces in the \nsensitivity for melanoma. Fu rther \nstudies are required to assess the \nimpact of automated instruments \nagainst human perfor mance in the \nclinical field.  \n \n5.7 Total body photogr aphy for early \nmelanoma dia gnosis  \nin high -risk subjects  \nTotal body phot ography (TBP) is widely \nused in the follow -up of high- risk \npatients [42], particularly those with \nlarge nu mbers of melanocytic naevi or \ndysplastic naevi. TBP has  \nbeen recommended for the detection of \nnew or changing pigmented l esions. Use \nof TBP is advocat ed in the fo llow-up of \nhigh-risk patients by the authors of \nmost stu dies. [43 \u201350] \nThe technique has been said to r educe \nthe need for unnecessary removal of \nbenign lesions to e xclude melanoma \n[45,46] and to increase the sensitivity \nand specificity of clinic al examination \nfor the detection of melanoma. [46,47] support the guidance. In addition, there \nwould be an additional re quirement for \nlaboratory staff, not calculated here. \nThe additional annual employment costs \nof the hist opathologists will be around \n\u00a3171,991 per network. (This cost has \nbeen included in the total cost for \nadditional staff required as a result of \nthe guidance, reported in t he \n\u2018Organisation of skin cancer se rvices\u2019 \nchapter.)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 22 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005)  \nSeveral authors point out that TBP was \nthe key fa ctor in the detection of most \nmelanomas in their high -risk \npopulations. [44 \u201346,48] Two authors \nreferred to the role of TBP in enabling \nthe detection of c linically subtle or \nundia gnosable melanoma. [46,47]  \nNo appropriately controlled or \nrandomised study has been unde rtaken \nto confirm these observations in a high -\nrisk population. Almost all melanomas \nare new or changing l esions and \nbaseline images are helpfu l in \nidentifying a new or changing l esion. \n \nEvidence summary  \nFrom a meta -analysis of nine level II \nstudies prospectively performed in a \nclinical setting, the diagnostic accuracy \nfor melanoma, as e xpressed by the \nrelative diagnostic odds ratio, was 15.6 \ntimes higher for dermosc opy compared \nwith naked eye examination. Sensitivity \nof derm oscopy was 18% (95% CI 9% \u2013\n27%; P=0.002) higher than for eye \nexam ination, but there was no evidence \nof an effect on specifi city. \nLoE: I , References: 21, 22, 24 \u201331 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 23 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005)  \nDermoscopy has been shown to reduce \nthe b enign:malignant ratio of excised \nmelanocytic lesions and reduce the \nnumber of patients referred for biopsy \nin a specialist se tting  \nLoE: II, References: 22, 23  \n \nFour level II studies show consisten tly \nthat sequential digital d ermoscopic \nimaging allows the detection of \nsuspicious dermoscopic change in \nmelanomas that lack dermoscopic \nevidence of melanoma at a partic ular \ntime \nLoE: II , References: 35 \u201338 \n \nTo date only three automated \ninstruments for the diagnosis of primary \nmelanoma  have been a ssessed against \nclinicians with a reasonable sa mple size \nin the clinical field. Here, instrument \nspecificity was either inferior or \nequivalent to specialist diagnosis, and \nsample sizes were inad equate to assess \ndifferences in sensitivity  \nLoE: I I, References: 25, 40, 41 \n \nEight level IV studies and one level III -3 \nstudy exa mined surveillance of high -risk  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 24 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005)  \nsubjects with total body photography \nbut only one included a compar ison arm \n(of lower -risk \nsubjects). All studies on high -risk \npatients showed ea rly mel anoma \ndetection and/or high melanoma \nincidence.  \nAll studies were designed to assess the \noutcomes of  \nsurveillance in high -risk groups r ather \nthan the value of TBP.  \nLoE: IV  \nReferences: 4 3\u201351 \nBemerkungen   Diese Leitlinie bezieht sich auf MM und \nauf NMSC.  \n \nReferenzen und ausf\u00fchrliche \nEvidenztabellen dieser Leitlinie werden \nwegen ihres Umfangs als separ ates \nDokument zur Ve rf\u00fcgung gestellt:  \nGB NICE Guideline Evidence R eview, S. \n174 bis 211.  Das Gutachten der HAS, der \nArtikel der AHRQ, auf den die \nLeitlinie sich bezieht, sowie \ndessen Aktualisierung aus dem \nJahr 2009 werden als \nZusatzmaterial zu dieser Tabe lle \nzur Ve rf\u00fcgung gestellt.  \n \nLiteratur:  \n \nLL Austr alien New Zealand Guidelines Group 2008  \n21. Agenziano G, Puig S, Zalaudek I, et al. Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. J Clin Oncol 2006;24: 1877- 1882  \n20. Bafounta ML, Beauchet A, Aegerter P, et al. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta -analysis using techniques adapted \nto the evaluation of diagnostic tests. Arch Dermatol 2001;137:1343 -1350  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 25 von 817 \n51. Banky JP, Kelly JW, English DR, et al. Incidence of new and changed nevi and melanomas detected using baseline images and der moscopy in patients at high risk for melanoma. Arch \nDermatol 2005;141:998 -1006  \n40. Bauer P, Cristofolini P, Boi S, et al . Digital epiluminescence microscopy: usefulness in the differential diagnosis of cutaneous pigmentary lesions. A statistical comparison between \nvisual and computer inspection. Melanoma Res 2000;10:345- 349 \n27. Benelli C, Roscetti E, Pozzo VD, et al. The dermoscopic versus the clinical diagnosis of melanoma. Eur J Dermatol 1999;9:470- 476 \n34. Binder M, Puespoeck -Schwarz M, Steiner A, et al. Epiluminescence microscopy of small pigmented skin lesions: short -term formal training improves the diagnostic performan ce of \ndermatologists. J Am Acad Dermatol 1997;36:197- 202 \n25. Bono A, Bartoli C, Cascinelli N, et al. Melanoma detection. A prospective study comparing diagnosis with the naked eye, dermatoscopy and telespectrophotometry. Dermatology \n2002;205:362- 366 \n26. Bo no A, Tolomio E, Trincone S, et al. Micro -melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter < or = 3 mm. Br J Dermatol \n2006;155:570- 573 \n17. Bowling J, Argenziano G, Azenha A, et al. Dermoscopy key point s: recommendations from the international dermoscopy society. Dermatology 2007;214:3 -5 \n22 .Carli P, de Giorgi V, Chiarugi A, et al. Addition of dermoscopy to conventional naked -eye examination in melanoma screening: a randomized study. J Am Acad Dermatol \n2004;50:683- 689 \n23. Carli P, De Giorgi V, Crocetti E, et al. Improvement of malignant/benign ratio in excised melanocytic lesions in the 'dermoscopy era': a retrospective study 1997 -2001. Br J Dermatol \n2004;150:687- 692 \n24. Carli P, Mannone F, De Giorgi V, e t al. The problem of false -positive diagnosis in melanoma screening: the impact of dermoscopy. Melanoma Res 2003;13:179- 182 \n28. Cristofolini M, Zumiani G, Bauer P, et al. Dermatoscopy: usefulness in the differential diagnosis of cutaneous pigmentary les ions. Melanoma Res 1994;4:391- 394 \n32. Dolianitis C, Kelly J, Wolfe R, et al. Comparative performance of 4 dermoscopic algorithms by nonexperts for the diagnosis of  melanocytic lesions. Arch Dermatol 2005;141:1008-\n1014 \n29. Dummer W, Doehnel KA, Remy W. Videomi croscopy in differential diagnosis of skin tumors and secondary prevention of malignant melanoma. Hautarzt 1993;44:772 -776 \n46. Feit NE, Dusza SW, Marghoob AA. Melanomas detected with the aid of total cutaneous photography. Br J Dermatol 2004;150:706- 714 \n36. Haenssle HA, Krueger U, Vente C, et al. Results from an observational trial: digital epiluminescence microscopy follow -up of atypical nevi increases the sensitivity and the chance of \nsuccess of conventional dermoscopy in detecting melanoma. J Invest Derm atol 2006;126:980- 985 \n41. Har-Shai Y, Glickman YA, Siller G, et al. Electrical impedance scanning for melanoma diagnosis: a validation study. Plast Reconstr Surg 2005;116:782 -790 \n45. Kelly JW, Yeatman JM, Regalia C, et al. A high incidence of melanoma foun d in patients with multiple dysplastic naevi by photographic surveillance. Med J Aust 1997;167:191- 194 \n35. Kittler H, Guitera P, Riedl E, et al. Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging. Arch Dermatol 2006;142:1113- 1119  \n19. Kittler H, Pehamberger H, Wolff K, et al. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002;3:159 -165 \n48. MacKie RM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high -risk groups. Lancet 1993;341:1618- 1620  \n18. Malvehy J, Puig S, Argenziano G, et al. Dermoscopy report: proposal for standardization. Results of a consensus meeting of the International Dermoscopy Society. J Am Acad \nDermatol 2007;57:84- 95 \n43. Marghoob AA, Kop f AW, Rigel DS, et al. Risk of cutaneous malignant melanoma in patients with 'classic' atypical -mole syndrome. A case -control study. Arch Dermatol 1994;130:993-\n998 47. Masri GD, Clark WH,Jr, Guerry D,4th, et al. Screening and surveillance of patients at hi gh risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol \n1990;22:1042- 1048  \n15. Menzies S, Crotty KA, Ingvar C, McCarthy WH. An Atlas of Surface Microscopy of Pi gmented  Skin Lesions: Dermoscopy. 2nd ed. Sydney: McGraw -Hill, 2003.  \n37. Menzies SW, Gutenev A, Avramidis M, et al. Short -term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch Dermatol 2001;137:1583 -1589 \n16. Menzies SW, Zalaudek I. Why perform dermoscopy? The evidence for its ro le in the routine management of pigmented skin lesions. Arch Dermatol 2006;142:1211- 1212  \n44. Rivers JK, Kopf AW, Vinokur AF, et al. Clinical characteristics of malignant melanomas developing in persons with dysplastic nevi. Cancer 1990;65:1232 -1236  \n38. Robinson JK, Nickoloff BJ. Digital epiluminescence microscopy monitoring of high -risk patients. Arch Dermatol 2004;140:49- 56 \n39. Rosado B, Menzies S, Harbauer A, et al. Accuracy of computer diagnosis of melanoma: a quantitative meta- analysis. Arch Dermatol 20 03;139:361- 7; discussion 366  \n42. Shriner DL, Wagner RF,Jr. Photographic utilization in dermatology clinics in the United States: a survey of university -based dermatology residency programs. J Am Acad Dermatol \n1992;27:565- 567 \n30. Stanganelli I, Serafini M, Bucch L. A cancer- registry -assisted evaluation of the accuracy of digital epiluminescence microscopy associated with clinical examination of pigmented s kin \nlesions. Dermatology 2000;200:11- 16 \n50. Tiersten AD, Grin CM, Kopf AW, et al. Prospective follow -up for malignant melanoma in patients with atypical -mole (dysplastic -nevus) syndrome. J Dermatol Surg Oncol 1991;17:44-\n48 \n31. Vestergaard ME, Macaskill P, Holt PE, et al. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta -analysis of studies performed in a \nclinical setting. Br J Dermatol 2008;159:669- 676 \n49. Wang SQ, Kopf AW, Koenig K, et al. Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy . J Am Acad \nDermatol 2004;50:15- 20 \n33. Westerhoff K, McCarthy WH, Menzies SW. Increase in the sensitivity for melanoma diagnosis by primary care physicians using skin surface microscopy. Br J De  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 26 von 817 \nLL Frankreich  French National Authority for Health 2005 ) \n17. AH RQ, Agency for Healthcare Research and Quality. Screening for Skin Cancer. File Inventory, Syste matic Evidence Review Number 2 [online]. AHRQ Publication 2001. Available: URL: \nhttp://www.ahrq.gov/clinic/prev/skncainv.htm  \n160. Bafounta ML, Beauchet A, Aeger ter P, et al. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta -analysis using techniques \nadapted to the evaluation of diagnostic tests. Arch Dermatol 2001;137:1343- 1350  \n161. Kittler H, Pehamberger H, Wolff K, et al. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002;3:159 -165 \n2.2. Frage I.3.  Konfokale Laserscan -Mikroskopie und optische Koh\u00e4renztomographie -  De-\nnovo -Recherche  \nFrage I.3.  Welche Hilfsmittel oder apparativen Verfahren k\u00f6nnen die klinische Diagnostik des MM ggf. weiter verbessern  \nBeantwortung durch Adaptation (s.o . I.2.) \nErg\u00e4nzende Recherche zu:   \n- Konfokale Laserscan -Mikroskopie (CLSM)  \n- Optische Koh\u00e4renztomographie (OCT)  \n \n2.2.1.  PICO, Suchw\u00f6rter  \nSuchw\u00f6rter  \nStichwort  melanoma  Confocal, laserscan microscopy  \nSynonyme  melanoma  Clsm  \nOber -/Unterbegriffe, MESH -Term  s. Suchstrategie  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 27 von 817 \n \n2.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  \"melanoma\"[tiab] AN D (\"confocal\"[tiab] OR \"laserscan microscopy\"[tiab] OR \n\u201cclsm\u201d[tiab]) NOT \"uveal\"[tiab] NOT \"models, animal\"[Mesh]  \n \n\"melanoma\"[tiab] AND (\"oct\"[tiab] OR \"optical coherence tomography\"[tiab] OR \n\u201coptical coherence tomographic\u201d[tiab] OR \u201cmultiphoton\"[tiab]) NOT \"uveal\"[tiab] \nNOT \"models, an imal\"[Mesh]  26.01.2012  275 \n \n \n92 \nCochrane Library  melanoma and (confocal or \"laserscan microscopy\" or clsm).ti,ab.  \n \nmelanoma and (oct or \"optical coherence tomography\" or \u201coptical coherence \ntomographic\u201d or \u201cmultiphoton\").ti,ab.  26.01.2012  \n \n26.01.2012 1 \n \n4 \nBemerkungen: Datum der Ers t-Recherche f\u00fcr Medline und Cochrane war der 21.09.2010. Eine letzte Update- Recherche erfolgte am 26.01.2012 f\u00fcr \nMedline bzw. am 19.01.2012 f\u00fcr Cochrane. In den Tabellen angegeben sind die Za hlen der letzten Update- Recherche.  \n \n31.08.2012: Aufgrund der eing egangenen Kommentare im Rahmen der Konsultationsphase in Bezug auf die  Literaturauswahl zur konfokalen \nLaserscanmikroskopie wurde die Literatur, die bei der systematischen Recherche gefunden wurden, reevaluiert. Die Tabelle wurde daraufhin erg\u00e4nzt \nentsprec hend der angegeben Ein - und Ausschlu\u00dfkriterien.  \n \nAbschlu\u00df Konsultationsphase, Stand 09/2012: Das Statement zur konfokalen Laserscanmikroskopie wurde aus der Leitlinie herausg enommen (Details: s. \n\u201eKommentare zur Konsulationsfassung\u201c). Eine \u00dcbera rbeitung der  Evidenztabelle nach erneuter sytematischer Literaturrecherche ist f\u00fcr das Update der \nLeitlinie geplant. \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 28 von 817 \n \n2.2.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  372 \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports, narrative Reviews, Bench Research  \n \nCLSM: nur Artikel, bei Sensitivit\u00e4t und Spezifit\u00e4t bestimmt wurden   \nAnzahl nach Abstractscreening  29 \nAnzahl ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewertung  9 \n \n2.2.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSubtopic:  \nOptical coherence \ntomography (OCT), \nMultiphoton laser \ntomography (MLT)         \nDimitrow et al. \n(2009)  To examine the \nclinical \napplicability of Diagnostic study  \n 83  patients  Sensitivity and \nspecificity in and \nex vivo  Overall sensitivity \n75% in vivo, 93% ex \nvivo Specificity and \nsensitivity for \nsingle criteria: see 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 29 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmultiphoton laser \ntomography with \nregard to statistical \nevaluation of \nsensitivity, \nspecificity, \naccuracy, and \nreliability.   \nAccuracy  \n \nInterobserver \nreliability   \nSpecificity 80% in \nvivo, 74% ex vivo  \n \nDiagnostic \naccuracy 85% in \nvivo, 97% ex vivo  \n \nInterobserver \nagreement: kappa \nvalues for different \ncriteria ranging \nfrom 0.6 to 0.8  full-text of \npublication  \n \n \nGambichler et al. \n(2007)  To visualize and \ncharacterize  \nmelanocytic skin \nlesions (MSL) by \nusing OCT in vivo, \ncompare OCT \nfeatures of benign \nnevi (BN) and MM, \nand histologically \nvalidate the OCT \nfindings. Diagnostic study  \n \n 75 patients with 92 \nMSL Frequency of \nseveral \ncharacteristics of \nlesions  See full -text fo r \nfrequency of all \ninvestigated \ncharacteri stics of \nlesions. The diagnostic \nperformance of \nOCT in the \ndiagnosis of MSL \ncould not be fully \ndetermined.  \nSensitivity and \nspecificity studies \nalso inclu ding \nother skin tumors \nhave not been \nperformed  \n 3b \nSubtopic:  \nConfocal laser scan \nmicroscopy (CLSM )         \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 30 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nGerger et al. \n(2007)  To validate \ndiagno stic confocal \nexam ination of \nmelanocy tic skin \ntumours us ing \nunselected t umour \nimages.  A total of 3709 \nunselected CLSM \ntumour imag es \nobtained from 20 \nmalignant \nmelanomas and 50 \nbenign naevi  60 patients  Sensitivity and \nspecificity  \n \nPositive and \nnegative predictive \nvalue (PPV, NPV)  \n \nDiagnostic \naccuracy  Sensitivity 97.5%  \n \nSpecificity 99%  \n \nPPV 97.5%  \n \nNPV 99%  \n \nDiagnostic \naccuracy 92.4% f or \nbenign naevi and \n97.6% for \nmelanoma i mages High risk of \nverific ation bias \n(no histol ogy if \ndiagnosed \u201con \nunequivocal \nclinical and \nconventional \nderm oscopic  \ncriteria as benign \nnevi\u201c)  \n \nComputerized \nimages were \nprovided, a loss in \nsensitivity or \nspecificity  through \nacquisition of the \nimages by an \nunexperienced \nexaminer could \ntherefore not be \nobserved  3b \nGerger et al. \n(2005)   To systematically \nvalidate CLSM in \ndiagnosing \nmelan ocytic skin \ntumors in an \nobserver-blinded \nmanner, and to \nevaluate Diagnostic study  \n \n 88 patients with \n117 lesions (90 \nbenign nevi, 27 \nmelan omas) Sensitivity, \nspecific ity \n \nPositive and \nnegative predictive \nvalue (PPV, NPV)  5 inde pendent \nobservers without \nprevious \nexperience in CLSM  \n \n2 Residents:  \nsensitiv ity 96.3%, \nspecificity 100% High risk of \nverific ation bias \n(selective \nhistopathological \nconfirm ation of \ndiagnosis)  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 31 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmorpholo gic \nfeatu res \ndetermined by \nCLSM for their \npresence or \nabsence, \ndiagnostic \nperfor mance, and \nreliability. and 99%, PPV 100% \nand 96.3%, NPV \n99%  \n \nSenior physician \nwithout \ndermat opathologic \nqualific ation:  \nsensitivity 92.6% \nand specifi city \n99%, PPV 96.2%, \nNPV 98% \n \n2 \nDermat opathologis\nts: \nsensitivity 96.3% \nand 59.3%, \nspecificity 94% and \n96%, PPV 81.3% \nand 80%, NPV 99% \nand 89.7%  \n \nOverall sensitivity \n88.2%, specificity \n97.6%, PPV 90.7%, \nNPV 96.9%.  \nGerger et al. \n(2006)   To systematically \ninvestigate the \ndiagnostic i mpact Diagnostic study  \n 119 patients with \n117 melanocytic \nand 45 non -Sensitivity, \nspecific ity \n Diagnostic \ndiffere ntiation of \nMM from BCC, BN, High risk of \nverific ation bias \n(see above)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 32 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nand reliability of \nwell described \nmorph ologic \nfeatures in a large \nseries of \nmelanocytic and \nnonmelanocytic \nskin tumors.  melanocytic skin \nlesions  Positive and \nnegative predictive \nvalue (PPV, NPV)  and SK reached \nsensitiv ity and \nspecificity va lues \nof 85.19% and \n98.52% (O bserver \n1), 92.59% and \n98.52% (O bserver  \n2), and 92.59% and \n99.26% (Observers \n3 and 4), \nrespectiv ely with \nthe follo wing \noverall \nperfor mance: \nsensitivity, 90.74%; \nspecificity, 98.89%; \nPPV, 94.22%; and \nNPV, 98.17%.   \nGerger et al. \n(2008)   To assess the \napplicability of \nimage analysis and \na machine learning \nalgorithm on \ndiagnostic \ndiscrim ination of \nbenign and \nmalignant \nmelanocytic skin \ntumours in in vivo \nconfocal laser -Diagnostic study  \n \n 60 patie nts (total \nof 857 CLSM \ntumour images \nincluding 408 \nbenign nevi and \n449 melanoma \nimages)  Sensitivity, \nspecific ity Correct \nclassific ation by \nCART anal ysis in \n97.55% and 96.32% \nof melan oma and \nnevi images, \noverall \nperfo rmance \n96.97%  \n \nHuman observer:  \nsensitiv ity 85.52%, Use of pre -selected \nCLSM images (high \nrisk of s election \nbias) 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 33 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nscanning \nmicrosc opy (CLSM).  specifi city 80.15%,  \noverall \nperfor mance \n82.84%, positive \npredictive value \n82.58%, negative \npredictive  \nvalue 83.42%  \nKoller et al. (2010)  To investigate the \napplicability of an \nautomated image \nanalysis system \nusing a m achine \nlearning algorithm \non diagnostic \ndiscrimination of \nbenign and \nmalignant \nmelanocytic skin \ntumours in \nreflectance \nconfocal \nmicroscopy (RCM) Diagnostic study  \n 178 patients with \n16269 RCM tumor \nimages  Diagnostic \naccuracy  Classification tree \nanalysis: \ncorrect \nclassific ation in \n93.60% of \nmelanoma and \n90.40% of nevi \nimages of the \nlearning set  \n \nWhen applied to \nthe ind ependent \ntest set 46.71 \u00b1 \n19.97% (range \n7.81\u201383.87%) of \nthe tumour images \nin benign \nmelanocytic skin \nlesions were \nclassified as \n\u2018mali gnant\u2019, in \ncontrast to 55.68 \u00b1 Risk of verification \nbias (verification \nby histopathology \ndependent on \nclinical \nexamination)  \n \nROC curve: see \nfull-text 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 34 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n14.58% (range \n30.65 \u201383.59%; t -\ntest: P < 0.036) in \nmalignant \nmelan ocytic skin \nlesions  \n \n78.95% of \nmelan ocytic skin \ntumours (62.50% \nof the me lanoma \nand 84.50% of the \nnevi) correctly \nclassified by \nindependent \nclinical \ndermatol ogist \nLangley et al. \n(2007)  The aim of this study \nwas to eval uate the \ndiagnostic acc uracy \nof CSLM compared \nto dermoscopy in a \nprospective \nexamina tion of \nbenign and \nmalignant \nmelan ocytic lesions.  Diagnostic study  \n \n. 125 patients  Sensitivity, \nspecific ity \n \nPositive and \nnegative predictive \nvalue (PPV, NPV)  Dermoscopy:  \nsensitivity 89.2%, \nspecificity 84.1%, \nPPV 70.2% , NPV \n94.9%  \n \nCSLM:  \nsensitivity 97.3%, \nspecifi city 83.0%, \nPPV 70.6%, NPV \n98.6%  \n \nNo melano mas No verification bias \n(all diagnoses were \nconfirmed \nhistolog ically)  \n \nClinical, \ndermat oscopic and \nconfocal imag ing \nwere pe rformed \nsequentially by a \nsingle obser ver; \nresult of clinical \nexamination and 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 35 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmisidentified when \nboth tec hniques \nwere used  \ntogether  dermatoscopy may \nlead to bias in \nconfocal \nexamin ation \nLorber et al. (2009)  To examine the \ncorrelation \nbetween \nobjectively \nreproducible \nimage -analysis \nfeatures und visual \nmorpho logy in \nmelan ocytic skin \ntumours using \nCLSM.  Diagnostic study  \n \n 60 patients with 70 \nmelanocytic skin \nlesions  Diagnostic \naccuracy  CART analysis of \nthe whole set of \nCLSM tumour \nimages correctly \nclass ified 97.55% \nof me lanoma \nimages and 96.32% \nof nevi im ages.  High risk of \nverific ation bias \n(selective \nhistopathological \nconfirmation of \ndiagnosis).  \n 3b \n \nAnmerkung: Bei Studien, die f\u00fcr zwei oder mehrere Teilfragen relevant sind, ist nur der Ergebnisteil und LoE erneut angegeben, f\u00fcr die \u00fc brigen \nFelder  wird auf die erste Erw\u00e4hnung der Studie in der Evidenztabelle verwiesen. \n2.2.5.  Literatur  \n \nDimitrow E, Ziemer M, Koehler MJ, et al. Sensitivity and specificity of multiphoton laser tomography for in vivo and ex vivo diagnosis of malignant melanoma. J Invest Derm atol \n2009;129:1752- 1758  \nGambichler T, Regeniter P, Bechara FG, et al. Characterization of benign and malignant melanocytic skin lesions using optical coherence tomography in vivo. J Am Acad Dermatol \n2007;57:629- 637 \nGerger A, Hofmann -Wellenhof R, Langsenlehner U, et al. In vivo confocal laser scanning microscopy of melanocytic skin tumours: diagnostic applicability using unselected tumour \nimages. Br J Dermatol 2008;158:329- 333 \nGerger A, Koller S, Kern T, et al. Diagnostic applicability of in vivo confocal la ser scanning microscopy in melanocytic skin tumors. J Invest Dermatol 2005;124:493- 498 \nGerger A, Koller S, Weger W, et al. Sensitivity and specificity of confocal laser -scanning microscopy for in vivo diagnosis of malignant skin tumors. Cancer 2006;107:193 -200 \nGerger A, Wiltgen M, Langsenlehner U, et al. Diagnostic image analysis of malignant melanoma in in vivo confocal laser -scanning microscopy: a preliminary study. Skin Res Technol \n2008;14:359- 363 \nKoller S, Wiltgen M, Ahlgrimm -Siess V, et al. In vivo ref lectance confocal microscopy: automated diagnostic image analysis of melanocytic skin tumours. J Eur Acad Dermatol Venereol \n2010  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 36 von 817 \nLangley RG, Walsh N, Sutherland AE, et al. The diagnostic accuracy of in vivo confocal scanning laser microscopy compared to de rmoscopy of benign and malignant melanocytic lesions: \na prospective study. Dermatology 2007;215:365- 372 \nLorber A, Wiltgen M, Hofmann -Wellenhof R, et al. Correlation of image analysis features and visual morphology in melanocytic skin tumours using in vivo confocal laser scanning \nmicroscopy. Skin Res Technol 2009;15:237- 241 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 37 von 817 \n \n2.3. Frage I.6., I.7., I.8., VII.6.  Ausbreitungsdiagnostik bei Patienten mit malignem Melanom  \u2013 \nDe-novo -Recherche  \nFrage I.6.  Welche Ausbreitungsdiagnostik ist bei asymptomatischen Patientie n bei Diagnose des Prim\u00e4rtumors bis Stadium IIA/ab Stadium IIB  \nindiziert? \nFrage I. 7. Welche Ausbreitungsdiagnostik ist bei Patientien mit Verdacht auf bzw. Nachweis von lokoregionaler Metastasierung indiziert? \nFrage I. 8. Welche Ausbreitungsdiagnostik ist b ei Patientien mit Verdacht auf bzw. Nachweis von Fernmetastasen indiziert? \nFrage VII .6. Welche Unersuchungen sind im Rahmen der Nachsorge bei asymptomatischen Patienten indiziert? \nF\u00fcr die Fragen I.7 und I.8 fand 2015 eine Aktualisierungsrecherche statt.  \n2.3.1.  PICO, Suchw\u00f6rter  \nVerfahren:  \n- LK-Sono  \n- R\u00f6ntgen -Thorax  \n- Abdomen -Sono  \n- MRT \n- CT \n- PET \n- PET/CT  \n- Szintigraphie  \n- Labor  \n \nPICO -Unterf ragen:  \n- Wie ist die Sensitivit\u00e4t und Spezifit\u00e4t des Verfahrens  zur Diagnose von Metastasen des MM bei Prim\u00e4rdiagnose?  \n- \u00c4ndert die Durchf\u00fchrung de s Verfa hrens  bei Patienten mit Prim\u00e4rdiagnose des MM das Krankheitsstadium?  \n- \u00c4ndert die Durchf\u00fchrung des Verfahrens bei Patienten mit Prim\u00e4rdiagnose des MM die Therapie?  \n- \u00c4ndert die Durchf\u00fchrung des Verfahrens bei Patienten mit Prim\u00e4rdiagnose des MM das \u00dcber leben?  \n- Wie hoch sind die zus\u00e4tzlichen Kosten bei Durchf\u00fchrung des Verfahrens bei Patienten mit Prim\u00e4rdiagnose des MM?   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 38 von 817 \n2.3.2.  Datenbanken, Suchstrategie, Trefferzahlen  \n2.3.2.1.  Prim\u00e4rrecherche 2012  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche   Der letzten \nUpdate-\nRecherc he: \n Insgesamt \n(Update-\nRecherche)  \nMedline  \"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND \n((\"ultrasono graphy\"[Mesh] OR \"ultrasonography\"[all fields] OR \n\"sonography\"[all fields]) OR (\"lymph nodes\"[all fields] OR (\"lymph\"[all fie lds] \nAND \"nodes\"[all fields]) OR \"lymph nodes\"[all fields] OR (\"lymph\"[ all fields] \nAND \"node\"[all fields]) OR \"lymph node\"[all fields]))  \n \n\"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND \n(\"chest X -ray\"[all fields] OR \"chest radi ography\"[all fields] OR \"Radiography, \nThoracic\"[Mesh])  \n \n\"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND \n((\"ultrasono graphy\"[Mesh] OR \"ultrasonography\"[all fields] OR \n\"sonography\"[all fields]) OR \"abd omen\"[all fields] OR \u201cabdomin al\"[all fields]) \nNOT (\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye neoplasms\"[Mesh])  \n \n\"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND \n(\"Magnetic Resonance Imaging\"[Mesh] OR \u201cMagnetic Resonance Imaging\u201d[all \nfields] OR \u201cmri\u201d[all f ields] OR \u201cmagnetic resonance\u201d[all fields]) NOT \n(\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye neoplasms\"[Mesh])  \n \n\"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND \n(\u201cTomography, X -Ray Computed\"[Mesh] OR \u201ccomputer tomography\u201d[all 26.01.2012  3153  \n \n \n \n \n \n83 \n \n \n \n588 \n \n \n \n \n595 \n \n \n \n \n936 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 39 von 817 \nDatenbank  Suchstrategie  Datum  Treffer \nfields] OR \u201cct\u201d[all fields] OR \"Tomography, Spiral Computed\"[Mesh] OR \n\"Tomography Scanners, X -Ray Compu ted\"[Mesh] OR \"Positron -Emission \nTomography\"[Mesh] OR \u201cpositron -emission tomogr aphy\u201d[all fields] OR \n\u201cpet\u201d[all fields] OR \"Tomography, Emission -Computed, Si ngle-Photon\"[Mesh] \nOR \u201csingle -photon emission computed tomography\u201d[all fields] OR \u201cspect\u201d[all \nfields]) NOT (\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye \nneoplasms\"[Mesh])  \n \n\"melanoma\"[tiab] AND (\u201cstaging\u201d[ tiab] OR \"diagnosis\"[ tiab]) AND \n(\"scintigraphy\u201d[ t iab] OR \u201cscinti*\u201d[tiab]) NOT (\"ophthalmology\"[Mesh] OR \n\"eye\"[Mesh] OR \"eye ne oplasms\"[Mesh])  \n \n\"melanoma\"[tiab] AND (\"LDH\"[all fields] OR \u201clactate dehydrogenase\u201d OR \n\"S100\"[all fields] OR \"MIA\"[tiab] OR \"melanoma- inhibiting activity\"[tiab]) \nAND (\u201cstaging\u201d[al l fields] OR \"diagnosis\"[all fields]) NOT \n(\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye ne oplasms\"[Mesh])  \n  \n \n \n \n \n \n \n \n66 \n \n \n \n594 \n \n \n \nCochrane Library  (melanoma and (staging or diagnosis) and (\"chest x -ray\" or \"ch est \nradiography\")).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (\"ultrasonography\" or \n\"sonography\" or \"ultr asound\" or sonogr*)).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (\"magnetic resonance\" or \nmri)).ti,ab. \n \n(melanoma and (staging or diagnosis)  and (\u201ccomputer tomography\u201d or ct or \n\u201cpositron emission tomography\u201d or pet or spect or \u201csingle -photon emission \ncomputed tomography\u201d or \u201cspect ct\u201d or \u201cpet ct\u201d)).ti,ab.  \n 19.01.2012  7 \n \n \n7 \n \n \n5 \n \n \n9 \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 40 von 817 \nDatenbank  Suchstrategie  Datum  Treffer \n(melanoma and (staging or diagnosis) and (scintigraphy or scinti*)).ti,ab.  \n \n(melanoma an d (staging or diagnosis) and (ldh or \"lactate dehydrogenase\" \nor s100* or mia or \"melanoma inhibiting activity\")).ti,ab. \n \n 4 \n \n10 \n \n \n \nEmbase  (melanoma and (staging or diagnosis) and (\"chest x -ray\" or \"chest \nradiography\")).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (\"ultrasonography\" or \n\"sonography\" or \"ultr asound\" or sonogr*)).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (\"magnetic resonance\" or \nmri)).ti,ab. \n \n(melanoma and (staging or diagnosis) and (\u201ccomputer tomography\u201d  or ct or \n\u201cpositron emission tomography\u201d or pet or spect or \u201csingle -photon emission \ncomputed tomography\u201d or \u201cspect ct\u201d or \u201cpet ct\u201d)).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (scintigraphy or scinti*)).ti,ab.  \n \n(melanoma and (staging or diagnosis) an d (ldh or \"lactate dehydrogenase\" \nor s100* or mia or \"melanoma inhibiting activity\")).ti,ab. 23.01.2012  79 \n \n \n546 \n \n \n431 \n \n \n777 \n \n \n \n142 \n \n317 \nBemerkungen: Datum der Erst -Recherche f\u00fcr Medline und Cochrane war der 17.08.2010. Die erste EMBASE -Recherche erfolgte  am 11.05.2011. Eine letzte \nUpdate -Recherche (initiale Suche, Erg\u00e4nzungsrecherche) erfolgte am 23.01.2012 f\u00fcr EMBASE, am 26.01.2012 f\u00fcr Medline bzw. am 19.01.20 12 f\u00fcr Cochrane. In \nden Tabellen angegeben sind die Za hlen der letzten Update- Recherche.  \nBez\u00fcgli ch Tumor -Marker:  da eine Meta -Analyse (Mocellin et al. 2008) vorliegt, wurden lediglich Studien eingeschlossen, die nicht in der Meta -Analse enthalten \nwaren, die nach der Metaanalyse erschienen sind oder die bestimmte Teilaspekte abdecken, die in der Meta -analyse nicht ber\u00fccksichtigt wurden.  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 41 von 817 \nDatenbank  Suchstrategie  Datum  Treffer \nBez\u00fcglich PET und PET/CT:  Die erste systematische Recherche zeigte zwei Meta -Analysen (Krug und Jimenez -Requena). Einzelne Studien wurden nur mit \naufgenommen, s ofern sie noch nicht in diesen beiden Meta -analysen entha lten waren oder Aspekte beinhalteten, die aus den Meta -analysen nicht hervorgingen. \nDa die Meta -Analyse von Xing erst im Rahmen einer Update -Recherche identifiziert wurde, sind einzelne Studien, die in der Meta -analyse enthalten sind, auch in \ndieser Tabelle aufgef\u00fchrt. Die Studien sind jedoch gekennzeichnet und haben einen dementsprechend schlechteren Ev idenzgrad.  \n \nBei gleicher Suchstrategie zu den Fragen I.6, I.7, I.8 und VII.6 und teils \u00dcberschneidungen der Studien sind alle relevanten Recherche -Ergebniss e in dieser \nTabelle zusammengefasst. Eine \u00dcbersicht \u00fcber die Zuteilung der Studien zu den verschiedenen Fragestellungen befindet sich am Ende der Tabe lle. \n \n2.3.2.2.  Aktualisierungsrecherche 2015  f\u00fcr I.7. und I.8  \nDatenbank  Suchstrategie  Datum  Treffer \nMedline  ((((\"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND((\"ultrasonography\"[Mesh] OR \n\"ultrasonography\"[all fields] OR\"sonography\"[all fields]) OR (\"lymph nodes\"[all fields] OR (\"lymph\"[all fields] \nAND \"nodes\"[all fields]) OR \"lymph nodes\" [all fields] OR (\"lymph\"[ all fields] AND \"node\"[all fields]) OR \"lymph \nnode\"[all fields])))) AND (\"2012.01.27\"[Date -  Publication] : \"3000\"[Date - Publication]))) \n \n((\"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND(\"chest X -ray\"[all fields] OR \"chest \nradiography\"[all fields] OR \"Radiography,Thoracic\"[Mesh]))) AND (\"2012.01.27\"[Date -  Publication] : \n\"3000\"[Date - Publication])  \n \n((\"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND((\"ultrasonography\"[Mesh] OR \n\"ultrasonography\"[all fields] OR\"sonography\"[all fields]) OR \"abdomen\"[all fields] OR \u201cabdominal\"[all \nfields])NOT (\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye neoplasms\"[Mesh]))) AND (\"2012.01.27\"[Date -  \nPublication] : \"3000\"[Date -  Publication])  \n \n((\"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND (\"Magnetic Resonance \nImaging\"[Mesh] OR \u201cMagnetic Resonance Imaging\u201d[all fields] OR \u201cmri\u201d[all fields] OR \u201cmagnetic resonance\u201d[all \nfields]) NOT (\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] O R \"eye neoplasms\"[Mesh]))) AND (\"2012.01.27\"[Date -  16.09.2015  716 \n \n \n \n \n14 \n \n \n \n170 \n \n \n \n \n192 \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 42 von 817 \nPublication] : \"3000\"[Date -  Publication])  \n \n((\"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND (\u201cTomography, X -Ray \nComputed\"[Mesh] OR \u201ccomputer tomography\u201d[all fields] OR \u201cct\u201d[ all fields] OR \"Tomography, Spiral \nComputed\"[Mesh] OR \"Tomography Scanners, X -Ray Computed\"[Mesh] OR \"Positron -\nEmissionTomography\"[Mesh] OR \u201cpositron -emission tomography\u201d[all fields] OR\u201cpet\u201d[all fields] OR \n\"Tomography, Emission -Computed, Single -Photon\"[Mes h] OR \u201csingle -photon emission computed \ntomography\u201d[all fields] OR \u201cspect\u201d[all fields]) NOT (\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye \nneoplasms\"[Mesh]))) AND (\"2012.01.27\"[Date -  Publication] : \"3000\"[Date -  Publication])  \n \n((\"melanoma\"[tiab] AND (\"LDH\"[all fields] OR \u201clactate dehydrogenase\u201d OR\"S100\"[all fields] OR \"MIA\"[tiab] OR \n\"melanoma -inhibiting activity\"[tiab]) AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) NOT \n(\"ophthalmology\"[Mesh]OR \"eye\"[Mesh] OR \"eye neoplasms\"[Mesh]))) AND (\"2012.01.27\"[Date - Publication] : \n\"3000\"[Date - Publication])   \n \n386 \n \n \n \n \n \n \n \n3 \n \n \nCochrane \nLibrary  (melanoma and (staging or diagnosis) and (\"chest x -ray\" or \"chest radiography\")).ti,ab.  \n \n(melanoma and (staging or diagnosis) and  (\"ultrasonography\" or \"sonography\" or \"ultr asound\" or \nsonogr*)).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (\"magnetic resonance\" or mri)).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (\u201ccomputer tomography\u201d or ct or \u201cpositron emission tomography\u201d  \nor pet or spect or \u201csingle -photon emission computed tomography\u201d or \u201cspect ct\u201d or \u201cpet ct\u201d)).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (scintigraphy or scinti*)).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (ldh or \"lactate dehydrogenase\" or s10 0* or mia or \"melanoma \ninhibiting activity\")).ti,ab.  16.09.2015 7 \n \n18 \n \n \n14 \n \n20 \n \n \n4 \n \n11 \n \nDie Update -Literatur -Recherche erfolgte am 16.09.2015 und schloss alle Studien mit ein, die ab dem 26.01.2012 auf Medline bzw. ab 2012 auf Cochran e \nerschienen sind.  E s wurden nur Studien aufgenommen, die einen hohen Evidenzlevel besitzen. Da in Hinblick auf die apparative Diagnostik keine r andomisiert \nkontrollierten Studien vorliegen, wurde in diesem Fall ein \u201ehohes Evidenzlevel\u201c bis LoE von 2b definiert.    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 43 von 817 \n2.3.3.  Auswahlkri terien  \n2.3.3.1.  Prim\u00e4rrecherche 2012  \nAuswahl der Literatur  \nGesamttre ffer 8349  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports, narrative Reviews, Bench Research  \nAnzahl nach Abstractscreening  296 \nAnzahl ausgew\u00e4hlt er Volltexte, vorges ehen f\u00fcr Bewertung  114 \n \n2.3.3.2.  Aktualisierungsrecherche 2015  \nAuswahl der Literatur  \nGesamttre ffer 1555  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports, narrative Reviews, Bench Research  \nAnzah l nach Abstractscreening  1202  \nAnzahl ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewertung  3  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 44 von 817 \n2.3.4.  Evidenztabelle (zusammengefa\u00dft f\u00fcr I.6., I.7., I.8., VII.6.)  \n2.3.4.1.  Prim\u00e4rrecherche 2012  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSubtopic  \nLYMPH NODE \nULTRASOUND         \nXing et al. (2011)  To examine the \nutility of \nultrasonography, \ncomputed \ntomography (CT), \npositron emission \ntomography (PET), \nand a combination \nof both (PET -CT) \nfor the staging and \nsurveillance of \nmelanoma \npatients.  Systematic review \nand met a-analysis  \n 10 528 patients \nwith cutaneous \nmelanoma at \nprimary diagnosis \nor under \nsurveillance \n(follow -up) Sensitivity, \nspecificity  \nDiagnostic odds\u2019 \nratio (OR)  Data for initial \nstaging of regional \nnodes:  \nSensitivity 60%  \nSpecificity 97%  \nDiagnostic OR 42  Very large patient \ncohort, but \npatients under \nfollow -up included  \n \n 1a \nBafounta et al. \n(2004)  To investigate \nwhether lymph -\nnode \nultrasonography \nimproves \ndetection of nodal \ninvasion during \nthe initial staging Systemati c review \nand meta -analysis \nof 12 published \ndiagnostic studies \nuntil December \n2003   6642 patients  \nPredominantly \nstage I and II, six \nstudies also stage \nIII, very few (1.9% \nin one study) stage \nIV Sensitivity and \nspecificity  \nOdds\u2019 ratios  \nPositive and \nnegativ e likelihood \nratios  Odds ratio of \nsonography: 1755 \n(95% CI 726 \u20134238)  \nOdds\u2019 ratio of \npalpation 21 (4 \u2013\n111) \nSonography:  \nPositive likelihood Variations in the \ndefinition of false \nnegatives and \nverification bias in \nincluded studies \n \n 1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 45 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nand follow -up of \npatients with \nmelanoma.  ratio 41.9, \nnegative likelihood \nratio 0.024  \nPalpation: \nPositive likelihood \nratio 4.55, \nnegative likelihood \nratio 0.22 \nVoit et al. (2010)  The aim of this \nstudy was to \nevaluate a number \nof specifically \ndefined \nmorphology US \npatterns and to \ncorrelate this with \ntumor involvement \nof the SN.  Prognostic and \ndiagnostic study  400 patients with \nCM before SLNE  Sensitivity, \nspecificity  \nPositive predictive \nvalue, negative \npredictive value  \nOverall and \ndistant -metastasis -\nfree survival  \n Highest sensitivity \nand PPV in \nfollowing \ncombination: \nprese nce of \nperipheral \nperfusion, loss of \ncentral echoes, \nand balloon -\nshaped lymph \nnodes  \nSensitivity 82%  \nSpecificity 80%  \nPPV 52%  \nNPV 94%  \n5-year OS \naccording to \nperipheral \nperfusion 81% and \n92% for present \nand absent  \n5-year OS for the Preliminary report \n(400 of 650 \npatients)  \n \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 46 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nloss of central \nechoes 49%  vs. \n92% when echoes \nstill present  \n5-year OS rates for \nthe presence and \nabsence of a \nballoon -shaped \nlymph node 48% \nand 92%  \nSibon et al. (2007)   To evaluate the \nability of high -\nresolution \nultrasonography \n(hrUS) to detect \nsentinel -node (SN) \nmelanoma \nmetastases \npreoperatively \nbefore sentinel -\nnode biopsy (SNB), \nto define hrUS \nresolution, and to \nevaluate which US \ncriteria should be \nused.  Diagnostic study  \n 131 consecutive  \npatients with 132 \n\u22651-mm thick or \nulcerated CM  \n Sensitivity and \nspecificity  \nPositive and \nnegative predictive \nvalue  \nPositive and \nnegative likelihood \nratios  Targeted high -\nresolution \nsonography for the \ndetection of SLN:  \nStringent criteria: \nSensitivity 8.8%  \nSpecificity 95.9%  \nPPV 42.9%  \nNPV 75.2%  \nNon-string ent \ncriteria: \nSensitivity 20.6%  \nSpecificity 89.8%  \nPPV 41.2%  \nNPV 76.5%  Patients with \nmucosal \nmelanoma \nincluded  \n \n 1b \nSaiag et al. (2005)   (1) to compare the \nrespective ability \nof ultrasonography Diagnostic study  160 consecutive \npatients with stage \nI to stage III CM  Sensitivity, \nSpecificity  Sonography:  \nSensitivity 76.9%  \nSpecificity 98.4%  Patients with \nmucosal \nmelanoma 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 47 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nand palpation to \ndetect nodal \nmetastasis during \ninitial stagin g and \nfollow -up in \npatients having \nmelanomas  \n(2) to assess which \nultrasound criteria \nshould be used to \ndefine metastasis \nin cases of \ncutaneous or \nmucosal \nmelanoma  \n(3), because scar \ntissue can modify \nultrasonographic \nimages, to \nevaluate whether \nultrasonography \nremains useful \nonce patients have \nundergone radical \nLD  \n Palpation:  \nSensitivity 41.5%  \nSpecificity 95.7%  \n included  \n \n \nStoffels et al. \n(2011 ) to clarify the \nreliability of \npreoperative \nultrasonography \n(US) in direct  Diagnostic study  221 patients with \nprimary malignant \nmelanoma with a \nBreslow  \nindex of >= 1.0 Sensitivity  \nSpecificity  \nPPV \nNPV US: \nSensitivity : 13.6%  \nSpecificity: 96.9%  \nPPV: 97.2%  \nNPV: 12,6%  Reference \nstandard for SLNE \nnot described  \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 48 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncomparison to the \nresult of SLNE and \nseeks to identify \npotential \nadvantages of \npreoperative \nultrasound if \nperformed  in \nconjunction with \nlymphoscintigraph\ny in detecting \nmalignant \nmelanoma \nmetastases in \nsentinel lymph \nnode (SLN).  mm  \nSLNE alone:  \nSensitivity: 94%  \nSpecificity: 98.6%  \nPPV 100%  \nNPV 98,3%  \n \nPreoperative US in \nconjunction with \ndynamic \nlymphoscintigraph\ny, followed by \nSLNE:  \ndetecting ratio: \n100% (n = 28) for \nmicrometastases,  \n98.6% (n = 42 \u2044 43) \nfor \nmacrometastases  \nHinz et a. (2011)   To evaluate \nwhether high -\nresolution \nultrasound \ncombined  \nwith power \nDoppler \nsonography (PDS) \nis an appropriate \ntool for \npreoperative Diagnostic study   81 consecutive \npatients with CM \nin whom \ndissection of SLNs \nwas indicated \nunderwent \nultrasound \nexaminations \nbefore and after \nthe preoperative \nlymphoscintigraphsensitivity, \nspecifity, \nPPV, NPV  \n \npositive likelihood \nratio \n \nnegative likelihood \nratio A total of 170 \nSLNs (mean 2.1 \nper patient) were \nremoved and \nexamined by \nhistopathology.  \n \nsensitivity, \nspecifity, \nPPV, NPV of \nultrasound: 22.2% patient cohort with \nonly 9 positive \nSLNs in total  \n \nNo information \nabout follow -up 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 49 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nidentification and \ncharacteriz ation of \nsentinel lymph \nnodes (SLNs) in \npatients with \ncutaneous \nmelanoma.  y. (95% CI = 2.8 \u2013\n60.0), 100% (9 5% \nCI = 97.7 \u2013100.0), \n100.0% (95% CI = \n15.8\u2013100.0), and \n95.8% (95% CI = \n91.6\u201398.3), \nrespectively. \n \npositive likelihood \nratio: 0  \n \nnegative likelihood \nratio: 0.78.  \nChai et a l. 2011  To assess \nfeasibility and \nstaging  \nresults of clinically \ntargeted \nultrasound (before \nlymphoscintigraph\ny) compared to \nSLNB.  Diagnostic study  325 patients with  \nmelanoma \nunderwent \nultrasound before \nSLNB without \npalpable \nlymphadenopathy \nin regional \nnoda l basins  Sensitivity, \nspecificity, PPV, \nNPV \n sensitivity of \nultrasound: 33.8%,  \nspecificity: 85.7%, \nPPV: 36.5%, NPV:  \n84.2%  \n No information \nabout time interval \nbetween US and \nSLNB  \n \nConfidence \ninterval not given  2b \nSanki et al. (2009)  To reassess \ntraditiona l \nultrasound \ndescriptors of \nsentinel lymph \nnode (SLN) Diagnostic study  716 CM patients  Sensitivity and \nspecificity  \nPositive and \nnegative predictive \nvalue  \nPositive and Targeted high -\nresolution \nsonography for the \ndetection of SLN:  \nSensitivity 24.3%  \nSpecificity 96.8%  Design \n(retrospective vs. \nprospective) not \ndescribed  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 50 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmetastases, to \ndetermine the \nminimum cross -\nsectional area \n(CSA) of an SLN \nmetastasis \ndetectable by \nultrasound (US), \nand to establish \nwhether targeted, \nhigh-resolution US \nof SLNs identified \nby \nlymphoscin tigraph\ny before initial \nmelanoma surgery \ncan be used as a \nsubstitute for \nexcisional SLN \nbiopsy.  negative likelihood \nratios  \nDiagnostic \naccuracy  PPV 60.3%  \nNPV 86.2%  \nDiagnostic \naccuracy 86.7%  \nTestori et al. (2005)  (1) To obtain, \nusing US, a pre -\noperative \nindication of the \npresence or \nabsence of \nmetastatic \ndeposits in the \nsentinel node (SN); \n(2) to obtain, using Diagnostic study  \n Of 300 melanoma \npatients who \nunderwent SNB, 88 \nreceived \nsonography of the \nlymph nodes \npreoperatively  Sensitivity, \nspecificity  \nPositive and \nnegative  predictive \nvalue  Sensitivity 94.1%  \nSpecificity 89.8%  \nPPV 64%  \nNPV 98.7%  Inclusion criteria \nfor patients who \nreceived pre -\noperative \nsonography \nunclear  \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 51 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nUS, the precise \npre-operative \nlocation of \nsuperficial or \ndeep, or peculiarly \nsited, SNs; and (3) \nto evaluate the \nrole of US in the \nearly d iagnosis of \nfalsenegative SNs \n(i.e. recurrences in \nthe lymph node \nbasin)  \nduring follow -up. \nHocevar et al. \n(2004)  The aim of this \nstudy was to \nevaluate the ability \nof a \ncombination of US \nand U S-FNAB to \nstage the regional  \nlymph node basins \nin patients with \nMM. Diagnostic study  \n 57 patients with \nCM, in whom SLN \nbiopsy was \nplanned  Sensitivity and \nspecificity  \nPositive and \nnegative predictive \nvalue  Sensitivity 71%  \nSpecificity 84%  \nPPV 59%  \nNPV 90%  Risk of verification \nbias \n \nDesign of study \nnot described \n(retrospective \nversus \nprospective)  \n \n 2b \nHafner et al. (200 4) To evaluate the \nsensitivity and \nspecificity of \nbaseline staging in \nthe early detection Diagnostic study  100 consecutive \npatients with CM > \n1.0 mm  \n Sensitivity, \nspecificity  \nPositive and \nnegative predictive \nvalue  Sensitivity 8%  \nSpecificity 88%  \nPPV 18%  \nNPV 73%  Risk of verification \nbias \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 52 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nof \nregional lymph \nnode metastases \nor distant \nmetast ases in \npatients with MM.  \nKunte et al. (2009)  The aim  of this \nstudy was to \nevaluate the ability \nof high resolution \nB-mode \nultrasonography \n(US) for pre -\noperative \nidentification and \ncharacterization of \nsentinel lymph \nnodes (SLN) in \npatients with \ncutaneous \nmelanoma.  Prospective \ndiagnostic study  \n 25 consecutive \npatients before \nSLN for CM  Sensitivity, \nspecificity  \nPositive and \nnegative predictive \nvalue  Sensitivity 33.3%  \nSpecificity 100.0%  \nPPV 100.0%  \nNPV 87.9%  Risk of verification \nbias \n \nSmall patient \ncohort \n 3b \nSchmid -Wendtner  \net al. (2004)  to evaluate \nwhether si gnal \nenhanced color \nDoppler \nsonography (CDS) \nis superior to \nnative CDS in \ndetection of Diagnos tic study  \n \n \n \n \n 22 melanoma \npatients  Sensitivity  \nSecificity  signal -enhanced \nsonography : \nsensitivity = \n92.3%, \nspecificity=100.0%\n. For melanoma \nmetastases, a \nsensitivity of Prospectiv e two -\ncenter study  \n \nlack of \nhistopathologic \ncorrelation in all \npresumptive  \nsonographic 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 53 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncharacteristic \nvascularity \npatterns that are \nimportant for the \ndifferentiation \nbetween benign \nand malignant \nlymphadenopathy \nin patients with \ncutaneous \nmelanomas.  90.0% and a \nspecificity of \n85.7% was \ncalculated. For \nboth P -values \n<0.05  diagnoses  \n \nsmall study group  \n \nsensitivity and \nspecifity of native \nCDS not given  \n \nstudy inclinded in \nXing et al. 2011 \nUren (1999)  \n \n to determine if \nhigh-resolution \nultrasound could \nidentify \nmetastases in \nnewly palpable \nlymph nodes \nfound during \nclinical follow -up \nfor melanoma, and \nto define the \nultrasound \nfeatures that were \nassociated with \nthis diagnosis  Diagnostic study  \n \n 52 patients  \n(61 individual \nnode fields)  \n \n \n  Ultrasound \nfeatures in \nmetastatic lymph \nnodes \n \nSensitivity  \n \nspecifity  specifity = 87%  \nsensitivity = 94%  \naccuracy = 89%  \n \nIf presence of 2 \nUS-features (=node \nthicker greater \nthan two -third of \nthe length and \nlow-level internal \nechos) were \npresent: Sensitivit y \n= 94%, specifity = \n100%, accuray 98%  No information \nabout the time \ninterval between \nultrasound and \nFNAB/excision \nbiopsy  \n \nSmall population  \n \nDifferent \nexamined fields: \naxilla, groin, \nsupraclaviculaire, \nsubmental, \ncervical  \n \nstudy inclinded in \nXing et al. 2 011 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 54 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSubtopic  \nCHEST X -RAY        \nWang et al. (2004)  To examine the \nyield of a chest \nradiograph and \nserum lactate \ndehydrogenase \n(LDH) in the work -\nup for newly \ndiagnosed \nlocalized \nmelanoma, and to \ninvestigate how \noften the results of \nchest radiograph \nand LDH alter the \ninitial surgical \nmanagement.  Diagnostic study  \n 210 CM patients \nwithout clinical \nevidence of \nmetastasis  \n False positives  \nAlteration of \nsurgical \nmanagement  False positives \n15/210 (7%)  \nAlteration of \nsurgical \nmanagement in 0%   \n 2b \nHafner et a l. (200 4) \n See above  Diagnostic study  100 consecutive \npatients with CM > \n1.0 mm  \n Sensitivity, \nspecificity  \nPositive and \nnegative predictive \nvalue  Sensitivity - \nSpecificity 96%  \nPPV 0%  \nNPV 100%  study inclinded in \nXing et al. 2011 2b \n \nVermeerenet  et al. \n(2011 ) to evaluate \ntherapeutic \nconsequences of \npreoperative \nstaging with Chest diagnostic study  248 medical \nrecords of patients \ntreated for primary \nmelanoma  \n False positives  Preoperative CXR \ndid not identify \npulmonary \nmetastasis and did \nnot change Reference \nstandard: \ncomplementary \nradiodiagnostic  \nimaging and/or 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 55 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nX-ray (CXR) in \npatients with a \nprimary melanoma \nplanned for \nsentinel node \nbiopsy (SNB).  CXR in 227 \npatients  \n \nCXRs were made \nprior to SNB  planned treatment \nstrategies. In 5%, \nthe CXR was  \ninconclusive \uf0e0 \nfalse positives  follow -up. \n \n \n \nPanagiotou et al.  \n(2001 ) To determine \nwhich imaging \nmodalities should \nbe performed \nduring the \nevaluation of \npatients with local-\nregional malignant \nmelanoma  Retrospective \nstudy  158 asymptomatic \npatients submitted \nto at leas t a chest \nX-ray, an \nabdominal US and \na CT of the chest, \nabdomen and \npelvis  true-positive and \nfalse-positive rate  \n TP: 26.6%  \nFP: 7.6%  \nIn 12% CT was the \nonly imaging \nmodality depicting \nmetastases \n \nhighest positive \nyield \n \nDuring the \nsurveillance \nperiod, 118 \nasymptomatic \npatients relapsed.  \n \nDetection of \nrelapse:  \n.- in 33.1% by \nphysical \nexamination  \n- in 38.1% by chest \nX-ray \n- in 16,9% by  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 56 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nabdominal CT  \nYancovitz et al. \n(2007)  To investigate \nwhether initial \nimaging led to a \nchange in stage or \ntreatment pla n  Diagnostic study  158 patients, 135 \nwith stage I/II \ndisease and 23 \nwith stage III \ndisease  \n True and false \npositives and \nnegatives  True positives 0/7 \n(0.0%),  \nFalse -positives 5/7 \n(71.4%) \nTrue negatives \n112/126 (88.9%)  \n2/126 lost to \nfollow -up study include d in \nXing et al. 2011 3b \nTsao et al. (2004)  To determine if \nearlier detection of \npulmonary \nmetastasis by \nroutine chest \nradiography (CR) is \nassociated with a \nprolonged \nsurvival.  Case-control study  \n 994 CM patients in \nstages I \u2013  IV  Overall survival  28/1938  chest x -\nrays leading to \nfirst diagnosis of \nCM stage IV (1.4%) \nOverall survival \naccording to \nKaplan -Meier \ncurve: no \ndifference between \npatients with \nknown stage IV at \nthe time of \ndiagnosis and \ninitial diagnosis of \nstage IV by x -ray \nFalse positives (of \nall x-rays): 3.5%  Cohort consisting \nof stage I \u2013  IV \npatients  \n \n 3b \nHofmann et al. \n(2002 ) Assessment of the \nperformance, Diagnostic study \nwith historical 661 patients \n(stage I/II: 630 True and false \npositives and 524 total chest x -\nrays Diagnostic \nstandard 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 57 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncosts and survival \nbenefits of staging \nmethods (history \nand physical \nexamination; chest \nX-ray; \nultrasonography of \nthe abdomen; high \nresolution \nsonography of the \nperipheral lymph \nnodes) at initial \nstaging and during \nfollow -up of stage \nI/II+III disease.  cohort; economical \nevaluation  \n patients, stage III: \n27 patients, stage \nIV: 4 pati ents)  negatives  \nDetection rate  \nCost-efficiency of \nimaging \nprocedures \nSurvival 1 true positive \n(0.2%) \n23 false positives \n(4.4%) \nDetection rate \n3.2% \nCost of chest x -ray \nat initial staging: \n11761 EUR  \n(1887 E UR due to \nfalse positive \nresults)  procedures varied \nover time; no \ndefined gold \nstandard of \ndiagnosis  \n \n \nTerhune et al. \n(1998 ) To evaluate the \nuse of an initial \nstaging chest x -ray \nfilm in \nasymptomatic \npatients who \npresent with \nlocalized primary \ncutaneous \nmelanoma.  Diagnostic study  \n 876 CM patients at \ninitial staging  \n \n True and false \npositives  \n. 130/876 (15%) \npatients with \nsuspicious \nfindings  \nAdditional workup \nled to 1/876 true \npositives (0.1%)  \n129/876 false \npositives (14.7%)  X-rays not \nobtained from all \npatients  \n\u201cInitial\u201d chest x -ray \nup to 6 months \nafter diagnosis  \n \n 3b \n \nIscoe et al. (1986)   The description of \npredictive value of \nclinical, laboratory \nand radiologic Diagnostic study  \n 393 consecutive \nCM patients  True and false \npositives  \nPositive and \nnegative predictive Number of chest \nx-rays: 345  \nTrue positives: 0  \nFalse positives: 8  Index test s not \ncarried out on all \npatients  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 58 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ninvestigations in \nthe staging of \npatients with \nclinical stage I \nmelanoma.  value  Positive predictive \nvalue: 0%  \nNegative predictive \nvalue: 97.6%   \nKhansur et al. \n(1989 ) To evaluate the \nrole of staging \nworkup in primary \nand recurrent \nmalignant \nmelanoma.  Diagnostic study  \n 115 patients with \nprimary CM (72 in \nlocalized stage) \nand 28 patients \nwith recurrent \ndisease   True and false \npositives  0/72 true positives  \n2/72 false \npositives (3%)  Criteria for \nselecting staging \nexaminations \nunclear  \n \n 3b- \nArdizzoni et al. \n(1987 ) To evaluate the \nyield, in terms of \ncost-benefit -ratio, \nof a multimodal \nstaging procedure \nconsisting of \nmultiple nuclear \nscans, chest X -ray \nand abdominal \nultrasonography to \ndetect silent \nmetastases in \nasymptomatic \nmelanoma patients  Diagnostic study  116 patients; \nclinically 93 in \nstage I and 23 in \nstage II  True and false \npositives and \nnegatives  \n Positive results: 0 \nof 116 chest x -\nrays \n0% true positives  \n0% false positives  \n2 patients with \nlung metastases \nlater in follow -up \n=> 2% false \nnegatives, 98% \ntrue negatives  Design \n(prospective vs. \nretrospective) not \nclear  \nFollow -up time not \ngiven  \n \n 3b- \nMeyer and Stol bach \n(1978 ) To evaluate \nradiographic \nevaluation for the Diagnostic study  \n 53 CM patients \nwithout symptoms \nto suggest distant True and false \npositives  4/53 true positives \n(8%) \n0 false positives  Cohort probably \nincluded patients \nwith lymph node 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 59 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nrecognition of \noccult sites of \nmetastatic disease \nbeyond the \nregional nodes in \nmalignant \nmelanoma.  metastasis   metastases  \n \n \nZartman et al. \n(1987 ) To answer the \nquestion whether \nextensive \ndiagnostic staging \nprocedures are \njustified for \npatients with \nprimary diagnos is \nof melanoma  Cohort study  90 CM patients \nwith level III and IV \nlesions  Positive results  No positive results \nfor chest x -ray Patients with \ncomplete staging \nincluded; \nindications for \ndifferent staging \nexaminations \nunclear  \n 4 \n \nGoerz et al. (1986)  To inve stigate \nwhich staging and \nfollow -up \nexaminations are \nnecessary for \npatients with \nmalignant \nmelanoma.  Diagnostic study  \n 378 patients with \nhistologically \nconfirmed CM \n(stage not given)  True and false \npositives  0% positive results \nfor chest x -ray at \ninitial s taging  \n \nDuring follow -up \nexaminations, \ndistant metastasis \nwas proven in \n34/378 patients, \nin 32 of them by \nphysical \nexamination, in 2 \nby chest x -ray.  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 60 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nKersey et al. (1985 ) To determine the \nvalue of staging \nand serial follow -\nup investigations \nin newly \ndiagnosed patients \nwith completely \nexcised primary \ncutaneous \nmalignant \nmelanoma  Diagnostic study  \n 393 patients at \nprimary diagnosis \nof CM  True and false \npositives  True positives 0  \nFalse positives \n8/345 (2%)  Extent of staging \nexaminations and \nextent/ length of \nfollow -up \ndepended on \ncenter and tumor \nsite \n \n 3b- \nCollins et al. (1993 ) \n to determine \nwhether the \ndetection of \nmetastatic disease \nwould be reduced \nif the lateral \nprojection were \nnot obtained.  Diagnostic study  follow -up of 227 \nconsecutive \npatients.  \n \n number of suspect \nlesions in PA and \nlateral radiographs  In 1 case  \nwas an \nabnormality \nevident on the \nlateral radiograph \nwhich was not \npreviously \ndetected on the PA \nfilms  \n \nNormal PA and \nlateral radiograph: \n60,8%. \nAbnormality \nequally visible on \nPA and lateral \nradiograph: 16,7%.  \nAbnormality more \neasily visualized Sensitivity and \nspecifity not given  \n \nNo reference test  \n \nPopulation not \ndescribed in detail  \n \nNo information \nabout the study \ndesign  \n \nNo information \nabout selection \ncriteria  \n \nSensitivity or \nspecificity  not \ngiven  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 61 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \non PA than on \nlateral radiograph: \n11%. \nAbnormality more \neasily visualized \non lateral than on \nPA radiograph: \n4,4%.  \nAbnormality on PA \nradiograph not \nvisualized on \nlateral projection \n6,6%. Abnormality \non lateral \nradiograph not \nvisualized on PA \nprojection: 0,44%   \nWebb (1977)  to describe the \nfrequency of \nradiographic \npatterns of \nthoracic \nmetastasis in  \npatients with \nmelanoma, and to \ncorrelate these \npatterns with the \nsymptoms, clinical \ncourse, and \nsurvival of the diagnostic study  \n \n 65 patien ts with \nmalignant \nmelanoma \nmetastatic to the \nthorax  \n radiographic \npatterns of \nthoracic \nmetastasis  \n \nSurvival rates  Abnormalities in \nchest x -ray in \n42/62 patients  \n  \n \nSurvival: see full-\ntext \n 11 patients \nreceived x -ray and \ntomogram  \n \nTissue specimen in \nonly 3 1 \n \nSmall population, \nasymptomatic \npatients included  \n \n 4 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 62 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npatients.  \nSubtopic  \nABDOMINAL \nULTRASOUND         \nHafner et al. (200 4)  See above  See above  100 consecutive \npatients with CM > \n1.0 mm  \n Sensitivity, \nspecificity  \nPositive and \nnegative predictive \nvalue  Sensitivit y - \nSpecificity 97%  \nPPV 0%  \nNPV 100%   2b \nPanagiotou et al. \n(2001 ) See above  See above  See above  See above  See above  See above  3b \nHofmann et al. \n(2002)  See above  See above  661 patients \n(stage I/II: 630 \npatients, stage III: \n27 patients, stage \nIV: 4 patient s) True and false \npositives and \nnegatives  \nDetection rate  \nCost-efficiency of \nimaging \nprocedures \nSurvival 487 total \nabdominal \nsonographies  \n2 true positive \n(0.4%) \n25 false positives \n(5.1%) \nDetection rate \n6.5% \nCost of chest x -ray \nat initial staging: \n16618 EUR  \n(6421 EUR due to \nfalse positive \nresults)  Diagnostic \nstandard \nprocedures varied \nover time; no \ndefined gold \nstandard of \ndiagnosis  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 63 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nPandalai et al. \n(2010 ) To evaluate the  \nclinical utility of \nstandardized \nradiographic \nstaging.  Diagnostic stuy  58 consecut ive \nasymptomatic \npatients with stage \nIII AJCC melanoma  \n \n \n. True- positive (TP) \nrate \nfalse-positive (FP) \nrate Initial staging \nexaminations: 9% \nTP, 91% FP  \n \nAll examinations: \n3% TP; 23% FP.  \n \nAnalyzed per \npatient, in 37 \n(64%) of 58 \npatients, >=1 \nexamination w as \ninitially reported \nas positive. 3 \npatients (5%) had a \nTP and 34 (59%) \nhad \u22651 FP report. \nThe positive \nreports of the \nstaging scans \ngenerated 45 \nadditional \nexaminations \n(0.78 per patient).  \n \nanalyzed by type \nof radiograph, the \n5 TP findings were \nfound in 3 (13% ) of \n23 suspicious \nchest CT scans, 1 Small sample size  \n \nSensitivity and \nspecificity not \ngiven  \n \nSmall number of \nMRI/CT of the \nhead, PET and \nbone scan  \n \nNo routine \nstandardized \nstaging procedure \nwas followed  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 64 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(5%) of 20 \nsuspicious \nabdomen and \npelvis CT scans, \nand in 1 (100%) of \n1 PET scans. Of \nthe 5 brain MRIs, 2 \nhead CT scans, \nand 1 bone scan \nthat were initially \nreported as \n\u2018\u2018suspicious,\u2019\u2019 \nnone was proven \nto be TP.  \n \nratio o f FP:TP: 34:3  \nKuan  et al. (1988 ) To emphasize the  \nsensitivity and \nspecificity of th e \nexaminations both \nfor the detection \nof space -\noccupying lesions \nand for the  \nassessment of \nextent of \nmetastatic disease  Retrospective \ncohort study  88 patients with \npathologically \nproven cutaneous \nmelanoma in \nvarious clinical \nstages  \n Sensitivity  \n \nspecificity  In patients who \nhad all 3 \nexaminations \n(n=24): Sensitivity \nin detecting intra -\nabdominal \nmetastasis:CT: \n94% vs. US: 62% \n(P< 0.05)  \nCT vs. LS: 38% (P< \n0.01)  \n \nIn patients with \nonly US and LS Poor information \nabout selection \ncriteria and \npopulation  \n \nPoor data about \npatients` follow -\nup \n \nSmall population  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 65 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(n=64):  \nSensitivity US: 88% \nvs. LS 54% (P< \n0.01).  \n \nCT detected \nmetastases \nsignificantly earlier \nthan US  \n(P=0.03) \nArdizzoni et al. \n(1987 ) See above  See above  116 patients; \nclinically 93 in \nstage I and 23 i n \nstage II  True and false \npositives and \nnegatives  \n 0/66 positives for \nliver involvement  \n1/66 true positives \nfor iliac lymph \nnode involvement \n(2%) \n1/66 false \npositives for iliac \nlymph node \ninvolvement (2%)  Design \n(prospective vs. \nretrospective) not \nclear fr om \ndescription  \nFollow -up time not \ngiven  \n \n 3b- \nGoerz et al. (1986):  See above  See above  378 patients with \nhistologically \nconfirmed CM  True and false \npositives  0% positive results  Stage of patients \nnot given  \n \n 3b- \nHolloway et al. \n(1997)  To determine the  \nfrequency of \ngallbladder \npathology, other diagnostic study  \n \n 464 patients with \ncutaneaous \nmelanoma except \none which arose Detection rate of \nmetatasis  Ultrasound \nappearances \ntypical of \ngallbladder No further \ninformation about \nthe population. 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 66 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nthan gallstones in \nthis group o \npatients.  on the nasal \nmucosa.  metastases in 4,1%  \nStutte (1989)  To describe \nultrasonographic \nfindings and to \nevaluate the \nsignificance of \nupper abdominal \nultrasonography in \nassessing the \nspread of \nmetastasizing \nmalignant \nmelanome d uring \nfollow up. \n Prognostic study  \n \nRetrospective \nstudy  42 patients with \ndistant metastases \nof CM  \n Mean overall \nsurvival  Mean survival \ntime:  \n- for patients with \n\u2264 3 liver \nmetastases \u2264 3 cm \ndiameter: 8,4 \nmonths  \n- for patients with \nnumerous \nmetastases or \nmetastases > 3cm \ndiameter: 4,3 \nmonths  \n- for patients  with \nisoechoic \nmetastases: 2,6 \nmonths.  No information \nabout inclusion \ncriterias  \n \nSmall pa tient \ncohort \n \n 4 \nZartman et al. \n(1987 ) See above  See above  90 CM patients \nwith level III and IV \nlesions  Positive results  No positive results \nfor abdominal \nsonography  Patients with \ncomplete staging \nincluded; \nindications for \ndifferent staging \nexaminations \nunclear  4 \nDoiron et al. (1981)  To discusses Diagnostic study  163 patients with False negatives Group 1:  Sensitivity and 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 67 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwhich of these \nimaging modalities \nyields the most \ninformation in \npatients with \nintraabdominal \nmetastatic \nmelanoma   \n malignant \nmelanoma in \nclinical stage III \nexamined by RN \nliver scan, US, and \nCT in various \ncombinations over \na 2-years -period. \n \nPatients were \ndivided into 3 \ngroups according \nto the \nexaminations: (1)  \nRN liver scan, US, \nand CT (38 \npatients)  \n(2) RN liver scans \nand CT (10 \npatients)  \n(3) US and RN liver \nscan.(115 patient s) (FN) \n \nFalse positives (FP)  CT, US and RN \ndemonstrated 20, \n22 and 23 normal \nresults \nrespectively and \n18, 17 and 15 \nabnormal results \nrespectively  \n1 FN (CT)  \n1 FN (US)  \n8 FP and 1 FN (RN)  \n \nGroup 2:  \nCT, RN \ndemonstrated \nboth 7 normal \nresults and both 3 \nnegative results. \n2FP and 1 FN (RN)  \n \nGroup 3:  \nUS and RN \ndemonstated 52 \nand 75 normal \nresults \nrespectively and  \n43 and 40 \nabnormal results \nrespectively  \n2 FP (US)  \n10 FP (RN)  specificity not \ngiven  \n \nNo information \nabout follow -up  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 68 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSubtopic  \nMRI        \nHausmann et al. \n(2011 ) to compare the \ndiagnostic \naccuracy  \nof whole -body MRI \nwith the standard \ndiagnostic \nalgorithm (whole -\nbody CT  \nand brain MRI) in \npatients with stage \nIII/IV MM.  diagnostic study  33 consecutively \nadmitted patien ts \nwith histologically \nconfirmed  \ndiagnosis of stage \nIII or IV MM  Sensitivity  \n \nspecificity  The sensitivity of \nwhole -body MRI \nwas \nobserverdependen\nt. \n \nSensitivity: \nMRI vs. CT: 73.4 % \nvs. 78.2 %, p = \n0.0744.  \n \nSensitivity in the \ndetection of small \n(1\u20135 mm) \npulm onary \nnodules: MRI vs. \nCT: 2.9 % vs. 66.9 \n%, p < 0.0001 \n \nOverall specificity:  \nMRI vs. CT: 83.4 % \nvs. 50.4 %, p < \n0.0001  Data interpretation  \nby two blinded \nexaminers  \n  2b \nPfannenberg et al. \n(2007)  \n to compare the \noverall and site -\nbased accuracy \nand impact  on Diagnostic study  \n 64 patients:  \n25 patients stage \nIII, 39 patients \nstage IV  Sensit ivity  \n \nSpecificity  \n The overall \naccuracy:  \nPET/CT: 86.7%  \nwbMRI: 78.8%  Cerebral lesions in \nwbMRI were \nrecorded, but \nexcluded from the 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 69 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npatient \nmanagement of \npositron emission \ntomography/comp\nuted tomography \n(PET/CT)  \nand whole -body \n(wb) magnetic \nresonance imaging \n(MRI) in staging of \nadvanced \nmelanoma.  \n \n  \n positive predictive \nvalue (PPV)  \n \nnegative predictive  \nvalue (NPV)  \n \naccuracy  CT: 75.0%  \nPET: 74.3%  \n \nPET vs. wbMRI: P = \n0.0007  \n \nPET vs. PET/CT:  \nP < 0.0001  \n. \nSensitivity, \nspecifity, TN, FN, \nTP, FP: see full \ntext/table 2  \n \n analysis because \nof the lack of \ncomparable PET \ndata.  \n \nThe selection of \ninclusion criteria \nled to \nunderestimated \ncalculated \nspecificity, \nbecause only the \nlesions suspicious \nof malignancy in \none of the \ndifferent methods \nwere included in \nthe study and \ncompared by \ndifferent methods.  \n \nStudy included in \nXing et al. 2011 \nand Krug et al. \n2008  \nDellestable et al. \n(2011 )  \n to assess the Se \nand specificity (Sp) \nof wb -MRI with a \ndiffusion sequence \nfor detecting Diagnostic study  40 patients were \nincluded and a \ntotal of 72 \nmetastases were \nnoted  Sensitivity  \n \nspecificity  CT: \nsensitivity: 80%, \nspecificity: 95%  \n \nPET/CT  no detailed \ninformation about \npatient cohort \n \nsmall patient 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 70 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma \nmetastasis \ncompared to \nPET/CT.  sensitivity: 74%  \nspecificity: 89%  \n \nWb-MRI  \nsensitivity: 83%  \nspecificity: 96%  \n \nThe sensitivity of \nMRI was distinctly \nsuperior to PET/CT \nfor both hepatic \nand pulmonary \nlesions.  \n \n cohort  \nLaurent et al. \n(2011)  to compare whole -\nbody MRI with a \nmulti -contrast \nprotocol including \na DW (Diffusion \nWeighted) \nsequence to PET -\nCT using (18)FDG \nfor staging \nadvanced \nmelanoma.  Diagnostic study  35 patients  Sensitivity  \n \nspecificity  sensitivity and \nspecificity for \nwhole -body M RI: \n82% and 97%  \n \nPET-CT: 72.8% and \n92.7%.  \n \nDW sequence \nallowed the \ndetection of 14 \nsupplementary \nmalignant lesions \n(20%) in \ncomparison with prospective \nblinded study  \n \nsmall patient \ncohort 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 71 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nstandard MRI \nprotocol. DW \nsequence has been \nshown to be the \nmost accurate for \ndetecting \nmetastases in the \nliver, bo ne, \nsubcutaneous and \nintra-peritoneal \nsites.  \nMueller -Horvat \n(2005 ) \n \n to compare \ncontrast -enhanced \nwhole -body \nmagnetic \nresonance imaging \n(wbMRI) and \nwhole -body \ncomputed  \ntomography \n(wbCT) to detect \ndistan t metastases \nfor staging.  Diagnostic study  \n \n 43 patients  \nAJJC stage III\u2013 IV \nmalignant \nmelanoma  Metastasis \ndetection rate  \n \n wbCT vs. wbMRI: \ndetection of 522 \nvs. 730 \nmetastases \n \nwbCT vs. wbMRI:  \n-pulmonary \nmetastases: 188 \nvs. 143  \n- metastases in \nkidneys, adr enal \nglands and lymph \nnodes: same \nnumber of \ndetected  lesions  \n- liver: 122 vs. \n199. \n- spleen 26 vs. 54  \n- subcutaneous 4 patients had \nchoroid malignant \nmelanoma  \n \nspecifity and \nsensitivity not \ngiven  \n \nno follow -up \n \nsmall population  \n \nuninterpretable \nresults not \ndescribed  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 72 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntissue 39 vs. 61  \n- muscle 4 vs. 11  \n- bone marrow 23 \nvs. 132  \nBrain 15 vs. 25  \n \nTherapy was \nmodified as a \nconsequence of \nwbMRI findings in \n10/41 (24%) \npatients.  \nSchlamann et al. \n(2008 ) To investigate the \nincidence of \ncerebral \nmetastasis in \nasymptomatic \nmelanoma patients \nin relation to the \nstage of disease to \nestimate the \nreasonability of \nthis examination. Diagnostic study  120 CM patients \nwithout other \nmalignancy or \nneurological \ndisease  Incidence of \ncerebral \nmetastasis  Stage I:  \n0/27 positive \nresults \nStage II:  \n1/29 positive \nresults (3%); \npatient in stage IIC  \nStage III/IV:  \n14/64 positive \nresults (22%)  Criteria for patient \nselection unclear \n \n 3b- \nFogarty et al. \n(2006)  To retrospectively \nevaluate the use of \nbrain magnetic \nresonance imaging \n(MRI) i n the initial \nstaging of patients Diagnostic study  100 of 193 \nconsecutive CM \npatients without \nneurological \nsymptoms  Detection rate  \nUpstaging by MRI  Patients in stages I \n\u2013 III: 0% positive \nresults  \nNo patients \nupstaged by \nstaging MRI  Patients in stages I \n\u2013 IV included  \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 73 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwith cutaneous \nmelanoma  \nSubtopic  \nPET        \nXing et al. (2011)   \n To examine the \nutility of \nultrasonography, \ncomputed \ntomography (CT), \npositron emission \ntomography (PET), \nand a combination \nof both (PET -CT) \nfor the staging and \nsurveillanc e of \nmelanoma \npatients.  Systematic review \nand meta -analysis  \n 10 528 patients \nwith cutaneous \nmelanoma at \nprimary diagnosis \nor under \nsurveillance \n(follow -up) Sensitivity, \nspecificity  \nDiagnostic odds\u2019 \nratio (OR)  Data for initial \nstaging of regional \nnodes:  \nSensitivity 30%  \nSpecificity 96%  \nDiagnostic OR \n9.45 Very large patient \ncohort, but \npatients under \nfollow -up included  \n \n 1a \nKrug et al. (2008)  To calculate \nsummary \nestimates of the \ndiagnostic \nperformance of \nfluorine 18 \nfluorodeoxyglucos\ne (FDG) positron  \nemissio n \ntomographic (PET) \nimaging in the Systematic review \nwith meta -analysis  \n 2905 CM patients \nin 28 studies of \nwhich 2096 \nunderwent PET \nalone and 809 \nunderwent PET/CT  Pooled sensitivity \nand specificity  \nPositive and \nnegative likelihood \nratio (LR+, LR -) \nDiagnostic odds\u2019 \nratio (OR)  \nChanges in \ndisease \nmanagement  Pooled sensitivity: \n83%  \nPooled specificity: \n85%  \nLR+: 4.56  \nLR-: 0.27  \nOverall diagnostic \nOR: 19.8  \nEarly-stage \nsubgroup (10 \nstudies, 755 In 17 studies, \npatients enrolled \nexclusively for \ninitial staging; in \n11 studies, \nproportion of  \ninitial staging \npatients 18 \u2013  97% \nOverall, many low -\nquality studies \nresp. small 1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 74 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ninitial staging of \ncutaneous \nmalignant \nmelanoma (CMM)  patients):  \nPooled diagnostic \nOR 4.3 (95% CI: 1, \n18) \nMean sensitivity \n60%  \n8 studies \nsuggested that \nFDG PET was \nassociated with \n33% (range, 15% \u2013\n64%) disease \nmanagement \nchanges  patients cohorts  \n \n \nJimenez -Requena et \nal. (2010)  The aim of this \nstudy was to \nperform a \nsystematic review \nof the literature to \nevaluate the \naccuracy of FDG -\nPET in staging  and \nrestaging of \ncutaneous \nmelanoma.  Systematic review \nwith meta -analysis  \n 444 CM patients \n(group I = regional \nstaging), stages I \u2013 \nIII, in 7 studies  Pooled specificity \nand sensitivity  \nPositive and \nnegative likelihood \nratio (LR+, LR -) \nSummary receiver -\noperating curve \n(ROC)  Group I (regional \nstaging):  \nPooled specificity: \n0.99 \nNo global \nhomogeneity for \nsensitivity, LR+ or \nLR- \nROC curves \ngrouped in the left \nmargin, indicating \nglobal high \nspecificity  Overall, many low -\nquality studies \nresp. small \npatients cohor ts \n \n 2a \nSchwimmer et al. \n(2000 )      Data included in \nJimenez -Requena   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 75 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \net al. (2010): Meta -\nanalysis of the \nperformance of \n(18)F -FDG PET in \ncutaneous \nmelanoma  \nBastiaannet et al. \n(2009)  \n to perform a head -\nto-head-\ncomparison of \nFDG-PET and CT in \nstaging of patients \nwith melanoma \nwith palpable \nlymph node \nmetastases (AJCC \nstage III) in terms \nof diagnostic \naccuracy and \nimpact on \ntreatment.  Prospective \nmulticenter study  \n \n In total 251 \nPatients with \npalpable and \nhistologically or \ncytologically \nproven lymph \nnode metastases \n(after negative \nsentinel lymph \nnode)  \n \n \n \n False negatives \n(FN) \n \ntrue positives (TP)  \n \nfalse positives (FP)  \n \ntrue negatives (TN)  \n \nsensitivity  \n FDG-PET detected \nmore metastatic \nsites (133 v 112, P \n= .03), detecting \nsignificantly more \nbone and \nsubcut aneous \nmetastases.  \n \nCT had more FN \nresults (n=17) than \nPET (n=11).  \n \nNumbers of FN, \nTP, FP and TN: see \nfull  \n \nSensitivity to \ndetect distant \nmetastases \nCT scan 78%  \nPET scan 86%  study included in \nXing et al. 2011 \nand Jimenez -\nRequena 2008  2b \n \n \n \nPfannenberg  et al. See above  See above  See above  See above  See above  See above  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 76 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(2007)  \nLaurent et al. \n(2011 ) See above  See above  See above  See above  See above  See above  2b- \nKoskivuo et al. \n(2007 ) to determine the \nclinical impact of \nwhole body \npositron emission \ntomography (FDG \nPET) to  \ndetect clinically \nsilent metastases \nin the follow -up of \npatients with high \nrisk melanoma.  Prospective study  30 asymptomatic \nmelanoma patients \n(AJCC stage IIB -\nIIIC) 7 -24 months \nafter the primary \nsurgery and \nsentinel node \nbiopsy.  Sensi tivity \n \nSpecificity  \n \nPPV \n \nNPV \n \nClinical impact  sensitivity and \nspecificity for \nmelanoma \nrecurrence: 86% \nand 96%, \nrespectively. \n \nPPV: 86%  \nNPV: 96%  \n \npositive PET \nfinding had an \nimpact on \ntreatment \ndecisions in every \ncase: 3 patients \nunderwent surgical \nresect ion, \n4patients received \nchemotherapy or \ninterferon. Small patient \ncohort \n \nStudy included in \nXing et al. 2011 \n 2b- \nMaubec et al. \n(2007 ) To determine the \nvalue of F -18 \nfluorodeoxy -D-\nglucose positron Diagnostic study  \n 25 CM patients \nwith lesions > 4 \nmm Sensitivity, \nspecificity  Initial tumor site:  \n14/19 true \nnegatives (74%)  \n5/19 false Prospective design  \n \nsmall number of \npatients  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 77 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nemission \ntomography \nscanning in the \ndetection of \nregional and/or \ndistant metastasis  positives (26%)  \nSensitivity 17%, \nspecificity 74%  \nMicroscopic lymph \nnode disease:  \n12/19 true \nnegatives (63%)  \n7/19 false \nnegatives (37%)  \nSensitivity 0%   \nStudy included in \nXing et al. 2011 \n \nEl-Maraghi and \nKielar (2008 ) To evaluate PET \nand PET/computed \ntomography  \n(CT) compared \nwith SLNB for \nstaging lo cal \nlymph nodes in \npatients with \nintermediate -risk \nmelanoma.  Systematic review \nwithout meta -\nanalysis  \n 20 studies; \nnumber of patients \nunclear because \nsome included \nstudies did not \nreport cohort size  True and false \nnegatives and \npositives  \nSensitivity and \nspecificity  \nPositive and \nnegative predictive \nvalue  Ranges (no meta -\nanalysis):  \nTP 0 \u2013  10% \nFP 0 \u2013  18% \nTN 60 \u2013  74%  \nFN 3 \u2013  40% \nSensitivity 0 \u2013  92% \nSpecificity 7 \u2013  \n100%  \nPPV 0 \u2013  100%  \nNPV 20 \u2013  85% \n \n Levels of evidence \naccording to \nauthors: 7 studies \n2b, 1 review 3 a, 3 \nreview 3b, 3 \nstudies 3b, 3 \nstudies 4, 2 \nletters/opinion \narticles 5  \nOverall, many low -\nquality studies \nresp. small \npatients cohorts  \n \n 3a \nPleiss et al. (2007)   to assess the \npotential of fluor -\n18-FDGPET  \nin order to Prognostic and \ndiagnostic study  \n \n 95 Patients with \nmaligant \nmelanoma who \nhad received a PET  overall 5 -year \nsurvival  \n \nsensitivity  Sensitivity, \nspecificity, and \naccuracy of FDG -\nPET were 91%, No information \nabout the final \nassessment of \nfindings (e.g. 3b \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 78 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nevaluate the \nsurvival prognosis \nin mel anoma    \nspecifity  86%, and 89%, \nrespectively, and \nof CT 58%, 91%, \nand 73%, \nrespectively. \n \nsurvival in patients \nwith \n-  both studies (CT \nand PET) being \nnegative: 5 -year \nsurvival, 83%  \n- both studies (CT \nand PET) being  \npositive: 5 -year \nsurvival, 61%; p < \n0.02 \n- PET being \npositive but CT \nstill negative: 5 -\nyear survival, 73%  histology and/or \nclinical follow -up)  \n \nNumber of TP and \nFP etc. missing. \nData for the \ncalculation of \nsensitivity/specific\nity not given  \n \nNo information \nabout the time -\nperiod between \nPET and CT  \n \n \nClark et al. (2006)  To investigate the \nutility of whole -\nbody PET imaging \nin 64 patients with \nT2 to T4 \nmelanomas prior \nto sentinel lymph \nnode dissection \nwithout clinically diagnostic study  64 CM patients \nwithout clinical \nevidence o f \nmetastasis  True and false \npositives and \nnegatives  \nChange in \nmanagement  PET scans normal \nin 60 of 64 \npatients (94%) \n2/64 (3%) false \npositives  \n2/64 true positives  \n19/64 false \nnegatives \n(regarding  22/64 patients \nwith T4 lesions  \n \nStudy included in \nXing et al. 2011 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 79 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsuspected \nmetastases sentinel node \nstatus)  \nNo change in \nmanagement by \nPET resu lts  \nVereecken et al. \n(2005) The purpose of \nthis study was to \nevaluate the \nimpact of \nextensive initial \nstaging on the \nmanagement of \nmelanoma \npatients.  Diagnostic study  43 patients with  \nintermediate/high \nrisk melanoma \n(Breslow thickness \n\u2265 1 mm or \nregression/ \nulceration)  Evidence of \nmetastasis  Paraclinical \ninvestigation (CT \nscan of the chest, \nCT of the \nabdomen, CT or \nNMR of the brain \nand whole body \nFDG PET scan) \nfailed to reveal any \nsign of evidence of \ndisseminated \ndisease in the \nseries of 43 \npatients.  \n \nPositivity:67%  \nSensitivity: 40%  \nPPV: 9,3%  Results concerning \nPET already \nconsidered in \nJimenez -Requena \net al. 2010, in \nKrug et al. 2008 \nand in Xing et al. \n2011  \n \nNo distinction \nbetween resu lts \nfor MRI and CT of \nthe brain. \n \nImaging results \nvalidated by 6 \nmonths follow -up.  3b \nStas et al. (2002)  \n \n to evaluate (1) the \nsensitivity and \nspecificity of PET \nscan at a single \nlesion level \ncompared with Retrospective \ndiagnostic study  \n \n \nCSP= chest X -ray, \nblood analysis, 100 PET scans on \n84 melanoma \npatients with \nregional or distant \nrecurrences \naccording to CSP  Sensitivity  \n \nSpecifity  \n \nAccuracy  \n At the single \nlesion level: \nSensitivity: \nPET: 85%  \nCSP: 81%  \nSpecificity:  Comparison of PET \nscan and CSP \nresults at a lesion -\nbased level \uf0e0 see \nfull-text \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 80 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nconventional \nscreening \nprocedures (CSP) \u2013  \nboth of these \naccompanied by  \nclinical \nexamination; and \n(2) the additional \nvalue of the PET \nscan at the level of \nthe individual \npatient and its \ntherapeutic impact \nfor different types \nof melanoma \nrecurrence. ultrasonography, \n(US), computed \ntomography (CT), \nmagnetic \nresonance imaging \n(MRI) and nuclear \nbone scans  \n  Therapeut ic \nimpact  \n PET: 90%  \nCSP: 87%  \nAccuracy:  \nPET 88%  \nCSP: 84%  \n \nThe overall \ntherapeutic impact \n(PET): 26%  \n \n Therapeutic \nimpact of PET scan \nresults \uf0e0 see full \ntext \n \nStudy included in \nJimenez -Requena \net al. 2010 and \nXing et al. 2011 \nWagner et al. \n(2011 ) To assess the rate \nof distant \nmetastases in \npatients with a \npositive SLN  \nbiopsy (SLNB).  Diagnostic study  46 con secutive \npatients with a \npositive SLNB \nunderwent PET or \nPET\u2013computed \ntomography within \n6 weeks of the \nSLNB procedure \nand without  \nany clinical sign of \nnodal involvement \nor of distant \nmetastasis.  \n FN Positive PET -scan: \n0% \nNonconclusive PET \nscan 13%  \nNegative  PET in \n87%,  \namong them 12% \npresented with \ndistant metastasis \nwithin 12 months.  46 PET procedures \nwere performed:  \nIn 22 patients: \nstand -alone PET \nand aCT scan with \na contrast \nmedium. In 24 \npatients: PET \u2013CT \nscan without \ninjection of \ncontrast medium. \n \nResul ts: no \ndifferentiation 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 81 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nbetween PET and \nPET/CT  \n \nImages were \ninterpreted by a \nspecialist aware of \nall the clinical \nfindings \uf0e0 not \nblinded  \nConstantinidou et \nal. (2008)  to evaluate the \nrole of PET or PET/  \ncomputed \ntomography (CT) \nas a routine \nprocedure in  \npatients with \npositive sentinel \nnode biopsy (SNB).  \n Diagnostic study  \n  \n \n 30 patients with \nBreslow thickness \nof at least 1mm \nand who had a \npositive sentinel \nnode biopsy.  Positive rate  Positive PET in 2 \npatients (6%)  \n \nLN dissection \npositive in 5 cases \n(16%) \n \nWith a median \nfollow -up of 24 \nmonths, 21 \npatients remained \ndisease \nfree.alteration of \nmelanoma \nmanagement in \nnone of the 30  Follow -up methods \nnot described in \ndetail  \n \nSmall patient \nnumber  3b- \n \n \nHorn et al. (2005) \n To investigate the \nclinical value of \nimplementing \nwhole -body FDG-Diagnostic study  \n \n 33 patients with \ncutaneous \nmalignant \nmelanoma and sensitivity  \nspecificity  \nNPV Sensitivity and a \nspecificity for \nmelanoma \nmetastases: 80% Small patient \ncohort \n \nOnly cases with 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 82 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nPET as a routine \ninvestigation in \nstage III melanoma \npatients with sub -\nclinical regional \nlymph node \nmetastases \ndiagnosed by SNB.  \n subclinical lymph \nnode metast ases \ndiagnosed by \nsentinel node \nbiopsy (SNB)  \n \n \n \n \n and 88%, \nrespectively.  \n \nNPV: 96%.  \n \n positive PET \nfindings received \nverification via CT \nscan, MRI, \nultrasonography \nor biopsy  \n \nSmall population  \n \nStudy included in \nKrug et al. 2008 \nand in Xing et al. \n2011  \nLoffler et al. (2003)  \n To disclose the \ndiagnostic benefit \nof scanning the \nlegs and to \nevaluate the \ntherapeutic benefit \nresult ing. Diagnostic study  \n 213 consecutive \nPET studies in 153 \npatients with \nsuspected or \nrecent melanoma  Detection rate  Suspicious \nfindings at the \nlegs in 53 patients \non 76 occasions.  \n \n38/53 showed \npathologic uptake \nin the torso as \nwell. In 15/53 \npatients it w as \nrestricted to the \nlegs. 11 of those \n15 patients had a \nprevious history in \nthat location. In 1 \npatient the finding \nwas a new and Sensitivity and \nspecificity not \ngiven  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 83 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nclinically relevant \nmetastasis, in 3 \nother patients the \nleg manifestations \nwere already \nknown.  \n \nIn 6 other patients \na valida tion of the \npositive PET \nfindings was not \npossible  \nKrug et al. (2000)  \n To assess the \ndiagnostic value of \nfluor-18-\nFluorodeoxy -\nglucose positron \nemission \ntomography (FDG -\nPET) in screening \nfor melanoma \nmetastases Diagnostic study  \n \n 94 melanoma \npatients who had \nbeen examined by \nwhole -body FDG-\nPET. 40 patients \nshowed evidence \nof lymphogenous, \n42 of \nhematogenous \nmetastasis.  \n Metastases -\ndetection rate  \n In no case did PET \nchange the \nstaging. In 13 \npatients, PET \nagreed wit h \nmorphological \ndiagnosis in the \nnumber of \nmetastatically \ninvaded organs. \nThis included 3 \npatients without \nmetastases. The \nestimated number \nof organs invaded \nby metastases was \nhigher with PET in \n5 patients and Different reference \ntests \n \nSensitivity and \nspecifity not given  \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 84 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nhigher with \nmorphological \nimaging \ntechniques i n 6 \npatients. Among \nthe PET findings \nwith higher or \nequivocal counts \nof organs with \nmetastases there \nwere 2 confirmed \nfalse-positive \nfindings.  \n \n(Results for the \ndifferent organs \n(lungs, liver\u2026): see \nfull text)  \nDietlein et al. \n(1999) \n To examine if  \n- FDG-PET can \nimprove staging of \npatients with \nmelanoma when \ncompared with \ncombinations of \nstandard \nradiological \nexaminations \ncurrently used in \nroutine practice?  Diagnostic study  91 FDG -PET \nexaminations \nperfomed on 68 \npatients with \nadvanced \nmelanoma.  True positives  \n \nFalse positives  FDG-PET detected \nmore lymph node \nand bone \nmetastases \n \nHigh proportion of \nnon-verifiable PET \nfindings  \n \nCompar ision of \nultrasonographic \nand radiological FDG-PET images \nfrom various \ninstitutes  \n \nDifferent staging \nexaminations  \n \nSensitivity \n/specificity not \ngiven  \n \nNo data  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 85 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n- if the setting of \nindications  for PET \ncan be opimized? \n methods with FDG -\nPET for examining \nthe lungs, \nabdominal organs, \nLN and skeleton: \nsee full -text. concerning follow -\nup \n \nStudy included in \nJimenez -Requena \net al. 2010  \nSubtopic  \nCT        \nXing et al. (2011)  See above  Systematic review \nand meta -analysis  \n 10 528 patients \nwith cutaneous \nmelanoma at \nprimary diagnosis \nor under \nsurveillance \n(follow -up) Sensitivity, \nspecificity  \nDiagnostic odds\u2019 \nratio (OR)  Data for initial \nstaging of regional \nlymph nodes:  \nSensitivity 9%  \nSpecificity 92%  \nDiagnostic OR \n1.13 Very large patient \ncohort, but \npatients under \nfollow -up included  \n \n 1a \nBastiaannet et al. \n(2009 ) \n See above  See above  See above  See above  See above  study included in \nXing et al. 2011 \nand Jimenez -\nRequena 2008  2b \n \nPfannenberg et al. \n(2007)  See above  See above  See above  See above  See above  See above  2b \nDellestable et al. \n(2011 ) See above  See above  See abov e See above  See above  See above  2b- \nHausmann et al. \n(2011 ) See above  See above  See above  See above  See above  See above   \n  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 86 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nPanagiotou et al. \n(2001 ) See above  See above  See above  See above  See above  See above  3b \nSawyer et al. (200 9) \n \n \n \n \n \n \n \n \n \n \n \n \n \n The a im of this \nstudy was to \ndetermine whether \nCT changes \nmanagement in \nAJCC IIB disease or \nworse with regard \nto initial staging \nscans and \nsubsequent follow \nup scans. A \nsecond objective \nwas to determine \nwhether CT of the \nhead and neck \nshould be \nperformed.  Diagn ostic study  \n 132 CM patients in \nstages IIB/C (42 \nIIB, 90 IIC)  True and false \npositives  \nChange in clinical \nmanagement  Region \u2013 number \nof scans with \nmetastases \u2013 \nchange in \nmanagement in %  \nChest \u2013 3 \u2013 0% \nAbdomen \u2013 2 \u2013 0% \nPelvis \u2013 0 \u2013 0% \nHead \u2013 3 \u2013 0.7% \nNeck \u2013 0 \u2013 0% \nTrue and false \npositives of \nregional CT scans: \nChest  \nTrue positives: 9 \n(81%)  \nFalse positives: 2 \n(19.0%) \nAbdomen  \nTrue positives: 7 \n(53%)  \nFalse positive: 6 \n(47%)  \nPelvis  \nTrue positives: 3 \n(38%)  \nFalse positives: 5 \n(62%)  No homogenous \nreference standard  \nValues for true and \nfalse positive \nbased on initial \nand follow -up \nscans; probably \nlower if only initial \nscans were \nconsidered  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 87 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nHead  \nTrue positives: 6 \n(100%)  \nFalse positives: 0  \nYancovitz et al. \n(2007 ) See above  Diagnostic study  158 patients,  135 \nwith stage I/II \ndisease and 23 \nwith stage III \ndisease  \n True and false \npositives and \nnegatives  Number of CT \nstudies: 57 chest, \n57 abdomen/ \npelvis, 57 head  \nPositives: \nChest CT 24 of 57  \nAbdomen/ pelvis \n11 \nCranial CT 2  \nTrue positives:  \nChest CT 0 of 57 \n(0.0%) \nAbdomen/ pelvis \nCT 0 of 57 (0.0%)  \nCranial CT 0 of 57 \n(0.0%) \nFalse positives: \nChest CT 21 of 57 \n(37%)  \nAbdomen/ pelvis \nCT 10 of 11 (18%)  \nCranial CT 2 of 57 \n(4.0%) \nTrue negatives:  \nChest CT 50 of 57 \n(88%)  study included in \nXing et al. 2011 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 88 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAbdomen/ pelvis \nCT 46 of 57 (81%)  \nCranial CT 53 of  \n57 (93%)  \n(Rest lost to \nfollow -up) \nNo false negatives  \nVan den Brekel et \nal. (1998)  To assess the \nvalue of CT \nscanning in \ndetecting lymph \nnode metastases \nin the neck from \nmalignant \nmelanoma and to \nlook at possible \nCT characteristics \nof such \nmetastases.  Diagnostic study  \n 26 CM patients \nwith neck CT \nbefore neck \ndissection, 8 of \nthem negative for \npalpation  \n Sensitivity and \nspecificity  \nTrue and false \npositives and \nnegatives  CT scans of the \nneck:  \n2/26 (8%) false \nnegatives (s lices of \n8 mm instead of 5 \nmm) \nSensitivity of both \npalpation and CT \nscanning 86%, \nspecificity 100%  Different reference \nstandards \n(comprehensive \nand selective neck \ndissection)  \nInclusion criteria \nunclear  \nOnly 8 \nasymptomatic \npatients  \n \n 3b \nIscoe et al. (1986 ):  See above  Diagnostic study  \n 393 consecutive \nCM patients  True and false \npositives  \nPositive and \nnegative predictive \nvalue (PPV, NPV)  Chest CT:  \nNumber of exams: \n59 \nTrue positives: 0  \nFalse positives: 9  \nPPV: 0%  \nNPV: 98.0%  \nCranial CT: \nNumber of exams: \n52 Index tests not \ndone on all \npatients  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 89 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nTrue positives: 0  \nFalse positives: 9  \nPPV: /  \nNPV: 98.1%  \nHeaston et al. \n(1983)  First, to determine \nprospectively the \nsensitivity and \nspecificity of \nconventional chest \nradiography, \ntomography, and \ncomputed \ntomography i n a \nselected group of \npatients with high \npropensity for \npulmonary \nmelanoma \nmetastases; \nsecond, to \nevaluate the \nimpact of the \ndiscovery of \npulmonary \nnodules on the \nclinical therapy of \nmelanoma.  Diagnostic study  42 CM patients in \nstages I \u2013  III (11 in \nstages  I \u2013 II) Sensitivity, \nspecificity  \nFalse -positive and \nfalse-negative rate  \nOverall accuracy  Chest CT:  \nSensitivity 100%  \nSpecificity 95%  \nFalse positives 2%  \nFalse negatives 0%  \nOverall accuracy \n98% Sensitivity and \nspecificity \ncalculated for a \ncohort including \nstage III melanoma \npatients; not \nenough data given \nto calculate for \nstage I and II alone  \n \n 3b \nAloia et al. (2006)  To analyse the \nefficacy of routine Diagnostic \nretrospective 270 staged \npatients with True positive and \nFalse negative rate TP detection rate \nof occult distant Calculation of \nsensitivity and 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 90 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nradiologic staging \nin asymptomatic \npatients with \nmicroscopic nodal \ninvolvement \nbefore completion \nof \nlymphade nectomy.  \n cohort study  \n positive SLNB \nmelanoma  \n \n \n metastases: 1,9%  \nFP: 12%.  \n specificity not \npossible  \n \nFalse and true \nnegatives not \ngiven  \nMiranda et al. \n(2004 ) \n To determine the \nrate of detectable \nsystemic \nmetastasis at the \ntime of SSL in  \nasymptomatic \npatients with \nmelanoma in \nNorth America \n \n Diagnostic study  \n \n 185 patients with \npathologic \nevidence of \nmetastasis to at \nleast 1 SLN \n Diagnostic yield of \nimaging studies:  \n 142 patients \nunderwent chest \nCT: \n- 1 positive finding  \n- 114 negative  \n-  27 \nindeterminate  \n \n146 patients \nunderwent CT of \nthe abdomen and \npelvis: \n- 1 positive \nfinding, - - 123 \nnegativ e \n- 22 \nindeterminate. \n \n96 underwent MRI \nimaging (brain), \n16 underwent CT Not in eve ry case \nof indeterminate \nfindings additional \ndiagnostic was \nperformed  \n \nSensitivity/specific\nity not given  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 91 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(brain):  \n- no positive \nfindings  \n- 105 negative  \n-  7 were \nindeterminate. \n \nCT of the chest \nand \nabdomen/pelvis/b\nrain: indeterminate \nrates were 19%, \n15% and 6,3% \nrespectively.  \nJohnson (1997)  \n To evaluate the \nyield and clinical \nimpact of \ncomputed \ntomography (CT) \nimaging in \notherwise \nasymptomatic \npatients with stage \nIII me lanoma \nmetastatic to the \nregional nodes  \n Diagnostic study  \n \n \n 127 asymptomatic \npatients stage III  \n(28 patients: \nmicroscopic \ndisease at ELND. \n99 patients with \npalpable disease \ndiagnosed by fine \nneedle aspirate, \nopen biopsy, or \nTLND)  \n True (TP) and false \npositives (FP)  \n \n 20 patients: TP CT \nscan revealing \nunsuspected \nmetastases.  \n \n15 patients: \nabnormal CT scans \nsubsequently \nshown to be a \nbenign process or \nsecond \nmalignancy.  \n \nNo difference in \nthe incidence of TP \nCT between the TP and FP rates: \nsee full  text \n \nFP and FN not \ngiven  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 92 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ngroups of patients \nwith clinically  \napparent vs. occult \nnodal disease.  \n \nsignificantly \nhigher incidence \nof abdominal and \npelvic metastatic \nsites identified by \nCT scan in patients \nwith inguinal \nnodal disease vs. \npatients with \naxillary or head \nand neck nodal \ndisease.  \nBuzaid et al. (1995 ) \n To determine the \nvalue of CT scans \nin the staging of \nasymptomatic \nmelanoma patients \nwho presented \nwith or developed \nlocalregional \ndisease as the first \nsite of recurrence \nand had both a \nnormal chest \nradiograph and Diagnostic study  \n \n 89 patients who \neither presented \nwith or developed \nlocalregional \ndisease as the first \nsite of recurrence  \n \n \n TP-rate \n \nTN-rate Findings on CT \nscan were TP for \nsix patients  \n(7%), FP for 2 0 \n(22%), and TN for \n63 (71%).  \n \n No detailed data \nabout the follow -\nup regime/time of \nfollow up  \n \nSensitivity and \nspecificity not \ngiven  \n \nStudy included in \nXing et al. 2011 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 93 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nserum lactate \ndehydrogenase \n(LDH) level.  \nKhansur et al. \n(1989 ) See above  Diagnostic study  \n 115 patients with \nprimary CM (7 2 in \nlocalized stage) \nand 28 patients \nwith recurrent \ndisease  True and false \npositives  Cranial CT:  \n0 true positives \nand 0 false \npositives in \npatients with \nlocalized disease  Criteria for \nselecting staging \nexaminations \nunclear  \n \n 3b- \nKuan et al. (1988)  See a bove See above  See above  See above  See above  See above  3b- \n \n \nGoerz et al. (1986):  See above  Diagnostic study  \n 378 patients with \nhistologically \nconfirmed CM  True and false \npositives  Whole -body CT:  \n2/378 true \npositives (distant \nmetastasis)  Stages not giv en \n \n 3b- \nKersey et al. (1985 ) See above  Diagnostic study  \n 393 patients at \nprimary diagnosis \nof CM  True and false \npositives  CT chest:  \n0/59 true positives  \n9/59 false \npositives (15%)  \nCranial CT: \n0/51 true positives  \n0/51 false \npositives  Extent of staging \nexam inations and \nextent/ length of \nfollow -up \ndepended on \ncenter and tumor \nsite \n \n 3b- \nPatten et al. (1990)  To determine Cross -sectional 125 CM patients  Prevalence of bone Examin ations: CT Not enough data 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 94 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwhether the \nfrequency of CT \ndetection of axial \nskeletal \nmetastases was \ngreater than that \nreported for plain \nfilm radiology and \nto determine if the \nthickness and \ndepth of \npenetration of the \nprimary melanoma \n(according to the \nBreslow and Clark \nclassifications) can \nbe used to predict \nthe occurrence of \nskeletal \nmetastases.  study  \n metastasis  abdomen (41%), \nchest (27%), pelvis \n(25%), and neck \n(7%) \n98/125 patients \n(78%) with CT \nevidence of \nmetastatic \nmelanoma  \n17/98 (17%) \nskeletal \nmetastases  \n2/17 only \nevidence of \nmetastatic disease  given to \ndifferentiate \nbetween \npreval ence of bone \nmetastasis in early \nstage and \nadvanced stage \nmelanoma  \n \n \nZartman et al. \n(1987 ) See above  Cohort study  90 CM patients \nwith level III and IV \nlesions  Positive results  No positive results \nin cranial CT  Patients with \ncomplete staging \nincluded; \nindications for \ndifferent staging \nexaminations \nunclear  4 \nSilverman et al. \n(1984 ) To assess the \nvalue of computed Cross -sectional \nstudy  70 CM patients  \n Prevalence of \nabdominal 52 scans of \nabdomen and Most patients \nsymptomatic at 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 95 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntomography in the \ndetection of \nabdominal spread \nof malignant \nmelanoma.   \n metasta ses pelvis, 5 of \nabdomen, 2 of \npelvis, 11 limited \nto the liver \nNodal enlargement \nin abdomen or \npelvis in 30%  \nLiver metastases in \n17%  \nAdrenal \nmetastases in 11%  \nNodular masses in \nthe subcutaneous \nfat in 8,6%  \nSplenic metastases \nin 2% \nMesenteric \nmetastases in 4%  time of CT scan \n(abdominal pain, \nabnormal liver \nfunction tests or \nliver imaging)  \n \n \nGinaldi et al. (1981 ) To investigate the \nvalue of CT as a \nstaging procedure \nin neurologically \nasymptomatic \nmelanoma \npatients, and to \ndescribe the \nneurological \nfeatures of \nmetastases and \ntheir incidence in Diagnostic study  \n 179 CM patients; \n74 of them with no \nneurological \nfindings  Detection rate  Cranial CT:  \nPositive results in \n9/74 patients \n(11%)   \n2/9 had known \nsingle metastases \nin the liver and \nlung, 2/9 others \nrecurrent local \ndisease, 5/9 other \nsystemic \nmetastases No clear \ndistinction \nbetween patients \nof different stages  \n \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 96 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma \npatients.  \nDoiron et al. (1981)  See above  See above  See above  See above  See abov e See above  4 \nSubtopic  \nPET/CT         \nXing e t al. (2011)  \n See above  Systematic review \nand meta -analysis  \n 10 528 patients \nwith cutaneous \nmelanoma at \nprimary diagnosis \nor under \nsurveillance \n(follow -up) Sensitivity, \nspecificity  \nDiagnostic odds\u2019 \nratio (OR)  Data for initial \nstaging of regional \nnodes:  \nSensitivity 11%  \nSpecificity 97%  \nDiagnostic OR \n4.39 Very large patient \ncohort, but \npatients under \nfollow -up included  \n \n 1a \nKrug et al. (2008)  See above  Systematic review \nwith meta -analysis  \n 2905 CM patients \nin 28 s tudies of \nwhich 2096 \nunderwent PET \nalone and 809 \nunderwent PET/CT \n(4 studies)  Positive and \nnegative likelihood \nratio (LR+, LR -) \nDiagnostic odds\u2019 \nratio (OR)  LR+ 9.68  \nLR- 0.10 \nDiagnostic OR \n37.6 \n 4 eligible studies \nabout PET/CT  \n \n 1a \nEssler et al. (2011 ) To assess the \nprognostic value \nof FDG PET/CT \ncompared to the \ntumor markers \nS100B and \nmelanoma diagnostic and \nprognostic study   125 consecutive \npatients  \n \nPatients who had a \nBreslow tumor \nthickness  .2.0 mm,  \nelevated S100B or specificities  \nsensitivities  \nNPV \nPPV \n Overall specificity \nfor FDG PET/CT:  \n96.8% (95% CI, \n89.1% to 99.1%)  \ncorresponding \nsensitivity: 96.8% \n(89.0% to 99.1%)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 97 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ninhibitory  \nactivity (MIA) in \npatients with high \nrisk melanoma.  MIA level   \nNPV for PET/CT  \n96.8% (89.1% to \n99.1%), PPV: 96.7% \n(89.0% to 99. 1%), \n \nPatients with \nelevated S100B - or \nMIA values or \nPET/CT positive \nfindings showed a \nsignificantly \n(p,0.001 each, \nunivariate Cox \nregression models)  \nhigher risk of \nmelanoma \nassociated death \nwhich was \nincreased 4.2 -, \n6.5- or 17.2 -fold, \nrespectively. \nEtchebehere et al. \n(2010 ) To assess the \nimpact of [F -18] \nFDG-PET/CT on \nthe restaging and \nchanging \nmanagement of \npatients with  \nmalignant Diagnostic study  78 patients  \n \n(Initial \nrestaging/before \nPET/CT): local \nrecurrence in 11 \npatients, \nlocoregional Impact on patient \nmanagement  \n \nSensitivity  \n \nSpecificity  \n \n In 27% of the \npatients the \nmanagement was \nchanged after the \n[F-18] FDG -PET/CT \nstudies. Upstaging  \nin 5 of 23 (22%) \npatients.  AJCC 2001 staging  \nSystem was used  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 98 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma.  recurrence in 23 \npatients and \ndistant recurrence \nin 44 of 78 \npatients.  \n  \nsensitivity, \nspecificity, PPV, \nNPV for  \nlesion detection: \n95% \n \naccuracy: 94.9%.  \n \n2FP, 2 FP \nKlode et al. (2010)  Comparison of \nSLNE and PET -CT \nin patients with \nearly-stage \nmalignant \nmelanoma  Diagnostic study  \n 61 CM patien ts in \nstages I and II \nbefore sentinel \nbiopsy  Sensitivity and \nspecificity  \nPositive and \nnegative predictive \nvalue (PPV, NPV)  Sensitivity 5.9%  \nSpecificity 100%  \nPPV 100%  \nNPV 78%  50% of eligible \npatients declined \nPET-CT  \n \n 2b \nVeit-Haibach et al. \n(2009 ) To eval uate the \ndiagnostic \naccuracy of \ncontrastenhanced \nFDG-PET/CT (ce -\nPET/CT), PET -only, \nand CT -only in \npatients with \nnewly diagnosed \nand resected \ncutaneous \nmalignant \nmelanoma.  Diagnostic study  \n 56 CM patients \nafter surgical \nresection who \nunderwent \ncombined PET/ CT \nimaging and had \nsufficient follow -\nup; 18 of them in \nstage III or IV  Sensitivity and \nspecificity  \nPositive and \nnegative predictive \nvalue (PPV, NPV)  Sensitivity and \nspecificity \nregarding N -stage:  \n38.5% and 100%  \nPPV and NPV \nregarding N -stage:  \nPET-CT 100% an d \n84.3%  \nSensitivity and \nspecificity \nregarding M -stage:  \nPET-CT 38.5% and \n100%  Insufficient data \nfor 24% of patients  \n \nStudy included in \nXing et al. 2011 \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 99 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nPPV and NPV \nregarding M -stage:  \nPET-CT 41.7% and \n93.2%  \nSingh et al. (2008)  To evaluate the \nrole of \npreoperative 18F -\nfluorodeoxyglucos\ne-positron \nemission \ntomography/ \ncomputed \ntomography \nscanning, \npreoperative \nlymphoscintigraph\ny (LS), and sentinel \nlymph node biopsy \nin patients with \nmalignant \nmelanoma.  Diagnostic study  \n 52 CM patients \ninitially classified \nas stage I or II, \nbefore sentinel \nbiopsy  Sensitivity and \nspecificity  \nPositive and \nnegative predictive \nvalue (PPV, NPV)  \nOverall diagnostic \naccuracy  18F-FDG PET \nimaging for the \ndetection of \nregional lymph \nnode metastases:  \nSensitivity 14.3%  \nSpecificity 94.7%  \nPPV 50%  \nNPV75%  \nDiagnostic \naccuracy 73%  Study included in \nXing et al. 2011 2b \nLagaru et al. (2007)  To analyse \nsensitivity and \nspecificity of \nPET/CT for the \ndetection of \nmetastases of \nmalignant \nmelanoma.  Diagnostic study  \n 106 CM patients \nwho had whole -\nbody FD G-PET/CT, \n30 of them with \nstages IIIC and IV  Sensitivity and \nspecificity  Per patient:  \nSensitivity 89.3%  \nSpecificity 88.0%  \nTrue positives 50  \nFalse positives 6  \nFalse negatives 6  \nTrue negatives 44  \nPer lesion:  Studies were done \nfor disease re -\nstaging in all \npatients; time \ninterval from initial \ndiagnosis not \ngiven  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 100 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSensitivity 89.6%  \nSpecificity 84.6%  \nTrue posi tives 78  \nFalse positives 8  \nFalse negatives 9  \nTrue negatives 44  Studie included in \nXing et al. 2011 \n \nPfannenberg et al. \n(2007)  See above  See above  See above  See above  See above  See above  2b \nStrobel et al. (2007)  To prospectively \ndetermine the \naccuracy of \npositron emission \ntomography \n(PET)/computed \ntomography (CT) \nwith added CT \nmorphologic \ninformation for \ndepiction of \nmetastases in \npatients with hig h-\nrisk melanoma and \nnegative findings \nfor metastases at \nPET, by using \nhistologic findings \nor additional \nimaging and/or \nfollow -up findings Diagnostic study  124 CM patients \nwith tumor \nthickness > 4 mm; \nClark level, III or \nIV; or known \nmetastases True and false \npositives and \nnegatives  \nSensitivity and \nspecificity  \nDiagnostic \naccuracy  Without dedicated \nCT readout:  \n45/124 true \npositives (36%)  \n3/124 false \npositives (2%)  \n68/124 true \nnegatives (55%)  \n8/124 false \nnegatives (6%)  \nSensitivity 85%  \nSpecificity 96%  \nDiagnostic \naccuracy 91%  \nWith dedicated CT \nreadout: \n52/124 true \npositives (34%)  \n4/124 false \npositives (3%)  \n67/124 true Cohort includes \npatients with \nalready known \nmetastasis  \n \nStudy included in \nXing et al. 2011 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 101 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nas reference \nstandard.  negatives (54%)  \n1/124 false \nnegatives (1%)  \nSensitivity 98%  \nSpecificity 94%  \nDiagnostic \naccuracy 96%  \nDellestable et al. \n(2011 ) See above  Diagnostic study  See above  See above  See above  See above  2b- \nWagner et al. \n(2011 ) To assess the role \nof routine staging \nwith FDG PET -CT \nin melanoma \npatients with \nlocalized high risk \nmelanoma.  Diagnostic study  48 consecutive \npatients with 1 < \nBT < 4 mm with \nulceration and \nwith BT >= 4 mm \nwere staged  \nwith PET -CT (initial \nstaging) prior to  \nSLNB.  sensitivity, \nspecificity, PPV, \nNPV For regional nodal \nassessment:  \nsensitivity, \nspecificity, PPV, \nNPV of PET: 43%, \n100%, 100% and \n78%, respectively.  \n \nFor distant \nmetastases: \npositive PET in 0%, \nnegative PET in \n13% and \nindeterminate PET \nin 13% of patients  Images were \ninterpreted by a \nspecialist, aware of \nall clinica l \nfindings/not \nblinded  \n \nSmall patient \ncohort, not \ndescribed in detail  \n \n 2b- \nMansour et al. \n(2010)  (1) to determine \nthe anatomic \nscatter plot of \nfalse-positive and Diagnostic study  342 CM patients \nwith PET/CT  \n True and false \npositives  True positives:  \nBreslow 0 \u2013  2 mm: \n46.9%  \nBreslow 2.01 \u2013  4 Limited purpose of \nthe study  \n(musculo -skeletal \nfindings in 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 102 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntrue-positive FDG -\navid sites; (2) to \ndescribe and \ndetermine the \ncharacteristics of \nfalse-positive FDG -\navid sites; and (3) \nto identify \npatterns that are \nuseful in \npredicting false -\npositive findings \nfor patient \nmanagement and \ncounseling.  mm: 18.8%  \nBreslow > 4 mm: \n34.4%  \nStage II: 3.2%  \nStage III: 33%  \nStage IV: 63.8%  \nFalse positives: \nBreslow 0 \u2013  2 mm: \n30% \nBreslow 2.01 \u2013  4 \nmm: 30%  \nBreslow > 4 mm: \n40% \nStage II: 27.3%  \nStage III: 45.4%  \nStage IV: 27.3%  PET/CT)  \nNo fixed \nindications for \nPET/CT  \n \nRevel et al. (2010) To assess the \nutility of PET -CT \n18FDG in a group \nof N patients with \ncutaneous head \nand neck \nmelanoma, \ncombined with \nSLNB.  Diagnostic study  \n 22 patients with \nN0 cutaneous \nhead and neck \nmelanoma with \nPET/CT before \nsentinel biopsy  Sensitivity and \nspecificity  Sensitivity 18%  \nSpecificity 84%   3b \nYancovitz et al. \n(2007)  See above  Diagnostic study  158 patients, 135 \nwith stage I/II \ndisease and 23 \nwith stage III True and false \npositives and \nnegatives  Number of PET/CT \nstudies:  \n42 \nPositives: study included in \nXing et al. 2011 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 103 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndiseas e \n 5/42 (12%)  \nTrue positives  \n1/42 (2%)  \nFalse positives: \n3/42 (7%)  \nTrue negatives:  \n37/42 (88%)  \nFalse negatives:  \n0 \nLost to follow -up: \n1/42  \nWagner et al. \n(2011 ) See above  See above  See above  See above  See above  See above  3b- \nAbbott et al. (2011)   to evaluate the \nrole of [18F] \nfluorodeoxyglucos\ne PET/CT as a \nsurveillance tool in \nasymptomatic \npatients with \nprimary cutaneous \nmelanoma  \n Diagnostic s tudy 34 patients with \nprimary cutaneous  \nmalignant \nmelanoma with \nAJCC stage III Metastases \ndetection  In 20 patients with \nmicroscopic stage \n3 \ndisease at \ndiagnosis: PET/CT \ndetected 2 of 3 \nrecurrences and 1 \nincidental breast \ncarcinoma.  \n \nIn 14 patients with \nmacroscopic stage \n3 \ndisease at, or \nsubsequent to, \ntheir initial  \nNo reference \nstandard  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 104 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndiagnosis: PET/CT \ndetected 4 of 4 \nrecurrences, \nmetastases in 1 \npatient who \nremains \nasymptomatic and  \n1 incidental \nthyroid carcinoma.  \nSubtopic  \nSPECT/CT         \nVan der Pl oeg \n(2009)  To explore \nwhether hybrid \nSPECT/CT  leads to \nbetter anatomical \nlocalization of \nsentinel nodes or \nto the depiction of \nextra sentinel \nnodes in patients \nwith melanoma \nwhen conventional \nimaging is \ninconclusive, and \nwhether this \ninfluences the \nsurgic al approach.  Cohort study  \n 85 CM patients \nwho underwent \nboth conventional \nlymphoscintigraph\ny and subsequent \nSPECT/CT  Additional \ndiagnostic value of \nSPECT/CT (change \nof surgical \napproach)  Additional \ndiagnostic value of \nSPECT/CT in 35% \n(30 patients)  \n Only pa tients with \nquestionable \nresults in lympho -\nscintigraphy or \nunusual drainage \npattern included  \n \n 2b \nSubtopic BONE         \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 105 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSCINTIGRAPHY  \nAu et al. (1984) To evaluate the \nyield and accuracy \nof preoperative \nradionuclide scans \nin patients with \nprimary melanoma \nfor the detection \nof occult \nmetastasis to \nbrain, liver and \nbone.  Diagnostic study  \n 192 CM patients; \n171 in stage I \n(localized) and 21 \nin stage II (lymph \nnode metastasis \naccording to old \nAJCC staging)  True and false \npositives, false \nnegatives  107/112 (96%) \ntrue negatives  \n5/112 (4%) false \npositives  \n0 true positinves  No information \nabout false \nnegatives (follow -\nup of patients with \nnegative results \nunclear)  \n \n 3b \nHofmann et al. \n(2002)  See above  Diagnostic study \nwith historical \ncohort; economical \nevaluation  \n 661 patients \n(stage I/II: 630 \npatients, stage III: \n27 patients, stage \nIV: 4 patients)  True and false \npositives and \nnegatives  \nCost-efficiency of \nimaging \nprocedures \n 325 total bone \nscintigraphies  \n0 true positives  \n62 false positives \n(19%)  \nDetection rate /  \nCost o f bone \nscintigraphy at \ninitial staging: \n80654 EUR  \n(4099 EUR due to \nfalse positive \nresults)  Diagnostic \nstandard \nprocedures varied \nover time; no \ndefined gold \nstandard of \ndiagnosis  \n \n 3b \nKhansur et al. \n(1989)  See above  Diagnostic study  \n 115 patients with \nprimary CM (72 in \nlocalized stage) True and false \npositives  0/141 true \npositives  \n3/141 false Criteria for \nselecting staging \nexaminations 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 106 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nand 28 patients \nwith recurrent \ndisease  positives (2%)  unclear  \n \nArdizzoni et al. \n(1987)  See above  Diagnostic study  116 patients; \nclinically 93 in \nstage I and 23 in \nstage II  True and false \npositives and \nnegatives  \n 68/73 (93%) true \nnegatives  \n5/73 (7%) false \npositives  \n0 true positives  Design \n(prospective vs. \nretrospective) not \nclear  \nFollow -up time not \ngiven  3b- \nKersey et al. (1985)  See above  Diagnostic study  \n 393 patients at \nprimary diagnosis \nof CM  True and false \npositives  True positives 0  \nFalse positives \n7/116 (6%)  Extent of staging \nexaminations and \nextent/ length of \nfollow -up \ndepended on \ncenter and tumor \nsite \n 3b- \nZartm an et al. \n(1987)  See above  Cohort study  90 CM patients \nwith level III and IV \nlesions  Positive results  No positive results \nfor bone \nscintigraphy  Patients with \ncomplete staging \nincluded; \nindications for \ndifferent staging \nexaminations \nunclear  \n 4 \nSubtopic  \nTUMOR MARKERS          \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 107 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nMocellin et  al. \n(2008)  Analysis of the \nprognostic value \nof S100B serum \nlevels in patients \nwith melanoma, \nwith special regard \nto stages I \u2013 III \n(AJCC)  Meta-analysis of \n20 prognostic \nstudies containing \n22 series of 3393 \npatients  \n5 series  \nconsidered \npatients in stages I \n\u2013 IV \n8 series \nconsidered \npatients in stage \nIV only  \n6 series \nconsidered \npatients in stages I \n\u2013 III only  \nOther \ncombinations in \nthe remaining 3 \nseries  \n 3393 patients with \nmelanoma, stages \nI \u2013 IV  \n \n Summary hazard \nratio for sur vival \n \n Summary hazard \nratio for survival  \n2.23 (95% CI 1.92 \n\u2013 2.58)  \nSummary hazard \nratio considering \nonly patients in \nstages I \u2013  III: \n2.28 (95% CI 1.8 \u2013\n2.89)  High degree of \nheterogeneity, \nwhich is not \npresent when only \nstudies of stages I \n\u2013 III are include d \nPublication bias \npresent (shown \nwith a funnel plot), \nbut after \ncorrection, Hazard \nRatio still \nsignificantly \nhigher for patients \nwith elevated \nS100B  \nPublication bias \nnot present when \nonly studies of \nstages I \u2013  III \nincluded  1a \nBalch et al. (2009)  To revi se the \nstaging system for \ncutaneous \nmelanoma on the \nbasis of data from \nan expanded \nAmerican Joint \nCommittee on Prognostic study  30,946 patients \nwith stages I, II, \nand III melanoma \nand 7,972 patients \nwith stage IV \nmelanoma  Survival rate  Elevated serum \nLDH: \nThe updated AJCC \nMelanoma Staging \nDatabase \ndemonstrated that \nan elevated serum \nLDH is an Study included just \nfor reference here; \nno data abou t LDH \nin earlier stages \nthan IV  \n \n 1b   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 108 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nCancer (AJCC) \nMelanoma Staging \nDatabase.  independent and \nhighly significant \npredictor of \nsurvival outcome \namong patients \nwith stage IV \ndisease. Thus 1 - \nand 2 -year over all \nsurvival rates for \nthose stage IV \npatients in the \n2008 AJCC \nMelanoma Staging \nDatabase with a \nnormal serum LDH \nwere 65% and 40%, \nrespectively, \ncompared with \n32% and 18%, \nrespectively, when \nthe serum LDH \nwas elevated at the \ntime of staging (P \n< .0001). \nTherefore, serum \nLDH should be \nmeasured at the \ntime stage IV \ndisease is \ndocumented, and \nif the LDH level is  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 109 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nelevated, those \npatients are \nassigned to M1c \nregardless of the \nsite of their distant \nmetastases.  \nNowecki et al. \n(2008 ) to assess the \nprognostic value \nof multimarker \nreverse \ntranscriptase - \npolymerase chain \nreaction (RT -PCR) \nassay in lymphatic \ndrainage (LY) after \nlymph node \ndissection (LND) \nand of \npreoperative \nserum lactate \ndehydrogenase \n(LDH) levels in \nAJCC stage III \nmelanoma \npatients.  Prognostic study  \n \n 255 consecutive \npatients with \nhistological \ndiagnosis of CM \nand regional \n(inguinal or \naxillary) LN \ninvolvement who \nunderwent radical \nLND \n \n Overall survival  \n \nDisease -free \nsurvival  \n \nRecurrence rate  estimated 3 -year \nOS rate for \npatients with \nincreased \npreoperative \nserum LDH level: \n41.3% (95% CI: \n28.4\u201354.6%), vs. \n55.3% (95% CI: \n45.8\u201364.9%) for \npatients with a \nnormal baseline \nserum LDH level (P \n= 0.007).  \n \ndisease recurren ce \nin 70% of patients \nwith an increased \npreoperative \nserum LDH level \ncompared with \n53% patients with \na normal serum \nLDH level (P =  \nResults for RT -\nPCR: see full -text 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 110 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n0.01).  \n \nNegative impact of \nincreased pre -\nlymphadenectomy \nserum LDH level \non OS of \nmelanoma patients \nwith \nmacrometastases \nafter TLND. Serum \nLDH level does not \ndifferentiate the \nprognostic groups \nin patients with \nmicrometastases  \nVereecken et al. \n(2009 ) To investigate the \nprognostic \nsignificance of \ngalectin -3 in \ncomparison to \nS100B, LDH and \nCRP Prognostic study  \n \n  83 patients in \nstage III and IV  Overall survival 3 groups of \npatients were \ndefined according \nto Gal -3 levels: <8 \nng/ml (group 1), \n8\u201310 ng/ml (group \n2), >10 ng/ml \n(group 3).  \n \nGroup 1 and 2: \nsimilar overall \nsurvival, group 3: \nworst ou tcome. \nmedian  LDH was omitted \nfrom the analysis \nbecause only 8 \npatients showed \nelevated LDH \nserum levels  \n \n 1b- \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 111 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsurvival was 4.1 \nmonths.  \n \nmultivariate Cox \nproportional \nhazards model: \nAJCC stage and \nCRP serum levels \n=most important \nindependent \nprognostic factors \n[HR =9.60, \nP=0.0002 and \nHR=2.75, P=0.002,  \nrespectively]. \n \nAt a cut -off value \nof \n10 ng/ml for  Gal-\n3, (on quatrivariate \nanalysis) serum \nGal-3: strong \nindependent \nprognostic value, \nsuperior to the \nother markers \n(HR=4.64, \nP=0.0001).  \nEssler et al. (2011 ) To assess the \nprognostic value Retrospective \ndiagnostic and 125 consecutive \npatients  specificities  \nsensitivities  S100B: Overall \nspecificity 85.7%  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 112 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nof FDG PET/CT \ncompared to the \ntumor markers \nS100B and \nmelanoma \ninhibitory  \nactivity (MIA) in \npatients with high \nrisk melanoma.  prognostic study    \nPatients who had a \nBreslow tumor \nthickness .2.0 mm,  \nelevated S100B or \nMIA level  NPV \nPPV \n (75.0% to 92.3%)  \ncorresponding \nsensitivity:45.2% \n(33.4% to 55.5%),  \nNPV 61.4% (50.9% \nto 70.9%). PPV: \n75.7% (59.9% to \n86.6%) \n \nMIA: O verall \nspecificity 95.2% \n(86.9% to 98.4%). \ncorresponding \nsensitivity 36.1% \n(25.2% to 48.6%), \nrespectively. NPV:  \n60.6% (50.8% to \n69.7%), PPV: 88.0% \n(70.0% to 95.8%).  \n \nPatients with \nelevated S100B - or \nMIA values or \nPET/CT positive \nfindings showed a \nsignific antly \n(p<0.001 each, \nunivariate Cox \nregression models) \nhigher risk of \nmelanoma  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 113 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nassociated death \nwhich was \nincreased 4.2 -, \n6.5- or 17.2 -fold, \nrespectively. \nKruijff et al. (2011)  Aim was to assess \nthe correlation and \nthe prognostic \nvalue of S -100B \nand S tandardized \nUptake Values \n(SUV) of \nFluorodeoxyglucos\ne (FDG)  Retrospective \ncohort study  62 patients with \npalpable nodal \nmetastases, \nwithout distant \nmetastases DFS and DSS  No relation was \nfound between S -\n100B and SUV.  \n \nDFS for patients \nwith an elevated \nvs. normal S -100B: \n31% vs. 44,6% (HR \n= 3.1; p = 0.02)  \n \nDFS for patients \nwith normal vs. \nelevated SUV: 42% \nvs. 29% (HR = 1.1; \np = 0.8).  \n \nDSS for patients \nwith normal vs. \nelevated S100B: \n60.7% va. 44.7% \n(HR = 2.2; p = \n0.07).  \n \nDSS for patients \nwith normal vs.  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 114 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nelevated SUV: \n59.1% vs. 43.5% \n(HR = 1.1; p = 0.8).  \n \nS-100B is \nassociated with \ntumor load and a \nstrong predictor \nfor DFS in stage III \nmelanoma  \nNeuss et al. (2011 ) To evaluate the \ncorrelation to \nclinical and \npathological \ndata.of the \nfollowing \npreoperat ive \nserum tumour \nmarkers: S100, \nNSE, Albumin, LDH \nand CRP  Prognostic study  \n patients in tumour \nstage III before \nradical lymph node \ndissection  Serum levels  The serum level of \nCRP correlated \nwith increasing \nnumber of LN \nnode metastases.  \n \nSignificant \nelevat ed serum \nlevels of S100 in \npatients with more \nthan one positive \nSLN   2b \nBouwhuis et al. \n(2011 ) To determine the \nprognostic value \nof S100B based on \nupdated \ninformation  \nusing serial \ndeterminations in Prognostic study  918 se rum \nsamples of 211 \nPatients who \nparticipated in the \nEORTC 18952 \ntrial, evaluating \nefficacy of distant metastasis - \nfree interval (DMFI)  \n \ndistant metastasis - \nfree survival \n(DMFS)  \n Multivariate \nanalyses:  \nDMFS:  \nHR of S100B >= \n0.2 versus S100B \n< 0.2 was 5.57 \n(95% CI 3.81 \u2013 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 115 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nstage IIb/III \nmelanoma \npatients.  adjuvant  \nintermediate doses \nof interferon a2b \n(IFN) versus \nobservation  \n \nSerum S100B \nlevels were \nmeasured during \ntreatment and \nfollow -up OS \n \nHR 8.16), P < 0.0001, \nafter adjustment \nfor stage, number \nof lymph nodes \nand sex.  \nIn stage IIb \npatients:  HR \nadjusted for \nsex=2.14 (95% CI \n0.71, 6.42) \nIn stage III \npatients: the HR \nadjusted for stage, \nnumber of LN and \nsex=6.76  \n(95% CI 4.50 \u2013\n10.16).  \n \nOS: \nHR: 4.73 (95% CI \n3.14\u20137.12), P < \n0.0001.  \nIn stage IIb \npatients: HR 2.73 \n(95% CI 0.79 \u20139.44; \nP = 0.11).  \nIn stage III \npatients:  \n5.46 (95% CI 3.52 \u2013\n8.45; P < 0.0001).  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 116 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSerial \ndetermination of \nS100B in stage IIb \u2013\nIII melanoma is a \nstrong \nindependent \nprognostic  \nMarker, the \nprognostic impact \nof S100B >= 0.2 \nlg/l is more \npronounced in \nstage III disease \nthan in stage IIb . \nPaschen et al. \n(2009)  To investigate the \ncorrelation \nbetween sULBP2, \nsMICA and S100B \nlevels and the \nprognostic value \nof sULBP2 levels  Prognostic study  \n 208 patients (25 in \nstage I/II, 54 in \nstage III, 129 stage \nIV)  \n50 healthy \ncontrols  \n Clinical sta ge \nTumor load  \nOverall survival \n \n S100B serum \nconcentrations \nsignificantly \ncorrelated with \nstage of disease  \nPatients with \nmeasurable tumor \nsignificantly \nhigher serum \nconcentrations of \nS100 than patients \nwith clinically non -\napparent tumor   2b \nAndr\u00e9s et al . (2008 )  To compare the \nvalue of tyrosinase Prospective \ndiagnostic and 90 CM patients in \nstages I \u2013  IV  Sensitivity  \nProgression -free Sensitivity of S100:  \n22.2% for stage I  Very small control \ngroup for S100 (2 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 117 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmRNA by reverse  \ntranscription \npolymerase chain \nreaction (RT -PCR) \nin peripheral blood \nand of serum S -\n100 protein in \npatients with \nmelanoma at  \ndifferent stages of \ndisease.  prognostic stu dy survival  \nOverall survival 10.5% for stage II  \n7.4% for stage III  \n94.1% for stage IV  \nMedian follow -up: \n312 days or to \ndeath  \nMedian \nprogression -free \nsurviv al 213 days \nfor elevated serum \nS100; not reached \nfor patients with \nnormal S100  \nMedian overall \nsurvival 282 days \nfor elevated serum \nS100; not reached \nfor patients with \nnormal S100 level  healthy subjects, 3 \npatients with \nbreast cancer, \nHodgkin \nlymphoma and \nEwing\u2019s sarcoma, \nrespectively)  \nAlso contains data \non tyrosinase  \nPatients in stage I \n\u2013 IV \n \n \nKruijff et al. (200 9) \n To investigate \nwhether the \nperioperative \nmeasurement of \nthe tumor markers \nS-100B has \nprognostic value  in \nFDG-PET and spiral \nCT staged patients  \nwith stage III \nmelanoma who are Prognostic study  \n \n \n 56 patients with \nclinically and \ncytologically \nproven regional \nnodal metastases \nof melanoma  \n Disease -free \nsurvival  \n \nPrognostic factors  2-year DFS in \npatients with  \n- elevated vs. non -\nelevated \npreoperative S -\n100B \nconcentrations: \n34% vs. 61% \n(HR:2.6, P=0.03)  \n- elevated vs. non -\nelevated Follow -up \ndiagnostic \nprocedures and \nfollow -up intervals \nnot stated in \narticle  \n \nDesign not \ndescirbed \n(prospective/retros\npective)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 118 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nselected for \ntherapeutic lymph \nnode dissection  postoperative S -\n100B  \nconcentrations: \n30% vs. 51% \n(HR:2.0, P =0.1).  \n \nIn multivariate \nanalysis: \nextranodal growth \n(HR 0.4, P = .05), \nand elevated \npreoperative S -\n100B \nconcentrations (HR \n2.6, P = .03) were \nsignificantly \nassociated with \ndecreased DFS.   \n \nWang et al. (2004)  See above  Diagnostic study  \n 210 CM patients \nwithout clinical \nevidence of \nmetastasis  \n True and false \npositives and \nnegatives  LDH results \navailable in 96 \npatients with \nmelanoma > 1 mm  \n82/96 (85%) wi thin \ninstitutional \nnormal range  \n14/96 patients \nwith elevated LDH, \nbut no detection \nof systemic \ndisease or  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 119 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nalteration in \nsurgical \nmanagement (15% \nfalse positives)  \nNo true positives  \nKaskel et al. (1999)  \n To evaluate the \nclinical and \nprognostic value \nof S-100 in \nperipheral blood \nof patients with \nmelanoma as a \nmarker for \nmetastasis.  \n Diagnostic study  \n 1396 samples of \n570 patients with \nmelanoma and 53 \ncontrol subjects \n \n(397: melanoma in \nsitu or stage I or II, \n104: stage III, 69: \nstage IV)  \n \n Sensitivity, \nspecifity, positive \npredictive value \n(PPV), negative \npredictive value \n(NPV), \ndetermination of \noptimal threshold \n(ROC).  \n For a cut -off of \n0.114 \u00b5/L  \n \nSensitivity: 94%  \nspecificity: 91%.  \n \nFor a cut -off of \n0,2\u00b5g/L:  \nsensitivity and \nspecifity both 92%  \n \nPPV value (cut -off \n0,114 \u00b5g/L) for \nnewly occurring \nmetastases: 65%, \nNPV (no \nmetastases): 99%. \nFN results \nincluded patients \nwith unknown \nprimary melanoma \nand those with \namelanotic \nmelanoma \nmetastases.  Part of the data on \nS-100 levels \nobtained in \nMunich have also \nbeen evaluated in \na different study \nby Berking et al.  \nfollow -up \nperformed in 197 \npatients only  \n \nROC: see full text  \n 2b  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 120 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nHofmann et al. \n(2009)  To determine the \nvalue of MIA \ntesting in early -\nstage melanoma  Diagnostic study  \n 1079 CM patients \nin stages I and  II \nReference group: \n313 \ndermatological \npatients without \nhistory of \nmelanoma or other \nmalignancy  Mean values  \nSensitivity  \nSpecificity  Mean MIA value \ndid not increase \nbased on stage  \nSensitivity of MIA \nfor metastasis:  \n67.6% in stage I \nand 65.6% in stage \nII \nSpecificity:  \n76.9% for stage I \nand 66.7% for \nstage II  \nMore frequent \nfalse-positive \nvalues in elderly \nwomen and in men \nwith an increased \nBreslow thickness  Different reference \nstandard for \npatients with \nabnormal \nlaboratory values  \n \n 2b- \nGarbe  et al. (2003)  To evaluate the \ndiagnostic \naccuracy of \nprotein S -100B, \nmelanoma -\ninhibitory activity \n(MIA), LDH, AP, \nand \ntyrosinase/MART -1 \nreverse Diagnostic and \nprognostic study  \n \n 296 consecutive  \nAJCC Stage II or III \nclinically disease -\nfree melanoma \npatients  \n \n120 healthy \ncontrols without \nmelanoma or other \nknown Sensitivity  \n \nSpecificity  \n \nDiagnostic \naccuracy  Cutoff levels:  \nS100: 0.12 \u00b5g/L  \nMIA: 10.49 ng/mL  \n \nSensitivity: S - 100: \n29%, PCR: 24%, \nMIA: 22%, AP: 17% , \nLDH: 2%  \n \nSpecificity: S -100: Different reference \nstandard (CT) for \npatients with \nabnormal \nlaboratory values \n(may lead to a \nhigher sensitivity \nof the tumor \nmarkers than in \nreality)  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 121 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntranscription -\npolymerase chain \nreaction (RT -PCR).  malignancies.  93%, PCR : 80%  \nMIA: 97%, AP: 89%  \nLDH: 90%  \n \nDiagnostic \naccuracy: MIA: \n86%, S100: 84%, \nAP: 79%, LDH: 77%  \nRT-PCR: 72%  \n \nROC analysis: \ndiagnostic \naccuracy:  \nS-100: 66%, MIA: \n62%, LDH: 53%, \nAP: 51%  \n \nSignificant P \nvalues for S -100 \n(0.001) and MIA \n(0.011), but not \nfor LDH (0.571), \nAP (0.807), and \nPCR (0.519).  \n \nSomer\u2019s Dxy : S -\n100 had the \nhighest predictive \nvalue  \n \nKaplan \u2013Meier  \nDetai led \ndescription of \nfollow up; no \ndrop-outs \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 122 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsurvival curves: \nhighly significant \ndifference in \nrecurrence -free \nsurvival time in the \ntime period after \nthe follow -up \nexaminations \nbetween patients \nwith normal and \npathologic values \nfor both MIA and \nS-100.  \nAgarwala et al. \n(2009 )  To assess each of \nthe three \nstratification \nfactors in this \nstudy \n(performance \nstatus, metastatic \nsite and LDH) for \nan interaction with \ntreatment on \nsurvival.  Prognostic study  \n \n 760 p atients (in \nstudy 301) and \n760 (in study \n18951)  \n Overall survival  LDH was within \nthe upper range of \nnormal for a large \nnumber of \npatients.  \n \nhighly ordered and \nmonotonic \nrelationship \nbetween LDH and \nsurvival: survival \nworsened as LDH \nbecame more \nelevated, even \nwhen LDH \nremained within \nnormal range.  Post-hoc analysis \nof two randomised \ntrials (Oblimersen \nGM301 and EORTC \n18951)  \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 123 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \nLDH and tumour \nsize poorly \ncorrelated; \nelevated LDH was \nnot associated \nwith any one \ndisease site. LDH \nwas highly \npredictive of \noblimersen effect.  \n \nKaplan \u2013Meier \nsurvival curves: \nsee full -text \nDeichmann et al. \n(2004)  LDH was \ncompared to CRP \nto evaluate, if LDH \nis of value in \ndiscriminating \nmelanoma patients \nentering AJCC \nstage IV from \npatients staying in \nAJCC stages I, II or \nIII. \n Diagnostic study  \n \n 91 patients with \nhistologically \nproven melanoma \nprogressing into \nstage IV, 125 \npatients stage I, II \nor III in follow -up \nexaminations  Sensitivity  \n \nspecificity  LDH not \nsignificantly \nelevated in \npatients entering \nstage IV melanoma \n(P=0.785), whereas \nCRP was \n(P<0.001).  \n \nLDH did not \ndiscriminate \nbetween the \ndefined groups of \npatients Sensitivity an d \nspecificity for LDH \nnot given  \n \nSmall population  \n \nNo information on \nblinding  2b-   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 124 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(AUC=0.491; 95% \nCI, 0.410, 0.581), \nwhereas CRP did \n(AUC=0.933; 95% \nCI, 0.900, 0.966; \nP<0.001).  \n \nCRP in diagnosing \nAJCC stage IV \nentry: cutoff =2,1 \nor 2,2mg/dl: \nspecificity=80%, \nsensitivitie=83,5%.  \n \ncutoff 2,4 or \n2,5mg/dl: \nspecificity = 83,2% \nand 85,66, \nrespectively. \nsensitivity of \n81,3%.  \n \nCutoff=2.9mg/dl:  \nSpecificity=89,6%  \nsensitivity=79,1  \n \ncutoff \npoint=3.0mg/dl:  \nspecificity=90,4  \nsensitivity=76,9   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 125 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nDeichmann (2001)       Same data as in:  \nDeichmann et al. \n(1999): S100 -Beta, \nmelanoma \ninhibiting activity, \nand lactate \ndehydrogenase \ndiscriminate \nprogressive from \nnon-progre ssive \namercan joint \ncommittee on \ncancer stage IV \nmelanoma   \nStoitchkov et al. \n(2003)  To define the \npotential use of \nthis new marker \nfor the follow -up \nof melanoma \npatients by means \nof serial \nmeasurement \n(before and after \ntreatments, and \nduring follow -up) Diagnostic study  60 melanoma \npatients  \n(24: stage I \u2013II, 18 \nstage III, 18 stage \nIV) Overall survival  \n \nChange in serum \nconcentrations by \ntherapeutic \ninterventions  In stage III  \npatients with \nelevated marker \nconcentration, LN \ndissection \ndecreased the \nS100B level  (from \n0.27 to  \n< 0.13 g/l, P= \n0.008), but not the \nL-dopa/L -tyrosine \nratio. \n \nChemotherapy \ndecreased the \nratio by  Small patient \nnumbers divided \ninto many \nsubgroups \n \nStudy included \nhere in addition to \nS100 meta -\nanalysis because \nof results about L -\ndopa/L -tyrosine \nratio \n \n 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 126 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n38% (P 0.04) and \nthe S100B level by \n45% (P 0.02) in \nstage IV \nresponders.  \n \nincrease in one or \nboth markers \nduring follow -up in \npatients with \nprogressive \ndisease:  \n \nshorter survival in \nstage IV patients \nwith high vs. \nnormal L -Dopa/L -\nTyrosine ratio at \ninclusion (3 vs. 15 \nmonths).Levels of \nS100B had no \nimpact on survival, \nin stage IV \npatients.  \n \nNo correlation \nbetween L -dopa/L -\ntyrosine ratio and \nS100 B.  \nStoitchkov et al. Prospective Diagnostic study  89 melanoma Sensitivity and overall sensitivity Precursor  study to   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 127 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(2002)  evaluation of the \npotential of the \nserum L -dopa/L -\ntyrosine ratio in \nthe management \nof melanoma, with \nan emphasis on \nstaging, tumour \nburden and \nprognosis (the \npredictive value \nfor disease \nprogression in \nmetastatic patients \nand survival).   \n patients with \nhistologically \nproven primar y \nand/or metastatic \nmelanoma or \nmeasurable \nmetastatic disease \n(by imaging).  \n \n \n(9 stage I, 33 \nstage II, 19 stage \nIII, 28 stage IV).  specificity  for melanoma: \n51% for the ratio \nand 66% for \nS100B.  \n(range: 33% (stage \nI) to 71% (stage IV) \nfor the ratio, 56 \u2013\n89% for S100B)  \n \nno statistical \ndifference between \nstages I, II and III \npatients for both \nmarkers. \nSignificant higher \nmedian ratio in \nstage IV.  \n \nIn stage III\u2013 IV \npatients, both \nmarkers were \nsignificantly \nhigher in evolutive \npatients than in \nstable ones.  \n \nThe ability \n(sensitivity/specifi\ncity) of markers to \npredict disease \nprogression in Stoitchkov et al., \n2003  \n \nPatients lost to \nfollow -up are not \nincluded in \nanalysis (risk of \nbias)  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 128 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmetastatic \npatients: 78%/67% \nfor the ratio, \n74%/83% for \nS100B (select cut -\noff) and 87%/33% \nusing the \nmanufacturer\u2019s \nreference values. \nKrahn et al. (2001) To evaluate tumor \nmarkers S100, \nMIA, LDH and \nalbumin in \nperipheral blood \nof melanoma \npatients  Diagnostic study  \n 373 melanoma \npatients (284 with \nmelanoma in situ \nor stage I/II and \n89 with melanoma \nstage III/IV; 54 of \nthese tumor free \nand 29 with newly \noccurred \nmetastases)  \n10 control \nsubjects  Sensitivity  \nSpecificity  Presence of lymph \nnode, visceral and \nbrain metastases:  \nSensitivity ( for \nnewly occurred \nmetastases) for \nLDH 48%, for MIA \n80%, for S100 86%  \nSpecificity for LDH \n98%, for S100 91%, \nfor MIA 62%  \nNo false positive \nresults in the \ncontrol group  No follow -up as \nreference standard \n(cross -sectional \ndesign)  \n \n 2b- \nDeichmann et al. \n(1999)  serum levels of \nS100 -beta (S100b) \nand melanoma -\ninhibiting activity \n(MIA) were \nassessed for the Diagnostic study  \n \n \n 71 consecutive \npatients with stage \nIV melanoma  \n \nControl group: 38 \nhealthy adult  Sensitivities  \nand specificities  \n \ndiscrimination \nability  Cut-offs:  \nS100b 0.12 \u03bc g/L, \nMIA 6.50 ng/mL \nAll tested serum \nparameters were \nsignificantly Patients received \ndifferent therapies  \n \nSmall population  \n \nNo information 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 129 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nability to \ndiscriminate \nprogressive from \nnonprogressive  \ndisease.   \n elevated in \npatients with \nprogressive \ndisease.  \n \nSensitivity:  \nS100b=91%  \nMIA=88%  \nLDH=79%  \n \nSpecificity:  \nS100b=76%  \nMIA=73  \nLDH=92%  \n \nIn calculating \nSomers\u2019 Dxy and \nROC-AUC values, \nS100b, MIA,  and \nLDH showed high \ndiscrimination  \nability. Multiple \nlogistic regression: \nLDH was the only \nstatistically \nsignificant marker \nfor progressive \ndisease.  about follow -up \n \n \nHofmann et  al. \n(2011)  to assess the \nutility of Diagnostic study  138 melanoma \npatients in stage III Sensitivity  \n MIA cut -off value \nof 12 ng \u2044mL: No information \nabout time interval 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 130 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma \ninhibitory activity \n(MIA) serum \nmarker in the \nfollow up and \nprimary diagnosis \nof stage III \nmelanoma patients  at time of primary \ndiagnosis and \nduring periodica l \nroutine follow up  Specificity  \n \n5-year survival rate  sensitivity: 69.2%, \nspecificity: 69.9%. \nPPV for relapsing \ndisease: 67.2%, \nNPV: 72.0%  \n \n5-year survival \nrate: 78.1% (MIA \n<12 ng\u2044mL) vs. \n72.7% (MIA >=12 \nng\u2044mL).  \n(P = 0.230).  between blood \nsample and \nstaging/restaging \nexaminations  \n \n\u201crelapse\u201d not \ndescribed in detail, \nstaging results not \ngiven.  \n \nGarnier et al. \n(2007)  L-DOPA/tyrosine \nratio (an index of \ntyrosinase \nactivity), \nmelanoma \nantigens S100B \nand MIA, lactate \ndeshydrogenase \n(LDH) and their \ncombinations were \nevaluated for \nclinical value as \ntumour markers in \nmelanoma.  Diagnostic study  \n 170 CM patients \n(stage I \u2013II: 57, III: \n54, IV: 59)  Sensitivity  \nSpecificity  \nIncrease with \ndisease \nprogression  \nOverall survival At inclusion: \nSensitivity/ \nspecificity of L -\nDOPA/tyrosine \nratio with S100:  \n73%/70%  \nL-DOPA/ tyrosine \nratio with LDH:  \n69%/69%  \nL-DOPA/ tyrosine \nratio with MIA:  \nL-DOPA/ tyrosine \nratio with MIA and \nLDH:  \n74%/68%  \nDuring fol low-up: \nDisease \nprogression (11  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 131 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nstage I \u2013II, 7 stage \nIII patients) \nincreased the L -\nDOPA/ tyrosine \nratio by +35.7%, \nbut not other \nmarker levels (MIA: \n+18%, S100B: -\n20%, LDH: - 9.7%) \nCox regression \nmodel: survival \npredictors were \nS100B and MIA  \nTas et al.  (2004)  To investigate the \nclinical value of \nS100 and MIA as \ntumor markers for \nmalignant \nmelanoma.  \n \n Diagnostic and \nprognostic study  \n 48 CM (5 in stage I \nand II, 22 stage III, \n21 in stage IV)  \nControl group: 15 \nhealthy subjects  Sensitivity, \nspecificity  \nOverall survival Only 5 patients in \nstages I and II \nincluded; none of \nthem had \nincreased MIA, 2 \nhad increased \nS100  \n \nOnly sensitivity of \nserum MIA \nstatistically \nsignificantly \ncorrelated  \n \nin Cox analysis, \nthe prognostic \nsignificance of MIA Small patient \nsample in stage I  \n \nSmall patient \nsample, especially \nin stage I  \n \nSmall control \ngroup of healthy \npeople, no details \ngiven  \n \nDetails of staging \nand follow -up (e.g. \ntime intervals, \nexaminations at \nfollow -up) not 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 132 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nlevel \nwas lost  reported  \nBanfalvi et al. \n(2002)  to compare the \nprognostic values \nof \nserum 5 -S-\nCysteinyldopa, S -\n100B and LDH \nconcentrations  \nin Stage III- IV \nmelanoma patients  Retrospective \ndiagnostic and \nprognostic study  \n \n \n Data from 179 \npatients Stage III-\nIV melanoma \npatients at \ndiagnosis:  \n(37 in Stage III, 142 \nin Stage IV).  \n \nThe age of \npatients ranged \nfrom 22 to 88 \nyears (mean 59.8). \nMedian follow up \ntime was 15 \nmonths.  \n \n63 patients (with  \nother skin \ndiseases) were \nenrolled as control \ngroup.  Specificity  \nSensitivity  \nPPV \n \nOverall Survival Stage III: 5 -S-CD \nwas 60 % \nsensitivity, 91.6 % \nspecificity, 93.8 % \nPPV \n \nStage IV:  \nLDH: \nSensitivity=48.5 %, \nSpecificity =83.3, \nPPV= 98.5.  \nS 100B: \nSensitivity=70.5, \nSpecificity = 100, \nPPV= 100.  \n5-S-CD \nSensitivity=69.1 \nSpecificity =50, \nPPV= 96,9  \n \ncalculated median \nsurvival: 4.6 \nmonths. Kaplan -\nMeyer analysis of \nthe survival of \npatients with \nelevated vs. \nnormal marker In stage III  data for \nsensitivity and \nspecificity for \nS100B and LDH \nnot given  \n \nNo further \ninformation about \nstaging (reference \nstandard)  3b \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 133 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nlevels indicated \nsignificant \ndifferences in case \nof all the 3 \nmarkers, with the \nshortest survival of \npatients with \nelevated S 100B or \nLDH levels \n(p<0.05).  \nMeral et al. (2001)  To investigate the \nhypothesis that \nthe decline in \nserum melanoma -\ninhibiting acitivity \n(MIA) levels \nfollowing initiation \nof treatment might \nhave prognostic \nvalue  Prognostic study  \n \n 35 patients with \nadvanced stage \nmelanoma (11 \nstage III, 24 stage \nIV) \n \nmean age 52.2 \nyears  \n \nControl group \nconsisting of 20 \nadults without \ndegenerative \ndiseases of \ncartilage or joint \npain Overall survival  The mean serum \nLDH, S100 and \nMIA levels of the \npatients with MM \nbefore treatment \nwere significantly \nhigher than in the \ncontrol group.  \n \nPatients with \nvisceral \ndissemination vs. \npatients with \nnodal spread: MIA -\nlevels 30.1 ng/ml \nvs.14.5 ng/ml. \nmean serum MIA \nlevel in the control \ngroup: 12.4 \u00b1 3.2 \nng/ml. (cut -off See original article \nfor overall survival \ncurves (Kaplan -\nMeier)  \n \nSurvival analysis \nwere not perfomed  \nwith serum S100 \nlevels  \n \nAnalysis of LDH \nkinetics revealed \nno useful \ninformation.`  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 134 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nlevel: 8.7 ng/ml \n(mean + 2SD).  \n \n1-year OS rates: no \nchange according \nto the site of the \nprimary tumour, \nthe type of \nsurgical or \nradiation \ntreatment or the \nchemotherapy \nregimen. \n \nAdvanced stage \nMM \npatients in whom \nserum MIA levels \ndid not decrease \nduring systemic \ntreatment had a \nless favourable \nprognosis.  \nBrouard et al. \n(2000)  To determine if \nserial PS100B is a \nmarker for \nmetastatic \nevolution by \nobservation of its \nlevel/variation/evaDiagnostic study  \n \n. \n \n 239 blood samples \nwere taken in 122 \npatients with \ncutaneous \nmelanoma (56 \npatients in \ncomplete Sensitivity and \nspecifictiy  The threshold to \nseparate patients \nwith met astases \nfrom those in \ncomplete \nremission was \n0,09\u00b5g/L Only results of 90 \npatients are \npresented. Drop \nouts are not \ncommented.  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 135 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nluation in patients \nin complete \nremission and \npatients receiving  \nchemotherapy   remission, 56 \npatients with \nmelanoma in \nprogression  \n (Specificity 92%, \nsensitivity 70%).  \n \nPPV (Stage III/IV): \n77%, NPV 89%   \n \n \n \nSchmitz et al. \n(2000)  To analyse the \nserum levels of \nS100B and MIA in \nnon-melanoma \ncontrol patients \nand melanoma \npatients to report \non the sensitivity \nand specificity of \nboth tumor \nmarkers  Diagnostic study  \n 87 CM patients  Specificity  \nPositive results  Specificity for \nS100 regarding \nthe diagnosis of \nmelano ma: \n85.8% with a cut -\noff value of 0.12 \n\u00b5g/l  \n94.6% with a cut -\noff value of 0.20 \n\u00b5g/l \nSpecificity for MIA: \n89.9% with a cut -\noff of 6.5 \u00b5g/l  \n97.4% with a cut -\noff of 8.5 \u00b5g/l  \nValues > 6.5 \u00b5g/l \nfor MIA prior to \ntreatment:  \n0% for stage I/ II  \n53.8% for stage II I  \n68.3% for stage IV  \nValues > 6.5 \u00b5g/l \nfor MIA post \ntreatment:  \n11.7% for stage I/II  No follow -up \n(cross -sectional \ndesign)  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 136 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n9.7% for stage III  \n6.9% for stage IV  \nValues > 0.12 \u00b5g/l \nfor S100 prior to \ntreatment:  \n50% for stage III  \n80% for stage IV  \nValues > 0.12 \u00b5g/l \nfor S100 post \ntreatment:  \n16.1% for stage I/II  \n18% for stage III  \n14.3% for stage IV  \nStahlecker et al. \n(2000)  To evaluate \nwhether MIA is a \nreliable tumor \nmarker in terms of \ncourse of disease, \ntherapy -\nmonitoring and \nprognostic value  Diagnostic s tudy \n  326 melanoma \npatients: 250 \nstage I, 52 stage II, \n5 stage III and 19 \nstage IV  \nControl group of \n100 healthy blood \ndonors  Positive results  \nSensitivity  \nSpecificity  \n Increased MIA \nlevels: \n4.4% in stage I (n = \n250)  \n11.5% in stage II (n \n= 52)  \n60.0% in st age III \n(n = 5)  \n89.5% in stage IV \n(n = 19).  \nElevated MIA 22 \npatients with no \nclinical evidence of \ndisease (stage I, II \nor stage III, IV after \nmetastatic \nsurgery)   3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 137 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n8 of them had \ndetection of \nmetastases at the \nsame time, 5 of \nthem 2 \u2013  6 months \nlater \n9 stayed  free of \nclinically \ndetectable disease \n(false positives = \n3%) \nBosserhoff et al. \n(1997 ) To investigate \nwhether MIA \nprovides a \nclinically useful \nparameter in \npatients with \nmalignant \nmelanomas, and \nto compare this \nwith the diagnostic \nvalue of S100.  Diagn ostic study  \n 112 CM patients \n(38 stage I, 13 \nstage II, 6 stage Ill, \nand 44 stage IV)  \n350 clinically \ntumor -free \npatients during a \nfollow -up period \nafter removal of a \nprimary stage I or \nII melanoma  \n \nControls: 72 \nhealthy blood \ndonors  \nAdditional \ncontrols: 50  \npatients with \nsepsis, 23 patients Positive rates  \nTP \nFN \n Positivity of MIA:  \n- 100% of sera \nfrom 50 patients \nwith stage III and \nIV \n- 13% of sera from \nstage I  \n- 23% of sera fro m \nstage II patients  \n- 9% of clinically \ntumor -free \npatients; 15 (4%) \nof these patients \ndeveloped \nmetastases  \n \nMIA-levels in \npatients with other \nmalignancies: see Sample of stage II \nand III patients \nsmall  \n \n \n5 patients during \nchemothera py of \nstage IV melanoma  \n \nSensitivity/specific\nity not given  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 138 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwith brain tumors, \n243 patients with \nadvanced \nepithelial and \nmesenchymal \ntumors  full-text \n \nS100 -positivity, \ncut-off: 0.15 \nng/ml  \n- 30/49 (61%) sera \nfrom stage III and \nIV pati ents  \n- 0% of stage I and \nII sera  \n- 4% of sera from \nhealthy donors  \n- 20% from septic \npatients, 16% from \npatients with \ngliomas, and 5% \nfrom patients with \nadvanced \ncarcinomas \npositive  \nBosserhoff et al. \n(1999 )      Same patient \ncohort as \nBosserhoff et al. \n(1997), less data  \n \n  \nHenze et al. (1997)  To examine serum \nS100 \nconcentrations of Diagnostic study  \n \n Blood samples \nfrom 73 patients \nwith malignant sensitivity  1/25 stage I/II \npatients, 3/14 \nstage III patients Small population  \n \nChoroid melanoma 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 139 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npatients with \ndifferent stages of \nmalig nant \nmelanoma and to \ndetermine the \nvalue of serum \nS100 in the follow -\nup of melanoma \npatients during \ntreatment  melanoma (25 \npatients: stage I/II, \n14: stage III, 34: \nstage IV)  \n \nControl group: \n130 healthy \npatients.  (sensitivity 21,4%) \nand 27/34 stage \nIV patients \n(sensitivity 79,4%) \nshowed detectable \nS100 levels.  \nFor metastastic \nmelanoma (stage \nIII/IV): sensitivity \n62,5%.  \n \nCorrelation \nbetween serum \nS100 and clinical \nstage (p=0,0899 \nstage I/II versus \np<0,0001 stage \nIII/IV)  included (n=1)  \n \nNo information \nabout staging \ngiven  \nDumitrascu et al. \n(2009)  To investigate S -\n100B and MIA in \nrelation to disease \ndevelopment  Diagnostic study  \n  51 patients with \nskin melanoma \n(34% stage I, 40% \nstage II, 15% stage \nIII and 11% stage \nIV) and 72 healthy \nvolunteers  \n True  and false \npositives  Mean serum level \nof S100 in healthy \nvolunteers: \n0.172 \u00b5g/l  \n5.55% FP  \nMean serum l evel \nof MIA in healthy \nvolunteers: \n7.28 \u00b5g/l  \nNo false positives  \nS-100B \nsignificantly Low patient \nnumbers for each \nstage  \nSelection critera \nfor patients and \nhealthy volunteers \nnot given  \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 140 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nelevated only in \nstage IV patients \n(p = 0.02)  \nMIA significantly \nelevated both \nstage II, III and IV  \nMIA levels \ndecreased after \nsurgical removal of \ntumors and/or \nafter good  \nresponse to \nspecific therapy; \nincrease followed \ntumor progression \nand poor clinical \nresponse to \ntreatment  \nVucetic et al. \n(2008)  To investigate \nwhethe r MIA \nserum level will be \nelevated in \npatients with  \nmetastases or \nlocal spreading of \nthe disease before \nany \nsymptom of such \nprogression is \nclinically apparent  Diagnostic study  \n 140 patients:  \n(50 with positive \nSN,  \n50 with negative \nSN,  \n20 controls with \ndysplastic nevi \n20 controls with \nbasal cell \ncarcinoma  \nExclusion \ncriterion: palpable Mean values  \nSensitivity  \nSpecificity  Mean MIA value in \npatients with \npositive sentinel \nnodes:  \n14.53 ng/ml  \nMean MIA value in \npatients with \nnegative sentinel \nnodes:  \n7.32 ng/ml  \nAt a cutoff value of \n8.5 ng/ml, 82% No follow -up as \nreference standard \n(cross -sectional \ndesign)  \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 141 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nlymph nodes  sensitivity and 82% \nspecificity of MIA  \nArenberger (2007)  quantification of \nthe following five \nmelanoma \nmarkers by \nestablishing a \nquantitativ e \nmultimarker real -\ntime RT -PCR assay: \nmelanoma antigen \nrecognized by T \ncells (Melan -\nA/MART -1), \nmelanosomal \nmatrix protein \n(gp100), \nmelanoma \nantigen -A3 family \n(MAGE -3), \nmelanoma \ninhibitory protein \n(MIA),  \nand tyrosinase.  \nAdditionally \nhuman  \ntelomerase reverse  \ntranscriptase \n(hTERT) was \nfocused on  Prospective study  \n \n 65 patients with  \nresected \ncutaneous \nmelanoma stage \nIIB\u2013III  \n33.9% stage IIA, \n24.6% stage IIB, \n12.3% stage IIC, \n15.4% IIIA,  \n9.2% stage IIIB and \n4.6% stage IIIC.  \n \nControl group: 23 \nhealthy donors  \n \n Detection rate  Tumour marker \nmean levels in \npatients with \nprogression: MIA, \n4.272\u00b12.183 \n(statistically \nsignificant \ndifference \ncompared with \ncut-off value, \nP<0.01); Melan -A, \n0.026\u00b10.016 \n(P>0.05); MAGE  \n3332.927\u00b1196.23\n9 (P<0.01); gp100, \n0.953 \u00b10.827 \n(P<0.05). MAGE -3 \nwas the most \nfrequent positive \nmarker (17x), than \ngp100 (10x), MIA \n(9x) and tyrosinase \n(1x). Melan -A did \nnot show any \nsignificant \nelevation \ncompared with \ncut-off. Small population  \n \nElevation of \ntumour markers \nvaries stro ngly \n(e.g. patient 35: \nMAGE -3= 36.4, in \npatient 2: MAGE -\n3=40 580).  \n \npoor information \nabout the \npatients` follow -\nup after the study.  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 142 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nThe final aim is \nthe routine usage \nof this method for \nrapid  \nscreening of early \nmetastasis and \ntreatment \nresponse in high -\nrisk melanoma \npatients.  \n  \nIn patients with  \nprogression, in \n39% three markers \nwere \nconcomitantly \npositive, in 28% \ntwo markers and \nin 33% one marker \nwere positive. \nArenberger (2007)  See above  See above  See above  See above  See above  Same \npopulation/same \nresults as in the \npreviously \ndescribed study \n(Arenberger P \n(2007): \nMultimarker real -\ntime reverse \ntranscription -PCR \nfor quantitative  \ndetection of \nmelanoma -\nassociated \nantigens: a novel \npossible staging \nmethod)    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 143 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSmit et al. (2008)  to evaluate S -100B \nfor monitoring \nresponse to \nchemoimmuno ther\napy followed by \nsurgery and its \npredictive value \nfor relapse and \noverall survival in \npatients with \nclinically \ndetectable \nlocalized disease.  \n \nAnother aim was \nto analyze the \nexpression of S -\n100B in the lymph \nnodes and in-\ntransit metastases \nof the includ ed \npatients and to \ncompare these \nfindings with the \nvalues of S -100B in \nthe serum. \n Prognostic study.  \n \n 44 patients with \nlocoregional -\nlymph  \nnode or intransit \nmetastases \n(cytologically \nproven, clinically \ndetectable \nregional \nmetastases of \nmelanoma without \nevidence of distant \nmetastases.  Overall survival  \n \nRenissionrate  \n Correlations \nbetween the \npattern  \nand intensity of S -\n100B expression \nin the tumor \nspecimen  \nand the value of \nserum the S -100B \ndid not reach \nstatistical \nsignificance  Small population  \n \n 3b- \nLugovi c et al. \n(2007)  To determine and \ncompare levels of \nS100, MIA, LDH Diagnostic study  \n 50 melanoma \npatients (30% in \nstage I, 52% in Positive results  Increased MIA in \n26% of stage I \npatients, 26% of No follow -up as \nreference standard  \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 144 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nand tyrosinase in \nthe serum of \npatients with MM \nin different \ndisease stages, \nand to conclude \nwhether these \nmight be useful \nprognostic tools \nfor MM \nprogression  stage II, 16% in \nstage III and 8% in \nstage IV)  stage II patients, \n0% of stage III \npatients and 50% \nof stage IV \npatients  \nIncreased S100 in \nof stage I patients,  \n9% of stage II \npatients, 0% of \nstage III patients \nand 50% of stage \nIV patients  \nIncreased LDH in \n26% of stage I \npatients, 4% of \nstage II patients, \n13% of stage III \npatients and 25% \nof stage IV \npatients   \nAuge et al.  (2005)  To compare the \nsensitivity and \nspecificity of S -100 \nand MIA and their \ncombination in \nadvanced \nmelanoma, and \nthe relationship \nwith prognostic \nfactors such as Diagnostic study  \n 182 CM patients: \n96 patients with  \nno evidence of \ndisease (NED, \nstages I and II) and \n86 patients with \nstages III, IV  Sensitivity  Sensitivity of S100 \n(cutoff > 0.2 \u00b5g/l):  \n53.8% for SSM, \n40% for ALM,  75% \nfor NM  \nSensitivity of MIA \n(cutoff > 14 ng/l):  \n61.5% for SSM, \n40% for ALM, 65% \nfor NM  No data given for \nspecificity  \nReference test not \ndescrib ed in detail  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 145 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ngrowth patterns \nand site of \nmetastases.  Slightly elevated \nlevels of S100 (< \n0.24 \u00b5g/l) and MIA \n(< 16.4 ng/ml) in \n1.2% and 3.2% of \nNED patients, \nrespectively  \nSensitivity of S100 \nfor LN metastasis \n58.3%, for multiple \nmetastases 58.3%, \nfor multiple with \nliver metastasis \n70%, for brain \nmetastasis 77%  \nand for lung \nmetastasis 30%  \nSensitivity of MIA \nfor LN metastasis \n54.1%, for multiple \nmetastases 62.5%, \nfor multiple with \nliver metastasis \n70%, for brain \nmetastasis 66.6% \nand for lung \nmetastasis 23%  \nGuba et al.  (2002)  To evaluate the \nassociation \nbetween pre - and Diagnostic and \nprognostic study  \n 70 patients with \nhistologically \nconfirmed Overall -survival  \nSpecificity  \n Mia positivity \nconcentrations:  \n>8,8ng/l.:  No data for \nsensitivity given  \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 146 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nposttreatment \nlevels of MIA and \nsurvival in 70 \npatients with \nadvanced \nmelanoma.   metastastic \nmelano ma. (50 \nstage III, 17 stage \nIV) - stage III: 46%  \n- stage IV: 65%  \n \nMedian OS in MIA \npositive patients \n(stage III/IV): 13 \nvs. 28 months in \npatients with \nnegative pre -\ntreatment MIA \nlevels. \n \nstaging -related \nanalysis:  \nstage III: median \nOS: 14 months in \nMIA positive \npatients vs. 28 \nmonths in \nnegative patients.  \nstage IV: 12 vs. 19 \nmonths \nrespectively. \n \nSpecifitiy (cut -\noff>8,8ng/l) = 95%  Small population  \n \n \nKlimek et al. (2002)  To evaluate the \nsensitivity of \nserum MIA levels \nin predicting the Diagnostic study  \n  39 patients with \nstage II, III and IV \nmelanoma  \n14 patients with Sensitivity  \nFalse positives  MIA: \n17% sensitivity for \nrecurrence  \n6% false positives  MIA values taken \nat different \nintervals after \ndiagnosis and 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 147 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nrisk of relapse in \npatients with AJCC \nstage II, III and IV \nmelanoma  clinically adva nced \nmelanoma (IV or \nunresectable III) as \npositive controls  \nSerum from 20 \npatients with \nprostate or small \ncell lung cancer to \nestablish a \nbackground \nreference range  No signi ficant \ndifference in the \nproportion of \npatients with \nelevated MIA levels \nbetween the group \nof patients who \nrelapsed (17%) and \nthose who did not \nrelapse (6%)  treatment of \nmelanoma  \n \n \nMatsushita  et al. \n(2002)  To compare the \nusefulness of the \nserum markers 5 -\nS-cysteinyldopa (5 -\nS-CD) and \nmelanoma \ninhibitory activity \n(MIA) in the \nmonitoring of \npostsurgical \nmelanoma patients  Diagnostic study  \n 45 CM patients (7 \nin stage I, 20 in \nstage II, 18 in \nstage III)  \n30 age -matched \nhealthy volunteers  Sensitivity  \nFalse positives  Sensitivity for \ndetection of \nrelapse: \n64% for MIA  \nFalse positives \n(non-progressive \npatients) for MIA \n8.3% (6/72) \n No selection \ncriteria for the \nincluded patients \ngiven  \n \nEvaluation per \nsample, not per \npatient  \nNo description of \nfollow -up  \n \n 3b- \nDreau et al. (1999)  To measure \nplasma MIA \nconcentration in \npatients with \nmetastatic \nmelanoma or Diagnostic study  \n 84 CM patients (16 \nin stage II, 29 in \nstage III and 39 in \nstage IV) under \ntreatment  \nMost of stage II Sensitivity and \nspecificity  At a threshold of \n4.5 ng/ml values \nfor discrimination \nbetween \nprogression and \nno progression Low patient \nnumbers for each \ntreatment modality  \nMethod of \nassigning patients \nto treatment 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 148 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npatients at high \nrisk for recurrence \ntreated with \nvarious \nimmunotherapy \nregimens  and III patients \n(36/45) were \ntreated with \npolyvalent \nmelanoma vaccine \nafter surgical \nresection; all \npatients treated \nwith IL -2 were \nstage IV  were: Sensitivity of \n82% and specificity \nof 71% before \ntreatment  \nSensitivity of 67% \nand specificity of \n79% after \ntreatment  regimens not \ndescribed  \n \n \nTofani et al. (1997)  To assess the \nreliability of NSE \nand S100 as \nindexes of disease \nactivity. Diagnostic and \ncross -sectional \nstudy  \n \n 53 consecutive \npatients with \nmelanoma  \n \n24 patients \npresented with \nlocal disease \n(stage I or 11), 29 \nhad metastases \n(stage III or IV).  \n \nTwenty healthy \nvolunteers were \nused as a control \ngroup.  Prevalence of \nincreased NSE and \nS100 levels  \n \nSensitivity and \nspecificity  In the whole \ngroup, elevation of  \nS-100 in 30% of \npatients. No \nelevated levels in \nthe subgroup of \n24 patients stage I \nand II. Inceased \nlevels in 55% of \npatients stage III \nand IV  \n \nSerum NSE: \nelevated in 26%. \n4/24 patients \n(16%) with \nmelanoma in \nstages I and II had \nincreased NS E \nvalues. Inceased Small patient \nsamples  \n \nStudy included in \naddition to S100 \nmeta -analysis \nbecause of results \nabout NSE  \n \nNo details about \nreference standard \nfor the calculation \nof sensitivity and \nspecificity  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 149 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nlevels in 34% of \npatients stage III \nand IV.  \n \n \nFor the whole \ngroup: sensitivity \nof S100 and NSE: \n30 and 26%, \nrespectively  \n \nFor patients I and \nII: \nPoor sensitivity for \nNSE, S -100 values \nwere normal in all \npatients.  \n \nFor patients stage \nIII and IV: \nsensitivity for  S -\n100 and NSE: 55% \nand 34% \nrespectively  \n(p < 0.5).  \nAktualisierungsrecherche 2015  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 150 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nRodriguez Rivera et \nal. 2014  To review the \ncollective \nexperience and \nutility of FDG -PET \nscans in the \ndetection of \nsystemic \nmetastases in \npatients w ith stage \nIII melanoma  Systematic review \nand meta -analysis  A total of 623 \npatients with stage \nIII melanoma  Sensitivity  \n \n \n \nSpecificty  \n \n \n \nPositive and \nnegative likelihood \nratios  \n \n \n \n \n \n \nSROC  \n \n \n \n \n \n \nDOR \n \n \n \n \nChange of \nmanagement  Sensitivity of FDG -\nPET:  89.42% (95% \nCI: 65.07 - 97.46)  \n \nSpecificity: 88.78% \n(95% CI: 77.04 -  \n94.91).  \n \nPooled positive \nlikelihood ratio:  \n7.97 (95% CI: 3.58 \n- 17.71)  \n \nNegative \nlikelihood ratio: \n0.12 (95% CI: 0.03 \n- 0.47).  \n \nArea under  \nthe summary \nreceiver operating \ncurve (SROC):  \n0.94 (9 5% CI: 0.92 \n- 0.96) \n \nDiagnostic odds \nratio \n(DOR): 66.84 (95% \nCI: 10.66 - \n418.89).  \n Small sample size, \n9 studies included  \n \nConfirmation bias \npossible: adequ ate \nreference test was \nnot applied \nproperly (biopsy, \nfurther \nradiological \nstudies and/or \nfollow -up) \n \n67% of the \npatients had \nclinically evident \nstage III disease \uf0e0  \nfindings possibly \nmore relevant for \npatients stage \nIIIb/c disease  IIa  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 151 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n Change in stage \nand/or \nmanagement was \nnoted in 22% \n(126/573) of \npatients when \nFDG-PET was \nutilized. \nBastiaannet et al. \n2012 \n - to assess \npredictive value of  \nFDG-PET and CT  \n- to analyze their \ncost-effectiveness \nin several \ndiagnosis \u2013 \ntreatment \ncombinations. Cohort study  253 melanoma \npatients  with \npalpable, proven  \nlymph node \nmetastases Sensitivity  \n \n \nSpecificity  \n \n \nAccuracy  \n \n \n \n \n \nPPV \nNPV \n \nCost-consequence \nanalysis  \n \n FDG-PET: \nSensitivity: 86,1% \n(CI: 78.4 \u201393.7)  \nSpecificity: 93,1% \n(CI: 89.3 \u201396.9)  \n \nCT \nSensitiviy: 78,2% \n(CI: 69.0 \u201387.4)  \nSpecificity: 93,7% \n(CI: 90.1 \u201397.3)  \n \nPPV, NPV, \naccuracy: see table \n2/full -text \n \nCost of diagnostic \nwork-up: \nWith CT: - 5,5% \nWith FDG -PET: \n+7,2%  \nWith both: +15,1% True-positive \nupstaging in 61 \npatients (CT) \nrespectively in 68 \npatients (FDG -PET) IIb  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 152 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n  \nBronstein et al. \n2012  \n To determine how \noften unexpected \nFDG PET -CT \nfindings result in \nchange of \nmanagement  of \nstage IV and \nclinically evident \nstage III melanoma \npatients with \nresectable disease \nbased on \nconventional \nimaging  Cohort study  patients with stage \nIV and clinically \nevident stage  \nIII melanoma  Metastases \ndetection rate  \n \n \n \nchange in surgical  \nmanagement  unexpected \nmelanoma \nmetastases in 12 % \nof scans  \n \nAs a result the \nsurgery was \ncancelled in two \npatients, and the \nplanned approach \nwas altered in  \nanother two \npatients to \naddress the \nunexpected sites  Small population  IIb \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 153 von 817 \n2.3.5.  Literatur  \nLiteratur :  Zuteilung zu  Fragestellung:  \nI.6 I.7 I.8 VII\n.6 \nAbbott et al. (2011 ) x x  x \nAgarwala et al. (2009 )    x  \nAloia et al. (2006)   x   \nAndr\u00e9s et al. (2008)  x x x  \nArdizzoni et al. (1987)  x    \nArenberger (2007)  x x   \nAu et al. (1984)  x    \nAuge et al. (2005)  x x x  \nBafounta et al. (2004)   x x x x \nBalch et al. (2009) (x) (x) (x) x \nBastiaannet et al. (2009)   x  x \nBastiaannet et al.  (2012 )  x x   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 154 von 817 \nLiteratur :  Zuteilung zu  Fragestellung:  \nI.6 I.7 I.8 VII\n.6 \nBosserhoff et al. (1997)  x x x x \nBouwhuis et al. (2011)  x x  x \nBronstein et al. (2012)   x x  \nBrouard et al. (2000)  x x x x \nBuzaid et al. (1995)   x   \nChai et al. (2011 ) x    \nClark et al. (2006)  x    \nCollins et al. (1993)     x \nConstantinidou et al. (2008)   x   \nDeichmann et al. (2004) x x x x \nDellestable et al. (2011 )   x  \nDietlein  et al. (199 9)  x x x \nDoiron et al . (1981)    x   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 155 von 817 \nLiteratur :  Zuteilung zu  Fragestellung:  \nI.6 I.7 I.8 VII\n.6 \nDreau et al. (1999)  x x x  \nDumitrascu et al. (2009 ) x x x  \nEtchebehere et al. (2010 )  x x  \nEl-Maraghi and Kielar (2008)  x    \nEssler et al. (2011 ) x x x x \nFogarty et al. (2006)  x x x x \nGarbe et al. (2003 )    x \nGarnier et al. (2007)  x x x  \nGinaldi et al. (1981)  x  x x \nGoerz et al. (1986)  x x x x \nGuba et al. (2002 )  x x  \nHafner et al. (200 4) x    \nHausmann et al. (2011 )  x x x  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 156 von 817 \nLiteratur :  Zuteilung zu  Fragestellung:  \nI.6 I.7 I.8 VII\n.6 \nHeaston et al. (1983 ) x x   \nHenze et al. (1997 )    x \nHinz et al. (2011 ) x    \nHocevar et al. (2004 ) x    \nHofmann et al. (2002 )  x   x \nHofmann et al. (2009 )    x \nHofmann et al. (2011 )  x  x \nHolloway et al. (1997)   x x x \nHorn et al. (2005 )  x   \nLagaru et al. (2007 )m x x x x \nIscoe et al. (1986 ) x    \nJohnson (1997 )  x   \nKaskel et al. (1999 )  x x x x  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 157 von 817 \nLiteratur :  Zuteilung zu  Fragestellung:  \nI.6 I.7 I.8 VII\n.6 \nKersey et al. (1985)  x   x \nKhansur et al. (1989 ) x x x x \nKlode et al. (2010 ) x    \nKoskivuo et al. (2007)  x x  x \nKrahn et al. (2001 ) x x x x \nKrug et al. (2000)   x x x \nKrug et al. (2008 ) x x x x \nKruijff et al. (2009 )  x   \nKruijff et al. (2011)   x   \nKuan et al. (1988)  x x x  \nKunte et al. (2009 ) x    \nLaurent et al. (2011)    x  \nL\u00f6ffler et al. (2003)   x x x  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 158 von 817 \nLiteratur :  Zuteilung zu  Fragestellung:  \nI.6 I.7 I.8 VII\n.6 \nLugovic et al. (2007)  x x x  \nMansour et al. (2010)  x x x x \nMatsushita et al. (2002 ) x x x  \nMaubec et al. (2007 ) x    \nMeyer and Stolbach (1978)  x    \nMiranda et al. (2004 )  x   \nMocellin et al. (2008)  x x x x \nMueller -Horvat (2005)   x x x \nNeuss et al.  (2011 )  x   \nPanagiotou et al. (2001)  x   x \nPandalai et al. (2010 )  x   \nPaschen et al. (2009 ) x x x x \nPatten et al. (1990 ) x x x x  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 159 von 817 \nLiteratur :  Zuteilung zu  Fragestellung:  \nI.6 I.7 I.8 VII\n.6 \nPfannenberg et al. (2007)   x x x \nPleiss et al.(2007)  x x x x \nRevel et al. (2010 ) x    \nRodriguez et al. ( 2014 )  x x  \nSaiag et al. (2005 ) x x  x \nSanki et al. (2009)  x    \nSawyer et al. (200 9) x   x \nSchlamann et al. (2008)  x x x x \nSchmid-Wendtner et al. (2004)  x x   \nSchmitz et al. (2000)  x x x  \nSibon et al. (2007)  x    \nSilverman et al. (1984)  x  x x \nSingh et al. (2008)  x     \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 160 von 817 \nLiteratur :  Zuteilung zu  Fragestellung:  \nI.6 I.7 I.8 VII\n.6 \nSmit et al. (2008)   x  x \nStahlecker et al. (2000)  x x x x \nStas M et al. (2002)   x x  \nStoffels et al. (2011 ) x x   \nStoitchkov et al.  (2003)  x x x  \nStrobel et al. (2007)  x x x x \nStucky et al. (2010 ) x x   \nStutte (1989)   x x x \nTas et al. (2004 ) x x x x \nTerhune et al. (1998)  x    \nTestori et al. (2005 ) x   x \nTofani et al. (1997)  x x x x \nTsao et al. (2004 ) x   x  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 161 von 817 \nLiteratur :  Zuteilung zu  Fragestellung:  \nI.6 I.7 I.8 VII\n.6 \nUren (1999)   x   \nVan den Brekel et al. (1998 ) x x  x \nVan der Ploeg (2009 ) x    \nVeit-Haibach et al. (2009 ) x x x  \nVereecken et al. (200 5) x    \nVereecken et al. (2009)   x x  \nVermeerenet al. (2011 ) x    \nVucetic et al. (2008) x    \nWagner et al. (2011 )  x   \nWang et al.  (2004)  x    \nWebb (1977 ) x x x x \nXing et al. (2011 ) x x x x \nYancovitz et al. (2007 ) x x    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 162 von 817 \nLiteratur :  Zuteilung zu  Fragestellung:  \nI.6 I.7 I.8 VII\n.6 \nZartman et al. (1987)  x    \n \n \nAbbott RA, Acland KM, Harries M, et al. The role of positron emission tomography with computed tomography in the follow -up of asympt omatic cutaneous malignant melanoma \npatients with a high risk of disease recurrence. Melanoma Res 2011;21:446- 449 \nAgarwala SS, Keilholz U, Gilles E, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM3 01 and EORTC 18951). Eur J Cancer \n2009;45:1807- 1814  \nAloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node -positive melanom a. J Clin Oncol 2006;24:2858- 2865  \nAndres R, Mayordomo JI, Visus C, et al. Prognostic significance and diagnostic value of protein S -100 and tyrosinase in patients with malignant melanoma. Am J Clin Oncol 2008;31:335-\n339 \nArdizzoni A, Grimaldi A, Repetto L, et al. Stage I -II melanoma: the value of metastatic work -up. Oncology 1987;44:87- 89 \nArenberger P, Arenbergerova M, Gkalpakiotis S, et al. Multimarker real -time reverse transcription -PCR for quantitative detection of melanoma -associated antigens: a novel po ssible \nstaging method. J Eur Acad Dermatol Venereol 2008;22:56- 64 \nArenberger P, Arenbergerova M, Vohradnikova O, et al. Early detection of melanoma progression by quantitative real -time RT -PCR analysis for multiple melanoma markers. Keio J Med \n2008;57:57- 64 \nAu FC, Maier WP, Malmud LS, et al. Preoperative nuclear scans in patients with melanoma. Cancer 1984;53:2095 -2097  \nAuge JM, Molina R, Filella X, et al. S -100beta and MIA in advanced melanoma in relation to prognostic factors. Anticancer Res 2005;25:1779- 1782 \nBafounta ML, Beauchet A, Chagnon S, et al. Ultrasonography or palpation for detection of melanoma nodal invasion: a meta -analysis. Lancet Oncol 2004;5:673- 680 \nBalch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and cl assification. J Clin Oncol 2009;27:6199- 6206  \nBanfalvi T, Boldizsar M, Gergye M, et al. Comparison of prognostic significance of serum 5 -S-Cysteinyldopa, LDH and S -100B protein in Stage III -IV malignant melanoma. Pathol Oncol \nRes 2002;8:183- 187 \nBastiaannet E, Wobbes T, Hoekstra OS, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma \nwith palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol  2009;27:4774- 4780  \nBastiaannet E, Uyl -de Groot CA, Brouwers AH, et al. Cost -effectiveness of adding FDG -PET or CT to the diagnostic work -up of patients with stage III melanoma. Ann Surg. \n2012;255(4):771- 776. \nBosserhoff AK, Kaufmann M, Kaluza B, et al. Mela noma -inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997;57:3149- 3153  \nBosserhoff AK, Lederer M, Kaufmann M, et al. MIA, a novel serum marker for progression of malignant melanoma. Anticancer Res 1999;19:2691- 2693  \nBouwhuis MG, Suciu S, Kruit W, et al. Prognostic value of serial blood S100B determinations in stage IIB -III melanoma patients: a corollary study to EORTC trial 18952. European journal \nof cancer (Oxford, England : 1990) 2011;47:361- 368 \nBronstein Y, Ng CS , Rohren E, et al. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive \nvalue after conventional imaging. AJR Am J Roentgenol. 2012;198(4):902- 908.Brouard M, Quillien V, Ollivier I, et al. Serum S100B protein and stage of cutaneous melanoma: a \nprospective study. Ann Dermatol Venereol 2000;127:56- 59 \nBuzaid AC, Tinoco L, Ross MI, et al. Role of computed tomography in the staging of patients with local -regional metastases of melanoma. J Clin Oncol 1995;13:2104- 2108  \nChai CY, Zager JS, Szabunio MM, et al. Preoperative Ultrasound is Not Useful for Identifying Nodal Metastasis in Melanoma Patients Undergoing Sentinel Node Biopsy: Preoperative \nUltrasound in Clinically Node -Negat ive Melanoma. Ann Surg Oncol 2011  \nClark PB, Soo V, Kraas J, et al. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Ar ch Surg 2006;141:284- 288 \nCollins CD, Padley SP, Greenwell F, et al. The efficacy of a single posteroanterior radiograph in the assessment of metastatic pulmonary melanoma. Br J Radiol 1993; 66:117- 119 \nConstantinidou A, Hofman M, O'Doherty M, et al. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Res 2008;18:56- 60  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 163 von 817 \nDeichmann M, Benner A, Bock M, et al. S100- Beta, melanoma -inhibiting activity, and lactate dehydrogenase discriminate progressive fro m nonprogressive American Joint Committee on \nCancer stage IV melanoma. J Clin Oncol 1999;17:1891- 1896  \nDeichmann M, Benner A, Kuner N, et al. Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100beta or mel anoma inhibitory \nactivity (MIA)? Melanoma Res 2001;11:291- 296 \nDeichmann M, Kahle B, Moser K, et al. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C -reactive protein in serum is superior to lactate \ndehydrogenase. Br J Ca ncer 2004;91:699- 702 \nDellestable P, Granel -Brocard F, Rat AC, et al. Impact of whole body magnetic resonance imaging (MRI) in the management of melanoma patients, in comparison with positron emi ssion \ntomography/computed tomography (TEP/CT) and CT. Annales de dermatologie et de v\u00e9n\u00e9r\u00e9ologie 2011;138:377 -383 \nDietlein M, Krug B, Groth W, et al. Positron emission tomography using 18F -fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and \nradiological methods of diagnos is. Nucl Med Commun 1999;20:255- 261 \nDoiron MJ, Bernardino ME. A comparison of noninvasive imaging modalities in the melanoma patient. Cancer 1981;47:2581 -2584  \nDreau D, Bosserhoff AK, White RL, et al. Melanoma -inhibitory activity protein concentrations in b lood of melanoma patients treated with immunotherapy. Oncol Res 1999;11:55- 61 \nDumitrascu G, Constantin C, Manda G, et al. Serum markers in skin melanoma --preliminary study. Roum Arch Microbiol Immunol 2009;68:125- 135 \nEl-Maraghi RH, Kielar AZ. PET vs sentin el lymph node biopsy for staging melanoma: a patient intervention, comparison, outcome analysis. J Am Coll Radiol 2008;5:924 -931 \nEssler M, Link A, Belloni B, et al. Prognostic value of [18F] -fluoro -deoxy -glucose PET/CT, S100 or MIA for assessment of cancer -associated mortality in patients with high risk melanoma. \nPLoS One 2011;6:e24632 \nEtchebehere EC, Romanato JS, Santos AO, et al. Impact of [F -18] FDG -PET/CT in the restaging and management of patients with malignant melanoma. Nucl Med Commun 2010;31:925-\n930 \nFogarty GB, Tartaguia C. The utility of magnetic resonance imaging in the detection of brain metastases in the staging of cut aneous melanoma. Clin Oncol (R Coll Radiol) 2006;18:360-\n362 Garbe C, Leiter U, Ellwanger U, et al. Diagnostic value and prognosti c significance of protein S -100beta, melanoma -inhibitory activity, and tyrosinase/MART -1 reverse transcription -\npolymerase chain reaction in the follow -up of high -risk melanoma patients. Cancer 2003;97:1737- 1745 \nGarnier JP, Letellier S, Cassinat B, et al. C linical value of combined determination of plasma L -DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer 2007;43:816- 821 \nGinaldi S, Wallace S, Shalen P, et al. Cranial computed tomography of malignant melanoma. AJR Am J Roentgenol 1981;136:145- 149 \nGoerz G, Schulte -Beerbuhl R, Roder K, et al. Malignant melanoma: which examinations are useful in staging and follow -up? Dtsch Med Wochenschr 1986;111:1230- 1233  \nGuba M, Steinbauer M, Ruhland V, et al. Elevated MIA serum levels are predictors of poor p rognosis after surgical resection of metastatic malignant melanoma. Oncol Rep 2002;9:981 -\n984 \nHafner J, Schmid MH, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol 2004;150:677- 686 \nHausmann D, Jochum S, Utikal J, et al. Compar ison of the diagnostic accuracy of whole -body MRI and whole -body CT in stage III/IV malignant melanoma. JDDG -  Journal of the German \nSociety of Dermatology 2011;9:212 -222 \nHeaston DK, Putman CE, Rodan BA, et al. Solitary pulmonary metastases in high -risk me lanoma patients: a prospective comparison of conventional and computed tomography. AJR Am J \nRoentgenol 1983;141:169- 174 \nHenze G, Dummer R, Joller -Jemelka HI, et al. Serum S100-- a marker for disease monitoring in metastatic melanoma. Dermatology 1997;194:208 -212 \nHinz T, Wilsmann -Theis D, Buchner A, et al. High -resolution ultrasound combined with power Doppler sonography can reduce the number of sentinel lymph node biopsies in cutaneo us \nmelanoma. Dermatology 2011;222:180- 188 \nHocevar M, Bracko M, Pogacnik A, e t al. The role of preoperative ultrasonography in reducing the number of sentinel lymph node procedures in melanoma. Melanoma Res 2004;14:533-\n536 \nHofmann MA, Gussmann F, Fritsche A, et al. Diagnostic value of melanoma inhibitory activity serum marker in th e follow -up of patients with stage I or II cutaneous melanoma. \nMelanoma Res 2009;19:17- 23 \nHofmann MA, Schicke B, Fritsch A, et al. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients. J Dermatol 2011;38:880 -886 \nHofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow -up in melanoma patients --monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002;87:151-\n157 Holloway BJ, King DM. Ultrasound diagnosis of metastatic mela noma of the gallbladder. Br J Radiol 1997;70:1122- 1125  \nHorn J, Lock -Andersen J, Sjostrand H, et al. Routine use of FDG -PET scans in melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol Imaging 2006;33:887- 892 \nIagaru A, Quon A, Johnson D , et al. 2 -Deoxy -2-[F-18]fluoro -D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol \n2007;9:50- 57 \nIscoe N, Kersey P, Gapski J, et al. Predictive value of staging investigations in patients with clinical  stage I malignant melanoma. Plast Reconstr Surg 1987;80:233- 239 \nJimenez -Requena F, Delgado -Bolton RC, Fernandez -Perez C, et al. Meta -analysis of the performance of (18)F -FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging 2010;37:284-\n300 \nJohnson TM,  Fader DJ, Chang AE, et al. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol 1997;4:396- 402 \nKaskel P, Berking C, Sander S, et al. S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2 -center study of 570 patients with melanoma. J Am Acad \nDermatol 1999;41:962- 969  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 164 von 817 \nKersey PA, Iscoe NA, Gapski JA, et al. The value of staging and serial follow -up investigations in patients with completely resected, primary, cutaneous malignan t melanoma. Br J Surg \n1985;72:614- 617 \nKhansur T, Sanders J, Das SK. Evaluation of staging workup in malignant melanoma. Arch Surg 1989;124:847 -849 \nKlimek VM, Williams L, Chapman PB. Serum levels of melanoma -inhibiting activity do not predict relapse in mel anoma patients. Cytokines Cell Mol Ther 2002;7:71- 74 \nKlode J, Dissemond J, Grabbe S, et al. Sentinel lymph node excision and PET -CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant \nmelanoma in American Joint Committee on Cancer stages I and II. Dermatol Surg 2010;36:439- 445 \nKoskivuo IO, Seppanen MP, Suominen EA, et al. Whole body positron emission tomography in follow -up of high risk melanoma. Acta Oncol 2007;46:685- 690 \nKrahn G, Kaskel P, Sander S, et al. S1 00 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin \nand lactate -dehydrogenase. Anticancer Res 2001;21:1311- 1316 \nKrug B, Crott R, Lonneux M, et al. Role of PET in the in itial staging of cutaneous malignant melanoma: systematic review. Radiology 2008;249:836- 844 \nKrug B, Dietlein M, Groth W, et al. Fluor -18-fluorodeoxyglucose positron emission tomography (FDG -PET) in malignant melanoma. Diagnostic comparison with convention al imaging \nmethods. Acta Radiol 2000;41:446- 452 \nKruijff S, Bastiaannet E, Kobold AC, et al. S -100B concentrations predict disease -free survival in stage III melanoma patients. Ann Surg Oncol 2009;16:3455- 3462  \nKruijff S, Bastiaannet E, Speijers MJ, et al. T he value of pre operative S -100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection. Eur J Surg \nOncol 2011;37:225- 232 \nKuan AK, Jackson FI, Hanson J. Multimodality detection of metastatic melanoma. J R Soc Med 1988;81:579- 582 \nKunte C, Schuh T, Eberle JY, et al. The use of high -resolution ultrasonography for preoperative detection of metastases in sentinel lymph nodes of patients with cutaneous melano ma. \nDermatol Surg 2009;35:1757- 1765  \nLaurent V, Trausch G, Bruot O,  et al. Comparative study of two whole -body imaging techniques in the case of melanoma metastases: advantages of multi -contrast MRI examination \nincluding a diffusion -weighted sequence in comparison with PET -CT. Eur J Radiol 2010;75:376- 383 \nLoffler M, Weckesser M, Franzius C, et al. Malignant melanoma and (18)F -FDG-PET: Should the whole body scan include the legs? Nuklearmedizin 2003;42:167- 172 \nLugovic L, Situm M, Buljan M, et al. Results of the determination of serum markers in patients with malignant melan oma. Coll Antropol 2007;31 Suppl 1:7- 11 \nMansour AA,3rd, Kelley MC, Hatmaker AR, et al. Verification of musculoskeletal FDG -PET-CT findings performed for melanoma staging. Ann Surg Oncol 2010;17:1144- 1151  \nMatsushita Y, Hatta N, Wakamatsu K, et al. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post -surgical relapse in melanoma patients: comparison with 5 -S-\ncysteinyldopa. Melanoma Res 2002;12:319- 323 \nMaubec E, Lumbroso J, Masson F, et al. F -18 fluorodeoxy -D-glucose positron emissi on tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. \nMelanoma Res 2007;17:147- 154 \nMays MP, Martin RC, Burton A, et al. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel ly mph node biopsy? Cancer 2010;116:1535- 1544 \nMeral R, Duranyildiz D, Tas F, et al. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. M elanoma Res 2001;11:627- 632 \nMeyer JE, Stolbach L. Pretreatment radiographic evaluation o f patients with malignant melanoma. Cancer 1978;42:125- 126 \nMiranda EP, Gertner M, Wall J, et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease.  Arch Surg \n2004;139:831- 6; discuss ion 836- 7 \nMocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta -analysis. Int J Cancer 2008;123:2370- 2376  \nMorton DL, Thompson JF, Cochran AJ, et al. Sentinel -node biopsy or nodal observation in mela noma. N Engl J Med 2006;355:1307- 1317  \nMuller -Horvat C, Radny P, Eigentler TK, et al. Prospective comparison of the impact on treatment decisions of whole -body magnetic resonance imaging and computed tomography in \npatients with metastatic malignant melanoma . Eur J Cancer 2006;42:342- 350 \nNeuss H, Koplin G, Raue W, et al. Analysing the serum levels of tumour markers and primary tumour data in stage III melanoma patients in correlation to the extent of lymph node \nmetastases --a prospective study in 231 patients.  Acta Chir Belg 2011;111:214- 218 \nNowecki ZI, Rutkowski P, Kulik J, et al. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcr iptase -polymerase chain reaction assay of lymph fluid after \nlymph node dissection and preoperative  serum lactate dehydrogenase level. Br J Dermatol 2008;159:597- 605 \nPanagiotou IE, Brountzos EN, Bafaloukos D, et al. Evaluation of imaging studies at the initial staging and during follow -up of patients with local -regional malignant melanoma. Journal of \nB.U.ON 2001;6:411- 414 \nPandalai PK, Dominguez FJ, Michaelson J, et al. Clinical Value of Radiographic Staging in Patients Diagnosed With AJCC Stage III Melanoma. Ann Surg Oncol 2010  \nPaschen A, Sucker A, Hill B, et al. Differential clinical significance of ind ividual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin \nCancer Res 2009;15:5208- 5215  \nPatten RM, Shuman WP, Teefey S. Metastases from malignant melanoma to the axial skeleton: a CT study of frequency and ap pearance. AJR Am J Roentgenol 1990;155:109- 112 \nPfannenberg C, Aschoff P, Schanz S, et al. Prospective comparison of 18F -fluorodeoxyglucose positron emission tomography/computed tomography and whole -body magnetic \nresonance imaging in staging of advanced mal ignant melanoma. Eur J Cancer 2007;43:557- 564 \nPleiss C, Risse JH, Biersack HJ, et al. Role of FDG -PET in the assessment of survival prognosis in melanoma. Cancer Biother Radiopharm 2007;22:740- 747 \nRevel A, Revel C, Dolivet G, et al. La TEP -TDM au 18FDG a -t-elle un int\u00e9r\u00eat dans la stadification ganglionnaire des m\u00e9lanomes malins cutan\u00e9s cervicofaciaux b\u00e9n\u00e9ficiant de la technique \ndu ganglion sentinelle ? \u00c0 propos de 22 cas. M\u00e9decine Nucl\u00e9aire 2010;34:528- 539 \nRodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerdi tchian AN. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta- analysis. \nSurg Oncol. 2014;23(1):11- 16.  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 165 von 817 \nSaiag P, Bernard M, Beauchet A, et al. Ultrasonography using simple diagnostic criteria vs palpation  for the detection of regional lymph node metastases of melanoma. Arch Dermatol \n2005;141:183- 189 \nSanki A, Uren RF, Moncrieff M, et al. Targeted high -resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primar y cutaneous melanoma. J \nClin Oncol 2009;27:5614- 5619  \nSawyer A, McGoldrick RB, Mackey SP, et al. Does staging computered tomography change management in thick malignant melanoma? J Plast Reconstr Aesthet Surg 2009;62:453- 456 \nSchlamann M, Loquai C, Goericke S, et al. Cerebral MRI in neurological asymptomatic patients with malignant melanoma. Rofo 2008;180:143- 147 \nSchmid -Wendtner MH, Dill -Muller D, Baumert J, et al. Lymph node metastases in patients with cutaneous melanoma: improvements in diagnosis by signal -enhanced color Doppler \nsonography. Melanoma Res 2004;14:269- 276 \nSchmitz C, Brenner W, Henze E, et al. Comparative study on the clinical use of protein S -100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res \n2000;20:5059- 5063  \nSchw immer J, Essner R, Patel A, et al. A review of the literature for whole -body FDG PET in the management of patients with melanoma. Q J Nucl Med 2000;44:153- 167 \nSibon C, Chagnon S, Tchakerian A, et al. The contribution of high- resolution ultrasonography in p reoperatively detecting sentinel -node metastases in melanoma patients. Melanoma Res \n2007;17:233- 237 \nSilverman PM, Heaston DK, Korobkin M, et al. Computed tomography in the detection of abdominal metastases from malignant mela noma. Invest Radiol 1984;19:309- 312 \nSingh B, Ezziddin S, Palmedo H, et al. Preoperative 18F -FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. \nMelanoma Res 2008;18:346- 352 \nSmit LH, Nieweg OE, Mooi WJ, et al. Value of ser um S -100B for prediction of distant relapse and survival in stage III B/C melanoma. Anticancer Res 2008;28:2297- 2302  \nStahlecker J, Gauger A, Bosserhoff A, et al. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.  Anticancer Re s 2000;20:5041- 5044  \nStas M, Stroobants S, Dupont P, et al. 18 -FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 2002;12:479 -490 \nStoffels I, Dissemond J, Poeppel T, et al. Advantages of preoperative ult rasound in conjunction with lymphoscintigraphy in detecting malignant melanoma metastases in sentinel lymph \nnodes: A retrospective analysis in 221 patients with malignant melanoma AJCC Stages i and II. Journal of the European Academy  of Dermatology and Ven ereology 2012;26:79 -85 \nStoitchkov K, Letellier S, Garnier JP, et al. Evaluation of the serum L -dopa/L -tyrosine ratio as a melanoma marker. Melanoma Res 2003;13:587- 593 \nStoitchkov K, Letellier S, Garnier JP, et al. Melanoma progression and serum L -dopa/L -tyrosine ratio: a comparison with S100B. Melanoma Res 2002;12:255- 262 \nStrobel K, Dummer R, Husarik DB, et al. High -risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007;244:566- 574 \nStutte H, M uller PH, d'Hoedt B, et al. Ultrasonographic diagnosis of melanoma metastases in liver, gallbladder, and spleen. J Ultrasound Med 1989;8:541 -547 \nTas F, Yasasever V, Duranyildiz D, et al. Clinical value of protein S100 and melanoma- inhibitory activity (MIA)  in malignant melanoma. Am J Clin Oncol 2004;27:225- 228 \nTerhune MH, Swanson N, Johnson TM. Use of chest radiography in the initial evaluation of patients with localized melanoma. Ar ch Dermatol 1998;134:569- 572 \nTestori A, Lazzaro G, Baldini F, et al. The ro le of ultrasound of sentinel nodes in the pre - and post -operative evaluation of stage I melanoma patients. Melanoma Res 2005;15:191- 198 \nTofani A, Cioffi RP, Sciuto R, et al. S -100 and NSE as serum markers in melanoma. Acta Oncol 1997;36:761- 764 \nTsao H, Fel dman M, Fullerton JE, et al. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved su rvival. Arch \nDermatol 2004;140:67- 70 \nUren RF, Howman -Giles R, Thompson JF, et al. High -resolution ultr asound to diagnose melanoma metastases in patients with clinically palpable lymph nodes. Australas Radiol \n1999;43:148- 152 \nvan den Brekel MW, Pameijer FA, Koops W, et al. Computed tomography for the detection of neck node metastases in melanoma patients. Eu r J Surg Oncol 1998;24:51- 54 \nvan der Ploeg IM, Valdes Olmos RA, Kroon BB, et al. The yield of SPECT/CT for anatomical lymphatic mapping in patients with melanoma. Ann Surg Oncol 2009;16:1537- 1542  \nVeit-Haibach P, Vogt FM, Jablonka R, et al. Diagnostic accuracy of contrast -enhanced FDG -PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging \n2009;36:910- 918 \nVereecken P, Awada A, Suciu S, et al. Evaluation of the prognostic significance of serum galectin -3 in American Joint Committ ee on Cancer stage III and stage IV melanoma patients. \nMelanoma Res 2009;19:316- 320 \nVereecken P, Laporte M, Petein M, et al. Evaluation of extensive initial staging procedure in intermediate/high -risk melanoma patients. J Eur Acad Dermatol Venereol 2005;19:66- 73 \nVermeeren L, Van Der Ent FW, Hulsewe KW. Is there an indication for routine chest x -ray in initial staging of melanoma?. J Surg Res 2011;166:114- 119 \nVoit C, Van Akkooi AC, Schafer -Hesterberg G, et al. Ultrasound morphology criteria predict metastati c disease of the sentinel nodes in patients with melanoma. J Clin Oncol \n2010;28:847- 852 \nVucetic B, Rogan SA, Hrabac P, et al. Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma. Melanoma Res 2008;18: 201-207 \nWagner T, Chevreau C, Meyer N, et al. Routine FDG PET -CT in patients with a high -risk localized melanoma has a high predictive positive value for nodal disease and high negative \npredictive value for the presence of distant metastases. J Eur Acad De rmatol Venereol 2011  \nWagner T, Meyer N, Zerdoud S, et al. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients wi th metastatic \ninvolvement of sentinel lymph node. Br J Dermatol 2011;164: 1235- 1240  \nWang TS, Johnson TM, Cascade PN, et al. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004;51:39 9-405 \nWebb WR, Gamsu G. Thoracic metastasis in malignant melanoma. A radiographic  survey of 65 patients. Chest 1977;71:176- 181 \nXing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta- analysis. J Natl Cancer Inst \n2011;103:129- 142 \nYancovitz M, Finelt N,  Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b -T3b melanoma. Cancer 2007;110:1107- 1114   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 166 von 817 \nZartman GM, Thomas MR, Robinson WA. Metastatic disease in patients with newly diagnosed malignant melanoma. J Surg Oncol 19 87;35:163- 164 \n2.4. Frage I.9. Ausbreitungsdiagnostik beim metastasierten okkulten Melanom  - Adaptation  \nFrage I.9.  Welche Untersuchungen sind beim metastasierten okkulten Melanom zur Prim\u00e4rtumorsuche und Ausbreitungsdiagnostik indiziert?  \nDie Frage wurde letztend lich Konsens -basiert beantwortet .  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 167 von 817 \n2.4.1.  Synopse Quellleitlinien (kurz)  \nThema/Fragestellung  LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada \nCancer Care O ntario \n2007  \n14. Welche Untersuchungen \nsind bei metastasiertem \nokkultem Melanom zur \nPrim\u00e4rtumorsuche und \nAusbreitungsdiagnostik \nindiziert? Klinische Untersuchung: \nAugen, G eh\u00f6rgang, Kopfhaut, \nevtl. Koloskopie (IV); PET zur \nweiteren \nAusbreitungsd iagnostik (IV)  Keine Angaben  Keine A ngabe  nur relevant f\u00fcr \nmedikament\u00f6se Therapien  \n2.4.2.  Empfehlung, Hintergrundstext und Literatur Australische Quell -Leitlinie  \n (mit Seitenangaben der Quellleitlinie)  \n LL Austr alien  \nNew Zealand Guidelines Group 2008  \nSchl\u00fcsselempfe hlungen  \n \n \n Recommendation  \nPatients with metastases and no obvious primary tumour be exa mined for primary melanomas in obscure \nsites. If none are found, a ssume that the  \nprimary melanoma has co mpletely regressed.  \nRecommendation grade:  \nD \n \nEvidenzgrundlage  Evidence summary  \nPatients with occult primary mel anoma usually present with lymph node disease, a soft tissue metastasis, or \nwidespread systemic disease, in the absence of a primary tumour and the diagnosis is made by patholog ical \nexamination of the  \nlymph node, or metastasis which shows  the characteristics of mela noma. Such patients should be examined  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 168 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group 2008  \ncarefully to exclude the possibility of a hi dden primary by examination of the eyes, inner ears and scalp, and \npossibly colonoscopy. The presenting lymph nodes or metastases should be treat ed appropriately \nregardless of the inability to detect the primary t umour and a PET scan should be performed  \nLevel IV , Referenz 1, 2  \n \nHintergrundtext  Melanoma is among a number of cancers in humans where the pr imary tumour cannot always be found. In \nsome  patients the primary may be in an obscure site such as the eye, ear or the intestine, but in the majority \nit is likely that the primary tumour has been d estroyed by the host\u2019s immune system via lymphocyte \nactivation.1,2 It is likely that total re gression occurs in 10 \u201320% of melanomas, though only those where \nthere have been metastases are diagnosable (about 5% of melanomas). Partial regre ssion of primary \ntumours is more  \ncommon and is often reported on pathology reports (30 \u201350%). Two recent studies have shown that those \npatients with metastases and an occult pr imary melanoma have a better prognosis than those with \nmetastases and a known primary mel anoma.3,4 This suggests  \nan intrinsically superior host tumour interaction in those with occult pr imary melanoma.  \nReferenzen  1. Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical analysis  \nof the cellular infiltrate in primary regressing and non -regressing m alignant melanoma. J Invest Dermatol \n1991; 97(2):197 \u2013202. \n \n2. Lowes MA, Bishop GA, Crotty K, Barnetson RS, Halliday GM. T helper 1 cytokine mRNA is increased  \nin spontaneously regressing primary melanomas. J Invest Dermatol 1997; 108(6):914 \u2013919. \n \n3. Vijuk G, Coates AS. Survival of patients with visceral metastatic me lanoma from an occ ult primary  \nlesion: a retrospective matched c ohort study. Ann Oncol 1998; 9(4):419 \u2013422. \n \n4. Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival after lymphadenectomy for nodal  \nmetastasis from an unknown primary melanoma. J Clin Oncol 2008; 26(4):535 \u2013541. \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 169 von 817 \nLiteratur  : \n1. Lee CC, Faries MB, Wanek LA, et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 2008;26:535 -541 \n2. Lowes MA, Bishop GA, Crotty K, et al. T helper 1 cytokine mRNA is incre ased in spontaneously regressing primary melanomas. J Invest Dermatol 1997;108:914- 919 \n3. Tefany FJ, Barnetson RS, Halliday GM, et al. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non- regressing malignant melanoma. J Inv est Dermatol \n1991;97:197- 202 \n4. Vijuk G, Coates AS. Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. Ann Oncol 1998;9:419- 422 \n \n2.4.3.  Erg\u00e4nzende Recherche, Datenbanken, Suchstrategien, Tre fferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  (\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND \n(\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND ((\"ultrasonography\"[Mesh] OR \n\"ultrasono graphy\"[all fields ] OR \"sonography\"[all fields]) OR (\"lymph nodes\"[all fields] OR \n(\"lymph\"[all fields] AND \"nodes\"[all fields]) OR \"lymph nodes\"[all fields] OR (\"lymph\"[ all \nfields] AND \"node\"[all fields]) OR \"lymph node\"[all fields]))  \n \n(\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND \n(\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND ((\"ultrasonography\"[Mesh] OR \n\"ultrasono graphy\"[all fields] OR \"sonography\"[all fields]) OR (\"lymph nodes\"[all fields] OR \n(\"lymph\"[all fields] AND \"nodes\"[all fields] ) OR \"lymph nodes\"[all fields] OR (\"lymph\"[ all \nfields] AND \"node\"[all fields]) OR \"lymph node\"[all fields]))  \n \n(\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND \n(\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND (\"chest X -ray\"[al l fields] OR \"chest \nradio graphy\"[all fields] OR \"Radiography, Thoracic\"[Mesh])  \n \n(\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND \n(\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND ((\"ultrasonography\"[Mesh] OR \n\"ultrasono graphy\"[all fields] OR \"sonography\"[all fields]) OR \"abdomen\"[all fields] OR \n\u201cabdominal\"[all fields]) NOT (\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye \nneoplasms\"[Mesh])  26.01.2012  \n \n \n \n \n \n \n \n \n \n \n \n 9 \n \n \n \n \n \n9 \n \n \n \n \n \n0 \n \n \n \n0 \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 170 von 817 \nDatenbank  Suchstrategie  Datum  Treffer \n \n(\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND \n(\u201cstaging\u201d[all fields ] OR \"diagnosis\"[all fields]) AND (\"Magnetic Resonance \nImaging\"[Mesh] OR \u201cMagnetic Resonance Imaging\u201d[all fields] OR \u201cmri\u201d[all fields] OR \n\u201cmagnetic resonance\u201d[all fields]) NOT (\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye \nneoplasms\"[Mesh])  \n \n(\"occult melano ma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND \n(\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND (\u201cTomography, X -Ray \nComputed\"[Mesh] OR \u201ccomputer tomography\u201d[all fields] OR \u201cct\u201d[all fields] OR \n\"Tomography, Spiral Co mputed\"[Mesh] OR \"Tomogra phy Scanners, X -Ray \nComputed\"[Mesh] OR \"Positron -Emission Tomography\"[Mesh] OR \u201cpositron -emission \ntomography\u201d[all fields] OR \u201cpet\u201d[all fields] OR \"Tomography, Emission -Computed, Single -\nPhoton\"[Mesh] OR \u201csingle -photon emission computed tomography\u201d[all field s] OR \n\u201cspect\u201d[all fields]) NOT (\"ophthalmolo gy\"[Mesh] OR \"eye\"[Mesh] OR \"eye \nneoplasms\"[Mesh])  \n \n(\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND (\u201cstaging\u201d[ \ntiab] OR \"diagnosis\"[ tiab]) AND (\"scintigraphy\u201d[ tiab] OR \u201cscinti*\u201d[tiab])  NOT \n(\"ophtha lmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye neoplasms\"[Mesh])  \n \n(\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND (\"LDH\"[all \nfields] OR \u201clactate dehydrogenase\u201d OR \"S100\"[all fields] OR \"MIA\"[tiab] OR \"melanoma-\ninhibiting activity\"[tiab]) AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) NOT \n(\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye neoplasms\"[Mesh])   \n \n3 \n \n \n \n \n8 \n \n \n \n \n \n \n \n0 \n \n \n \n3 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 171 von 817 \n \nAuswahl der Literatur  \nGesamttre ffer 25 \nGesam ttreffer nach Dublettenelimination   \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports, narrative Reviews, Bench Research  \nAnzahl nach Abstractscreening  1 \nAnzahl ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewertu ng 1 \nBemerkungen: Eine Erg\u00e4nzungsrecherche f\u00fcr den Zeitraum nach 2008 wurde am 26.10.2011 auf Medline durchgef\u00fchrt, die Update -Recherche erfolgte am \n26.01.2012. Oben aufgef\u00fchrt sind die Trefferzahlen der letzten Recherche. Hierbei wurde eine weitere relev ante Studie identifiziert.  \n \n2.4.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nTos T et al. (2011): \nExtensive \nScree ning for \nPrimary Tumor is \nRedundant in \nMelanoma  \nof Unknown this article \nquestions whether \nextensive physica l \nexamin ations \n(opthalmoscopy, \notoscopy, rhino -\npharygoscopy, retrospective study  \n \n \n 103 patients  \ndiagnosed with \nunknown primary \ntumor during the \nperiod 1986 \u20132006  \n \n Metast ases \ndetection rate  39 (38%) presented \nprimarily with a \ncutaneous or a \nsubcutaneous \nMetastasis, 63 \n(61%) with a lymph \nnode meta stasis. 1  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 172 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nPrimary  laryngoscopy, \nsigmoideoscopy, \nand in women, \ngynecological \nexamination) are \nnecessary.  patient pr esented \nwith a bone \nmetastasis (1%). 87 \npatients (84%) \nwere examined by \nan \nophthalmologist. A \nchoroidal \nmelan oma was \nsuspected as the \nprimary tumor in 1 \npatient. 84 \npatients (82%) \nwere exa mined by \nan oto -rhino -\nlaryngologist, \nwhereby no \nprimary tumor was \nfound. 95 p atients \n(92%) were \nexamined by \nsigmoide oscopy/  \nrectoscopy. No \nprimary tumor was \nfound. Of the 36 \nwomen, 32 had a \ngynecological \nexamination (89%), \nrevealing no \nprimary tumor.  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 173 von 817 \n2.4.5.  Literatur:  \nTos T, Klyver H, Drzewiecki KT. Extensive screening for primary tumor is redundant in melanoma of unknown primary. J Surg Oncol 2011;104:724- 727  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 174 von 817 \n3. AG Sentinel Node Bi opsie  \n3.1. Frage II.1. Sentinel -Node -Biopsie  \u2013 De-novo -Recherche  \nFrage II.1 . In welchen F\u00e4llen ist die Sentinel- Biopsie indiziert? \n3.1.1.  PICO, Suchw\u00f6rter  \nPICO -Unterfragen:  \n- Senkt die Durchf\u00fchrung einer Sentinel -Biopsie die Rezidzivrate  \n- Senkt die Durchf\u00fchrung einer Sen tinel- Biopsie die Mortalit\u00e4t  \n- Wie ist die Sensitivit\u00e4t und Spezifit\u00e4t einer Sentinel- Biopsie zum Nachweis einer lokoregion\u00e4ren Lymphknotenmetastasierung? \nSuchw\u00f6rter : s. hierf\u00fcr au ch Suchstrategie  \nOber -/Unterbegriffe, Mesh Term  melanoma  survival, mortality,  relapse, \nrecurrence, sensitivity, specificity, \naccuracy, outcome, prognos*, \npredict*, assoc*  s. Suchstrategie  \n \n3.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  \u201cmelanoma\u201c[tiab] AND ( \u201csentinel\u201c[tiab] OR \u201cSentinel Lymph Node Biopsy\u201d[MeSH]) \nAND (\u201csurvival\u201d[tiab] OR \u201cmortality\u201d[tiab] OR \u201crelapse\u201d[tiab] OR \u201crecurrence\u201d[tiab] OR 26.01.2012  1039  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 175 von 817 \nDatenbank  Suchstrategie  Datum  Treffer \n\u201csensitivity\u201d[tiab] OR \u201cspecificity\u201d[tiab] OR \u201caccuracy\u201d OR \u201coutcome\u201d[tiab] OR \n\u201cprognos*\u201d[tiab] OR \u201cpr edict*\u201d[tiab] OR \u201cassoc*\u201d[ti ab])  \n \nCochrane Library  (melanoma and (sentinel or \"sentinel lymph node biopsy\" or snb or slne or sln) and \n(survival or mortality or relapse or recurrence or sensitivity or specificity or \naccuracy or ou tcome or predict* or prognosis or as soc*)).ti,ab.  26.01.2012  43 \nEmbase  (melanoma and (sentinel or \"sentinel lymph node biopsy\" or snb or slne or sln) and \n(survival or mortality or relapse or recurrence or sensitivity or specificity or \naccuracy or ou tcome or predict* or prognosis or assoc*)) .ti,ab.  23.01.2012  1751  \n2. Suche/Erg\u00e4nzungen     \nMedline  (sentinel[title] OR \"snb\"[title] OR \"slne\"[title] OR \"sln\"[title]) predict* melanoma[title]  26.01.2012  1176  \nBemerkungen:  \nEine erste Literaturrecherche in Medline und und Cochrane erfolgte am 07.10 .2010 bzw. f\u00fcr Embase am 11.05.2011. Die zweite Recherche \n(Erg\u00e4nzungsrecherche) wurde am 18.04.2011 durchgef\u00fchrt. Die Update -Recherche wurde am 23.01.2012 f\u00fcr Embase bzw. am 26.01.2012 f\u00fcr Medline und am \n19.01.2012 f\u00fcr Cochrane durchgef\u00fchrt. In der Tabelle  angegeben sind die Tref ferzahlen der letzten Recherche.  \n \nDie Beantwortung der Frage st\u00fctzt sich in erster Linie auf die Meta -Analysen. Weitere Studien wurden hinzugezogen, wenn sie Aspekte abd ecken, die in der \nMeta-Analyse nicht ber\u00fccksichtigt wurden bzw.  die nach der letzten Meta -Analyse ver\u00f6ffentlicht wurden. Im Rahmen der Update -Recherche wurde, neben \neinzelnen Studien, weitere Sy stematische Reviews bzw. Meta -Analyse identifiziert. Einzelne relevante Studien wurden mit aufgenommen, da nur spezielle \nMelanompopulationen in der Metaanalyse bzw. im Review eingeschlossen wurden (Pat ienten mit Melanomen >4mm bzw. SNB im Kopf/Hals -Bereich)  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 176 von 817 \n3.1.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  2970  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e, dt \nAusschlusskriterien  Case Reports, narrative Reviews  \nAnzahl nach Abstractscreening  77 \nAnzahl ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewertung  48 \n \n3.1.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nValsecchi et al. \n(2011)  To perform a \nmeta -analysis of all \npublished studies \nof sentinel lymph \nnode (SLN) biopsy \nfor staging \npatients with \nmelanoma.  Systematic review \nwith meta -analysis  \n \n Melanoma \npatients; 53.4% \nmale, median age \n54 years  Proportion of \nsuccessfully \nmapped (PSM)  \n \nFalse-negative rate \n(FNR), post -test \nprobability \nnegative (PTPN) \nand positive \npredictive value \n(PVP) in the same \nnodal basin Weighted PSM: \n98.1% (improved in \nmore recent \nstudies and in \narticles with better \nquality s cores)  \n \nDistribution of FNR \namong studies \nranged from 0.0% \nto 34%, weighted \nsummary estimate Very large number \nof patients \n(25240).  \n \nNo significant \ndifferences in \nresults were seen \nwhen data from \nthree large clinical \ntrials or from \ncertain geographic \nregions were 1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 177 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nrecurrence and for \ndistant/all \nrecurrences  12.5%  \n \nPTPN for same \nnodal basin \nrecurrence ranged \nfrom 0.0% to \n10.4%, summary \nestimate across \nstudies 3.4%  \n \nWeighted summary \nestimate of PVP for \nnodal recurrence \n7.5% \n \nWeighted estimate \nfor FNR for distant \nrecurrence 17.4%, \nfor total \nrecurrences 29.9%  \n \nWeighted estimate \nfor PTPN for \ndistant recurrence \n4.4%, for total \nrecurrence 10.5%  \n \nProbability of \nadditional nodal \ninvolvement in \nCLND for patients excluded, or in \nother su bgroup \nanalyses.  \n \nNo statement \npossible about \nproportion of \npatients with \npositive SNB \nexperiencing \nsubsequent nodal \nrecurrence despite \nCLND.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 178 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nwith positive SN B: \n20.1%  \n \nPVP for distant and \nany recurrence \n21.0% and 35.9%  \nWarycha et al. \n(2009)  To estimate the \nrisk, potential \npredictors, and \noutcome of SLN \npositivity in \npatients wi th thin \nmelanomas.  Systematic review \nwith meta -analysis  \n Patients with thin \n(\u22641 mm) primary \nmelanoma  \n \nTotal number of \npatients: 3651  SLN positivity rate  \n \nHeterogeneity  \n \nMelanoma -related \ndeaths  Pooled SLN \npositivity rate 5.6%  \n \nSignificant \nheterogeneity \namon g studies; \nremained \nsignificant in \nsubgroups of \nstudies with high \nvs. low quality \nscores, indicating \nother covariates or \npatient selection \ncriteria that are \nresponsible for \nheterogeneity  \n \nNo statistical \nevidence of \npublication bias  \n \n4 melanoma -\nrelated deat hs Unclear source of \nheterogeneity in \nthis meta -analysis \n(may hint to \nunknown \nprognostic factors \nin patients with \nthin melanoma \nwhich need further \ninvestigation)  \n \nUlceration and \nClark level > III \nhave been \ncorrelated with a \nworse prognosis in  \npatients with thin \nmelanoma, but \nmight not be \nassociated with \npositive SLN   1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 179 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nwere reported  \nKunte et al. (2010)  To assess which \nfactors predict the \noccurrence of \nmicrometastasis \nand overall \nprognosis and \nwhether SLNB \nshould also be \nperformed in \npatients with thin \nprimary tumors.  Prognostic study  \n \n 854 patients with \nmalignant \nmelanoma (56.8% \nmale, 43.2% \nfemale), mean age \n52.9 years  SLN status  \n \nDisease -free \nsurvival (DFS)  \n \nOverall survival \n(OS) Rate of positive \nSLNs: 24.9%  \n \nProbability of \nfinding a positive \nSLN 5.7% i n \npatients with \ntumor thickness \u2264 \n0.75 mm, 57.3% in \npatients with \ntumor thickness > \n4 mm  \n \nSLN positive in \n36.8% of patients \nwith nodular \nmelanoma (NM), \n27.1% of patients \nwith secondary \nnodular superficial \nspreading \nmelanoma, 26.1% \nin acral lentiginous \nmelanoma, 13.4% \nin superficial \nspreading \nmelanoma, 8.8% \nSpitzoid melanoma \nand 38.3% of Prospective design  \n \nFor detailed p \nvalues according \nto tumor thickness \netc. see original \nfile. \n \nProspective design \nand large patient \nnumbers  \n \nPatients lost to \nfollow -up not \ndescribed for key \ncharacteristics \n(potential source \nof \nselection/attrition \nbias) 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 180 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nulcerated \nmelanomas  \n \nIn multivariate \nanalysis, tumor \nthickness and \nhistological tumor \ntype significantly \nassociated with \nSLN status  \n \nMelanoma with \ntumor > 4 mm \nrevealed 11.6 8-\nfold risk for a \npositive SLN in \ncomparison with \ntumors < 1 mm  \n \n9.8% (63/641) of \nSLN negative \npatients had a \nrecurrence of the \ndisease, 8.4% \n(54/641) died of \nthe disease (5 -year \nsurvival rate: \n90.1%, mean DFS \n117.9 months, OS \n119.8 months)  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 181 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nOf SLN positiv e \npatients, 39.4% \nhad a recurrence, \n28.6% died of the \ndisease (mean DFS \n80.75 months, OS \n94.91 months, 5 -\nyear survival rate: \n58.1%  \nMays et al. (2010) To evaluate \nprognostic factors \nin the subset of \npatients with a \nmelanoma Breslow \nthickness between \n1 and  2 mm and to \ndetermine whether \nall such patients \nrequire SLN \nbiopsy.  Prognostic study  \n \n 1110 patients with \ncutaneous \nmelanoma \nbetween 1 mm and \n2 mm in thickness  Rate of positive \nand negative SLNs  \n \nOverall survival \n \nDisease -free \nsurvival  Group A: \nmelanoma f rom 1 \nmm to 1.59 mm in \nthickness  \n \nGroup B: \nmelanoma from \n1.60 mm to 2.0 \nmm in thickness (n \n= 348)  \n \nOn multivariate \nanalysis, Breslow \nthickness, age and \nlymphovascular \ninvasion were \npredictive of \npositive SLN  \n Post-hoc analysis \nof the multi -center, \nrandomi zed \nSunbelt Melanoma \nTrial \n \nSee full text (p. \n1539) for complete \npartition tree  1b \nTestori et al. To investigate the Observational 1313 consecutive Overall survival  Overall SLN Large patient 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 182 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n(2009)  relationship \nbetween primary \ntumor \ncharacteristics, \nSLN findings, and \nthe clinical \noutcome  study  \n \n patients   \nPredictors of SLN \npositivity and \nsurvival  identification rate \n99.3%  \n \nPatients were \ncategorized into \nfour different \nsubgroups: (1) \npatients with \nnegative SLN after \npathological \nexamination who \nnever developed \nregional lymph \nnode metastases \nduring follow -up; \n(2) patients with \npathological \ndiagnosis of \nmetastasis in the \nSLN without any \npositive NSLNs; (3) \npatients with \npositive SLNs and \nsecondary deposits \nin NSLNs at CLND; \nand (4) patients \nwith negative SLNs \nwho develope d \nclinically \ndetectable regional \nmetastases in the cohort  \n \nLong median \nfollow -up  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 183 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nSNB lymphatic \nbasin during \nfollow -up. \n \n5-year OS rates \nwere 93%, 71.3%, \n50.4% and 49.8% \nfor groups A, B, C, \nand D, respectively  \nMorton et al. \n(2006)  Same stu dy as \nMorton et al. \n(2005)  Same study as \nMorton et al. \n(2005)  Same study as \nMorton et al. \n(2005)  Relapse rate  \n \nDisease -free \nsurvival  \n \nMelanoma -specific \nmortality and \nsurvival  Frequency of \nrelapse at any site: \n26.8% in the \nobservation group \nand 20.7% in the  \nbiopsy group  \n \nDisease -free \nsurvival rate at 5 \nyears: in the \nbiopsy group \n78.3%; in the \nobservation group \n73.1%  \n \nMelanoma -specific \ndeath: 13.8% in the \nobservation group \nand 12.5% in the \nbiopsy group  \n Here, an intention -\nto-treat analysis \nwas performed \n(missing in Morton \net al., 2005)  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 184 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nMelanoma -specific \nsurvival rate: \n90.1% and 93.2%, \nrespec tively, at 3 \nyears, and 86.6% \nand 87.1%, \nrespectively, at 5 \nyears  \n \nMelanoma -specific \nmortality rate in \nthe biopsy group: \n9.7% when sentinel \ntumor -free and \n26.2% if sentinel \npositive  \n \nEstimated disease -\nfree survival rate at \n5 years: 53.4% for \npositive and 8 3.2% \nfor negative \nsentinel; \ncorresponding \nvalues for \nmelanoma -specific \nsurvival 72.3% and \n90.2%, respectively   \nMcMasters et al. \n(2001)  To identify \nprognostic factors Prognostic study  \n Total of 1058 \npatients evaluated; Positive sentinel \nnode  SLN identification \nrate 99.7%  Prospective design  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 185 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nthat are predictive \nof sentinel lymph \nnode (SLN) \nmetastasis in \nmelanoma.   961 patients had \ncomplete data and \nwere included in \nthe statistical \nanalysis   \n  \nSLN positivity 22%  \n \nIndependent \npredictors of SLN \nmetastasis, in \norder of \nimportance: \nBreslow thickness, \nClark level, \nulceration, and \npatient age  Subgroup analysis \nof Melanoma \nSunbelt Trial \n(multi -center, \nrandomized trial); \ntherefore patients \npartially identical \nwith patients in \nMays et al. (2010)  \nRondelli et al. \n(2011 ) to assess the \nprognostic role of \nSLN in thick \nmelanoma in  \nterms of disease -\nfree survival (DFS) \nand overall survival \n(OS). Systematic review \nwith meta -analysis  \n \n 9 studies included \nwith a total of \n1261 patients  DFS \n \nOS \n \nIRR \n \nincidence rate \nratios (IRD)  \n \nincidence rate \ndifference (IRD)  Overall, DFS: 71% \nin patients with a \nnegative SLN, 39% \nin patients with a \npositive SLN after a \nmedian follow -up \nof 33 months (IRR \n1.83, 95% CI = \n1.56\u20132.14).  \n \nOS: 71% in patients \nwith a negative \nSLN, 49% in \npatients with a \npositive SLN (IRR \n1.44, 95% CI = \n1.25\u20131.65).  Only retrospective \nstudies included in \nmeta -analysis  2a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 186 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nSmith et al. (2012 ) to compare \nmelanoma -specific \nsurvival among \npatients with head \nand neck \ndesmoplastic \nmelanoma based \non SLN status  Prognostic study  244 patients with \ndesmoplastic \nmelanoma of the \nhead and neck \nwho underwent \nSLNB  5-year disease -\nspecific survival \n(DSS)  \n \n On univariable and \nmultivariable \nanalysis, SLN \npositivity did not \nsignificantly affect \nDSS in head and \nneck desmoplastic \nmelanoma (P =.19 \nand P =.48, \nrespectively).  2b \nBurton et al. \n(2011 ) to determine \nwhether regression \npredicts nodal \nmetastasis, \ndisease -free \nsurvival (DFS), or \noverall survival \n(OS). Prognostic study  2220 patients who \nunderwent SLN \nbiopsy; those with \ntumor -positive SLN \nunderwent \ncompletion \nlymphadenectomy  \n \n(261 with \nregression; 1959 \nwithout \nregression)  \n \n DFS \n \nOS \n \nPrognostic factors  On multivariate \nanalysis, factors \nindependently \npredictive of DFS \nincluded Breslow \nthickness, \nulceration, and \nSLN status (P < \n0.05 in all cases); \nthe same factors \nalong with age, \ngender, and \nanatomic tumor \nlocation were \nsignificantly \nassociated with OS \n(P < 0.05 in all \ncases). Regression \nwas not \nsignifican tly Post hoc analysis \nof a multicenter \nprospective \nrandomized trial \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 187 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nassociated with \nDFS (risk ratio [RR], \n0.94; 95% \nconfidence interval \n[CI], 0.67 -1.27; P = \n0.68) or OS (RR, \n1.01; 95% CI, 0.76-\n1.32; P = 0.93).  \nDe Vries et al. \n(2011 ) To assess the lon g-\nterm outcome \nafter sentinel \nlymph node biopsy \n(SLNB) in \nmelanoma \npatients.  Prognostic study  450 melanoma \npatients who \nunderwent SLNB  \n(Survival and \nprognostic factors \nwere analyzed for \n429 patients)  Relapse rate  \n \nFN-rate \n \nPrognostic factors  In 29% relapse  \nduring follow -up; \n46% in the SLN -\npositive group who \nunderwent CLND \nand 22% in the \nSLN-negative \ngroup (p < 0.001).  \n \nFN- rate 11%.  \n \nOn multivariate \nanalysis strongest \nprognostic factors \nfor DFS: primary \nmelanoma \nulceration and SLN \npositivity (HR: 2.2 \nand 2.3; p < \n0.001). For DSS the \nsame was found, \nHR of 2.1 for CLND was \nperformed in 119 \npatients and these \npatients were \nanalyzed for \nrecurrence and \nsurvival.  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 188 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nulceration and 2.0 \nfor SLN positivity \n(p=0.001 and \np=0.002 \nrespectively).  \n \n10-Year DFS was \n71% for SN -\nnegative patients \ncompared with \n48% for SLN -\npositive patients (p \n< 0.001). 10 -Year \nDSS was 77%  for \nnode -negative \npatients compared \nto 60% for SLN-\npositive patients (p \n< 0.001).  \nMurali et al (2011 ) To investigate in \ndetail the influence \nof SN tumor  \ncharacteristics and \nclinical and \nprimary tumor \nparameters on \nregional lymph \nnode recurrence, \ndistant metastasis,  \nand survival.  Prognostic study  409 patients with \nprimary cutaneous \nmelanoma who \nunderwent  \nSNB  DFS \n \nmelanoma -specific \nsurvival (MSS)  Primary t umor \nfeatures (presence \nof ulceration and \nsatellites) and \npresence of ENS in \nSNs were \nindependent \npredictors of DFS, \nDMFS, and MSS. In \naddition, poorer \nDFS was Same patient \ncohort as Murali et \nal. (2010): Non -\nSentinel Node Risk \nScore (N -SNORE): A \nScoring System for \nAccurately \nStratifying Risk of \nNon-Sentinel Node \nPositivity in \nPatients With 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 189 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nindependently \nassociated with \nprimary tumor site \n(head/neck and \nlimbs vs. trunk), \nSN \ntumor featu res \n(MaxSize >2 mm, \npresence of PLI) \nand positive NSN \nin CLND; other \nfactors \nindependently \npredictive of DMFS \nwere male sex, \nprimary tumor \nfeatures (absence \nof TILs), and SN \ntumor MaxSize \n>10 mm; and age \n\u226550 years was an \nadditional \nindependent \npredictor of  MSS. \nCLND status was \nnot an \nindependent \npredictor of DMFS \nor MSS.  Cutane ous \nMelanoma With \nPositive Sentinel \nLymph Nodes \nG\u00f6ppner et al. To investigate the Prognostic study  87 patients  Recurrence -Free Multivariate  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 190 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n(2011 ) prognostic \nrelevance of SLNB \nand other risk \nfactors in the \nsubgroup of \nmelanomas > 4.0 \nmm and to \ncompared it to \npreviously \npublished results. with thick \nmelanomas 1 4.0 \nmm (T4).  Survival  \n \nOverall survival analysis: SLN and \nulceration, \nanalyzed as \nseparate risk \nfactors as well as \ntheir combination, \npredicted a highly \nreduced life \nexpectancy in \nterms of \nrecurre nce-free \nsurvival (RFS).  \nSLN, but not \nulceration, also \npredicted overall \nsurvival (OS)  \nKoskivuo et al. \n(2011 ) to evaluate the \naccuracy and \nprognostic value of \nthe routine use of \nSNB in elderly \npatients with \ncutaneous \nmelanoma.  Prognostic study  423 co nsecutive  \npatients >= 70 \nyears with CM \nAJCC stage I \u2013II \n FN-rate \n \nSensitivity  \n \nDiagnostic \naccuracy  \n \nRelapse -free \nsurvival rate  \n \nCancer specific \nsurvival rate  \n \nPrognostic factors  Recurrence in \n18.9% of patients \n(median follow -up: \n2\u00b75 years)  \n \nFN-rate: 8 \u00b73% \nSensitivity: 91.7%  \noverall diagnostic \naccuracy: 98\u00b70 %  \n \nat 5 years: relapse -\nfree survival rate: \n80\u00b70% in SN -\nnegative patients  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 191 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nand 39% in SN -\npositive patients  \n \ncancer -specific \nsurvival rates: \n88\u00b76% and 46% \nrespectively (P < \n0\u00b7001).  \n \nmultivariable \nanalysis: SN  \nmetastasis (P < \n0\u00b7001), a Breslow \nthickness of >= 2 \u00b70 \nmm (P = 0 \u00b7007) \nand presence of \nulceration (P = \n0\u00b7012) were \nindependent \nprognostic factors \nfor cancer -specific \nsurvival.  \nTejera -Vaquerizo \net al. (2012) To determine \nwhether growth \nrate (GR) of \ncutaneous \nmelanoma predicts \nthe histological \nsentinel lymph \nnode (SLN) Prognostic study  698 patients with \ninvasive primary \ncutaneous \nmelanoma in \nwhom the SLN was \nidentified  Growth rate  \n \nPrognostic factors  \n Multivariate \nlogistic regression \nanalysis: \nGR, Breslow \nthickness, and the \npresence of \nmicroscopic \nsatellitosis surrogate measure \nfor GR in primary \ninvasive melanoma \nwas c alculated as \nthe ratio of \nBreslow thickness \nto time to \nmelanoma 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 192 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npositivity  independently \nassociated with \nSLN positivity. \n \nprobability of SLN \npositivity: 8.2% for \nslow growth \nmelanomas (<0.10 \nmm/mo) compared \nwith 19.8% for \nintermediate -\ngrowth melanomas \n(0.10 -0.50 \nmm/mo) and \n37.7% for fast -\ngrowth melanomas \n(>0.50 mm/mo).  \n \nSLN positivity was \nthe most \nimportant \nprognostic factor \nfor DFS (HR, 2.13; \n95% CI, 1.20 -3.76) \nand for OS (HR, \n3.99; 95% CI, 1.67-\n9.53).  development.  \nWhite et al. 2011  Prognostic study  undergoing \nsentinel lymph \nnode (SLN) biopsy 3463 patients (561 \n(16.3%) had a \npositive SLN Predictive factors  multivariate \nanalysis: \nincreasing Breslow retrospective and \nprospective data  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 193 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nfor primary \nmelanoma  biopsy)  thickness, \nlymphovascular \ninvasion, \nulceration, \nyounger age, the \nabsence of \nregression, and \ntumor location on \nthe trunk were \nstatistically \nsignificant \npredictors of a \npositive SLN  multivariate \nanalysis performed \nwith data of 1526 \npatients (with \ncomplete records)  \n \n \nYonick et al. \n(2011)  To elucidate \npathologic factors \nthat are predictive \nof SLN positivity  Prognostic study  \n \n 1199 patients  Correlation \nbetween \nhistopathological \nfeatures and SLN \npositivity  Thin melanomas in \n39%; of these, 31% \nunderwent SLNB  \n \nPositive SLNs \nfound in 11%  \n \nMultiple logistic \nregression: \nulceration and \nthickness \nassociated with \nSLN positivity  \n \nFor scoring \nsystem, see full \narticle  Retrospective \nstudy  \n \nNo de fined \ninclusion criteria \nfor SNB  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 194 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nCadili and Dabbs \n(2010)  To identify the \npredictors of SLN \nmelanoma \nmetastasis.  Prognostic study  \n \n 348 patients with \nmalignant \nmelanoma  Relative risk  73% negative and \n27% positive SLN  \n \nBreslow thickness \nand nodular type  \nsignificantly \ncorrelated with \npositive SLN; head \nand neck tumour \nlocation \nsignificantly \ncorrelated with \nnegative SLN  Retrospective \ndesign  \n \nCorrelation of \nhead and neck \ntumour and \nnegative SLN result \nmay be caused by \ninsufficient \nexperience in head \nand ne ck SLNEs in \nthis institution. 2b \nKretschmer et al. \n(2010)  To investigate the \nimpact of the \nconstitutional \nfactor age on the \nclinical courses of \nmelanoma patients \nwith sentinel \nlymph node (SLN) \nbiopsy.  Prognostic study  \n \n 2,268 consecutive \npatients  Correla tion \nbetween \nhistological \nparameters/SNB \nstatus and age  \n \nMelanoma -specific \noverall survival \n \nAdjusted relative \nrisk According to \nmultivariate \nanalysis, factors \npredictive for poor \noverall survival: \nage, \nmicrometastasis to \nSLN, Breslow \nthickness and \nepiderm al \nulceration  \n \nIn multivariate \nlogistic regression \nanalysis, age of < \n40 years was \nsignificantly Retrospective \ndesign  \n \nLarge patient \nsample  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 195 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nrelated to a 2 -fold \nprobability of SLN -\npositivity  \nRoach et al. (2010)  To investigate the \nsignificance of \nmitoti c rate (MR) in \nmelanoma  Prognostic study  \n \n 551 patients had \nMR data reported  Overall survival  \n \nDisease -free \nsurvival  \n \nOdds\u2019 ratio (OR) \nfor SLN positivity  High MR: thicker \ntumors, higher \nrate of ulceration, \ntwice as many \npositive SLNs \n(31.3% vs. 14.7%)  \n \nTumor thickness \nand ulceration \nsignificant survival \npredictors upon \nmultivariate \nanalysis  \n \nFor SLN -negative \nand nonulcerated \npatients, MR \ngroups were not \nsignificant for OS  Retrospective \ndesign  2b \nMandal a et al. \n(2009)  To investigate if \nthe tumour \ninfiltrat ing \nlymphocytes (TILs) \nare able to predict \nthe sentinel lymph \nnode (SLN) Prognostic study  \n \n 1251 consecutive \npatients with CM  Overall survival \n \nDisease -free \nsurvival  \n \nCorrelation \nbetween TIL status TIL status of lesion \ncorrelated with the \nBreslow thickness, \nClark level and \nregression  \n \nNo difference in Retrospective \nanalysis (though of \nprospective \ndatabase)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 196 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npositivity, the \ndisease -free \nsurvival (DFS) and \noverall survival \n(OS) in clinical \nstages I -II AJCC \nprimary cutaneous \nmelanoma (PCM).  and SLN status  other variables \nevaluated, \nincluding SLN \nstatus or the \nprese nce of \nulceration, among \npatients with brisk, \nnon-brisk and \nabsent TILs \n \nSLN identified in \n394 patients \n(97.5%) \n \n18.8% positive \nSLNs \n \nIn multivariate \nanalysis, \nincreasing Breslow \nthickness, \nanatomical site \nand absence of \nTILs independently \nassociated with \npositive SLN  \n \n5-year DFS 75.9% \nin negative SLNs, \n35.2% in positive \nSLNs  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 197 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n5-year OS 88.7% \nversus 42.9%, \nrespectively  \nSocrier et al. \n(2009)  To determine if \nregression in \nmelanoma is \nassociated with a n \nincreased risk of \nsentinel lymph \nnode (SLN) \nmetastasis.  Prognostic study  \n \n 397 consecutive \nmelanoma patients  Odds\u2019 ratio (OR)  SLN positive in 16% \nof melanomas with \nregression and \n29% without \nregression  \n \nAdjusted OR for \nregressive \nmelanoma: 0.9  \n Retro - or \nprospective design \nunclear  2b \nGutzmer et al. \n(2008)  To investigate the \nvalue of the status \nof the sentinel \nlymph node (SLN) \nin patients with \nthick melanomas \n(Breslow thickness \n\u2265 4 mm)  Prognostic study  \n \n  152 patients  Recurrence -free \nsurvival  \n \nOverall survival \n \nCorrelation \nbetween \nhistological \nproperties of \nprimary tumour \nand SLN positivity  \n \nRelative risk (RR) \nfor SLN positivity  Probability of \nrecurrence -free 5 -\nyear-survival: 42.5 \n\u00b1 5% overall, 26.3 \n\u00b1 6.6 % for SLN+ \nand 58.7 \u00b1 7.1 % \nfor SLN - \n \nIn multiv ariate \nanalysis the \npathological status \nof the SLN had a \nhighly significant \nprognostic value (p \n= 0.000009); \nrelative risk (RR) Retrospective \ndesign  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 198 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n3.3 \n \nThe 5 -year overall \nsurvival 53.2 \u00b1 5.4 \n% (37.5 \u00b1 8.1 % \nwith positive SLN \nand 67.6 \u00b1 6.7 % \nwith negative SLN)  \nRoulin et al. \n(2008)  To confirm the \naccuracy of \nsentinel node \nbiopsy (SNB) and \nits morbidity, and \nto investigate \npredictive factors \nfor SN status, \ndisease -free \nsurvival (DFS) and \ndisease -specific \nsurvival (DSS).  Prospective \nprognostic study  \n \n 327 consecutive \npatients with \nprimary melanoma  Recurrence rate  \n \nSensitivity and \nfalse-negative rate \nof SNB  \n \n5-year disease -free \nsurvival (DFS)  \n \n5-year disease -\nspecific survival \n(DSS)  Success rate of \nSNB 99.1%  \n \nOverall SNB + WE \nmorbidity 7.6%  \n \nSNB positivit y rate \n22.6%  \n \nMean Breslow \nthickness of \nprimary melanoma \n1.95 mm for SN-\nnegative cases and \n3.22 mm for SN-\npositive cases  \n \nBreslow thickness \nonly statistically \nsignificant \npredictor for \nmetastases Follow -up \npresumably too \nshort to discover \nall recurrences \n(median follow -up \n33 months; \nmedian time of \nrecurrence 30 \nmonths, mean 34 \nmonths)  \n \nNo control group  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 199 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \n46% of positive \nand 11% of \nnegative SN \npatients recurred  \n \nFalse-negative rate \n8.6%, sensitivity \n91.4%.  \n \n5-year DFS 43% for \npatients with \npositive SN and \n83.5% for patients \nwith negative SN  \n \n5-year DSS 49.1% \nfor SN -positive \npatients and 87.4% \nfor SN -negative \npatients  \nCecchi et al. \n(2007)  To report the \nexperience with \nlymphatic mapping \n(LM) and sentinel \nlymph node biopsy \n(SLNB) in a \nselected group of \npatie nts with thin \nprimary cutaneous Prospective cohort \nstudy  \n \n 50 patients with \nthin melanomas  Prevalence of SLN -\npositivity in thin \nmelanomas  SLN positivity rate \n4% \n \n CLND only \nperformed on SLN -\npositive patients \n(risk of verification \nbias) 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 200 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmelanomas.  \nKaur et al. (2008)  To understand the \nsignificance of \nregression in \nmelanoma and \nprovide further \ninformation on \nwhether patients \nshould be \nsubjected to \nsentinel lymph \nnode biopsy (SLNB) \non the basis of \nregression. Prognostic study  \n \n 146 consecutive \nmelanoma pat ients  Correlation \nbetween \nhistopathologic \nparameters and \nSLN positivity  Statistically \nsignificant greater \nproportion of \nindividuals without \nregression showed \nsentinel lymph \nnode (SLN) \npositivity \n(p=0.028) \ncompared with \npatients without \nregression  \n \nCorrela tion of age, \nsex, site and \npresence of \ntumour infiltrating \nlymphocytes (TIL) \nwith regression \nand sentinel node \nstatus not \nstatistically \nsignificant  Retrospective \ndesign, but 1 \u2013  6 \nyears prospective \nfollow -up in 79% of \nthe patients \n(recording survival \nand m etastasis)  2b \nMorris et al. \n(2008) To assess whether \nthe presence of RG \nwas associated \nwith a higher \nprobability of a Prognostic study  \n \n 1349 patients with \ncutaneous \nmelanoma  Correlation \nbetween \nregression and SLN \npositivity  \n 10% of patients \nwith RG and 18% \nof patients with \nNRG who \nunderwent SLN Retrospective \ndesign  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 201 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npositive SLN or an \nincreased risk of \nlocal or distant \nrecurrence. Overall survival  \n \nDisease -free \nsurvival  biopsy had a \npositive SLN  \n \nWhen stratified by \nBreslow depth \ncategory, there \nwas no evidence of \nan increase d risk \nof a positive SLN in \nthose with RG  \n \nOS not \nsignificantly \ndifferent between \nthe two groups  \n \nDFS significantly \nlonger for those \nwith RG  \nPaek et al. (2007 ) To verify previous \nresults in which \nincreasing mitotic \nrate and \ndecreas ing age \npredicted sentinel \nlymph node (SLN) \nmetastases in \npatients with \nmelanoma, and to \ncreate a prediction Prognostic/ \ndiagnostic study  \n \n 910 patients with \ncutaneou s \nmelanoma  Correlation \nbetween \nhistological \nfeatures and SLN \npositivity  \n \nOR for SLN \npositivity  \u22651 positive SLNs \nidentified in 26.7% \nof patients  \n \nThe best \nmultivariate model \nincluded the \nfollowing single \nvariables: patient \nage, Breslow \ndepth, the Retro spective \ndesign  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 202 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmodel for the \nbetter selection of \nwhich patients \nwith melanoma \nshould undergo \nSLN biopsy.  presence of \nangiolymphatic \ninvasion, the \nnumber of \nmitoses, and body \nsite location of the \nmelanoma  \nTaylor et al. (200 7) To evaluate the \nprognostic \nimplications of \ntumor -infiltrating \nlymphocytes (TILs)  Prognostic study  \n 887 patients who \nunderwent SLN \nmapping for \ncutaneous \nmelanoma  Correlation of \nhistopathologic \nfeatures with SLN \npositivity  \n \nOverall survival \n \nDisease -free \nsurvival  SLN identification \nrate 98.6%  \n \nSLN positivity rate \n17.6%  \n \nBy multivariate \nlogistic regression \nanalysis, male sex, \nthickness, \npresence of \nulceration, and \nabsence of TILs \nwere \nindependently \nassociated with \npositive SLN  \n \nWhen brisk and \nnonbrisk TILs were \nanalyzed \nseparately, both \nlevels were  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 203 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsignificant \npredictors of a \nnegative SLN \ncompared with \nabsent TILs, by \nunivariate and \nmultivariate \nanalysis  \n \nHistologic status \nof SLN was the \nmost significant \npredictor of DF S \nand OS  \n \nNegative SLN: 5-\nyear DFS 80.0%  \n \nPositive SLN: 5 -\nyear DFS 32.8%  \n \nWhen stratified by \nSLN status, no \nsurvival advantage \npresent with TILs \nMorton et al. \n(2005)  The objective of \nthis study was to \nevaluate, in an \ninternational \nmulticenter phase Randomized \ncontrolled clinical \nmulti -center trial \n \n. 2001 patients with \ninvasive primary \ncutaneous \nmelanoma  Accuracy of \nsentinel node \nidentification  \n \nDissected -basin Overall rate of SN \nidentification: \n95.3%  \n \n6.3% of patients Method of \nrandomization \ndescribed in \nMorton et al. \n(2006)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 204 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nIII trial, the \naccuracy, use, and \nmorbidity of \nintraoperative \nlymphatic mapping \nand sentinel node \nbiopsy (LM/SNB) \nfor staging the \nregional nodal \nbasin of patients \nwith early -stage \nmelanoma.  recurrence in \npatients with \nnegative sentinel \nnode  \n \nSurgical morbidity  with tumor -\nnegative SNs \ndeveloped regional \nnodal recurrence \nat a median \nfollowup of 54 \nmonths  \n \nIncidence of at \nleast one local \nwound \ncomplication: \n13.9% in the WEO \narm and 13.8% in \nthe LM/SNB arm  \n \nSurgical morbidity:  \n37.2% for LM/SNB \nwith immediate \nCLND vs 10.1% for \nLM/SNB witho ut \nCLND   \nNo intention to \ntreat analysis (ITT); \ninstead an as -\ntreated analysis \nwas performed  \nRoka et al. (2005)  To investigate the \naccuracy of SLNB \nand the clinical \noutcome of \npatients.  Prognosti c study  \n \n 309 patients with \nmalignant \nmelanoma  Disease -free \nsurvival  \n \nOverall survival  SNB success rate: \n96.8%  \n \nSLN positivity rate: \n23% \n \nFalse -negative \nSLNB rate: 9.2%  Prospective design  \n \nRelatively short \nmean follow -up \ntime \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 205 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \nAmong patients \nwith one or more \nmetastatic SLN, \n21% had further \nmetastases in non -\nSLNs in the \ndissected basin  \n \nMicrometastasis in \nSLN in 68%, \nmacrometastasis \nin 32%  \n \n3-year DFSl for \nnegative and \npositive SLN \npatients: 82 and \n55%, respectively  \n \n3-year overall \nsurvival for \nnegative and \npositive SLN: \npatients 93% and \n83%, respectively  \n \nBy multivariate \nanalysis, Breslow \nthickness the only \nstatistically  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 206 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsignificant \nprognostic factor \nwith respect to \noverall survival \nCu\u00e9llar et al. \n(2004)   To describe \nindependent \nprognostic factors  \nother than tumour \nthickness useful in \nSLN candidate \nselection.  Prognostic study  \n \n 94 MM patients  Correlation \nbetween potential \nprognostic factors \nand SLN positivity  SLN positivity rate \n20.2%  \n \nNo positive SLN in \nMM \u2264 1.0 mm and \nin patients with \nregression  > 50%  \n \nSmall cell and \nulceration were \nsignificant \nprognostic factors \nin multivariate \nanalysis  \n \nSLN positivity rate \nfor small cell: \n56.9%  \n \nSLN positivity rate \nfor ulceration: \n35.5%  \n \nSLN positivity rate \nfor small cell and \nulceration: 86.3%  Retrospective \ndesign 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 207 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nMacripo et al. \n(2004)  To analyse the \nparameters \nassociated with a \nhigher risk of \noccult nodal \nmetastases, to \nevaluate the \nclinical outcome of \nmelanoma patients \nwho underwent \nSLN procedure, \nand to identify by \nmeans of \nmultivariate \nanalysis the \nprognostic \nparameters with \nindependent \npredictive value on \ndisease -free \nsurvival (DFS) in \nnode -positive and \nnegative patients.  Prognostic study  \n \n 274 melanoma \npatients with \nmelanoma \u2265 1 mm \nor ulceration, \nregression or Clark \nlevel IV/V  Status of SLN \n(negative, \nmicrometastasis or \nmacrometastasis)  \n \nDisease -free \nsurvival  SLN positivity rate \n16.8%  \n \nSubsequent radical \nnode dissection \nrevealed further \nmelanoma \nmetastases in 33% \nof patients with \nmacrometastases \nand 10% of \npatients with \nmicrometastases  \n \nRelapse rate of \nSLN-positive \npatients: 54.3%  \n \nRelapse rate of \nSLN-negative \npatients: 10.9%  \n \n5-year DFS and OS \n42% for SLN+ and \n69% for SLN - \n \nSLN status \n(micrometastases/ \nmacrometastases) \nand thickness were \nindependent Prospective design  \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 208 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nprognostic factors \nin the SLN -positive \ngroup  \n \nLow-risk group: \nmicrometastases \nand Breslow \nthickness \u2264 2 mm; \n2-year DFS 100%  \n \nIntermediate -risk \ngroup: \nmacrometastases \nor Breslow \nthickness >2 mm; \n2-year DFS 71%  \n \nHigh-risk group: \nmacrometastases \nand Breslow \nthickness >2 mm; \n2-year DFS 28%  \nStitzenberg et al. \n(2004)  To investigate if \nlymphatic mapping \nand sentinel \nlymphadenectomy \n(LM/SL) with a \nfocused \nexamination of the \nsentinel node (SN) Prognostic study  \n \n 146 patients with a \nmelanoma tumor \nthickness of \u2264  1.0 \nmm Correlation of \nhistopathological \nfactors and SLN \npositivity  SLN positivity rate \n4% \n \nOn multivariate \nanaly sis, none of \nthe clinical or \nhistopathologic \nfactors examined Retrospective \ndesign  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 209 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nwill detect a \nsignificant number \nof SN metastases \nin patients with \nthin melanoma \nand which clinical \nor histopathologic \nfactors may serve \nas predictors of SN \ntumor \ninvolvement. significantly \nassociated with SN \ntumor involvement \nin patients with \nthin melanoma  \n \nNone of the \npatients had non -\nSN tumor \ninvolvement  \nMraz -Gernhard et \nal. (1998)  To devel op a \nprognostic model, \nbased on clinical \nand pathological \ndata, to estimate \nthe probability of \nmicrometastasis in \nthe sentinel lymph \nnode in patients \nwith malignant \nmelanoma.  Prognostic study  \n \n 215 patients with \nAJCC stages I and \nII cutaneous \nmalignant \nmelanoma  Incidence of SLN \npositivity \ndepending on \nhistological \nfeatures  SLN positivity rate \n21.4%  \n \nOnly tumor \nthickness \nsignificantly \ncorrelated with \nSLN positivity  \n \nIncidence of \npositive SLN \naccording to \nnumber of high \nrisk features \n(HRFs):  \n14% with no HRF  \n31% with 1 HRF  \n47% with 2 HRFs  \n75% with 3 or Retrospective \ndesign  \n \nSimilar rate of SLN \npositivity in \nmelanomas \nbetween 1.0 and \n2.9 and > 5 mm \nmay be due to \nselection bias \n(exclusion of \npatients with \nevidence of \nregional lymph \nnode metastasis) \n=> may also be \ntrue for other \nstudies  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 210 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmore HRFs  \nSatzger et al. \n(2011)  To analyze the \npossible effect of \nSLND on the \nprognosis of \nmelanoma \npatients.  Prognostic study  \n \n 673 consecutive  \nmelanoma patients  Overall survival \n \nRecurrence -free \nsurvival  Pre-SLN group: \n25.7%  melanoma \nrelated deaths  \n \nSLN group: 17.6%  \n \n5-year melanoma-\nspecific survival \nrates: 80.3% in pre -\nSLN patients, \n84.8% in SLN \npatients  \n \n5-year survival \nrates: 72.8% in SLN \npositive patients, \n89.9% in SLN \nnegative patients \n89.9%  \n \nRelapse rate 39.0% \nin pre -SLN \npatients, 23.6% in \nSLN patients  Retrospective \ndesign  \n \nHistorical control \ngroup  2b- \nEllis et al. (2010)  To clarify \nindications, \npredictive factors, \nand outcomes of Prognostic and \ndiagnostic study  \n \n 397 patients with \nmelanomas  Correlation \nbetween \nhistological \nproperties and SLN Breslow thickness \n> 2 mm, upper \nextremity \nprimaries, and Retrospective \ndesign  \n \nDifficult definition 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 211 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsentinel node \nbiopsy.  positivity  \n \nSensitivity and \nspecificity, NPV \nand PPV  \n \n ulceration were \npredictive for SLN+ \nstatus  \n \nSLN positivity rate \n12%; for lesions > \n1 mm 16%  \n \nFalse-negative rate \n4.0% \n \nSensitivity of SLNB \n75.4%, with a \nnegative predictive \nvalue of 95.4% and \naccuracy of 96.0%; \nspecificity and \npositive predictive \nvalue 100%  of \u201cfalse -positives\u201d \n(here declared as \n0, but not  defined)  \nKretschmer et al. \n(2008) To determine \nsurgical morbidity \nin melanoma \npatients with \nsentinel \nlymphnodectomy \nand complete \nregional lymph \nnode dissection  Cohort study  \n \n 315 melanoma \npatients  Complication rate  Mortality 0%  \n \nMorbidity rate \nrelated to general \nanaesthesia 0%  \n \nComplication \nrates:  \n65.5% after CLND, \n13.8% after SLNE  \n Most data \nprospectively \nrecorded (325 vs. \n40 nodal basins)  \n \nSurgical morbidity \nnot recorded for \nall patients who  \nunderwent SLNE or \nCLND (possible \nsource of bias)  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 212 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n19.5% in inguinal \ndissection, 9.2% in \naxillary dissection  \nde Rosa et al. \n(2011 ) to examine the \ntest performance \nof sentinel node \nbiopsy in head and \nneck melanoma, \nincluding the \nidentification rate \nand false -negative \nrate Systematic review \nwithout meta -\nanalysi s \n \n \n(32 studies eligible \nfor analysis)  3442 patients  predictive value \npositive (PPV) and  \nnegative (PVN) for \nnodal recurrence  \n \nposttest \nprobability  \n \nFN-negative rate  \n \n Positive sentinel \nnode biopsy: in \n15% \nof patients.  \n \nSubsequent \ncompletion neck \ndissect ion revealed \nadditional \npositive nodes in \n13.67%.  \n \npredictive value \npositive for nodal \nrecurrence: 13.1%,  \n \nposttest \nprobability \nnegative: 5%.  \nMedian FN -\nnegative rate for \nnodal recurrence \nwas 20.4%.  Distinct portions \nof the included \nstudies were used \nto determine PVP, \nPTPN\u2026  \n \n32 studies \nclinically \nheterogeneous  3a \nDoeden et al. \n(2009)  We directly \ncompared the \nrelative Prognostic study  \n \n 94 patients with \nprimary cutaneous \nmelanoma, 57 of Overall survival  \n \nDisease -free SLN positivity rat e \n75% in LI -positive \npatients, 39% in LI -Small sample size \n(57 with known \nSLN status)  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 213 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ncontribution of \nlymphatic and \nhematogenous \npathways in a \ncohort of patients \nwith primary \ncutaneous \nmelanoma with 3 \nyears of clinical \nfollow up. which had a known \nSLN status  survival  \n \nCorrelation \nbetween lymphatic \ninvasion (LI) resp. \nvascular invasion \n(VI) and SLN \npositivity  negative patients  \n \nPresence of LI was \nindependent of \ntumor thickness \nand not associated \nwith distant \nmetastasis  \n \nKaplan -Meier \nanalyses did not \ndetect a significant \ndifference in the \noverall or disease -\nfree survival in LI-\npositive or LI -\nnegative patients  \n \nBy multivariate \nanalysis, LI was not \na significant risk \nfactor for SLN \nmetastasis   \nRetrospective \ndesign  \nLeiter  et al. (2010 ) To investigate the \npotential survival \nbenefit of sentinel \nlymph node \ndissection (SLND).  Prognostic study  \n \n 879 patients with \nprimary cutaneous \nmelanoma  Incidence of \nmetastasis  \n \nOverall survival \n \nRecurrence -free \nsurvival  Rate of regional \nlymph node \nmetastasis: 16.5% \nin non- SLND \ncollective, 7.3%   in \nSLND collective; no \ndifference in Retrospective \ndesign  \n \nHistorical control \ngroup without \nconsistent \nreporting of 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 214 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsatellite/in -transit \nmetastases and \ndistant metastases  \n \nDisease -free \nsurvival improved \nin the SLND \ncollective  ulceration  \n \n \nMassi et a l. (2006)  To evaluate \nwhether tumour \nlymphangiogenesis \nand the expression \nof vascular \nendothelial growth \nfactor C (VEGF -C) \nis related to the \nrisk of SLN \nmetastasis and to \nclinical outcome in \na case \u2013control \nseries of patients \nwith melanoma.  Case-control stu dy \n \n 15 patients \naffected by \nprimary cutaneous \nmelanoma with \nmetastasis to SLN \nwere matched with \na group of 30 \npatients without \nSLN metastasis.  Correlation \nbetween LV and \nSLN positivity  \n \nOverall survival Number and area \nof peritumorous \nand intratumorous \nlymphatics was \nsignificantly higher \nin melanomas \nassociated with \nSLN metastasis \nthan in non -\nmetastatic \nmelanomas  \n \nNo significant \ndifference in VEGF -\nC expression by \nneoplastic cells \nbetween \nmetastatic and \nnon-metastatic \nmelanomas  \n \nIn multivariate Retrospective \ndesign  \n \nSmall patient \nsample  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 215 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nanalysis, \nperitumorous LV \ndensity was an \nindependent \nvariable affecting \noverall survival \nDadras et al. \n(2005)  To investigate \nwhether the extent \nof tumor \nlymphangiogenesis \ncan predict \nmelanoma \nmetastasis to \nsentinel lymph \nnodes.  Prognostic study  \n \n 45 consecutive \npatients with \nnonmetastatic (n = \n27) or metastatic \n(n = 18) primary \ncutaneous \nmelanoma to the \nSLN. Odds\u2019 ratio  Mean tumor \nthickness in SLN -\npositive patients \n3.01 \u00b1 0.52mm, in \nSLN-negative \npatients 1.70 \u00b1  \n0.31mm  \n \nAdditional \nprognostic \nparameters such \nas tumor \nulceration, mitotic \nactivity, regression \nand number of \ntumor infiltrating \nlymphocytes did \nnot differ between \ngroups \n \nFrequency of \nintratumoral \nlymphatics in SLN -\npositive patients Small patient \nsample  \n \nRetrospective \ndesign  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 216 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n83.3 \u00b1 0.09%, in \nSLN-negative \npatients 59.3 \u00b1  \n0.09%  \nRoaten et al. \n(2005)  To investigate the \nassumption that \nSLNB has fewer \ncomplications than \nelective regional \nlymph node \ndissection (RLND).  Cohort study  \n \n 339 consecutive \npatients \nundergoing S LNB \nfor melanoma  \n \n Complication rates  SLN positivity rate \n19.6%  \n \nComplication rate \n5.9% for SNB, \n19.5% for RLND  Retrospective \ndesign  \n \nNo clear inclusion \ncriteria and \ndifferent \ncharacteristics \n(thicker tumors, \nmore men, longer \nfollow -up) in \ncontrol group wh o \nreceived RLND  \n \nRole of closed \nsuction to be \ninvestigated \nfurther  3b \nLeong et al. (2003)  To examine the \nrole of sentinel \nlymph node biopsy \n(SLNB) in patients \nwith a previous \nwide local excision \n(WLE).  Prospective case -\ncontrol study  \n \n 168 patients with \nclinically \nnodenegative \ntruncal or \nextremity \nmelanoma and \nBreslow thickness \nof \u2265 1 mm.  Number of positive \nSLNB  \n \nFalse -negatives  \n \nDisease -free \nsurvival  \n SLN positivity rate \n32.3% both for \ncases and controls  \n \nNo significant \ndifference in \nrelapse -free \nsurvival: 72.3% for Follow -up time \nspan too short for \nreliable \nassessment of \nsurvival  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 217 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nA total of 103 of \nthe 168 patients \nwere referred after \ntheir WLE. Overall survival  cases, 81.7% for \ncontrols at 2 years; \n \nNo significant \ndifference in \noverall survival: \n94.7% incases, \n96.8% in controls \nat 2 years  \nMcCready et al. \n(2001 ) To document \nexperience with \nsentinel lymph -\nnode biopsy in \npatients who have \nalready undergone \na wide local \nexcision for \nmelanoma because \nin many centres \nprevious wide \nexcision has been \na cont raindication \nfor sentinel lymph \nnode biopsy.  Prospective cohort \nstudy  \n \n 100 patients with \ncutaneous \nmelanoma  \n \n Accuracy of biopsy  \n \nFalse -negative \nrates  SLN positivity rate \n31%  \n \nAt completion \nlymphadenectomy, \n29% rate of other \npositive nodes in \nthe dissec ted basin  \n \n  Only a historical \ncontrol group \navailable  \n \nSmall patient \nnumbers, \nespecially in the \nfalse-negative \ngroup  3b \nNguyen et al. \n(2001)  To determine \nwhether primary \nmelanoma \nhistopathologic \nfeatures could be Prognostic study  \n \n 112 consecutive \nmelanoma patients  Correlation \nbetween \nhistological \nfeatures and SLN \npositivity  SLN positivity rate \n20% \n \nFalse -negative rate \n2.4% Retrospective \ndesign  \n \nNo explicit \ninformation about 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 218 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \napplied to predict \nsentinel node \nstatus.   \nIn multivariate \nanalysis, the most \nsignificant cutoff \nfor prediction of \nnode positivity was  \na thickness of 1.5 \nmm \n \nAdditional \nhistologic features \nsignificantly \npredictive of occult \nmicrometastases: \nulceration and \nlymphovascular \ninvasion  inclusion criteria \nfor SLNE  \nPasquali et al. \n(2011 ) To test the \ndiscrimination, the \ncalibration and the \nNPV of MSKCC \nnomogram in 543 \npatients  Diagnostic study  543 patients   positive SN in 147 \npatients (27%).  \n \nMean predicted \nprobability: 17.8% \n(95%CI: 16.8 -\n18.8%). Nomogram \ndiscrimination was \nsignificant (area  \nunder the curve = \n0.68; P < 0.0001) \n(R(2) = 0.99).  \n  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 219 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nCut-off values \nbetween 4% and \n9% led to a NPV, \nSNB reduction and \noverall error rates \nranging between \n100 and 91.2%, \n2.2 and 27.2%, and \n0 and 2.3%, \nrespectively. \n \nincidence of SN \nmetastasis was \nhigher th an that \nobserved in the \nMSKCC series (27% \nvs 16%).  \n \n3.1.5.  Literatur  \nBurton AL, Gilbert J, Farmer RW, et al. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma. Am Surg 2011;77:1009- 1013  \nCadili A, Dabbs K. Predictor s of sentinel lymph node metastasis in melanoma. Can J Surg 2010;53:32- 36 \nCecchi R, Buralli L, Innocenti S, et al. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol 2007;34:512- 515 \nCuellar FA, Vilalta A, Rull R, et al. Small cell melan oma and ulceration as predictors of positive sentinel lymph node in malignant melanoma patients. Melanoma Res 2004;14:277- 282 \nDadras SS, Lange -Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. M od Pathol 2005;18:1232- 1242  \nde Rosa N, Lyman GH, Silbermins D, et al. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg 2011;145:375- 382 \nde Vries M, Speijers MJ, Bastiaannet E, et al. Long -term follow -up revea ls that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary \ncutaneous melanoma. Eur J Surg Oncol 2011;37:681- 687 \nDoeden K, Ma Z, Narasimhan B, et al. Lymphatic invasion in cutaneous melanoma is assoc iated with sentinel lymph node metastasis. J Cutan Pathol 2009;36:772- 780 \nEllis MC, Weerasinghe R, Corless CL, et al. Sentinel lymph node staging of cutaneous melanoma: predictors and outcomes. Am J Surg 2010;199:663- 668 \nGoppner D, Ulrich J, Pokrywka A, et  al. Sentinel lymph node biopsy status is a key parameter to stratify the prognostic heterogeneity of malignant melanoma in high -risk tumors >4.0 \nmm. Dermatology 2011;222:59- 66 \nGutzmer R, Satzger I, Thoms KM, et al. Sentinel lymph node status is the most i mportant prognostic factor for thick (> or = 4 mm) melanomas. J Dtsch Dermatol Ges 2008;6:198- 203 \nKaur C, Thomas RJ, Desai N, et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol 2008;61:297 -300 \nKoskivuo I , Hernberg M, Vihinen P, et al. Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma. Br J Surg 2011;98:1400- 1407   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 220 von 817 \nKretschmer L, Starz H, Thoms KM, et al. Age as a key factor influencing metastasizing patterns and disease -specific survival after sentinel lymph node biopsy for cutaneous melanoma. \nInt J Cancer 2010  \nKretschmer L, Thoms KM, Peeters S, et al. Postoperative morbidity of lymph node excision for cutaneous melanoma -sentinel lymphonodectomy versus complete regional lymph  node \ndissection. Melanoma Res 2008;18:16- 21 \nKunte C, Geimer T, Baumert J, et al. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1 049 patients with \ncutaneous melanoma. Melanoma Re s 2010;20:330- 337 \nLeiter U, Buettner PG, Bohnenberger K, et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metas tasis \nafter nodal involvement. Ann Surg Oncol 2010;17:129- 137 \nLeong  WL, Ghazarian DM, McCready DR. Previous wide local excision of primary melanoma is not a contraindication for sentinel lymph node biopsy of the trunk and extremity. J Surg \nOncol 2003;82:143- 146 \nMacripo G, Quaglino P, Caliendo V, et al. Sentinel lymph node  dissection in stage I/II melanoma patients: surgical management and clinical follow -up study. Melanoma Res 2004;14:S9-\n12 \nMandala M, Imberti GL, Piazzalunga D, et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease -free and overall survival in clinical stages I -II \nAJCC skin melanoma: outcome analysis from a single -institution prospectively collected database. Eur J Cancer 2009;45:2537- 2545  \nMassi D, Puig S, Franchi A, et al. Tumour lymphangiogenesis is a possibl e predictor of sentinel lymph node status in cutaneous melanoma: a case- control study. J Clin Pathol \n2006;59:166- 173 \nMays MP, Martin RC, Burton A, et al. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node bio psy? Cancer 2010;116:1535- 1544 \nMcCready DR, Ghazarian DM, Hershkop MS, et al. Sentinel lymph -node biopsy after previous wide local excision for melanoma. Can J Surg 2001;44:432- 434 \nMcMasters KM, Wong SL, Edwards MJ, et al. Factors that predict the presence  of sentinel lymph node metastasis in patients with melanoma. Surgery 2001;130:151- 156 \nMorris KT, Busam KJ, Bero S, et al. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol 2008;15: 316-322 \nMorton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early -stage melanoma: accuracy and morbidity in MSLT -I, an international multicenter trial. Ann Surg 2005;242:302-\n11; discussion 311- 3 \nMorton DL, Thompson JF, Cochran AJ, et al. Se ntinel -node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307- 1317  \nMraz -Gernhard S, Sagebiel RW, Kashani -Sabet M, et al. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch \nDermatol 1998;134:983 -987 \nMurali R, Desilva C, Thompson JF, et al. Factors predicting recurrence and survival in sentinel lymph node -positive melanoma patients. Ann Surg 2011;253:1155- 1164  \nNguyen CL, McClay EF, Cole DJ, et al. Melanoma thickness and hi stology predict sentinel lymph node status. Am J Surg 2001;181:8- 11 \nPaek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positiv ity in melanoma. Cancer 2007;109:100- 108 \nPasquali S, Mocellin S , Campana LG, et al. Maximizing the clinical usefulness of a nomogram to select patients candidate to sentinel node biopsy fo r cutaneous melanoma. Eur J Surg \nOncol 2011;37:675- 680 \nRoach BA, Burton AL, Mays MP, et al. Does mitotic rate predict sentinel lymp h node metastasis or survival in patients with intermediate and thick melanoma? Am J Surg 2010;200:759 -\n63; discussion 763- 4 \nRoaten JB, Pearlman N, Gonzalez R, et al. Identifying risk factors for complications following sentinel lymph node biopsy for  melano ma. Arch Surg 2005;140:85- 89 \nRoka F, Kittler H, Cauzig P, et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer 2005;92:662- 667 \nRondelli F, Vedovati M, Becattini C, et al. Prognostic  role of sentinel node biopsy in patients with thick melanoma: a meta -analysis. J Eur Acad Dermatol Venereol 2011  \nRoulin D, Matter M, Bady P, et al. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a singl e institution. Eu r J Surg Oncol 2008;34:673- 679 \nSatzger I, Meier A, Hoy L, et al. Sentinel node dissection delays recurrence and prolongs melanoma -related survival: an analysis of 673 patients from a single center with long -term \nfollow -up. Ann Surg Oncol 2011;18:514- 520 \nSmith VA, Lentsch EJ. Sentinel node biopsy in head and neck desmoplastic melanoma: An analysis of 244 cases. Laryngoscope 2012;122:116- 120 \nSocrier Y, Lauwers -Cances V, Lamant L, et al. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. Br J Dermatol \n2010;162:830- 834 \nStitzenberg KB, Groben PA, Stern SL, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm ). Ann Surg \nOncol 2004;11:900- 906 \nTaylor RC, Patel A, Panageas KS, et al. Tumor -infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007;25:869- 875 \nTejera -Vaquerizo A, Nagore E, Herrera -Acosta E, et al. Prediction of Sentinel Lymph Node Positivity by Growth Rate of Cutaneous Melanoma. Arch Dermatol 2012  \nTestori A, De Salvo GL, Montesco MC, et al. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 pa tients (SOLISM -IMI). Ann Surg \nOncol 2009;16:2018- 2027  \nValsecchi ME, Silbermins D, de Rosa N, et al. Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Melanoma: A Meta -Analysis. J Clin Oncol 2011  \nWarycha MA, Zakrzewski J, Ni Q, et al. Meta -analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm). Cancer 2009;115:869- 879 \nWhite J, R.L.R, Ayers GD, et al. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Annals of Su rgical Oncology \n2011;18:3593- 3600  \nYonick DV, Ballo RM, Kahn E, et al. Predictors of positive sentinel lymph node in thin melanoma. Am J Surg 2011;201:324- 7; discussion 327- 8  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 221 von 817 \n3.2. Frage II.5. und III.4. Tumorlast am Sentinel -Node und komplettierende \nLymphadenektomi e \u2013 De-novo -Recherche  \nFrage II.5 . Hat die Tumorlast am Sentinel- Node eine prognostische Bedeutung?  \nFrage III .4. Ist eine komplettierende LAD bei Mikrometastasen am SLN indiziert? \n3.2.1.  Datenbanken, Suchstrategien, Trefferzahlen  \n3.2.1.1.  Prim\u00e4rrecherche 2012  \nDatenbank  Suchstrategie  Datum  Treffe\nr \nMedline  melanoma[title] AND ((\"sentinel\"[tiab] OR \"sentinel lymph node\"[tiab] OR sln[tiab] OR \nslne[tiab]) AND ((\"tumor load\"[tiab] OR \"tumor burden\"[tiab]) OR (prognosis[tiab] OR \nsurvival[tiab])) OR starz OR dewar OR rotterdam OR s -classification)  26.01.2012  747 \nCochrane Library  (melanoma and (sentinel or \"sentinel lymph node\" or sln or slne) and (\"tumor load\" or \n\"tumor burden\" or prognosis or survival or starz or dewar or rotterdam or \"s \nclassific ation\")).ti,ab.  19.01.2012  27 \nEmbase  (melanoma and (sentinel or \"sentinel lymph node\" or sln or slne) and (\"tumor load\" or \n\"tumor burden\" or prognosis or survival or starz or dewar or rotterdam or \"s \nclassific ation\")).ti,ab.  23.01.2012  872 \nBemerkungen: Eine erste Literaturrecherche in M edline und und Cochrane erfolgte am 01.02.2011 bzw. f\u00fcr Embase am 11.05.2011. Die Update -Recherche \nwurde am 23.01.2012 (Embase) bzw. am 26.01.2012 (Medline) und am 19.01.2012 (Cochrane) durchgef\u00fchrt. In der Tabelle angegeben  sind die Trefferzahlen \nder letz ten Reche rche.  \n \nDa die Literaturbasis f\u00fcr die Fragen II.5 und III.4 die gleiche ist (bei gleicher Suchstrategie), diente die Tabelle sowohl der AG chirurgische Ther apie als auch der \nAG Sentinel als Grundlage zur Beantwor tung der Fragen III.4 bzw. II.5.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 222 von 817 \n3.2.1.2.  Aktualisierungsr echerche 2015  \nDatenbank  Suchstrategie  Datum  Treffer \nMedline  \u201cmelanoma\u201c[tiab] AND ( \u201csentinel\u201c[tiab] OR \u201cSentinel Lymph Node Biopsy\u201d[MeSH]) AND \n(\u201csurvival\u201d[tiab] OR \u201cmortality\u201d[tiab] OR \u201crelapse\u201d[tiab] OR \u201crecurrence\u201d[tiab] OR \n\u201csensitivity\u201d[ tiab] OR \u201cspecificity\u201d[tiab] OR \u201caccuracy\u201d OR \u201coutcome\u201d[tiab] OR \n\u201cprognos*\u201d[tiab] OR \u201cpr edict*\u201d[tiab] OR \u201cassoc*\u201d[tiab]) AND (\"2011.01.11\"[Date - \nPublication] : \"2015.09.16\"[Date -  Publication])  16.09.2015  499 \nCochrane Library   16.09.2015 51 \nBemerkungen:  Die bisherige Empfehlung aus der S3 -Leitlinie Melanom zu der Schl\u00fcsselfrage \u201eHat die Tumorlast am Sentinel -Node eine prognostische \nBedeutung?\u201c (AG Sentinel) basiert auf Studien mit einem Evidenzlevel von 2b. Da es nur wenige Studien gibt mit einem h\u00f6heren  Evidenzlevel, wurden auch \ndiesmal Studien in die Evidenztabelle aufgenommen, die ein Evidenzlevel bis schlechtestens 2b haben.  \n \nDa die Literaturbasis f\u00fcr die Fragen II.5 und III.4 die gleiche ist (bei gleicher Suchstrategie), diente die Tabelle sowohl d er AG chirurgische Ther apie als auch der \nAG Sentinel als Grundlage zur Beantwortung der Fragen III.4 bzw. II.5.  \n \nDie Suche in Cochrane erbrachte ein relevantes Review, was wiederrum nur eine Studie inkludierte.  \n \n3.2.2.  Auswahlkriterien  \n3.2.2.1.  Prim\u00e4rrecherche 2012  \nAuswahl  der Literatur  \nGesamttreffer (inkl. Dupletten)  1646  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 223 von 817 \nAusschlu sskriterien  Case Re ports, narrative Reviews  \nAnzahl nach Abstractscreening  79 \nAnzahl ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewer tung 25 \n3.2.2.2.  Aktualisierungsrecherche 2015  \nAuswahl der Literatur  \nGesamttreffer (inkl. Dubletten)  550 \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nAusschlu sskriterien  Case Re ports, narrative Reviews  \nAnzahl nach Abstractscreening  408 \nAnzah l ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewertung  11 \n3.2.3.  Evidenztabelle # \n3.2.3.1.  Prim\u00e4rrecherche 2012  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nMocellin et al. \n(2007)  To investigate the \nprognostic value of \nPCR status of SLN.  Systematic review \nand meta -analysis  \n \n 4019 patients who \nunderwent SLN \nbiopsy for clinical \nstage I to II Recurrence rate  \n \nOverall survival \n Pooled positivity \nrate: 20.3% \npathology -based  \n Funnel plot did not \nshow publication \nbias 1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 224 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ncutaneous \nmelanoma  Sensitivity, \nspecificity, positive \nand negative \npredictive value \n(PPV, NPV)  In patients with \npathology -negative \nSLN: PCR positive \nin 42.3%  \n \nIn patients with \npathology -positive \nSLN: PCR negative \n(false negative) in \n49% \n \nPCR positivity in \npatients with \npathology -positive \nSLN: 95.1%  \nIn patients with \npathology -negative \nSLN: 46.6%  \n \nDisease recurrence \nrate: 16.8% among \nPCR-positive \npatients; 8.7% in \nPCR negative \npatients  \n \nPCR sensitivity \n57.4%, specificity \n61.1%, accuracy \n60.6%, PPV 16.8%, \nNPV 91.3%   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 225 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nElsaesser et al. \n(2012 ) investigated \nsurvival \nprobabilities and \nprognostic factors \nin sentinel lymph \nnode biopsy (SLNB) \nstaged patients \nwith cutaneous \nmelanoma (CM) \nwith the aim of \ndefining \nsubgroups of \npatients who are at \nhigher risk for \nrecurrences and \nwho should be \nconsidered for \nadjuvant c linical \ntrials.  Cohort study  \n 1909 SLNB staged \npatients with \nprimary CM  5-year-OS \n \nPrognostic factors  5-year OS in SLNB \nnegative patients: \n90.3% (IB 96.2%, \nIIA 87.0%, IIB \n78.1%, IIC 72.6%).  \n \n5-year OS in \npatients with \nmicrometastases \n(stage IIIA/B): \n70.9% which was \nclearly less \nfavorable than for \nstages I -II. \nMultivariate \nanalysis revealed \ntumor thickness, \nulceration, body \nsite, \nhistopathologic \nsubtype and SLNB \nstatus as \nindependent \nsignificant \nprognostic factors.   2b \nQuaglino et al. \n(2011 ) to evaluate which \nprognostic \nvariables could \npredict NSLN \ninvasion in SLN -Cohort study  \n 603 patients who \nhad undergone \nSLNB for \nmelanoma  OS \n \nprognostic \nvariables on CLND \nresults and disease Breslow thickness, \nulceration and \nmicro/macrometas\ntatic pattern of SLN \ninvasion carried a Retrospective chart \nreview  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 226 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npositive patients \nand their impact \non the overall \nsurvival (OS).  course.  significantly \nindependent \nhigher likelihood \nof NSLN \ninvolvement; Starz \nclassification did \nnot maintain a \nstatistical \nsignificance in \nmultivariate \nanalysis.  \n \nNSLN involve ment, \nwas found in \n33.3% of patients \nwith one and \n55.9% with \n\u2265adverse \nparameters (p = \n0.0001).  \nVan der Ploeg et \nal. (2011)  To determine the \nrole of tumor load \nand tumor site in \nthe SN as \nprognostic factors \nfor survival and a s \npredictive factors \nfor NSN positivity. Cohort study  \n \n 1080 patients with \npositive SLN  NSN status  \n \nOverall survival Significant factors \nregarding NSN \nstatus: age, study \ncenter, histology \nand location of the \nprimary, Clark \nlevel, Breslow \nthickness, \nRotter dam criteria, \nRotterdam criteria Retrospective \ndesign  \n \nLarge patient \ncohort \n \nFor detailed \nsurvival rates see \noriginal article  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 227 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nII, III, and IV, \nDewar criteria, \nDewar criteria II, \nand RDC criteria  \n \nRate of additional \npositive lymph \nnodes in the group \nof patients with \nsubmicrometastas\nes (\u2264 0.1 mm, \nRotterdam \ncriteria): 9%  \nPatients with 0.1 \nto 1.0 mm: 16%  \nMurali et al (2011)  To investigate in \ndetail the influence \nof SN tumor \ncharacteristics and \nclinical and \nprimary tumor \nparameters on \nregional lymph \nnode re currence, \ndistant metastasis,  \nand survival.  Cohort study  \n 409 patients with \nprimary cutaneous \nmelanoma who \nunderwent  \nSNB  DFS \n \nmelanoma -specific \nsurvival (MSS)  Primary tumor \nfeatures (presence \nof ulceration and \nsatellites) and \npresence of ENS in \nSNs were \nindependent \npredictors of DFS, \nDMFS, and MSS. In \naddition, poorer \nDFS was \nindependently \nassociated with \nprimary tumor site \n(head/neck and Same patient \ncohort as Murali et \nal. (2010): Non -\nSentinel Node Risk \nScore (N -SNORE): A \nScoring System for \nAccurately \nStratifying Risk of \nNon-Sentinel Node \nPositivity in \nPatients With \nCutaneous \nMelanoma With \nPositive Sentinel \nLymph Nodes 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 228 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nlimbs vs. trunk), \nSN \ntumor features \n(MaxSize >2 mm, \npresence of PLI) \nand positive NSN \nin CLND; other \nfactors \nindependen tly \npredictive of DMFS \nwere male sex, \nprimary tumor \nfeatures (absence \nof TILs), and SN \ntumor MaxSize \n>10 mm; and age \n\u226550 years was an \nadditional \nindependent \npredictor of MSS. \nCLND status was \nnot an \nindependent \npredictor of DMFS \nor MSS.  \nBalch et al. (2 010) To determine the \nsurvival rates and \nindependent \npredictors of \nsurvival using a Cohort study  \n \n 2313 patients with \nstage III disease  Overall survival  5-year survival for \npatients with \nmicrometastases: \n67% \n Patient cohort \npartially identical \nwith Balch et al. \n2004 and 2009  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 229 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ncontemporary \ninternational \ncohort of patients \nwith stage III \nmelanoma.  When stratified by \ntumor thickness, \nulceration, and  \nnumber of \ninvolved nodes, 5 -\nyear-suvival rates \nwere: 87% for a \nsingle nodal \nmicrometastasis \narising from a \nnonulcerated \nprimary melanoma \n\u2264 2.0 mm in \nthickness, 23% for \npatients with four \nor more nodal \nmacrometastases \nfrom an ulcerated \nprimary melanoma \ngreater than 6.0 \nmm in thickness  \n \nFor patients with \nnodal \nmicrometastases \nindependent \npredictors of \nsurvival were \npatient age, sex, \ntumor thickness, \nulceration, primary For survival curves \nsee original article   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 230 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nanatomic site, and \nnumber of tumor -\nbearing lymph \nnodes \n \nFor patients with \nnodal \nmacrometas tases, \nage, ulceration, \nanatomic site, and \nnumber of tumor -\nbearing lymph \nnodes \nindependently \npredicted survival  \nMeier et al. (2010)  To compare the \nRFS and OS of 697 \nmelanoma patients \nas predicted by \nvarious \nclassification \nsystems.  Cohort study  \n \n 697 consecutive \npatients with \nprimary cutaneous \nmelanoma \n(Bresl ow tumor \nthickness \u2265 1 mm)  Recurrence -free \nsurvival  \n \nOverall survival CLND positivity \nrate 15.4%  \n \n21% recurrence \nrate \n \n14% mortality rate \n(causes related to \nmelanoma)  \n \nIn multivariate \nanalysis, \nindependent \npredictors for RFS \nwere greatest Suggestion of new \nclassification \nsystem Hannover II  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 231 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ndimension of the \nlargest tumor cell \ndeposit (cutoff \npoint, <0.1 mm vs \n\u2265 0.1 mm), TPD \n(cutoff point, \u2264  2 \nmm vs >2 mm), \nand capsular \ninvolvement; TPD \nand capsular \ninvolvement also \nfor OS  \nBalch et al. (2009)  To revise th e \nstaging system for \ncutaneous \nmelanoma on the \nbasis of data from \nan expanded \nAmerican Joint \nCommittee on \nCancer (AJCC) \nMelanoma Staging \nDatabase.  Cohort study  \n \n 3,307 stage III \npatients.  Overall survival  Independent \npredictors for \nsurvival: number \nof tumo r-bearing \nnodes, tumor \nburden at the time \nof staging (ie, \nmicroscopic v \nmacroscopic), \npresence or \nabsence of primary \ntumor ulceration, \nand thickness of \nthe primary \nmelanoma  \n \n5-year survival \nrates: 70% for For stage III \nsurvival curves, \nsee Fig. 1 in the \npublication. \n \nPatient cohort \npartially identical \nwith Balch et al. \n2004  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 232 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npatients with T1 -\n4N1M0 \nmelanomas,  39% \nfor patient s with \nT1-4N3M0 \nmelanomas  \nvan Akkooi et al. \n(2008 ) to evaluate the \nsurvival rate of  \nminimal SN tumor \nburden  Cohort study  388 SN po sitive \npatients  overall survival \n(OS) SN tumor burden \nincreased \nsignificantly with \ntumor thickness.  \n \nestimated 5 -year \noverall survival:  \n- for SUB -\nmicrometastases  \n<0.1 mm SN tumor \nburden: 91%  \n- for 0.1 - to 1.0 -\nmm SN tumor \nburden:  61%  \n- for >1 mm SN \ntumor burden: 51%  \n- for </=0.2 mm: \n89%. \n \nIndependent \nprongostic factors \nin OS (multivariate \nanalysisi):  \n- SN tumor burden  Retrospective \ndesign  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 233 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n- T4 primary \ntumors  \nSatzger et al. \n(2008)  To compare \ndifferent \nparameters of the \nSLN and to identify \nthe paramet ers \nthat are most \nimportant for the \nprediction of non -\nsentinel lymph \nnode (NSLN) \ninvolvement. Cohort study  \n \n 180 patients with \nprimary cutaneous \nmelanoma  NSLN involvement  NSLN involvement \nin the CLND \nspecimen in 16.0% \nof patients  \n \nPrimary \nmelanomas \nsignif icantly \nthicker, more often \nulcerated, and \nregressive in \npatients with NSLN \ninvolvement \ncompared with \npatients without \nNSLN involvement  \n \nUpon multivariate \nanalysis, the three \nsignificant \nparameters were \npositivity by H&E \n(versus \nimmunohistochemi\nstry alone) , relative \ntumor area > 10%, \nand presence of \nperinodal Patient population \nsubgroup of Meier \net al. (2010)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 234 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nintralymphatic \ntumor  \nDebarbieux e t al. \n(2007)  To confirm the \nprognostic value of \nSLN biopsy (SLNB); \nto correlate patient \nprognosis to the \nmicromor phometri\nc features of SLN \nmetastasis in SLN -\npositive patients; \nand to correlate \nthese \nmicromorphometri\nc features to the \nlikelihood of \npositive \ncompletion lymph \nnode dissection \n(CLND).  Cohort study  \n \n 455 patients  Overall survival  \n \nDisease -specific \nsurvival  SLN positivity rate \n22% \n \nSurvival \nsignificantly \nshorter in SLN -\npositive than in \nSLN-negative \npatients  \n \nPrognostic factor \nof disease -free \nsurvival: \nextracapsular \ninvasion  \n \nPrognostic factors \nof disease -specific \nsurvival: \nulceration, \nmaximum \ndiameter of largest \nmetastasis  10 patients lost to \nfollow -up 2b \nSatzger et al. \n(2007 a) To determine the \nprognostic \nrelevance of \nhistopathological Cohort study  \n 169 patients with \nprimary cutaneous \nmelanoma \n(Breslow\u2019s tumour Overall survival \n(OS) \n \nRelapse -free Relapse rate 30%  \n \nMortality rate 20% \n(15% melanoma -Patient population \nsubgroup of Meier \net al. (2010)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 235 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ncharacteristics of \nmicrometastases \nin the SLN.  thickness \u2265 1 mm) \nand positive SLN \ndiagnosed from \nApril 2000 to \nDecember 2004.  survival (RFS)  related, 5% \nunrelated)  \n \nIndependent \nprognostic factors \nin multivariate \nanalysis: \ninvasion of capsule \n(present versus \nabsent), tumor \npenetrative depth \n(TPD) with a cut -off \nof 2 mm (< 2 mm \nversus \u2265 2 mm) \nand deposit size (< \n30 cells versus \u2265 \n30 cells)  \nvan Akkooi et al. \n(2006)  to identify  a SN \npositive patient \ngroup, which can \nbe spared CLND  Cohort study  \n 77 SN -positive \npatients  \n Disease -free \nsurvival  \n \nEstimated 5 -year \nsurvival  \n \nNon-SN-positivity  \n Estimated 5 -year \nOS rates:  \n<0.1 mm SN tumor \nburden: 100%  \n0.1\u20131.0 mm SN \ntumor burden:  \n63%  \n>1.0 mm SN tumor \nburden: 35%  \n \nDistant metastases \nin <0,1 mm SN-\npositive patients:  Retrospective \ndesign  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 236 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n1/16 = 6.3%  \n \nDistant metastasis -\nfree survival in \n<0,1 mm SN \npositive patients: \n91%  \n(identical to the 5 -\nyr OS of SN \nnegative patients)  \n \nno additional non -\nSN positivity for \nSN-micro -\nmetastases <0.1 \nmm. \n \nmultivariate \nanalysis: SN tumor \nburden was the \nmost important \nprognostic factor \nfor DFS (P = 0.005) \nand OS (P = 0.03).  \nShivers et al. \n(2007)  To determine the \nrelevance of low -\nvolume disease of \nthe sent inel lymph \nnode detected only \nby RT -PCR-based Cohort study  \n \n 311 Patients with \nmelanoma  Overall survival  \n \nRelapse -free \nsurvival  \n \nSensitivity and SLN positivity rate: \n19% in histology, \n67% by PCR  \n \nRecurrence rate:  \n42% of Very long follow -\nup time (up to 15 \nyears)  \n \nChange in \ntechnique during 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 237 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nassays.  specificity of \nhistology and PCR \nregarding the \nprediction of \nrecurrence/death  histologically and \nPCR positive \npatients  \n22% of \nhistologically \nnegative, but PCR \npositive patients  \n6.6% for \nhistologically and \nPCR negative \npatients  \n \nPrediction of \ndeath:  \nSensitivity of \nhistology 47%, \nspecificity 87%  \nSensitivity of PCR \n88%, specificity \n38%  the course of time  \nBaehner et al. \n(2012 ) To (1) quantitate \ntumor burden in \nsentinel lymph \nnodes (SLNs), and \n(2) assess the \nindepe ndent \ncontributions of \nSLN tumor burden \nand primary \nmelanoma Cohort study  \n 63 patients with \none or more \npositive SLNs were \navailable  Progression -free \nsurvival (PFS)  \n \nOS Cox proportional -\nhazard regression \nmodel: After \nadjusting for age \nand gender, both \nMMS maximum \nmetastasis size \n(MMS)and PMT \nprimary melanoma \nthickness were  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 238 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nthickness (PMT) \nwith respect to \nprogression -free \nsurvival (PFS) and \noverall survival \n(OS). highly significant \nand provided \nindependent \nprognostic \ninformation.  \nFink et al. (2011 ) to predict the  \nlikelihood of \nfurther non- SN \nmetastases on the \nbasis of  \nearlier published \nmicromorphometri\nc classifications of \nSN \nmetastases Cohort study  Specimens of 124 \npositive -SN basins \nand subsequent  \ncomplete lymph \nnode dissection \n(121 patients)  NSN-posit ivity metastases in non -\nSNs were found in \n30 lymph node  \nbasins (24.2%).  \n \nClassification \naccording to \nDewar:  \nSignificant \ncorrelation \nbetween the \nmicroanatomic \nlocation of the \nmetastases and \nnon-SN \ninvolvement \n(P=0.004).  \n \nClassification \naccording to Starz:  \nSignificant \ncorrelation \nbetween \nS.classification of Retrospective \nstudy  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 239 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nSN and non -SN \nstatus (P<0.001)  \n \nClassification of \nthe size of the SN \nmetastases \naccording  \nto the Rotterdam \ncriteria for SN \ntumor burden: \nsignificant \ncorrelation with \nadditional non -SN \ninvolvement  \n(P=0.00 7)  \n \nno statistically \nsignificant \ndifference between \nthe three \nclassifications \n(P=0.6).  \nMurali et al. (2010)  To investigate \nclinicopathologic \nfactors that predict \nNSN positivity in \nan attempt to \nidentify patients \nwho may be safely \nspared completion Cohort study  \n \n 409 patients  NSN positivity  \n \n Predictive of NSN \nstatus in \nmuultivariate \nanalysis: \nclinical \ncharacteristics \n(sex), primary \ntumor Retrospe ctive \ndesign  \n \nFor details of the \nscore, see original \narticle  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 240 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nlymph node \ndissection (CLND).  characteristics \n(ulceration and \nregression), and \n%PosSN \nRiber -Hansen et al. \n(2009)  To use objective \nstereological \ntechniques to \ncorrelate \naccurately total \nSLN tumour \nburden with \nrecurrence and \npatient survival. Cohort study  \n \n 335 consecutive \nmelanoma patients  Recurrence rate  \n \nOverall survival SLN positivity rate \n30.3%  \n \nBenign naevus \ninclusions in 36.1% \nof  SLN patients  \n \nRecurrence rate \n10.4% (25.3% for \npatients positive in \nhistology, 3.9% for \nnegative patients)  \n \nMortality rate from \nmetastatic dis ease \n6.7% (14.1% for \npatients positive in \nhistology, 3.5% for \nnegative patients)  Description of \nstudy drop -outs \ndescribed in \nanother \npublication  2b- \nVan der Ploeg et \nal. (2009)  To evaluate the \nmicromorphometri\nc \nStarz classification \nin melanoma \npatients.  Cohort study  \n \n 70 patients with a \ncutaneous \nmelanoma  Disease -free \nsurvival (DFS)  Lymph node \nrecurrence rate:  \n0% in S -I, S-II \n12% in S -III \n \nOverall 3 -year Small patient \ncohort 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 241 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsurvival:  \n100% in S -I, S-II  \n80% in S -III  \n \n3-year disease -free \nsurvival rates: were \n83% in S -I, S-II  \n60% in S -III  \nFrankel et al. \n(2008)  To examine \nwhether the size \nand location of the \nmetastases within \nthe SLN may help \nfurther stratify the \nrisk of additional \npositive NSLN. Cohort study  \n \n 144 melanoma \npatients  Presence of \nmetas tatic non -\nsentinel nodes  Independent \npredictors of \nadditional disease \nin CLND:  \nprimary location \non the head and \nneck or lower \nextremity, Breslow \nthickness > 4 mm, \nthe presence of \nangiolymphatic \ninvasion, \nsatellitosis, \nextranodal \nextension, three or \nmore po sitive SLN \nand tumor burden \nwithin the SLN>1% \nsurface area  Design not \nconsequently \nprospective  2b- \nSatzger et al. \n(2007b)  To determine the \nprognostic Cohort study  \n 477 patients with \nprimary cutaneous Overall survival \n(OS) 3 groups were \ndifferentiated Patient population \nsubgroup of Meier 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 242 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsignificance of \nisolated HMB45 \nand/or Melan A \npositive cells \n(immunhistochemi\ncally positive cells, \nIPC) i n melanoma \nSLN.  melanoma   \nRelapse -free \nsurvival (RFS)  according to the \nfindings in the \nSLN: Group 1 \nincluded 308 \npatients with \nhistologically and \nimmunohistochemi\ncally negative SLN, \ngroup 2 included \n47 patients with \nIPC, and group 3 \nincluded 122 \npatients with \nmicrometastases.  \n \nRelapse rate: \n11.7% of SLN \nnegative patients, \n12.8% of IPC+ \npatients, 37.7% of \nhistology+ patients  \n \nMortality rate: 5.5% \nof SLN neg ative \npatients, 6.4% of \nIPC+ patients, \n23.8% of \nhistology+ patients  et al. (2010)  \nNamikawa et al. \n(2012 ) to re-evaluate \nmicroscopic Cohort study  \n 450 patients, \nincluding the 149 LN positivity -rate additional LN \npositivity rate of retrospect ive study  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 243 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nclassifications of \nmetastatic sentinel \nlymph nodes (SLN) \nin the Japanese \npopulatio n cases with SLN \nmetastasis,  0% only in patients \nwith a maximum \ndiameter category \nof less than 0.1 \nmm.  \n \nAs compared with \nthat in the SLN \nmetastasis -\nnegative cases, the \nprognosis was \npoorer in cases \nwith SLN \nmetastasis, even \nthose with lesions \nfalling under the \nmaximum \ndiameter category \nof less than 0.1 \nmm, invasion \ndepth category of \nSI (</=0.3 mm) \nand microanatomic \nlocation category \nof subcapsular.  \nStarz et al. (2004 ) to identify the \nrelevant predictors \nfor the presence \nversus absence of \nnonsentinel lymph Cohort study  \n SLNE cohort: 324 \npatients  \n \npre-SLNE \ncohort:274 Overall  survival  \n \nsurvival without \ndistant metastases  S-classification  \nwas the most \nsignificant \nindependent \npredictor of the  Patients who \nunderwent SLNE \uf0e0 \nsame population \nas in Starz et al. \n2001 (see above)  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 244 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nnode metastases \nin CLND specimens  consecutive \nmelanoma patients  presence/absence \nof NSN -metastases \nin binary logistic \nregression: (P = \n.010; adjusted \nrelative risk = \n3.31).  \n \nsurvival without \ndistant \nmetastases: Highly \nsignificant \ndivergence of the  \nKaplan -Meier \ncurves of the pre -\nSLNE- and SLNE -\ncohort (P = .0057 \nby log rank test).  \n \nOverall survival:  \nKaplan -Meier \ncurves diverge \nafter about 4 years \nof follow -up (P -= \n.03). \n \nCox regressions: S -\nclassificatio n is a \nsignificant \nindependent \npredictor for  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 245 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ndistant metastasis \n(P = .014) and \noverall survival (P \n= .009)  \nBogenrieder et al. \n(2011 ) to predict the \nabsence of non- SN \nmetastases \nin a multicentre \nstudy of patients \nwith a positive SN  \nbased on primary \nmelanoma features \nand SN tumour  \nload. Cohort study  \n 70 SN positive \npatients  NSN-positivity  18/70 patients had \nnon-SN \nmetastases.  \n \nNo non -SN-\nmetastases in \npatients with:  \n- a Bres low \nthickness <2.0 mm \nand an SN  \ntumour load <0.2 \nmm2  \n- a Breslow  \nthickness <2.0 mm \nand SN penetrative \ndepth <600 lm  \n- a Breslow \nthickness <2.0 mm \nand a diameter of \nthe largest SN \ndeposit <500 lm  \n \nlogistic regression: \nthe SN metastatic  \narea was the only \nindependent factor Differences in \nsurvival between \ndifferent \nmicroanatomic \nlocations of \nsentinel node \nmetastases not \ninvestigated  \n \nNo follow -up \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 246 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npredicting the  \npresence of non-\nSN metastases  \nDewar et al. (2004)  to identify criteria \nthat might be used  \nin selecting \npatients who \nshould undergo \nCLND  Cohort study  \n \n \n \n 146 SN -positive \npatients  \n NSN-positivity   evidence of \nmelanoma \nmetastases in NSN \nin 24 of CLND \nspecimens (16.4%)  \n \nsignificant \ncorrelation \nbetween the \nmicroanatomic \nlocation and NSN \ninvolvement \n(subcapsular \nmetastatic \ndeposits in 26%: \nno NSN -\ninvolvement.  \nSN-metastases \nwith different \nmicroanatomic \nlocation: NSN -\ninvolvement in \n22,2%)  \n \nstrong correlation \nbetween depth of \nmetastatic deposit Retrospective \nstudy  \n \ndifferences  \nin survival between \ndifferent \nmicroanatomic \nlocations of \nsentinel node \nmetastases not \ninvestigated  \n \nNo follow -up \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 247 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nfrom the capsule \nof the SN and NSN \ninvolvement (3/24 \npatien ts (12.5%) \nwith positive NSNs \nhad deposits less \nthan 1mmin \ndepth.)  \nStarz et al. (2001)  predictive capac ity \nof S-classification  \n Cohort study  \n \n \n \n 342 patients with \nprimary melanoma \nand SLNE (389 \nlymph node  \nRegions)  \n \n62 patients with \npositive SLNs: \n \n42 received RCLND  \n \n \n Presence of \nmetastases \n \nsurvival  325 SLNs: S0  \n24 SLNs: S1  \n22 SLNs: S2  \n18 SLNs: S3.  \n \nCorre lation of the \nS categories with \nthe T categories \n(of the  \npTNM \nclassification) \n(Spearman \ncorrelation; P = \n0.0001),  \n \noccurrence of \nmelanoma -positive \nnon-SLN \nsignificantly \nincreased from 0 \nof 12 in S1 SLNs to \n2 of 13 in S2 SLNs Short follow -up \n \nUlceration of the \nprimary melanoma \nnot included in \nthis analysis  \n \n(multivariate \nanalysis directly \nusing the T and S \nclassifications as \nvariables was not \npossible)  \n \n \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 248 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nand 9 of 15 in S3 \nSLNs (P = 0.0 01; \nchi-square test).  \n \nThe risk of \ndeveloping distant \nmetastases was \ndependent on the \nT classification (P < \n0.0001; log rank \ntest) and S -\nclassification (P < \n0.0001)  \n \nT classification of \nthe primary \nmelanoma and S-\nclassification= \nhighly significant \npredic tor for \ndistant metastasis \n(P < 0.001).  \n \nIt turned out to be \nan independent \nfactor of influence \non distant \nmetastasis and \nsurvival in \nmultivariate Cox \nanalyses, which  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 249 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nincluded tumor \nthickness, primary \ntumor site, patient \ngender, and \npatient age as \ncovaria tes. \n \n3.2.3.2.  Aktualisierungsrecherche 2015  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nMorton et al. 2014  \n \n To evaluate the \noutcomes in \nmelanoma patients \n(SNB vs. nodal \nobservation)  \n \n RCT Melanoma patients  \n(CL III and a \nBreslow thickness \n>/= 1 mm and CL \n>/= IV and any \nBreslow thickness)  \n \n1661 patients \nunderwen t \nrandomization: \n \nObservation group: \nwide excision and \nnodal observation \nwith \nlymphadenectomy \nfor \nnodal relapse  5- and 10 -year-\nMelanoma specific \nsurvival  \n \n5- and 10 -year \ndisease -free \nsurvival  \n \nSurvival with \ntumor -positive and \ntumor -negative SN  \n \nIncidence of SN -\nmetastases and \nincidence of \nclinically detected \nnodal metastases \n Melanoma specific \nsurvival rate: \n20.8% with and \n79.2% without \nnodal metas tases  \n \nintermediate -\nthickness \nmelanomas:  \n- 10-year \ndisease -free \nsurvival rates: \nbiopsy group \n71,3 +/ - 1,8% \nvs. \nobservation \ngroup 64,7+/ - \n2,3% \n- distant \ndisease -free 10-year follow -up/ \n215 patients were \nlost to follow -up \n \nDifferent sentinel \nmapping \nprocedures \n \nDifferent follow -up \nprocedures in \nparticipating sites  \n \nHigh rate of false \nnegative biopsy \nresults  \n \nAscertainment bias  \n 1b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 250 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \nbiopsy group  : \nwide excision and \nSNB with \nimmediate \nlymphadenectomy \nfor nodal \nmetastases \ndetected on biopsy   survival: \nsignificantly \nimproved \nwhen patients \nwith nodal \nmetastases \nreceived \nimmediate \nrather  than \ndelayed \nlymphadenect\nomy  \n- 10-year \nmelanoma -\nspecific \nsurvival rates: \nbiopsy group \n81.4\u00b11.5% vs. \nobservation \ngroup \n78.3\u00b12.0%   \n- 10-year \nmelanoma -\nspecific \nsurvival rate: \n62.1\u00b14.8%  \nfor patients \nwith \nmetastasis vs. \n85.1\u00b11.5% for \npatients \nwithout \nmetastasis  \n \nthick melanomas:  \n- 10-year \ndisease -free For further details \nand survival \ncurves: see full -\ntext and appendix  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 251 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsurvival rates: \nbiopsy group \n50,7 +/ - 4,0% \nvs. \nobservation \ngroup 40,5+/ -\n4,7% \n- 10-year \nmelanoma -\nspecific \nsurvival rates: \nno significant \ntreatment -\nrelated \ndifference \nbetween the \nbiopsy and \nthe \nobservation \ngroup (data \nsee full -text) \n- 10-year \nmelanoma -\nspecific \nsurvival rate: \n48.0\u00b17.0%  \nfor patients \nwith \nmetastases \nvs. 64.6\u00b14.9%  \nfor patients \nwithout \nmetastases \n \nSimilar rates of \nnodal metastases  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 252 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nin biopsy and \nobservation group  \nNagaraja et al.  \n2013  \n to determine which \nof the \nclinicopathologic  \nprognostic factors \ncould be used to \npredict the \npresence of \npositive non -SLNs.  Systematic \nresearch with \nmeta -analysis  54 studies \nincluded with a \ntotal number of \npatients of 8388   The pooled \nestimates \nsignificantly \nassociated with the \nhigh likelihood of \nNSN metastases \nwere: ulceration  \n(OR: 1.88, 95% CI: \n1.53-2.31), \nsatellitosis (OR: \n3.25, 95% CI: 1.86 -\n5.66), \nneurotropism (OR: \n2.51, 95% CI: 1.39 -\n4.53), >1 positive \nSLN (OR: 1.77, 95% \nCI: 1.2 -2.62), Starz \n3 (old) (OR: 1.83, \n95% CI: 0.89 -3.76), \nangiolymphatic \ninvasion (OR: 2.46, \n95% CI:  \n1.34-4.54), \nextensive location \n(OR: 2.22, 95% CI: \n1.74-2.81), \nmacrometastases \n>2 mm (OR: 1.95, differences in \nsample size, \npopulations \nstudied, protocols \nfor pathologic \nprocessing and \nexamination of  \nprimary tumors \nand SNs, and \nmethods of data \nanalysis, as well as \nthe effects of \ninterobserver \nvariation in \npathologic \ninterpretation. \n \nRetrospect ive \nstudies included  2a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 253 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n95% CI: 1.61 -2.35), \nextranodal \nextension  \n(OR: 3.38, 95% CI: \n1.79-6.40) and \ncapsular  \ninvolvement (OR: \n3.16, 95% CI: 1.37 -\n7.27).  \n \nCharacteristics \nassociated with \nlow risk of NSN \nmetastases:  \nsubcapsular \nlocation (OR: 0.51, \n95% CI: 0.38 -0.67), \nRotterdam  \nCriteria <0.1 mm \n(OR: 0.29, 95% CI: \n0.17-0.50) and  \nStarz I (new) (OR: \n0.44, 95% CI: 0.22 -\n0.91).  \nEgger et al. 2014  \n to determine  \nthe classification \nscheme that best \npredicts \nnonsentinel node \n(NSN) metastasis, Retrospective \nstudy  157 patients with \nmelanoma >=1.0 \nmm Breslow  \nthickness who \nunderwent SLN \nbiopsy  N-SN metastases \nafter CLND  \n \nOverall survival \n \nDisease free independent \npredictors of a \npositive NSN: \nmaximum \ndiameter, \nmaximum area, This study \nreviewed \npathologic slides \nof tumorpositive  \nSLNs from the \nSunbelt Melanoma 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 254 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ndisease -free \nsurvival (DFS), and \noverall survival \n(OS). survival  nonsubcapsular \nlocation according \nto Dewar\u2019s, and \nthe SIII class \naccording  \nto Starz \n(significant for cut -\noff of 1mm)  \n \nmultivariate \nanalysis: maximum \ndiameter (cut -off \nof 3 mm) was the \nonly classification \nsystem that was an \nindependent risk \nfactor predicting \nDFS (hazard ratio \n2.31, p = 0.0181) \nand OS (hazard \nratio 3.53, p = \n0.0005).  Trial and  \nthe University of \nLouisville \nMelanoma \nDatabase  \nSatzger et al. 2014  \n to determine  \nthe therapeutic \nimpact of CLND  Retrospective \nstudy  305 SLN -positive \npatien ts \n \nMatched -pair \nanalysis  between \ngroups :  \n- 58/305 did not \nundergo CLND   \n \n \n \nRecurrence -free \nsurviva l \n \nOverall survival Matched -pair-\nanalysis: \nCLND vs. non -\nCLND:  \n \nRecurrence -free \nsurvival (P= 0.765)  \n Small patients \nnumber  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 255 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n- 58/305 \nunderwent CLND  \n \nSubgroup analysis \nin patients with \nSLN \nmicrometastases < \n0,1mm  : \n- 72/106 patients \nunderwent CLND  \n- 34/106 did not \nundergo CLND  \n  \n \nRecurrence rates  Overall survival (P \n= 0.844)  \n \nRecurrence rates  \n17/58 (29%) \nvs.15/58 (26%)  \n(P=1.000).  \n \nSubgroup analysis:  \nCLND vs. non -\nCLND:  \n \nOverall survival \nP=0.610  \n \nRecurrence -free-\nsurvival: P=0.346  \n \nRecurrence rates:  \n5/72 (7%) vs. 4/34 \n(9%)  \n \nMultivariate \nanalysis: \nindependent \nprognostic factors:  \n- ulceration of the \nprimary melanoma \n(absent  \nversus present)  \n- the largest  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 256 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ndimension of \ntumor cell deposit  \n(</=0.1 versus \n>0.1 mm)  \n- age of patients  \n(</=60 versus >60 \nyears),  \nVan der Ploeg et \nal. 2012  \n to evaluate the \nimpact of  \nimmediate CLND \non the outcome of \npatients with SN -\npositive melanoma  Retrospective \nstudy  \n \n 1174 Patients wi th \nSLN metastases, \n1113 underwent \nCLND, 61 did not  \n Disease -free-\nsurvival  Matched pair \nanalysis:  \nCLND did not \nsignificantly \ninfluence disease -\nspecific survival \n(HR 0 \u00b786, 0 \u00b746 to \n1\u00b761; P = 0 \u00b7640).  \n \nMultivariate \nanalysis: DSS:  \n \n- SN tumour \nburden \ncharacteri stic was \nsignificant  \nprognostic factor,  \n- CLND had no \nsignificant \ninfluence on \nprognosis  \n \n3- and 5 -year DSS Selection bias: \npatients who did \nnot undergo CLND \nhad more \nfavourable \nprognostic factors  \n \nSmall number of \npatients without \nCLND  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 257 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nrates:  \nNon-CLND: 74% \nand 66%  \nCLND: 76,9% and \n66,9%  \n(HR 0.89, 0.58-  \n1.37; P=0.600)  \nMatched -pair-\nanalyses  \nCLND: 79% and \n69% (HR 0.86, \n0.46-1.61; P \n=0\u30fb640) \nVan der Ploeg et \nal. 2014  \n To evaluate indices \nof SN tumour \nburden (intranodal \nlocation, \ntumour penetrative \ndepth (TP D) and \nmaximum size of \nSN tumour \ndeposits)  Retrospective \nstudy  \n \n 11 melanoma \ncenters  : 1539 \npatients with \npositive SLN, CLND \nin 1381 patients  Disease -free \nsurvival  \n \nMelanoma -specific \nsurvival  \n \nN-SLN metastases -\nrate Breslow thickness, \nulceration, Clark \nlevel of invasion, \nnumber of SNs \nremoved and all \nmicromorphometri\nc \nparameters were \nsignificant \npredictors of  \nNSN status (p < \n0.05)  \n \nAs continuous \nvariables \nmeasured in \nmillimetres,  Heterogeneity in \nSN biopsy \nprotocols and \nclinicopathologic \nfeatures of the \npatient cohorts  \n \nNot all patients \nwith \nmicrometastases \n<0,1mm in  the SLN \nunderwent CLND  \n \n \n11 melanoma \ncenters used \nvarious 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 258 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmaximum SN \nmetastasis size \n(odds ratio (OR) = \n1.11,  \n95% confidence \ninterval (C I): 1.07 \u2013\n1.15, p < 0.001) \nand \ntumour penetrative \ndepth (OR = 1.26, \n95% CI: 1.15 \u2013 \n1.38, p < 0.001) \nwere significant \npredictors of NSN \nstatus  \nin the overall \ncohort \n \nPatients with \nsubcapsular \nmicrometastases \n<0.1 mm in \nmaximum \ndimension had the \nlowest frequen cy \nof NSN metastasis \n(5.5%).  \n \n \nSignificant \nprognostic factors classification \nsystems  \n\uf0e8 Variation in \nthe \nprediction of \nN-SLN-\npositivity  \n\uf0e8 4 differents  \nmultivariate \nregression \nmodels for \nMSS \n \nFurther details: see \nfull-text   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 259 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nfor poorer MSS in \nthe \nmultivariate \nmodels included \nthe presence of \nnonsubcapsular  \nmetastases, TPD > \n1 mm and \nmaximum  \nSN tumour size > 1 \nmm \n \nA maximum  \nSN tumour size > 1 \nmm  \nwas the most \nconsiste nt \nindependent \npredictor of NSN -\npositivity and \npoorer  \nDFS and MSS in \nindividual centres, \nand in the \ncombined  \ncohort.  \nBamboat et al. \n2014  \n to \n- determine the \npattern  \nof initial Retrospective \nstudy  495 patients with \npositive SLN  \n \n167 patients (34%) Recurrence rates  \n \nsurvival  Recurrences in  81 \npatients (49 %), no -\nCLND, with a  \nmedian time to Patient selection \nbias (e.g. patients \nin the no -CLND \ngroup were 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 260 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nrecurrence \nbetween the no -\nCLND and CLND  \ngroups \n- determine \nmelanoma -specific \nsurvival of both  \npatient groups  \n \n underwent nodal \nobservation  \n \n328 (66%) \nunderwent C LND \n  \n recurrence of 9 \nmonths, and in \n179 patients (55 \n%), CLND,  with a \nmedian  \ntime of 12 months \n(p = 0.46)  \n \nregional \nrecurrence rates: \n16 %, no CLND, vs. \n18 %, CLND; p = \n0.58 \n \n- nodal only:  \n(15 %, no \nCLND, vs. \n6 %, CLND; \np = 0.002)  \n- systemic \nonly (8 %, \nno CLND, \nvs. 27 %, \nCLND; \np<0.001)  \n \nmedian recurrence -\nfree survival: 34.5 \n, CLND, vs. 20.9 \nmonths, no CLND; \np = 0.02  \n \nmelanoma -specific significantly older \nthan those \nundergoing CLND \n(66 vs. 56 years; \np<0.001)  \n \npatient, tumor and \nSLN characteristics \nsee tables/full text  \n \nbig differences in \nmedian follow -up \ntime between \ngroups: 23 and 80 \nmonths for the no - \nCLND and CLND \ngroups, \nrespectively   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 261 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsurvival: not \nreached, no CLN D \nvs. 110 months, \nCLND; p = 0.09.  \n \n \nFeldmann et al. \n2013  \n To validate the \naccuracy of N -\nSNORE in \nmelanoma patients \nwith positive  \nSLN Retrospective \nstudy  106 melanoma \npatients with \npositive SLN, who \nhad undergone \ncomplete lymph \nnode dissection \n(CLND) \nsubsequently,  \n Non-sentinel -\nlymph -node -\npositivity rate  13 patients: score \n0 \n63 patients: score \n1-3 \n19 patients: score \n4-5 \n6 patients: score 6 -\n7 \n5 patients: score \n>8.  \n \n NSLN positivity \nrates f or these 5 \nrisk groups were: \n7.7%, 18.2%,  \n21.1%, 33.3%, and \n80%, respectively.  \n \ncontingency \ncoefficient: 0.322; \np-value:  0.025  Small patient \ncohort \n \n 2b- \nKibrit\u00e9 et al. 2015  to evaluate  \nthe significant Retrospective \nstudy  957 patients who \nunderwent SLNB  Factors for \npredicting SLN multivariate \nanalysis: 3 factors Bias: not all \npatients with 2b- \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 262 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nfactors associated \nwith positive \nsentinel  \nand subs equent \nlymph nodes \nstatus.   \nSubsequent \nlymphadenectomy \nin 171 patients  \n \n  \n positivity  demonstrate a \nsignificant effect  \n(P <0.05) for \npredictin g SLN \npositivity : Breslow \nthickness,  \nLVI, tumor \nlocation.  \n \nBreslow thickness \n>/= 2 mm or SLN \nwith macroscopic \nburden >/=2mm  \nare the only \nstatistically \nsignificant \nvariables \npredicting the \ncompletion \nlymphadenectomy \nlymph nodes \nstatus (multivariate \nanaly sis):  \n \nSubsequent \npositive lymph \nnodes in  \n- 9/100 (9%) \npatients with \ntumor load \n<2mm  \n- 24/71 (33,8%) positive SN \nunderwent \nlymphadenectomy    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 263 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npatients with \ntumor load >/= \n2mm  \n \nKim et al. 2015  \n To  examine the \nprognostic rol e of \ntumor burden in \nSLN on overall \nsurvival (OS) and \ndiseasefree \nsurvival (DFS) in \npatients with \ncutaneous \nmelanoma using \ndifferent \nmicroscopic \nclassifications and \nto assess clinical \nand histological \npredictors of \nadditional NSLN \nmetastases.  retrospective  study  138 patients with \npositive SLN status  \n111 patients \nunderwent CLND  Overall survival  \n \ndisease -free \nsurvival  Most significant \ncut-off point for \nboth OS \n(p<0.0001) and \nDFS (p=0.0064): \n1mm  \n \nEstimated  5-year-\nOS: 75.6% in \npatients with SLN \ntumor burden \n\u22641mm vs. 34.6% in \npatients with SLN \ntumor burden \n>1mm.  \n \nonly statistically \nsignificant \npredictor of \nmetastatic disease \nin NSLNs (by \nmultivariate \nanalysis):  the \nnumber of  \npositive SLN \n(OR=4.27; 95% Different \npathological \nprotocols used to \nexamine SLN  \n \nSmall patient \ncohort 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 264 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nCI=1.1 5-15.82; \np=0.03)  \n \nWevers et al. 2013  \n To identify factors \npredicting NSN \npositivity and to \nassess the validity \nof the N -SNORE in \nan independent \npatient cohort.  Retrospective \nstudy  130 patients who \nunderwent CLND \nafter a positive \nSNLB   Presence of \nregression was \nassociated with a \npositive NSN in \nmultivariable  \nlogistic regression \n(OR 6.3; 95%CI \n1.1-36.1;  \np = 0.04).  \n \nThe N- SLN \npositivity rates for \nthe N -SNORE rsik \ngroups were 5.9 %, \n19.8%, 24.5%, and \n47.6%, respectively \n( p= 0.04) (after \nadjustment \nbecause of missing \ndata on perinodal \nlymphatic invasion:  \np = 0.003)  \n \n missing data were \nimputed to enable \nmultivariate \nanalysis  \n\uf0e8 Risk of \nbias 2b- \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 265 von 817 \n3.2.4.  Literatur  \nBaehner FL, Li R, Jenkins T, et al. The Impact of Primary Melanoma Thickness and Microscopic Tumor Burden in Sentinel Lymph Nodes on Melanoma Patient Survival. Ann Surg Oncol \n2011 \nBalch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classificat ion. J Clin Oncol 2009;27:6199- 6206  \nBalch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases  versus \nmacrometastases. J Clin Oncol 2010;28:2452- 2459 \nBamboat ZM, Konstantinidis IT, Kuk D, Ariyan CE, Brady MS, Coit DG. Observation after a positive sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol. \n2014;21(9):3117- 3123.  \nBogenrieder T, van Dijk MR, Blokx WA, et al. No non -sentinel no de involvement in melanoma patients with limited Breslow thickness and low sentinel node tumour load. Histopathology \n2011;59:318- 326 \nDebarbieux S, Duru G, Dalle S, et al. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognos is and completion lymph node dissection. Br J Dermatol \n2007;157:58- 67 \nDewar DJ, Newell B, Green MA, et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol \n2004;22:3345- 3349  \nEgger ME, Bower MR, Czyszczon IA, et al. Comparison of sentinel lymph node micrometastatic tumor burden measurements in melanoma. J Am Coll Surg. 2014;218(4):519 -528. \nElsaesser O, Leiter U, Buettner PG, et al. Prognosis of Sentinel Node Staged Patients wi th Primary Cutaneous Melanoma. PLoS One 2012;7:e29791 \nFeldmann R, Fink AM, Jurecka W, Rappersberger K, Steiner A. Accuracy of the non -sentinel node risk score (N -SNORE) in patients with cutaneous melanoma and positive sentinel lymph \nnodes: a retrospective study. Eur J Surg Oncol. 2014;40(1):73- 76. \nFink AM, Weihsengruber F, Duschek N, et al. Value of micromorphometric criteria of sentinel lymph node metastases in predicting further nonsentinel lymph node metastases  in \npatients with melanoma. Melanoma Res 201 1;21:139- 143 \nFrankel TL, Griffith KA, Lowe L, et al. Do micromorphometric features of metastatic deposits within sentinel nodes predict no nsentinel lymph node involvement in melanoma? Ann Surg \nOncol 2008;15:2403- 2411  \nKibrite A, Milot H, Douville P, et al. Predictive factors for sentinel lymph nodes and non- sentinel lymph nodes metastatic involvement: a database study of 1,041 melanoma patients. Am \nJ Surg. 2015.  \nKim C, Economou S, Amatruda TT, Martin JC, Dudek AZ. Prognostic significance of microscopic tumor burden in sentinel lymph node in patients with cutaneous melanoma. Anticancer \nRes. 2015;35(1):301- 309. \nMeier A, Satzger I, Volker B, et al. Comparison of classification systems in melanoma sentinel lymph nodes --an analysis of 697 patients from a single ce nter. Cancer 2010;116:3178-\n3188 \nMocellin S, Hoon DS, Pilati P, et al. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta -analysis of prognosis. J Clin Oncol \n2007;25:1588- 1595  \nMorton DL, Thompson JF, Cochran A J, et al. Final trial report of sentinel -node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599- 609. \nMurali R, Desilva C, Thompson JF, et al. Factors predicting recurrence and survival in sentinel lymph node -positive melanoma patie nts. Ann Surg 2011;253:1155- 1164  \nMurali R, Desilva C, Thompson JF, et al. Non -Sentinel Node Risk Score (N -SNORE): a scoring system for accurately stratifying risk of non -sentinel node positivity in patients with \ncutaneous melanoma with positive sentinel ly mph nodes. J Clin Oncol 2010;28:4441- 4449   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 266 von 817 \nNagaraja V, Eslick GD. Is complete lymph node dissection after a positive sentinel lymph node biopsy for cutaneous melanoma a lways necessary? A meta -analysis. Eur J Surg Oncol. \n2013;39(7):669- 680. \nNamikawa K, Yamaz aki N, Nakai Y, et al. Prediction of additional lymph node positivity and clinical outcome of micrometastases in sentinel lymph nodes in cutaneous m elanoma: A \nmulti -institutional study of 450 patients in Japan. J Dermatol 2012;39:130- 137 \nQuaglino P, Ribero  S, Osella -Abate S, et al. Clinico -pathologic features of primary melanoma and sentinel lymph node predictive for non- sentinel lymph node involvement and overall \nsurvival in melanoma patients: A single centre observational cohort study. Surg Oncol 2011;20: 259-264 \nRiber -Hansen R, Nyengaard JR, Hamilton -Dutoit SJ, et al. Metastatic melanoma volume in sentinel nodes: objective stereology -based measurement predicts disease recurrence and \nsurvival. Histopathology 2009;54:796- 803 \nSatzger I, Meier A, Zapf A, Niebu hr M, Kapp A, Gutzmer R. Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor  burden in the sentinel \nnode? Melanoma Res. 2014;24(5):454- 461. \nSatzger I, Volker B, Al Ghazal M, et al. Prognostic significance of  histopathological parameters in sentinel nodes of melanoma patients. Histopathology 2007;50:764 -772 \nSatzger I, Volker B, Meier A, et al. Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes. Ann Surg Oncol 2008;15:1723- 1732  \nShivers S, Jakub J, Pendas S, et al. Molecular staging for patients with malignant melanoma. Expert Rev Anticancer Ther 2007;7:1665 -1674  \nStarz H, Balda BR, Kramer KU, et al. A micromorphometry -based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with \nmelanoma. Cancer 2001;91:2110- 2121 \nStarz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s -classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol \n2004;11:162S -8S \nvan Akkooi AC, de Wilt JH, Verhoef C, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol \n2006;17:1578- 1585  \nvan Akkooi A C, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melano ma patients: a \nmulticenter study in 388 patients with positive sentinel nodes. Ann Surg 2008;248:949- 955 \nvan der Ploeg AP, van Akkooi AC, Haydu LE, et al. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 \nsentinel node- positive melanoma patients. Eur J Cancer. 2014;50(1):111 -120. \nvan der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in Patients With Sentinel Node -Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and \nDewar Topography Criteria. J Clin Oncol 2011  \nvan der Ploeg AP, van Akkooi AC, Rutk owski P, et al. Prognosis in patients with sentinel node -positive melanoma without immediate completion lymph node dissection. Br J Surg. \n2012;99(10):1396 -1405.  \nvan der Ploeg IM, Kroon BB, Antonini N, et al. Is completion lymph node dissection needed in ca se of minimal melanoma metastasis in the sentinel node? Ann Surg 2009;249:1003 -1007 \nWevers KP, Murali R, Bastiaannet E, et al. Assessment of a new scoring system for predicting non -sentinel node positivity in sentinel node -positive melanoma patients. Eur J  Surg Oncol. \n2013;39(2):179- 184. \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 267 von 817 \n4. AG Chirurgische Therapie  \n4.1. Frage III.1. Sicherheitsabst\u00e4nde bei Prim\u00e4rexzision  \u2013 De-novo -Recherche  \nFrage III.1 . Welche Sicherheitsabst\u00e4nde sollen bei radikaler Exzision des Prim\u00e4rtumors eingehalten werden? \n4.1.1.  PICO, Suchw\u00f6rter  \nSuchw\u00f6rter  \nStichwort  melanoma  therapy, treatment, management, surgery, surgical procedures, excision  \nSynonyme  melanoma  safety margin, excision margin, surgical ma rgin, narrow, wide  \nOber -/Unterbegriffe, Mesh Term  s. Such sstrategie  \n \n4.1.2.  Datenbanken, Suchstra tegien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline \"melanoma\"[tiab] AND (\u201ctherapy\u201d[all fields] OR \u201ctreatment\u201d[all fields] OR \n\u201cmanag ement\u201d[all fields] OR \" surgery \"[all fields] OR \u201csurgical\u201d[all fields] OR \u201csurgical \nprocedures,  operative\u201d[mesh] OR \"excision\"[all fields]) AND (\u201csafety margin\u201d[all fields] \nOR \u201cexcision margin\u201d[all fields] OR \u201csu rgical margin\u201d[all fields] OR \u201cnarrow\u201d[all fields] \nOR \u201cwide\u201d[all fields])  26.01.2012 1235  \nCochrane Library  (melanoma and (therapy or treat ment or management or surgery or surgical or \nexcision) and (\"safety margin\" or \"excision margin\" or \"surgical margin\" or narrow or 19.01.2012  51  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 268 von 817 \nDatenbank  Suchstrategie  Datum  Treffer \nwide)).ti,ab.  \nEmbase  (melanoma and (therapy or treatment or management or surgery or surgical or \nexcision) and  (\"safety margin\" or \"excision margin\" or \"surgical margin\" or narrow or \nwide)).ti,ab.  23.01.2012 1642  \nBemerkungen:  \nEine erste Literaturrecherche in Medline und und Cochrane erfolgte am 06.09.2010 bzw. f\u00fcr Embase am 11.05.2011. Die Update -Recherche wurde  am \n23.01.2012 (Embase) bzw. am 26.01.2012 f\u00fcr Medline und am 19.01.2012 f\u00fcr Cochrane durchgef\u00fchrt. In der Tabelle angegeben sind  die Treffe rzahlen der \nletzten Recherche.  \n \n4.1.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  2928  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nVer\u00f6ffentlichung ab 1970  \nAusschlusskriterien  Case Reports (Case series included) , narrative Reviews  \nAnzahl nach Abstractscreening  61 \nAnzahl ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewertung  12 \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 269 von 817 \n \n4.1.4.  Evidenztabelle  \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \nMocellin et al.  \n(2011 ) To quantify the \nimpact of excision \nmargins on \ndisease -specific \nsurvival of patients \nwith primary \ncutaneous \nmelanoma  systematic review \nof RCT with Meta -\nanalysis  5 eligible RCT  \n \nA total of 3295 \npatients enrolled  \n(1633 (49.5%) were \nallocated to narrow \nexcision and 1662  \n(50.5%) to wide \nexcision)  locoregional \ndisease -free (LDFS)  \n \ndisease -free (DFS)  \n \ndisease -specific \n(DSS)  \n \noverall survival  \n \n. Narrow margins: \nrisk of both \nlocoregi onal \ndisease recurrence \n(HR: 1.30, CI: \n1.07\u20141.57; P = \n0.01) and death by \ndisease (HR: 1.28, \nCI: 1.07 \u20141.53, P = \n0.01). As regards \nDFS, the borderline \ndisadvantage (HR: \n1.13, CI: 0.995 \u2014\n1.28; P = 0.06) \nbecomes \nsignificant when \nconsidering RCT \nthat enrolled \npatients with \nthicker melanoma \n(HR: 1.19, CI: \n1.02\u20141.39, P = \n0.03). When death \nby any cause (OS) \nwas analyzed: \nnarrow vs. wide \nexcision margins The lack of DSS \ndata from all the \navailable RCT  \n \n \n4 of the 5 RCT \nincluded in \nsystematic review \nof Sladden et al. \n2010 (Cohn -\nCedermark et al \n(2000), Balch et al \n(2001), Khayat et \nal (2003), Thomas \net al (2004)  1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 270 von 817 \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \n(HR: 1.05, 95%CI: \n0.95\u2013 \n1.16, P = 0.32  \nSladden et al. \n(2010)  To assess the \neffects of different \nexcision margins \nfor primary \ncutaneous \nmelanoma.  \n Systematic  review \nof 5 randomised \ncontrolled trials \n(RCTs) of surgical \nexcision of \nmelanoma \ncomparing \ndifferent width \nexcision margins  \n 1633 participants \nin the narrow \nexcision margin \ngroup and 1664 in \nthe wide excision \nmargin group  Primary outcomes:  \n1. Time to deat h \n(any cause)  \n2. Time to \ncombined endpoint \nof death (any \ncause) or \nrecurrence  \n(local, in transit, \nregional, distant)  \n \nSecondary \noutcomes:  \n1. Quality of Life  \n2. Adverse \nevents/outcomes  No significant \ndifference in \noverall survival \nwhen comparing \nnarrow with  wide \nexcision  \n \nOverall survival \nwide excision: \nHazard Ratio 1.04 \ncompared with \nnarrow excision; \nnot significant  \n \nRecurrence -free \nsurvival wide \nexcision: Hazard \nRatio 1.13 \ncompared with \nnarrow excision; \nnot significant  Limited RCT data \nassessing \ntreatment  of thin \nmelanomas < 1 \nmm and thick \nmelanomas \u2265 4 \nmm. \n \n \nMelanomas in \nspecific body sites \nnot sufficiently \ninvestigated  \n \n 1a \n \nGillgren et al. \n(2011 )  to test whether \nsurvival was diff \nerent for a wide \nlocal excision  \nmargin of 2 cm randomised,  \nmulticentre trial 936 patients with \ncutaneous \nmelanoma thicker \nthan 2 mm, at \nclinical stage IIA \u2013C Overal l survival  5-year overall  \nsurvival was 65% \n(95% CI 60 \u201369) in \nthe 2 -cm group \nand 65% (60 \u201370) in  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 271 von 817 \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \ncompared with a 4 -\ncm exci sion \nmargin   \n(465 were \nrandomly allocated \nto treatment with a \n2-cm resection \nmargin, 471 to \nreceive treatment \nwith a 4 -cm \nresection margin)  the 4 -cm group \n(p=0 \u00b769) \n \nSubtopic: Margins \nin special \nlocalizations         \nJahn et al. (2006)  To define \nprognostic factors \nfor melanoma of \nthe ear and to \nevaluate surgical \nstrategies for \nexcision margins, \nhistological \nevaluation and \nsentinel lymph \nnode biopsy (SLNB) \nin order to achieve \nbetter cosmetic \nand functional \nresults. Prognostic study  \n \n 161 patients with \nstage I and II \nmelanoma of the \nexternal ear.  \n Recurrence -free \nand disease -\nspecific survival Recurrence -free \nsurvival rate 83% \nover 3 years and \n79% over 5 years  \n \nTumour thickness \nand Clark invasion \nlevel were the only  \nsignificant risk \nfactors for disease -\nspecific survival in  \nKaplan \u2013Meier \nunivariate anal ysis. Prospective study \ndesign  \n \nPatients not \nrandomized \nbetween groups \nwith different \nexcision margins; \nrecommendations \nfor excision \nmargins were \nreduced during the \nobservation period \n(1976 \u2013 2004); \nconfounding by \nother historical \nfactors possible. 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 272 von 817 \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nFor de tails on \nrecurrence -free \nsurvival in relation \nto surgical margin, \nsee Fig. 2 in full-\ntext of the article. \nHazan et al. (2008)  To review clinical \nand histologic \nfeatures of lentigo \nmaligna (LM) and \nlentigo maligna \nmelanoma (LMM) \nand determine \nsurgical margin \nnecessary for \ncomplete excision. Cross -sectional \nstudy  \n \n 117 patients  Required surgical \nmargin and \nnumber of stages \nfor complete \nexcision of LM and \nLMM Mean total surgical \nmargin required \nfor excision of LM: \n7.1 mm and 10.3 \nmm for LMM  \n \nMean numbe r of \nstages required to \ncompletely excise \na lesion: 1.67  Small number of \ninvasive melanoma  \n \nNo data about \nrecurrence rates  3b \nFurukawa et al. \n(2007)  To evaluate how \namputation level \nand cutaneous \nmargin affects \nprognosis and \nreconstructive \nchoice.  Progno stic study  \n \n 15 patients (6 \nmen, 9 women) \nwith melanoma of \nthe thumb between  Disease -free \nsurvival  \n \n Significant \nprognostic factors: \nstage and \nthickness  \n \nLevel of \namputation and \nexcision margin \nnot significant  Small patient \nsample  \n \n 3b \nMohrle et al. \n(2003) To evaluate clinical \nparameters and Prognostic study  \n 368 patients with \nfacial melanoma  Overall survival (5 \nyears)  Significant \npredictors for Patients not \nrandomized 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 273 von 817 \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \nsurgical strategies \ninfluencing the \nprognosis of \npatients with facial \nmelanoma.  Survival and \nhistory of 3960 \npatients in stages I \nand II were \nprospectively \nrecorded between \n1980 and 1999. Of \nthese, 368 \nmelanomas were \nlocalized in the \nface, 140 on the \ncapillitium and 76 \non the neck.  \n \nSurgical margins \nwere successively \nreduced during the \nobservation period, \nstarting from 5 cm \nin 1980.  \n \nFor functional and \naesthetic reasons, \nrecommendations \nfor surgical \nmargins could not \nalways be followed \nin the head and \nneck regions.  \nRecurrence -free \nsurvival (5 years)  survival: tumour \nthickness, Clark \nlevel and \nulceration, surgery \nwith 3D histology \nand histological \ntumour subtype  \n between groups \nwith different \nexcision margins; \nrecommendations \nfor excision \nmargins were \nreduced during the \nobservation period \n(1976 \u2013 2004); \nconfounding by \nother historical \nfactor s possible.  \nPockaj et al. (2003)  To evaluate the Prognostic study, 84 patients with Lymph node Local recurrence in Retrospective 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 274 von 817 \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \nprognostic \nvariables and \nclinical \nramifications of \nmelanoma of the \near. retrospective \ndesign  \n \n invasive melanoma \nof the external ear  \n involvement  \n \nLocal, reg ional and \nsystemic \nrecurrence  13% \n \nRecurrence of \nmelanoma in the \nlymph nodes in \n12% \n \nSystemic \nmetastases in 22%  \n \nType of resection \ndid not influence \nsystemic \nrecurrence \n(P=0.41) design  \n \nPatient numbers \nnot sufficient for \nan evaluation of \nthe influence of \ndifferent surgical \nprocedures on \nrecurrences  \nTseng et al. (1997)  The purpose of the \nstudy was to \ninvestigate the \nsurgical \nmanagement of \ncutaneous \nmelanomas of the \nhands and feet.  Prognostic study  \n \n 116 patients with \nmelanomas of the \nhands (n = 26) and \nfeet (n = 90)  Recurrence rate  In melanomas <1.5 \nmm thickness, no \nlocal recurrences  \n \nMetastases \ndeveloped in 5%  \n \nNo local recurrence \nor metastasis in \npatients with < 1.5 \nmm acral -\nlentiginous \nmelanoma  \n \nOf 79 patients with No control groups  \n \nData on elective \nlymph node \ndissection biased \n(decision about \nELND was left to \nthe surgeon) and \nnot sufficient \n(small numbers of \npatients)  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 275 von 817 \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma \u2265 1.5 \nmm, 15 (19%) \npresented with \nregional node \ndisease  \n \nAll 13 patients with \nsubungual \nmelanomas had \nlesions \u22651.5 mm in \nthickness; 6 (46%) \nof 13 had evidence \nof nodal disease at \nthe time of \npresentation or at \nELND or had \nregional node \nmetastases \ndevelop within 1 \nyear of initial \ndiagnosis  \n \nIn patients with \nALM, 71% \npresented with \nlesions \u22651.5 -mm \nthick and were \ntreated with wide \nexcision or \namputation; local \nrecurrence in two  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 276 von 817 \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \n(6%) of these \npatients, but nodal \nmetastases or \nsystemic disease or \nboth in 19 (56%) of \n34 patients  \nHudson et Krige \n(1995)  To analyse the \noutcome of local \ntreatment and \npatient survival \nusing a 3 cm local \nexcision margin \nand split skin \ngrafting  Prognostic study  \n \n 16 men and 3 \nwomen  Overall survival  \n \nTime to \nprogression  12 patients with \nstage I disease: \nmean Breslow \ndepth 2.7 mm  \n \nAll 12 had local \nexcision of the \nprimary lesion with \n3 cm margins and \nskin grafts applied \nto the galea; 6 \ndeveloped regional \nlymph node \nmetastases, 3 \ndeveloped \nsystemic \nmetastases (all of \nwhom died)  \n \nOne patient \npresented with \nstage II disease \nand developed \nlocal recurrence  Very small patient \nnumbers  \n \nNo control group  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 277 von 817 \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n5 patients in stage \nIII disease were \ntreated by wide \nlocal excision and \ntherapeutic lymph \nnode dissection; all \ndied after a mean \nof 9.6 months \n(range 3 \u2013  22 \nmonths)  \nThen et al. (2009)  To report early \ncure rates for \nperiocular \nmelanoma using \nSlow-Mohs surgery \nwith en -face \nmargin sectioning. Retrospective, \nmulticenter, \nnoncomparative \ncase series \n \n. 14 patients with \nperiocular MM  Number of stages \nneeded for \ncomplete excision  \n \nRecurrence rate  most common site : \nlower eyelid (8/14, \n57.1%). Breslow \nthickness ranged \nfrom 0.27 to 1.70 \nmm, with four \ncases less than \n0.76mm and one \ncase greater than \n1.5mm. Five cases \nwere a Clark level II \nor greater. \nComplete excision \nwas achieved with \none level (6 cases) \nor two or three \nlevels (8 cases), \nwith 2- to 3-mm \nmargins at each Very low LoE (case \nseries, \nretrospective \ndesign)  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 278 von 817 \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \nlevel in all but one \ncase. With median \nfollow -up of 36 \nmonths, there were \ntwo local \nrecurrences (2/14, \n14.3%).  \nSubtopic: Vertical \nmargins         \nKenady et al. \n(1982 ) To dete rmine \nwhether the \npresence oor \nabsence of muscle \nfasciae in patients \nwith stages 0 and I \nmalignant \nmelanoma \ncorrelates with \nprognosis.  Retrospective \nprognostic study  \n \n 202 patients with \nprimary melanoma \nof the trunk and \nproximal limbs  Recurrence rate  \n \nSurvival rate  Sites of first \nrecurrence or \nsurvival not \nsignificantly \naffected by the \nexcision of fasciae  AJCC 1978 staging \nsystem used \nretrospectively  \n \nPossible \nconfounding by the \nfact that the \ncontrol group is \nhistorical (other \npotential changes \nin melanom a \nmanagement in the \nmeantime)  2b \n \n4.1.5.  Literatur  \nFurukawa H, Tsutsumida A, Yamamoto Y, et al. Melanoma of thumb: retrospective study for amputation levels, surgical margin and reconstruction. J Plast Reconstr Aesthet Surg \n2007;60:24- 31 \nGillgren P, Drzewiecki K T, Niin M, et al. 2 -Cm Versus 4 -Cm Surgical Excision Margins for Primary Cutaneous Melanoma Thicker than 2 Mm: a Randomised, Multicentre Trial. Lancet \n2011;378:1635- 1642  \nHazan C, Dusza SW, Delgado R, et al. Staged excision for lentigo maligna and lentigo m aligna melanoma: A retrospective analysis of 117 cases. J Am Acad Dermatol 2008;58:142 -148  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 279 von 817 \nHudson DA, Krige JE. Results of 3 cm excision margin for melanoma of the scalp. J R Coll Surg Edinb 1995;40:93- 96 \nJahn V, Breuninger H, Garbe C, et al. Melanoma of t he ear: prognostic factors and surgical strategies. Br J Dermatol 2006;154:310 -318 \nKenady DE, Brown BW, McBride CM. Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and su rvival rates. Surgery 1982;92:615- 618 \nMocellin S , Pasquali S, Nitti D. The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins. Ann Surg 2011;253:238-\n243 \nMohrle M, Schippert W, Garbe C, et al. Prognostic parameters and surgical strateg ies for facial melanomas. J Dtsch Dermatol Ges 2003;1:457- 463 \nPockaj BA, Jaroszewski DE, DiCaudo DJ, et al. Changing surgical therapy for melanoma of the external ear. Ann Surg Oncol 2003;10:689- 696 \nSladden MJ, Balch C, Barzilai DA, et al. Surgical excisio n margins for primary cutaneous melanoma. Cochrane Database Syst Rev 2009;(4):CD004835  \nThen SY, Malhotra R, Barlow R, et al. Early cure rates with narrow -margin slow -Mohs surgery for periocular malignant melanoma. Dermatol Surg 2009;35:17- 23 \nTseng JF, Tana be KK, Gadd MA, et al. Surgical management of primary cutaneous melanomas of the hands and feet. Ann Surg 1997;225:544- 50; discussion 550- 3 \n \n4.2. Frage III. 2. Prophylaktische Lymphadenektomie  - Adaptation  \nFrage III.2.  In welchen F\u00e4llen ist eine elektive (prophy laktische) LAD indiziert?  \n4.2.1.  Synopse Quellleitlinien  (kurz)  \nThema/Fragestellung  LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care O ntario 2007  \nIn welchen F\u00e4llen is t die \nadjuvante (prophylaktische) \nLAD ind iziert?  Nicht empfohlen (I)  Keine Angaben  Prophylaktische LAD bringt \nkeinen Vorteil (A)  (nur relevant f\u00fcr \nmedikament\u00f6se Therapien ) \n \n4.2.2.  Empfehlung,  Hintergrundstext und Literatur Australische  Quell Leitlinie  \n(mit Seit enangaben der Quellleitlinie)  \n LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  \nSchl\u00fcsselempfe hlungen  keine  \n keine  \n S. 42  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 280 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  \n Standard  \nLe curage prophylactique \nsyst\u00e9matique est contre -\nindiqu\u00e9. \n \nStandard  \nDie prophylaktische LAD ist \nkontr aindiziert. \nHintergrundtexte  S. 83  \n \nA systematic review of rando mised \ncontrolled trials comparing elective \nlymph node dissection with surgery \ndelayed until the time of clinical \nrecurrence showed no significant overall \nsurvival benefit for patients undergoing \nelective lymph node dissection. [12]  \nTherefore, except in rare circu mstances, \nelective lymph node disse ction is not \nrecommended for melanoma pat ients.  \n \nS. 84 \n \nEvidence summary  \nElective lymph node dissection is not \nrecommended, regardless of the \nBreslow thic kness of the primary \ntumour  S. 93  \n \nLymph node clearance  \nOne systematic review found no \nstatistically significant a dvantage in \nterms of overall mortality aris ing from \nelective lymph node dissection \ncompared to delayed lymph node \ndissection at the onset of clinical \nsymptoms.  \nOne RCT of elective versus delayed \nregional lymph node dissection in \npatients with melanoma found that the \nroutine use of immediate node \ndissection had n o signif icant impact on \nsurvival, while the status of regional \nnodes significantly pre dicted survival. \n \nS. 232 \u2013  234 (NICE Guideline Ev idence \nReview)  S. 30 \u2013 31 \n \nCurage ganglionnaire \nprophyla ctique syst\u00e9matique  \n \nDESCRIPTION DES \u00c9T UDES  \nLa m\u00e9ta -analyse de Lens et al. a \n\u00e9valu\u00e9 l\u2019impact sur la survie \nglobale du curage ganglionnaire \nprophyla ctique chez les \npatients porteurs d\u2019un \nm\u00e9lanome sans m\u00e9tastases \ngangl ionnaires cliniquement \nd\u00e9celables [84]. Quatre essais \nrandomis\u00e9s ont \u00e9t\u00e9 inclus , soit \nun total de 1 704 p atients [84 -\n89]. \nL\u2019un de ces essais n\u2019a pas pu \n\u00eatre utilis\u00e9 pour l\u2019analyse \nquantitative, car les donn\u00e9es  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 281 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  \nLoE: I  \nReferences: 7, 12   \nSummary of the supporting evidence for \nthe recomme ndations  \nObservational study evidence su ggests \nthat the  status of the regional node \nbasin is a strong pr edictor of survival, \nalong with primary t umour \ncharacteristics such as Breslow \nthickness and ulceration. Syst ematic \nreview and RCT evidence does not \ndemonstrate that elective lymph node \ndissection carries a survival benefit over \na policy of observing patients with \nprimary mel anoma after wide excision. \nHowever the syste matic review by Lens \net al. (2002a) suggests that some \npatients will benefit from elective lymph \nnode dissection.  \n \nEvidence based clinical guid elines from \nthe UK reco mmend that in  \npatients with melanoma, the pre sence \nof disease in one node indicates radical \nlymph node disse ction but that elective \nlymph node disse ction in the absence of \nlymph node disease should not be \nperformed.  \nObservational stu dy evidence su ggests \nthat the prevalence of lymphoedema disponibles dans la publication, \net apr\u00e8s v\u00e9rification aupr\u00e8s des \nauteurs, \u00e9taient i nsuffisantes \n[87]. \n \nSURVIE GLOBALE  \nAucun des quatre essais \nrandom is\u00e9es n\u2019a montr\u00e9 de \nb\u00e9n\u00e9fice  \nen faveur du curage [85 -89] \n(Tableau IX) . La m\u00e9ta -analyse \nn\u2019a retrouv\u00e9 aucune diff\u00e9rence \nde survie \u00e0 5 ans entre le \ncurage ganglionnaire et \nl\u2019absence de curage \ngangl ionnaire (odd ratio = 0,86 \n[IC95 : 0,6 8-1,09]) [84] (Tableau \nX). \n \nCOMPLICATIONS  \nAucune information concernant \nles complications n\u2019est \ndisponible dans la m\u00e9ta -\nanalyse.  \nCe type de curage a toujours \nune ce rtaine morbidit\u00e9, plus \nimportante pour le membre \ninf\u00e9rieur que pour le membre \nsup\u00e9rieur. La fr\u00e9quence des  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 282 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  \namongst p atients who have undergone \ncomplete level I -III \naxillary lymph node disse ction for \nmelanoma is 10%, and 53% after \nadditional axillary radiothe rapy. \n\u2022 The systematic review by Lens et al. \n(2002a), calculated a pooled odds  \nratio for overall mortality as 0.86 in  \nfavour of elective lymph node dissection \nover delayed lymph node dissection at \nthe onset of clinical symptoms (95% CI \n0.68-1.09). The au thors concluded that \nalthough the result was not s tatistically \nsignificant and although the pr imary \nstudies had flaws, the possibi lity exists \nthat some subgroups of patients with \nmelan oma will benefit from elective \nlymph node di ssection.  \n\u2022 The RCT by Cascinelli et al. (1998) \ncompared elective ver sus delay ed \nregional lymph node dissection in \npatients with melanoma and found  \nthat the routine use of immed iate node \ndissection had no impact on survival \n(hazard ratio 0.72, 95% CI 0.5 -1.02), \nwhilst the status of regio nal nodes \naffected survival significantly. The  \nauthors co ncluded  \nthat regional node dissection o ffers compl ications pr\u00e9coces est de \n10 \u00e0 \n15 % dans les meilleures s\u00e9ries \nlors de curages inguinaux [90, \n91]. Le taux de lymphoed\u00e8mes \ntardifs varie de 6 \u00e0 15 % au \nmembre inf\u00e9rieur, 6 % au \nmembre sup\u00e9rieur [90, 92].  \n \nCOMMENTAIRES \nM\u00c9THODOLOGIQUES ET \nCLINIQUES  \nLa validit\u00e9 clinique des essais \nrandomis\u00e9s inclus dans la m\u00e9ta -\nanalyse est critiquable, en \nraison de la r\u00e9ali sation du \ncurage ganglionnaire sur la \nseule base de l\u2019examen \nclinique. \nL\u2019int\u00e9r\u00eat du curage \nprophylactique reste \ncontrovers\u00e9 et le curage \nganglionnaire ne peut \ns\u2019envisager que dans les \nlocalis ations o\u00f9 il existe une \nvoie de drainage unique, soit \nessentiellement les l\u00e9sions des \nmembres.   \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 283 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  \nincreased survival in patients with node \nmetastases only.  \n\u2022 The retrospective, case series study \nby Kretschmer et al. (2005) found that \noverall survival at 5 years in patients \nwho underwent d elayed \nlymph node dissection following in itial \nwide excision of melanoma was  \n37.4%. Disease free survival in this \ngroup of patients was 11.6%.  \n\u2022 Evidence based guidelines pr oduced \nby Roberts et al. (2002) on behalf of the \nBritish Association of Dermatologists \nstate  that ele ctive lymph node \ndissection is not indica ted in patients \nwith melanoma and clinically negative \nlymph n odes. \n\u2022 Evidence based guidelines produced \nby the Scottish Intercoll egiate  \nGuidelines Network (2003) reco mmend \nthat in patients with melan oma, th e \npresence of disease in one node \nindicates radical lymph node dissection \nbut that elective lymph node dissection \nin the a bsence of lymph node disease \nshould not be performed.  CONCLUSION DE LA \nLITT\u00c9RATURE  \nAucun b\u00e9n\u00e9fice du curage \nganglio nnaire prophylactique \napr\u00e8s ex\u00e9r\u00e8se de m\u00e9lano me n\u2019a \n\u00e9t\u00e9 d \u00e9montr\u00e9. Le curage \nganglionnaire prophylactique \nsyst\u00e9matique n\u2019am\u00e9liore pas la \nsurvie globale par rapport au \ncurage ga nglionnaire retard\u00e9 ou \n\u00e0 l\u2019absence de curage \nganglionnaire chez les patients \natteints d\u2019un m\u00e9lanome cutan\u00e9 \ncliniquement NO (ni veau de \npreuve A).  \n \nS. 30 -  31 \nSystematische prophylaktische \nLymphadenektomie (LAD)  \n \nBESCHREIBUNG DER STUDIEN  \nDie Metaanalyse von Lens et al. \nhat den Einfluss der \nprophylaktischen LAD auf das \nGesamt\u00fcberleben bei P atienten \nmit Melanom ohne klinisch \nnachweis bare \nLymphknotenmet astasen \nausgewertet [84].  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 284 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  \nVier randomisierte Studien mit \neiner Gesamtzahl von 1 704 \nPatienten sind dabei \neingeschlossen worden [84 -89]. \nEine dieser Studien konnte nicht \nf\u00fcr die quantitative Analyse \nverwendet werden, da die Daten \nin der P ublikation auch nach \nVerifikation bei den Autoren \ninsuffizient waren [87]. \n \nGESAMT\u00dcBERLEBEN  \nKeine der vier randomisierten \nStudien konnte einen Vorteil der \nLAD zeigen [85 -89] (Tabelle IX) .  \nDie Metaanalyse ergab keinen \nUnterschied in der 5 -Jahres - \n\u00dcberl ebensrate zwischen \nDurchf\u00fchrung und Nicht -\nDurchf\u00fchrung der ele ktiven \nLAD (Odds -Ratio = 0,86 [IC95 : \n0,68-1,09]) [84] (Tabelle X) . \n \nKOMPLIKATIONEN  \nIn der Metaanalyse sind keine \nInformationen \u00fcber \nKomplikationen ve rf\u00fcgbar.  \nDiese Art der LAD geht immer \nmit einer  gewissen Morbidit\u00e4t  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 285 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  \neinher, an der unteren \nExtremit\u00e4t ausgepr\u00e4gter als an \nder oberen Extremit\u00e4t.  \nDie H\u00e4ufigkeit der \nFr\u00fchkomplikatio nen reicht von \n10 bis 15% in den besseren \nSerien der inguinalen \nLymphadenektomien [90, 91].  \nDie Rate der sp\u00e4ten \nLymph\u00f6deme  reicht von 6 bis \n15% an den unteren \nExtremit\u00e4ten und betr\u00e4gt ca. \n6% an den oberen Extremit\u00e4ten \n[90, 92].  \n \nMETHODOLOGISCHE UND \nKLINISCHE KOMMENTARE  \nDie klinische Validit\u00e4t der in die \nMeta-Analyse eingeschlossenen \nrandomisierten St udien ist \nfragw\u00fcrdig, da die \nDurchf\u00fchrung der LAD allein \nmit dem Ergebnis der klinischen \nUntersuchung begr\u00fcndet \nwurde.  \nDie Frage der prophylaktischen \nLAD bleibt kontrovers. Sie kann \nzudem nur bei \nTumorlokalisationen in B etracht  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 286 von 817 \n LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  \ngezogen werden, an denen nur \nein lymphatischer Abfluss weg \nexistiert, d.h. im Wesentlichen \nbei L\u00e4sionen an den \nExtremit\u00e4ten.   \n \nSCHLUSSFOLGERUNG AUS DER \nLITERATUR  \nEs konnte nach Exzision des \nMelanoms kein Vorteil der \nprophylaktischen LAD gezeigt \nwerden. Sie ver bessert im \nVergleich zur sp\u00e4ten LAD oder \nzum Verzi cht auf LAD nicht das \n\u00dcberleben bei Patienten mit \nmalig nem Melanom im \nklinischen Stadium N0 \n(Evidenzlevel A).  \nBemerkungen   Diese Leitlinie bezieht sich auf MM und \nauf NMSC.  \n \nReferenzen und ausf\u00fchrliche \nEvidenztabellen dieser Leitlinie werden \nwegen ihres Umfangs als separates \nDokument zur Ve rf\u00fcgung gestellt:  \nGB NICE Guideline Evidence R eview, S. \n232 bis 238.  Im Volltext der Leitlinie \ntabellarische Darstellung der \neinbezogenen St udien (S. 30).  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 287 von 817 \nLiteratur:  \nLL Austr alien New Zealand Guidelines Group 2008  \n7. National Comprehensive Cancer Network. Melanoma: Clinical Practice Guidelines in Oncology. version 2. 2007. National Comprehe nsive Cancer Network  \n12. Lens MB, Dawes M, Goodacre T, et al. Elective lymph node dissection in patients with melanoma: systematic review and meta -analysis of randomized controlled trials. Arch Surg \n2002;137:458- 461 \n \nLL GB NICE 2006  \nCascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial . WHO Melanoma Programme. \nLancet 1998;351:793- 796 \nLens MB, Dawes M, Goodacre T, et al. Elective lymph node dissection in patients with melanoma: systematic review and meta -analysis of randomized controlled trials. Arch Surg \n2002;137:458- 461  \nRoberts DL, An stey AV, Barlow RJ, et al. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 2002;146:7 -17 \nScottish Intercollegiate Guidelines Network. Cutaneous m elanoma. A national clinical guideline. 2003 http://www.sign.ac.uk/pdf/sign72.pdf  \nStarritt EC, Joseph D, McKinnon JG, et al. Lymphedema after complete axillary node dissection for melanoma: assessment using a new, objective definition. Ann Surg 2004;240:866- 874 \nWhite RR, Stanley WE, Johns on JL, et al. Long -term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg 2002;235:879- 887 \n \nLL Frankreich  French National Authority for Health 2005 ) \n90. Baas PC, Schraffordt Koops H, Hoekstra HJ, et al. Groin dissection  in the treatment of lower -extremity melanoma. Short -term and long -term morbidity. Arch Surg 1992;127:281 -286 \n86. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melan omas for patients 60 years of age and younger. Ann Surg \n1996;224:255- 63; discussion 263- 6 \n91. Beitsch P, Balch C. Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node di ssection. Am J Surg 1992;164:462- 5; discussion 465- 6 \n85. Casci nelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the t runk: a randomised trial. WHO Melanoma \nProgramme. Lancet 1998;351:793- 796 \n92. Karakousis CP, Heiser MA, Moore RH. Lymphedema after groin dissection. Am J Surg 1983;145:205- 208 \n84. Lens MB, Dawes M, Goodacre T, et al. Elective lymph node dissection in patients with melanoma: systematic review and meta -analysis of randomized controlled trials. Arch Surg \n2002;137:458- 461  \n87. Sim FH, Tay lor WF, Pritchard DJ, et al. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study.  Mayo Clin Proc 1986;61:697- 705 \n88. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977;297:627- 630 \n89. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420- 2430  \n  \n \n \n \n \n \n   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 288 von 817 \n4.3. Frage III.3. Therapeutische Lymphadenektomie  \u2013 De-novo -Recherche  \nFrage III.3 . In welchen F\u00e4llen ist die therapeutische LAD indiziert? \n4.3.1.  PICO- Unterfragen  \n- Hat die therapeutische LAD bei Patienten mit klinisch feststellbaren LK -Metastasen einen Einfluss auf das \u00dcberleben?  \n- Hat die therapeu tische LAD bei Patienten mit klinisch feststellbaren LK -Metastasen einen Einfluss auf die rezidivfreie Zeit? \n- Hat die therapeutische LAD bei Patienten mit klinisch feststellbaren LK -Metastasen einen Einfluss auf die Lebensqualit\u00e4t ? \n \nSuchw\u00f6rter  \nStichwort, S ynonyme,  Ober -\n/Unterbegriffe, Mesh Term  s. Suchsstrategie  \n \n4.3.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  melanoma AND (\"lymph node \nexcision\"[MeSH Terms] OR \n(\"lymph\"[All Fields] AND \"node\"[All \nFields] AND \"excision\"[All Fields]) OR \n\"lymph node excision\"[All Fields] OR \n\"lymphadenectomy\"[All Fields] OR \n\u201clymph node dissection\u201d[All Fields] OR \n\u201clymphonodectomy\u201d[All Fields])  08.03.2011  3408  \nMedline Update -Recherche  melanoma AND (\"lymph node 11.01.2011  3754   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 289 von 817 \nDatenbank  Suchstrategie  Datum  Treffer \nexcision\"[MeSH  Terms] OR \n(\"lymph\"[All Fields] AND \"node\"[All \nFields] AND \"excision\"[All Fields]) OR \n\"lymph node excision\"[All Fields] OR \n\"lymphadenectomy\"[All Fields] OR \n\u201clymph node dissection\u201d[All Fields] OR \n\u201clymphonodectomy\u201d[All Fields])  \nCochrane Libr ary (melanoma and ((lymph and node and \nexcision) or lymphadenectomy or \n\"lymph node disse ction\" or \nlymphonodectomy)).ti,ab.  08.03.2011  93 \nEmbase  (melanoma and ((lymph and node and \nexcision) or lymphadenectomy or \n\"lymph node disse ction\" or \nlymphonodectomy)) .ti,ab.  11.05.2011 2148  \n2. Suche/Erg\u00e4nzungen     \n    \nBemerkungen: Eine erste Literaturrecherche in Medline und und Cochrane erfolgte am 08.03.2010 bzw. f\u00fcr Embase am 11.05.2011. Zweite Medlin e-Recherche \n(Update -Recherche) erfolgte am 11.01.2011.  Da die F rage III.3. letztendlich konsensbasiert beantwortet wurde (s.3.3.3.) ,  wurde a uf eine Update -Recherche \nAnfang 2012 verzic htet. \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 290 von 817 \n4.3.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  5995  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports, narrative Reviews  \nAnzahl nach Abstractscreening  61 \nAnzahl ausgew\u00e4hlter und bewerteter Volltexte, vorges ehen f\u00fcr Bewertung  27 \nBemerkungen: Aufgrund des Fehlens von Studien, die das Outcome von Patienten, die eine therapeu tische LAD erhalten haben, mit dem von Patienten vergleicht, \ndie diese LAD trotz bestehender LK -Metastasen nicht erhalten haben, entschieden sich die Experten der AG chirurgische Therapie f\u00fcr eine konsensbasierte statt \nevidenzbasierte Beantwortung der Frag e.  \n \n4.3.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nPilko et al. (2011)  To compare the \noverall survival of \ndifferent groups of \nstage III cutaneous \nmelanoma patients  Prognostic study  \n \nCohort study  \n \n 325 patients with \nstage III melanoma  \n Overall survival \n(OS) \n \nDisease -free \nsurvival (DFS)  The mean follow -\nup was 44 months \n(range 1 \u2013  168 \nmonths).  \n \nThe 5 -year DFS for \nthe whole group \nwas 36.6%, 5- year \nOS was 52.6%.  Retrospective \ndesign (prospective \ndatabase)  \n \nShort follow -up in \nsome patients  \n \nNo control group \n(comparison of 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 291 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \nOn multivariate \nanalysis, age, \nBreslow thickness, \npresence of \nulceration, number \nof involved lymph \nnodes, type of \nlymph node \ndissection and size \nof SN metastasis \nwere independent \nprognostic factors \nfor OS.  lymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n \nPasquali et al. \n(2010)  To investigate \nwhether patients \nwith melanoma \nwho undergo \nlymphadenectomy \nafter a positive \nsentinel  \nlymph node (SN) \nbiopsy (SNB) have a \nbetter prognosis \ncompared wit h \npatients who are \ntreated for \nclinically evident \ndisease.  Systematic review  The included 6 \nstudies \nencompassed 2633 \npatients who had \nAJCC stage III \nmelanoma.  \n \n Overall survival  Hazard ratio for \noverall survival \n(TLND vs. CLND):  \nSummary measure \n1.602  Study included \nhere for the data \non therapeutic \nnode dissection \n(not completion \nnode dissection \nafter SNB)  \n \nSystematic review \nand original data, \nbut different \nobjective of the \nstudy (therapeutic \nvs. completion \nnode dissection, \nnot therapeutic vs. 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 292 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ncontrol grou p), \ntherefore lower \nlevel of evidence \nconcerning the \nquestion of \nindication for \ntherapeutic node \ndissection  \nRutkowski et al. \n(2010)  To compare \noutcomes of \npatients with \nclinical nodal \nmelanoma \nmetastases without \na detectable \nprimary tumor \n(MUP) with th ose \nwith a known \nprimary site (KPM). Prognostic study  \n \nCohort study  \n \n 459 consecutive \nmelanoma \npatients, stages IIIB \nand IIIC  Overall survival  \n \nDisease -free \nsurvival  \n \nRecurrence rates  3-year and 5 -year \nOS rates: 48.0% \nand 41.4%, \nrespectively, for \nthe MUP group \n(median 36.2 \nmonths) and 42.0% \nand 36.0%, \nrespectively, for \nthe KPM group \n(median 25.7 \nmonths).  \n \n3-year and 5 -year \nDFS rates: 47.0% \nand 44.0%, \nrespectively, for \nthe MUP group \n(median 14.9 \nmonths) and 31.1% \nand 28.3%, \nrespectively, for Retrospective \ndesign  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 293 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nthe KPM group \n(median 11.7 \nmonths).  \n \nDisease \nrecurrences:in the \nMUP group 31 \npatients; 52.5%, in \nthe KPM group 299 \ncases; 74.8%  \nAllan et al. (20 08) To review the \nexperience of \nroutine ilioinguinal \ndissection for all \npatients presenting \nwith palpable \nmetastatic \nmelanoma in the \ngroin. prognostic and \ndiagnostic study  \n \nCohort study  \n \n 72 patients  \n Disease -free \ninterval  \n \nDisease -free \nsurvival  \n \nOverall survival \n \nPelvic lymph node \nstatus  \n \nDiagnostic value of \npreoperative CT  \n \nComplication rate \n(lymphoedema)  22 (30.6%) of 72 \npatients with \nhistologically \ninvolved pelvic \nlymph nodes.  \n \nPreoperative CT \naccuracy for pelvic \nlymph node \ninvolvement:  \nsensitivity 6 0.0% \nspecificity 100.0%, \nPPV 100.0%  \nNPV 86.2%.  \n \nMedian time to \nfirst recurrence: \n8.7 months (0.8 \u2013\n69.7 months). \nRegional Retrospective \ndesign  \n \nSmall patient \ncohort \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissecti on not \npossible)  \n \nConfounder: \nadjuvant therapy  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 294 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nrecurrence in 6 \n(8.3%) of 72 \npatients (at a \nmedian of 4.9 \nmonths (0.9 \u201332.0 \nmonths).  \n \nExtranodal spread \nadversely \nassociated with \ndisea se-free \nsurvival.  \n \n5-year DFS: 38% \n(95% CI 26 \u201350), OS \n47% (95% CI 33 \u2013 \n60). \n \nLymphoedema was \nreported in 32 \n(44.4%) of 72 \npatients.  \nLee et al. (2008)  Clinical outcomes \nof patients with \nMUP and known \nprimary melanoma \n(MKP) with regional \nnodal metastases \nwere compared to \ninvestigate the Prognostic study  \n \nCohort study  \n 1,571 patients who \nunderwent \ntherapeutic \nregional \nlymphadenectomy  \n \n(262: MUP, 1,309: \nMKP)  Overall survival  \n \nDisease -free \nsurvival  significant factors \non multivariate \nanalysis: age, sex, \nnodal tumor \nburden, decade of \ndiagnosis, status \nof primary.  \n Retrospective \ndesign  \n \nNo control  group \n(comparison of \nlymph node \ndissection vs. no \nlymph node 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 295 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nprognostic \nsignificance of \nMUP.   Greater risk was \nassociated with \nage \u2265 60 years, \nmale sex, \nincreased number \nof tumor -involved \nnodes (>1), and \nMKP. The risk of \ndeath was 40% \nlower in the MUP \ngroup than the \nMKP group (HR = \n1.507).  \n \n5-year and 10 -year \nrates of OS for \npatients with MUP \nversus patients \nwith MKP were 58% \n\u00b1 7% versus 40% \u00b1  \n7%, respectively, \nand 52% \u00b1  7% \nversus 36% \u00b1  7%, \nrespectively.  \n \nMedian OS was \nalso significantly \nlonger in the MUP \ngroup than the \nMKP group (165 \nmonths vs. 34 dissection not \npossible)  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 296 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmonths).  \nVan Akkooi et al. \n(2007)  To evaluate \nmorbidity and \nmortality following \nTLND, and disease -\nfree (DFS) and \noverall survival \n(OS) following \nTLND.  Prognostic study  \n \nCohort study  \n 236 melanoma \npatients who \nunderwent TLND  Overall survival \n \nDisease -free \nsurvival  \n \nRegional control \nrate \n \nComplication rate  \n mean follow -up \nafter TLND: 29 \nmonths (range 0 \u2013 \n280 months).  \n \nestimated 5 -year \nDFS and OS for the \n236 patients after \nTLND: 19% and \n26%.  \n \nestimated 5 -year \nregional control \nrate after TLND: \n79%.  \n \nMedian time to \ndisease \nprogression: 7 \nmonths.  \n \nestimated 5 -year \nDFS according to \nsite of tumor: 23% \n(extremities) and \n9% (central tumors)  \n \nestimated 5 -year \nDFS for different Retrospective \ndesign  \n \nNo follow -up in \nsome patients  \n \nNo control group \n(comparison of \nlymph  node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n \nFor data on \ncomplications, see \noriginal article  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 297 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ncategories of nodal \nstatus (N1, N2, \nN3): 31%, 15% and \n10%, respectively.  \n \nsignificant \ndifferent estimated \n5-year OS rate for \ndifferent intervals \nof diagnosis until \nTLND.  \nYoung et al. (2006)  To investigate \nrates of long -term \nsurvival for \npatients with \nregional (nodal) \nmelanoma.  Prognostic study  \n \nCohort study  \n 1422 patients with \nstage III melanoma \nwho received \ncomplete \nlymphadenectomy   \n \n Overall survival  \n \nMelanoma -specific \nsurvival  maximum follow -\nup: 386 months \n(32 years)  \n \nrates of 15 -, 20- \nand 25 -year \nmelanoma -specific \nsurvival: 36% \u00b1  1%, \n35% \u00b1 1%, and 35% \n\u00b1 1%, respectively.  \n \nMedian melanoma -\nspecific OS: 28.1 \nmonths in the \npalpable and 90 \nmonths in the non-\npalpable group.  \n \nWhen stratified by Retrospective \ndesig n \n \nLong follow -up \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 298 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nclinical status of \nregional nodes, \nsurvival rates were \nsignificantly lower \nif nodes were \npalpable.  \nPienkowski et al. \n(2005 ) to perform a \nsingle -institution \nanalysis of factors \ninfluencing the \nclinical outcomes \nof cutaneous \nmelanoma (C M) \npatients \nundergoing \ntherapeutic \nlymphadenectomy \n(LND).  Cohort study  353 consecutive \nmelanoma patients \nwith metastases to \nregional lymph \nnodes Overall survival  \n \nDisease -free \nsurfvival  Estimated 5 -year \noverall survival \nratio:44%   \n \n5-year disease free \nsurvival rate: 35%  \n \nindependent \npredictors of poor \nOS (multivariate \nanalysis):  \n- extracapsular \nmelanoma invasion \n(p 3mm (p = \n0.007)  \n- male sex \n(p=0.011)  \n- CM site in \nhead/neck region \n(p = 0.05)  \n \nnegative factors for \nDFS:  \n- nodal Retrospective \ndesign  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 299 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nextracapsular \nmelanoma \nexten sion (p < \n0.0001)  \n- male sex (p < \n0.0001).  \nSerpell et al. \n(2003)  To review regional \ndisease control \nand morbidity in a \nseries of \nlymphadenectomie\ns  Cohort study  \n \n 64 melanoma \npatients have \nundergone 73 \nRLND for \nmetastatic regional \nmelanoma  Overall survival  \n \nRecurrence rate  \n \nComplication rate  \n \n median time to \ndiagnosis of \nregional lymph \nnode disease: 11.2 \n(interquartile range \n2\u201348) months.  \n \nregional control:  \n92% \nlocal recurrences \n(LR): 8%  \n \nLR all occurred \nwithin 12 months \nof \nlymphad enectomy, \nall but 1 patient \nwith LR have died \nwithin 12 months.  \n \nrate of LR local \nrecurrence was \nsimilar with or \nwithout Retrospective \ndesign  \n \nSmall pat ient \ncohort \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n \nFor data on \ncomplications, see \noriginal article  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 300 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npostoperative \nradiotherapy.  \n \n34/64 patients \ndied, median time \nto death=12 \nmonths (range 2 \u2013\n35 months).  \nFisher (2002)  To evaluate the \neffects on survival, \ndisease -free \ninterval, and \nrecurrence \npatterns for \npatients \nundergoing \nelective, \ntherapeutic, and \ndelayed lymph \nnode dissection for \nmalignant \nmelanoma of the \nhead and neck.  Cohort study  \n \n 1444 melanoma \npatients:  \n- 219 patients with \nELND, \nhistologically \nproven negative \nlymph nodes \n- 27 patients wit h \nELND, \nhistologically \nproven positive \nlymph nodes \n- 106 patients with \nDLND for regional \nlymph node \nrecurrence  \n- 112 patients with \nTLND for clinically \npositive lymph \nnodes  Disease -free \nsurvival  \n \nOverall survival overall rate of \nnodal recurrence \nfor all pa tients: \n129/1045 patients \n12%.  \n \nsignificant \nimprovement in \nsurvival for DLND \nwhen compared \nwith patients  \nundergoing ELNDQ \nor TLND (P=0.01).  \n \nFive-year survival \nafter DLND and \nTLND was 56% and \n36%, respectively.  \n \n Retrospective \ndesign  \n \nStudy included \nhere for data on \ndelayed lymph \nnode dissection \n(DLND); for further \ndata on ELND and \nTLND see original \narticle  \n \nNo control group \nfor DLND \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 301 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nPathak et al. (2002)  To determine the \nrates of regional \nrecurrence for \nnode -positive \nmelanoma after \nneck dissection \nalone.  Cohort study  \n \n 31 patients who \nunderwent neck \ndissection for \nnode -positive \nmelanoma  Recurrence rate  \n \nMean time to \nrecurrence  \n \nOverall survival \n mean follow -up: \n45.3 mont hs with a \nSD of 35.3 months \nand a range of 1 to \n108 months.  \n \nregional recurrence \nrate at 5 years for \nmelanoma: 31%.  \n \nmean time to \nrecurrence: 78 \nmonths (95% CI: 63 \nto 93 months).  \n \nmean survival for \npatients \nundergoing neck \ndissection: 61 \nmonths.  Small patient \ncohort \n \nVery short follow -\nup in some \npatients \n(recurrence rate \nmay be \nunderestimated)  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n 3b \nWhite et al. (2002)  To examine the \nlong-term \noutcomes of \npatients with \nmelanoma \nmetastatic to \nregional lymph \nnodes.  Cohort study  \n \n 2,505 patients  Overall survival  \n \nRecurrence -free \nsurvival  For regional lymph \nnode metastases:  \nmedian overall \nsurvival: 3.4 years,  \n \nmedian recurrence -\nfree survival: 1.5 \nyears.  \n \nEstim ated overall Retrospective \ndesign  \n \nMissing data led to \nexclusion of \npatients  \n \nNo control group \n(comparison of \nlymph node 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 302 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsurvival rates(95% \nCI) at 5, 10, 15, \n20, and 25 years: \n43% (41 \u201345%), 35% \n(33\u2013 37%), 28% \n(25\u201330%), 23% (20 \u2013 \n26%), and 19% (13 \u2013\n24%), respectively.  \n \nEstimated \nrecurrence -free \nsurvival rates at 5, \n10, 15, and 20 \nyears: 33% (31 \u2013\n35%), 28% (26 \u2013\n30%),  25% (23 \u2013\n27%), and 22% (18 \u2013\n26%) respectively,  \n \nBoth curves \nappeared to \nplateau at \napproximately \n20%, no first \nrecurrences after \n21 years.  dissectio n vs. no \nlymph node \ndissection not \npossible)  \n \n \nHughes et al. \n(2000 ) to identify disease - \nand treatment -\nrelated factors that \ninfluence the 132 patients  \nWith clinically \ndetectable LN -\nmetastases  Morbidity  \n \nOverall survival \n no difference in \npostoperative \nmorbidity or major \nlymphoedema Retrospective \nstudy  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 303 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \noutcome of \npatients \nundergoing \ntherapeutic groin \ndissection for \nclinically \ndetectable \nmelanoma lymph \nnode metastases   \n60 patients: \nsuperficial inguinal \nlymph node \ndissection (SLND)  \n \n72 patients: \ncombined \nsuperficial inguinal \nand pelvic lymph \nnode dissection \n(CLND)  Recurrence rate  between SLND and \nCLND  \n \noverall 5 -year-\nsurvival -rate:  \n- 34% \n \n5-year-survival -\nrate: \n-pelvic lymph node \nmetastases (CLND): \n19% \n- no pelvis lymph \nnode metastases \n(CLND): 17%  \n(P = 0.015)  \n \n \nFactors with \nsignificant impact \non survival \n(univariate \nanalysis):  \n- age (P = 0.003)  \n- number of \ninvolved superficial \nlymph nodes (P = \n0.001)  \n- presence of \nextracapsular \nspread (P = 0.003)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 304 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \nSystemic \nrecurrence rate:  \n62% \n \nMedian time to \nsystemic \nrecurrence: 9 \nmonths  \n. \nCascinelli et al. \n(1998)  To evaluate the \nefficacy of \nimmediate node \ndissection in \npatients with \nmelanoma of the \ntrunk and without \nclinical evidence of \nregional node and \ndistant metastases.  Randomized \ncontrolled trial  \n \n Of 240 pati ents \n \n122: wide excision \nand immediate \nnode dissection  \n \n118: wide excision \nand dissection \ndelayed until the \ntime of appearance \nof clinically \ndetectable node \nmetastases.  \n Time to first \nrecurrence  \n \nOverall survival 36/118 patients \n(30.5%) developed \nregional node \nmetastases \n \nmedian lag \nbetween excision \nof primary tumour \nand the diagnosis \nof regional node \nmetastases: 8.3 \nmonths \n(interquartile range \n3.7\u201316.2). \nminimum delay: \n0.43 months, \nmaximum 55.0 \nmonths  \n \n\u201cDelayed\u201d patients Study included \nhere for the data \non delayed node \ndissection (not \nimmediate node \ndissection)  \n \nProspective, \nrandomized \ndesign, but \ndifferent objective \nof the study \n(elective vs. \ntherapeutic node \ndissection, not \ntherapeutic vs. \ncontr ol group), \ntherefore lower \nlevel of evidence \nconcerning the 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 305 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nhad a survival rate \nat 5 years of 51.3% \n(95% CI 41.7 \u201360.1).  question of \nindication for \ntherapeutic node \ndissection  \nJonk et al. (1998)  To identify \nprognostic factors \ndetermining overall \nsurvival in patients \nwith surgically \ntreated neck node \nmetastases o f \ncutaneous \nmelanoma  Cohort study  \n \n 70 surgically \ntreated with \ncurative intent for \ncervical lymph \nnode metastasis  \n \n- radical neck \ndissection: 64 \npatient -  - \nmodified radical \nneck dissection: 4 \npatients  \n- postero- lateral \nneck dissection:2 \npatients.  Overal l survival  overall survivals \nafter 5 and 10 \nyears: 23% and \n20%, respectively. \nMedian survival: 22 \nmonths.  \n \nFollowing a \ntherapeutic neck \ndissection, 5 -year \nsurvival rate: 22%  \n \nfollowing elective \ndissection, 5 -year \nsurvival rate: 29%  \n (difference not \nsignificant).  Retrospective \ndesign  \n \nSmall patient \ncohort \n \nPatients \npredominantly \nmale  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n 3b \nKarakousis and \nDriscoll (1996)  To report the \nexperience with \ngroin diss ection \nfor melanoma  Cohort study  \n \n 205 patients who \nunderwent groin \ndissection  \n \n Overall survival \n \nDisease -free \nsurvival  \n \nComplication rate  Estimated -overall \n5-year survival and \ndisease -free \nsurvival rates for \npatients with \nhistologically \nproven negative Retrospective \ndesign  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 306 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nnodes: 73% and \n67% respectively, \nrates for those \nwith positive \nnodes: 39% and \n29%, respectively. \n10-year survival \nrate for patients \nwith negative \nnodes was 63% and \nfor those with \npositive nodes \n33%.  \n \nmedian length of \nsurvival for \npatients with \nclinically p ositive \nnodes: 29 months, \nfor the 40 with \nnegative nodes: 52 \nmonths. 5 - and 10 -\nyear survival rates: \nin the former \ngroup: 37% and \n32% respectively, \nin the latter group: \n43% and 35%.  \n \nFor patients with \npositive nodes only lymph node \ndissection not \npossible)  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 307 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nin the inguinal \nregion: 5 -year \noverall and \ndisease -free \nsurvival rates were \n43% and 35% \nrespectively; for \npatients with \npositive nodes in \nboth the inguinal \nand deep node \ngroups: 34% and \n21%. Estimated 10 -\nyear survival rate \nfor the former \ngroup: 39%. for the \nlatter group: 25% \nat 92 months.  \nKarakousis et al. \n(1994)       Patient cohort is a \nsubset of \nKarakousis and \nDriscoll (1994); see \nabove   \nGadd and Coit \n(1992)  To analy ze the \npatterns of initial \nrecurrence and \noutcome of \npatients with \nrecurrence of Cohort study  \n \n 403 patients with \nrecurrences after \nlymphadenectomy;  Disease -free \ninterval  \n \nsurvival  The median \ndisease -free \ninterval: 11.2 \nmonths, range \nfrom 1 to 157 \nmonths.  Retrospective \ndesign  \n \nMissing tumor \ncharacteristics for \ncirca half of the 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 308 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmelanoma \nfollowing axillary \nor inguinal \nlymphadenectomy   \nMedian survival of \npatients with:  \n \n- single -site \nrecurrence: 11 \nmonths, with a 5 -\nyear survival rate \nof 10%  \n \n- multiple sites: 3 \nmonths, no 5 -year \nsurvivors  \n \n- nonvisceral \nsingle -site \nrecurrence: 1 8.5 \nmonths with a 5 -\nyear-survival rate \nof 14%  \n \n- single visceral \nrecurrence: 6 \nmonths with a 5 -\nyear-survival rate \nof 3%  \n \n- surgical resection \nof single -site \nrecurrences: 17 \nmonths with a 5 -patient population; \nalso missing \ntreatment \ninformation in \nsome patients  \n \nNo separate \nanalysis for \nelective and \ntherapeutic \ndissections  \n \nComparison \nbetween surgical \nand nonsurgical \ntherapy, but \ngroups not \nrandomized   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 309 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nyear survival rate \nof 14% (Complete \nresection: median \nsurvival: 1 9 \nmonths, partial \nresection: 6 \nmonths)  \n \n- nonsurgical \ntherapy: 5 months \nwith a 5 -year \nsurvival rate of 2%  \n \n- surgical resection \nof multiple site \nrecurrences:  \n7 months  \n \n- nonsurgical \ntherapy of multiple \nsite recurrences: 3 \nmonths  \n  \nMorton et al. \n(1991)  To evaluate the \nimportance of \nvarious prognostic \nfeatures after \nlymphadenectomy.  Cohort study  \n \n. 1134 patients with \nlymph node \nmetastases  \n \n737 patients in \nwhom complete \ninformation was Overall survival 5-, 10- and 15 -year \nsurvival: 46%, 41%, \nand 38%, \nrespectively. \n \nMultivariate \nanalysis:the Missing \ninformation in \nmany patients, \nwho were excluded \nfrom the analysis  \n \nRetrospective 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 310 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \navailable  number of involved \nnodes (p = 0.001), \nthe location on an \nextremity (p = \n0.0059), the depth \nof the primary (p = \n0.0334), the \npatient's sex (p = \n0.0627), and \nclinical stage (p = \n0.0942) were \nsignificantly \ncorrelated with \nsurvival.  design  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n \nFor ma thematical \nmodel of \nprognosis, see \noriginal article  \nKarakousis et al. \n(1990 ) To report on \nresults and \ncomplications of \naxillary node \ndissection in \nmelanoma  Cohort study  \n  133 melanoma \npatients who \nunderwent axillary \nnode dissection  \n \n Overall survival  \n \nDisease -free \nsurvival  \n \nComplication rate  estimated 5 -year \ndisease -free \nsurvival rate for \npatients with:  \n \n- histologically \nnegative nodes: \n80% \n \n- histologically \npositive nodes: \n23%. \n \n- palpable nodes: \n13% \n For data on \ncomplications, see \noriginal article  \n \nRetrospective \ndesign  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 311 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n- clinically negative \nnodes: 60%.  \n \nIn patients wit h \nclinically & \nhistologically \ninvolved nodes: the \ngreater the number \nof involved nodes, \nthe shorter was the \ndisease -free \nsurvival time after \nnode dissection.  \n \nConsidering all \npatients with \nelective and \ntherapeutic node \ndissections: \nrecurrence in 53 \npatien ts (40%), 74% \nof them within 2 \nyears.   \nKarakousis et al. \n(1986)       Patient cohor t is a \nsubset of \nKarakousis and \nDriscoll (1994); see \nabove   \nFinck et al. (1982)  To review the Cohort  study  82 melanoma Disease -free Significant Retrospective 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 312 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nresults of \nilioinguinal \ndissection and to \ncompare results \nfor patients with \ninguinal and iliac \nnode involvement \nwith those with \nonly inguinal \ninvolvement.  \n patients with \ninguinal lymph \nnode metastases.  \n interval  \n \nOverall survival difference in \ndisease -free \ninterval for \npatients with \ninguinal and iliac \nnode metastases \nand patients who \nhad only inguinal \ninvolvement . \n(p < 0.01).  \n \nDisease \nrecurrence: - 20/24 \n(83.3%) patients \nwith positive iliac \nnodes  \n- 32/58 (55.2%) \npatients with \nnegative iliac \nnodes.  \n \nMedian disease -\nfree interval: \n- 5.8 months for \npatients with iliac \nmetastases  \n- 25.6 months for \npatients without \niliac nodal \ninvolvement.  \n design  \n \nSmall patient \ncohort \n \nMissing \ninformation on \nprimary tumour \ncharacteristics in \nmany pat ient files  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 313 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nMedian survival:  \n- for patients with \niliac metastases: \n20.0 months  \n- for patients with \nnegative iliac \nnodes:52,1 months  \nVeronesi et al. \n(1982)  To investigate \nwhether regional \nlymph nodes \nshould or should \nnot be removed in \nstage I melanoma \npatients (elective \ndissection).  Randomized \ncontrolled trial  \n \n 553 stage I \nmelanoma patients  Overall survival  The type of \ntreatment given \ndid not modify the \nchances of cure for \nthe patients, even \nif adjusted by \nsingle significant \nfactors or by all of \nthem.  \n \n5-year overall \nsurviv al rates for \ndelayed dissection:  \n57.9% for males  \n76.5% for females  \n \n10-year overall \nsurvival rates for \ndelayed dissection:  \n48.7% for males  \n62.0% for females  \n \n Prospective design  \n \nStudy included \nhere for the data \non therapeutic \nnode dissection \n(not elective  \ndissection)  \n \nDifferent objective \nof the study \n(therapeutic vs. \ncompletion node \ndissection, not \ntherapeutic vs. \ncontrol group), \ntherefore lower \nlevel of evidence \nconcerning the \nquestion of \nindication for \ntherapeutic node \ndissection  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 314 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \nPredominantly \nwomen in study \ngroup  \nSandeman (1966)  To review the \nresults of radical \nsurgery and other \nmethods in the \ntreatment of \nregionally \nadvanced \nmelanoma  Cohort study  \n \n 113 patients with \nmalignant \nmelanoma in \nstages I -III  Overall survival  5-year OS survival \nfor patient s who \noriginally \npresented in stage \nI, depending on \ntreatment method:  \nSurgery 27%  \nIrradiation 23%  \nCombined 67%  \n \n5-year overall \nsurvival for \npatients who \noriginally \npresented in stage \nII, depending on \ntreatment method:  \nSurgery 27%  \nIrradiation 33%  \nCombined 0 /4 \n \nStage III: 5 -year \nsurvival for \nirradiation 33%  \n \nInsufficient data Retrospective \ndesign  \n \nInsufficient control \ngroup of patients \nwho did not \nreceive treatment  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 315 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nfor \u201cno treatment\u201d \ngroup and stage III \nwith other \ntreatment \nmodalities  \nPrice and Duval \n(1963) To determine \nwhether or not \nprognosis in \nmalignant \nmelanoma is \naffected by \nregional lymph \nnode excision  Cohort study  \n \n 50 patients with \nmalignant \nmelanoma arising \non an extremity  Overall survival 27 of 50 patients \nhad clinically \npositive nodes on \npresentation. Of \nthese 2 refused \ntreatment (0% \nsurvivors) and  \n \n27/25 patients \nwith clinical \npositive nodes \nreceived  \nregional lymph \nnode dissection: \n20% survivors  \n \n14/23 patients \nwith had clinically \nnegative nodes; \nreceived regional \nlymph node \ndissection: 43 % \nsurvivors   \n \n Retrospective \ndesign  \n \nSmall patient \ncohort \n \nVery old patient \ncohort (1931 \u2013  \n1956), \nquestionable \ntransferability to \ncurrent situation  \n \nVery small, \nprobably biased \ncontrol group (2 \npatients with \nclinically involved \nnodes who refused \ntreatment ) \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 316 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nBowsher et al. \n(1986)  To evaluate short \nand long term \npostoperative \nmorbidity, \nmortality and local \nrecurrence rate \nafter regional node \ndissection for \nmelanoma  Cohort study  \n \n 86 patients who \nreceived regional \nnode dissection for \nmelanoma  \n(28% proph ylactic, \n72% therapeutic)  Recurrence rate  \n \n Local recurrence \nafter dissection:  \n \n- cervical: 33%  \n- axillary: 13%  \n- inguinal: 9%  \n- axillary for trunk \nlesions: 21%  \n- axillary for arm \nlesions: 6%  \n \n Retrospective \ndesign  \n \nSmall patient \ncohort \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n \nFor data on \nprophylactic RND \nand complications, \nsee original article  3b- \nFortner et al. \n(1964)  To present results \nof groin dissection \nin malignant \nmelanoma  Cohort study  \n \n 220 patients who \nhad undergone a \ngroin dissection \nfor malignant \nmelanoma  Overall survival  \n \nRecurrence rate  \n \nComplication rate  5-year-survival -rate \nof patients with \ndissection: \n- unilateral groin \ndissection: 33,5%  \n- histologically \npositive nodes: \n23,3 %  \n- histological \nnegative nodes: \n78,8%  \n-radical groin Very old patient \ncohort (1931 \u2013  \n1956), \nquestionable \ntransferability to \ncurrent situation  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 317 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ndissection: 31,6%  \n- nodal \ninvolvement by \nmetastatic cancer \nconfined to the \nsuperficial groin: \n41,6%  \n- positive nodes in \nboth superficial \nand deep groups: \n8,7% \n \nComplication -rate \n- during operation: \n3% \n- postope rative:  \nApproximately 60%  \n \nMortality rate \nwithin 30 days \nafter operation: \n<0,5%  \n \nMorbidity rate \n(relative to other \nthan wound \nproblems: 19,4%)  \n \nRecurrence rate \ntotal for first year: \n55,8%  dissection not \npossible)  \n \nFor further \nprognostic data \nsee original article   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 318 von 817 \n4.3.5.  Literatur  \nAllan CP, Hayes AJ, Thomas JM. Ilioinguinal lymph node dissection for pa lpable metastatic melanoma to the groin. ANZ J Surg 2008;78:982- 986 \nBowsher WG, Taylor BA, Hughes LE. Morbidity, mortality and local recurrence following regional node dissection for melanoma. Br J Surg 1986;73:906- 908 \nCascinelli N, Morabito A, Santinami M , et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Me lanoma Programme. \nLancet 1998;351:793- 796 \nFinck SJ, Giuliano AE, Mann BD, et al. Results of ilioinguinal dissection for stage II me lanoma. Ann Surg 1982;196:180- 186 \nFisher SR. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998. Laryngoscope \n2002;112:99- 110 \nFORTNER JG, BOOHER RJ, PACK GT. Res ults of Groin Dissection for Malignant Melanoma in 220 Patients. Surgery 1964;55:485- 494 \nGadd MA, Coit DG. Recurrence patterns and outcome in 1019 patients undergoing axillary or inguinal lymphadenectomy for melano ma. Arch Surg 1992;127:1412- 1416  \nHughes TM D, A'Hern RP, Thomas JM. Prognosis and surgical mananagement of patients with palpable inguinal lymph node metastases from me lanoma. Br J Surg 2000;87:892- 901 \nJonk A, Strobbe LJ, Kroon BB, et al. Cervical lymph -node metastasis from cutaneous melanoma of th e head and neck: a search for prognostic factors. Eur J Surg Oncol 1998;24:298 -302 \nKarakousis CP, Driscoll DL. Groin dissection in malignant melanoma. Br J Surg 1994;81:1771- 1774  \nKarakousis CP, Driscoll DL, Rose B, et al. Groin dissection in malignant mela noma. Ann Surg Oncol 1994;1:271- 277 \nKarakousis CP, Emrich LJ, Rao U. Groin dissection in malignant melanoma. Am J Surg 1986;152:491- 495 \nKarakousis CP, Hena MA, Emrich LJ, et al. Axillary node dissection in malignant melanoma: results and complications. Sur gery 1990;108:10- 17 \nLee CC, Faries MB, Wanek LA, et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 2008;26:535- 541 \nMorton DL, Wanek L, Nizze JA, et al. Improved long -term survival after lymph adenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients \nfrom the John Wayne Cancer Clinic. Ann Surg 1991;214:491- 9; discussion 499- 501 \nPasquali S, Mocellin S, Campana LG, et al. Early (sentinel lymph node biopsy -guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases : personal \nexperience and literature meta -analysis. Cancer 2010;116:1201- 1209  \nPathak I, Gilbert R, Yoo J, et al. Outcome of neck dissection for node -positive melanoma. J Otolaryngol 2002;31:147- 149 \nPienkowski A, Nowecki ZI, Rutkowski P, et al. Analysis of survival and prognostic factors in patients with cutaneous melanoma  after therapeutic lymphadenectomy. Nowotwory \n2005;55:207- 212 \nPilko G, Besic N, Zgajnar J, et al. Pro gnostic heterogeneity after the excision of lymph node metastases in patients with cutaneous melanoma. Surg Oncol 2011;20:26 -34 \nPRICE WE, DUVAL MK,Jr. Regional Lymph Node Dissection and Malignant Melanoma. Effect of Survival. Arch Surg 1963;87:747 -750 \nRutkowski P, Nowecki ZI, Dziewirski W, et al. Melanoma without a detectable primary site with metastases to lymph nodes. Dermatol  Surg 2010;36:868- 876 \nSandeman TF. The radical treatment of enlarged lymph nodes in malignant melanoma. Am J Roentgenol Radium Ther  Nucl Med 1966;97:967- 979 \nSerpell JW, Carne PW, Bailey M. Radical lymph node dissection for melanoma. ANZ J Surg 2003;73:294- 299 \nvan Akkooi AC, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol 2007;33:102- 108 \nVeronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420 -2430  \nWhite RR, Stanley WE, Johnson JL, et al. Long -term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg 2002;235:879- 887 \nYoung SE, Martinez SR, Faries MB, et al. Can surgical therapy alone achieve long -term cure of melanoma metastatic to regional nodes? Cancer J 2006;12: 207-2 \n \n \n \n   \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 319 von 817 \n4.4. Frage II I.7. Operative Therapie bei Fernmetastasen  \u2013 De-novo -Recherche  \nFrage III.7 . Wann ist bei Fernmetastasen eine operative Therapie indiziert?  \n4.4.1.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  (\u201cmelanoma\u201d[tiab] AND (\"neoplasm metastasis\"[MeSH Terms] OR (\"metastasis\"[tiab])) \nAND (\"surgery\"[All Fields] OR \u201cmetastasectomy\u201d[All Fields])  26.01.2012  3878  \n2. Suche/Erg\u00e4nzungsrecherche     \nMedline  (\u201cmelanoma\u201d[tiab] AND (\"neoplasm metastases\"[MeS H Terms] OR (\"metast ases\"[tiab]) \nOR (\u201cmetastatic\u201d[tiab])) AND (\"surgery\"[All Fields] OR \u201cmetastase ctomy\u201d[All Fields])  26.01.2012  4137  \nCochrane Library  (melanoma and (metastasis or metastases) and (surgery or metastasectomy)).ti,ab.  19.01.2012  89 \nEmbase  (melanoma and metastasis and (surgery or metastasectomy)).ti,ab.  \n(melanoma and metastases and (surgery or metastasectomy)).ti,ab.  23.01.2012 806 \n1342  \nBemerkungen: Eine erste Literaturrecherche in Medline und und Cochrane erfolgte am 26.04.2011 bzw. f\u00fcr Emb ase am 11.05.2011. Eine Erg\u00e4nzungsrecherche \nin Medline erfolgte am 08.12.2011. Die Update -Recherche wurde am 23.01.2012 (Embase) bzw. am 26.01.2012 ( Medline) und am 19.01.2012 (Cochrane) \ndurchgef\u00fchrt. In der Tabelle angegeben sind die Trefferzahlen der le tzten R echerche.  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 320 von 817 \n4.4.2.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  inkl. Dupletten  10252  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt, ab Erscheinungsjahr 1978  \npopulation \u2265 20 patients  \nAusschlusskriterien  narrative Reviews, Case  Reports, gemischte Kollektive mit anderen Krebsarten, Studien au sschlie\u00dflich zu Gehirn -\nMetastasen (andere AG)  \nAnzahl nach Abstractscreening  93 \nAnzahl ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewertung  31 \n \n4.4.3.  Evidenztabelle  \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nSubtopic \nPulmonary \nMetastases         \nPetersen et al. \n(2007)  to discriminate  \npredictors of \nsurvival for \npatients with \npulmonary \nmetastatic Cohort study  \n \n 1720 patients with \nmetastatic \npulmonary \nmelanoma  \n \n318 patients Survival \n \n1-, 2- and 5 -year-\nsurvival  \n \n OS (n=1720)  \n- 1 year: 34%  \n- 2-year: 14%  \n- 5 years: 6%.  \n \nmedian survival: Retrospective \ndesign \n \ncomplete follow -up \non all patients  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 321 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nmelanoma.  underwent \nresection (with \ncurative intent)  \n  7.3 months.  \n \ncomplete vs \nincomeplete \npathologic \nresection:  \n- median su rvival: \n19 vs. 11 months  \n- 5-year survival: \n21 vs. 3% \n(P<0.0001).  \n \nsingle vs. r epeated \nmetastase ctomy:  \n- median su rvival: \n17 vs.15 months \n(P<0.9).  \n \nSignificant \npredi ctors of \nsurvival \n(multivariate \nmodel):  \n- nodular \nhistologic type \n(P=0.033)  \n- disease -free \ninterval (P<0.001) \n- number of \npulmonary \nmeta stases large sample  \n \ndata collection \nduring a span of \n35 years.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 322 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \n(P=0.012)  \n- presence of \nextrathoracic \nmetast asis \n(P<0.001)  \n- performance of \npulmonary \nmeta stasectomy \n(P<0.001).  \n \n \ndisease-free \ninterval after \nsurgery > 5 years: \nSurvival: 19 \nmonths (vs 7 \nmonths, P<0.01)  \n \nPatients without \nextra thoracic \nmeta stasis: 18 (vs \n8 \nmonths, P<0.01). \nLeo et al (2000)  To evaluate the \nlong-term results \nof lung \nmetastasect omy for \nmelanoma and  to \ndefine a su bset of \npatients with better Cohort study  \n \n. 328 patients who \nunde rwent lung \nmetastase ctomy  \n \nSurgical patients \nunderwent \nresection with Overall survival \n \nMortality  \n \nPrognostic factors \nof survival  5-year-survival: \n18% 10 -year-\nsurvival: 14%  \nmedian su rvival 17 \nmonths.  \n \nR0-resection:  Retrospective \ndesign \n \n \nOld patient cohort \n(1945 -1995) \n/questionable 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 323 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nprognosis.  curative intent only  \n  5- and 10 -year \nsurvival: 22% and \n16%(m edian \nsurvival 19 \nmonths)  \n \nR1/R2 -resection: \n5-year-survival: 0%  \n(median survival \n11 months).  \n \nLong - term survival \naccor ding to the \nradicality  of \nmeta stasectomy \n(16% vs 0% at 10 \nyears, P < 0.01)  \n \nindependent \nunfavou rable \nprognostic factors:  \n- time to \npulmonary \nmeta stases (TPM) \n<36 months  \n- presence of \nmultiple \nmetast ases  \n \nPatients without \nthese risk fa ctors: transferability to \ncurrent situation  \n \nBias: chemo -\n/radiotherapy  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 324 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \n5-year-survival \nrate:29%  \n \nPatients w ith 1 risk \nfactors: 5 -year-\nsurvival rate:20%  \n \nPatients with 2 risk \nfactors or \nincomplete \nresection: 5 -year-\nsurvival  \nrate:7%  \n \n- mortality rate \n67% \n- in the R0 group: \n65% \n- in the R1 \u20132 \ngroup: 80%).  \n \n5-year-survival \ninpatients with \nintrathoracic \nrecurrence a nd \nfurther surgery: \n19% \nHarpole et al. \n(1992)  To analyse patients \nfrom a melanoma \ndata base  Cohort study  945 patients \nwithpulmonary \nmetases.  1-, 3- and 5 -year \nsurvival -rates  \n 1-, 3- and 5 -year \nsurvival -rates: 30%, \n9% and 4%  Retrospective \nanalysis \n 2b- \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 325 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \n- overall risk of \npulmonar y \nmeta stastic \ndisease?  \n- pulmonary \nresection as a \nprimary therapy for \nmetast ases? \n- multivariate risk \nfactors for survival?   survival   \nMultivariate \npredictors of \nimproved survival \n(p<0,001):  \n-complete \nresection of \npulmonary di sease \n- longer time for \nformation of \nmeta stases  \n-treatment with \nchemotherapy  \n-1 or 2 pulmonary \nnodules  \n- lymph nodes \nnegative for \nmetastases \n(p<0,005)  \n-histologic type \n(p<0,04)  \n \ncurative resection \nfor a sol itary \nnodule (n=84) vs. \nno oper ation \n(n=142): 2 -year \nand 5 -year \nsurvival: 42% \nversus 20% \n(p<0,001)  No information \nabout follow up  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 326 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nNeuman et al. \n(2007)  to evaluate the  \nnatural history of \nstage -IV melanoma \nmetastatic to the \nlung and identify \nfactors predic tive \nof survival. Cohort study  \n 122 patients with \nstage -IV mel anoma \nand pulmonary \nmetastases \n  factors pedicitive \nof survival  \n \nsurvival  \n \ntime to recurrence  \n \n5-year-surviva l Median survival: \n14 months  \n5-year su rvival: 8%  \n \nFactors \nindependently \npredictive of \nsurvival:  \n- solitary \npulmonary \nmetast asis (HR \n2.7, CI 1.6 \u20134.4, \np<0.0005)  \n- absence of extra -\npulmonary disease \n(HR 1.9, CI 1.2 \u2013\n3.1, P=0.01).  \n- metastase ctomy \n(HR 0.42, C I 0.21 \u2013\n0.87, P = 0.02).  \n \nmedian survival of \npatients with \nmeta stasectomy \nvs. no surg ical \ntreatment:  \n- 40 vs. 13 months  \n \nMedian time to \nrecurrence: 5 \nmonths  Retrospective \ndesign \n \nNo information \nabout staging  \n \nSmall number of \npatients who \nreceived \nmetastase ctomy \n(n=26) \n \nPatients with \npulmon ary \nmetastases and \nconcurrent  \nskin/subcutaneous\n/distant nodal \ndisease were \nincluded  \n \nBias: systemic \ntherapy 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 327 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \n \nestimated 5 -year \nsurvival of patients \nundergoing \nmeta stasectomy: \n29%.  \n \nPatient who were \nfollowe d up 3 \nand/or 5 years:  \n3-year- survival: \n50%  \n5-year- survival: \n23%  \nAndrew et \nal.(2006)  To describe the  \nexperience with \npulmonary \nmetastase ctomy  cohort study  \n \n 86 patients 1-4 \npulmonary \nmetastases.  \n \n(10 patients with \nunknown pr imary \nsite) \n relapse -free \nsurvival  \n \noverall- survival  \n \n5-year-survival  \n \n overall median \ntime to relapse: \n8.4 months  \n \nmedian survival: \n35 months.  \n \n5-year survival \nrate: 33%  \n \n48/86 patients \ndied \n(median survival \ntime = 24 months),  \n \n16% of patients Retrospective \ndesign \n \nShort follow -up \n \nPatients received \ndifferent \npostsurg ical \ntherapies  \n \n 3b   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 328 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nwere relapse -free \nat a median fo llow-\nup of 35 months.  \n \nmedian survival of \npatients with a \nsolitary vs. \nmultiple lesions: \n41 vs. 25 months  \n(P = .05)  \nSchuhan et al. \n(2011 ) to determine the \nclinical cours e, \noutcome and \nprogno stic factors \nin a su bset of \npatients recently \ntreated by \nmetastase ctomy.  Cohort study  30 patients with \npulmonary \nmetast ases from \nmalignant \nmelanoma who \nunderwent \npulmonary \nresection \n \nComplete \npulm onary \nresection in 27 \npatients  5-year s urvival rate  \n \nMedian survival \n \nprognostic \nparam eter for OS  Cumulative 5 -year \nsurvival rate after \npulmonary \nresection: 35.1%, \nmedian survival: \n18.3 months.  \n \npatients with \ncomplete \npulmonary vs. \npatients with \nincomplete \nresection: median \nsurvival: 20.5 \nmont hs vs. 13.0 \nmonths  \n \ncompleteness of \nresection=no \nstatistically Small patient \ncohort 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 329 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nprogno stic factor \nfor survival.  \n \nMultivariate \nanalysis: only \nsignificant \nprognostic \nparam eter for \noverall survival: \ngender (9.4 \nmonths vs. 25.0 \nmonths for the \nfemale and male \ngroup, respe ctively \n( P = 0.022).  \nDelaunay et al. \n(1991 ) to assess the value \nof surgery in terms \nof survival and to \ndelimit its \nindications  cohort study  \n \n \n 38 patients with \npulmonary \nmetast ases of \nmalignant \nmelanoma  \n Overall -survival  \n \nDisease -free \nsurvival \n \n5-year survival rate  median survival: \n15 months (range \n2-144 months).  \n \n5-year-survival: \n20% \n \nmedian disease -\nfree-survival: 10,5 \nmonths.  \n \nStatistical \nsignif icance in \nsurvival \n(incomplete vs. Retrospective \nmulticenter study  \n \nNo information \nabout follow -\nup/recruitment \nperiod \n \n10 patients \nreceived neo -\nadjuvant trea tment  \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 330 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nradical surgery: \np<0,0001)  \n \nPogrebniak et al. \n(1988 ) To update and \nreexamine the \nefficacy of excision \nof pulmonary \nmelan oma \nmetastases Cohort study  \n \n 49 patients with \nresection  of \npresumed \npulmonary \nmetastases from \nmalignant \nmelan oma \n \n \n \n survival  Benign disease \n(n=13), metasta stic \ndisease (n=32), \nlung ca ncer (n=1)  \n \nSurvival (benign \nvs. malignant \ndisease): 169 vs. \n22 months  \n \nMedian survival \nafter thoracotomy \n(malignant \ndisease): 13 \nmonths.  \n \nNo diffe rence in \nsurvival after \ncomplete vs. \nincomplete \nresection. \n \n2-year-survival for \npatients with 1 vs. \n>1 nodule \nresected: 30% vs. \n10%  retrospective study  \n \nscreening met hods \nout of use, \nquestionable \ntransferabil ity to \ncurrent situ ation 3b-   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 331 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nMathisen et al \n(1979)  To determine the \nefficacy of \nresection of \npulmonary \nmetastases from \nmalignant \nmelanoma  Cohort study  33 patients who \nunderwent \nthoracotomy for \nresection of \nsuspected \npulmonary \nmetast ases from \nmalignant \nmelanoma  survival  11 patien ts: non -\nmalignant disease  \n \n10 unresectable \ndisease: median \nsurvival: 10,5 \nmonths (3 -20) \n \n12 were rendered \ndisease -free, \nmedian survival: \n12 months (3 -35).  \n \n5-year survival: 0%  Retrospective \nstudy  \nSmall population  \n \nPopulation not \ndescribed  \n \nOld patient coh ort \n(1957 -1978) \nquestionable \ntransferabil ity to \ncurrent data  \n \n10 patients \nreceived \npostoperative \nchemotherapy  3b-  \nSubtopic \nAbdominal/ \nretroperitoneal \nmeta stases         \nSanki et al. (2009 ) To assess survival, \nmorbidity and \nmortality following \ntherapeutic  or \npallia tive resection \nof gastr ointestinal \n(GI) tract melanoma \nmetast ases retrospective \nprognostic cohort \nstudy  117 patients who \nunderwent \noperations for \nacute and/or sub -\nacute sym ptoms or \nfor imminently \nsymptomatic GI \nmetast ases Mortality  \n \nPostoperative \ncomplications  \n \nsurvival  Mortality rate after \nGI resection: 1.4%  \n \npost-operative \ncompl ications -rate: \n2,5% \n \n1-, 2- and 5 -year  2b \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 332 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \ndetected \nradiolog ically survival rates:  \n-  for all p atients: \n57%, 39% and 27%  \n- for patients \nhaving palliative \nresect ions: 34%, \n19% and 0%.  \n \nThe median \nsurvival: \n- after surgical \nresection: 16.4 \nmo.  \n- after resection \nwith cur ative \nintent: 22.6 mo.  \n-  following \npalliative \nresection: 7.7 mo.  \n \nsignificant \nprogno stic \nindicators of \nsurvival (on \nmultivar iate \nanalysis):  \n- presence of \nresid ual \nintraabdominal \ndisease \n- presence of non - \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 333 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nGI meta stases at \nthe time of surgery \nor after su rgery \nwere the  \nOllila et al. (1996 ) To evaluate the \nrole of surgery in \nthe survival of \npatients with \nmelanoma \nmetastatic to the \ngastrointe stinal (GI) \ntract Retrospective \nprognostic c ohort \nstudy  124 patients with \nmetastatic \nmelanoma in the \nstomach, small \nintestine, colon, or \nrectum Operative \nmorbi dity and \nmortality  \n \nrelief of sym ptoms  \n \nmedian and 5 -year \nsurvival median DFI: 23.2 \n(range, 1 -154) \nmonths.  \n \n1 operative death  \n \n1 major oper ative \ncompl ication  \n \nAfter surgery r elief \nof sym ptoms in \n97%  \n \nmedian su rvival in \npatients with \ncurative resection \nvs. palliative \nprocedures and \nnonsurgical \ninterventions: 48.9 \nvs 5.4 and 5.7 \nmonths, \nrespe ctively  \n \nprogno stic fact ors \nfor long -term  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 334 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nsurvival \n(multivariate \nanalysis):  \n- complete \nresection of GI \ntract metast ases \n- GI tract as the \ninitial site of \ndistant \nmetast ases.  \nHodgson et al. \n(2007)  To determine the \nrole of resectional \nsurgery in \nmeta stastic \nmelanoma of the \nabdomen  Cohort study  \n \n 25 patients  \n \n(5 patients had \noccult tumours)  \n \n Survival  \n \nmorbidity  \n \nmorta lity median survival \nafter abdominal \nresection: 8.3 \n(range 0.4 \u201341.1) \nmonths.  \n \n1-year survival: \n36% \n \n1-year-survival \nafter su rgery with \ncurative vs. \npalliative intend: \n89 vs 10%, P < \n0.0001)  \n \nSuperior survival in \npatients with \u22642 \nmetastases \ncompared with \u22652 Retrospective \nstudy  \n \nSmall population  \n \nNo information \nabout follow -up 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 335 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \n(P = 0.0001)  \n \nIntent of surgery \n(curative vs \npallia tive) was the \nonly factor \nsignif icant \non multivariate \nanalysis (P = \n0.001).  \n \nRelief of \npreoper ative \nsympt oms: 87%  \n \nOper ative \nmorbidity: 12%  \n \n30-day morta lity: \n4%. \nMittendorf et al. \n(2008)  to determine the \nnatural history of \nmelanoma \nmetast asis to the \nadrenal gland and \nthe a ppropriate \nrole for surgical \nintervention  Cohort study  154 patients with \nadrenal metastasis  \n \n22 patients \nunde rwent surgical \nresection  \n \n \n surgical treatment  \n \nsurvival median OS:6.4 \nmonths (range 0,2 -\n97 months).  \n \nmedian OS for \npatients with:  \n- synchronous \nmetastatic disease: \n6.6 months  \n- isolated adrenal Retrospective \ndesign \n \nSmall population  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 336 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nmeta stasis: 18.7 \nmonths \n(p<0,0001)  \n \nmedian OS for \npatients with a \ndisease-free \ninterval of:  \n- <1 year: 7 \nmonths  \n- >1 year: 11 \nmonths ( P=0,35 ). \n \nAfter a median \nfollow-up of 12.6 \nmonths, 9/22 \n(41%)  \nPatients who \nunderwe nt surgical \nresection were \nalive, incl. 7 \nwithout \nrecurrence.  \n \nSurvival of patients \nwho u nderwent \nsurgery vs. those \nmanaged \nnonoper atively \n(p<0,0001).   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 337 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nPawlik et al. \n(2006)  To evaluated the \nefficacy of hepatic \nresection in \npatients with \nmetastatic oc ular \nand cutaneous \nmelanoma and to \nassesse fa ctors that \ncould affect \nsurvival after \nresection Cohort study  \n \n 40 patients with \nmetastatic \nmelan oma \ninvolving  \nthe liver who were \ntreated with \nhepatic resection \nwith \ncurative intent  \n \n Survival  \n \n5-year-survival  \n \nTime to recurrence  median time to \nrecurrence: 8.3 \nmonths  \n \nmedian survival: \n28.2 months \n(range,4.6 \u201393 .7 \nmonths)  \n \n5-year su rvival \nrate: 10.9%.  \n \n5-year survival rate \nfor patients with a \nprimary ocular \nmelanoma: 20.5%.  \n \n5-year survival rate \nfor patients with \ncutaneous \nmelan oma \n(P=0.03).  \n \nNo \nclinicopathologic \nfactors predictive \nof su rvival after \nhepatic resection  Retrospective \ndesign \n \nPatients with \nocular melanoma \nincluded  \n \nSome patients ha d \nother metastatic \nsites (not onl y \nliver) which were \nnot op erated  \n \nBias: 17 patients \n(70.8%) received \nsome form of \nsystemic therapy  3b \nRicaniadia et al. \n(1995)  to investigate the  \nrole of surgical Cohort study  \n 68 patients with \nclinical indic ations Complication rate  \n median survival  for \npatients unsuitable Retrospective \ndesign 3b   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 338 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nintervention in  \npatient with GI \nmetastasis and to \ndefine the group of \npatients who would \nbenefit surgical \nresection.   of involvement of \nthe \ngastrointest inal \n(GI) tract with \nmetastatic \nmelanoma  \n \n47 patients \nunde rwent \nabdominal surgery  Survival  \n \n5-year-survival  for surgery: 2.9 \nmonths.  \n \nRelief of \npreoper ative \nsymptoms after \nsurgery: 73%  \n \nPostoperative \ncomplications: 29%  \n \nDeath within 30 \ndays of surgery: \n11% \n \nmedian survival: \n- after surgery vs. \nno surgery: 5.66 \nvs. 2.9 months \n(P=0.0035) \n- after complete \nresection and no \nother disease vs. \nresection and \nother metastasis \npresent: 27,6 vs. \n5.1 months  \n- after by -pass \nprocedure: 1,9 \nmonths  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 339 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \n5-year survival:  \n- after co mplete \nresection and no \nother ev idence of \ndisease: 28.3%  \n(the other groups \nhad only 1 -year \nsurvivors)  \nSzynglarewicz et \nal. (2012)  To asses the role of \ncolorectal su rgery \nin the treatment of \nmetastatic \nmelan oma and to \nidentify p atients \nwho can most \nbenefit from \nsurgical rese ction. Cohort study  34 consecutiv e \npatients with skin \nmelanoma  \nwho underwent \nsurgical resection \nof large bowel \nmeta stasis  \n \n9 patients: \nemergency surgery \nfor obstruction, 25 \npatients had an \nelective proc edure.  \n \nIntend of surgery: \ncurative in 14 \npatients, palliative \nin 20 patients  \n Mortality \n \nMorbidity  \n \nMedian survival \n \n1-, 2-, and 5 -year \nsurvival rates  \n \nPrognostic factors  postoperative \nmortality: 0%  \n \npostoperative \nmorbidity: 9%.  \n \nMedian survival \nfollowing surgery: \n11.5 (4 -68) \nmonths. 1 -, 2-, and \n5-year survival \nrates:  \n50%, 32%, and 17 % \nrespectively.  \n \nMedian survival \nsignificantly \nincreased in \npatients without \nextra -abdominal \nmetastases, with \nno ev idence of Small patient \ncohort \n \nNo information \nabout R1 -Status  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 340 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nnon-large bowel \nmetastases, if the \nDFI >24 months \nand when curative \nresection was \nperformed.  \n \nmost important \nprognostic factors \non mu ltivariate  \nanalysis: \nappa rently \ncomplete or \npallia tive resection \nand the absence or \npresence of \nextraabdominal \nmeta stases  \nde Wilt et al. \n(2003)  To analyse \nindications for \nsurgery, \ncomplications , and \noverall survival with \nthe aim of \nclarifying the \nindications for \nsurgical treatment \nin such patients  Cohort study  \n \n 15 patients who \nunderwent surgical \ntreatment of \nmeta stases  \n \n98 patients were \ntreated \nconserv atively  \n \n. Postoperative \nmorbidity  \n \nOverall survival  \n \n1-year-survival rate  \n \n2-year-survival rate  \n patients with \nsplenectomy: \nmedian OS: 11 \nmonths  \n1-year survival \nrate: 35%, 2 -year-\nsurvival -rate 21%  \n \npatients with \nsingle splenic \nlesion and \nsplenectomy: retrospective \ndesign  \n \nSmall patient \nnumber \n \nMedical/conservati\nve treatment not \ndescribed in detail,  \n4 patients who \nunderwent \nsplenect omy were 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 341 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nmedian OS: 23 \nmonths.  \n1-year survival \nrate: 70%, 2 -year-\nsurvival -rate: 50%  \n \nconservatively \ntreated patients:  \nmedian OS: 4 \nmonths. 1 -year \nsurvival rate: 13%, \n2-year-survival -rate \n3% \n \nsurvival of patients \nwith splenic \nmeta stases treated \nsurgically vs. \nconserv atively: \nP=0.02  \n \nSurvival after \nsplenectom y with \npalliative vs. \ncurative intent: \nP=0,07  included in clinical \ntrials.  \n \nNo information \nabout follow -up \nBerger et al. \n(1999 ) \n To determine \nwhether surgery \ninfluences \noutcomes  Retrospective \ncohort study  Fifty patients with \nmelanoma \nmetasta tic to the \nGI tract  Mortality rate  \n \nsurvival  operative mortality \nrate: 2.5%  \n \nmean survival  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 342 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \ntimes for the \nunexplored and \nunresected \ngroups: 4.1 \nmonths  \n \nsignificantly \nincreased survival:  \n- in the pa rtial-\nresection group \n(8.9 months) \ncompared with the \nunrese ctable \ngroup ( P<0. 001).  \n- in the co mplete -\nresection group \n(23.5 months) than \nin the less than \ncomplete \nresection -group \n(P<0.0001).  \nKhadra et al. \n(1990)  To examine if a \nsurgical approach \nof metatases in the \nGIT is justified. Cohort study  \n \n 56 patients with \nsymptomatic \nmelanoma of the \ngastr ointestinal \ntract (GIT) treated \nsurgically  \n \n(13 occult primary)  \n complication rat e  \n \npostoperative \nsurvival  \n \noverall survival \n \ntime to recurrence  relief of symptoms \nin 44 p atients post  \npostoper atively.  \n \npostoperative \ncomplications: \n8/56 p atients (2 \ndied)  \n Retrospective \ndesign \n \nMethods o f follow -\nup not described  \n \nNo information \nabout metastases \nother than in GIT -3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 343 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \n mean \npostoperative OS \nafter 1st vs. 2nd \nmetastases: 11 .7 \n(range 1 -60) vs. \n3,6 m onths (range \n0-12 months)  \n \nmedian time of \nrecurrence: 12 \nmonths (range 3 -\n47 months)  \n \nmean OS for \nulcerated vs. non -\nulcerated tumor: \n46,6 vs. 84,9 \nmonths.  \n \nmean OS when \nprimary t umor \n<1,5 mm vs. >1,5 \nmm: 11,7 vs. 9,5 \nmonths.  tract \n \nBias: Adjuvant \ntherapy \n(chemotherapy in \n26 patients, \nradiotherapy in 1 \npatients, \nimmunothe rapy in \n4 patients)  \n \nChua et al. (2010 ) To evaluate the \nefficacy of surgical \nmetastase ctomy on \nsurvival ou tcomes.  Retrospective \ncohort study  23 patients with \nvisceral \nmetast ases from \nmelanoma (15 \nunderwent surgical \nresection)  disease -free \ninterval  \n \nOverall survival DFI: 49 (range, 5 \nto 559) months  \n \nMedian OS: 9 \nmonths. 1 - and 3 -\nyear su rvival: 39% Small patient \ncohort 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 344 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nand 30%, \nrespe ctively.  \n \nSurvival was \ninfluenced by -  the \nnumber of \nmetastases ( P = \n0.05) and the \ntreatment r eceived \n(P = 0.03).  \n \nAfter \nmetastasect omy: \nDFI and OS: 14 and \n21 months, \nrespe ctively. 1 - \nand 3 -year \nsurvival: 60% and \n40%, resp ectively.  \n \nSignificant longer \nsurvival for \npatients with \nsingle site vs. >1 \nsite of metast asis \n(P = 0.005)  \nBranum et al. \n(1991) To evaluate the \nrole of resection in \nthe manag ement of \nmelanoma  Retrosp ective \ncohort study  28 patients with \nmelanoma  \nmetasta tic to the \nadrenal gland  Survival \n \n5-year-survival  Mean survival in \nthe group that \nunderwent \nresection for cure:  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 345 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nmetastatic to the \nadrenal gland  59 months (3 to \n112 months)  \n \nsurvival in the \ngroup with \nunresectable \ntumors: 15 months \n(1.5 to 132 \nmonths).  \n \n5-year-survival:  \n- 4/8 patients who \nunderwent \nresection for cure  \n1/14 p atients with \nunresectable \ntumors  \nSubtopic di fferent \nmetasta tic sites         \nWasif et. (2011)  to study the  \nimpact of \nmeta stasectomy on \nsurvival in these \npatients. Prognostic factors  4229 patients with \nstage IV melanoma  \n \npatients were \nsubdivided into \nM1a di sease \n(cutaneous \nmetastases) and \nMbc disease \n(visceral Median survival  \n \n5-year-survival  median survival of \nthe study \npopul ation: 7 \nmonths.  \n \nPatients who \nunderwent \nmeta stasectomy \n(33.6%) vs. \npatients without Those who had \nmeta stasectomy \nperformed were \ncompared with \npatients that did \nnot. 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 346 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nmetast ases). metastasectomy:  \nmedian OS: 12 \nmonths vs 5 \nmonths  \n5-yeas OS: 16% vs. \n7% (P < 0.001).  \n \nIn patients with \nM1a disease (n = \n1,994): m edian \nsurvival of 14 \nmonths vs. 6 \nmonths, 5 -year OS: \n20% vs. 9% (P < \n0.001).  \n \nYounger age and  \ndiagnosis from \n2001 to 2006 were \npredi ctors of \nmetastase ctomy. \nMetastase ctomy \nwas an \nindependent and \nsignif icant \npredictor of \nsurvival for the \nentire cohort (HR \n0.59, 95% CI 0.55 \u2013\n0.63).   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 347 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nEssner et al (2004)  to evaluate the \noutcome of \npatients with \nadvanced -stage \nmelanoma treated \nby surgical \nresection with \ncurative intent. Cohort study  \n 4426 patients \nstage IV \nmelanoma,  \n1574 (35%) \nunde rwent sur gical \nresection with \ncurative i ntent; \n 5-year-survival rate  \n \npredictive factors \non survival  5-year survival \nrate: patients who \nunderwent surg ical \nresection vs. \nnonsurgical \ntreatment: \nmean\u00b1SD, 23%\u00b12% \nvs. 6%\u00b15% \n(P<0.001)  \n \n5-year survival \nrate: \npatients with  a \nsolitary vs. >/=4 \nmeta stases: 29%\u00b1 \n2% vs. 11%\u00b13% \n(P<0.001)  \n \nmedian su rvival is \nslightly higher for \npatients with skin \nor subc utaneous \nsites (alone) than \nfor LN, GIT or lung \nsites, no \nsignificant \ndifferences in the \nestimated 5 -year \nsurvival rate \n(P=0.29)  \n retrospective study  \n \nNo information \nabout adjuvant \ntherapies  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 348 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \npredictive factors \non multivariate \nanalyses:  \n- earlier primary \ntumor stage (I vs \nII) (P<0.001)  \n- absence of \nintervening stage \nIII metastases \n(P=0.02) \n- solitary \nmetastasis \n(P<0.001)  \n- disease -free \ninterval >36 \nmonths from AJCC \nstage I or II to \nstage I V (P=0.005)  \nBrand et al. (1997 ) \n to identify \nimpo rtant \nprognostic factors \nassociated with \nStage IV \nmelanoma . Retrospective \nprognostic c ohort \nstudy  3258 melanoma  \npatients  \n \n442 melanoma \npatie nts with \ndistant metastases  Overall survival  \n \nPrognostic factors  median su rvival \ntime: 7 months  \n \n2-year, 5 -year, and \n10-year su rvival \nrates: 11.9%, 6.7%, \nand 4.7%, \nrespe ctively.  \n \nOf the modalities \nof the rapy given, \nonly surgery  was  2b \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 349 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nassoc iated with \nprolon ged su rvival \n(P< 0.0001)  \n \nFactors \nsignificantly \nrelated to short \nterm su rvival: \n- primary \nmetast asis to the \nskin (P = 0.006)  \n- - the brain (P = \n0.015)  \n- >1 meta static site \n(P = 0.002)  \n- Karnofsky \nperfo rmance \nstatus <80 (P = \n0.0035)  \n- subsequent >/=2 \nnew m etastatic \nsites (P = 0.0025)  \nTauceri et al \n(2009)  to agree on the  \nrole of surgery in \npatients with \nmetastatic \nmelanoma  cohort study  \n \n 84 consecutive \npatients ope rated \non for stage IV \nmelanoma  \n \n survival  \n \n1-, 3- and 5 -year-\nsurvival rate  \n \nMortality  \n \nmorbidity postoperative \nmortality: 0  \n \noverall morbidity: \n15%. \n \nminimal and \nmaximal survival: retrospective \ndesign \n \nbias: 90.5% \nunde rwent \nadjuvant the rapies  \n 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 350 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \n1.5 and 142.5 \nmonths, \nrespectively. \n \nmean OS: 56.7 \nmonths (1 year: \n72.1%, 3 years: \n46.5%, 5 years: \n23.16%).  \n \nsurvival of \nreitera tive surgery \nvs. single \nsurgery:62.7  vs \n42.4 months, \nmedian 50.9 vs \n16.0, p=0.03.  \n \nReiter ative \nsurgery was shown \nas an independent \nprognostic factor  \n(p<0.05).  \nOllila et al. (1999 ) To examine \nwhether a 2nd \nmetastasect omy \ncould prolong the \nsurvival of p atients  \nwith recurrent \nstage IV melanoma.  Retrospective \ncohort study  131 patients who \ndeveloped \nrecurrent stage IV \ndiseas  DFI to recurrence  \n \nSurvival \n \n5-year-survival  Median DFI: 8 \n(range 0.6 \u201391.8) \nmonths.  \n \nMedian survival:  \n18.2 months after \ncomplete Possibly \noverlapping \npopulation/ Ollila \net al. 1996  \n \n \n2 gynecologic 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 351 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nmeta stasectomy \nvs. 12.5 months or \n5.9 months after \npallia tive surgical  \nprocedure or \nnonsurgical \nmanag ement, \nrespectively.  \n \n5-year survival: \n20.0% after \ncomplete surgical \nmetastase ctomy \nvs. 7.0% and 2.1% \nafter \npalliative surgical \nand nonsurgical \nintervention, \nrespe ctively.  \n \nprognostic fa ctors \nfor survival:  \n- prolonged DFI \n(P=0,0001) \n- complete surgical \nmeta stasectomy  \n(P=0,0001) tumor sites \nincluded  \nGohl et al . (1996)  To examine the \nvalue of surgical \ntreatment of Cohort study  \n \n In 174 cases \nsurgery was \nperfomed, in 70 Survival  Median survival  \n- after R0 (curative \nsurgery): 13 Retrospective \ndesign \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 352 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \ndistant metastases \nof malignant \nmelanoma  patients with \ncurative intent. 15 \npatients with \noccult melanoma.  \n \n months  \n- R1/R2: 6 months.  \n- Patients without \ntreatment: 3 \nmonths  \n \nstatistically \nsignificant \ndifference in 1 -\nyear-survival for \npatients who \nunde rwent curative \nsurgery \nvs.palliative \nsurgery.  \n \n5-year-survival and \n10-year-survival \nafter curative \nsurgery: 24% and \n7% respe ctively  No information \nabout adjuvant \ntherapy \n \nStaging of patients \nnot described  \n \n \nKarakousis CP et \nal. (1994)  To evaluate \nsurgical trea tment \nduring the \nmanagement of \npatients with a \nsmall number  of \nresectable lesions \nin an effort to \nprolong their life  Cohort study  \n 114 with \ndisseminated \nmelanoma \namenable to \nsurgical resection  \n \n \n Survival  \n \nEstimated 5 -year-\nsurvival  \n \n5-year-survival rate  Median survival \nafter \nmetastasect omy: \n19 months  \n \nestimated 5 -year \nsurvival rate: 22%.  \n \n5-year su rvival rate Retrospective \ndesign \n \nbilateral nodal \nmetastasis or \nspread fro m one \ngroin  to the \ncontr alateral groin \nwas consi dered 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 353 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nfor those with:  \n-distant \nsubcutan eous \nmetast ases: 33% \n- distant LN \nmeta stases: 22% \n- pulmonary \nmeta stases: 74%  \n(P=0.72).  \n \n5-year survival rate \nfor : \n- combined group \nof s.c. and nodal \nmetast ases: 28% \n- pulm onary and \nvisceral sites: 17%  \n \nSignificant \nprognostic \nparam eters:  \n- thickness of the \nprimary mel anoma  \n(p=0.05)  \n- number of \nmetastatic lesions \n(p=0.03)  \n- prior di sease-free \ninterval (p=0.05) .  likely to be \nregional spread \nand these patients \nwere ex cluded  \n \n \n93% underwent \nchemotherapy, \n27% r adiotherapy, \n5% no further \ntherapy  \n \nOverett et al. To review Cohort study  176 patients who Survival  estimated 2 - and Retrospective 3b   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 354 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \n(1985)  clinic opathologic \nfactors that \ndetermine the \nsuccessful \nresection \nof tumor, survival, \nand quality of life   \n unde rwent surgical \nintervention for \ndistant metastases  \nof  \n \n  \n2- and 5 -year-\nsurvival -rate \n \nMortality  \n \nRelapse rate  5-year su rvival \nrate: 2 1 % and \n13%, r espectively  \n \nmedian su rvival \ntime: 8.5 months.  \n \nEstimated 2 -year \nand 5-year \nsurvival -rate after \ncomplete resection \nof single-site- vs. \nmultiple-site \nlesions: 47% and \n33% vs. 17% and \n9%, respectively (P \n< 0.01).  \n \nOperative morta lity \nRate: 1.4%  \n \nrelapse -rate: 66%  \n \nMedian interval to \nrelapse in case of \nincomplete vs. \ncomplete \nresection: 3 vs. 9 \nmonths (P = 0.07).  \n \n5-years survival design \n \nOld patient cohort \n(1965 -1979), \nquestionable \ntransferabil ity to \ncurrent situ ation \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 355 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nafter repeated \nresection: 20%  \n \nmedian su rvival in \ncase of repeated \nresection vs. \nincomplete \nresection  of new \ndisease: 26 vs. 8 \nmonths (P<0.0005) \nGarbe (1996)  to identify patients \nwith prolonged  \nsurvival in stage IV \ndisease and to  \nanalyse the \npossible impact of \ntherapy  \non the course of \nthe disease.  Retrospective \nreview \n \n 263 patients \nhaving stage IV \nmelanoma  \n \n111 patients: \nsurgery and/or \nradiation therapy. \n(17 surgery alone)  \n \n89 patients: \nsyste mic treatment  \n \n48 patients: both \nsystemic and local \ntherapy. \n \n111 patients: no \ntreatment.  Survival  22 patients treated \nwith multimodality \nsurvived > 24 \nmonths (me dian \nSurvival: 33 \nmonths)  \n \n16: both systemic \ntreatment and \nsurgery and/or \nradiation, 3: \nsystemic drug \ntherapy, 3:only \nlocal trea tment.  \n \n 12/22 pati ents \nbecame tumour  \nfree after initial \nsurgery or \nradiation. Confounder \nadjuvant the rapy 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 356 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \n \n2-year-survival for \npatients wit hout \ntreatment:0%  \nKarakousis et al. \n(1983 ) to identify, or \nconfirm, favorable \ncharacteri stics that \nmay improve \npalliation  Cohort study  79 consecutive \npatients with \nresectable, \nrecurrent \nmalignant \nmelanoma were \ntreated with \nsurgical exc ision \n \n Survival  \n \n significant survival \ndifference between \nStage IV su rvivors \n(36 months) and \nthose who \nmanifes ted disease \nprogre ssion (12 \nmonths) (P < 0.02).  \n \nCharacteristic of \nthose patients who \nremain diseas e \nfree: \n- initial presence \n</=3 m etastatic \nlesions  \n- long prior \ndisease-free \ninterval  Retrospective \ndesign \n \nSmall population  \n \nNo information \nabout staging  \n \nPoor information \nabout follow -up \n 3b- \nWornom et al. \n(1983) To examine the \nefficacy of surgery \nas palliative \ntreatment in 65 \npatients with \ndistant met astatic Cohort study  \n 65 patients with \ndistant metastatic \nmelanoma \namen able to \nsurgical  \n Survival  \n \nmorta lity overall operative \nmortality: 11%  \n \nRelief of symptoms \nafter excision of:  \n- 77% of brain Retrospective \ndesign \n \nMost patients \nreceived \nchemother apy 3b- \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 357 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nmelanoma \namenable to \nsurgical exc ision metastases,  \n- 100% of lung \nmetastases \n- 88% of di stant LN \nand s.c. \nmetast ases \n- 100% of \nabdom inal \nmetastases  \n \nMedian survival \nafter exc ision of:  \n- brain metast ases: \n8 months  \n-  lung m etastases: \n9 months  \n- abdominal \nmeta stases 8 \nmonths  \n- distant s.c., LN \nmeta stases: 15 \nmonths.  \n \nmedian survival of \npatients with  \n- combined \nvisceral and \nresected \nsuperficial \nmetast ases: 14 \nmonths, 5 -year  \nNo information \nabout staging  \n \nNo detailed \ninformation  about \npopulation   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 358 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \nsurvival: 0%  \n- resection of \nsuperficial \nmetastases \nand no detec table \nevidence of \nvisceral \nmetastasis: 17 \nmonths. 5 -year \nsurvival: 14%  \n \n2-year su rvival: \n29% for both \ngroups.  \nFeun et al. (198 2) To discuss the \nnatural hi story of \nStage IVA \nmelanoma  \nand the role of \nadjuvant therapy  Cohort study  \n \n 102 patients with \nmalignant \nmelan oma who \nhad di stant \nmetastases \nsurgica lly resected \nand were judged \nto be clinically free \nof disease  \n \n survival  \n \ndisease -free-\nsurvival  median survival: \n18 months.  \n \nsurvival d epending \non site of r esected \nmetastases:  \n- brain: 15 m onths  \n- lung: 16 months  \n- intraa bdominal \n18 m onths  \n- skin and/or LN \n23 months  \n \nDisease -free \ninterval not \ninfluenced by site  Retrospective \ndesign \n \n35 patients who \nhad surgery vs. 67 \npatients who \nreceived adj uvant \ntherapy  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 359 von 817 \nStudy  Aims  Design  Population  Outc omes  Results  Comments  LoE  \n \nSimilar survival of \npatients who had \nmetastases \nresected from \nseveral organs at \nthe same time and \npatients with one \nresected site  \n \ngroup treated with \nsurgery only vs. \nadjuvant group:  \nmedian disease -\nfree interval and \nsurvival:  \n6 and 16 months \nvs. 6 and 21 \nmonths, \nrespe ctively  \n \n4.4.4.  Literatur  \nAndrews S, Robinson L, Cantor A, et al. Survival after surgical resection of isolated pulmonary metast ases from malignant melanoma. Cancer Control 2006;13:218- 223 \nBerger AC, Buell JF, Venzon D, et al. Management of symptomatic malignant melanoma of the gastrointestinal tract. Ann Surg Oncol 1999;6:155- 160 \nBrand CU, Ellwanger U, Stroebel W, et al. Prolonged  survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer \n1997;79:2345- 2353  \nBranum GD, Epstein RE, Leight GS, et al. The role of resection in the management of melanoma metastatic to the adren al gland. Surgery 1991;109:127- 131 \nChua TC, Saxena A, Morris DL. Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases. Ann Acad Med Singapore 2010;39:634- 639 \nde Wilt JH, McCarthy WH, Thompson JF. Surgica l treatment of splenic metastases in patients with melanoma. J Am Coll Surg 2003;197:38- 43 \nDelaunay MM, Amici JM, Avril MF, et al. Surgery of pulmonary metastasis from malignant melanoma. Results and criteria of surgical excision]. Ann Dermatol Venereol 19 91;118:287- 295 \nEssner R, Lee JH, Wanek LA, et al. Contemporary surgical treatment of advanced -stage melanoma. Arch Surg 2004;139:961 -6; discussion 966- 7 \nFeun LG, Gutterman J, Burgess MA, et al. The natural history of resectable metastatic melanoma (Stage I VA melanoma). Cancer 1982;50:1656- 1663 \nGarbe C. Increased survival in distant melanoma metastasis and the effect of treatments. Analysis of the disease course of patients with a survival of 2 years or more]. Hautarzt \n1996;47:35- 43  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 360 von 817 \nGohl J, Meyer T, Haas C, et al. Is surgical therapy of distant metastases of malignant melanoma worthwhile?]. Langenbecks Arch Chir Suppl Kongressbd 1 996;113:122- 126 \nHarpole DH,Jr, Johnson CM, Wolfe WG, et al. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardio vasc Surg 1992;103:743 -8; discussion 748- 50 \nHodgson R, Fink MA, Jones RM. The role of abdominal resectional surgery in metastatic melanoma. ANZ J Surg 2007;77:855- 859 \nKarakousis CP, Moore R, Holyoke ED. Surgery in recurrent malignant melanoma. Cancer 1983; 52:1342- 1345 \nKarakousis CP, Velez A, Driscoll DL, et al. Metastasectomy in malignant melanoma. Surgery 1994;115:295- 302 \nKhadra MH, Thompson JF, Milton GW, et al. The justification for surgical treatment of metastatic melanoma of the gastrointestinal tract.  Surg Gynecol Obstet 1990;171:413- 416 \nLeo F, Cagini L, Rocmans P, et al. Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 2000;83:569 -572 \nMathisen DJ, Flye MW, Peabody J. The role of thoracotomy in the management of pulmonar y metastases from malignant melanoma. Ann Thorac Surg 1979;27:295- 299 \nMittendorf EA, Lim SJ, Schacherer CW, et al. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg 2008;195:363 -8; discussion 368- 9 \nNeuman HB, Patel A, Hanlon C , et al. Stage -IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol 2007;14:2847 -2853  \nOllila DW, Essner R, Wanek LA, et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 1996;131:975 -9; 979-80 \nOllila DW, Hsueh EC, Stern SL, et al. Metastasectomy for recurrent stage IV melanoma. J Surg Oncol 1999;71:209 -213 \nOverett TK, Shiu MH. Surgical treatment of distant metastatic melanoma. Indications and results. Cancer 1985;56:1222 -1230  \nPawlik TM, Z orzi D, Abdalla EK, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease.  Ann Surg Oncol \n2006;13:712- 720 \nPetersen RP, Hanish SI, Haney JC, et al. Improved survival with pulmonar y metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg \n2007;133:104- 110 \nPogrebniak HW, Stovroff M, Roth JA, et al. Resection of pulmonary metastases from malignant melanoma: results of a 16 -year experien ce. Ann Thorac Surg 1988;46:20- 23 \nRicaniadis N, Konstadoulakis MM, Walsh D, et al. Gastrointestinal metastases from malignant melanoma. Surg Oncol 1995;4:105- 110 \nSanki A, Scolyer RA, Thompson JF. Surgery for melanoma metastases of the gastrointestinal trac t: indications and results. Eur J Surg Oncol 2009;35:313- 319 \nSchuhan C, Muley T, Dienemann H, et al. Survival after pulmonary metastasectomy in patients with malignant melanoma. Thorac Cardiovasc Surg 2011;59:158 -162 \nSzynglarewicz B, Ekiert M, Forgacz J, e t al. The role of surgery in the treatment of colorectal metastases from primary skin melanoma. Colorectal Dis 2012  \nTauceri F, Mura G, Roseano M, et al. Surgery and adjuvant therapies in the treatment of stage IV melanoma: our experience in 84 patients. La ngenbecks Arch Surg 2009;394:1079- 1084  \nWasif N, Bagaria SP, Ray P, et al. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol  2011;104:111- 115 \nWornom IL,3rd, Smith JW, Soong SJ, et a l. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg 1986;204:181- 185 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 361 von 817 \n5. AG Adjuvante Therapie  \n5.1. Frage IV.1. A djuvante Chemotherapie -  Adaptation  \n5.1.1.  Synopse Quellleitlinien  \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE  2006  LL Frankreich  \nFrench National \nAuthority for Health \n2005   LL Kanada  \nCancer Care O ntario  \n2007  \nBeeinflusst eine \nadjuvante Chemo therapie \ndas Ge samt\u00fcberleben \nund/oder die rezidivfreie \nZeit von \nMelanompatien ten?  Nein  \n \nKein zytotoxisches \nMedikament hat ei ne \n\u00dcberle genheit gege n\u00fcber \nBeobachtung gezeigt  Nein  \n \nKeine Evidenz f\u00fcr \nadjuvante Chemotherapie \nnach erfol gter \nchirurgischer Therapie  Nein  \n \nDacarbazin verbessert \nnicht das \u00dcberleben in \nadjuvanter Situ ation  \n Nein  \n \nKeine Verbesserung des \nGesamt\u00fcberleben s durch \nadjuvante Chemotherapie  \n \nZugrunde li egende \nEvidenz  S. 93, keine Verkn\u00fcpfung \nmit zugrundeliegender \nEvidenz  \n Manual: S. 81, keine \nVerkn\u00fcpfung mit \nzugrundeli egender \nEvidenz Evidenz R eview: S. \n537 (\u201ekeine Rolle im \nadjuvan ten Setting\u201c) 10 \nStudien zit iert  Niveau A 5 randomisierte \nStudien wur den untersucht \n+ Bezug auf Cancer Care \nOntario 2002  \n Ergebnis aus 9 random. \nStudien  \n \n \nUpdate Recherche am 11.01.2011  \nSuchstrategie Medline: (melanoma[tiab] OR melanoma[MeSH]) AND (chemotherapy[tiab] OR vindesine [tiab] OR dacarbacine[tiab] AND \nadjuvant[tiab])  \nTreffer: 483, Auswahl: Eigentler et al. 2008, Retsas et al. 1994   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 362 von 817 \nLiteratur:  \n \nEigentler TK, Radny P, Hauschild A, et al. Adjuvant treatment with vindesine in comparison to observation alone in patients with m etastasized melanoma after complete \nmetastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Res 2008;18:35 3-358 \nRetsas S, Quigley M, Pectasides D, et al. Clinical and histologic involvement of regional  lymph nodes in malignant melanoma. Adjuvant vindesine improves survival. Cancer \n1994;73:2119- 2130  \n5.1.2.  Empfehlung und Hintergrundstext franz\u00f6sische Quell Leitlinie  \nQuellleitlinie: Recommandations pour la Pratique Clinique : Standards, Options et Recommandation s 2005 \nOriginaltext (Evidenztabellen und Text siehe Quell LL ab S.39)  \u00dcbersetzung  \nDESCRIPTION DES \u00c9TUDES  \nAu total, 5 essais randomis\u00e9s ont \u00e9t\u00e9 retenus pour l\u2019analyse critique. Aucun nouvel essai \nrandomis\u00e9 n\u2019a \u00e9t\u00e9 retrouv\u00e9 dans le cadre de la mise \u00e0 jour 2 005. Deux essais ont compar\u00e9 \nl\u2019administration de dacarbazine versus observation *114, 130+, un essai a compar\u00e9 la \ndacarbazine versus placebo [127] et 1 essai a \u00e9valu\u00e9 l\u2019association de dacarbazine \u00e0 d\u2019autres \nsubstances versus observ ation *131+. Un seul essa i a \u00e9tudi\u00e9 le m\u00e9thyl -CCNU [116]. Le CCOPGI a \nr\u00e9vis\u00e9 en 2002 la synth\u00e8se m\u00e9thodique avec analyse quantitative initialement pu bli\u00e9e en 1997 \n[12].  \n \nSURVIE GLOBALE  \nAucune des 4 \u00e9tudes qui ont \u00e9valu\u00e9 la dacarbazine (DITC) n\u2019a rapport\u00e9 de diff\u00e9rence \nsignificative en termes de su rvie globale [114, 117, 127, 130, 131]. L\u2019analyse pool\u00e9e des \ndonn\u00e9es r\u00e9alis\u00e9e par le CCOPGI sur 7 essais randomis\u00e9s n\u2019a pas retrouv\u00e9 de diff\u00e9rence \nsignific ative sur la survie globale \u00e0 3 ans (odd ratio = 1,03 [IC95 : 0,74 -1,43] [12]. L\u2019\u00e9t ude de \nFisher et al. qui a compar\u00e9 m\u00e9thyl -CCNU versus observation n\u2019a pas retrouv\u00e9 de diff\u00e9rence \nsignificative entre les deux bras compar\u00e9s [116].  \n \n \nCOMMENTAIRES M\u00c9THODOLOGIQUES ET CLINIQUES  \nLa dacarbazine est la mol\u00e9cule qui a \u00e9t\u00e9 la plus \u00e9tudi\u00e9e, seule o u association avec le BCG. Un \nseul essai randomis\u00e9 a \u00e9t udi\u00e9 \u2019efficacit\u00e9 du m\u00e9thyl -CCNU sur une population de 136 patients, \nce qui limite la port\u00e9e des conclusions qui pourront \u00eatre \u00e9tablies concernant cette mol\u00e9cule.  \n \nCONCLUSIONS DE LA LITT\u00c9RATURE  \nLa dacar bazine en situation adjuvante n\u2019am\u00e9liore pas la survie des patients porteurs d\u2019un \nm\u00e9lanome cutan\u00e9 op\u00e9r\u00e9 (niveau de preuve A). Les donn\u00e9es dispo -nibles sont insuffisantes pour \nconclure sur le b\u00e9n\u00e9fice/risque du methyl - CCNU en situation adjuvante chez les p atients \nporteurs d\u2019un m\u00e9l anome cutan\u00e9.  \n \nStandards, Options et Recommandations  \nLes traitements adjuvants syst\u00e9miques \u00e0 base de levamisole, BCG ou dacarbazine ne sont pas \nrecommand\u00e9s en dehors d\u2019essais th\u00e9rapeutiques.  Beschreibung der Studien  \nInsgesamt wurd en 5 randomisierte Studien f\u00fcr eine kritische Analyse ausg ew\u00e4hlt. Im Rahmen \ndes Update 2005 wurde keine neue randomisierte Studie gefunden. Zwei Studien haben \nDacarbazin versus Beobachtung verglichen [114,130], eine Studie hat Dacarbazin gegen \nPlacebo verg lichen [127] und 1 Studie hat Dacarbazin in Kombination mit anderen Substanzen \nversus B eobachtung evaluiert. [131] Nur eine Studie untersuchte Methyl -CCNU [116]. Die \nCCOPGI hat 2002 ein systematisches Review von 1997mit Metaanalyse \u00fcberarbeitet [12].  \n \n \nGesamt\u00fcberleben  \nKeine der 4 Studien, die Dacarbazin untersucht haben, haben einen signifika nten Unterschied in \nBezug auf das Gesamt\u00fcberleben gezeigt [114, 117, 127, 130, 131]. Die gepoolte Analyse der \nDaten, die durch die CCOPGI aus 7 randomisierten Studien d urchgef\u00fchrt wurde, fand keinen \nsignifikanten Unte rschied bezogen auf das Gesamt\u00fcberleben nach 3 Jahren (odds ratio = 1,03 \n[IC95 : 0,74- 1,43] [12 ]. Die Studie von Fisher et al. , die Methyl -CCNU ve rsus Beobachtung \nverglichen hat, fand keinen signifikanten Unt erschied zw ischen den Vergleichsarmen [116].  \n \n \nMethodologische und Klinische Kommentare  \nDacarbazin ist die am meisten untersuchte Substanz, allein oder zusammen mit BCG. Nur eine \nrandomisierte Sudie \u00fcberpr\u00fcfte die Wirksamkeit von M ethyl-CCNU an einer Popul ation von 136 \nPatienten, dies beschr\u00e4nkt die Auss agekraft dieser Substanz.  \n \nSchlussfolgerungen aus der Literatur  \nDacarbazin verbessert nicht das \u00dcberleben von Patienten mit operiertem k utanem Melanom in \nadjuvanter Situation (Level A). Die Daten f\u00fcr Methyl -CCNU sind insuffizient um \u00fcber \nBenefit/Risiko in adjuvanter Situation bei P atienten mit kutanem Melanom zu entscheiden.  \n \n \nStandard, Optionen und Empfehlungen \nEine adjuvante systemische Therapie mit Levamisole, BCG oder Dacarbazin wird ausserhalb von \nTherap iestudien nicht empfohlen.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 363 von 817 \n \nLiteratur:  \n \n12.CCOPGI, (Cancer Care Ontario Practice Guidelines Initiative). Systemic adjuvant therapy for patients at high risk for recu rrent melanoma. Practice Guideline Report No 8 -1 [online]. \n2002. Available: URL: http://w ww.cancercare.on.ca/index_practiceGuidelinesandEvidencesum maries.htm#list \n131. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with  a poor prognosis or melanoma metastases. \nCan Med A ssoc J 1983;128:929- 933 \n116. Fisher RI, Terry WD, Hodes RJ, et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of th e National Cancer Institute randomized clinical \ntrial. Surg Clin North Am 1981;61:1267- 1277  \n130. Hill GJ,2nd, Moss SE, Golomb FM, et al. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study C OG PROTOCOL 7040. Cancer 1981;47:2556-\n2562 \n127. Lejeune F, Macher E, Kleeberg UR, Rumke P, Prade M, Thomas D, et al. An asses sment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after \nremoval of a primary melanoma of the skin: a phase III adjuvant study (EORTC protocol 18761). Eur J Cancer 1988;24:S81- 90.  \n114. Veronesi U, Adamus J, Aubert C, et al . A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913- 916 \n \n \n5.1.3.  Empfehlung und Hintergrundstext kanadische  Quell Leitlinie  \nQuellleitlinie : Systemic Adjuvant Therapy for Patients at High Risk for Recurr ent Melanoma: Updated Guideline Recommend ations \n(Cancer Care Ontario) 2009  \nKEY EVIDENCE  Chemotherapy  \nData from randomized controlled trials do not suggest an improvement in OS with adjuvant chemotherapy alone for p atients with resected \nhigh-risk melanoma  (10 trials).  \nOUTCOMES  Chemotherapy  \nTen trials of chemotherapy are summarized in Table 9 (33,41,45 -52). None of the trials were limited to high -risk patients. Two trials compared \ndacarbazine with observation (45,46), one compared dacarbazine with placebo  (33), and five trials evaluated dacarbazine in combination with \nother agents (including immunomodulatory agents such as BCG) that are not commonly used at present, against observation alone  (47-51). \nThere was also a trial of methyl lomustine (methyl- CCNU)  versus control (41) and a trial of carmustine (BCNU) combined with actinomycin -D and \nvincristine versus control (52). In the largest study of chemoth erapy (46), 47% of patients treated with dacarbazine were alive after three years \ncompared with 42% of con trol (p=0.64). Only the study by Hansson et al (49) reported a statistically significant survival benefit for patients who \nreceived chemotherapy as adjuvant treatment (p<0.025). That was the smallest of the chem otherapy trials, with only 26 patients random ized to \nthree treatment groups. Data from the two active -treatment arms (da -carbazine alone and dacarbazine in combination with CCNU and \nvincristine) were co mbined and compared with results for nine patients in the control group, but that trial is far too small to permit any \nconclusions. Three -year mortality rates, from the text or from survival curves in the published reports from seven studies, were pooled and are \npresented in Figure 3. Three studies were not included in the meta -analysis because the numb er of deaths at three years could not be  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 364 von 817 \nascertained (45,51) or because no survival data were r eported (47). The mortality risk ratio from the pooled analysis (0.94; 95% CI, 0.84 to \n1.06; p=0.3) does not demonstrate any difference between chemotherapy and control. No heterogeneity was found among the results from \nthese st udies (p=0.52). Because response rates to chemotherapy in advanced disease have been unsatisfactory, there is no current inter est in \npursuing chemotherapy alone in the adjuvant setting.  \nLiteratur:  \n48. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with  a poor prognosis or melanoma metastases. \nCan Med Assoc J 1983;128:929- 933 \n41. Fisher RI, Terry WD, Hodes RJ, et al. A djuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical \ntrial. Surg Clin North Am 1981;61:1267- 1277  \n49. Hansson J, Ringborg U, Lagerlof B, et al. Adjuvant chemotherapy of maligna nt melanoma. A pilot study. Am J Clin Oncol 1985;8:47- 50 \n45. Hill GJ,2nd, Moss SE, Golomb FM, et al. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant St udy COG PROTOCOL 7040. Cancer 1981;47:2556-\n2562 \n47. Jacquillat C, Banz et P, Maral J. Clinical trials of chemotherapy and chemoimmunotherapy in primary malignant melanoma. Recent Results Cancer Re s 1982;80:254- 258 \n52. Karakousis C, Blumenson L. Adjuvant chemotherapy with a nitrosourea- based protocol in advanced malignant mela noma. Eur J Cancer 1993;29A:1831- 1835  \n50. Karakousis CP, Emrich LJ. Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG. J Surg Oncol 1987;36:235 -238 \n33. Lejeune FJ, Macher E, Kleeberg U, Rumke P, Prade M, Thomas D, et al. An assessment of  DTIC versus levamisole or placebo in the treatment of high risk stage I patients after \nsurgical removal of a primary melanoma of the skin. Eur J Cancer Clin Oncol. 1988;24 Suppl 2:S81 -S90.  \n46. Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913- 916 \n \n5.2. Frage IV.2. Adjuvante Vak zinierung \u2013 Adaptation  \n5.2.1.  Synopse Quellleitlinien  \n LL Australien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench Na tional Authority \nfor Health 2005  LL Kanada  \nCancer Care Ontario 2007  \nBeeinflusst eine adjuvante \nVakzinationstherapie das \nGesamt\u00fcberleben und/oder \ndie rezidivfreie Zeit von \nMelanompatienten?  \n Nein \n \nKeine \u00dcberlegenheit von \nVakzinierungen gegen\u00fcber \nBeobachtu ng \n \n Nein \n \nVerwendung von Impfstoffen \nist experimentell  \n \n Nein \n \nAucun des proc\u00e9d\u00e9s de \nvaccination utilis\u00e9s jusqu\u2019\u00e0 ce \njour \nn\u2019a mis en \u00e9vidence une \ndiff\u00e9rence significative sur la \nsurvie  Nein \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 365 von 817 \n LL Australien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench Na tional Authority \nfor Health 2005  LL Kanada  \nCancer Care Ontario 2007  \nsans r\u00e9cidive ou sur la survie \nglobale des patients atteints  \nd\u2019un m\u00e9la nome cutan\u00e9 \nr\u00e9s\u00e9qu\u00e9 avec ou sans \nenvahissement  \nganglionnaire et dont \nl\u2019\u00e9paisseur est sup\u00e9rieure \u00e0 \n1,5 mm  \n(niveau de preuve B1).  \nKeine Vakzinierung hat einen \nsignifikanten Unterschied \nzwischen rezidivfreiem \n\u00dcberleben oder \nGesamt\u00fcberleben zeigen \nk\u00f6nnen (Td > 1,5 N0 und N+)  \n \nNiveau BI  \nEntspricht in etwa Level of \nEvidence nach Oxford 1b  \n \nSchl\u00fcsselempfehlung  Zur Vakzinierung keine \nSchl\u00fcsselempfehlung  Zur Vakzinierung keine \nSchl\u00fcsselempfehlung  Les proc\u00e9d\u00e9s de vaccination \nne sont pas indiqu\u00e9s dans le  \ntraitement adjuvant des \npatients op\u00e9r\u00e9s d\u2019un \nm\u00e9lanome  \ncutan\u00e9 en dehors d\u2019essais \nth\u00e9rapeutiques.  \nRecommandation: Option  Zur Vakzinierung keine \nSchl\u00fcsselempfehlung   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 366 von 817 \n LL Australien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench Na tional Authority \nfor Health 2005  LL Kanada  \nCancer Care Ontario 2007  \n \nVakzinierungstherapien sind \nals adjuvante Behandlung bei \nPatienten nach Operation \neines kutanen Melanoms \nausserhalb von klinischen \nStudien nicht indiziert. \nZugrunde liegende Evidenz  S. 93, keine Verkn\u00fcpfung mit \nzugrundeliegender Evidenz  Manual:  \nS. 81, keine Verkn\u00fcpfung mit \nzugrundeliegender Evidenz  \nEvidenz Review:  \nS.538, kein verbessertes OS, \nmanche zeigen verbessertes \nrezidivfreies \u00dcberleben, \nVakzinierung wichtiges \nForschungsfeld  \n7 Studien  Diskutiert werden Studien \nmit:BCG, GMK, Melanomzell -\nLysat (VMCL), Melanom \nOncolysat (VMO), allogenes \nMelanomvakzin, polyvalentes \nMelanomvakzin, GM2 -KLH, \nTIL 9 rand omisierte Studien \nwurden zusammengefasst \n(virales Oncolysat, \nGanglioside, polyvalentes \nVakzin, Melanomzell- Lysat, \n\u201ewhole -cell\u201cVakzin) aufgrund \nder Heterogenit\u00e4t der Studien \nwurden die Daten nicht \ngepoolt. Keine Studie konnte \nein verbessertes \u00dcberleben \nzeigen. \nEine Subgruppenanalyse \nSWOG 9035 zeigte einen \n\u00dcberlebensbenefit f\u00fcr HLA -A2 \nund/oder HLA -C3 positive \nPatienten der Vakzin -Gruppe, \ndazu wurde jedoch keine \nklinische Empfehlung \nabgeleitet  \nIm Update 10 Studien: \nEORTC18961, signifikant  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 367 von 817 \n LL Australien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench Na tional Authority \nfor Health 2005  LL Kanada  \nCancer Care Ontario 2007  \nschlechteres \nGesamt\u00fc berleben f\u00fcr GM2 -\nKLH21 Arm  \n \n5.2.2.  Empfehlung und Hintergrundstext franz\u00f6sische Quell Leitlinie  \nQuellleitlinie : Recommandations pour la Pratique Clinique : Standards, Options et Recommandations 2005  \nOriginaltext (Evidenztabellen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \nVACCINATION  \n \nBCG th\u00e9rapie \n\u2022 Description des \u00e9tudes  \nDeux essais randomis\u00e9s ont \u00e9t\u00e9 retenus et ont compare l\u2019administration de \nBCG versus observation d\u2019une part, et BCG versus l\u2019association BCG et \ndacarbazine (Tableau XV) [114, 115]. L\u2019\u00e9tude de L\u2019OMS a concern\u00e9 761 \npatients randomis\u00e9s en 4 bras (observation versus BCG seul versus \ndacarbazine seule versus association BCG et dacarbazine) [114] L\u2019\u00e9tude de  \nAgarwala et al. pr\u00e9sente les r\u00e9sultats \u00e0 long terme d\u2019un essai sur 734 patients \nmen\u00e9 entre 1974  et 1978 [115]. Les patients ont \u00e9t\u00e9 randomis\u00e9s selon 4 bras \nconstituant 2 cohortes. La premi\u00e8re cohorte a compar\u00e9 BCG versus \nobserv ation et la seconde BCG et dacarbazine versus BCG seul.  \n\u2022 Survie globale  \nAucun des 2 essais n\u2019a mis en \u00e9vidence une diff\u00e9rence significative en termes \nde survie globale dans les diff\u00e9rents bras compar\u00e9s [114, 115]. Dans une \nanalyse en sous -groupe, l\u2019\u00e9tude de l\u2019OMS a observe une diff\u00e9rence Vakzinierung  \n \nBCG Therapie  \n\u2022Beschreibung der Studien  \nZwei randomisierte Studien wurden ausgew\u00e4hlt und haben die Gabe von BCG \nversus Beobachtung einerseits und BCG versus gemeinsame Gabe von BCG \nund Dacarbazin verglichen (Tab. XV) [114, 115]. Die Stud ie der WHO betraf \n761 randomisierte Patienten in 4 Armen (Beobachtung versus BCG allein \nversus DTIC allein versus BCG plus DTIC) [114]. Die Studie von Agarwala et al. \npr\u00e4sentierte die Langzeitergebnisse einer Studie an 734 Patienten, die \nzwischen 1974 und 1978 durchgef\u00fchrt wurde [115]. Die Patienten wurden in \n4 Arme randomisiert die Teil zweier Kohorten waren. Die erste Kohorte \nverglich BCG versus Beobac htung, die zweite BCG plus DTIC versus BCG \nallein. \n\u2022Gesamt\u00fcberleben  \nKeine der zwei Studien hat einen sign ifikanten Unterschied in Bezug auf das \nGesamt\u00fcberleben in den Vergleichsarmen gezeigt[114, 115].  In einer  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 368 von 817 \nOriginaltext (Evidenztabellen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \nsignificative sur la survie globale en faveur du traitement par BCG pour les \npatients pr\u00e9sentant 2 \u00e0 3 ganglions envahis (45 % versus 31,7 % \u00e0 3 ans ; p = \n0,01).  \n\u2022 Survie sans r\u00e9cidive  \nAucun des 3 essais n\u2019a mis en \u00e9vidence une diff\u00e9rence significative en termes \nde survie globale dans les diff\u00e9rents bras compar\u00e9s [114 -116].  \n\u2022 Toxicit\u00e9  \nLes r\u00e9sul tats de toxicit\u00e9 ont \u00e9t\u00e9 rapport\u00e9s dans les 2 \u00e9tudes [114, 115], mais \nseule l\u2019\u00e9tude de Agarwala et al. a pr\u00e9sent\u00e9 des r\u00e9sultats d\u00e9taill\u00e9s. Aucune \ntoxicit\u00e9 l\u00e9tale n\u2019a \u00e9t\u00e9 ra pport\u00e9e. Des ad\u00e9nopathies r\u00e9gionales et des r\u00e9actions \nsyst\u00e9miques corr\u00e9l\u00e9es au trait ement par le BCG ont \u00e9t\u00e9 observ\u00e9es dans 10 \u00e0 \n13 % des cas [115].  \n\u2022 Commentaires cliniques et m\u00e9thodologiques  \nLes r\u00e9sultats de l\u2019analyse en sous- groupes r\u00e9alis\u00e9e dans l\u2019\u00e9tude de l\u2019OMS sont \nm\u00e9thodologiquement tr\u00e8s critiquables [114]. D\u2019une part, l\u2019analyse en  sous-\ngroupe n\u2019\u00e9tait pas pr\u00e9vue initialement dans le protocole et, d\u2019autre part, \nl\u2019existence de ce r\u00e9sultat isol\u00e9 n\u2019a pas de coh\u00e9rence clinique, puisque la \ndifference de survie n\u2019est significative que pour le sous -groupe de patients \navec 2 ou 3 ganglions e nvahis, ce qui rend ces r\u00e9sultats difficilement \ninterpr\u00e9tables. \nVaccins m\u00e9laniques  \n\u2022 Description des \u00e9tudes  \nQuatre essais randomis\u00e9s sont disponibles :  \n\u2013 2 essais ont compar\u00e9 un vaccin m\u00e9lanique versus observation [117 -119] \n(Tableau XVI),  \n\u2013 2 essais ont co mpar\u00e9 l\u2019administration d\u2019un vaccin m\u00e9lanique versus placebo \n[120-122] (Tableau XVII).  \nAu total, 1 677 patients ont \u00e9t\u00e9 randomis\u00e9s dont 1 230 \u00e9valuables. Aucune \ndes 4 \u00e9tudes n\u2019a inclus de patients porteurs d\u2019un m\u00e9lanome dont l\u2019\u00e9paisseur \n\u00e9tait inf\u00e9rieure \u00e0 1 ,5 mm. Les interventions \u00e9valu\u00e9es dans les 4 essais \nrandomis\u00e9s ont \u00e9t\u00e9 :  Subgruppenanalyse fand sich in der Studie der WHO einen signifikanten \nUnterschied f\u00fcr das G esamt\u00fcberleben zugunsten einer Behandlung mit BCG \nf\u00fcr Pati enten mit 2 -3 positiven Lymphknoten. (45 % versus 31,7 % nach 3 \nJahren ; p = 0,01).  \n\u2022Rezidivfreies \u00dcberleben  \nKeine der drei Studie zeigte einen signifikanten Unterschied in Bezug auf das \nGesamt\u00fcberleben in den unterschiedlichen Vergleichsarmen [114 -116].  \n\u2022Toxizit\u00e4t  \nErgebnisse zur Toxizit\u00e4t wurden in beiden Studien berichtet [114, 115], aber \nnur die Studie von Agarwala et al. pr\u00e4sentiere detaillierte Ergebnisse. Keine \nletale Toxizit\u00e4t wurde berichtet. Regionale Adenopathien und \nSystemreakti onen wurden korell ierten in 10 bis 13% mit einer Behandlung mit \nBCG [115].  \n\u2022Klinische und Methodische Kommentare  \nDie Ergebnisse der Subgruppenanalyse die in der Studie der WHO \ndurchg ef\u00fchrt wurde sind methodisch sehr kritisierbar [114]. Zum einen war \ndie Su bgruppenanalyse ur spr\u00fcnglich nicht im Protokoll vorgesehen und, zum \nanderen hat dieses isolierte Ergebnis keinen klinischen Zusammenhang, da \nder Unte rschied im \u00dcberleben nur f\u00fcr die Subgruppe mit 2 oder 3 positiven \nLymphkn oten signifikant war, wodurch diese Ergebnisse schwi erig zu \ninterpretieren sind. \nMelanom Impfstoffe  \n\u2022Beschreibung der Studien  \nVier randomisierte Studien stehen zur Verf\u00fcgung:  \n-Zwei Studien haben einen Melanom Impfstoff versus Beobachtung verglichen \nobservation [117 -119] (Tab. XVI),  \n-Zwei Studien haben die G abe eines Melanom Impfstoffes versus Placebo \nverglichen [120 -122] (Tab. XVII).  \nInsgesamt wurden 1 677 Patienten randomisiert, von denen 1 230 auswertbar \nwaren. Keine der vier Studien hat Melanompatienten mit einer Tumordicke \nvon weniger als 1,5mm eingeschl ossen. Die untersuchten Interventionen in  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 369 von 817 \nOriginaltext (Evidenztabellen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \n\u2013 lysat cellulaire de vaccin m\u00e9lanique (VMCL) [117],  \n\u2013 lysat de cellules tumorales irradi\u00e9es (Melacine\u00ae) provenant de deux lign\u00e9es \nallog\u00e9niques + un adjuvant [118, 119],  \n\u2013 vaccin issu  de quatre lign\u00e9es allog\u00e9niques + virus de la variole att\u00e9nu\u00e9 [120, \n121],  \n\u2013 vaccin issu de trois lign\u00e9es allog\u00e9niques et une lign\u00e9e x\u00e9nog\u00e9nique + un \nadjuvant (aluminium) [122] \n \n \n \n\u2022 Survie globale  \nTrois des 4 essais randomis\u00e9s disponibles ont \u00e9valu\u00e9 l\u2019impac t sur la survie \nd\u2019un vaccin m\u00e9lanique versus placebo ou observation [117, 120 -122]. La \nsurvie globale \u00e9tait le crit\u00e8re de jugement secondaire pour ces \u00e9tudes. \nAucune difference de survie globale n\u2019a \u00e9t\u00e9 mise en \u00e9vidence apr\u00e8s un suivi \nm\u00e9dian variable selon  les \u00e9tudes compris entre 2,5 ans et 8 ans. Dans le \nquatri\u00e8me essai, le suivi n\u2019a pas \u00e9t\u00e9 suffisant pour permettre l\u2019analyse de la \nsurvie gl obale [118, 119].  \n \n\u2022 Survie sans r\u00e9cidive  \nLes 4 essais randomis\u00e9s disponibles ont \u00e9valu\u00e9 l\u2019impact sur la survie san s \nrechute d\u2019un vaccin m\u00e9lanique versus placebo ou observation. La survie sans \nrechute \u00e9tait le crit\u00e8re de jugement principal pour 3 \u00e9tudes ; le crit\u00e8re de \njugement principal n\u2019\u00e9tait pas pr\u00e9cis\u00e9 pour la quatri\u00e8me \u00e9tude. Aucune \ndifference significative de su rvie sans rechute n\u2019a \u00e9t\u00e9 r etrouv\u00e9e. Des analyses \nen sous -groupes ont \u00e9t\u00e9 propos\u00e9es dans certaines \u00e9tudes. L\u2019\u00e9tude SOGT -\n9035 a notamment \u00e9valu\u00e9 l\u2019interaction entre antig\u00e8nes HLA et la survie sans \nr\u00e9cidive [119]. La survie sans r\u00e9cidive a \u00e9t\u00e9 augment\u00e9e dans  le groupe vaccin \nchez les patients qui exprimaient 2 ou plus de 5 antig\u00e8nes de classe I (97 \npatients trait\u00e9s par vaccin versus 78 patients dans le groupe observation ; p = \n0,0002). Avec les antig\u00e8nes HLA A2 et C3, la survie sans rechute a \u00e9t\u00e9 de 77 den vier randomisierten Studien waren:  \nZelllysat Impfstoff (VMCL) [117]  \nLysat aus bestrahlten Tumorzellen (Melacine\u00ae) aus zwei allogenen L inien plus \nein Adjuvant [118, 119],  \nImpfstoff aus vier allogenen Linien plus  abgeschw\u00e4chtes Varizellen V irus \n[120,121],  \nImpfstoff aus drei allogenen Linien und einer xenogenen Linie plus ein \nAdjuvant (Aluminium) [122]  \n \n\u2022Gesamt\u00fcberleben  \nDrei der vier randomisierten verf\u00fcgbaren Studien haben den Einfluss auf das \n\u00dcberleben eines Mela nom Impfstoffes versus Placebo oder Beobachtung \nuntersucht [117, 120 -122]. Das Gesamt\u00fcberleben war der sekund\u00e4re \nEndpunkt dieser Studien. Einen Unterschied im Gesamt\u00fcberleben konnte in \nkeiner der Studien nachgewiesen werden, die ein medianes Follow up \nzwischen 2,5 und 8 Jahren hatten. In der vierten Studie war das Follow up f\u00fcr \neine Analyse des Gesamt\u00fcberlebens nicht ausreichend. [118, 119].  \n \n\u2022Rezidivfreies \u00dcberleben  \nDie vier verf\u00fcgbaren randomisierten Studien haben den Einfluss auf das \nrezidivfreie \u00dcberleb en eines Melanom Impfstoffes versus Placobo oder \nBeobac htung untersucht. Das rezidivfreie \u00dcberleben war der prim\u00e4re \nEndpunkt in Drei Studien, f\u00fcr die vierte Studie war der prim\u00e4re Endpunkt nicht \nklar. Es wurde kein signifikanter Unterschied im rezidivfreie n \u00dcberleben \ngefunden. In einigen Studien wurden Subgruppenanalysen vorgeschlagen. Die \nStudie SOGT -9035 beinhaltet eine Untersuchung der Interaktion zwischem \nHLA Ant igenen und rezidivfreiem \u00dcberleben [119]. Ein verl\u00e4ngertes \nrezidivfreies \u00dcbe rleben wurde in der Impfstoff Gruppe unter den Patienten die \n2 oder mehr als 5 Antigene der Klasse I exprimierten, beobachtet (97 mit \nImpfstoff behande lte Patienten versus 78 Patienten im Beobachtungsarm; p = \n0,0002). Mit den Antigenen HLA A2 und C3 war das rezidivfreie \u00dc berleben  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 370 von 817 \nOriginaltext (Evidenztabellen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \n% dans  le groupe vaccin versus 64 % dans le groupe observation (p = 0,004).  \n \n \n\u2022 Toxicit\u00e9  \nLa toxicit\u00e9 a \u00e9t\u00e9 \u00e9valu\u00e9e dans les 4 \u00e9tudes [117, 118, 121, 122]. Les donn\u00e9es \nde toxicit\u00e9 sont clairement pr\u00e9sent\u00e9es dans 2 des 4 \u00e9tudes. Globalement, peu \nd\u2019effets ind\u00e9sirab les ont \u00e9t\u00e9 observ\u00e9s. Dans l\u2019\u00e9tude de Sondak et al., 9 % des \npatients ont pr\u00e9sent\u00e9 une toxicit\u00e9 de grade 3 (r\u00e9actions locales s\u00e9v\u00e8res, \nmalaises et fatigue, troubles visuels, fi\u00e8vre, diarrh\u00e9es, thrombop\u00e9nies et \n\u00e9ruptions cutan\u00e9es), 64 % ont pr\u00e9sent\u00e9 des tox icities de grade 2 et 23 % ont \npr\u00e9sent\u00e9 des toxicit\u00e9s de grade 1 [118]. L\u2019\u00e9quipe de Hersey et al. a \nessentiellement observ\u00e9 des toxicit\u00e9s de grade 2 (\u00e9ryth\u00e8mes et ulc\u00e9ration au \nsite d\u2019injection chez 47 % des patients ; lymphop\u00e9nie pour 33 % d\u2019entre eux) \net de grade 1 (malaises et fi\u00e8vre respectivement chez 35 % et 20 % des \npatients).  \n \n\u2022 Commentaires m\u00e9thodologiques et cliniques  \nToutes les \u00e9tudes ont r\u00e9alis\u00e9 les analyses en intention de traiter. Trois des 4 \n\u00e9tudes pr\u00e9sentent clairement le calcul du nombre de  patients a priori (sur la \nsurvie sans rechute) [117 -119, 122]. L\u2019\u00e9tude de Bystryn et al. a \u00e9t\u00e9 arr\u00eat\u00e9e \npr\u00e9matur\u00e9ment et n\u2019a port\u00e9 que sur 38 patients au lieu des 210 patients \ninitialement pr\u00e9vus. De ce fait, le suivi n\u2019a pas \u00e9t\u00e9 suffisant (inf\u00e9rieur \u00e0 2 a ns \npour la majorit\u00e9 des patients) et n\u2019a pas permis l\u2019analyse de la survie globale \n[122]. Pour 3 des 4 \u00e9tudes, les populations \u00e9tudi\u00e9es peuvent \u00eatre appl iqu\u00e9es \n\u00e0 la pratique courante [117 -119, 122]. En revanche, dans l\u2019\u00e9tude de Wallack \net al. la population  trait\u00e9e est un peu complexe et h\u00e9t\u00e9rog\u00e8ne par rapport \u00e0 \nla pratique courante bien que correspondant \u00e0 des types cliniques d\u00e9finis et \nreconnus par la classification AJCC. Toutes les variables pertinentes n\u2019ont pas \n\u00e9t\u00e9 prises en compte lors de la randomisat ion, puisque seul le nombre de \nganglions envahis a \u00e9t\u00e9 condid\u00e9r\u00e9 [120 -121].  \n 77% in der Impfstoff Gruppe veruss 64% im Beobachtungsarm (p = 0,004).  \n\u2022Toxizit\u00e4t  \nDie Toxizit\u00e4t wurde in allen vier Studien untersucht [117, 118, 121, 122]. \nDaten zur Toxizit\u00e4t sind in zwei der vier Studien klar dargestellt. Insgesamt \nwurden nur w enig Nebenwirkungen beobachtet. In der Studie von Sondak et \nal. zeigten 9% der Patienten eine Grad 3 Toxizit\u00e4t (schwere Lokalreaktion, \nUnwohlsein und Fatigue, visuelle Probleme, Fieber, Durchf\u00e4lle, \nThrombopenien und Hautausschl\u00e4ge), 64% zeigten eine Grad 2  Toxizit\u00e4t und \n23% eine Grad 1 Toxizit\u00e4t [118]. Das Team von Hersey et al. beobachtete im \nWesentlichen Grad 2 Toxizit\u00e4ten (Erytheme und Ulzerationen am \nInjektionsortbei 47% der Patienten; Lymph openie bei 33%) und Grad 1 \nToxizit\u00e4ten (Unwohlsein und Fieber b ei 35% und 20% der Patienten)  \n \n\u2022Klinische und Methodische Kommentare  \nAlle Studien haben eine Intent to treat (ITT) Analyse durchgef\u00fchrt. Drei der \nvier Studien pr\u00e4sentieren eine klare Fallzahlberechnung a priori f\u00fcr das \nrezidivfreie \u00dcberleben [117 -119, 122] . Die Studie von Bystryn et al. wurde \nvorze itig beendet und wurde nur an 38 statt der 210 urspr\u00fcnglich geplanten \nPatienten durchgef\u00fchrt. Aus diesem Grund war die Dauer der \nNachbeobac htung nicht ausreichend (weniger als 2 Jahre f\u00fcr die Mehrheit der \nPatiente n) und erlaubt keine Analyse des Gesamt\u00fcberlebens [122]. In drei der \nvier Stud ien wurden Populationen untersucht, die auf die derzeitige Praxis \n\u00fcbertragen werden k\u00f6nnen [117 -119, 122]. Demgegen\u00fcber ist die in der \nStudie von Wallack et al. behandelte Patien tenpopulation recht komplex und \nheterogen im Vergleicht zur derzeitigen Praxis obwohl die klinischen Stadien \ndurch die AJCC Klassifikation angegeben wurden. F\u00fcr die Randomisierung \nwurden nicht alle Variablen sondern nur die Anzahl der beteiligten \nLymphknot en ber\u00fcc ksichtigt wurde [120 -121].  \n \nIFN\u03b1 versus GMK \n\u2022Beschreibung der Studien   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 371 von 817 \nOriginaltext (Evidenztabellen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \n \nIFN alpha  versus GMK \n\u2022 Description des \u00e9tudes  \nUne seule \u00e9tude randomis\u00e9e est disponible [123] (Tableau XVIII) . Cette \u00e9tude \na compar\u00e9 l\u2019IFN  alpha 2b hautes doses versus vaccine GM K (ganglioside GM2 \nconjugu\u00e9 avec de l\u2019h\u00e9mocyanine (KLH) combin\u00e9e \u00e0 une mol\u00e9cule adjuvante \nQS-21). Cette \u00e9tude a port\u00e9 sur des patients atteints d\u2019un m\u00e9lanome de \nstades IIB ou III r\u00e9s\u00e9qu\u00e9s.  \n\u2022 Survie globale  \nLa survie globale a \u00e9t\u00e9 \u00e9valu\u00e9e apr\u00e8s un suivi m\u00e9d ian de 16 mois. Une \ndiff\u00e9rence statist iquement significative a \u00e9t\u00e9 mise en \u00e9vidence en faveur des \npatients trait\u00e9s par l\u2019IFN  alpha  2b. La survie globale \u00e0 2 ans a \u00e9t\u00e9 de 78 % \ndans le bras IFN \u03b12b versus 73 % dans le bras GMK (p = 0,035) [123].  \n\u2022 Survie sans r\u00e9cidive  \nLa survie sans r\u00e9cidive a \u00e9t\u00e9 \u00e9valu\u00e9e apr\u00e8s un suivi median de 16 mois. Une \ndiff\u00e9rence statistiquement significative a \u00e9t\u00e9 mise en \u00e9vidence en faveur des \npatients trait\u00e9s par l\u2019IFN  alpha  2b. La survie sans r\u00e9cidive \u00e0 2 ans a \u00e9t\u00e9 de 62 \n% dans le bras IFN  alpha 2b versus 49 % dans le bras GMK (p = 0,027) [123].  \n\u2022 Toxicit\u00e9  \nLes toxicit\u00e9s les plus fr\u00e9quemment observ\u00e9es dans le bras IFN  alpha 2b ont \n\u00e9t\u00e9 des toxicit\u00e9s de grade 3 de type fat igue, cytop\u00e9nies, \u00e9l\u00e9vation du taux \ndes e nzymes du foie et symptoms neurologiques. Quarante -cinq pour cent \ndes p atients traits par l\u2019IFN  alpha  2b ont arr\u00eat\u00e9 le traitement en raison des \neffets ind\u00e9s irables. Les toxicit\u00e9s ont \u00e9t\u00e9 globalement moins fr\u00e9quentes  dans \nle bras GMK. La toxicit\u00e9 la plus rapport\u00e9e chez les patients trait\u00e9s par GMK a \n\u00e9t\u00e9 une r\u00e9a ction locale au niveau du site d\u2019injection. Aucun d\u00e9c\u00e8s toxique n\u2019a \n\u00e9t\u00e9 ra pport\u00e9.  \n\u2022 Commentaires m\u00e9thodologiques et cliniques  \nLes analyses ont toutes \u00e9t\u00e9 r\u00e9alis \u00e9es en intention de traiter. Les auteurs se \nsont bas\u00e9s sur les r\u00e9sultats positifs de l\u2019\u00e9tude ECOG1684 pour d\u00e9finir le \nprotocole de leur essai d\u00e9finissant ainsi l\u2019interf\u00e9ron -alpha \u00e0 haute dose Eine einzige randomisierte Studie ist verf\u00fcgbar [123]. Diese Studie hat \nHochdosis IFN \u03b12b versus GMK Vakzin (Ganglioside GM2 konjugiert mit KLH \nkomb iniert mit einem adjuvanten Molek\u00fcl QS -21) verglichen. Diese Studie \nwurde an Melanom Patienten im resezierten Stadium IIB oder III durchgef\u00fchrt.  \n\u2022Gesamt\u00fcberleben  \nDas Gesamt\u00fcberleben wurde nach einer medianen Nachbeobachtung von 16 \nMonaten evaluiert. Ein statistisch signifikanter Un terschied wurde f\u00fcr die mit \nIFN alpha  2b behandelten Patienten gesehen. Das Gesamt\u00fcberleb en nach 2 \nJahren war 78% im IFN alpha 2b Arm versus 73% im GMK Arm (p = 0,035) \n[123].  \n\u2022 Rezidivfreies \u00dcberleben  \nDas rezidivfreie \u00dcberleben wurde nach einer medianen Nachbeo bachtung von \n16 Monaten evaluiert. Ein statistisch signifikanter Un terschied wurde f\u00fcr die \nmit IFN alpha  2b behandelten Patienten gesehen. Das rezidivfreie \u00dcberleben \nnach 2 Jahren war 62% im IFN\u03b1 2b Arm versus 49% im GMK Arm (p = 0,027) \n[123].  \n\u2022Toxizit\u00e4t  \nDie am h\u00e4ufigsten beobachteten Toxizit\u00e4ten im IFN alpha  2b Arm waren Grad \n3 Toxizit\u00e4ten vom Typ Fatigue, Zytopenie, Anstieg der Leberenzyme und \nneurologische Sym ptome. 45% der Patienten im IFN alpha 2b Arm haben die \nTherapie aufgrund von Nebenwirkungen gesto ppt. Die Nebenwirkungen \nwaren insg esamt weniger h\u00e4ufig im GMK Arm. Die am h\u00e4ufigsten berichtete \nNebenwi rkung im GMK Arm waren Lokalreaktionen am Injektionsort. Es \nwurde keine t\u00f6dliche Nebenwirkung berichtet. \n\u2022Klinische und Methodische Kommentare  \nAlle Analy sen wurden als Intent to treat Analyse durchgef\u00fchrt. Die Autoren \nhaben sich auf die positiven Ergebnisse der Studie ECO1684 gest\u00fctzt, um die \nHochdosis Interferon -alpha Therapie in ihrem Protokoll als Kontrollarm zu \ndefinieren [104], obwohl sich diese Ergeb nisse nachtr\u00e4glich nicht best\u00e4tigt \nhaben. Da dadurch ein echter Kontrollarm fehlt, ist es nicht m\u00f6glich g\u00fcltige \nSchlussfolgerungen zu ziehen. Die untersuchte Population ist gemischt (77%  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 372 von 817 \nOriginaltext (Evidenztabellen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \ncomme contr\u00f4le [104], bien que ces r\u00e9sultats n\u2019aient pas \u00e9t\u00e9 con firm\u00e9s par la \nsuite. De ce fait, l\u2019absence de vrai bras contr\u00f4le invalide consid\u00e9rablement les \nconclusions. La population \u00e9tudi\u00e9e est mixte (77 % de patients pr\u00e9sentaient \nun envahissement ganglionnaire) et la stadification NO (23 %) est h\u00e9t\u00e9rog\u00e8ne \n(45 % de s patients ont \u00e9t\u00e9 \u00e9valu\u00e9s cliniquement et 46 % ont eu une \u00e9valuation \nhistologique). L\u2019interpr\u00e9tation des r\u00e9sultats est donc rendue plus complexe, \npuisque dans les autres \u00e9tudes, la proportion de patients sans envahissement \nest g\u00e9n\u00e9ralement major itaire. Pa r ailleurs, le suivi m\u00e9dian n\u2019\u00e9tant que de 16 \nmois, l\u2019\u00e9valuation de la survie doit \u00eatre interpr\u00e9t\u00e9e avec pr\u00e9caution. \n \n \nTumor infiltrating lymphocytes (TIL)  \n\u2022 Description des \u00e9tudes  \nUne \u00e9tude est disponible [124, 125] (Tableau XIX) . Il s\u2019agitd\u2019une \u00e9tude \nprospective rand omis\u00e9e comparant un traitement par TIL+ IL -2 versus IL-2 \nseule chez 88 patients porteurs d\u2019un m\u00e9lanome de stade III (AJCC) apr\u00e8s \ncurage ganglionnaire. Le suivi m\u00e9dian a \u00e9t\u00e9 de 46,9 mois. \n\u2022 Survie globale, survie sans r\u00e9cidive  \nAucune diff\u00e9rence  significative en termes de survie globale et de survie sans \nr\u00e9cidive n\u2019a \u00e9t\u00e9 mise en \u00e9vidence entre les 2 groupes. N\u00e9anmoins, une \ndiff\u00e9rence significative a \u00e9t\u00e9 observ\u00e9e entre les deux bras de traitement dans \nun sous groupe de patients (avec un seul gangl ion envahi, mais pas de \npr\u00e9cision sur la rupture capsulaire), notamment sur la survie globale et le \ntaux de rechute.  \n\u2022 Toxicit\u00e9  \nGlobalement, le traitement par TIL a \u00e9t\u00e9 tr\u00e8s bien tol\u00e9r\u00e9. Aucune toxicit\u00e9 de \ngrades 3 ou 4 n\u2019a \u00e9t\u00e9 observ\u00e9e. Les principaux eff ets ind\u00e9sirables ont \u00e9t\u00e9 une \ninflammation au site  \nde l\u2019injection et une asth\u00e9nie. \n \n\u2022 Commentaires m\u00e9thodologiques et cliniques  der Patienten haben eine Lymphknotenbeteiligung) und die Stadieneinte ilung \nNO (23%) ist heterogen (45% der Patienten wurden klinisch klassifiziert und \n46% der Patienten wurden histologisch klassifiziert). Die Interpretation der \nErgebnisse ist daher komplex, da in anderen Studien die Mehrzahl der \nPatienten keine Lymphknotenb eteiligung hat. Da auch die \nNachbeobachtungszeit nur 16 Monate betrug, m\u00fcssen die \n\u00dcberlebenszeitanalysen mit Vorsicht i nterpretiert werden.  \n \nTumor infiltrating lymphocytes (TIL)  \n\u2022Beschreibung der Studien  \nEine Studie steht zur Verf\u00fcgung [124, 125]. Es ist e ine prospektive \nrandom isierte Studie die eine Therapie mit TIL+IL -2 versus IL -2 allein bei 88 \nMelanom Patienten im Stadium III (AJCC) nach einer Lymphknotenausr\u00e4umung \nvergleicht. Die mediane Nachbeobachtungszeit betrug 46,9 Monate. \n\u2022Gesamt\u00fcberleben, Rezidi vfreies \u00dcberleben  \nIn Bezug auf das Gesamt\u00fcberleben und das rezidivfreie \u00dcberleben wurde kein \nsignifikanter Unterschied zwischen den 2 Gruppen beobachtet. Dennoch \nwurde bei einer Subgruppe (bei Beteiligung nur eines Lymphknoten aber ohne \nAngaben zur Kapsel\u00fcberschreitung) zwischen den Behandlungsarmen ein \nsignifikanter Unterschied bezogen auf Gesamt - und rezifivfreies \u00dcberleben \ngesehen.  \n\u2022Toxizit\u00e4t  \nInsgesamt wurde die Behandlung mit TIL sehr gut toleriert. Keine Grad 3  \noder 4 Toxizit\u00e4ten wurden beobachtet. Di e haupts\u00e4chlichen Nebenwirkungen \nwaren Entz\u00fcndungen am Injektionsort und Asthenie.  \n \n\u2022Klinische und Methodische Kommentare  \nDie Methode der Randomisation wurde im Artikel nicht berichtet und das \nFehlen eines echten Kontrollarms machen es schwierig g\u00fcltige \nSchlussfolg erungen zu ziehen. Nachtr\u00e4glich durchgef\u00fchrte \nSubgruppenanalysen (die zum Zeitpunkt der Randomisierung nicht  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 373 von 817 \nOriginaltext (Evidenztabellen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \nLa m\u00e9thode de randomisation n\u2019est pas d\u00e9crite dans les articles et l\u2019absence \nde r\u00e9el bras contr\u00f4le limite consid\u00e9rablement la port\u00e9e des concl usions qui \npourront \u00eatre \u00e9tablies. Les analyses en sous -groupes conduites a posteriori \n(non pr\u00e9vues initialement lors de la randomisation) ne permettent pas \nd\u2019extrapoler des conclusions sur les crit\u00e8res de jugement. Il est \u00e9galement \nimportant de relever les contraintes techniques li\u00e9es \u00e0 ce proc\u00e9d\u00e9 dont le \nsucc\u00e8s est conditionn\u00e9, dans un premier temps, par la production de TIL chez \nles patients concern\u00e9s.  \n \nConclusions de la litt\u00e9rature \nAucun des proc\u00e9d\u00e9s de vaccination utilis\u00e9s jusqu\u2019\u00e0 ce jour n\u2019a mis en \n\u00e9vidence une diff\u00e9rence significative sur la survie sans r\u00e9cidive ou sur la \nsurvie globale des patients attaints d\u2019un m\u00e9lanome cutan\u00e9 r\u00e9s\u00e9qu\u00e9 avec ou \nsans env ahissement ganglionnaire et dont l\u2019\u00e9paisseur est sup\u00e9rieure \u00e0 1,5 \nmm (niveau de preuve B1). \n vorgesehen waren) machen Schlussfolg erungen aus den Ergebnissen nicht \nm\u00f6glich. Es ist auch wichtig die technischen Zw\u00e4nge zu bedenken, da in \neinem ersten Schritt die Produktion von TIL bei den betroffenen Patienten \nerfolgen muss.   \n \nSchlussfolgerung aus der Literatur  \nKeine der Impfverfahren die bis heute verwendet wurden haben einen \nsignif ikanten Unterschied f\u00fcr das Gesamt\u00fcberleben oder rezid ivfreie \n\u00fcberleben bei Patienten mit reseziertem Melanom, oder ohne \nLymphknotenbeteil igung und mit einer Tumordicke gr\u00f6sser als 1,5mm \nerbracht (niveau de preuve B1).  \nEntspricht in etwa Level of Evidence nach Oxford 1b  \n \n5.2.3.  Empfehlung und Hintergrundstext kanad ische Quell Leitlinie  \nQuellleitlinie : Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma: Updated Guideline Recommend ations \n(Cancer Care Ontario) 2009  \nNine randomized trials of vaccines are summarized in Table 8, one of a viral onc olysate ,  one of a ganglioside , one of \na polyvalent vaccine , one of vaccinia melanoma cell lysate , and five of whole -cell vaccines . Six RCTs compared \nvaccine with observation, while three trials were double -blind . Seven of the nine trials were confined to patients with \nnodal involvement, and the majority of patients in one of the other trials were node positive . None of the reported \ntrials have shown a statistically significant improvement in overall survival for patients treated with vaccines, an \nobservati on co nfirmed in a recent update of the SWOG 9035 trial . However, in that study, the subset analysis of \npatients who were positive for human leukemic antigen (HLA) -A2 and/or HLA- C3 demonstrated a significant five -year  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 374 von 817 \noverall survival benefit of 93% for vac cine patients compared with 74% for patients in the obse rvation group \n(p=0.009). This clearly hypothesis -generating observation cannot be used to direct clinical decisions. For obvious \nreasons attesting to heterogene ity of the studies and vaccines employed , we have elected not to pool those data in \nour analysis.  \nLiteratur:  \nLL Frankreich  French National Authority for Health 2005 ) \n115. Agarwala SS, Neuberg D, Park Y, et al. Mature results of a phase III randomized trial of bacillus Calmette -Guerin (BCG) versu s observation and BCG plus dacarbazine versus BCG in \nthe adjuvant therapy of American Joint Committee on Cancer Stage I -III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 2004;100:1692- 1698  \n122. Bystryn JC, Zeleniuch- Jacquotte A, Oratz R, et al. Double -blind trial of a polyvalent, shed -antigen, melanoma vaccine. Clin Cancer Res 2001;7:1882- 1887  \n124. Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor -infiltrating lymphocytes as adjuvant therapy for  stage III melanoma. Cancer \nImmunol Immunother 2002;51:539 -546 \n116. Fisher RI, Terry WD, Hodes RJ, et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of th e National Cancer Institute randomized clinical \ntrial. Surg Cli n North Am 1981;61:1267- 1277  \n117. Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high -risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J \nClin Oncol 2002;20:4181- 4190  \n123. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High -dose interferon alfa -2b significantly prolongs relapse -free and overall survival compared with the GM2 -KLH/QS -21 vaccine in \npatients with resected stage IIB -III melanoma: results of intergroup trial E1694/S9512/C509801. J  Clin Oncol 2001;19:2370- 2380  \n125. Labarriere N, Pandolfino MC, Gervois N, et al. Therapeutic efficacy of melanoma -reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 2002;51:532 -\n538 \n118. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate- thickness, node -negative melanoma with an allogeneic tumor vaccine: overall results of a \nrandomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058- 2066  \n119. Sosman JA, Unger JM, Liu PY, et al . Adjuvant immunotherapy of resected, intermediate- thickness, node -negative melanoma with an allogeneic tumor vaccine: impact of HLA class I \nantigen expression on outcome. J Clin Oncol 2002;20:2067- 2075  \n114. Veronesi U, Adamus J, Aubert C, et al. A randomi zed trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913- 916 \n120. Wallack MK, Sivanandham M, Ditaranto K, et al. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim  analysis of data from a phase \nIII, multi -institutional trial. Ann Surg 1997;226:198- 206 \n121. Wallack MK, Sivanandham M, Whooley B, et al. Favorable clinical responses in subsets of patients from a randomized, multi -institutional melanoma vaccine trial. An n Surg Oncol \n1996;3:110- 117 \n \nLL Kanada Cancer Care O ntario 2007  \nEggermont AM, Suciu S, Ruka W, Marsden J, Testori A, Corrie P. EORTC 18961: Post -operative adjuvant ganglioside GM2 -KLH21 vaccination treatment vs observation in stage II (T3 -\nT4N0M0) melanoma:  2nd interim analysis led to an early disclosure of the results. J Clin Oncol. 2008;26(May 20 suppl):9004.  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 375 von 817 \n5.3. Frage IV.3. Adjuvante Extremit\u00e4tenperfusion -  Adaptation  \n5.3.1.  Synopse Quellleitlinien  \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 20 06 LL Frankreich  \nFrench National Authority for \nHealth 2005  LL Kanada \nCancer Care O ntario \n2007  \nBeeinflusst eine adjuvante \nExtremit\u00e4tenperfusion das \nGesamt\u00fcberleben und/oder \ndie rezidivfreie Zeit von \nMelanompatienten?  Adjuvant regional drug \ntherapy improve s disease free \ninterval but does not improve \noverall survival  \nLevel II  \n - \n La perfusion de melphalan sur membre \nisol\u00e9 ne semble pas am\u00e9liorer la survie \nglobale des patients atteints d\u2019un \nm\u00e9lanome cutan\u00e9 Niveau de preuve C  \nEine adjuvante Extremit\u00e4tenperfusion \nmit Melphalan scheint das \nGesam t\u00fcberleben von \nMelanompatienten nicht zu verbes sern. \nNiveau C  - \nSchl\u00fcsselempfe hlung Prophylactic isolated limb \nperfusion (ILP) is not \nrecommen ded \nGrade A  - La perfusion de membre isol\u00e9 n\u2019est pas \nrecommand\u00e9e en dehors d\u2019essais \nth\u00e9rapeutiques et doit \u00eatre r\u00e9alis\u00e9e par \ndes \n\u00e9quipes e ntra\u00een\u00e9es.  \nRecommandation: Option  \nEine Extr emit\u00e4tenperfusion wird \nausserhalb klinischer St udien nicht \nempfohlen und soll durch erfahrene \nTeams durc hgef\u00fchrt werden.  - \nZugrunde li egende Evidenz  1 Studie  \nKoops, H.S. et al. 1998  \n - 2 Studien  \nKoops, H.S. et al. 1998  \nGhussen, F. et al. 1989  - \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 376 von 817 \n5.3.2.  Empfehlung und Hintergrundstext franz\u00f6sische Quell Leitlinie  \nQuellleitlinie: Recommandations pour la Pratique Clinique : Standards, Options et Recommandations 20 05 \nOriginaltext (Evidenztabelle und Text siehe Quell LL ab S.40)  \u00dcbersetzung  \nPerfusion de melphalan sur membre isol\u00e9  \n \nDESCRIPTION DES \u00c9TUDES  \nDeux \u00e9tudes randomis\u00e9es ont \u00e9tudi\u00e9 l\u2019effet d\u2019une perfusion sur membre isol\u00e9 \nde melphalan apr\u00e8s ex\u00e9r\u00e8se d\u2019un melano ma primitif isol\u00e9 [134, 135] (Tableau \nXXI). Les 2 essais ont \u00e9valu\u00e9 respectivement 107 et 832 patients dont \nl\u2019\u00e9paisseur de la tumeur \u00e9tait sup\u00e9rieure \u00e0 1,5 mm. Dans l\u2019\u00e9tude de Ghussen \net al. la perfusion de melphalan a \u00e9t\u00e9 associ\u00e9e \u00e0 une hyperthermie. \n \nSURVIE GLOBALE, SURVIE SANS R\u00c9CIDIVE  \nSeule une des deux \u00e9tudes randomis\u00e9es a montr\u00e9 un avantage en termes de \ncontr\u00f4le local et de survie globale en faveur du traitement sur membre isol\u00e9 \npar une association hyperthermie -melphalan apr\u00e8s ex\u00e9r\u00e8se d\u2019un melanoma \nprimitif isol\u00e9 [134]. L\u2019\u00e9tude de Koops et al. n\u2019a pas montr\u00e9 de diff\u00e9rence \nsignificative en termes de survie globale [135]. Une analyse en sous -groupe a \ncependant mis en \u00e9vidence une survie sans r\u00e9cidive plus \u00e9lev\u00e9e chez les \npatients qui ont eu un curage ganglionnaire (RR = 0,75 [IC95 : 0,55 -0,98]) et \nplus particuli\u00e8rement chez les patients dont la tumeur \u00e9tait inf\u00e9rieure \u00e0 3 mm \n(RR = 0,56 [IC95 : 0,36 -0,88]) [135]. Aucune diff\u00e9rence en termes de survie \nglobale n\u2019a \u00e9t\u00e9 observ\u00e9e dans les analyses en sousgroupes.  \n \nTOXICIT\u00c9  \nLes toxicit\u00e9s ont \u00e9t\u00e9 principalement de grade 1 et globalement plus \nimpo rtantes dans les groupes de patients perfus\u00e9s [134, 135]. Les toxicit\u00e9s \nles plus fr\u00e9quentes ont \u00e9t\u00e9 la douleur et les infections du membre, souvent \nlocalis\u00e9es au niveau du  site de la perfusion. La plupart des complications ont \ncependant \u00e9t\u00e9 r\u00e9versibles.  \n Isolierte Extermit\u00e4tenperfusion mit Melphalan  \n \n\u2022Beschreibung der Studien  \nZwei randomisierte Studien haben den Effekt einer isolierten \nExtre mit\u00e4tenperfusion mit Melphalan nach Exizision des Prim\u00e4rmelanoms \nuntersucht. Die beiden Studien haben 107 und 832 Patienten mit einer \nTumordicke ab 1,5 mm eingeschlossen. In der Studie von Ghussen et al. war \ndie Perfusion mit Melphalan mit Hyperthermie kom biniert.  \n \n\u2022Gesamt\u00fcberleben, Rezidivfreies \u00dcberleben  \nNur eine der beiden Studien zeigte einen Vorteil in Bezug auf lokale Kontrolle \nund Gesamt\u00fcberleben zugunsten einer Therapie mit isolierter \nExtremit\u00e4tenperfusion mit Hyperthermie -Melphalan nach Exzision ei nes \nPrim\u00e4rmelanoms. Die Studie von Koops et al. zeigte keinen signifikanten \nUnterschied in Bezug auf das Gesamt\u00fcberleben. Eine Subgruppenanalyse \nzeigte jedoch ein verl\u00e4ngertes rezidivfreies \u00dcberleben bei Patienten mit \nLymphknotendissekt ion (RR = 0,75 [IC95  : 0,55 -0,98])  \n[Kommentar: in der Originalarbeit bezieht sich das verl\u00e4ngerte rezidivfreie \n\u00dcberleben auf Patienten OHNE Lymphknotendissek tion: \u201c\u2026The difference was \nsignificant for patients who did not undergo ele ctive lymph node dissection \n(ELND).\u201d]   \nund besonders bei P atienten mit einem Tumordicke unter 3mm (RR = 0,56 \n[IC95 : 0,36 -0,88]). Die Subruppenanalysen ergaben keine Unterschiede in \nBezug auf das Gesa mt\u00fcberleben.  \n \n\u2022Toxizit\u00e4t  \nToxizit\u00e4ten waren haupts\u00e4chlich Grad 1 und insgesamt am wichtigsten in den  \nGruppen der perfundierten Patienten. Die h\u00e4ufigsten Toxizit\u00e4ten waren  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 377 von 817 \nOriginaltext (Evidenztabelle und Text siehe Quell LL ab S.40)  \u00dcbersetzung  \nCOMMENTAIRES M\u00c9THODOLOGIQUES ET CLINIQUES  \nL\u2019\u00e9tude de Ghussen et al. a \u00e9t\u00e9 arr\u00eat\u00e9e pr\u00e9matur\u00e9ment en raison d\u2019une \nanalyse interm\u00e9diaire qui a montr\u00e9 l\u2019existence d\u2019un b\u00e9n\u00e9fice  \u00e9vident en \ntermes de survie sans r\u00e9cidive en faveur des patients qui ont re\u00e7u une \nperfusion hyperthermique de melphalan (p < 0,001). Au total, 115 patients \nont \u00e9t\u00e9 i nclus, dont 107 \u00e9valuables. Le calcul a priori du nombre de sujets \nn\u00e9cessaires n\u2019\u00e9tant pas  pr\u00e9sent\u00e9, la puissance de l\u2019\u00e9tude ne peut \u00eatre \nrecalcul\u00e9e et la fiabilit\u00e9 des r\u00e9sultats est limit\u00e9e. Les analyses en sous -\ngroupes d\u00e9finies a posteriori ne permettent pas d\u2019\u00e9tablir de conclusions \nfiables en regard de ces r\u00e9sultats. Les populations des 2 \u00e9t udes ne sont pas \ncomparables. \u00c0 noter \u00e9galement que pr\u00e8s de 10 ans s\u00e9parent les 2 \u00e9tudes et \nque les protocoles de traitement ont \u00e9t\u00e9 diff\u00e9rents (hyperthermie dans l\u2019\u00e9tude \nde Ghussen et al.).  \n \nCONCLUSIONS DE LA LITT\u00c9RATURE  \nLa perfusion de melphalan sur memb re isol\u00e9 ne semble pas am\u00e9liorer la \nsurvie globale des patients atteints d\u2019un melanoma cutan\u00e9 (niveau de preuve \nC).  Schmerzen und Infektionen in der Extremit\u00e4t, h\u00e4ufig am Ort der Infusion. Die \nmeisten Komplikationen waren jedoch reversibel. \n \n\u2022Klinische und Methodische Kommentare  \nDie Studie von Ghusse n et al. wurde vorzeitig beendet, da eine \nZwischenan alyse einen Benefit in Bezug auf das rezidivfreie \u00dcberleben \nzugunsten einer hype rthermen Perfusion mit Melphalan gezeigt hat (p < \n0,001). Insgesamt wurden 115 Patienten eingeschlossen, davon waren 107 \nauswertbar. Die erforderliche Fal lzahlberechnung wurde nicht dargestellt, die \nPower der Studie konnte nicht berechnet werden und die Verl\u00e4sslichkeit der \nDaten ist limitiert. Die nachtr\u00e4glich definierten Subgruppenanalysen lassen \nkeine verl\u00e4sslichen Schlus sfolgerungen aus den Ergebnissen zu. Die \nPopulationen aus den beiden Studien sind nicht vergleichbar. Es ist zu \nbeachten, dass fast 10 Jahre zwischen den beiden Studien lag und die \nBehandlungsprotokolle unterschiedlich waren (Hyperthermie in der Studie von \nGhussen et al.)  \n \n\u2022Schlussfolgerung aus der Literatur  \nEine adjuvante Extremit\u00e4tenperfusion mit Melphalan scheint das \nGesamt\u00fcberleben von Melanompatienten nicht zu verbe ssern. (Niveau de \npreuve C)  \n \nLiteratur:  \n \nGhussen F, Kruger I, Smalley RV, et al. Hypertherm ic perfusion with chemotherapy for melanoma of the extremities. World J Surg 1989;13:598 -602 \nKoops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high -risk limb melanoma: results of a multicenter randomized phase III tri al. European \nOrganization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organ ization Melanoma Program Trial 15, and the North \nAmerican Perfusion Group Southwest Oncology Group -8593. J Clin Oncol 1998;16:2906- 2912  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 378 von 817 \n5.4. Frage IV.4. Adjuvante Immunstimulation -  Adaptation  \n5.4.1.  Synopse Quelleitlinien  \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National \nAuthority for Health \n2005  LL Kanada \nCancer Care O ntario \n2007  \nBeeinflusst eine \nunspezifische \nImmunstimulation (BCG, \nLevamisol) das \nGesamt\u00fcberleben und/oder \ndie rezidivfreie Zeit von \nMelanompatie nten? - \n - \n Le levamisole en situation \nadjuvante n\u2019am\u00e9liore pas la \nsurvie  \ndes patients porteurs d\u2019un \nm\u00e9lanome cutan\u00e9 op\u00e9r\u00e9 \n(niveau de preuve A).  \n \nEine adjuvante Therapie mit \nLevamisole ve rbessert nicht \ndas \u00dcberleben von  \nMelanompatienten. (Niveau \nde pre uve A)  After the review of the \navailable information with \nrespect to levamisole, we \nhave concl uded that, if \nlevamisole has an im pact on \nthe clinical course of \nmalignant melanoma when \ngiven in the adjuvant setting, \nthat effect is marginal  \n \n(BCG wurde nicht in die \nLiteratursuche eingschlossen)  \nSchl\u00fcsselempfe hlung - - Les traitements adjuvants \nsyst\u00e9miques \u00e0 base de \nlevam isole, BCG ou \ndacarbazine ne sont pas \nrecommand\u00e9s en d ehors \nd\u2019essais th\u00e9rapeutiques.  \n \nAdjuvante  systemische \nTherapien mit Levamisol, BCG \noder Dacarbazine werden  \nausse rhalb von klinischen Keine Empfehlung zu \nLevamisole enthalten   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 379 von 817 \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National \nAuthority for Health \n2005  LL Kanada \nCancer Care O ntario \n2007  \nStudien nicht em pfohlen.  \nZugrunde li egende Evidenz  - \n - 4 Studien, 1 Metaanalyse aus \nder kanadischen LL 2002  \n \nLoutfi et al 1987, Lejeune et \nal. 1988, Quirt et al 1991, \nSpitler et al. 1991, Cancer \nCare Ontario Practice \nGuidelines Initiative 2002  4 Studien  \n \nSpitler et al 1980, Loutfi et al \n1987, Lejeune et al. 1988, \nQuirt et al 1991, Spi tler et al. \n1991  \n \nUpdate Recherche am 07.03.20 11 \nSuchstrategie Medline:  melanoma [tiab] AND levamisole [tiab], Treffer: 50 , Darunter seit 2005 keine neuen randomisierten Studien zu \nLevamisol   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 380 von 817 \n5.4.2.  Empfehlung und Hinte rgrundstext franz\u00f6sische Quell Leitlinie  \nQuellleitlinie: Recommandations pour la Pratique Clinique : Standards, Options et Recommandations 2005  \nOriginaltext (Evidenztabelle siehe Quell LL ab S.38)  \u00dcbersetzung  \n LEVAMISOLE  \n \n\u2022Description des \u00e9tudes  \nQuatre es sais randomis\u00e9s ont \u00e9valu\u00e9 l\u2019efficacit\u00e9 du levamisole  \n(immunomodulateur) en situation adjuvante chez les patients  \nporteurs d\u2019un m\u00e9lanome cutan\u00e9 op\u00e9r\u00e9 [126 -129]. Aucun nouvel  \nessai randomis\u00e9 n\u2019a \u00e9t\u00e9 retrouv\u00e9 dans le cadre de la mise \u00e0 jour \n2005. Trois essai s ont compar\u00e9 levamisole versus placebo [126, \n127, 129] et 1 essai a \u00e9valu\u00e9 levamisole versus observation [128].  \n \n\u2022Survie globale  \nAucun des 3 essais contre placebo n\u2019a rapport\u00e9 de diff\u00e9rence  \nsignificative en termes de survie globale [126, 127, 129]. \nL\u2019\u00e9tud e du NCIC a observ\u00e9 une diff\u00e9rence significative de la  \nsurvie \u00e0 5 ans en faveur des patients trait\u00e9s par levamisole  \npar rapport \u00e0 l\u2019absence de traitement (78 % versus 62 % ;  \np = 0,027) [128]. L\u2019analyse pool\u00e9e des donn\u00e9es r\u00e9alis\u00e9e par le  \nCCOPGI n\u2019a pas retr ouv\u00e9 de diff\u00e9rence significative (odd  \nratio = 0,90 [IC95 : 0,63 -1,30]) [12].  \n \n\u2022Commentaires m\u00e9thodologiques et cliniques  \nLes doses de levamisole administr\u00e9es dans les 4 \u00e9tudes sont  \ntr\u00e8s h\u00e9t\u00e9rog\u00e8nes, ce qui ne permet pas d\u2019\u00e9tablir de conclusions  \nconcernant la relation effet -dose. La population incluse  \ndans l\u2019\u00e9tude du NCIC est h\u00e9t\u00e9rog\u00e8ne (seuls 50 % des  \npatients sont des patients \u00e0 haut risque de r\u00e9cidive).  \n LEVAMISOLE  \n \n\u2022Beschreibung der Studien  \nVier randomisierte Studien haben den Effekt von Levamisole \n(Immunmodul ator) bei Patienten in der adjuvanten Situation nach Exzision \neines kutanen Melanoms u ntersucht [126-129].  Keine neue randomisierte \nStudie wurde im Rahmen der Aktualisierung 2005 gefunden. Drei Studien \nhaben Levamisole gegen Placebo verglichen [126, 127, 129]  und eine \nStudie hat Levamisole gegen Beobachtung unte rsucht [128].  \n \n \n\u2022Gesamt\u00fcberle ben \nKeine der drei Studien versus Placebo berichtete einen signifikanten \nUnterschied in Bezug auf das Gesamt\u00fcberleben [126, 127, 129].  \nDie Studie der  NCIC (National Cancer Institute of Canada Clinical Trials \nGroup) hat einen signifikanten Unterschied des \u00dcberlebens nach 5 Jahren \nf\u00fcr Pataienten die mit Levamisole behandelt wurden  im Vergleich zu \nunbehandelten Patienten gezeigt. Die Metaanalyse durch die CCOPGI hat \nkeinen sign ifikanten Unterschied gezeigt. (odd ratio = 0,90 [IC95 : 0,63 -\n1,30]) [12].  \n \n\u2022Klinische und Methodische Kommentare  \nDie in den vier Studien verabreichten Dosierungen von Levamisole waren \nsehr heterogen, daher lassen sich keine Schlussfolgerungen zur \ndosisabh\u00e4ngigen Wirkung ziehen. Die eingeschlossene Population in der \nNCIC Studien ist seh r heterogen (nur 50% der Patienten sind \nHochrisikopatienten)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 381 von 817 \nOriginaltext (Evidenztabelle siehe Quell LL ab S.38)  \u00dcbersetzung  \n\u2022Conclusions de la litt\u00e9rature  \nLe levamisole en situation adjuvante n\u2019am\u00e9liore pas la survie  \ndes patie nts porteurs d\u2019un m\u00e9lanome cutan\u00e9 op\u00e9r\u00e9 (niveau  \nde preuve A).   \n\u2022Schlussfolgerung aus der Literatur  \nEine adjuvante Therapie mit Levamisole verbessert nicht das \u00dcberleben \nvon  Melanompatienten. (Niveau de pre uve A)  \n \nLiteratur :  \n \n12. CCOPGI, (Cancer Care Onta rio Practice Guidelines Initiative). Systemic adjuvant therapy for patients at high risk for recurrent melanoma. Practice Gui deline Report No 8 -1 [online]. \n2002. Available: URL: http://www.cancercare.on.ca/index_practiceGuidelinesandEvidencesummaries.htm#list . \n127. Lejeune F, Macher E, Kleeberg UR, Rumke P, Prade M, Thomas D, et al. An assessment of DTIC versus levamisole or placebo in the treatment of high ri sk stage I patients after \nremoval of a primary melanoma of the skin: a phase III adjuvant study (EORTC protocol 18761). Eur J Cancer 1988;24:S81- 90.  \n126. Loutfi A, Shakr A, Jerry M, et al. Double blind randomized prospective trial of levamisole/placebo in  stage I cutaneous malignant melanoma. Clin Invest Med 1987;10:325- 328 \n128. Quirt IC, Shelley WE, Pater JL, et al. Improved survival in patients with poor- prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National \nCanc er Institute of Canada Clinical Trials Group. J Clin Oncol 1991;9:729- 735 \n129. Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991;9:736- 740 \n \n5.4.3.  Empfehlung und Hintergrundstext kanadische  Quell Leitlinie  \nQuellleitlinie: Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma: Updated Guideline Recommend ations \n(Cancer Care Ontario) 2009  \nLevamisole is an anti-helminthic with disputed immunostimulatory properties in vitro. On  the basis of that activity, levamisole has been \ninvestigated as adjuvant therapy in a number of cancers. Apart from results as adjuvant therapy in colon cancer when combined  with a \ncytotoxic agent, the trials in other cancers have been negative.  \nThere are  four randomized controlled trials of levamisole in melanoma, of which three are placebo -controlled (30 -33). The (NCIC) study (34) \nenrolled a heterogeneous group of patients with 50% being at high risk of recurrence (personal communication, B. Zee). The to tal dose of \nlevamisole used in this level I study was 800 mg over a two -week period for an 80 kg individual. Three smaller trials evaluated total doses of \n450 mg (31,31), 600 mg (32), and 600 to 1000 mg (33) over a two -week period. Whether those differences in dose are substantive is difficult \nto know in the absence of any data that demonstrate a dose -response relationship for levamisole with any measure of activity. \nAlthough the initial report by Spitler et al (31) described a survival trend in favour of levam isole compared with placebo in the subgroup of \npatients without lymph node disease (p=0.07, two -sided), there was no survival difference between trea tments for the total study population. \nThat lack of benefit was confirmed by a subsequent report of long -term follow -up (30). Loutfi et al (32) and Lejeune et al (33) co ncluded that  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 382 von 817 \nthere was no meaningful impact on survival with levamisole compared with placebo. The only study in which levamisole had an im pact, albeit a \nmarginal one, was the study from the  NCIC (34) in which there was a statistically significant difference in the survival rate in favour of \nlevam isole when the five -year point estimates of overall survival were assessed (78% for levamisole versus 62% for control, p=0.027, 2 -sided). \nHowever, w hen the whole survival exp erience was compared between the groups, the difference in survival was not significant (p=0.08, two -\nsided). That difference represented a risk reduction in mortality of 29% and was observed in all risk groups, including the g roup to which this \nsystematic review is directed. \nWithout an intermediate marker of activity for levamisole, it is impossible to categorically state whether or not there are s ubstantive differences \nin the reg imens used in those four trials. This systematic rev iew is directed at a specific segment of the population involved in those trials. \nWhile a meta -analysis re stricted to data from the high -risk subgroup might help to reconcile the seemingly disparate findings, survival results \nare not reported separately fo r that p atient subgroup, and data for individual cases are generally not available. However, it is our belief that the \nregimens evaluated are unlikely to be substantially different in their clinical activity and that the impact of levamisole do es not diffe r across \nrisk groups. A meta -analysis of five -year death rates (Figure 2), a bstracted from survival curves in published reports, yields a risk ratio of 0.94 \n(95% CI, 0.75 to 1.20; p=0.6). No heterogeneity was found among the r esults from these studies (p=0 .19). \nAfter the review of the available information with respect to levamisole, we have concluded that, if levamisole has an impact  on the clinical \ncourse of m alignant melanoma when given in the adjuvant setting, that effect is marginal. \nAdverse effects \nMorbidity from levamisole is generally mild, although it was severe enough to result in discontinuation of therapy in 41% of pa tients in the \nNCIC study (34), 44% in the Loutfi et al study (compared with 16% in the placebo group) (32), and 17% in the Lejeune et al study (compared with \nno patients in the placebo group) (33). Data on toxicity was reported for two of the placebo- controlled trials (32,33). In the study by Loutfi et al, \n22% of patients on levamisole repo rted a flu -like syndrome (compared with 3% on  placebo), 14% reported nausea and vomiting (compared with \n8% on placebo), and 14% reported musculosk eletal symptoms (compared with no patients on placebo) (32). The most commonly reported \nadverse events in the Lejeune et al study were nausea and v omiting (27% with levamisole versus 10% with placebo), weakness (27% versus 14%), \nand anorexia (22% versus 8%) (33). Hematologic abnormalities were noted for 7% of patients on levamisole and none of the placebo group in \nthe Loutfi et al study (32), and for 16% and  5%, respectively, of those groups in the Lejeune et al study (33). No treatment -related mortality has \nbeen observed in the four levamisole studies summarized here.  \n \nLiteratur : \n \n33. Lejeune FJ, Macher E, Kleeberg U, Rumke P, Prade M, Thomas D, et al. An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after \nsurgical removal of a primary melanoma of the skin. Eur J Cancer Clin Oncol. 1988;24 Suppl 2:S81 -S90. \n32. Loutfi A, Shakr A, Jerry M, et al. Double blind ra ndomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 1987;10:325 -328  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 383 von 817 \n34. Quirt IC, Shelley WE, Pater JL, et al. Improved survival in patients with poor- prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer \nInstitute of Canada Clinical Trials Group. J Clin Oncol 1991;9:729- 735 \n30. Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991;9:73 6-740 \n31. Spitler LE, Sagebiel R. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. N Engl J M ed 1980;303:1143- 1147  \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 384 von 817 \n5.5. Frage IV.5. und IV.6. Adjuvante Interferon alpha Therapie \u2013 De novo Recherche  \nFrage IV. 5. Beeinflusst eine Therapie mit IFN -alpha das Gesamt\u00fcberleben und/oder die rezidivfreie Zeit von Melanomp atienten?  \nFrage IV. 6. Welche Patientengruppe profitiert von einer Interferon -alpha -Therapie?  \n5.5.1.  PICO, Suchw\u00f6rter  \n \nPICO - Schema  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients, clinical stage II \nand III  IFN-alpha treatment  Observation  OS, PFS  \n \nSuchw\u00f6rter  \nStichwort  melanoma  Interferon -alpha  adjuvant   \nSynonyme   Interferon  alpha, Interferon \nalpha,  IFN -\u03b1, IFN-alpha    \nOber -/Unterbegriffe  interferon -alpha -2b, \ninterferon -alpha -2a, \nmultiferon    \nMesh Term  melanoma  Interferon -alpha    \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 385 von 817 \n5.5.2.  Datenbanken , Suchstrategien , Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer (Auswahl)  \n1. Suche     \nMedline  (melanoma[ tiab] OR melanoma[MeSH]) AND (Interferon -alpha[tiab] OR \nInterf eron-alpha[MeSH] OR \u201cInterferon alpha\u201d[tiab] OR IFN -alpha  [tiab] OR \nIFN-alpha[tiab] OR interf eron-alpha -2b[tiab] OR interferon -alpha -2a[tiab] OR \nmultiferon[tiab]) AND (adj uvant[tiab])  12.04.11 404 (25)  \nCochrane Library  (melanoma and interferon alpha and adjuvant).mp.  12.04.11  46 (8, davon 7 Dubletten, 1 Studie \ndazu R udolf Z 1994)  \nEmbase  (melanoma and (Interferon alpha or IFN alpha or interferon alpha 2b or \ninterferon alpha 2a or multiferon) and  (adjuvant)).ti,ab.  11.05.11 301 (nach Dublettenelimination 0 \ndazu) \nUpdate Suche     \nMedline  s.o. 30.01.12  427 (2 dazu: Petrella, Egge rmont)  \nCochrane Library  s.o. 30.01.12  47 (0 dazu)  \nEmbase  s.o. 23.01.12  308 (0 dazu)  \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 386 von 817 \n5.5.3.  Auswahlkriterien  \nAuswahl der  Literatur  \nGesamttreffer  782 \nEinschlusskriterien  system. Reviews , klinische Studien  zu adjuvanter Therapie mit Interferon alpha bei Patienten mit Rezidivrisiko, \ntumorfreies St adium I -III \nIntervention: IFN alpha Monotherapie, Vergleichsgruppe: Beobachtung  \nSprachen: e,dt  \nAusschlusskriterien  Nicht systematische Reviews  \nKohorten Studien, Case Reports  \nKombinationstherapien  \nVergleichsgruppe Chemotherapie, andere Systemtherapien  \nTherapiestudien mit Interferon alpha im Stadium IV  \nKollektive mit gemischten Tumore ntiti\u00e4ten  \nAnzahl ausgew\u00e4hlter Studien (8 Reviews, 16 RCTs, davon 2 nur als Abstract vorliegend ) 24 \nAnzahl in Reviews zus\u00e4tzlich ber\u00fccksichtigter Studien (E2696+E1694 kein Obs Arm, Kokoschka, Rusciani mangelnde \nQualit\u00e4t)  4 \nAnzahl der ausgeschlossenen Stu dien nach Bewertung (Rudolf)  1 \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 387 von 817 \n5.5.4. Evidenztabelle - Kurzfassung  \nRCT No. of patients  OS p RFS p LoE \nLow Dose        \nPehamberger, AMCG, 1998  311 no benefit, HR n.r.  - benefit, HR n.r.  <0.2 1b \nGarbe, DeCOG, 2008  444 HR = 0.62  0.0045  HR = 0.69  0.018  1b \nKleeberg, EORTC 18871, 2004  484 HR = 0.96  0.72 HR = 1.04  0.71 1b \nHancock, UKCCCR, 2004  674 OR = 0.94  0.6 OR = 0.91  0.3 1b \nCascinelli, WHO, 2001  444 no benefit, HR n.r.  0.72 no benefit, HR n.r.  0.5 1b \nCameron, SMG, 2001  95 no benefit, HR n.r.  >0.2 no bene fit, HR n.r.  - 1b \nKirkwood, E1690, 2000  642 HR = 1.04\u00a7 0.813  HR = 1.19\u00a7 0.171  1b \nGrob, FCGM, 1998  489 no benefit, HR n.r.  0.059  benefit, HR n.r.  0.035  1b \nIntermediate Dose        \nHansson, Nordic trial, 2011  855 HR = 0.91  0.642  HR = 0.80  0.030  1b \nEggerm ont, EORTC 18952, 2005  832 \n835 HR = 1.00*  \nHR = 0.85*  0.96 \n0.11 HR = 0.95*  \nHR = 0.83*  0.59 \n0.05 1b \nHigh Dose        \nAgarwala, E1697, 2011  1150  no benefit, HR n.r.  - no benefit, HR n.r.  -  \nMcMasters, Sunbelt Trial, 2008  218 HR = 1.07  0.79 HR = 0.82  0.46  \nKirkwood, E1690, 2000  642 HR = 1.0\u00a7 0.995  HR = 1.28\u00a7 0.054  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 388 von 817 \nRCT No. of patients  OS p RFS p LoE \nKirkwood, E1684, 1996/2004  287 Upd.: HR = 1.22\u00a7 \nbenefit, HR n.r.  0.18 \n0.0237  Upd.: HR = 1.38\u00a7 \nbenefit, HR n.r.  0.02 \n0.0023  1b \nCreagan, NCCTG, 1995  262 HR = 0.9  0.53 HR = 0.83  0.37 1b \nPegylate d       \nEggermont, EORTC 18991, 2008  1256  HR = 0.98  0.78 HR = 0.82  0.01 1b \n*13 month, 25 month interferon; DMFS not RFS was calculated, \u00a7 HR relates to proportion alive and proportion relapsfree (> 1 = Favour IFN)  \nAgarwala 2011, Mc Masters 2008: only abstract available  \n5.5.5.  Hochdosis versus Niedrigdosis Interferon alpha  \n \nRandomisierte Studie HDI versus LDI versus Beobachtung: kein signifikanter Un terschied  \nRCT No. of patients  OS p RFS p LoE \nKirkwood et al. 2000  HDI n=215, HDI vs. Obs  \nLDI n=215, LDI vs. Obs  \nHDI vs. LDI*  HR = 1.0\u00a7 \nHR = 1.04\u00a7 \nRR = 1.02*\u00a7   \nFavour LDI, n.s.  n.s. \nn.s. \n0.92*  HR = 1.28\u00a7 \nHR = 1.19\u00a7 \nRR = 0.93*\u00a7, \nFavour HDI, n.s.  n.s. \nn.s. \n0.50*  1b \n* Data not reported, calculated based on event data RR=(events/group A)/(events group B), p value: Fishe r's exact test ; \u00a7 HR relates to proportion alive and proportion relapsfree  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 389 von 817 \n \nSubgruppenvergleich Metaanalyse Mocellin et al. 2010: 6 HDI Studien versus 7 LDI und IDI Studien, kein signifikanter Untersch ied \nStudy  No. of trials \n/ patients  OS \nHR (95% CI)  \n No. of trials \n/ patients  PFS \nHR (95% CI)  \n No. of trials \n/ patients  OS \nHR (95% CI)  \n No. of trials \n/ patients  PFS \nHR (95% CI)  \n Subgroup  \ncomparison  LoE \nMocellin et \nal. 2010  HDI LDI or IDI  OS p=0.99  \nPFS p=0.05  2b \n 5/3114  0.89 \n(0.77 \u2013 1.02) 6/3221  0.75 \n(0.68 \u2013 0.83)  7/4590  0.89 \n(0.81 \u2013 0.98)  8/4901  \n 0.85 \n(0.78 \u2013 0.93)    \n \nVergleich Hochdosis versus Niedrigdosis Interferon alpha Studien im Stadium der lokoregion\u00e4ren Metastasierung  (AJCC 2009: St.  III) \nRCT \nLow Dose Anteil \nPatienten mit \nlokoreg. Met.  OS p RFS p RCT \nHigh Dose  Anteil \nPatienten mit \nlokoreg. Met.  OS p RFS p \nCascinelli, \nWHO, 2001  97%  no \nbenefit, \nHR n.r.  0.72 no \nbenefit, \nHR n.r.  0.5 Kirkwood, \nE1684,  \n2004 \n(Update), \n1996 89% Upd.: no \nbenefit: \nHR = \n1.22\u00a7  \nbenefit, \nHR n.r.  0.18 \n \n \n \n0.0237  Upd.: HR \n= 1.38\u00a7 \n \n \nbenefit, \nHR n.r.  0.02 \n \n \n \n0.0023  \nHancock, \nUKCCCR, \n2004  81% OR = \n0.94 0.6 OR = \n0.91 0.3 Kirkwood, \nE1690, 2000 74%  HR = 1.0\u00a7 0.995  HR = \n1.28\u00a7 0.054  \nKirkwood, \nE1690, 2000  74%  HR = \n1.04\u00a7 0.813  HR = \n1.19\u00a7 0.171  Creagan, \nNCCTG, 1995  61%  HR = 0.9  0.53 HR = 0 .83 0.37 \nGarbe, \nDeCOG, 2008  61% HR = \n0.62 0.0045  HR = \n0.69 0.018         \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 390 von 817 \nRCT \nLow Dose Anteil \nPatienten mit \nlokoreg. Met.  OS p RFS p RCT \nHigh Dose  Anteil \nPatienten mit \nlokoreg. Met.  OS p RFS p \nKleeberg, \nEORTC \n18871, 2004  60% HR = \n0.96 0.72 HR = \n1.04 0.71       \nCameron, \nSMG, 2001 St II + III  \nAnteil n.r. no \nbenefit, \nHR n.r.  >0.2 no \nbenefit, \nHR n.r.  -       \nPehamberger\n, AMCG , 1998 0% no \nbenefit, \nHR n.r.  - benefit, \nHR n.r.  <0.2       \nGrob, FCGM, \n1998 0% no \nbenefit, \nHR n.r.  0.059  benefit, \nHR n.r.  0.035        \n\u00a7 HR relates to proportion alive and proportion relapsfree  \n \n5.5.6.  Evidenztabelle n \u2013 Langfassung  \n5.5.6.1.  Evidenztabelle \u2013 Systemati sche Reviews and Metaanalyse n \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nPetrella et al. 2012  To conduct \nanother update of \nthe evidence and \nrecommendations. \nThis report \nsumma rises the Systematic review \n(Update)  \n \nadjuvant treatment \nfor stage AJCC \nstage IIB, IIC and 7 new RCTs:  \n \nEORTC 18991  \nSunbelt Trial \nPectasides et al. \n2009  OS \n \n \n \n \nDFS HDI vs. Obs: no \nsign. ben efit \nHazard Ratio:  \n0.93 [0.78,1.12] \n \nHDI vs. Obs: sign. most LDI studies \nnot included  \n \nConflict of Interest: \nThe first author \nreceived consulting 1a-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 391 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nevidence pu blished \nbetween July 2005 \nand June 2010 that \ninformed the \ndevelopment of \nrevised \nrecomme ndations \nfor adjuvant \ninterf eron therapy \nby the Melanoma \nDSG. III. EORTC  18952  \nStadler et al. 2006 \nDeCOG 2008  \nDeCOG 2010  \n \nMetaanalyses:  \nMocellin et al.  \nWheatley et al.  Benefit \nHazard Ratio:  \n0.77 [0.65, 0.92] \nP = 0.004; 9% \nabsolute risk  \nreduction at 5 \nyears  fees or honoraria \ngreater than \n$5000 from \nSchering -Plough in \nthe past 2 years.  \nEggermont et al. \n2011  To present a meta -\nanalysis of the two \nlargest adjuvant \nIFN/PEG -IFN \nrandomised trials \nin a combined total \nof 2644 patients \nwith high -risk \nmelanoma (stage \nIIb/III)  Metaanalysis of 2 \nstudies \n EORTC 18991  \nEORTC 18952  \n \n2644 patients with \nhigh-risk \nmelanoma stage \nIIb/III  OS \n \n \n \n \nRFS \n \n \n \n \nDMFS  \n \n IDI+p eg IFN vs. \nObs: no sign. \nbenefit \nHazard Ratio:  \n0.94 [0.80, 1.11] \n \nsign. benefit  \nHazard Ratio:  \n0.85 [0.76, 0.95] \np=0.004  \n \nsign. benefit  \nHazard Ratio:  \n0.89 [0.79, 1.00] \np=0.36 Conflict of Inte rest: \nAlexander M.M. \nEggermont: \nConsu ltant in \nadvisory boards for \nmelan oma for \nMerck, BMS, Roche, \nGSK. Poulam Patel: \nAd hoc adv isory \nboards for \nSchering -Plough \nResearch Institute \n\u2013 honor aria paid.  1a- \nGarbe et al. 2011  to present the \nsuccess of current \ntreatments and the Systematic review  \n \nadjuvant and Interferon alpha:  \n11 RCTs  \n Metaanalysis  \n \nOverall survival 12 RCTs  \n \nSignificant Number needed to \ntreat not rep orted  \n 1a- \n(SR with \nheterogen e\nity)  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 392 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npromise of those \nstill in clinical \ndevelopment t hat \nmay yield \nincremental \nimprovements in \nthe treatment of \nadvanced, \nmetasta tic \nmelanoma  palliative \ntreatments  NCCTG  \nECOG 1684  \nECOG 1690  \nEORTC 18952  \nSMG  \nWHO  \nDeCOG  \nFCGM  \nUKCCCR  \nAMCG  \nEORTC 18 991 \n \n (OS) \n \n \n \n \n \nDisease free \nsurvival (DFS)  improvement  \nodds ratio = 0.88, \n95% CI = 0.79 \u2013\n0.99, p<0.03 \n \nSignificant \nimprovement  \nodds ratio = 0.83, \n95% CI = 0.75 \u20130.92 \np<0.0001 No quality \nassess ment of \nstudies \n \nupdated data of \nE1684 (Kir kwood \n2004) and EORTC \n18871 (Kleeberg \n2004) not i ncluded  \n \nConflict of Interest: \nClaus Garbe: \nConsultant/advisor\ny role: Roche \nPharma, MSD, \nBristol- Myers \nSquibb, Swedish \nOrphan, Genta, \nGlaxoS mithKline; \nResearch \nfunding/contracted \nresearch: Roche \nPharma, MSD, \nBristol-Myers \nSquibb, Swedish \nOrphan, Genta, \nGlaxoSmit hKline;  \nAxel Hauschild: \nConsu ltant/advisor\ny role: Abraxis \nOnco logy, Bayer  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 393 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSchering, Bristol -\nMyers Squibb, \nEssex \nPharma/Schering -\nPloug h; Honoraria: \nGlaxoSmithKline, \nMerck, Onyx \nPharmaceuticals, \nPfizer, Roche \nPharma, Synta \nPharm aceuticals \nCorp.; John M. \nKirkwood: \nConsu ltant/advisor\ny role: Schering \n(for FDA review of \nPegIFN), \nGlaxoSmit hKline \n(for chairma nship \nof vaccine steering \ncommi ttee). \nMocellin et al. \n2010  to examine the \neffect of IFN -alpha \non DFS and OS in \npatients with high -\nrisk cutaneous \nmelan oma Systematic review  \n \nAdjuvant treatment \nwith interferon \nalpha 14 RCTs ( \npublished 1990 \u2013  \n2008)  \n8122 p atients  \n \nNCCTG  \nECOG 1684  \nAMCG  \nFCGM  OS  \n \n \n \n \n \n \n \n Significant \nimprovement  \nHR for death = \n0.89, 95% CI = \n0.83\u20130.96;  \nP=.002  \n \nNumber needed to \ntreat 29 patients  absolute risk \nreduction not \nreported  \n \nReported hazard \nratio were used for \nmeta -analysis  \n \n 1a- \n(SR with \nheterogen e\nity)  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 394 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nECOG 1690  \nSMG  \nWHO  \nECOG 1694  \nE2696  \nUKCCCR  \nEORTC 18871  \nEORTC 18952  \nDeCOG  \nEORTC 18991  \n DFS  \nSignificant \nimprovement  \nHR for disease \nrecurrence = 0.82, \n95% CI = 0.77 \u2013\n0.87;  p<.001 \n \n \n updated data of \nE1684 (Kirkwood \n2004) not i ncluded  \nData of E1694 and \nE2696 (contr ol \nvaccination arm \nwith p otentially \nworse outcome) \nwere included  \n \nOS benefit was \nobserved only \nwhen trials that \nused low or \ninterm ediate IFN -a \ndoses were \nconsidered  \n \nFunding: no funds \ninvolved  \nAll authors \ndeclared no \nconflict of inte rest. \nVerma et al. 2006 To examine the \nrole of systemic \nadjuvant therapy  Systematic review  Interferon alpha: \n13 RCTs, \npublished 1980 -\n2004  \n \nMetaanalysis: \nE1684, E1690, OS \n \n \n \n \n \n Metaanalysis  \nE1684, E1690, \nE1694:  \nsignificant \nImprovement   \nRR (2 years) 0.85, \n95% CI = 0.73 \u2013Number needed to \ntreat not reported  \n \nNo quality \nassess ment of \nstudies \n 1a- \n(SR with \nheterogen e\nity)  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 395 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nE1694  \n  \n \n \n \n \n \n 0.99;  \nP=.03  \nnot significant \nafter e xclusion of \nE1694:  \nHR 0.87, 95% CI = \n0.71\u20131.07;  \nP=.18  only 3 RCTs were \nincluded into \nmetaanalysis  \n \nother RCTs and  \npublished \nmetaanalyses were \nreported \nnarratively  \n \nFunding: \nSupported by \nCancer Care \nOntario and the \nOntario Ministry of \nHealth and Long -\nTerm Care.  \nPirad et al. 2004  to evaluate the \neffect of IFN -alpha \non the relapse rate \n(RR) and the \noverall survival \n(OS). Systematic review  9 RCTs  \n2 880 p atients  \n \nECOG 1684  \nNCCTG  \nECOG 1690  \nRusciani  \nFCGM  \nAMCG  \nSMG  \nKokoschka  \nWHO  Metaanalysis  \n \nOS \n \n \n \n \n \nRR \n  \n \nno significant \nbenefit \nOR = 0.87; 95% CI \n=0.74 \u20131.02; p = \n0.1029  \n \nSignificant lower \nOR = 0.74; 95% CI \n= 0.64 \u20130.86; p = \n0.0001  Number needed to \ntreat not reported  \n \nNo quality \nassess ment of \nstudies \n \nheterogeneity tests \nare non -significant \n(=homogeneous \neffects of studies),  \nbut studies were \nheterogeneous in 1a- \n(SR with \nheterogen e\nity)  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 396 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nregard to the \nschedules, the \nclassif ication used \nand the m edian \ntime of follow -up \n \nFunding/Conflict \nof interest: not \nmentioned  \nWheatley et al. \n2003  To assess all the \navailable evidence \nfor adjuvant \ninterf eron-alpha  Metaanalysis  12 RCTs  \n \nECOG 1684  \nECOG 1690  \nNCCT G  \nE2696  \nEORTC 18952  \nWHO  \nUKCCCR  \nFCGM  \nAMCG  \nSMG  \nKleeberg (18871)  \nKleeberg (DKG -80)  Metaanalysis  \n \nOS \n \n \n \n \nRFS \n  \n \nno significant \nbenefit \nHR = 0.93; 95% CI \n0.85-1.02; p=0.1  \n \nsignificant benefit  \nHR = 0.83; 95% CI \n0.77-0.90; \np=0.000003  \n \n Number needed to \ntreat not reported  \n \nfew studies were \nused without \nexisting \npublication, data \nof EORTC 18871 + \nDKG-80 were not \nreprodu cible \nwithin the later \npublication \n(Kleeberg et al. \n2004)  \n \nFunding/Conflict \nof interest: not \nmentioned  1a- \n(SR with \nheterogen e\nity) \nLens et  al. 2002  to assess the \nbenefit of IFN Systematic review  9 RCTs, 8 RCTs \nincluded, 3 178 OS \n analysis on \navailable data for 2 High quality SR  \n 1a- \n(SR with  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 397 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nalpha therapy in \nmalignant \nmelanoma  patients  \n \nAMCG  \nFCGM  \nECOG 1684  \nECOG 1690  \nNCCTG  \nSMG  \nUKCCCR  \nWHO   \n \n \n \n \n \n \n \n \nRFS \n \n \n \n \n \n \n \n \n \n \n 771 patients from \n6 trials  \nno study with \nbenefit \n \nECOG 1684: \nsignif icant benefit, \nnot con firmed  \n \n \nanalysis on \navailable data for 2 \n020 p atients from \n4 trials  \n1 study with \nbenefit  \n \nECOG 1684 \nsignif icant benefit, \nconfirmed  \nECOG 1690: \nsignif icant benefit, \nnot con firmed  \n \n Number needed to \ntreat reported for \neach individual \ntrial \n \nno metaanalysis \ndue to \nheterogene ity of \nstudies, the \nauthors state that \nany \nrecommendation \nshould be made on \nthe basis of an \nevaluation of the \nindividual studies. \n \n \n \n \n \n \n \nFunding: Center \nfor Evidence -Based \nMedicine, \nUnivers ity of \nOxford  heterogen e\nity) \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 398 von 817 \n5.5.6.2.  Evidenztabelle \u2013 Niedrigdosis  IFN alpha  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nGarbe et al. 2008  \n \nDeCOG  to improve \ndisease -free \nsurvival ( DFS) and \noverall survival \n(OS) with \ninterferon (IFN) a2a \nwith or without \ndacarbazine (DTIC) \ncompared with \nobservation alone  RCT \n \nTreatment groups  \nLDI \n(LDI plus DTIC)  \nOBS 444 patients, \nresected Stage III  \n \nn=148  \n(n=148)  \nn=148   \nOS \n \n \n \n \n \n \nDFS \n LDI vs OBS  \nsignif icant benefit  \nHR 0.62; 97.5% CI: \n0.42-0.89; \np=0.0045;  \nevents: 65/148 vs \n88/148  \n \nsignificant benefit  \nHR 0.69; 97.5% CI: \n0.49-0.96; \np=0.018;  \nevents: 84/148 vs \n102/148  \n \n Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding:  \nGerman Cancer Aid \n(Deutsche \nKrebshilfe); \nGerman Cancer \nSociety (Frankfurt, \nGermany); \nHoffmann -LaRoche \nAG (Grenzach -\nWhylen, Ge rmany).  1b \nHancock et al. \n2004  \n \nUKCCCR  To evaluate low -\ndose extended \nduration interferon \nalfa-2a RCT \n \n \nTreatment groups  \nLDI \nOBS 674 patients, \nresected stage IIB \nand stage III  \n \nn=338  \nn=336   \n \nOS \n \n \n \n \n \nRFS LDI vs OBS  \nno benefit  \nOR 0.94; 95% CI: \n0.75-1.18; p=0.6;  \nevents: 151/338 vs \n156/336  \n \nno benefit  \nOR 0.91; 95% CI: \n0.75-1.10; p=0.3;  \nevents: 211/338 vs \n215/336  Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: The study \nwas supported by \na grant from Roche \nProducts  \nLtd 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 399 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nKleeberg et al. \n2004  \n \nEORTC 18871  to evaluate the \nefficacy and \ntoxicity of low \ndose recombinant \ninterferon -alpha 2 \nb (rIFN -alpha2b) (1 \nMU) or \nrecombinant \ninterferon gamma \nin comparison with \nan un treated \ncontrol group  RCT \n \nTreatment groups  \nOBS \nvery LDI alpha  \n(very LDI gamma)  \n 728 p atients Stage \nII-III \n \nn=244  \nn=240  \n(n=244)  \n  \n \nOS \n \n \n \n \n \nRFS LDI vs. OBS  \nno benefit  \nHR 1.04; 95% CI: \n0.84-1.30;  \nevents: 137/240 vs \n148/244  \n \nno benefit  \nHR 0.96; 95% CI: \n0.76-1.21;  \nevents: 159/240 vs \n158/244  \n Jadad Score 2 of 5  \nnot placebo \ncontrolled, not \nblinded, \nrandomization \nscheme not \ndescribed  \n \nFunding:Essex and \nBoeri nger-\nIngelheim, grant \nnumber 3U10 -\nCA11488 -18S1 \nthrough 5U10 -\nCA11488 -33 from \nthe National  \nCancer Institute  1b \nCascinelli et al. \n2001  \n \nWHO  to see whether \ninterferon alpha -2a \nincreased survival \nprospects in stage \nIII melanoma \npatients  RCT \n \n \nTreatment groups  \nOBS \nLDI 444 patients with \nlymph node \ninvolvement  \n \nn=219  \nn=225   \n \nOS \n \n \n \n \nRFS LDI vs. OBS  \nno be nefit \nHR n.r., p=0.72 \nevents: 146/225 vs \n138/219  \n \nno benefit  \nHR n.r., p=0.5; \nevents: 162/225 vs \n158/219  Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: not \nmentioned  1b \nCameron et al. \n2001  To test the \npossible disease -RCT \n 95 patients with at \nleast 3mm Breslow  \n LDI vs. OBS  \nno benefit  Jadad Score 2 of 5  \nnot placebo 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 400 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nSMG free and o verall \nsurvival a dvantage \nof a short, 6 -\nmonth course of \nlow-dose IFN for \npatients with high -\nrisk, surgically \nresected, \nmalignant \nmelan oma.  \n \nTreatment groups  \nOBS \nLDI thickness or lymph \nnode involvement  \n \nn=49  \nn=46  OS \n \n \n \n \nRFS HR n.r., p>0.2; \nevents: 31/46 vs \n36/49  \n \nno benefit  \nHR n.r., p>0.1; \nevents: 32/46 vs \n35/49  controlled, not \nblinded, \nrandomization \nscheme not \ndescribed  \n \nFunding: not \nmentioned, IFN \nsupplied b y \nSchering -Plough  \nKirkwood et al. \n2000  \n \nE1690  To evaluate the \nefficacy of high-\ndose IFNalpha2b \n(HDI) for 1 year \nand low -dose \nIFNalpha2b (LDI) \nfor 2 years versus \nOBS RCT \n \nTreatment groups  \nOBS \n(HDI)  \nLDI 642 patients, 75% \nnodal involvement  \n \nn=212  \n(n=215)  \nn=215   \n \nOS \n \n \n \n \n \nRFS LDI vs. OBS  \nno benefit  \nHR 1.04\u00a7; 95% CI: \n0.78-1.38; \np=0.813;  \nevents: 96/215 vs \n93/212  \n \nno benefit  \nHR 1.19\u00a7; 95% CI: \n0.93-1.53; \np=0.171;  \nevents: 122/215 vs \n127/212  Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: not \nreported  \nassistance of \nSchering-Plough \nResearch Institute \nand Schering -\nPlough Oncol ogy \nBiotech with \nposttrial data \ncollection 1b \nGrob et al. 1998 \n \nFCGM  To assess the \nefficacy of \nadjuvant low dose \ninterferon a lpha RCT \n \n \n 489 patient s, \ntumor thickness > \n1.5mm without \nclinically  \n \nOS \n LDI vs. OBS  \nno benefit  \nHR n.r., p=0.059 \nevents: 59/244 vs Jadad Score 3 of 5  \nnot plac ebo \ncontrolled, not \nblinded  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 401 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nTreatment groups  \nOBS \nLDI detectable node \nmetastases \n \nn=245  \nn=244   \n \n \nRFS 76/245  \n \nsignificant benefit  \nHR n.r., p=0.035 \nevents: 100/244 vs \n119/245   \nFunding: grant \nfrom Hoffman -La \nRoche Ltd, also \nprovided the \ninterferon \u0001 -2a \n(Roferon -A). \nPehamberger et al. \n1998  \n \nAMCG  To investigate \nwhether adjuvant \nIFNalpha2a \ndiminishes the \noccurrence of \nmetastases and \nthus prolongs \ndisease-free \nsurvival in \nmelanoma p atients  RCT \n \nTreatment groups  \nOBS \nLDI 311 patients, \ntumor thickness > \n1.5mm  \n \nn=157  \nn=154   \n \nOS \n \n \n \n \nRFS LDI vs. OBS  \nno benefit  \nHR n.r.,  \nevents: 17/154 vs \n21/157  \n \nsignificant ben efit \nHR n.r., p=<0.2 \nevents: 37/154 vs \n57/157  Jadad Score 2 of 5  \nnot placebo \ncontrolled, not \nblinded, \nrandomization \nscheme not \ndescribed  \n \nFunding:  \nin part by \nHoffmann -La \nRoche, Vienna, \nAustria. 1b \nRusciani et al. \n1997  to study the use of \nrecombinant \ninterferon -alpha \n(IFN-alpha) as \nadjuvant therapy \nfor patients with \nStage I and Stage II \nmelanoma  RCT \n \nTreatment groups  \nObs  \nLDI 84+ 70 patients, \nstages I+II,  \n \nn=70  \nn=84  DFS Significant ben efit \nevents LDI vs. OBS  \n11/84 vs 21/70  \n Jadad Score 0 of 5  \nmatched controlls, \nno randomis ation, \nnot placebo \ncontrolled, n ot \nblinded, no \ndescri ption of \ndropouts  \nStudy excluded  2b  \nlow qua lity \nRCT \n \nstudy \nexcluded   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 402 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nKokoschka et al. \n1990  To evaluate the \nefficacy of rIFN \nalpha 2b therapy \nin high -risk \nmelanoma patients \nstage I and stage II  \n Cohort Study  \n \nTreatment groups  \nOBS \nLDI 135 patients, \nstages I+II  \n \n \nn=82  \nn=53  \n OS \nDFS no significant \nbenefit Cohort Study  \nOnly included in SR \nby Pirad et al. 2b \n \nstudy \nexcluded  \n\u00a7 HR relates to proportion alive and proportion relapsfree (> 1 = Favour IFN)  \n \n5.5.6.3.  Evidenztabelle - Mittlere Dosis IFN alp ha \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nHansson et al. \n2011  \n \nNordic IFN trial  To investigate \nwhether adjuvant \ntherapy with \nintermediate -dose \ninterferon alfa -2b \nfor 1 or 2 years \nwould improve \noutcomes in \npatients with stage \nIIB-IIC or  III \nresected cut aneous \nmelanoma  RCT  \n \nTreatment groups  \nOBS \nIDI 12 months  \nIDI 24 months  \n  855 p atients stage \nIIB-IIC \n \nn=284  \nn=285  \nn=286   \n \nOS \n(12 months + 24 \nmonths)  \n \n \n \nPFS \n(12 months + 24 \nmonths)  \n \n \n \n IDI vs. OBS  \nno benefit  \nHR 0.91; 95% CI:  \n0.74-1.10; \np=0.642;  \nevents: 285/571 vs \n148/284  \n \nsignificant benefit  \nHR 0.80; 95% CI: \n0.67-0.96; \np=0.030;  \nevents: 338/571 vs \n183/284  \n Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: Schering -\nPlough; the \nRadiumhemmet \nResearch F unds, \nStockholm; and the \nStockholm County \nCouncil  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 403 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n24 months alone  no benefit  \n \n \nEggermont et al. \n2005  \n \nEORTC 18952  to assess the effect \nof two reg imens of \ninterferon of \nintermediate dose \nversus o bservation \nalone  RCT \n \nTreatment groups  \nIntermediate IFN, \n13 months  \nIntermediate IFN, \n25 months  \nOBS 1388 patients  \n \n \nn=553  \n \nn=556  \n \nn=279   \n \nOS \n13 months  \n \n25 months  \n \n \n \n \nDFS \n13 months  \n \n25 months  IDI vs. OBS  \nno benefit  \nHR 1.00; 95% CI: \n0.79-1.25; p=0.96;  \nHR 0.85; 95% CI: \n0.67-1.07; p=0.11;  \nevents: 535/1109 \nvs 146/279  \n \nno benefit  \nHR 0.97; 95% CI : \n0.78-1.20; p=0.72;  \nHR 0.83; 95% CI: \n0.67-1.03; p=0.05;  \nevents: 679/1109 \nvs 183/279  Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: not \nmentioned  \nThe authors  \ndeclared that they \nhave no conflict of \ninterest. 1b \n \n5.5.6.4.  Evidenztabelle - Hochdosis  IFN alpha  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nKirkwood et al. \n2004/1996  \n \nUpdate E 1684  To update the \nanalyses  \n \nTo evaluate RCT \n \nTreatment groups  \nOBS 287patien ts, \nstages IIb and III  \n \nn=137   \n \nOS \n HDI vs. OBS  \nUpdate: no benefit  \nHR 1.22; 95% CI: \nn.r.; p=0.18;  Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 404 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nInitial Data E1684  \n \n \n Interf eron alfa -2b \nas an adjuvant \ntherapy  \n \n HDI  n=143   \n \n \n \n \n \nRFS \n \n \n \n Initial: significant \nbenefit \nHR n.r., p=0.0237 \nevents 81/143 vs \n90/137  \nsignificant ben efit \nUpdate: HR 1.38, \np=0.02 \nInitial: HR n.r., \np=0.0 023 \nevents HDI vs. OBS  \n90/143 vs \n103/137   \nFunding: grants \nfrom the National \nInstitutes of  \nHealth, Bethesda, \nMD. \nUpdate: Grant CA -\n23318, awarded by \nthe National \nCancer Institute, \nUnited States \nDepartmen t of \nHealth and H uman \nServices.  \nKirkwood et al. \n2000  \n \nE1690  To evaluate the \nefficacy of high-\ndose IFNalpha2b \n(HDI) for 1 year \nand low -dose \nIFNalpha2b (LDI) \nfor 2 years versus \nOBS RCT \n \nTreatment groups  \nOBS \nHDI \n(LDI) 642 patients, 75% \nnodal involvement  \n \nn=212  \nn=215  \n(n=215)   \n \nOS \n \n \n \n \n \nRFS HDI vs OBS  \nno ben efit \nHR 1.00; 95% CI: \n0.75-1.33; \np=0.995;  \nevents HDI vs. OBS  \n98/215 vs 93/212  \n \nno ben efit \nHR 1.28; 95% CI: \n1.00-1.65; \np=0.054;  \nevents HDI vs. OBS  \n114/215 vs \n127/212  \nevents LDI vs. OBS  Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nImpact on RFS only \nsignif icant by Cox \nmultivariable \nanalysis \n \nFunding: not \nreported  \nassistance of \nSchering-Plough \nResearch Institute \nand Schering -1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 405 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n122/215 vs \n127/212  Plough Oncol ogy \nBiotech with \nposttrial data \ncollection \nCreagan et al. \n1995  \n \nNCCTG  To report a \nprospe ctive \nrandomized trial \ndesigned  \nto determine the \nclinical efficacy in \nterms of \nrecurrence  \nrates, time to \nrecurrence, and \npatient survival \nfollowing  \nIFN-a2a given as \npostsurgical \nadjuvant therapy \nto selected  \npatients with high -\nrisk stage I and II \nmalignant  \nmelanoma  RCT \n \nTreatment groups  \nOBS \nHDI 262 patients, \nstages I and II  \n \nn=131  \nn=131   \n \nOS \n \n \n \n \n \nRFS HDI vs OBS  \nno ben efit \nHR 0.83; 95% CI: \n0.61-1.13; p=0.24;  \nevents: 68/131 vs \n72/131  \n \nno ben efit \nHR 0.90; 95% CI: \n0.64-1.25; p=0.53;  \nevents: 77/131 vs \n85/131  \n Jadad Score 2 of 5  \nnot placebo \ncontrolled, not \nblinded, \nrandomization \nscheme not \ndescribed  \n \nFunding:  \nsupported in part \nby Public Health  1b \nAgarwala et al. \n2011  \n \nE1697  To assess the \nbenefit of 4 weeks \nof HDI co mpared \nwith O bservation \nin relation to the RCT \n \n \nTreatment groups  \nOBS 1150 patients  \nT2N0, T3N0, \nT4N0, T1 -4N1a -2a \n \nn=596   \n \n \n5-year survival \nrate no benefit  \nIFN vs OBS  \n \n0.82 vs 0.85 \n only ASCO a bstract \navailable    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 406 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nRFS and OS of \npatients with \nresectable \ninterm ediate and \nhigh- risk \nmelanoma  HDI 4 weeks  n=581   \nRFS \n 6.8 vs 7.3 years  \n \nMcMasters et al. \n2008  \n \nSunbelt Trial  To evaluate the \nrole of high -dose \ninterf eron alfa -2b \n(IFN) or completion \nlymph node \ndisse ction (CLND) \nin patients with \nmelanoma staged \nby sentine l lymph \nnode (SLN) biopsy  RCT \n \n \nTreatment groups  \nObservation  \nHDI \n 218 patients, after \nSLN biopsy, 1 \npositive node \n \nn=106  \nn=112  OS \n \n \n \nRFS no benefit  \nHR 1.07; CI: 0.65 -\n1.78; p=0.79  \n \nno benefit \nHR 0.82; 95% CI: \n0.47-1.40; p=0.46  only ASCO a bstract \navailable   \nKirkwood et al. \n2001  \n \nE 1694  To evaluate the \nefficacy of HDI for \n1 year versus \nvaccin ation with \nGM2 RCT \n \nTreatment groups  \nHDI  \nvacination  874 p atients, \nstages IIB/III  \n \nn=385  \nn=389  OS \n \n \n \n \nRFS significant ben efit \nevents IFN vs. \nVacc.  \n52/385 vs 81/389  \n \nsignificant ben efit \nevents IFN vs. \nVacc.  \n98/385 vs \n151/389  Included in SR \nalthough no OBS \nArm \n \nFunding: Eastern \nCooperative \nOnco logy Group \ngrant no. NIH CA \n39229 -16 and R03 \ngrant no. \nCA75950 -02.  \nKirkwood et al. To evaluate the RCT 107 patients, RFS  significant ben efit Included in SR   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 407 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n2001  \n \nE2696  toxicity and other \neffects of the \nestablished \nadjuvant high -dose \nIFNalpha2b \nregimen in relation \nto immune \nresponses to GMK  \nTreatment groups  \nVacc+HDI day 1  \nVacc+HDI day 28  \nVacc \n stages IIB, III, and \nIV \n \nn=36  \nn=36  \nn=35   \n \n \nno OS analysis due \nto short fo llow up  events IFN+Vacc \nvs. Vacc.  \n28/72 vs 19/35  although no OBS \nArm \n \nFunding: \nunrestricted grant \nfrom Dr Craig \nTendler of \nSchering Plough \nResearch Institute, \nprovision of the \nvaccine by Drs \nRobert Israel and \nPaul Maddon of \nProge nics, Inc.  \n \n  \n \n   \n \n   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 408 von 817 \n5.5.6.5.  Evidenztabelle - Pegyliertes  IFN alpha  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nEggermont et al. \n2008/2011  \n \nUpdate EORTC \n18991  \nInitial Data EORTC \n18991  To present the \nlong-term results \nat 7.6 -years follow \nup \n \nTo determine \nwhether pegylated \ninterf eron alfa -2b \ncan facilitate \nprolonged \nexposure while \nmaintaining \ntolerability  RCT \n \nTreatment groups  \nObservation  \nPeylated IFN alfa -\n2b 1256 patients, \nresected Stage III  \n \nn=629  \nn=627   \n \nOS \n \n \n \n \n \n \n \n \n \n \n \nRFS PegIFN vs. OBS  \nno benefit  \nUpdate:  \nHR 0.96; 95% CI \n0.82-1.11; p=0.57 \nEvents: 332/627 vs \n336/629  \n \nInitial:  \nHR 0.98; 95% CI \n0.82-1.16.; p=0.78 \nevents: 262/627 vs \n263/629  \n \nsignificant benefit  \nUpdate:  \nHR 0.87; 95% CI \n0.76-1.00, p=0.05 \nevents: 384/627 vs \n406/629  \nInitial:  \nHR 0.82; 95% CI \n0.71-0.96; p=0.01 \nevents: 328/627 vs \n368/629  Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: Schering \nPlough Research \nInternational. 1b \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 409 von 817 \n5.5.7.  Subgruppenanalysen  \n \nSubgruppenvergleich Metaanalyse Mocellin et al. 2010: Stadium II ve rsus Stadium III, kein signifikanter Unterschied  \nStudy  No. of trials \n/ patients  OS \nHR (95% CI)  No. of trials \n/ patients  PFS \nHR (95% CI)  \n No. of trials \n/ patients  OS \nHR (95% CI)  \n No. of trials \n/ patients  PFS \nHR (95% CI)  \n Subgroup  \ncomparison  LoE \nMocellin et  \nal. 2010  Stadium II  Stadium III  OS p=0.36  \nPFS p=0.42  2a \n 1/499  0.70  \n(0.50 \u2013 0.98) 2/810  0.70  \n(0.55 \u2013 0.88) 3/2144  0.87  \n(0.68 \u2013 1.11) 3/2144  0.82  \n(0.72 \u2013 0.93)   \n \n \nSubgruppenanalysen der eingeschlossenen randomisierten Studien  \nStudy  Subgroup / No. of  patients  OS, HR  p PFS, HR  p LoE \nHansson et al. 2011  \n \n(Intermediate Dose)  All patients / n=855  0.91 0.642  0.80 0.030  1b \nStage IIB -IIC / n=166  n.r. - Favour IFN, n.s.  0.082  3b \nStage III, palpable nodes / n=554  n.r. - Favour IFN  0.015  3b \nStage III, 1 pos. node / n=374  n.r. - Favour IFN, n.s.  - 3b \nStage III, 2 -3 pos. node, n=201  n.r. - Favour IFN, n.s.  - 3b \nStage III, >/= 4 pos. node / n=114  n.r. - Favour IFN  0.038  3b \nUlzeration, n=238  1.05, Favour Obs, n.s.  0.809  1.04, Favour Obs, n.s.  0.829  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 410 von 817 \nStudy  Subgroup / No. of  patients  OS, HR  p PFS, HR  p LoE \nEggermont et al. 2011  \n \n(Intermediate Dose+ \nPegylated Interferon \nalpha)  2 studies, all patients, n = 2644  0.94 0.36 0.85  0.004  1a- \nN1, n=1154  0\u00b781  0.07 0.78 0.01 3b \nN2, n=1031  1\u00b701 0.92 0.91  0.25 3b \nNo Ulceration, n=1336  1\u00b711  0\u00b720 0.92  0.30 3b \nUlceration, n=849  0.72  0.001  0\u00b775 0.001  3b \nUlceration + N1, n=484  0.58  0.0003  0.69  0.003  3b \nUlceration + N2, n=365  0.89  0.41 0.83 0.15 3b \nMcMasters et al. 2010  \n \n(High Dose)  SN-, Ulceration, n=127  n.s.  n.s.  3b \nSN+, Ulceration, n=75  n.s.   0.016 9 3b \nSN+, no Ulceration, n=147  n.s.  n.s.   \nKleeberg et al. 2004  \n \n(Low Dose)  St. IIb vs. St. III  IFN benefit: similar  3b \nHancock et al. 2004  \n \n(Low Dose)  stage, age, sex  IFN benefit: n.s. differences  3b \nKirkwood et al. 2000  \n \n(Benefit of High Dose)  T4 N0 M0    1.46 0.20 3b \nT1-4 N1 M0    1.16 0.74 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 411 von 817 \nStudy  Subgroup / No. of  patients  OS, HR  p PFS, HR  p LoE \n T1-4 N1-2 M0    1.57 0.20 3b \nRecurrent N+   1.27 0.18 3b \nN0   1.46 0.19 3b \nN1   1.0 0.99 3b \nN2-3   1.92 0.02 3b \nN>=4    1.15 0.58 3b \nCreagan et al. 1995  \n \n(High Dose)  Stage I    n.s. 0.93 3b \nStage II   Favour IFN, n.s.  0.09 3b \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 412 von 817 \n5.5.8.  Toxizit\u00e4t  \nStudy  Treatment \ngroups  \n(number of \npatients)  Treatment  \nrelated deaths  Discontinuatio\nn because of \ntoxicity  Number of \npatients with  \nGrade 3 or 4 \nToxicities (%) Fatigue  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Depression  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Neutropenia  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Hepatotoxicity  \nNumber of \npatients with \nany Grade Tox. \n(%) / w ith \nGrade 3 or 4 \nTox. (%)  \nAgarwala et al. \n2011 OBS (n=596)  \n \nHDI 4 weeks \n(n=581)  n.r. n.r. n.r. n.r. n.r. n.r. n.r. \nEggermont et \nal. 20 08 \n \n OBS (n=629)  \nPeylated IFN \nalfa-2b (n=627)  n.r.  \n n.r.  \n n.r.  \n n.r.  \n n.r.  \n n.r.  \n n.r.  \n \nHansson et al. \n2011 \n \nNordic IFN \ntrial OBS \n(n=284)  \n \nIDI 12 months \n(n=285)  \n \nIDI 24 months \n(n=286)  \n n=0  \n \n \nn=72 (25%)  \n \n \nn=72 (25%)  \n n.r. n=106 (37%) /  \nn=5 (2%)  \n \nn=267 (94%) / \nn=28 (10%)  \n \nn=266 (93%) / \nn=32 (11%)  n=108 (38%) / \nn=1 (<1%)  \n \nn=210 (74%) / \nn=17 (6%)  \n \nn=214 (75%)  n.r. n=41 (14%) / \nn=2 (1%)*  \n \nn=118 (41%) / \nn=2 (1%)*  \n \nn=122 (43%) / \nn=6 (2%)*  \n*ALAT  \nKirkwood et \nal. 1996  OBS (n=140)  \nHDI (n=146)  n.r.  \n n.r. n.r. n.r. n.r. n.r. n.r.  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 413 von 817 \nStudy  Treatment \ngroups  \n(number of \npatients)  Treatment  \nrelated deaths  Discontinuatio\nn because of \ntoxicity  Number of \npatients with  \nGrade 3 or 4 \nToxicities (%) Fatigue  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Depression  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Neutropenia  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Hepatotoxicity  \nNumber of \npatients with \nany Grade Tox. \n(%) / w ith \nGrade 3 or 4 \nTox. (%)  \nEggermont et \nal. 2008  \n \nEORTC 18991  OBS (n=629, \nTox. assessed \nn=613)  \n \nPeylated IFN \nalfa-2b (n=62 7, \nTox. assessed \nn=608)  n.r.  \n \n \n \nn=191 (31%)  n=74 (12%)  \n \n \n \nn=278 (46%)  n=252 (41%) / \nn=7 (1%)  \n \n \nn=574 (94%) / \nn=97 (16%)  n=153 (25%) / \nn=3 (<1%)  \n \n \nn=360 (59%) / \nn=39 (6%)  n.r. n=221 (36%) / \nn=10 (2%)*  \n \n \nn=479 (79%) / \nn=66 (11%)*  \n*Liver function \ntest \nGarbe  et al. \n2008 \nDeCOG LDI (n=148)  \n(LDI plus DTIC)  \nOBS (n=148)  n.r. n=20 (14%)  n=13 (9%)  n.r. n.r. n.r. n.r. / n=0  \nEggermont et \nal. 2005  \n \nEORTC 18952  Intermediate \nIFN, 13 months \n(n=553, tox. \nassessed n= \n521) \n \nIntermediate \nIFN, 25 months \n(n=556, tox. \nassessed  n= \n532) \n n=0 n=87 (16%)  \n(N=539)  \n \n \n \n \nn=108 (20%) \n(N=539)  n.r. \n \n n.r. / 78 (15%)  \n \n \n \n \n \nn.r. / n=67 \n(13%)  \n \n \n \n n.r. / n=62 \n(12%)  \n \n \n \n \nn.r. / n=56 \n(11%)  \n \n \n \n n.r. n.r. / n=16 (3%)  \n \n \n \n \n \nn.r. / n=21 (4%) \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 414 von 817 \nStudy  Treatment \ngroups  \n(number of \npatients)  Treatment  \nrelated deaths  Discontinuatio\nn because of \ntoxicity  Number of \npatients with  \nGrade 3 or 4 \nToxicities (%) Fatigue  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Depression  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Neutropenia  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Hepatotoxicity  \nNumber of \npatients with \nany Grade Tox. \n(%) / w ith \nGrade 3 or 4 \nTox. (%)  \nOBS (n=279, \ntox. assessed \nn= 252)  n.r. / n=5 (2%)  n.r. / n=9 (4%)  n.r. / n=1 (<1%)  \nHancock et al. \n2004 \n \nUKCCCR  LDI (n=338, \ntox. assessed \nrange 322 -\n327))  \n \nOBS (n=336)  n=0 n=50 (15%)  n=56 (17%)  n=265 (78%) / \nn=22 (7%)  \n \n \nn=116 (38%) / \nn=4 (1%)  n=179 (55%) / \nn=11 (3%)  \n \n \nn=94 (31%) / \nn=5 (2%)  n.r. n=113 (35%) / \nn=7 (2%) \n \n \nn=65 (22%) / \nn=1 (<1%)  \nKleeberg et al. \n2004 \n \nEORTC 18871  OBS (n=244)  \n \nvery LDI alpha \n(n=240)  \n \n(very LDI \ngamma, \nn=244)  \n n.r.  \n \nn=11 (5%)  n.r. n.r. n.r. n.r. n.r. \nCascinelli et \nal. 2001  \n \nWHO  OBS (n=219)  \n \nLDI (n=225)  n.r. n=0 n.r. n.r. n.r. n.r. n.r.  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 415 von 817 \nStudy  Treatment \ngroups  \n(number of \npatients)  Treatment  \nrelated deaths  Discontinuatio\nn because of \ntoxicity  Number of \npatients with  \nGrade 3 or 4 \nToxicities (%) Fatigue  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Depression  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Neutropenia  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Hepatotoxicity  \nNumber of \npatients with \nany Grade Tox. \n(%) / w ith \nGrade 3 or 4 \nTox. (%)  \nCameron et al. \n2001 \n \nSMG OBS \n \nLDI n=0 n=0 n.r. n.r. n.r. n.r. n.r. \nKirkwood et \nal. 2000  \n \nE1690  OBS (n=212)  \n \nHDI (n=215)  \n \nLDI (n=215)  n=0 n.r. n.r. n.r. / n=0  \n \nn.r. / n=51 \n(24%)  \nn.r. / n=7 (3%)  n.r. / n=0  \n \nn.r. / n=20 (9%)  \n \nn.r. / n=5 (2%)  n.r. / n=0  \n \nn.r. / n=94 \n(44%)  \nn.r. / n=12 (6%)  n.r. / n=6 (3%)  \n \nn.r. / n=61 \n(29%)  \nn.r. / n=9 (4%)  \nGrob et al. \n1998 \n \nFCGM  OBS (n=245)  \n \nLDI (n=244)  n=0 n=35 (14%)  n.r. \n \nn=24 (10%)  n.r. \n \nn=118 (48%) / \nn=5 (2%)  n.r. \n \nn=40 (16%) / \nn=3 (1%)  n.r. \n \nn.r. / n=6 (2%)  n.r. \n \nPeha mberger \net al. 1998  \n \nAMCG  OBS (n=157)  \n \nLDI (n=154)  n.r. n=5 (3%)  n.r. n.r. n.r. n.r. n.r. \nKirkwood et \nal. 1996  \n \nE 1684  OBS (n=137)  \n \nHDI (n=143)  n=2 (lethal \nhepatic \ntoxic ity) 26% 67% n.r. \n \nn=140 (100%) / \nn=69 (48%)*  n.r. \n \nn=118 (83%) / \nn=40 (28%)*  n.r. \n \n n.r. \n \nn=89 (62%) / \nn=20 (14%)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 416 von 817 \nStudy  Treatment \ngroups  \n(number of \npatients)  Treatment  \nrelated deaths  Discontinuatio\nn because of \ntoxicity  Number of \npatients with  \nGrade 3 or 4 \nToxicities (%) Fatigue  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Depression  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Neutropenia  \nNumber of \npatients with \nany Grade Tox. \n(%) / with \nGrade 3 or 4 \nTox. (%)  Hepatotoxicity  \nNumber of \npatients with \nany Grade Tox. \n(%) / w ith \nGrade 3 or 4 \nTox. (%)  \n*constitutional \nsymptoms \nincluding \nfatigue *neurologic  \nCreagan et al. \n1995 \n \nNCCTG  OBS (n=131)  \n \nHDI (n=131)  n.r. \n n.r. \n n.r. \n n.r. \n \nn=117 (89%) / \nn=26 (20%)  n.r. \n n.r. \n n.r. \n \n \n5.5.9.  Metaanalysen  \nEine Metaanalyse wurde mit 1 3 Studien  (14 Vergleiche)  unter Einschluss der in bisher igen Metaanalysen  nicht erfassten Studie von Hansson et \nal. 2011  wurden nach den definierten Ein-  und Ausschlusskriterien durchgef\u00fchrt  (kein Einschluss bei fehlendem Beobachtungsarm, damit \nAusschluss E1694 und  E2696: Vergleichsarm jew. Vakzine).  \nAufgrund der Heterogenit\u00e4t der Studien keine Metaanalyse \u00fcber alle 14 Vergleiche, sondern getrennt nach verschiedenen Dosis Schemata:  \n- Hochdosis Interferon alpha  \n- Mittlere Dosis Interferon alpha  \n- Niedrigdosis Interferon alpha  \n \nLimit ation : unterschiedliche  Follow up Perioden innerhalb der Studien  \nAuswertung durch Review Manager 5.1, The Cochrane Collaboration   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 417 von 817 \nAbbildung 1:  Hochdosis  Interferon alpha versus Beobachtung  \nOutcome: Mortalit\u00e4t  Risk Ratio: 0.98 CI [0.87, 1.10] n.s       \n \n \n  \n \n  \n \nOutcome: Progression  Risk Ratio: 0.88 CI [0.80, 0.97] sign.  \n \n  \n \n  \n \nAbbildung 2:  Mittlere Dosis Interferon alpha versus Beobachtung  \n \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 418 von 817 \nOutcome: Mortalit\u00e4t  Risk Ratio: 0.94 CI [0.85, 1.03] n.s  \n \n \n \n  \n \n  \nOutcome: Progression Risk Ratio: 0.93 CI [ 0.86, 1.00] sign.  \n  \n \n \n \n \n \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 419 von 817 \nAbbildung 3:  Niedrigdosis Interferon alpha versus Beobachtung  \nOutcome:  Mortalit\u00e4t  Risk Ratio: 0.93 CI [0.86, 1.00]  sign.  \n \n \n \n   \n \n Outcome:.  Progression Risk Ratio: 0.93 CI [0.88, 0.99] sign.  \n \n   \n \n  \n \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 420 von 817 \n5.5.10.  Literatur  \n \nAgarwala SS, Lee SJ , Flaherty LE, et al. Randomized phase III trial of high -dose interferon alfa -2b (HDI) for 4 weeks induction only in patients with intermediate - and high- risk melanoma \n(Intergroup trial E 1697) . ASCO Meeting Abstracts 2011;29:8505  \nCameron DA, Cornbleet MC , Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma -  the Scottish study. Br J Cancer 2001;84:1146- 1149  \nCascinelli N, Bufalino R, Morabito A, et al. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994;343:913- 914 \nCreagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa- 2a in selected patients with malignant melanoma. J Clin Oncol \n1995;13:2776- 2783  \nEggermont AM, Suciu S, MacKie R, et al. Post -surgery adjuva nt therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC \n18952): randomised controlled trial. Lancet 2005;366:1189- 1196  \nEggermont AM, Suciu S, Santinami M, et al. EORTC 18991 phase III trial : Long -term adjuvant pegylated interferon -{alpha}2b (PEG -IFN) versus observation in resected stage III melanoma: \nLong -term results at 7.6 -years follow -up. ASCO Meeting Abstracts 2011;29:8506b  \nEggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with  pegylated interferon alfa -2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a \nrandomised phase III trial. Lancet 2008;372:117- 126 \nEggermont AM, Suciu S, Testori A, et al. Ulceration and stage are predictive of inter feron efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. \nEur J Cancer 2012;48:218- 225 \nGarbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects . Oncologist 2011;16:5- 24 \nGarbe C, Radny P, Linse R, et al. Adjuvant low -dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective -randomized phase III DeCOG trial in \nmelanoma patients with regional lymph node metasta sis. Ann Oncol 2008;19:1195- 1201  \nGrob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha -2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable \nnode metastases. French Cooperative Gro up on Melanoma. Lancet 1998;351:1905- 1910  \nHancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high -risk melanoma: the AIM HIGH Study --United Kingdom Coordinating Committee on Cancer Research randomized \nstudy of adjuvant low -dose extended -durati on interferon Alfa -2a in high -risk resected malignant melanoma. J Clin Oncol 2004;22:53- 61 \nHansson J, Aamdal S, Bastholt L, et al. Two different durations of adjuvant therapy with intermediate -dose interferon alfa -2b in patients with high -risk melanoma (No rdic IFN trial): a \nrandomised phase 3 trial. Lancet Oncol 2011;12:144- 152 \nKirkwood JM, Ibrahim J, Lawson DH, et al. High -dose interferon alfa -2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the \nMulti center Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 2001;19:1430- 1436  \nKirkwood JM, Ibrahim JG, Sondak VK, et al. High - and low -dose interferon alfa -2b in high -risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J C lin Oncol \n2000;18:2444- 2458  \nKirkwood JM, Ibrahim JG, Sosman JA, et al. High -dose interferon alfa -2b significantly prolongs relapse -free and overall survival compared with the GM2 -KLH/QS -21 vaccine in patients \nwith resected stage IIB -III melanoma: results o f intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370- 2380  \nKirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adj uvant high -dose interferon for melanoma. Clin Cancer Res \n2004;10:1670- 1677  \nKirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa -2b adjuvant therapy of high- risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST \n1684. J Clin Oncol 1996;14:7 -17 \nKokoschka EM, Trautinger F, Knobl er RM, et al. Long -term adjuvant therapy of high -risk malignant melanoma with interferon alpha 2b. J Invest Dermatol 1990;95:193S -197S  \nLens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002;20:1818- 1825  \nMcMasters KM. The Sunbelt Melanoma Trial. Ann Surg Oncol 2001;8:41S -43S \nMocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high -risk melanoma: a systematic review and meta- analysis. J Na tl Cancer Inst 2010;102:493-\n501 \nPehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa -2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J \nClin Oncol 1998;16:1425- 1429  \nPetrella T, Verm a S, Spithoff K, et al. Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic R eview and Practice Guideline. Clin Oncol (R \nColl Radiol) 2012  \nPirard D, Heenen M, Melot C, et al. Interferon alpha as adjuvant post surgical treatment of melanoma: a meta -analysis. Dermatology 2004;208:43- 48 \nRudolf Z. Adjuvant treatment of malignant melanoma with interferon after radical surgery -  Part II. Effect of recombinant alpha interferon. Radiology and Oncology 1994;28:183- 187 \nRusciani L, Petraglia S, Alotto M, et al. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3 -year randomized trial with recombinant interferon -alpha after 3 and 5 years of \nfollow -up. Cancer 1997;79:2354- 2360 \nVerma S, Quirt I, McCready D, et al. S ystematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006;106:1431 -1442  \nWheatley K, Ives N, Hancock B, et al. Does adjuvant interferon -alpha for high- risk melanoma provide a worthwhile benefit? A meta -analy sis of the randomised trials. Cancer Treat Rev \n2003;29:241- 252  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 421 von 817 \n6. AG Medikament\u00f6se Therapie bei Metastasierung  \n6.1. Frage V.1 . Lokale medikament\u00f6se Therapie  Intransitmetastasen \u2013 De novo Recherche  \nFrage V.1.  Welche therapeutischen (au\u00dfer operativen) Ma\u00dfnahmen sin d bei Satelliten - und In transit -Metastasen effektiv?  \n6.1.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients with locoregional \nmetastases Local therapies (except surgery, \nradiotherapy, extremity perfusion)  Standard of  care Efficacy  \n \nSuchw\u00f6rter  \nStichwort  melanoma  Satellite Metastasis  \nIn-Transit Metastasis  therapy  interleukin -2, IL-2; rose \nbengal ; imiquimod ; DNCB, \ndinitrochlorobenzene ; DPCP, \ndiphencyprone ; interferon \nbeta, interferon -\u00df; \nelectrochemotherapy  \nSynonyme   Local recurrence  \nLocoregional spread  treatment   \nOber -/Unterbegriffe      \nMesh Term  melanoma  Neoplasm Recurrence, Local  therapeutics    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 422 von 817 \n6.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  \n6.1.2.1.  Prim\u00e4rrecherche 2012  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedli ne (\"melanoma\"[tiab] OR \"melanoma\"[MeSH])  \nAND (\"Satellite metastases\"[tiab] OR \"Satellite metastasis\"[tiab]  \nOR \"In -transit metastases\"[tiab] OR \"In -transit metastasis\"[tiab]  \nOR \"Intransit metastases\"[tiab] OR \"Intransit metastasis\"[tiab]  \nOR \"Local recu rrence\"[tiab] OR \"Locoregional recurrence\"[tiab]  \nOR \"Locor egional spread\"[tiab] OR \"Locoregional metastases\"[tiab]  \nOR \"Locoregional metastasis\"[tiab] OR intratumo*[tiab] OR \"intralesional\"[tiab]  \nOR \"Neoplasm Recurrence, L ocal\"[MeSH])  \nAND (\"therapy\"[tia b] OR \"treatment\"[tiab] OR \"therapeutics\"[MeSH]  \nOR \"interleukin -2\"[tiab] OR \"IL -2\"[tiab] OR \"rose bengal\"[tiab] OR \"imiquimod\"[tiab]  \nOR \"dinitrochlor obenzene\"[tiab] OR \u201eDNCB\u201c[tiab] OR\u201cdiphencyprone\u201c[tiab]  \nOR \"DPCP\"[tiab] OR \"interferon beta\"[tiab] OR \"i nterferon -\u00df\u201c[tiab]  \nOR \"electrochem otherapy\"[tiab])  16.12.10  2322  \nEmbase  (melanoma and (\"satellite metast*\" or \"In -transit metast*\" or \"Intransit metast*\" or \"local \nrecurrence\" or \"locoregional recurrence\" or \"locoregional spread\" or \"locoregio nal metast* \" or \n\"locoregional metast*\") and (therapy or treatment)).ti,ab.  12.10.10  579 \nMedline - Erweiterung \nder Suchstrategie  (\"melanoma\"[tiab] OR \"melanoma\"[MeSH])  \nAND (\"Satellite metastases\"[tiab] OR \"Satellite metastasis\"[tiab]  \nOR \"In -transit metastases\"[tiab ] OR \"In -transit metastasis\"[tiab]  \nOR \"Intransit metastases\"[tiab] OR \"Intransit metastasis\"[tiab]  \nOR \"Local recurrence\"[tiab] OR \"Locoregional recurrence\"[tiab]  \nOR \"Locoregional spread\"[tiab] OR \"Locoregional metastases\"[tiab]  \nOR \"Locoregional metasta sis\"[tiab] OR intratumo*[tiab] OR \"intralesional\"[tiab]  06.04.11  2467   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 423 von 817 \nDatenbank  Suchstrategie  Datum  Treffer \nOR \"Neoplasm Recurrence, Local\"[MeSH] OR \"cutaneous metastases\"  \nOR \"skin metastases\" OR \"cutaneous melanoma metastases\"  \nOR \"skin melanoma metastases\")  \nAND (\"therapy\"[tiab] OR \"treatment\"[tiab]  \nOR \"therapeutics\"[MeSH] OR \"i nterleukin -2\"[tiab] OR \"IL -2\"[tiab]  \nOR \"rose bengal\"[tiab] OR \"imiquimod\"[tiab] OR \"dinitrochlorobenzene\"[tiab]  \nOR \u201eDNCB\u201c[tiab] OR\u201cdiphencyprone\u201c[tiab] OR \"DPCP\"[tiab] OR \"interferon beta\"[tiab] OR \n\"interferon -\u00df\u201c[tiab] OR \"elec trochem otherapy\"[tiab])  \nUpdate Suche     \nMedline  s.o. 31.01.12  2586  (3 dazu: \nBoyd et al. 2011 , \nFlorin  et al. 2011 , \nKis et al. 2011 ) \nCochrane Library  s.o. 31.01.12  13 (0 dazu)  \nEmbase  s.o. 23.01.12 668 (0 d azu) \n \n6.1.2.2.  Aktualisierungsrecherche 20 15 \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  (((\"melanoma\"[tiab] OR \"melanoma\"[MeSH])AND (\"Satellite metastases\"[tiab] OR \"Satellite \nmetastasis\"[tiab]OR \"In -transit metastases\"[tiab] OR \"In -transit metastasis\"[tiab]OR \"Intransit \nmetastase s\"[tiab] OR \"Intransit metastasis\"[tiab]OR \"Local recurrence\"[tiab] OR \"Locoregional 16.09.15  572  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 424 von 817 \nDatenbank  Suchstrategie  Datum  Treffer \nrecurrence\"[tiab]OR \"Locoregional spread\"[tiab] OR \"Locoregional metastases\"[tiab]OR \"Locoregional \nmetastasis\"[tiab] OR intratumo*[tiab] OR \"intralesional\"[tiab] OR \"Neopl asm Recurrence, Local\"[MeSH] \nOR \"cutaneous metastases\"OR \"skin metastases\" OR \"cutaneous melanoma metastases\"OR \"skin \nmelanoma metastases\")AND (\"therapy\"[tiab] OR \"treatment\"[tiab]OR \"therapeutics\"[MeSH] OR \n\"interleukin -2\"[tiab] OR \"IL -2\"[tiab]OR \"rose ben gal\"[tiab] OR \"imiquimod\"[tiab] OR \n\"dinitrochlorobenzene\"[tiab]OR \u201eDNCB\u201c[tiab] OR\u201cdiphencyprone\u201c[tiab] OR \"DPCP\"[tiab] OR \"interferon \nbeta\"[tiab] OR \"interferon -\u00df\u201c[tiab] OR \"electrochemotherapy\"[tiab]))) AND (\"2012.01.27\"[Date -  \nPublication] : \"3000\"[Date -  Publication])  \nCochrane \nLibrary  (melanoma and (\u201cSatellite metastasis\u201d or \u201c In -transit metastases\u201d)).ti,ab.  16.09.2015  2 (0 dazu)  \n  \n6.1.3.  Auswahlkriterien  \n6.1.3.1.  Prim\u00e4rrecherche 2012  \nAuswahl der Literatur  \nGesamttreffer  3267  \nEinschlusskriterien  Thematis che \u00dcbereinstimmung (gemeinsame Berichte verschiedener Tumorentit\u00e4ten wurden ausgeschlossen)  \nSprachen: e, dt  \nKlinische Studien  \nBei nicht Vorhandensein von Studien Einschluss von Fallserien ab 3 Patienten  \nAusschlusskriterien  Nicht systematische Reviews  \nCase Reports \nIntratumorale Therapie als Systemtherapie   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 425 von 817 \nAuswahl der Literatur  \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  63 \nAnzahl ausgew\u00e4hlter Volltexte  36 \nDie ausgew\u00e4hlten Arbeiten wurden wie folgt zusammengefasst:  \nImmunmodulation ( Interleukin -2, Imiquimod, BCG, Interferon beta, GM- CSF, Interferon gamma, Mycobacterium smegmatis ) \nAblative  Therapien ( Elektrochemotherapie, lokale  Chemo therapie, Bengal Rosa, Carbon Laser)  \nContac t Sensitizer ( Dinitrochlorobenzene, Diphencyprone)  \n \n6.1.3.2.  Aktualisierungsrecherche 2015  \nAuswahl der Literatur  \nGesamttreffer  574 \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e, dt  \nKlinische Studien , Phase III  \nSystematische Reviews  \nAusschlusskriterien  Nicht systematische Reviews  \nCase Reports \nIntratumorale Therapie als Systemtherapie  \nAnzahl ausgew\u00e4hlter Volltexte  5 \nDie ausgew\u00e4hlten Arbeiten wurden wie folgt zusammengefasst:  \nImmunmodulation (Interleukin- 2, Imiquimod, BCG, Interferon beta, GM -CSF, Interferon gamma, Mycobacterium smegmatis)  \nAblative Therapien (Elektrochemotherapie, lokale  Chemotherapie, Bengal Rosa, Carbon Laser)  \nContact Sensitizer (Dinitrochlorobenzene, Diphencyprone)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 426 von 817 \n6.1.4.  Evidenztabelle  \n6.1.4.1.  Prim\u00e4rrecherche 2012  \n \nImmunmodulation (Interleukin -2, Imiquimod, Interferon alpha, Interferon beta, Interferon gamma, BCG)  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nBoyd et al. 2011  To document the  \nresponse of in -\ntransit metasta ses \nto intra -lesional IL -\n2 inje ction Case Series  \n \nTreatment:  \nIL-2 intralesional \nbiweekly  39 patients with \n629 intransit \nmeta stases  Response  \n \n \n \n \n \n \n \n5 year survival  \n Patients:  \nCR 51%  \nPR 31%  \nNo response 18%  \n \nLesions: \nResponserate 76%  \n \nComplete \nrespon ders versus \npartial responder \n80% versus 33% \n(p= 0.012) Response was \nevaluated for \npatients and for \ntreated lesions \nseparately. \nLimitations: \nLack of control \ngroup \n 4 \nFlorin et al. 2011  To treat cutaneous \nmetastases of \nmalignant \nmelanoma in a  \nseries of patients \nwith imiquimod \nand 5 -fluorouracil \ncreams  Case Series  \n \nTreatment:  \n5-fluorouracil  \ncream in the \nmorning and 5% \nimiqu imod cream \nat night, 5 days \nper week, un til \nresponse  5 patients with 45 \nintransit \nmeta stases  Response  CR = 19 lesions  \nPR = 25 lesions  \nSD = 1 lesion  \n \n \n Lack of control \ngroup  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 427 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nWeide et al. 2010  To confirm the \nprevious results \nwith intralesional \nIl-2 in a larger \ncohort and to \nidentify relevant \npatient or regimen \ncharacteristics \nassociated with \nresponse to \ntreatment and with \noverall surv ival. Phase II \nprospective open \nlabel study  \n \nTreatment was \ninitiated at 3 MIU \nIL-2 daily, \ndose escalation 1.5 \nMIU each \ntreatment  \nday. Schedule: 3 \ntimes weekly  51 patients \nenrolled, 48 \npatients evaluable  \nwith injectable \ndermal or \nsubcut aneous \nmetast ases, Stage \nIII (69%) or Stage IV \n(31%)  \nno concomitant \nsystemic \nchemoth erapeutic  \n \n894 of 917 \nseparately treated \nmetastases (97.5%) \nwere evaluable for \nlocal tumor \nresponse  Clinical Response  \n \n \n \n \n \n \n \n \n \nOverall Survival \n \n \n \nToxicity  Patients:  \nComplete local \nresponse 33 \npatients (69%), \n(Stage III 82%, \nStage IV 40%)  \nLesions: 78.7% CR \nrate, 0.7% PR rate,  \n16.3% stable \nmeta stases, and \n4.3% progressive \nlesions. \nOverall Survival \nafter 2 years:  \nStage III 77%, Stage \nIV 53%)  \nToxicity: only grad \n1 and 2 toxicity, \n(injection site \nreaction, injection \npain, fever, \nnausea, f atigue)  Response was \nevaluated for \npatients and for \ntreated lesions \nseparately. \nResponse for \npatients applied to \nlocal r esponse.  \nLimitations: \nLack of control \ngroup  \n 4 \nDehesa et al. 2009  To describe the \nexperience over 2 \nyears with the use  \nof intralesional IL -2 \nto treat cutan eous \nmetastases of \nmalignant \nmelanoma in 7 Case Series  \n \nTreatment: twice \nweekly, starting \nwith 3 MIU Il -2 7 melanoma \npatients with \nsatellit osis an \ncutaneous \nmetastases   \n244 les ions \n \nno other organs Response  \n \n \n \n \n \n \nToxicity  Lesions:  \nComplete \nremission 95.9% of \ntreated lesions  \nPartial remission:  \n3.7% of treated \nlesions  \nToxicitiy: few mil d Limitations:  \nCase Series,  \nsmall sample size  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 428 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npatients.  involved  side e ffects (grade \n1-2). \nFujimura et al. \n2009  To report 3 \npatients who were \ntreated with \nperitumoral \ninjection of \ninterf eron beta  Case Series  \n \nTreatment: \nperitumoral \ninterf eron beta  3 melanoma \npatients Sta ge IV \nM1a Reponse  Target lesion: 1 \nCR, 2 PR  \n Limitations:  \nCase Series,  \nsmall sample size  4 \nGreen et al. 2006  To investigate the \ncombination of \ntopical imiquimod \nand intralesional \nIL-2, to treat a \nsmall cohort of \npatients with \naccessible \nmelan oma \nmetastas es \nresistant to other \ntreatments  Phase I/II \nprospe ctive open \nlabel study  \n \nTreatment: after 4 \nweeks of 5% \nimiquimod cream \ndaily, start of IL -2 \nintralesional or \nsubcut aneously in \naddtion to \nimiquimod cream  13 patients, Stage \nIII or IV with \ncutan eous and/or \nsubcutaneous \nlesions  \n \n182 lesions  Response  Lesions: \nCR:  74 lesions \n(40,7%)  \nPR: 18 lesions \n(9,9%)  \nSD: 53 lesions \n(29,1%)  \nPD:  33 lesions \n(18,1%)  \n4 lesions were not \nassessable (2,2%)  Regressed lesions \nwith remained \npigmentation were \nclassified as PR \n(possibl e \nexplan ation for low \nCR rates compared \nto other stu dies) \nLimitations:  \nheterogenous \ntreatment \nschedules  4 \nKhorana et al. \n2003  To determine the \nsafety and \ntolerabil ity of \nintratumoral \ninjection with \nadeno-IFN-g, and \nto determine the \nmaximum Phase I single -\ncenter dose -\nescalation study  \n \nTreatment: 4 \nsuccessive dose \nlevels: 107 \ninfect ious units (iu) 11 patients with \nhistologically \nconfirmed locally  \nrecurren t or \nmeta static \nmalignant \nmelanoma  Safety  \nToxicity  \n \n \n \n \n \n No treatment \nrelated death, no  \ngrade 4 or dose -\nlimiting toxicities \nMost frequently \nobserved \ntoxicitie sgrade 1 \npain and/or Limitations:  \nLack of control \ngroup  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 429 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntolerated dose  (n=3), 108 iu \n(n=3), 109 iu \n(n=3), and 1010 iu \n(n=2) per injection \nper week for 3 \nweeks.   \n \n \n \nResponse  redness at the \ninjected site in \n8/11 (72%) \npatients, and \ngrade 1  fatigue in \n5/11 (45%) \npatients.  \nLocal response:  \n5 of 11 patients:  \nminor d ecrease in \nsize (<25%) of the \ninjected lesion  \nDistant response: \nSD: 1 of 11 \npatients  \nPD: 10 of 11 \npatients  \nPaul et al. 2003  To examine the \neffect of \nintrale sional beta -\ninterferon \ninjections \ncombined with \nradiotherapy in \npatients with \nmeta static \nmalignant \nmelan oma Case Series  \n \nTreatment:  \nsimultaneous  \nexternal beam \nradiotherapy and \nintralesional \ninjection of beta -\ninterferon. 3\u2013 \n5 Mio IE / 3x/week  20 patients with  \ninoperable \nmelanoma \nmetast ases Response  17 patients \nevalu able \nCR: 12 patients \n(70%)  \nPR: 5 patients \n(30%)  Limitations:  \nLack of control \ngroup  \nCombined \ntreatment with \nradioth erapy 4 \nRadny et al. 2003  To investigate the  Phase II 24 melanoma Response  Lesions:  Response was 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 430 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfeasibility, efficac y, \nand safety of \nintralesionally \ninjected IL -2 in 24 \nmelanoma pat ients \nwith skin and soft -\ntissue metast ases prospective open \nlabel study  \n \nTreatment: 2 -3 \ntimes weekly, 1 -57 \nweeks, max. daily \ndose 12 MIU IL -2 patients with skin \nand soft -tissue \nmeta stases  \n16 patients Stage \nIII \n8 patients Stage IV  \n \n245 lesions   \n \n \n \n \n \n \n \n \n \nSafety CR: 209 lesions \n(85%)  \nPR: 21 lesions (6%)  \nPD: 7 lesions (3%) \n8 lesions (3%) were \nnot a ssessable  \nPatients, local \nresponse:  \nCR: 15 patients  \nPR:  3 p atients  \nMain toxicities \n(grade I+II): Local \nreaction, Fever, \nFlu-like sym ptoms, \nPain, Fatigue, \nNausea/vomiting  evaluated for \npatients and for \ntreated lesions \nseparately. \nResponse for \npatients applied  \nto local re sponse.  \nLimitations:  \nsingle c entre \nstudy, lack of \ncontrol group  \nBong et al. 2002  to study \nimiquimod as an \nadjuvant for  \ntreating cutaneous \nmetastases of \nmalignant \nmelanoma  Case Series  \n \nTreatment: Twice \ndaily application of \nimiquimod 5% \ncream, 21 -28 \nweeks  3 melanoma \npatients with \nmultiple cutaneous \nin-transit \nmetastases Response  >90% regression in \n2 patients, in one \npatient complete \nresponse after \naddition of \nintralesional Il- 2 Limitations:  \nSmall series  4 \nSi et al. 1996  To examine \nwhether \nintralesional \ninjections of GM -\nCSF induce \nregression of Phase I study  \n \nTreatment: weekly \ninjections of 15 -\n50mg GM -CSF into \ntwo subcut aneous 13 melanoma \npatients  with at \nleast 3 \nsubcutaneous \nmetastases Stage \nIII or IV (6 patients)  Response  \n Local response:  \nPR 1 patient  \nSD 8 patients  \nPD 4 patients  \n - 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 431 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsubcutanuous \nmetastases in \npatients with \nmelanoma and \ninfluence lymphoid \ninfiltrates in and \naround the \nmeta stases  metastases up to 6 \nmonths  \nTan et al. 1993  To determine the \nrole of BCG \nimmunotherapy in \nmalignant \nmelanoma  Systematic review  \n \nStage I and II: RCTs \nof BCG (adjuvant \ntherapy)  \n \nStage III: RCTs \n(combination BCG -\nchemother apy) + \ntrials on \nintralesio nal and \noral BCG \nmonotherapy  Stage III, \nintrale sional \ntherapy (local \ntherapy):  \n15 non placebo \ncontrolled trials of \nintralesional BCG \nwere ident ified  \n Response  Stage III, \nintrale sional BCG \ntrials: \nPooled average \ncomplete \nresponse: 19%, PR \n26%, e xtended \nsurvival 13% of \npatients. Thre efold \ngreater rate of \nregression with \nintralesional BCG \nfor intrade rmal \nmetastases \ncompared with \nsubcutaneous \nand/or viscera l \nmetastases Selected \nintrale sional BCG \ntrials were not \ndescribed in detail:  \nnumber of treated \nlesions and lesions \nresponse not \nindicated, control \ngroups not \nindicated  4* \nFierlbeck et al. \n1992  To compare the \neffect of \nintralesional b eta-Case Series  \n \nTreatment:  10 pat ients with \ncutaneous or \nsubcutaneous Lesion Response  Group 1 (n =8) \nCR:2, PR:1, SD:3, \nPD:2 Limitations:  \nSmall sample size  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 432 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ninterferon at \ndifferent dosages  Group 1: 5x106 I.E. \nrIFN-beta 3x/week  \nGroup 2:  5x106 I.E. \nrIFN-beta 1x/week  \nGroup 3:  3x106 I.E. \nrIFN-beta 1x/week  melanoma \nmetast ases \n \n19 lesions  Group 2 (n=8)  \nCR:3, PR:2, SD:2, \nPD:1 \nGroup 3 (n=3)  \nCR:0, PR:0, SD:1, \nPD:2 \nVon Wussow et al. \n1988  To study the \neffects of higher \nIFN concentrations \non malignant \nmelanoma \nmetastases, \npatients we re \ntreated with \nintalesional IFN \ninjections. Retrospective \nevaluation  \n \nTreatment:  \nSystemic and \nintralesional \nInterferon alpha  51 patients  Lesion Response  Intralesional \ntreatment (lesions \nn= 51)  \nCR n=16  \nPR n=7  \nNC n=26  \nPD n=2  26 patients were \ntreated with \nhuman i nterferon \nalpha and 25 \npatients with \nrecombinant \ninterferon alpha  4 \nLokich et al. 1979  To describe the \ntreatment with \nintralesional \nmethanol \nextraction residue \nof bacillus \nCalmette Guerin \n(MER-BCG) Case Series  \n \nTreatment:  \nSingle injection \nwith MER -BCG 6 patients with \ncutaneous or \nsubcut aneous \nmelanoma \nmetastases \n9 lesions  Lesion response  Complete \nregression: 3 \nlesions  \nPartial regression: \n2 lesions  \nErythema/no \nregression: 4  - 4 \nVosika et al. 1979  To investigate the \nclinical \npharmacol ogy and \nefficacy  of Phase I study  \n \nTreatment: every 1 \nor 2 weeks CWS/P3  15 melanoma \npatients Stage III \nand IV (8 patients)  Response injected \nand non- injected \nlesions  In 6 (40%) of the \n15 patients, \nresponse  \n(CR+PR) of at least Limitations:  \nSmall series, lack \nof co ntrol group  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 433 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nintralesional \nimmonotherapy \nutilizing a vaccine \ncomposed of \nMycobacterium \nsmegmatis cell \nwall skeleton and \nthe mycobacterial \nglypolipid fraction  one injected lesion \nwas observed. In 4 \nof these 6 patients, \nnoninjected \ndisease also \nresponded. 1 \npatient had PR of \npulmonary \nmetastasis in \naddition to CR of  \ninjected lesion. \nNathanson et al. \n1979  To compare the \nefficacy of \ntreatment with \nBCG when it was \naltern atively \nadministered \neither by \nintrale sional \ninjection, or \nintradermally in a \nnontumor bearing \nsite, using the \nmultipuncture \n(Tine) technique  Randomised \nprospective study  \n \nTreatment:  \nIL-BCG Group: BCG \nintralesiona lly in \nthe base of each \nlesion once a week \nfor 6 weeks (up to \n5 lesions)  \nMPV-BCG: Multiple \npuncture BCG once \na week for 6 weeks  59 patients w ith \nhistologically \nproven, surgically  \nincurable \nmelan oma, with \nmeasur able lesions \nin or assoc iated \nwith the skin   \n \n \n \nResponse  Rate \n \nSurvival \n \n \nToxicity  \n IL-BCG vs. MPV -\nBCG \n(44 patients \nevalu able)  \n \n45% vs.  9% for  \n \n21.1 vs. 13.3 \nmonths  \n \nMore severe \ntoxici ty was \nobserved in the IL -\nBCG group, but no \ndeaths were seen \ndue to toxicity in \neither group  the study design \ndoes not cover the \nquestion of \nlitera ture search \n(efficacy of local \ntreatments \ncompared to \nstandard \ntreatment), the \nstudy is therefore \ndownclass ified as \nlevel 4 study  \n \nLimitations:  \nImbalance of \ngroups: more male \npatients in the IL -\nBCG group, \nrandomization 4*  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 434 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nscheme not \ndescribed  \nStorm et al. 1979  To describe the \ntreatment with \nintralesional bacille \nCalmette Guerin \nand hyperthermic \nperfusion  Case S eries \n \nTreatment: \nInjection of lesions \nwith Glaxo strain \nbacille Calmette \nGuerin every 2 -3 \nweeks  27 melanoma \npatients with \nlocally recurrent \ndisease  Response  Complete or \ntransient local \ndisease control: 20 \nof 27 patients  \n number of treated \nlesions not \nindicated  4 \nKrown et al. 1978  To determine the \noptimal dose, \nschedule and \ntoxicity of MER \n(methanol \nextraction residue \nof bacillus \nCalmette -Guerin) \ngiven by the il \nroute, and to \ncompare it with \nBCG in terms of \ntumor regression \nand side effects.  Phase I study  \n \nTreatment: 1 -5 \nlesions were \ninjected with 0.1 - \n0.5 mg of MER on \nthe first day, the \ndose was adjusted \ndaily, d epending \nupon the degree of \nlocal reaction and \nsystemic effects  22 patients with \nskin and \nsubcutan eous \nmetastases without \nvisceral metastases   \n \nResponse  \n \n \n \n \nToxicity  18 patients \nevalu able \nCR of all injected \nlesions: 8 patients  \nPR: 4 patients  \n6 patients did not \nrespond  \nFever (100%), \nChills (45%), \nMalaise (50%), \nHeadache (45%), \nNausea and \nvomiting (18%), \nHypotension (14%),  \nLethargy (14%), \nCyanosis ( 9%), \nConfusion (5%)  number of treated \nlesions not \nindicated  4 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 435 von 817 \nAblative Therapien (Elektrochemotherapie, lokale Chemotherapie, Bengal Rosa, Carbon Laser)  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nKis et al. 2011  To investigate ECT \ntreatm ent in \nmelanoma patients  Case Series  \n \nTreatment:  \nECT with i.v. \nbleomycin (15 \nmg/m2) under \ngeneral sed ation 9 patients with \n158 cutaneous and \nsubcutaneous \nmeta stases  Response  CR 23%  \nPR 39%  \nNo change 30%  \nPD 8%  - 4 \nFoote et al. 2009  To report three \ncases o f \nintralesio nal rose \nbengal treatment \nfollowed by \nradiotherapy  Case Ser ies 3 patients with  \ncutaneous \nmetas tastes  Response  Local complete \nresponse in all 3 \npatients  - 4 \nThompson et al. \n2008  To investigate the \ntherapeutic \npotential of PV -10 \n(Rose Bengal) i n \npatients with stage \nIII metastatic \nmelanoma.  Open label phase II \nstudy  \n \nTreatment:  \nOne single IL \ninjection of PV- 10 \nin 1-3 target \nlesions  11 patients with \nlocoregionally \nrecurrent \nmelanoma, Stage \nIII \n \n26 lesions treated  \n28 lesions \nuntreated (to \nassess po tential \nbystander effect)  lesion response  \noverall response  \nbystander effect  \ntoxicity  25 lesions \nevalu able: \nCR 36% (n=9)  \nPR 12% (n=3)  \nSD 28% (n=7)  \nPD 24% (n=6)  \nPatients:  \nCR 27% (n=3)  \nPR 27% (n=3)  \nSD 27% (n=3)  \nPD 18% (n=2)  \nApparent \nbystander effect in \nuntrea ted tumours \nin 27% of patients  - 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 436 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nToxicity:  \ntransient mild to -\nmoderate pain at \nthe treatment site \n(n=8), local \ninflammation \n(n=4),  \ntreatment site \npruritus (n=3), \nmild \nphotosensitivity \nreaction (n=1), \nmild insomnia  \nsecondary to \ninjection site pain \n(n=1)  \nQuaglino et al. \n2008  To prospectively \nevaluate clinical \nactivity and \ntolerability of ECT \nwith i.v. bleomycin  Prospective Phase \nII study  \n \nTreatment:  \nECT with i.v. \nbleomycin  14 patients, Stage \nIII Response (8 weeks \nafter ECT)  \nLocal tumor \ncontrol rate  Patients (n=14):  \nCR n=7 (50%)  \nPR n= 6 (43%)  \nPD n= 1 (7%)  \nLesions (n=160):  \nCR 62%  \nPR 33%  \n2 years local \ntumor control rate: \n74.5%  - 4 \nGaudy et al. 2006  To assess whether \nEP therapy \nimproves the local A prospective \ninternally \ncontrolled study 12 patients Stage \nIII (4 patients) and \nStage IV ( 8 patients  \n \n Lesions treated \nwith bleomycin + \nEP (n=30) versus the study design \ndoes not cover the \nquestion of 4*  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 437 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncontrol of skin \nmetastases of \nmelanoma by \nintralesional \nbleomycin  with \nrandom ization of \nmelanoma skin \nmetastases in each \nindividual to \nintralesional \ninjections of \nbleomycin alone or \nto intrale sional \ninjections of \nbleomycin with EP  under \nchemother apy)  \n54 lesions   \nLocal response \n(lesions)  \n \n \nTolerance  bleomycin alone \n(n=24):  \nCR  36% (11 of 30) \nvs. 8% (2 of 24)  \np = 0.016  \n \nAll patients \nreported \ndiscomfort during \nthe EP proc edure, \nincluding local \npain for 9 p atients \n(75%) at the \ntreatment site and \nmuscle spasm with \nmyocl onia in 3 \ncases (25%). No \nclinical or biologic \nsystemic toxi city. literature search \n(efficacy of local \ntreatme nts \ncompared to \nstandard \ntreatment), the \nstudy is therefore \ndownclass ified as \nlevel 4 study  \n \nLimitations: \nNo comparison to \nstandard \ntreatments (e.g. \nsurgery, \nradiotherapy)  \nByrne et al. 2005  to evaluate the \neffect of EPT after \nintratumoral \ninjection of \nbleomycin, and to \ncompare this with \nthe effect of \nintratumoral \ninjection of \nbleomycin alone  Phase II, \nrandomized, open -\nlabel \nstudy comparing \nintralesional \nbleomycin + EPT \nwith intralesional  \nbleomycin alone. \n \nTreatment:  \nInjectin of 19 patients, stage \nIII or IV with at \nleast 2 cutaneous \nand/or \nsubcutaneous \nmetastases \n \n36 evaluable \nlesions, lesions \nwere randomized \nto treatment  lesion response  \n bleomycin only (19 \nLesions)  \nCR  26% (n =5) \nPR 5% (n=1)  \nSD 15% (n=3)  \nPD 53% (n=10)  \n \nbleomycin plus EPT \n(17 lesions, plus 1 \nlesion crossed \nover)  Response was \nevaluated for \ntreated lesions. No \ndata available for \nduration of \nresponse  \nLimitations:  \nNo comparison to \nstandard \ntreatments (e.g. \nsurgery, 4*  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 438 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nbleom ycin followed \nby ele ctrical \npulses, possible \nretrea tment at wek \n4, 8 or 12  CR  72% (n=13)  \nPR 5% (n=1)  \nSD 18% (n=3)  \nPD 5% (n=1)  \n \np=0.002  radiotherapy)  \nOratz et al. 2003  To evaluate the \nuse of a novel \nintrale sional \nchemother apy \u2013 \ncisplatin / \nadrenaline \ninject able gel \u2013  for \nthe treatment of \nrefractory or \nrecurrent \ncutaneous and soft \ntissue melan oma \nmetastases open -label, \nmulticentre study  \n \nTreatment: up to \nsix weekly \nintratumoral \ninjections of \ncispla tin/adrenalin\ne gel within an 8 \nweek period or \nuntil co mplete \nresponse  25 patients with \n244 lesions were \nevaluable for \nefficacy  Respo nse \nToxicity  CR was achieved in \n114 tumours \n(47%), PR in 16 \ntumours (7%). \nMedian time to an \nindivid ual tumour \nresponse was 62 \ndays (range 1 \u2013534 \ndays). M edian \nduration of an \nindividual tumour \nresponse (n = 124)  \nwas 347 days \n(range 30 \u2013783 \ndays).   4 \nRols et  al. 2000  To apply the \nelectrochemothera\npy method  Case Series  \n \nTreatment:  \n10 mg/m2 dose of \nbleomycin i.v. \nfollowed by short, \nintense electric \npulses 4 patients  \n55 metastases  Response  Objective \nresponses of \ntreated \nmeta stases:  more \nthan 90%  \nComplete response \nrate 9%  Small series  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 439 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSersa et al. 2000  To evaluate the \nantitumor \neffectiveness of \nelectrochemother a\npy using \nintratumoral \ncisplatin \nadministration  \non cutaneous \ntumor nodules in \nmalignant \nmelanoma  \npatients  Phase II open -label \nStudy  \n \nTreatment:  \nIntrat umoral \ncispla tin followed \nby electrical pulses \nversus cisplatin \nalone ve rsus \nelectric pu lses \nalone versus \ncontrol  10 patients with \ncutaneous \nmeta stases, Stage \nIII or IV  \n \nECT group: 82 \nlesions  \ncisplatin group:  \n27 lesions  \nelectric pulses  \ngroup: 2 lesions  \nuntreated controls: \n22 lesions  Lesion response  ECT group (n=82): \nCR 68% (n=56), PR \n10% (n=8), SD 15% \n(n=12), PD 7% \n(n=6)  \nCisplatin group \n(n=27):  \nCR 19% (n=5), PR \n19% (n=5), SD 30% \n(n=8), PD 33% \n(n=9)  \nElectric pulses \n(n=2):  \nSD 50% (n=1), PD \n50% (n=1)  \nControl group \n(n=22):  \nSD 36% (n=8), PD \n64% (n=14)  No details given \nhow l esions are \nallocated to \ndifferent treatment \ngroups  \nLimitations: \nNo comparison to \nstandard \ntreatments (e.g. \nsurgery, \nradiotherapy)  \nSmall sample size  4 \nGlass et al. 1996 To report the \neffects of ECT in 5 \npatients with \nmetastatic \nmalignant \nmelanoma  Case Series  \n \nTreatment:  \nIntralesional \nbleomycin followed \nby pulses of \nelectricity \ndelivered via \nneedle electrodes \nor cal iper 5 patients with \ncutaneous \nmetastatic \nmelanoma  \n \n23 lesions treated \nwith E CT \n3 lesions with \nelectic pulses \nalone  \n9 lesions Lesion response  ECT: \nCR 78% (n=18)  \nPR 17% (n=4)  \nSD 4% (n=1)  \nElectric pulses \nalone: No response  \nBleomycin alone: \nNo response  \n - 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 440 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nbleomycin alone  \n \nContact Sensitizer (Dinitrochlorobenzene, Diphencyprone)  \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \nTerheyden et al. \n2006  To gain more \ninsight to criteria \nof response to \ncombined \ntreatment with \nepifocal DNCB and \nintravenous DTIC, \ndata were collected \nin this \nretrospective study  retrospective study  \n \nTreatment:  \nepifocal DNCB and  \nintravenous DTIC  72 evaluable \npatients with \nrecurrent \nmelanoma  \nStage III n=39  \nStage IV n=33  Response  \n \n \n \n \n \n \nProgression free \nsurvival  \n \nOverall survival Stage III, patients \nn=39  \nResponse  \nCR n=15 (39%)  \nPR n=9 (23%)  \nSD n=9 (23%)  \nPD n=6 (15%)  \nMedian PFS: 10 \nmonths (range 3 \u2013 \n120 months)  \nmedian OS 14 \nmonths (range 3 \u2013 \n120 months)  - 4 \nDamian et al. 2009  To report DPCP \ntreatment of 7 \npatients with \ncutan eous \nmetastastic \nmelanoma  Case Series  \n \nTreatment:  \n2 weeks after \nsensitization \nweek ly applicatio \nof DPCP cream to \nall cutan eous \nmetastases 7 patients with  \ncutaneous \nmetas tastes  Response  CR 4 patients  \nPR 3 patients  - 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 441 von 817 \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \nTrcka et al. 1998  To describe an \nimmunochemother\napy for metastatic \nmelanoma  \n Case Series  \n \nTreatment:  \nepifocal DNCB and  \nintravenous DTIC  15 evaluable \nmelanoma p atients  Response  n=15  \nCR n=4  \nPR n=3  - 4 \nStrobbe et al. 1997  To describe the \nexperience with a \ncombination of \nDNCB and DTIC in \nselected patients \nwith regional \ncutaneous \nmetastases Case Series  \n \nTreatment:  \nLocal DNCB  2% \nsolution in acetone \nalone for 4 weeks, \nstart of DTIC i.v. \nafter 4 weeks  59 patients with \nthe presence of \nlocoregional \nmetastases, Stage \nIII 63% (n=37) or \nStage IV 37% \n(n=22).  \n \n Response  Overall Response \n(patients)  \nCR 25% (n=15)  \nPR+SD 12% (n=7)  \nPD 63% ( n=37) \nLocal Response \n(patients)  \nCR+PR 68% (n=40)  No detailed data \nregarding local \nresponse available  \nLimitations: \nCombination \ntherapy 4 \nCohen et al. 1978  To compare \nefficacy and \ntoxicity of \nintralesional BCG \nversus intralesional \nDNCB in patients \nwith loc oregional \nmetastatic \nmelanoma  Randomized \nprospective Study  \n \nTreatment:  \nBCG group: \nintralesional BCG \ninjecitons every 4 -\n6 weeks  \nDNCB group: \ntopical application \nuntil \nhypersensitivity \noccured (within 2 \nweeks) thereafter \nintralesional 18 patients with \nintradermal or \nsubcutaneous \nmelan oma \nmetastases, Stage \nIII  \n \nRandomisation in \ntwo treatment \ngroups: 9 patients \nreveived BCG with \n177 dermal and 22 \nsubcutaneous \nlesions, 9 patients \nreveived DNCB Response  \n \n \n \n \n \n \n \n \n \n \n \n \nSurvival \n Lesion response:  \nBCG group  \nRegression dermal \nlesions: 90% \n(n=157), \nsubcut aneous \nlesions: 45% \n(n=10) \nDNCB group  \nRegression dermal \nlesions: 90% \n(n=453), \nsubcutaneous \nlesions: 43% \n(n=27) the study design \ndoes not cover the \nquestion of \nlitera ture search \n(efficacy of local \ntreatments \ncompared to \nstandard \ntreatment), the \nstudy is therefore \ndownclass ified as \nlevel 4 study  4*  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 442 von 817 \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \ninjections every 4 -\n6 wee ks with 504 dermal \nand 63 \nsubcutaneous \nlesions  \nToxicity  Overall Survival at \n39 months : 33% in \nboth groups.  \nToxicity BCG vs. \nDNCB  \nFever (88% vs. 0%), \nChills (84% vs. 0%), \nNausea 1(40% vs. \n0%), Major \nulcer ation (44% vs. \n4%), Cellulitis \n(antibi otics) (16% \nvs. 2%), Distant \ninfection (8% vs. \n0%) Diss eminated \nintravascular \ncoagul ation, \nincluding  one near \nfatality. (12% vs. \n0%) \n* the study design does not cover t he question of literature search (efficacy of local treatments compared to standard treatment), the study is therefore \ndownclass ified as level 4 study   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 443 von 817 \n6.1.4.2.  Aktualisierungsrecherche 2015  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAndtbacka et al. \n2015  To evaluate \nwhether treatment \nwith T -VEC \nresulted in an \nimproved durable \nresponse rate \n(DRR) compared \nwith GM -CSF in \npatients with \nunresected stage \nIIIB to IV \nmelanoma.  RCT \n \nTreatment:  \n \nGroup A: \nTalimogene \nLaherparepvec \n(n=295)  \n \nGroup B:  \nGM-CSF (n =141)  Not surgically \nresectable, stage \nIIIB to IV melanoma \nsuitable for direct \nor ultrasound -\nguided injection (at \nleast one \ncutaneous, \nsubcutaneous, or \nnodal lesion or \naggregation of \nlesions 10 mm in \ndiameter).  Durable Response \nRate \n \nOverall Response \nRate \n \nOverall Survival DRR was higher \nwith T -VEC (16.3%; \n95% CI, 12.1% to \n20.5%) than GM -\nCSF (2.1%; 95% CI, \n0% to 4.5%]; odds \nratio, 8.9; P \n<.001).  \n \nOverall response \nrate was higher in \nthe T -VEC arm \n(26.4%; 95% CI, \n21.4% to 31.5% v \n5.7%; 95% CI, 1.9% \nto 9.5%) .  \n \nMedian OS was \n23.3 months (95% \nCI, 19.5 to 29.6 \nmonths) with T -\nVEC and 18.9 \nmonths (95% CI, \n16.0 to 23.7 \nmonths) with GM -\nCSF (hazard ratio, \n0.79; 95% CI, 0.62 \nto 1.00; P .051).  T-VEC efficacy was \nmost pronounced \nin patients with \nstage IIIB, IIIC, or \nIVM1a disease and \nin patients with \ntreatment -naive \ndisease.  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 444 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nByers et al. 2014  To evaluate the \ncurrent evidence \nregarding the \nefficacy and side \neffect profile of \nintra-lesional IL -2 \ntherapy for \ntreating in -transit \nmelanoma  Systemic review  \n \nInclusion crit eria: \nphase II or III \nstudies that \nexamined IL -2 \ninjected directly \ninto \ncutaneous/subcuta\nneous melanoma \nmetastases and \nevaluated the \nclinical response.  \n \nExclusion criteria: \nStudies that were \nphase I, non -\nhuman, had fewer \nthan five subjects, \nor had quality  \nscores of less than \nthree (of six) \naccording to \nNewcastle -Ottawa \nQuality \nAssessment Scale \nfor cohort studies.  \n \nThe literature \nsearch yielded 277 \ncitations. 49 140 patients with \n2,182 lesions we re \ntreated in these six \nstudies.  \n Response Rates by \nLesion  \n \nResponse Rates by \nSubject  \n \nSide Effects  Heterogeneity was \nseen in IL -2 dosage \nand treatment \ninterval.  \nResponse rate was \nvariable as well. \nPooling the \nlesions, complete \nresponse was seen \nin 78%.  \n \nPooling subjects, \n50% achieved a \ncomplete \nresponse.  \n \nTreatment was \ngenerally well \ntolerated, with \nlocalized pain and \nswelling, and mild \nflu-like symptoms.  Problem with \nheterogeneity of \nincludes studies \nregarding dosing \nof IL-2 described. \nHowever, IL -2 \ntreatment \nintralesionally \napplied judged as \nsufficient and well \ntolerated  2a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 445 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nunique and \npotentially relevant \nstudies were \nidentified and their \nabstracts further \nevaluated. 2 8 \narticles did not \naddress the \nresearch question, \n2 were phase I \nstudies and 4 were \ncase reports with \ntoo few subjects. \nFour studies were \nfound to be \nevaluating \nsystemically \ndelivered IL -2 (not \nintra-lesional). 2 \nstudies used IL -2 \nindirectly \nadministered \nthrough vectors. 2 \nstudies were found \nto be long -term \nfollow -up of \nprevious studies \nand one study did \nnot assess the \nclinical outcome. \nThe remaining 6  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 446 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \narticles matched \nour criteria and \nwere subjected to \nquality \nassessment.  \nSisti et al. 2015 To critically assess \nthe studies \nevaluating the \nmonotherapy with \nImiquimod cream \nin the treatment of \ncutaneous \nmetastases from \nmelanoma  Systemic review  \n \nMEDLINE,  EMBASE, \nCochrane Library, \nand Google Scholar \ndatabases were \nsearched with the \npurpose of study \nselection. The \nterms \"melanoma\" \ncombined with \n\"metastases\" and \n\"imiquimod\" were \nused as database \nqueries. The only \ninclusion criterion \nwas: clinical \nhuman studi es \nevaluating IMG \nmonotherapy in \nmetastatic \nmelanoma. Any \nsimultaneous \ncombination \ntherapy was 17 patients treated \nin 11 studies  Not pre -specified \nin report  \n \nResponse rate and \nclinical outcome \naccording to \ndifferent dosing \nschedules reported  Response rate was \nvariable. Pooling \nthe lesions, \ncomplete \nregression of \nmelanoma \nmetastases wa s \nseen in 82.3% of \nthe patients. There \nwas no significant \ndifference in terms \nof clinical outcome \nwhen comparing \nthe frequency of \nImiquimod \napplication. Review mainly \nincluded case \nreports, so \nbaseline quality of \nselected papers \nwas low. Whereas \nthe search  strategy \nis well described, \noutcomes \nobjectives of the \nreview are missing. 3a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 447 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nexcluded.  \n57 studies \nidentified of which \n46 did not meet \ninclusion criteria, \nleaving 11 case \nstudies.  \n \nA modified quality \nassessment tool \nfor observational \nstudies was used.  \nMali et al. 2012 To consolidate \ncurrent experience \nwith clinical \nelectochemotherap\ny (ECT) of \ncutaneous or \nsubcutaneous \ntumours from the \neffectiveness point \nof view and to \nprovi de a \ntransparent and \nobjective \nframework for \ndiscussion on \ndifferences in \neffectiveness of \nclinical ECT.  Systematic search \nof 16 bibliographic \ndatabases was \nperformed to \nobtain articles \nregarding clinical \nECT using search \nterms \n\u201celectrochemother\napy\u201d and \u201c clinical\u201d \nand time range \nbetween 1st \nJanuary 1991 and \n18th October \n2011.  \n \nResults from initial \nsearch: 1181 431 patients and \n1,894 tumours  Response of indi -\nvidual tumors: \n \nComplete response \n(CR),  \n \nPartial response \n(PR),  \n \nNo change (NC),  \n \nProgressive \ndisease (PD) ,  \n \nObjective response \n(OR; including CR \nand PR)  \n  \n \n \nCR 56.8%  (for \nMelanoma)  \n \nSpecified for each \nstudy only  \n \n \n \nSpecified for each \nstudy only  \n \nOR 80.6% (for \nMelanoma)  \n \n The search \nstrategy is well \ndescribed. More \noutcomes declared \nthan reported  2a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 448 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nreferences;  \n44 reports \nincluded in \nanalysis  \n \nThe risk of bias of \nincluded studies \nwas assessed \nindependently by 2 \nout of 3 authors \naccording to the  \nrecommendations \nof the Cochrane \nCollaboration. No response (NR; \nincluding NC and \nPD)  \n Specified for each \nstudy only  \n \nSpratt et al. 2014   To perform the \nfirst meta -analysis \nof the efficacy of \nskin-directed \ntherapies for \ncutaneous \nmetastases.  Systematic \nliterature searches \nwere conducted in \nfour databases \n(MEDLINE [via \nPubMed], EMBASE, \nThe Cochrane \nLibrary, a nd \nClinicalTrials.gov) \nfor human- only \nstudies.  \nThe search \nstrategy contained \ntwo major \ncomponents linked \ntogether with the 47 studies \nreporting on 915 \npatients with \n4,313 cutaneous \nmetastases of skin \ntumours (CMs) \nwere include d for \nanalysis.  Complete \nResponse (CR)  \n \n \n \nObjective response \nrate (ORR)  1,890 (54.4%) of \nthe 3,477 \nassessable patients \nhad a CR.  \n \n \nAll 4,313 CMs were \nassessable for ORR \nanalyses, of which \n2,970 (68.9%) had \nORRs. ORR was \ndefined in 42 \nstudies as the sum \nof CR plus PR.  \n \nThe ORR for all Probably the most \nsufficient and \ncomprehensive \nreviews including a \nmeta -analysis of \ntreatment of \ncutaneous \nmetastases of skin \ntumors  2a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 449 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAND operator: (1) \nskin-directed \ntherapy: surgery, \nexcision, topical, \nintralesional \ntherapy, injection, \nphotodynamic, \nphotochemo-\nthera py, \nelectrochemothera\npy, radiation, \nradiotherapy, \nbrachytherapy AND \n(2) skin metastasis: \ncutaneous \nmetastasis/metast\nases, dermal \nmetas -\ntasis/metastases.  studies was 60.2% \n(95%CI, 50.6% to \n69.0%).  \n \n6.1.5.  Literatur  \n \nAndtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015;33(25):2780 -2788.  \nBong AB, Bonnekoh B, Franke I, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous  metastases of malignant melanoma. Dermatology 2002;205:135-\n138 \nBoyd KU, Wehrli BM, Temple CL. Intra -lesional interleukin -2 for the treatment of in -transit melanoma. J Surg Oncol 2011;104:711- 717 \nByers BA, Temple -Oberle CF, Hurdle V, McKinnon JG. Treatment  of in-transit melanoma with intra- lesional interleukin -2: a systematic review. J Surg Oncol. 2014;110(6):770- 775. \nByrne CM, Thompson JF, Johnston H, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (elec trochemotherapy) . Melanoma Res 2005;15:45- 51 \nCohen MH, Jessup JM, Felix EL, et al. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional  Bacillus Calmette -\nGuerin versus intralesional dinitrochlorobenz ene. Cancer 1978;41:2456- 2463  \nDamian DL, Shannon KF, Saw RP, et al. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol 2009;50:266- 271 \nDehesa LA, Vilar -Alejo J, Valeron -Almazan P, et al. Experience in the treatment of cutaneous in -transit melanoma metastases and satellitosis with intralesional interleukin -2]. Actas \nDermosifiliogr 2009;100:571- 585 \nFierlbeck G, d'Hoedt B, Stroebel W, et al. Intralesional therapy of melanoma metastases with recombinant interferon -beta]. Hautarzt 1992;43:16- 21  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 450 von 817 \nFlorin V, Desmedt E, Vercambre -Darras S, et al. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5 -fluorouracil. Invest New Drugs \n2011 \nFoote MC, Burmeister BH, Thomas J, et al. A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. Melanoma Res 2010;20:48- 51 \nFujimura T, Okuyama R, Ohtani T, et al. Perilesional treatment of metastatic melanoma with interferon -beta. Clin Exp Dermatol 2009;34: 793-799 \nGarcia MS, Ono Y, Martinez SR, et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high -dose intralesional interleukin 2 in combination with topical \nimiquimod and retinoid cream. Melanoma Res 2011  \nGaudy C, Richard MA, Folchetti G, et al. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 2006;10:115-\n121 \nGlass LF, Pepine ML, Fenske NA, et al. Bleomycin -mediated electrochemotherapy of metastatic melan oma. Arch Dermatol 1996;132:1353- 1357 \nGreen DS, Bodman -Smith MD, Dalgleish AG, et al. Phase I/II study of topical imiquimod and intralesional interleukin -2 in the treatment of accessible metastases in malignant melanoma. \nBr J Dermatol 2007;156:337- 345 \nKhorana AA, Rosenblatt JD, Sahasrabudhe DM, et al. A phase I trial of immunotherapy with intratumoral adenovirus -interferon -gamma (TG1041) in patients with malignant melanoma. \nCancer Gene Ther 2003;10:251- 259 \nKis E, Olah J, Ocsai H, et al. Electrochemotherapy of Cutaneous Metastases of Melanoma -A Case Series Study and Systematic Review of the Evidence. Dermatol Surg 2011  \nKrown SE, Hilal EY, Pinsky CM, et al. Intralesional injection of the methanol extraction residue of Bacillus Calmette -Guerin (MER) into cutane ous metastases of malignant melanoma. \nCancer 1978;42:2648- 2660  \nLokich JJ, Garnick MB, Legg M. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivativ e. Oncology 1979;36:236- 241 \nMali B, Jarm T, Snoj M, Sersa G, Miklavc ic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta -analysis. Eur J Surg Oncol. 2013;39(1):4- 16. \nNathanson L, Schoenfeld D, Regelson W, et al. Prospective comparison of intralesional and multipuncture BCG in recurrent intrade rmal melanoma. Cancer 1979;43:1630- 1635  \nOratz R, Hauschild A, Sebastian G, et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with  cutaneous and soft tissue metastases of malignant melanoma. \nMelanoma Res 2003;13:59- 66 \nPaul E, Muller I, Renner H, et al. Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional beta- interferon injection. Melanoma Res \n2003;13:611- 617 \nQuaglino P, Mortera C, Osella -Abate S, et al. Electrochemotherapy with i ntravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008;15:2215- 2222 \nRadny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin -2 in soft -tissue melanoma metastases. Br J Cancer 2003;89:1620- 1626  \nRols MP, Bachaud JM, Giraud P, et al. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 2000;10 :468- 474 \nSersa G, Stabuc B, Cemazar M, et al. Electrochemotherapy with cisplatin: clinical experience in malignant melan oma patients. Clin Cancer Res 2000;6:863- 867 \nSi Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intral esional GM -CSF. Melanoma Res 1996;6:247- 255 \nSisti A, Sisti G, Oranges CM. Topical trea tment of melanoma skin metastases with imiquimod: a review. Dermatol Online J. 2015;21(2).  \nSpratt DE, Gordon Spratt EA, Wu S, et al. Efficacy of skin -directed therapy for cutaneous metastases from advanced cancer: a meta -analysis. J Clin Oncol. 2014;32(28) :3144- 3155.  \nStorm FK, Sparks FC, Morton DL. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmett e Guerin and hyperthermic perfusion. Surg Gynecol Obstet \n1979;149:17- 21 \nStrobbe LJ, Hart AA, Rumke P, et al. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Res 1997;7:507 -512 \nTan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette -Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg O ncol 1993;19:985- 990 \nTerheyden P, Kortum AK, Schulze HJ, et al. Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey o f the \nGerman Dermatologic Co -operative Oncology Group. J Cancer Res  Clin Oncol 2007;133:437- 444 \nThompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 2008;18:405- 411 \nTrcka J, Kampgen E, Becker JC, et al. Immunochemotherapy of malignant melanoma. Epifocal administration of dinitrochlorobenzene (DNCB) combined with systemic chemotherapy with \ndacarbazine (DTIC)]. Hautarzt 1998;49:17- 22 \nvon Wussow P, Block B, Hartmann F, et al. Intralesional interferon -alpha therapy in advanced malignant melanoma. Cancer 1988;61:10 71-1074 \nVosika GJ, Schmidtke JR, Goldman A, et al. Intralesional immunotherapy of malignant melanoma with mycobacterium smegmatis cell wall skeleton combined with trehalose dim ycolate \n(P3). Cancer 1979;44:495- 503 \nWeide B, Derhovanessian E, Pflugfelder A, e t al. High response rate after intratumoral treatment with interleukin -2: results from a phase 2 study in 51 patients with metastasized \nmelanoma. Cancer 2010;116:4139- 4146 \nWeide B, Eigentler TK, Pflugfelder A, et al. Survival after intratumoral interleukin -2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow -up. \nCancer Immunol Immunother 2011;60:487- 493 \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 451 von 817 \n6.2. Frage V.2. und V.3. Systemtherapie Einzelsubstanzen  \u2013 De novo Recherche  \nFrage V.2. : F\u00fcr welche Substanzen konnten ob jektive Remissionen im metastasierten Stadium (First - und S econdline) gezeigt werden?  \nFrage V.3. : F\u00fcr welche Substanzen konnte eine Verbesserung des Gesamt\u00fcberl ebens im metastasierten Stadium (First - und Secondline) gezeigt \nwerden?  \n6.2.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema  \nPopulation  Intervention  Comparison  Outcome  \nAdvanced melanoma patients stage \nIV, unresectable stage III  Systemic treatment  Standard of care/Placebo/Standard \nof care+Placebo  Overall Survival, Response, D uration \nof Response  \n \nSuchw\u00f6rter  \nStichwort  melanoma  phase III  \nphase 3  Chemotherapy  Stage IV  \nStage 4  \nSynonyme   random*   Palliative  \nOber -/Unterbegriffe    Systemic thera py Salvage  \nmetastatic  \nDisseminated  \nMesh Term  melanoma  Clinical Trial, Phase III  \nRandomized Co ntrolled Trial  Drug Therapy   \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 452 von 817 \n6.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  \n6.2.2.1.  Prim\u00e4rrecherche 2012  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  (melanoma[tiab] OR melanoma[MeSH]) AND (Clinical Trial, Phase III [Publication Type] OR \nRandomized Controlled Trial [Publication Type] OR \u201cphase 3\u201d OR \"phase III\"[tiab] OR \nrandom*[tiab]) AND (\u201csystemic therapy\u201d[tiab] OR chemotherapy[tiab] OR \"drug \ntherapy\"[MeSH] OR metastatic[tiab] OR palliative[tiab] OR advanced[tiab] OR \"stage IV\"[tiab] \nOR \"stage 4\"[tiab] OR sal vage[tiab])  26.07.11  1091  (Auswahl: 38)  \nMedline \u2013erweiterte \nSuchstr ategie  (melanoma[tiab] OR melanoma[MeSH]) AND (Clinical Trial, Phase III [Publication Type] OR \nRandomized Controlled Trial [Publication Type] OR \u201cphase 3\u201d OR \"phase III\"[tiab] OR \nrandom*[tiab]) AND (\u201csystemic the rapy\u201d[tiab] OR chemotherapy[tiab] OR \"drug \ntherapy\"[MeSH] OR diss eminated [tiab] OR metastatic[tiab] OR palliative[tiab] OR \nadvanced[tiab] OR \"stage IV\"[tiab] OR \"stage 4\"[tiab] OR sal vage[tiab])  05.12.11  1142 (Avril et al. 2004 \ndazu)  \nCochrane Library  (melanoma and (random* or phase 3) and (systemic therapy or chemotherapy or m etastatic \nor palliative or advanced or salvage)).ti,ab.   17.10.11 385 (Auswahl: 2 5, abz. \nDuble tten: 2 dazu ) \nEmbase  (melanoma and (random* or phase 3) and (systemic therapy or chemo therapy or metastatic \nor palliative or advanced or sa lvage)).ti,ab.  04.10.11  894 (Auswahl: 33, abz. \nDuble tten: 3 dazu)  \nUpdate Suche  \nMedline s.o. 30.01.12 1145 (2 dazu : Kim et al. \n2012, Kirkwood et al. \n2012)  \nMedline s.o. 01.08.12 1221 (2 dazu: Flaherty et  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 453 von 817 \nDatenbank  Suchstrategie  Datum  Treffer \nal. 2012, Hauschild et al. \n2012)  \nCochrane Library  s.o. 30.01.12  389 (0 dazu)  \nEmbase  s.o. 23.01.12  937 (0 dazu)  \n \n6.2.2.2.  Aktualisierungsrecherche 2015  \nDatenbank  Suchstrategie  Datum  Treffer \nMedline  (((melanoma[tiab] OR melanoma[MeSH]) AND (Clinical Trial, Ph ase III [Publication Type] OR \nRandomized Controlled Trial [Publication Type] OR \u201cphase 3\u201d OR \"phase III\"[tiab] OR \nrandom*[tiab]) AND (\u201csystemic therapy\u201d[tiab] OR chemotherapy[tiab] OR \"drug \ntherapy\"[MeSH] OR disseminated[tiab] OR metastatic[tiab] OR pallia tive[tiab] OR \nadvanced[tiab] OR \"stage IV\"[tiab] OR \"stage 4\"[tiab] OR salvage[tiab]))) AND \n(\"2011.12.06\"[Date - Publication] : \"3000\"[Date -  Publication])  16.09.15  451 \nCochrane Library  (melanoma and (random* or phase 3) and (systemic therapy or chemother apy or m etastatic \nor palliative or advanced or salvage)).ti,ab.   16.09.15 67   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 454 von 817 \n6.2.3.  Auswahlkriterien  \n6.2.3.1.  Prim\u00e4rrecherche 2012  \nAuswahl der Literatur  \nGesamttreffer  2547 \nEinschlusskriterien  RCTs zur medikament\u00f6sen Systemtherapie bei Melanompatienten im Stadium IV / nicht resektables Stadium III  \nInterventionsarm: Monotherapie oder Monotherapie + Standardtherapie  \nBeobachtungsarm: Placebo, Standardtherapie oder Placebo + Standardtherapie  \nPublikationsjahr ab 1980  \nAusschlusskriterien  Case Reports, Kohortenstudien  \nDosis findungsstudie  \nKolle ktive mit gemischten Tumorentit \u00e4ten \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  48 \nAnzahl der ausgeschlossenen Studien nach Sichtung der Volltexte  8 \nAnzahl ausgew\u00e4hlter Volltexte  40 \nDie ausgew\u00e4hlten Arbeiten wurden wie f olgt zusammengefasst:  \nZielgerichtete Therapien  /small molecules   (Trametinib, Dabrafenib, Selumetinib, Bevacizumab, Vemurafenib, Intetumumab, Bosentan, Sorafenib, Elesclomol, Tamoxifen)  \nImmuntherapien, Immunmodulation (Ipilimumab, Vakzine, Lenalidomide, Th ymosin, PF -3512676, Interferon alpha, Thalidomide, Histamine)  \nChemotherapien/Chemosensitizer  (DHA -paclitaxel, Dacarbazine, Temozolomide, Lomeguatrib, Oblimersen, Cisplatin, Fotemustine, Vindesine, Detorubicin)  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 455 von 817 \n6.2.3.2.  Aktualisierungsrecherche 2015  \nAuswahl der Literatur  \nGesamttreffer  518 \nEinschlusskriterien  Systematische Reviews / Metaanalysen  \nPhase III RCTs zur medikament\u00f6sen Systemtherapie bei Melanompatienten im Stadium IV / nicht resektables Stadium III  \nInterventionsarm: Monotherapie oder Monotherapie + Standardtherapie  \nBeobachtungsarm: Placebo, Standardtherapie oder Placebo + Standardtherapie  \nPublikationsjahr ab 1980  \nAusschlusskriterien  Phase I/II RCTs  \nCase Reports, Kohortenstudien  \nDosisfindungsstudie  \nKolle ktive mit gemischten Tumorentit \u00e4ten \nAnzahl ausge w\u00e4hlter Volltexte  \nZielgerichtete Therapien /small molecules -RCTs  \nImmuntherapien, Immunmodulation- RCTs  \nChemotherapien/Chemosensitizer -RCTs  \nReviews  N= 28  \n7 \n10 \n4 \n7 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 456 von 817 \n6.2.4.  Evidenztabelle  \n6.2.4.1.  Prim\u00e4rrecherche 2012  \n \nZielgerichtete Therapien  / small molecules \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nFlaherty et al. \n2012  To compare \ntrametinib (MEK \nInhibitor) with \ndacarbazine  or \nTaxol  in patients \nwith metastatic \nmelanoma with the \nBRAF V600E or \nBRAF V600K \nmutation RCT, open label  \n \nTreatment:  \nGroup A  \ntramet inib (2 mg \norally twice daily)  \n \nGroup B  \ndacarb azine, 1000 \nmg/m\u00b2 i.v.  \nor paclitaxel \n175mg/m\u00b2 i.v.  \non day 1 every 3 \nweeks  322 patients with \nmetastatic \npreviously \nuntreated or \ntreated melanoma \nwith the BRAF \nV600E or BRAF \nV600K mut ation  \n \n \nOverall Survival \u2013 \n6 months  \n \n \nProgression free \nsurvival  \n \n \n \nOverall Response \nrate \n \nDuration of \nResponse  trametinib vs. \nchemotherapy  \n \n81% vs. 67% (HR \n0.54; 95% CI, 0.32 \nto 0.92; p = 0.01) \n \n4.8 vs. 1.5 months \n(HR 0.45; 95% CI, \n0.33 to 0.63; \nP<0.001)  \n \n22% vs. 8% \n(p=0.01)  \n \n \n5.5 months vs. \nnot yet reached  Jadad Score 4  \nIndependent \nreview of tumor \nassessment  \n \nFunding:  \nGlaxoSmithKline. 1b \nHauschild et al. \n2012  To compare  \ndabrafenib with \ndacarbazine \nchemotherapy in \npreviously \nuntreated mel RCT, open label  \n \nTreatment:  \nGroup A  \ndabrafenib  (150 \nmg orally twice 250 patients with \npreviously \nuntreated, \nmetastatic \nmelanoma with the \nBRAF V600E  \n \n \nOverall Survival  \n \n dabrafenib vs. \ndacarb azine \n \nHR 0,61 (95% CI, \n0,25\u20131,48)  \n Jadad Sco re 4 \nIndependent \nreview of tumor \nassessment  \n \nFunding:  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 457 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nanoma patients \nwhose tumours \nharboured a \nBRAFV600E \nmutation.  daily) \n \nGroup B  \ndacarb azine, 1000 \nmg/m\u00b2 i.v. on day \n1 every 3 weeks  mutation  Progression free \nsurvival  \n \n \n \nOverall Response \nrate  \n \nDuration of \nResponse  5,1 vs. 2,7 months \n(HR 0,30; 95% CI, \n0,18\u20130,51; \np<0\u20220001)  \n \n50% vs. 6%  \n \n \n5.5 months vs. not \nyet reached  GlaxoSmithKline.  \nChapman et al. \n2011  To compare \nvemurafenib with \ndacarbazine in 675 \npatients with \npreviously \nuntreated, \nmetastatic \nmelanoma with the \nBRAF V600E \nmutation RCT, open label  \n \nTreatment:  \nGroup A  \nvemurafenib (960 \nmg orally twice \ndaily) \n \nGroup B  \ndacarb azine, 1000 \nmg/m\u00b2 i.v. on day \n1 every 3 weeks  \n 675 patients with \npreviously \nuntreated, \nmetastatic \nmelanoma with the \nBRAF V600E   \n \n \nOverall Survival \u2013 \n6 months  \n \n \n \n \n \n \n \nOverall Response \nrate  \n \nDuration of \nResponse  Vemurafenib vs. \nDTIC \n \n84% (95% CI, 78 to \n89) vs. 64% (95% \nCI, 56 to 73), HR \nfor death in the \nvemurafenib group \n0.37 (95% CI, 0.26 \nto 0.55; P<0.001), \nsign. \n \n48% vs. 5%, \np<0.001, sign.  \n \nnot yet estimated  Jadad Score 2  \nno description of \ndropouts, tumor \nassessment not \nblinded, only 439 \npatients (65%) were \nevaluated for \ntumor response, \n48 patients in the \nDTIC Group \nreceived no study \ntreatment  \n \nFunding:  \nHoffmann \u2013La \nRoche  1b \nO\u00b4day et al. 2011  To evaluate the \nsafety and efficacy RCT, double -blind \n(Group A+B)  129 \nchemotherapy - \n DTIC vs. DTIC+ \nintetumumab vs. Jadad Score 5  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 458 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nof Intetumumab \n(CNTO 95), a fully \nhuman anti -\nalpha(v) -integrin \nmonoclonal \nantib ody  \nTreatment q3w:  \n \nGroup A  \n1000 mg/m\u00b2 \ndacarbazine + \nplacebo, (n=32)  \n \nGroup B  \n1000 mg/m\u00b2 \ndacarbazine + 10 \nmg/kg \nintetumumab \n(n=32) \n \nGroup C  \n10 mg/kg \nintetumumab \n(n=33) \n \nGroup C  \n5 mg/kg \nintetum umab \n(n=32) naive patients   \n \n \n \nMedian Overall \nSurvival \n \nOverall Response \nRate \n \n \nDuration of \nResponse  intetumumab \n10mg vs. \nintetumumab 5mg  \n \n8 vs. 11 vs. 15 vs. \n9.8 months, n.s.  \n \n10% (n=3) vs. 3% \n(n=1) vs. 6% (n=2) \nvs. 0%, n.s.  \n \n3.9, 7.3, and 10.3+ \nmonths vs. 7.0 \nmonths vs. 6.3 and \n8.2+ months  Funding:  \nCentocor Ortho \nBiotech, Inc., \nMalvern,  \nPA, USA.  \n \nKefford et al. 2010  To evaluate the \neffects of bosentan \n- a dual endothelin \nreceptor \nantagonist - in \npatients recei ving RCT, double -blind  \n \nTreatment:  \n \nGroup A  \nDTIC 1000 mg/m2 80 patients with \npreviously \nuntreated \nmetastatic \nmelanoma   \n \n \nMedian Overall \nSurvival \n DTIC+Bosentan vs. \nDTIC+Placebo  \n \n13.0 months ( 95% \nCI, 7.8 -16.6) vs. \n10.6 months (95% Jadad Score 4  \ntumor assessment \nnot described as \nblinded  \n \nFunding:  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 459 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfirst-line \ndacarbazine \ntherapy for stage \nIV metastatic \ncutaneous \nmelan oma every 3 weeks  \nstarting on Day 1 \n+Bosentan 500 mg \ntwice a day (n=4 0) \n \n \nGroup B  \nDTIC 1000 mg/m2 \nevery 3 weeks  \nstarting on Day \n1+Placebo (n=40)   \n \n \n \n \nOverall Response \nRate \n \nDuration of \nResponse  CI, 6.9 -14.7), n.s., \n(HR, 1.044; 95%  \nCI, 0.584- 1.865; p \n= 0.8841)  \n \nnot reported  \n \n \nnot reported  Actelion \nPharm aceuticals \nLtd., \nAllschwil, \nSwitzerland. \nHauschild et al. \n2009  To evaluate the \nefficacy and safety \nof sorafenib with \ncarboplatin and \npaclitaxel (CP) in \npatients with \nadvanced \nmelanoma  RCT, double -blind  \n \nTreatment:  \n \nGroup A  \npaclitaxel 225 \nmg/m2 plus \ncarbo platin (AUC \n6) + sor afenib \n400mg (n=13 5) \n \nGroup B  \npaclitaxel 225 \nmg/m2 plus \ncarbo platin (AUC \n6) + pl acebo \n(n=135)  270 patients with \nadvanced \nmelan oma \n(unresectable \nstage III or stage \nIV) that had \nprogressed during \nor after r eceiving \nat least one cycle \nof a regimen \ncontaining \ndacarb azine or \ntemozolomide in \nthe advanced \nsetting \n \n  \n \n \nMedian Overall \nSurvival \n \n \n \n \n \nOverall Response \nRate \n \nDuration of \nResponse  C/P + Sorafenib vs. \nC/P + Placebo  \n \n42.0 weeks (9.7 \nmonths) vs. 42.0 \n(9.7 months), n.s.,  \nHR 1.01 (95% CI, \n0.76 to 1.36; \np=0.92)  \n \n12% (n=16) vs. 11% \n(n=15), n.s., p=1.0 \n \nnot reported  Jadad Score 5  \n \nFunding:  \nBayer AG and Onyx \nPharmaceut icals, \nInc. 1b \nO\u00b4Day et al. 2009  To evaluate RCT, double -blind  81 metastatic  Elesclomol Jadad Score 4  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 460 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwhether the \naddition of \nelesclomol to \nweekly paclitaxel \ncould i mprove \nefficacy in patients \nwith stage IV \nmetastatic \nmelanoma   \nTreatment:  \n \nGroup A  \nelesclomol 213 \nmg/m\u00b2 plus \npaclitaxel 80 \nmg/m(2) (E + P) \n(n= 53)  \n \nGroup B  \npaclitaxel 80 \nmg/m\u00b2 alone  \n(n= 28)  \n melanoma p atients \nwith one or fewer \nprior standard \nchemotherapy \nregimens   \n \n \nMedian Ove rall \nSurvival \n \nProgression Free \nSurvival  \n \n \nOverall Response \nRate \n \n \n \nDuration of \nResponse  +Paclitaxel vs. \nPaclitaxel  \n \n11.9 vs. 7.8 \nmonths  \n \n \n3.7 months vs. 1.8 \nmonths, sign., \np=0.035  \n \n15.1% (n=8) vs. \n3.6% (n=1) \n(p=0.153) ,n.s., \np=0.153  \n \nrange 58+  to 188+ \ndays (censored \npatients), 107, 136 \ndays vs. 115 days  Tumor assessment \nby investigators, \nRandomization \nwithout \nstratification, M1c \npatients \nunbalanced (25.8% \nvs. 75%)  \n \nFunding:  \nSynta \nPharmaceut icals, \nLexington, MA.  \nMcDermott et a l. \n2008  To evaluate the \nefficacy and safety \nof sorafenib plus \ndacarbazine in \npatients with \nadvanced \nmelanoma  RCT, double -blind  \n \nTreatment:  \n \nGroup A  \nsorafenib plus \ndacarbazine (n = \n51)  \n \nGroup B  101 \nchemotherapy -\nnaive pa tients with \nstage III \n(unresect able) or \nIV melanoma   \n \n \n \nMedian Overall \nSurvival \n \n \nOverall Response \nRate Sorafenib + DTIC \nvs. \nPlacebo + DTIC  \n \n45.6 weeks vs. \n51.3 weeks, n.s., \np=0.927  \n \n24% (n=12) vs. 12% \n(n=6), n.s., Jadad Score 5  \n \nFunding:  \nBayer HealthCare \nPharmaceuticals  \nand Onyx \nPharm aceuticals \nInc. 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 461 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nplacebo plus \ndacarbazine (n = \n50)  \n  \n \nDuration of \nResponse  p=0.193  \n \n26.9 vs. 23.0 \nmonths, n.s., \np=0.194  \n \nAgarwala et al. \n1999  To test the benefit \nof adding \ntamo xifen to \ndacarbazine and \ncarboplatin \nchemotherapy for \npreviously \nuntreated patien ts \nwith m etastatic \nmelanoma  RCT, open label  \n \nTreatment:  \n \nGroup A  \ncarboplatin 300 \nmg/m\u00b2 and \ndacarbazine 1g/m\u00b2 \nplus tamoxifen 20 \nmg/day (D+C+T)  \n \nGroup B  \n(D+C)  \n 56 metastatic \nmelanoma \npatients, without \nprior \nchemotherapy  \n  \n \nMedian Overall \nSurvival \n \n \nOverall Response \nRate \n \n \nDuration of \nResponse  D+C+T vs. D+C  \n \n4.6 months vs. 7 \nmonths, n.s., \np=0.1377 \n \n14.3% (n=4) vs. \n10.7% (n=3), n.s., \n(p=1.0) \n \n3, 3, 6, and 6 \nmonths vs. 2, 16 \nmonths + lost to \nfollow up at 31 \nmonths  Jadad Score 2  \nunblinded tumor \nassessment, no \ndescription of \ndropouts and \nwithdrawals, small \nsample size  \n \nFunding:  \nNot declared  1b \n \nImmuntherapien, Immunmodulation  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nHersh et al. 2011  To evaluate the \nsafety and efficacy \nof ipilimumab  RCT, open label  \n \nTreatment:  72 chemotherapy -\nnaive patients  \n  \n \n Ipi alone (n=32) vs. \nIpi+DTIC (n=32)  \n Jadad Score 2  \nsmall sample size  \nrandomization 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 462 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nalone and i n \ncombination with \ndacarbazine (DTIC) \nin patients with \nunresectable, \nmetastatic \nmelanoma  Group A  \nipilimumab at 3 \nmg/kg every 4 \nweeks for four \ndoses alone (n=37)  \n \nGroup B  \nipilimumab at 3 \nmg/kg every 4 \nweeks for four \ndoses with u p to \nsix 5-day courses \nof DTIC at 250 \nmg/m\u00b2/day (n=35)   Median Overall \nSurvival \n \n \n \nOverall Response \nRate \n \n \n \nDurable Complete \nResponse  11.4 months (95% \nCI, 6.1 -15.6) vs. \n14.3 months (9 5% \nCI, 10.2 -18.8), n.s.  \n \n5.4% (95% CI, 0.7-\n18.2) vs. 14.3% \n(95% CI, 4.8 -30.3), \nn.s. \n \nn=2 (1.6+/1.85+ \nyears) vs. n=2 \n(1.73+/1.76+ \nyears)  scheme not \ndescribed, tumor \nassessment not \nblinded  \n \nFunding:  \nBristol- Myers \nSquibb Co.  \n \nRobert et al. 2011  To evaluate \nipilimumab  (10 \nmg per kilogram) \nplus dacarbazine \nin patients with \npreviously \nuntreated \nmetastatic \nmelanoma  RCT, double -blind  \n \nTreatment:  \n \nGroup A  \nIpilimumab (10 mg \nper kilogram) plus \ndacarbazine (850 \nmg/m\u00b2)  \n \nGroup B  \ndacarbazine (850 \nmg/m\u00b2) plus \nplacebo 502 patients with \npreviously \nuntreated \nmetastatic \nmelanoma   \n \n \nMedian Overall \nSurvival  \n \n \n \n \n \n \nOverall Survival  \n1 year  \n2 years  \n3 years  \n Ipi+DTIC vs.  \nPlacebo+DTIC  \n \n11.2 months (95% \nCI, 9.4 to 13.6) vs. \n9.1 months (95% \nCI, 7.8 to 10.5)  \n(hazard ratio for \ndeath with \nDITC+Ipi,  \n0.72; p<0.001)  \n \n47.3% vs. 36.3%  \n28.5% vs. 17.9%  \n20.8% vs. 12.2%  \n Jadad Score 5  \n \nFunding:  \nBristol- Myers \nSquibb.  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 463 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nOverall Response \nRate \n \nDuration of \nResponse  15.2% vs. 10.3%, \nn.s. (p = 0.09)  \n \n19.3 months (95% \nCI, 12.1 to 26.1) \nvs. 8.1 months \n(95% CI, 5.19 to \n19.8) (p=0.03)  \nSchwar tzentruber \net al. 2011  To investigate if \nthe combination of \na melanoma \nvaccine with \ninterle ukin-2, an \nimmune activa ting \nagent, could \nimprove outcomes  RCT, open label  \n \nTreatment:  \n \nGroup A  \ninterleukin -2 alone \n(720,000 IU per \nkilogram of body \nweight per dose)  \n \nGroup B  \ngp100: 209 -\n217(210M) plus \nincomplete \nFreund's adjuvant \n(Mont anide ISA -51) \nonce per cycle, \nfollowed by \ninterleukin -2 \n \n \n 185 patients with \nstage IV or local ly \nadvanced stage III \ncutaneous \nmelanoma, \nexpression of \nHLA*A0201, an \nabsence of brain \nmetastases, and \nsuitability for high -\ndose inte rleukin -2 \ntherapy   \n \nMedian Overall \nSurvival \n \n \n \n \n \nOverall Response \nRate \n \nDuration of \nResponse  IL-2 vs. IL -\n2+Vaccine  \n \n11.1 mo nths (95% \nCI, 8.7 to 16.3); vs. \n17.8 months (95% \nCI, 11.9 to 25.8) \nn.s. (p=0.06)  \n \n6% vs. 16%, \np=0.03  \n \n \nnot reported  Jadad Score 4  \ntumor assessment \nblinded  \n \nFunding:  \nNational Cancer \nInstitute, Indiana \nUniversity Health \nGoshen, Goshen \nHospital and \nHealth Ca re \nFoundation, \nChiron, and \nNovartis  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 464 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nHodi et al. 2010  To compare \nipilimumab , \nadmini stered with \nor without a \nglycoprotein 100 \n(gp100) pe ptide \nvaccine with gp100 \nalone in patients \nwith pr eviously \ntreated metastatic \nmelanoma  RCT, double -blind  \n \nTreatment:  \n \nGroup A  \nipilimumab plus \ngp100 (n=403)  \n \nGroup B  \nipilimumab alone \n(n=137)  \n \nGroup C  \ngp100 alone \n(n=136)  676 HLA -A*0201 -\npositive patients \nwith previously \ntreated \nunresect able stage \nIII or IV mel anoma   \n \n \n \nMedian Overall \nSurvival  \n \n \n \n \n \nOverall Response \nRate \n \n \n \nMedian Duration of \nResponse  \n \n \nTreatment related \ndeaths  ipilimumab  \n+gp100 vs. \nipilimumab vs. \ngp100  \n \n10.0 months vs. \n10.1 months vs. \n6.4 months, sign., \n(hazard ratio for \ndeath, 0.68; \np<0.001).  \n \n5.7% (n=23) vs. \n11% (n=15) vs. \n1.5% (n=2), sign., \np=0.04  \n \n \n11.5 (5.4\u2013NR) vs. \nNR (28.1 \u2013NR) vs. \nNR (2.0 \u2013NR) \nmonths  \n \nn=14  Jadad Score 5  \ntumor assessment \nby investigators  \n \nFunding:  \nMedarex and \nBristol-Myers \nSquibb  1b \nEisen et al. 2010  To compare the \ntreatment with \nlenalidomide  to \nplacebo in 306 \npatients with \nmetastatic  RCT, double -blind  \n \nTreatment:  \n \nGroup A  \nlenali domide (25 306 patients with \npreviously treated \nmetastatic \nmalignant \nmelanoma   \n \n \nMedian Overall \nSurvival \n lenal idomide  vs. \nplacebo  \n \nmedian 5.9 \nmonths (range 5.1 -\n7.7) vs. 7.4 Jadad Score 5  \n \nFunding:  \nCelgene \nCorpor ation, \nSummit, New 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 465 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmalignant \nmelan oma mg/d on Days 1 -21 \nof a 28 -day cycle  \n(n=154)  \n \n \nGroup B  \nplacebo  \n(n=152)  \n  \n \n \nOverall Re sponse \nRate \n \nDuration of \nResponse  months range 5.5 -\n8.2); n.s., p=0.32  \n \n5.3% vs 5.8%; n.s., \np=0.82 \n \nnot reported  Jersey.  \nMaio e t al. 2010  To evaluate the \nefficacy and safety \nof combining \nThymosin alpha 1  \nwith daca rbazine \nand interferon alfa \nin patients with \nmetastatic \nmelanoma  RCT, open label  \n \nTreatment:  \nGroup A: DTIC+IFN \nalpha+ Thymosin \nalpha 1 (1.6mg)  \n \nGroup B: DTIC+IFN \nalpha+ T hymosin \nalpha 1 (3.2mg)  \n \nGroup C: DTIC+IFN \nalpha+ Thymosin \nalpha 1 (6.4mg)  \n \nGroup D: \nDTIC+Thymosin \nalpha 1 (3.2mg)  \n \nGroup D: DTIC+IFN \nalpha  571 \nchemotherapy -\nnaive patients    \n \n \n \nMedian Overall \nSurvival \n \n \n \n \n \n \nOverall Response \nRate \n \n \nMedian duration of \nResponse  \n \n \nClinical benefit DIT1.6 vs. DIT3.2 \nvs. DIT6.4 vs. \nDT3.2 vs. DI  \n \n9.3 vs. 8.6 vs. 10.3 \nvs. 9.3 vs. 6.6 \nmonths, n.s.  \nDTI+DT vs. DI, PP \npopul ation: HR = \n0.74; 95% CI, 0.57 - \n0.95; p=0.02 \n \n7.2% vs. 10.3% vs. \n6.1% vs. 12.1% vs. \n4.1%, n.s.  \n \n7.4 vs. 8.3 vs. 7.9 \nvs. 7.7 vs. 6.3 \nmonths  \n \nDT3.2 vs. DI:  Jadad Score 4  \ntumor assessment \nblinded  \n \nFunding: Sigma -\nTau SpA, Pomezia, \nItaly \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 466 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n (CR+PR+SD)  \n 49.5% vs. 32.0%  \nP=0.009  \n \n \n \nWeber et al. 2011  To assess the \nobjective response \nrate of PF -\n3512676 , a CpG \noligodeoxynucl eoti\nde, alone in 2 \ndoses or in \ncombination with \ndacarbazine (DTIC) \nin patients with \nunresectable stage \nIIIB/C or stage IV \nmalignant \nmelanoma  RCT, open label  \n \nTreatment:  \n \nGroup A  \nPF-3512676 10 mg  \n(n=46) \n \nGroup B  \nPF-3512676 40 mg  \n(n=46) \n \nGroup C  \nPF-3512676  40 mg \nplus DTIC (850 \nmg/m\u00b2)  \n(n=45) \n \nGroup D  \nDTIC (850 mg/m\u00b2)  \nalone  \n(n=39) 184 patients with \npreviously \nuntreated \nmetastatic \nmelanoma   \n \n \n \n \n \nMedian Overall \nSurvival \n \n \nOverall Response \nRate \n \nDuration of \nResponse  PF-3512676 10mg \nvs. PF -3512676 \n40mg vs. PF -\n3512676 40 mg + \nDTIC vs. DTIC  \n \n9.4 vs. 8.4 vs. 9.0 \nvs. 11.7 months, \nn.s. \n \n2% vs. 0% vs. 16% \nvs. 8%, n.s.  \n \nnot estimated \n(number to small)  Jadad Score 3  \n \nFunding:  \nnot declared  1b \nSchade ndorf et al. \n2006  To demonstrate \nthe superiority of RCT, open label  \n 108 metastatic \nmelanoma patients  \n DC vaccination  vs. \nDTIC Jadad Score 3  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 467 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nautologous \npeptide -loaded \ndendritic cell (DC) \nvaccin ation over \nstandard \ndacarbazine (DTIC) \nchemoth erapy in \nstage IV melanoma \npatients  Treatment:  \n \nGroup A  \nDC vaccines loaded \nwith MHC class I \nand II- restricted \npeptides (n=53)  \n \nGroup B  \nDTIC 850 mg/m\u00b2 \n(n=55) with no prior \nsystemic \nchemother apy  \nMedian Overall \nSurvival \n \nOverall Response \nRate \n \n  \n9.3 months vs. \n11.6 months n.s.  \n \nITT: 3.8% (n=2) vs. \n5.5% (n=3), n.s.  \n(PP:4.9 vs. 4.8%)  Funding:  \nGerman Cancer Aid  \n \nKaufmann et al. \n2005  To compare TMZ \nalone and TMZ \nplus IFN-alpha  in \nterms of objective \nresponse (OR), \noverall survival, \nand safety  RCT, open label  \n \nTreatment:  \n \nGroup A  \nTMZ alone (n=146)  \n \nGroup B  \nTMZ + s.c. IFN -\nalpha (n=148)  294 patie nts with \nuntreated stage IV \nmetastatic \nmelanoma   \n \n \nMedian Overall \nSurvival \n \n \n \n \nResponse Rate  \n \n \n \n \n \nDuration of \nResponse  TMZ vs. TMZ + s.c. \nIFN-alpha  \n \n8.4 months (95% \nCI, 7.07 to 9.27) \nvs. 9.7 months \n(95% CI, 8.26 to \n11.18), n.s., \np=0.16 \n \n13.4% (n=18 of \n134 patients) vs. \n24.1% (n=33 of \n137 p atients, \nsign., p=0.036 \n \nLonger in Group B  Jadad Score 3  \nunblinded tumor \nassessment by \ninvestigators  \n \nFunding:  \nEssex Pharma \nGmbH (Munich, \nGermany)  1b \nDanson et al. 2003  To determine RCT, open label  181 patients   TMZ vs. TMZ+IFN Jadad Score 2  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 468 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nresponse rates, \noverall survival, \nand t olerability of \nthe regimens \ntemoz olomide with \ninterf eron alfa -2b \nand, separately, \nwith thalidomide in \npatients with \nadvanced \nmetasta tic \nmelanoma.   \nTreatment:  \n \nGroup A  \nTMZ (n=59)  \n \nGroup B  \nTMZ + Interferon \nalfa-2b (n=62)  \n \nGroup C  \nTMZ + Thalid omide  \n(n=60)  \n \n \nMedian Overall \nSurvival \n \nOverall Response \nRate \n \nResponse duration  vs. \nTMZ+Thalidomide  \n \n5.3 vs. 7.7 vs. 7.3 \nmonths  \n \n9% vs. 18% vs. 15%  \n \n \nrange 2.4 -  21.2 \nmonths  dropouts and \nwithdrawals not \ndescribed \n \nAgarwala et al. \n2002  To determine \nwhether the \naddition of \nhistamine  to a \nsubcutaneousr egi\nmen of interle ukin-\n2 (IL-2) would \nimprove the \nsurvival of \nmetastatic \nmelanoma patients  RCT, open label  \n \nTreatment:  \n \nGroup A  \nIL-2 plus histamine \n(n=152)  \n \nGroup B \nIL-2 alone  (n=153)  305 metastatic \nmelanoma patients \nwith or without \nprevious systemic \ntherapy except IL -2  \n \n \nMedian Overall \nSurvival \n \n \n \nOverall Response \nRate \n IL-2 + histamine  \nvs.  \nIL-2 alone  \n \n272 days (9.1 \nmonths) vs. 245 \ndays (8.2 months), \nn.s., p=0.12 5 \n \n3% (n=5) vs. 3% \n(n=5), n.s.  Jadad Score 2  \nunblinded tumor \nassessment  \ndropouts and \nwithdrawals not \ndescribed  \n \nFunding:  \nnot declared  1b \nYoung et al. 2001  To evaluate DTIC \n+IFN-alpha in \npatients with \nmeta static \nmelanoma  RCT, open label  \n \nTreatment:  \n \nGroup A  61 advanced \nmelanoma patients \nwithout pr evious \nDTIC or IFN  \n  \n \n \nMedian Overall \nSurvival DTIC + IFN-alpha  \nVs. DTIC  \n \n4.8 months (95% \nCI 2.0 -8.0) vs. 7.2 Jadad Score 3  \nunblinded tumor \nassessment, small \nsample size  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 469 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nDTIC +IFN -alpha  \n(n=30) \n \nGroup B  \nDTIC \n(n=31) \n  \n  \n \n \n \nSurvival 6 months  \n \nOverall Response \nRate \n \nDuration of \nResponse  months (95% CI \n4.4-9.0), n.s., \np=0.70 \n \n40% vs. 58%  \n \n18% (n=4) vs. 23% \n(n=6), n.s., p=0.59 \n \nmedian 212 days \n(95% CI 140 \u2013648) \nvs. median 180 \ndays (95% CI 131 \u2013\n349) Funding:  \nCancer Research  \nCampaign and \nRoche \nPharmaceut icals \nFalkson et al. 1998  To investigate the \nresponse rate, time \nto treatment \nfailure (TTF), \noverall survival, \nand to xicity in \npatients with \nmetastatic \nmelanoma treated \nwith dacarbazine \nalone, dacarbazine \nplus interferon \n(IFN), dacarbazine \nplus tamoxifen \n(TMX), or \ndacarbazine plus RCT, open label  \n \nTreatment:  \n \nGroup A  \nDTIC alone (n=69)  \n \nGroup B (n=68)  \nDTIC + IFN  \n \nGroup C (n=66)  \nDTIC + TMX  \n \nGroup D  \nDTIC + IFN + TMX \n(n=68) 271 metastatic \nmelanoma patients \nwith no  pnor \nchemotherapy \nexcept for \nadjuvant IFN   \n \n \n \n \nMedian Overall \nSurvival \n \n \n \n \nOverall Response \nRate DTIC alone vs. \nDTIC + IFN  vs. \nDTIC + TMX vs. \nDTIC + IFN + TMX  \n \npooled over the 4 \nGroups: 8.90 \nmonths (95% CI, \n8.08 -10.8), n.s., \np=0.85 \n \n15% vs. 21% vs. \n18% v s. 19% (of \n250 p atients)  Jadad Score 3  \nunblinded tumor \nassessment  \n \n \nFunding:  \nin part by Public \nHealth grants no. \nCA 21692, CA \n23318, CA 07190, \nCA 18663, CA \n16395, CA 66636, \nand CA 21115 \nfrom the National \nCancer Institute, \nNational Institutes 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 470 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nIFN plus TMX  of Health, and  the \nDepartment of \nHealth and Human \nServices, B ethesda. \nMD \nSparano et al. \n1993  To compare the \nresponse rate, \nsurvival, and \ntoxicity of \ntreatment with \nhigh-dose \nintrave nous bolus \ninterle ukin-2 (IL-2) \nplus interf eron \nalfa-2a (IFN-alpha) \nwith high -dose IL -2 \nalone in patients \nwith advanced \nmelan oma \n RCT, open label  \n \nTreatment:  \n \nGroup A  \nIL-2 + Interf eron \nalfa-2a  \n \nGroup B  \nIL-2 alone  85 patients   \n \n \nMedian Overall \nSurvival \n \nResponse Rate  \n \n \n \n \nDuration of \nResponse  IL-2 + IFN alpha \nvs. IL -2 alone  \n \n9.7 months vs.  \n10.2 months, n.s.  \n \n10% (4 of 41 \npatients) vs. 5% (2 \nof 44 patients), \nn.s., p=0.30  \n \n11.5 months \n(range, 2.0 to \n15.7+)  Jadad Score 3  \nunblinded but \nindependently \nreviewed tumor \nassessment  \n \nFunding:  \nNational Institutes \nof Health, \nBethesda, MD, \ncontracts no. N O1-\nCM73702, NO1-\nCM73703, N01 -\nCM73704, NO1-\nCM73705, NO1-\nCM73706, and \nNO1-CM73707; \nNational Institutes \nof Health Clinical \nResearch Center \ngrant no. MOI -\nRR00054 to Tufts \nUniversity School \nofMedicine; and by \nHoffman La -Roche, 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 471 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nInc \nThompson et al. \n1993  To as sess the \ncombination of \ndacarb azine and \ninterferon -alpha \n2a versus \ndacarbazine alone \nas systemic \ntherapy for \nmetastatic \nmalignant \nmelan oma RCT, open label  \n \nTreatment:  \n \nGroup A  \nDTIC plus IFN \nalpha 2a  \n \nGroup B  \nDTIC alone  170 patients   \n \n \nMedian Overall \nSurvival \n \nResponse Rate  \n \n \n \nDuration of \nResponse  DTIC + IFN \nalpha2a vs. DTIC  \n \n229 vs. 269 days  \n \n \n21% (95% CI 13 -\n31%) vs. 17% (95% \nCI 10 -27%) \n \n258 vs. 286 days   1b \nFalkson et al. 1991  To assess if results \nwith DTIC could be \nimproved by using \na combin ation of \nDTIC and IFN alfa-\n2b in metastatic \nmalignant \nmelanoma.  RCT, open label  \n \nTreatment:  \n \nGroup A  \nDTIC plus \ninterf eron alfa -2b \n(n=30) \n \nGroup B  \nDTIC alone (n=31)  64 metastatic \nmelanoma p atients   \n \n \nMedian Overall \nSurvival  \n \n \nOverall Response \nRate \n \n \nDuration of \nRespon se DTIC + IFN alfa -2b \nvs. DTIC  \n \n17.6 months vs. \n9.6 months, sign.,  \np < 0.01  \n \n53% (n=16) vs. \n20% (n=6), sign., \np=0.007  \n \nNot reported  Jadad Score 2  \nRandomization \nscheme not \ndescribed, \nunblinded tumor \nassessment, small \nsample size, \nimbalance of \ngroups (more male \npatients in Group \nB) \nFunding:  \nIFN alfa -2b was \nsupplied by \nScherag South \nAfrica, 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 472 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nJohannesburg.  \n \nChemotherapy/Chemosensitizer  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nBedikian et al. \n2011  To compare the \nefficacy and \ntoxic ity profi les of \nDocos ahexaenoic \nacid (DHA) -\npaclitaxel with \nthose of \ndacarb azine RCT, open label  \n \nTreatment:  \nGroup A  \nDHA-paclitaxel, \n900 mg/m\u00b2 i.v. on \nday 1 every 3 \nweeks (n=194)  \n \nGroup B  \nDacarb azine, 1000 \nmg/m\u00b2 i.v. on day \n1 every 3 weeks \n(n=199)  393 chemonaive \npatients with \nmetastatic \nmelanoma  \n  \n \n \nMedian Overall \nSurvival \n \n \n \n \n \nOverall Response \nrate \n \nDuration of \nResponse  DHA-paclitaxel vs. \nDTIC \n \n267 days (8.8 \nmonths) (95% CI \n220\u2013297) vs. 226 \ndays (7.4months) \n(95% CI 192 \u2013263), \nn.s. \n \n5.2% (n=10) vs. \n5.5% (n=11), n.s.  \n \n134 days (4.4 \nmonths) (95% CI \n77 to not \nestimated) vs. not \nestimated due to \ncensoring pattern  Jadad Score 3  \ntumor assessment \nnot d escribed as \nblinded  \n \nFunding:  \nLuitpold \nPharmaceut icals, \nInc. 1b \nPatel et al. 2011  To compare the \nefficacy of an \nextended sc hedule \nescalated dose of RCT, open label  \n \nTreatment:  \n 859 \nchemotherapy -\nnaive patients   \n \n \nMedian Overall TMZ vs. DTIC  \n \n \n9.1 months vs. Jadad Score 3  \n \ntumor assessment \nwas not blinded  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 473 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntemozolomide \nversus standard \ndose dacarbazine  Group A  \noral temozolomide \n150mg/m\u00b2/day for \nseven consecutive \ndays every 2weeks \n(n=429)  \n \nGroup B  \nDacarbazine, i.v. \n1000mg/m\u00b2/day \non day 1 every 3 \nweeks (n=4 30) Survival  \n \n \nOverall Response \nRate \n \n \nDuration of \nResponse  9.4months, n.s. \n(p=1.0) \n \n14.5% (n=58) \nvs.9.8% (n=38), \np=0.05 \n \n4.6 vs. 11.2 \nmonths, p=0.015, \nsign.  \nFunding:  \nSchering Plough, \nUK National Cancer \nResearch Network  \n \nRanson et al. 2007 To evaluate tumor \nresponse, \npharmacodynamic \neffects, and safety \nof a combination \nof lomeguatrib \n(LM), an O6 -\nmethylguanine \nDNA-\nmethyltransf erase \n(MGMT) \ninactivator, and \ntemozolomide \n(TMZ), TMZ alone, \nand LM/TMZ after \ndisease \nprogression on \nTMZ alone in RCT, open label  \n \nTreatment:  \n \nGroup A  \nlomeguatrib \n40mg/d, 2h later \nTMZ 125mg/m2/d, \norally, 5 days every \n4 week s (n=52)  \n \nGroup B  \nTMZ 125mg/m2/d, \norally, 5 days every \n4 weeks (n=52)  104 patients with \nunresectable stage \nIII or IV cutaneous \nmelanoma who \nhad no prior \nsystemic \nchemotherapy  \n  \n \n \n \nMedian Overall \nSurvival \n \n \n \n \nOverall Response \nRate \n LM/TMZ vs. TMZ  \n \n \n \n7.6 mon ths (95% \nCI, 6.9 - 10.3 \nmonths) vs. 7.7 \nmonths (95% CI, \n6.3 - 10.7 months), \nn.s. \n \n13.5% (n=7) vs. \n17.3% (n=9), n.s.  \n Jadad Score 2  \nRandomization \nscheme not \ndescribed, tumor \nassessment not \nblinded  \n \nFunding:  \nKudos \nPharmaceuticals, \nowned by \nAstraZeneca.  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 474 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npatients with \nadvanced \nmelanoma  \nBedikian et al. \n2006  To evaluate \nwhether targeting \nBcl-2 using an \nantisense \noligonucleotide \n(oblimersen \nsodium) could \nimprove the \nefficacy of \nsystemic \nchemotherapy in \npatients with \nadvanced \nmelanoma.  RCT, open label  \n \nTreatment:  \n \nGroup A  \nOblimersen (7 \nmg/kg /d by \ncontinuous \ni.v.infusion for 5 \ndays) + DTIC \n(n=386)  \n \nGroup B  \nDTIC (n=385)  771 \nchemotherapy -\nna\u00efve patients   \n \n \nMedian Overall \nSurvival \n \nPFS \n \n \nOverall Response \nRate \n \nDurableResponse  Oblimersen + DTIC  \nvs. DTIC  \n \n9.0 v 7.8 months; \np=0.077  \n \n2.6 v 1.6 months;  \np=0.001  \n \n13.5% vs. 7.5% \np=0.007  \n \n7.3 vs. 3.6% \np=0.027  Jadad Score 4  \nIndependent \nblinded tumor \nassessment  \n \nFunding: Genta, \nInc. 1b \nBafaloukos et al. \n2005  To evaluate and \ncompare the \nactivity and safety \nprofile of the \ncombination \nCisplatin + TMZ \nversus sin gle-agent \nTMZ in patients \nwith advanced \nmelanoma  RCT, open label  \n \nTreatment:  \n \nGroup A  \nTMZ 200 \nmg/m\u00b2/day orally \nd1-5q28 (n=66)  \n \nGroup B  \nTMZ + Cisplatin \n200 mg/m\u00b2 daily 132 metastatic \nmelanoma patients \nwith no previous  \nchemotherapy   \n \n \nMedian Overall \nSurvival \n \nOverall Response \nRate \n \n \nDuration of \nResponse  TMZ vs. TMZ + \nCisplatin  \n \n11.5 months vs. \n12 months, n.s.  \n \n16 patients (26%) \nvs. 19 patients \n(29%), n.s.  \n \n5.7 months vs. 9.4 \nmonths, n.s., Jadad Sc ore 2  \nRandomization \nscheme not \ndescribed, tumor \nassessment not \nblinded  \n \nFunding:  \nKudos \nPharmaceuticals, \nowned by \nAstraZeneca.  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 475 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \non days 1 -5 and 75 \nmg/m\u00b2 of cisplatin \non day 1 (n=66)  p=0.35  \n \nAvril et al. 2004  To compare \nfotemustine and \ndacarbazine (DTIC) \nin patients with \ndisseminated \ncutaneous \nmelanoma.  RCT, open la bel \n \nTreatment:  \n \nGroup A  \nFotemustine \n100mg/m\u00b2; \nweekly, 3 weeks, (n \n= 112)  \n \nGroup B  \nDTIC 250 \nmg/m\u00b2/d; 5d every \n4 weeks, (n = 117)  229 patients   \n \n \nMedian Overall \nSurvival \n \nResponse Rate  \n \n \nDuration of \nResponse  Fotemustine vs. \nDTIC \n \n7.3 vs. 5.6 \nmonths, p = 0. 067 \n \n13.4% vs. 6.0% (p= \n0.057)  \n \nn.s. difference  Jadad Score 3  \n \nFunding:  \nInstitut de \nRecherches \nInternationales \nServier, \nCourbevoie, France  1b \nMiddleton et al. \n2000  To compare \ntemozolomide and \ndacarbazine (DTIC) \nin terms of overall \nsurvival, \nprogression -free \nsurvival (PFS), \nobjective response, \nand safety  RCT, open label  \n \nTreatment:  \n \nGroup A  \nTemozolomide \n(n=156)  \n \nGroup B  \nDTIC (n=149)  305 advanced \nmelanoma patients \nwithout previous \ntreatment for \nmetastatic disease   \n \nMedian Overall \nSurvival \n \n \n \n \nPFS \n \n \n TMZ vs. DTIC  \n \n7.7 months vs. 6.4 \nmonths, n.s., HR \n1.18 (95% CI, 0.92 \nto 1.52), p=0.20 \n(ITT population)  \n \n1.9 vs. 1.5 \nmonths; HR 1.37; \nsign., p=0.012 \n Jadad Score 3  \nunblinded tumor \nassessment, \ndifferent time \npoints for \nassessment \nbetween groups  \n \nFunding:  \nNot declared  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 476 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nOverall  Response \nRate \n \n \nDuration of \nResponse  13.5% (21 of 156) \nvs. 12.1% (18 of \n149), n.s.  \n \nlonger in the TMZ \ngroup; 18 of the \n21 TMZ \nresponders \nsurvived longer \nthan 12 months vs. \n11 of the 18 DTIC \nresponders  \nKeilholz et al. \n1997  To determine \nwhethe r the \naddition of \nCisplatin to a \ncytokine treatment \nregimen with IFN \nalpha and high-\ndose IL -2 \ninfluences survival \nof patients with \nmetastatic \nmelanoma  RCT, open label  \n \nTreatment:  \n \nGroup A  \nIFN alpha 10 x 106 \nU/m2 sc. on days \n1 through 5 + IL -2 \non days 3 th rough \n8  \n(18 mIU/m2/6 h,  \n18 mIU/m2/12 h,  \n18 mIU/m2/24 h, \nand 4.5 \nmIU/m2/24 h x 3)  \n \nGroup B  \nIFN alpha + IL -2 + 138 metastatic \nmelanoma \npatients, no prior \ntherapy with \nCisplatin   \n \n \n \nMedian Overall \nSurvival \n \n \nOverall Response \nRate \n \nDuration of \nResponse  IFN alpha + IL -2 vs. \nIFN alpha + IL -2 + \nCisplatin  \n \nall patients: 9 \nmonths, n.s. \nbetween groups  \n \n18% vs. 33%, sign., \np=0.04 \n \n17 vs. 6 months, \nn.s., p=0.057 Jadad Score 3  \ntumor assessment \nnot blinded  \n \nFunding:  \nChiron BV, \nAmsterdam, the \nNetherlands and  \nHoffmann- La \nRoche AG, \nGrenzach, \nGermany  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 477 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nCisplatin 100 \nmg/m2 on day 1  \nJungnelius et al. \n1998  To investigate if \nthe addition of \nCisplatin to the \ncombination DTIC \nand Vindesine \ncould increase \nsurvival.  RCT, open label  \n \nTreatment:  \n \nGroup A  \ndacarbazine + \nvindesine  + \ncisplatin (DVP) \n(n=161)  \n \nGroup B  \ndacarbazine + \nvindesine (DV) \n(n=165)  326 metastatic \nmelanoma \npatients, no prior \nchemotherapy   \n \nMedian Overall \nSurvival \n \n \nOverall Response \nRate \n \nDuration of \nResponse  DVP vs. DV  \n \n7.2 months vs. 5.9 \nmonths, n.s., \np=0.22 \n \n31.4% vs. 21%, n.s.  \n \n \n6.0 months for the \nwhole study \npopulation  Jadad Score 2  \nRandomization \nscheme not \ndescribed, \nunblinded tumor \nassessment  \n \nFunding:  \nNot declared  1b \nRingborg et al. \n1989  To evaluate \ntreatment with \ndacarbazine alone \nor in combination \nwith vindesine in \npatients with \ndisseminated \nmalignant \nmelanoma  \n RCT, open label  \n \nTreatment:  \n \nGroup A  \ndacarbazine + \nvindesine (n=59)  \n \nGroup B  \ndacarbazine alone \n(n=51) \n 119 patients (110 \nevaluable)  \n \n \n  \n \n \n \nMedian Overall \nSurvival \n \nOverall Response \nRate \n \nDuration  of \nResponse  dacarbazine + \nvindesine vs. \ndacarbazine alone  \n \n5.8 months vs. 4.7 \nmonths, n.s.  \n \n25% vs. 18%, n.s., \np>0.20 \n \n171 days vs. 123 \ndays, n.s.  Jadad Score 1  \nNo description of \ndropouts, \nrandomization \nscheme not \ndescribed, \nunblinded tumor \nassessment  \n \nFunding:  \nSwedish Cancer \nSociety and Eli Lilly \nCompany  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 478 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nChauvergne et al. \n1982  To evaluate the \nefficacy of \ndetorubicin in \ncombination with \nDTIC versus DTIC \nalone  RCT, open label  \n \nTreatment:  \n \nGroup A  \nDTIC (250 mg/m2, \ni.v., over 4 days \nevery three weeks) \n+ detorubicin (120 \nmg/m2, i.v. every \nthree weeks)  \n \nGroup B  \nDTIC alone  51 patient  \n  \n \n \nMedian Overall \nSurvival \n \nOverall Response \nRate \n \n \nDuration of \nResponse  DTIC + detorubicin \nvs. DTIC alone  \n \n8 months vs. 5 \nmonths, n.s.  \n \n36% (n=8 of 22 \npatients) vs. 15% \n(n=4 of 26), n.s.  \n \n6 months vs. 5 \nmonths,n.s.  Jadad Score 2  \nRandomization \nscheme not \ndescribed, \nunblinded tumor \nassessment, small \nsample size  \n \nFunding:  \nNot declared  1b \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 479 von 817 \n6.2.4.2.  Aktualisierungsrecherche 2015  \n6.2.4.2.1.  RCTs - Chemotherapy/Chemosensitizer  \nStudy  Aims  Design  Populat ion Outcomes  Results  Comments  LoE \nBedikian et al. \n2014  To prospectively \ninvestigate \nwhether \nDacarbazine in \ncombination with \noblimersen was \nsuperior to \nDacarbazine plus \nplacebo in patients \nwith advanced \nmelanoma and low \nbaseline LDH levels \n(r0.8ULN).  2-arm, phase III \nRCT \n \nGroup A:  \nOblimersen \n7mg/kg/day by \ncontinuous iv \ninfusion for 5 days \n(120h), \nimmediately \nfollowed by  \nDacarbazine \n1000mg/m2 iv \n(n=157)  \n \nGroup B:  \nPlacebo by \ncontinuous iv \ninfusion for 5 days \n(120h), \nimmediately \nfollowed by  \nDacarbazine \n1000mg /m2 iv \n(n=157)  \n Chemotherapy -\nnaive patients with \nadvanced \nmelanoma and \nLDH at 0.8ULN OS  \n \n \nPFS \n \n \nOverall Response \nRate (ORR)  \n \nDurable Response \nRate  13.5m vs 13.1m  \n(HR: 1.04; p=0.73)  \n \n2.8m vs. 2.7m  \n(HR: 0.85, p=0.23)  \n \n17.2% vs. 12.1% \n(p=0.19)  \n \n10.8% vs. 7. 5% \n(p=0.32)  Jaded -Score: 5  \n \nFunding:  \nGenta  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 480 von 817 \nStudy  Aims  Design  Populat ion Outcomes  Results  Comments  LoE \nDaponte et al. \n2013  To assess the \neffect of adding \nfotemustine \nand/or IFN to \nstandard therapy \nwith dacarbazine \nalone in patients \nwith advanced \nmalignant \nmelanoma  4-arm, phase III \nRCT \n \nGroup A:  \nFotemustin \n100m g/m2 d1 \nDacarbazine \n900mg/m2 d2 \nq21 \n(n=64)  \n \nGroup B:  \nFotemustin \n100mg/m2 d1 \nDacarbazine \n900mg/m2 d2 \nq21 \nInterferon -\u03b12b 5UI \n3x/week  \n(n=68)  \n \nGroup C:  \nDacarbazine \n900mg/m2 d2 \nq21 \n(n=70)  \n \nGroup D:  \nDacarbazine \n900mg/m2 d2 \nq21 Patients with \nadvanced \nmelanoma  OS \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nPFS \n \n \n \n \n \n \n \n \n \n Median OS was 7.9  \nmonths (95% CI \n6.6-10.2) for \npatients receiving \nfotemustine \n(groups A + B) \ncompared with 8.6 \nmonths (95% CI \n6.3-10.4) without \nfotemustine \n(groups C + D) \n(p=0.28). Median \nOS was 9.1 months \n(95% CI 6.3 -11.1) \nwith IFN -\u03b12b \n(groups B + D) and \n7.7 months (95% \nCI 6.3-9.7) without  \n(groups A + C) \n(p=0.68).  \n \nMedian PFS was \n2.7 months (95% \nCI 2.4 -3.8) with \nfotemustine and \n2.5 months (95% \nCI 2.3 -3.7) \n(p=0.55) without.  \nMedian PFS was \n2.8 months (95% \nCI 2.4 -3.9) in IFN -Jaded -Score: 3  \n \nFunding:  \nNational Cancer \nInstitute, Naples  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 481 von 817 \nStudy  Aims  Design  Populat ion Outcomes  Results  Comments  LoE \nInterferon -\u03b12b 5UI \n3x/week  \n(n=58)  \n \n \n \n \nResponse  \n \n \n \n \n \nToxicity  \u03b12b-treated \npatients compared \nwith 2.5 months \n(95% CI 2.3 -2.9) \nwithout IFN -\u03b12b \n(p=0.28).  \n \nn (%)  \nGroup A: 32 (34%)  \nGroup B: 33 (26%)  \nGroup C: 34 (27%)  \nGroup D: 31 (23%)  \n \nProvided as table \nonly \nFlaherty et al. \n2014  To determine \nwhether \ncarboplatin, \npaclitaxel, and \nsorafenib improve \noverall survival \ncompared with \ncarboplatin and \npaclitaxel in \nchemotherapy -\nnaive patients with \nmetastatic \nmelanoma.  2-arm, phase III \nRCT \n \nGroup A:  \nCarboplatin AUC 6 \nq21 \nPaclitaxel \n225mg/m2 q21 \nSorafenib 400mg \npo BID \n(n=410)  \n \nGroup B:  \nCarboplatin AUC 6 \nq21 Cutaneous, \nmucosal, or \nunknown primary \nsite melanoma, \nmetastatic or \nunresectable \ndisease.  OS \n \n \n \n \n \n \nPFS \n \n \n \n \nObjective Tumor \nResponse (ORR)  \n 11.1 months (95% \nCI, 10.3 to 12.3  \nmonths) for CPS \nand \n11.3 months (95% \nCI, 9.8 to 12.2 \nmonths) for CP \n(p=.878)  \n \n4.9 months for CPS \nand 4.2 months for \nCP (p=.092) \n \n20% for CPS and \n18% for CP Jaded -Score: 5  \n \nFunding:  \nNational Cancer \nInstitute (NCI)  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 482 von 817 \nStudy  Aims  Design  Populat ion Outcomes  Results  Comments  LoE \nPaclitaxel \n225mg/m2 q21 \n(n=413)  Toxicity  (p=.427)  \n \nMore patients on \nthe CPS arm had \ngrade 3 or higher \ntoxicities (84% v \n78%; p=.027), with \nincreased rash, \nhand -foot \nsyndrome, and \nthrombocytopenia \naccounting for \nmost of the \ndifference.  \nO\u2019Day et al. 2013  To confirm the \nefficacy and \ntolerability of \nElesclomol in \ncombination with \npaclit axel versus \npaclitaxel alone in \npatients with \nadvanced \nmelanoma  2-arm, phase III \nRCT \nGroup A:   \nElesclomol 213 \nmg/m2 and \nPaclitaxel 80 \nmg/m2 weekly for \n3 weeks followed \nby one week drug \nholiday   \nGroup B:  \nPlacebo +  \nPaclitaxel 80 \nmg/m2 weekly for \n3 weeks fol lowed Patients with \nadvanced (stage IV) \nmelanoma of \ncutaneous origin \nand one or more \nmeasurable lesions  PFS \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Median PFS was \n3.4 months in the \ncombination group \nand1.9 months in \nthe paclitaxel \ngroup(HR,0.89;95%\nCI,0.73to1.08). A \nprospectively \ndefined subgroup \nanalysis revealed a \nstatistically \nsignificant \nimprovement in \nmedian PFS for the \ncombination in \npatients with Jaded -Score: 5  \n \nFunding:  \nSynta \nPharmaceuticals  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 483 von 817 \nStudy  Aims  Design  Populat ion Outcomes  Results  Comments  LoE \nby one week drug \nholiday  \n \nPatients were \nstratified by prior \nsystemic \ntreatment, M1 \nsubclass, and \nbaseline lactate \ndehydrogenase \n(LDH) levels   \n \n \nOS normal baseline \nLDH. \n \nThe study was \nstopped when an \nearly overall \nsurvival data \nanalysis indicated \nan imbalance in \ntotal deaths \nfavouring \npaclitaxel, \npredominantly in \npatients with high \nLDH levels.  \n \nMedian OS was \n10.6 months in the \ncombina tion group \nand 11.4 months \nin the paclitaxel \ngroup (HR, 1.10; \n95% CI, 0.92 to \n1.32;p=.18).  \n \n \n   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 484 von 817 \n6.2.4.2.2.  RCTs - Immuntherapie/Immunmodulation  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAndtbacka et a l. \n2015  To evaluate \nwhether treatment \nwith T -VEC \nresulted in an \nimproved durable \nresponse rate \n(DRR) compared \nwith GM -CSF in \npatients with \nunresected stage \nIIIB to IV \nmelanoma.  2-arm, phase III \nRCT \n \nTreatment:  \n \nGroup A: \nTalimogene \nLaherparepvec \n(n=295)  \n \nGroup B:  \nGM-CSF (n=141)  Not surgically \nresectable, stage \nIIIB to IV melanoma \nsuitable for direct \nor ultrasound -\nguided injection (at \nleast one \ncutaneous, \nsubcutaneous, or \nnodal lesion or \naggregation of \nlesions 10 mm in \ndiameter).  Durable Response \nRate \n \nOvera ll Response \nRate \n \nOverall Survival DRR was higher \nwith T -VEC (16.3%; \n95% CI, 12.1% to \n20.5%) than GM -\nCSF (2.1%; 95% CI, \n0% to 4.5%]; odds \nratio, 8.9; P \n<.001).  \n \nOverall response \nrate was higher in \nthe T -VEC arm \n(26.4%; 95% CI, \n21.4% to 31.5% v \n5.7%; 95% C I, 1.9% \nto 9.5%).  \n \nMedian OS was \n23.3 months (95% \nCI, 19.5 to 29.6 \nmonths) with T -\nVEC and 18.9 \nmonths (95% CI, \n16.0 to 23.7 \nmonths) with GM -\nCSF (hazard ratio, \n0.79; 95% CI, 0.62 \nto 1.00; P .051).  \n Jadad -Score: 3  \n \nT-VEC efficacy was \nmost pronounced \nin pat ients with \nstage IIIB, IIIC, or \nIVM1a disease and \nin patients with \ntreatment -naive \ndisease.  \n \n \nFunded by:  \nAMGEN  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 485 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nLarkin et al. 2015  To confirm and \nextend [ findings of \na phase 2 trial ], we \nreport one of the \ncoprimary end \npoints \n(progression -free \nsurvival)  of a \nrandomized, \ndouble -blind, \nmulti -center, phase \n3 trial (CheckMate \n067) that was \nconducted to \nevaluate the safe -ty \nand efficacy of \nnivolumab alone or \nnivolumab comb -\nined with ipilimu -\nmab in comparison \nwith ipilimumab \nalone in patients \nwith previously \nuntreated meta -\nstatic melanoma.  3-arm, phase III, \nRCT \n \nGroup A:  \nNivolumab alone \n(n=316) 3mg/kg \nq14 (plus \nIpilimumab -\nmatched placebo);  \n \nGroup B:  \nNivolumab comb -\nined with Ipilimu -\nmab  \n(n=314)  \nNivolumab 1mg/kg \nq21 plus \nIpilimumab 3 \nmg/kg q21 for 4 \ndoses, fol lowed by \nNivolumab 3mg/kg \nq14 \n \nGroup C:  \nIpilimumab alone  \n(n=315)  \n3mg/kg q21 for 4 \ndoses (plus \nNivolumab -\nmatched placebo).  Stage III \n(unresectable) or \nstage IV melanoma \npatients, no prior \nsystemic treatment \nfor advanced \ndisease. \nAvailability of \ntissue collected \nfrom metastatic or \nunresectable \ntumors (archival or \nrecently biopsied \nsamples) for the \nassessment of PD -\nL1 status; and \nknown BRAF V600 \nmutation status.  Progression -free \nsurvival (PFS)  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nOverall survival  \nObjective \nResponse Rate  \n \nTumor PD -L1 \nexpression as a \npredictive \nbiomarker for \nefficacy outcomes.  Median PFS: 11.5 \nmonths (95% CI, \n8.9 to 16.7) with \nnivolumab plus \nipilimumab, vs. 2.9 \nmonths (95% CI,  \n2.8 to 3.4) with \nipilimumab \n(hazard ratio for \ndeath or dis ease \nprogression, 0.42; \n99.5% CI, 0.31 to \n0.57; P<0.001), vs \n6.9 months (95% \nCI, 4.3 to 9.5) with \nnivolumab (HR for \nthe comparison \nwith ipilimumab, \n0.57; 99.5% CI, \n0.43 to 0.76; \nP<0.001).  \n \n \nNot reported on  \n \n \n \nIn patients with \ntumors positive for \nthe PD -L1, median \nPFS was 14.0 Jadad -Score: 5  \n \nOverall survival \ndata (coprimary \nend point) not \navailable so far.  \nStudy not powered \nto confirm benefit \nof Nivo+Ipi vs Nivo \nalone.  \n \nPD-L1 status of \ntumor tissue as \nstratification factor \n \nFunded by:  \nBristol- Myers \nSquibb  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 486 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nSafety  months in the \nnivolumab -plus-\nipilimumab group \nand in the \nnivolumab group, \nbut in patients \nwith PD -L1\u2013\nnegative tumors, \nprogression -free \nsurvival was longer \nwith the \ncombination \ntherapy than with \nnivolumab alone \n(11.2 months [95% \nCI, 8. 0 to not \nreached] vs. 5.3 \nmonths [95% CI, \n2.8 to 7.1]).  \n \nTreatment -related \nadverse events of \ngrade 3 or 4 \noccurred in 16.3% \nof the patients in \nthe nivolumab \ngroup, 55.0% of \nthose in the \nnivolumab -plus-\nipilimumab group, \nand 27.3% of those  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 487 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nin the ipilimumab  \ngroup.  \n \nMaio et a l. 2015  To conduct a \nmilestone survival \nanalysis of data \nfrom a randomized \ncontrolled phase III \ntrial to con \ufb01rm the \nsurvival bene \ufb01t of \nipilimumab in \npatients with \nadvanced \nmelanoma.  OS follow up from \na RCT  \n \nGroup A: \nIpilimumab \n10mg/kg q21 + \nDTIC 850mg/m2 \n(n=250)  \n \nGroup B:  \nDTIC  850mg/m2+ \nPlacebo  \n(n=252)  Untreated stage \nIIIc, N3 \n(unresectable) or \nstage IV melano ma \n Overall survival  \n \n5-Y-OS Median survival \nfollow -up for the \nipilimumab plus \ndacarbazine group \nwas 11.0 months \n(range,0.4 to 71.9 \nmonths) and was \n8.9 months (range, \n0.1 to 73.2 \nmonths) for the \nplacebo plus \ndacarbazine group. \nThe updated \nmedian OS was \n11.2months(95% \nCI, 9.5 to 13.8 \nmonths) in the \nipilimumab plus \ndacarbazine group \nand was 9.1 \nmonths (95% CI, \n7.8 to 10.5 \nmonths) in the \nplacebo plus \ndacarbazine group \n(HR, 0.69; 95% CI, \n0.57 to 0.84). OS Jadad -Score: Not \napplicable  \n \nUpdated OS data \nfrom a previously \npublished trial. \nDifferent dosing of \nIpilimumab in \ncontrast to the \napproved one in \nthe EU  \n \nFunded by:  \nBristol- Myers \nSquibb  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 488 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nrates in the \nipilimumab plus \ndacarbazine group \nwere cons istently \nhigher than those \nin the placebo plus \ndacarbazine group. \nAt a minimum \nfollow -up of 5 \nyears, 18.2% of \npatients in the \nipilimumab plus \ndacarbazine group \nwere still alive \ncompared with \n8.8% of patients in \nthe placebo plus \ndacarbazine group \n(P.002).  \nMcDermott et al. \n2013  To describe the \nsafety and long -\nterm ef\ufb01cacy of \nipilimumab among \npatients from the \npivotal phase III \nMDX010 -20 study \nwho survived 2 \nyears or longer Updated data from \na 3-arm phase III \nRCT \n \nOf 676 patients \ntreated in \nMDX010 -20, 474 \nwere randomized \nat least 2 years \nbefore the study \ncut-off date a nd Patients with \nunresectable stage \nIII or IV melanoma \nwho had been \ntreated previously \nwith chemotherapy \nor interleukin -2 (IL-\n2) were \nrandomized 3:1:1.  \n Long term OS (2 -3 \nY OS rate)  \n \n \n \n \n \n \n \n \n \u22652 years  \nIpi+gp100  \n54 of 284 (19%)  \nIpi \n24 of 95 (25%)  \ngp100  \n16 of 95 (17%)  \n \n\u22653 years  \nIpi+gp100  \n24 of 156 (15%)  Jadad-Score: Not \napplicable  \n \nSubset analysis of \nthe MDX010 -20 \nstudy  \n \nFunded by:  \nBristol- Myers \nSquibb  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 489 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwere eligible for \nthis analysis.  \n \nGroup A:  \nIpilimumab \n3mg/kg q 21 for 4 \ndoses plus gp100 \nvaccine 2mL sc \nq21 for 4 doses   \n(n=284)  \n \nGroup B:  \nIpilimumab \n3mg/kg q21 for 4 \ndoses \n(n=95) \n \nGroup C:  \ngp100  2mL sc q21 \nfor 4 doses \n(n=95)  \n \n \n \n \nSafety  Ipi \n13 of 53 (25%)  \ngp100  \n5 of 50 (10%)  \n \nSafety in patients \nwith \u22652 years\u2019 \nsurvival was \ncomparable to that \nin the overall study \npopulation.  \n \nRibas et al. 2013  To evaluate overall \nsurvival (OS) and \nother safety and \nef\ufb01cacy end points \nin patients with \nadvanced \nmelanoma treated \nwith \ntremelimumab or 2-arm RCT, phase \nIII \n \nGroup A:  \nTremelimumab 15 \nmg/kg once every \n90 days  \n(n=328)  \n Patients with \ntreatment -naive, \nunresectab le stage \nIIIc or IV melanoma  OS \n \n \n \n \n \n \n \n Median OS by ITT \nwas12.6months \n(95%CI, 10.8 -14.3 \nmonths) in the \ntremelimumab arm \nand 10.7 months \n(95% CI, 9.4 to \n12.0 months) in \nthe c hemotherapy Jadad -Score: 3 \n \nFunded by:  \nPfizer 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 490 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nstandard -of-care \nchemotherapy.  Group B:  \nPhysician\u2019s choice \nof standard -of-care \nchemotherapy \n(temozolomide or \ndacarbazine, \nn=327).   \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nORR \n \n \n \n \n \n \n \n \n \n \n \n \n arm \n(HR,0.88;P.127).  \n \nSurvival at 2 and 3 \nyears was 26.4% \n(95% CI, 22.0% to \n31.7%) and 20.7% \n(95% CI, 16.7% to \n25.6) in patients \ntreated with \ntremelimumab and \n22.7% (95% CI, \n18.5% to 27.8%) \nand 17.0% (95% CI, \n13.3% to 21.7%), in \npatients in the  \nchemotherapy \narm.  \n \nORR based on \ninvestigator \nassessment were \nsimilar in both \nstudy arms:10.7% \nin the \ntremelimumab arm \nand 9.8% in the \nchemotherapy arm \nThere were no \nsigni\ufb01 cant \ndifferences  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 491 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nResponse duration  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nSafety  between study \narms in rate of \ncomplete or partial \nresponse.  \n \nMedian response \nduration (de \ufb01ned \nas time from \nrandom \nassignment to \nprogression or \ndeath resulting \nfrom disease \nprogression for the \nobjective \nresponders) was \nsigni\ufb01 cantly longer \namong \ntremelimumab \nresponders \ncompared with \nchemotherapy \nresponders: 35.8 \nmonths (range, 5.6 \nto 44.3 months) \nversus 13.7 \nmonths (range, 4.0 \nto 44.3 months; P \n.0011).  \n \nGrade 3/4 AEs   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 492 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nTremelimumb: 52%  \nChemo: 37%  \nGrade 5:  \nTremelimumab: 7%  \nChemo: 4%  \nRobert el at. 2013  To describe the \nrationale for \nretreatment with \nipilimumab and to \nprovide resultant \nef\ufb01cacy and safety \noutcomes  Subset of a 3 -arm \nRCT \n \nGroup A:  \nIpilimumab \n3mg/kg q 21 for 4 \ndoses plus gp100 \nvaccine 2mL sc \nq21 for 4 doses   \n(n=29) \n \nGroup B:  \nIpilimumab \n3mg/kg q21 for 4 \ndoses \n(n=9)  \n \nGroup C:  \ngp100  2mL sc q21 \nfor 4 doses \n(n=2)  Patients with \nunresectable stage \nIII or IV melanoma \nwho had been \ntreated previously \nwith chemotherapy \nor interleukin -2 (IL-\n2) were \nrandomized 3:1:1.  BOOR  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nSafety  Best overall \nresponse rates \n(CR+PR) for 31 \nretreatment -\neligible patients in \nthe ipilimumab \nplus gp 100 and \nipilimumab plus \nplacebo groups \nwere 3 of 23 \n(13.0%) and 3 of 8 \n(37.5%), \nrespectively, and \ndisease control \nrates were 65.2% \nand 75.0%.  \n \nDrug -related \nadverse events \nwere reported in \n25 patients \n(86.2%), 7 patients \n(77.8%), and 2 \npatients (100%) in \nthe ipilimumab Jadad -Score: not \napplicable  \n \n \nSubset analysis of \nthe MDX010 -20 \nstudy  \n \nFunded by:  \nBristol- Myers \nSquibb  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 493 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nplus gp100, \nipilimumab plus \nplacebo, and \ngp100 plus \nplacebo arms, \nrespectively. The \nmost common \nadverse events \nwere irAEs, \noccurring in \n15patients (51.7%), \n7 patients (77.8%), \nand 1 patient \n(50.0%) in the \nrespective groups.  \nRobert at al. 2015  To determine \nwhether \nnivolumab, as \ncompared with \ndacarbazine, \nimproves overall \nsurvival among \npre-viously \nuntreated patients \nwho have \nadvanced \nmelano ma without \na BRAF mutation  2-arm RCT, phase \nIII \n \n1:1 randomisation  \n \nGroup A:  \nNivolumab 3mg/kg \nq14 plus a \ndacarbazine -\nmatched placebo \nevery 3 weeks  \n \nGroup B:  \nDacarbazine \n1000mg/m2 q21 Unresectable, \npreviously \nuntreated stage III \nor IV melanoma \nwithout a BRAF \nmutation.  OS \n \n \n \n \n \n \n \n \n \n \n \n \n \nInvestigator -1 Y-OS rate of \nsurvival was 72.9% \n(95% confidence \ninterval [CI], 65.5 \nto 78.9) in the \nnivolumab group, \nas compared with \n42.1% (95% CI, \n33.0 to 50.9) in \nthe dacarbazine \ngroup (HR for \ndeath, 0.42; \n99.79% CI, 0.25 to \n0.73; P<0.001).  \n Jadad -Score: 5  \n \nBRAF wt patients \nonly \n \nPD-L1 status of \ntumor tissue as \nstratification factor \n \nFunded by:  \nBristol- Myers \nSquibb  \n \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 494 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nplus a nivolumab -\nmatched placebo \nevery 2 weeks.  assessed PFS  \n \n \n \n \n \n \n \n \n \nORR  \n \n \n \n \n \n \n \n \nPD-L1 expression \nin the tumor as a \npredictive \nbiomarker of OS  Median PFS was \n5.1 months in the \nnivolumab group \nvs 2.2 months in \nthe dacarbazine \ngroup (HR for \ndeath or \nprogression of \ndisease, 0.43; 95% \nCI, 0.34 to 0.56; \nP<0.001).  \n \nORR was 40.0% \n(95% CI, 33.3 to \n47.0) in the \nnivolumab group \nvs 13.9% (95% CI, \n9.5 to 19.4) in the \ndacarbazine group \n(odds ratio, 4.06; \nP<0.001).  \n \nRegardless of PD -\nL1 status, \nnivolumab -treated \npatients had \nimproved OS, as \ncompared with \ndacarbazine -\ntreated patients \n(unad -justed HR  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 495 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfor death among \npatients with \npositive PD -L1 \nstatus, 0.30 [95% \nCI, 0.15 to 0.60]; \nunadjusted hazard \nratio for death \namong those with \nPD-L1 negative or \nindeterminate PD -\nL1 status, 0.48 \n[95% CI, 0.32 to \n0.71]). In the \nnivolumab group, \nthe median OS was \nnot reached in \neither PD -L1 \nsubgroup. In the \ndacarbazine group, \nthe median OS was \nslightly longer in \nthe subgroup with \npositive PD -L1 \nstatus than in the \nsubgro up with \nnegative or \nindeterminate PD -\nL1 status (12.4 vs. \n10.2 months)  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 496 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nRobert et al. 2015  To compare PD -1 \ninhibition with \nCTLA-4 blockade in \na controlled, \nrandomized trial \ninvolving patients \nwith advanced \nmelanoma  3-arm RCT, phase \nIII \n \nGroup A:  \nPembrolizumab \n10mg/kg q14  \n \nGroup B:  \nPembrolizumab \n10mg/kg q21  \n \nGroup C:  \nIpilimumab \n3mg/m2 q21 for 4 \ncycles  Patients had to had \nhistolog ically \nconfirmed, \nunresectable stage \nIII or IV melanoma \nand had received \nno more than one \nprevious systemic \ntherapy for \nadvanced disease. \nKnown BRAF V600 \nmutational status \nwas required. PFS \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nOS \n \n \n \n \n \n \n \n \n \n Estimated 6 -month \nPFS rates were \n47.3% for \npembrolizumab \nevery 2 weeks, \n46.4% for \npembrolizumab \nevery 3 weeks, and \n26.5% for \nipilimumab (HR for \ndisease \nprogression, 0.58; \nP<0.001 for both \npembrolizumab \nregimens vs \nipilimumab; 95% \nconfidence \ninterval s [CIs], 0.46 \nto 0.72 and 0.47 \nto 0.72).  \n \nEstimated 12 -\nmonth OS rates \nwere 74.1%, 68.4%, \nand 58.2% (HR for \ndeath for \npembrolizumab \nevery 2 weeks, \n0.63; 95% CI, 0.47 \nto 0.83; P = \n0.0005; HR for Jadad -Score: 3  \n \nPD-L1 status of \ntumor tissue as \nstratification factor \n \nFunded by:  \nMerck Sharp & \nDohme  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 497 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \nORR \n \n \n \n \n \n \n \n \n \n \n \nDuration of \nresponse \n \n pembrolizumab \nevery 3 weeks, \n0.69; 95% CI, 0.52 \nto 0.90; \nP=0.0 036).  \n \nORR was improved \nwith \npembrolizumab \nadministered every \n2 weeks (33.7%) \nand every 3 weeks \n(32.9%), as \ncompared with \nipilimumab (11.9%) \n(P<0.001 for both \ncomparisons).  \n \nResponses were \nongoing in 89.4%, \n96.7%, and 87.9% \nof patients, after a \nmedian fo llow-up \nof 7.9 months.  \nSchadendorf et al. \n2015  To provide a more \nprecise estimate of \nlong-term survival \nobserved with \nipilimumab \ntherapy, we Primary analysis \npooled OS data for \n1,861 patients \nfrom 10 \nprospective and \ntwo retrospective Patients with \nadvanc ed \nmelanoma  OS Among 1,861 \npatients, median \nOS was 11.4 \nmonths (95% CI, \n10.7 to 12.1 \nmonths).  Jadad -Score: not \napplicable  \n \nMixed cohorts, \nmaybe data from \nEAPs more 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 498 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nconducted  a \npooled analysis of \nOS data across \nmultiple  studies  in \nadvanced  \nmelanoma.  \n studies of \nipilimumab, \nincluding two \nphase III trials. \nPatients were \npreviously treate d \n(n=1,257) or \ntreatment naive \n(n=604), and the \nmajority of \npatients received \nipilimumab 3 \nmg/kg (n=965) or \n10 mg/kg (n=706).  \n \nSecondary analysis \nof OS data \n(n=4,846) with an \nadditional 2,985 \npatients from an \nexpanded access \nprogram.   \nThe survival curve \nbegan to plateau \naround year 3, \nwith follow -up of \nup to 10 years. \nThree -year survival \nrates were \n22%,plateau \naround year 3, \nwith follow -up of  \nup to 10 years.  \n \nThree -year survival \nrates were 22%, \n26%, and 20% for \nall patients, \ntreatment -naive \npatients, and \npreviously treated \npatients, \nrespectively.  \n \nIncluding data \nfrom the expanded \naccess program, \nmedian OS was 9.5 \nmonths (95% CI, \n9.0 to 10.0 \nmonths), with a \nplateau at 21% in valuable because it \nreflects the \nstandard of care \nmore precisely. \n \nFunded by:  \nBristol- Myers \nSquibb  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 499 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nthe survival curve \nbeginning around \nyear 3.   \nWeber et al. 2015  To assessed the \nefficacy and safety \nof nivolumab \ncompared with \ninvestigator\u2019s \nchoice of \nchemotherapy \n(ICC) as a second -\nline or later -line \ntreatment in \npatients with \nadvanced \nmelanoma.  2-arm phase III \nRCT \nRandomisation \nschedule 2:1  \n \nGroup A:  \nNivolumab 3 \nmg/kg q14  \n(n=272)  \n \nGroup B:  \nInvestigator\u2019s \nchoice of \nchemotherapy \n(ICC) \n(dacarbazine 1000 \nmg/m\u00b2 q21 or \npaclitaxel 175 \nmg/m\u00b2 combined \nwith carboplatin \narea under the \ncurve 6 q21)  \n(n=133)  Patients had \nunresectable or \nmetastatic \nmelanoma, and \nprogressed after \nipilimumab, or \nipilimumab and a \nBRAF inhibitor if \nthey were \nBRAFV600 \nmutation -positive.  ORR \n \n \n \n \n \n \n \n \n \nPFS \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nSafety  38 (31.7%, 95% CI \n23.5\u201340.8) of the \n120 patients in the \nnivolumab group \nand in five (10.6%, \n3.5\u201323.1) of the 47 \npatients in the ICC \ngroup archived an \nobjective response.  \n \nMedian PFS was \n4,7 months (95% CI \n2,3\u20136,5) for the \nnivolumab group \nand 4 ,2 months \n(2,1\u20136,3) for the \nICC group (HR \n0.82; 99 .99% CI \n0\u00b732\u20132\u00b705) \n6-month PFS was \n48% (95% CI 38 \u2013\n56) in the \nnivolumab group  \nand 34% (18 \u201351) in \nthe ICC group.  \n \nGrade 3 \u20134 Jadad -Score: 3  \n \nBRAF -Mutation \nstatus, PDL1 -\nexpression and \nbest response to \nIpilimumab used \nas stratification \nfactors.  \n \nORR/PFS only \nreported for a \nsubset of patients \n \nFunded by:  \nBristol- Myers \nSquibb  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 500 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntreatment -related \nadverse events \noccurred in 24 (9%) \nof the 268 patients \nin the nivolumab \ngroup versus 32 \n(31%) of the 102 \npatients in the ICC \ngroup.  \n \n6.2.4.2.3.  Zielgerichtete Therapien /small molecules   \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nFlaherty  et al. \n2012  Not specified in \nreport  Open -label, 2 -\narmed Phase III \nRCT \n \nGroup A:  \nTrametinib  \n(n=214)  \n \nGroup B:  \nChemotherapy \n(DTIC or Paclitaxel)  \n(n=108)  Patients who had \nhistologically \nconfirmed, unre -\nsectable stage IIIC \nor IV cutaneous \nmelanoma with a \nV600 E or V600K \nBRAF mutation \nwere eligible. \nUp to one previous \nchemotherapy \nschedules allowed. Progression -free \nsurvival (PFS)  \n \n \n \n \n \n \n \n \nOverall survival \n(OS)  \n \n \n \n 4.8 month s in the \nTrametinib group \nas compared with \n1.5 months in the \nchemotherapy \ngroup (HR for \nprogression, 0.45; \n95% CI, 0.33 -0.63; \nP<0.001)  \n \n6-month OS rate in \nthe ITT population \nwas 81% in the \nTrametinib group \nand 67% in the \nchemotherapy Jaded -Score: 3  \n \nFunding:  \nGlaxoSmithKline  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 501 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nOverall response \nrate (ORR)  \n \n \n \n \n \n \nDuration of \nresponse  \n \n \n group. The HR for \ndeath in the \nTrametinib group \nwas 0.54 (95% CI, \n0.32-0.92; \nP=0.01), even \nthough 51 of 108 \npatients (47%) in \nthe chemotherapy \ngroup crossed over \nto receive \nTrametinib. \nMedian overall \nsurvival had not \nbeen reached at \nthe time of this \nreport.  \n \nORR 22% (95% CI, \n17-28) in the \nTrametinib group \nand 8% (95% CI, 4 -\n15) in the \nchemotherapy \ngroup  \n \nMedian duration of \nresponse was 5.5 \nmonths (95% CI, \n4.1 to 5.9) in the \nTrametinib group  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 502 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \n \n \nSafety  (in 47 pts.) and \nhad not been \nreached in the \nchemotherapy \ngroup (in 9 pts).  \n \nRash, diarrho ea, \nand peripheral \noedema were the \nmost common \ntoxic effects in the \nTrametinib group \nand were managed \nwith dose \ninterruption and \ndose reduction; \nasymptomatic and \nreversible \nreduction in the \ncardiac ejection \nfraction and ocular \ntoxic effects \noccurred \ninfreq uently. \nSecondary skin \nneo-plasms were \nnot observed.  \nHauschild et al. \n2012  To assess whether \nDabrafenib was \nbetter than Open -label, 2 -\narmed Phase III \nRCT, randomly Patients aged 18 \nyears or o lder with \npreviously PFS (by \ninvestigator)  \n Median PFS was \n5.1 months for \nDabrafenib and 2.7 Jaded -Score: 3  \n \nFunding:  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 503 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nstandard \nDacarbazine \nchemo -therapy, we \ndid a phase 3, \nmulti -centre, \nrandomised trial in \npreviously \nuntreated \nmelanoma patients \nwhose tumours \nharboured a \nBRAFV600E \nmutation.  assigned 3:1  \n \nGroup A:  \nDabrafenib 150mg \nbid p.o.  \n(n=187)  \n \nGroup B:  \nDacarbazine \n1000mg/m2 iv q21  \n(n=63) untreated, stage IV \nor unresectable \nstage III \nBRAFV600E \nmutation -positive \nmelanoma   \n \n \n \n \n \n \nPFS (by \nIndependent \nReview)  \n \n \n \n \n \n \nOS \n \n \n \n \nORR \n \n \n \n \n \n \n \n \n months for \nDacarbazine, with \na HR of 0.30 (95% \nCI 0.18 \u20130.51; \np<0.0001).  \n \nMedian PFS for \nDabrafenib was 6.7 \nmonths versus 2.9 \nmonths for \nDacarbazine (HR \n0.35; 95% CI 0.20 \u2013\n0.61).  \n \nThe overall survival \nHR was 0.61 (95% \nCI 0.25 \u20131.48) in \nfavour of \nDabrafenib.  \n \nConfirmed OR was \nreported by the IR \nin 93 (50%, 95% CI \n42.4\u201357.1) of 187 \npatients randomly \nassigned to \nDabrafenib (6 [3%] \nhad a complete \nresponse and 87 \n[47%] had a partial \nresponse). In the GlaxoSmithKline   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 504 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nPFS after cross -\nover \n \n Dacarbazine \ngroup, confirmed \nresponses were \nseen by the IR in \nfour (6%, 95% CI \n1.8\u201315.5) of 63 \npatients.  \n \nConfirmed OR was \nreported by the \ninvestigator in 99 \n(53%, 95% CI 45.5 -\n60.3) of the 187 \npatients (6  [3%] \nhad a CR and 93 \n[50%] had a PR).  \nConfirmed \nresponses for the \nDacarbazine group \nwere reported by \nthe investigator in \n12 (19%, 10.2 \u2013\n30.9) patients (all \n12 patients had a \npartial response).  \n \n28 patients \nrandomly assigned \nto Dacarbazine \nhave crossed ove r \nto Dabrafenib at  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 505 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \n \n \n \n \n \nDuration o f \nresponse  \n \n \n \n \n \n \n \n \n \n \n \n \n \nQuality of life  \n \n \n \n \nSafety & \nTolerability  \n data cutoff; 13 \n(46%) patients have \nhad PR but, among \nthese patients, no \nCR has been \nnoted.  \n \nThe estimated \nmedian duration of \nresponse for \nDabrafenib was 5.5 \nmonths for IR and \n5.6 months for \ninvestigator \nassessment.  \nThe estimated \nmedia n duration of \nresponse for \nDacarbazine was \nnot reached at \ntime point of data \ncut. \n \nQuality of life \nanalyses are \nongoing and will \nbe reported \nseparately.  \n \nIn patients \nreceiving  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 506 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nDabrafenib, the \nmost common AEs \nwere cutaneous \n(hyperkeratosis, \npapillomas, \npalm ar-plantar \nerythrodysaesthesi\na), pyrexia, fatigue, \nheadache, and \narthralgia. Toxic \neffects of grade 3 \u2013\n4 were uncommon.  \nLarkin et al. 2014 To confirm and \nbuild on these \nearly data, we \nreport on the \nprimary end po int \nof coBRIM, an \ninter-national, \nmulticenter, \nrandomized phase \n3 study that \nevaluated the \nefficacy and safety \nof cobimetinib \ncombined with \nvemurafenib in \npreviously \nuntreated patients \nwith advanced Double -blinded, 2 -\narmed Phase III \nRCT \n \nGroup A:  \nVemurafenib 960 \nmg bid po  \nCobimetinib (at a \ndose of 60 mg \nonce daily for 21 \ndays, followed by 7 \ndays off) (n=247)  \n \nGroup B:  \nVemurafenib 960 \nmg bid po  \nPlacebo  \n(n=248)  Histologically \nconfirmed \nunresectable, \nlocally advanced \nstage IIIC or stag e \nIV melanoma with \na BRAF V600 \nmutation detected \nwith the use of a \nreal-time \npolymerase -chain -\nreaction assay \n(Cobas 4800 BRAF \nV600 Mutation \nTest, Roche \nMolecular Systems)  PFS as assessed by \nthe investigator,  \n \n \n \n \n \n \n \n \n \n \n \n \n \nOverall Survival \n \n VEM+COBI: Median \nPFS of 9.9 months \n(95% CI, 9.0 to not \nreached), as \ncompared with 6.2 \nmonths (95% CI, \n5.6 to 7.4) in \npatients treated \nwith VEM and \nplacebo. HR for \ndeath or \nprogression of \ndisease: 0.51 (95% \nCI, 0.39 to 0.68; \nP<0.001)  \n \nThe interim \nanalysis of OS in Jaded -Score: 5  \n \nFunding:  \nF Hoffmann -La \nRoche -Genentech  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 507 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nBRAF -mutated \nmelanoma.   \n \n \n \n \n \n \n \n \n \nORR \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDuration of \nresponse  \n \n \n the ITT -population \nshowed that the \nrate of overall \nsurvival at 9 \nmonths for the \ncombination of \nVEM+COBI was 81% \n(95% CI, 75 -87), as \ncompared with \n73% (95% CI, 65 - \n80) with \nVEM+Placebo  \n \n68% of patients in \nthe combination \ngroup had an \nobjective response, \nas compared with \n45% in the control \ngroup (P<0.001).  \nThe rate of \ncomplete response \nwas also \nsignificantly higher \nin the combination \ngroup than i n the \ncontrol group (10% \nvs. 4%).  \n \nThe median \nduration of  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 508 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \n \nPFS as assessed by \nan independent \nreview facility  \n \n \n \n \n \n \nSafety  response was 7.3 \nmonths in the \ncontrol group, and \nthe median was \nnot reached in the \ncombination \ngroup.  \n \n11.3 months for \nVEM+COBI (95% CI \n5.6-7.5) vs 6.0 \nmonths  for \nVEM+Placebo (95% \nCI 8.5 -NE); HR 0 .6 \n(95% CI 0.45 -0.79, \np=0.0003)  \n \nThe combination \nof VEM and COBI \nwas associated \nwith a higher \nfrequency of \ncertain events than \nthe single -agent \ntherapy, including \ncentral serous \nretinopathy, \ngastrointestinal \nevents (diarrhoea, \nnausea, or \nvomiting), photo - \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 509 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsensitivity, \nelevated \naminotransferase \nlevels, and an \nincreased creatine \nkinase level; the \nmajority (>50%) of \nthese individual \nevents were grade \n1 or 2. We \nobserved \nequivalent rates of \ngrade 3 events \n(49%) in the two \nstudy groups and \nsubstantially fewer \ngrade 4 events (9% \nin the control \ngroup vs. 13% in \nthe combination \ngroup).  \nLong et al. 2014  To compare the \ncombination of \nDabrafenib and \nTrametinib with \nDabrafenib alone \nas first -line therapy \nin pat ients who \nhad metastatic \nmelanoma with Double -blinded, 2 -\narmed Phase III \nRCT \n \nGroup A:  \nDabrafenib 150mg \nbid po  \nTrametinib 2mg/d  \n(n=211)  Histologically \nconfirmed, \nunresecta ble stage \nIIIC or stage IV \nmetastatic  \nmelanoma with \nBRAF V600E or \nV600K mutations, \nas determined by PFS (inve stigator -\nassessed)  \n \n \n \n \n \n \n In the ITT \npopulation, \nmedian PFS was \nlonger in the \nDabrafenib \u2013Tra-\nmetinib group than \nin the Dabrafenib -\nonly group (9.3  \nmonths vs. 8.8 Jaded -Score: 5  \n \nFunding:  \nGlaxoSmithKline  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 510 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nBRAF V600E or \nV600K mutations   \nGroup B:  \nDabrafenib 150mg \nbid po  \nPlacebo  \n(n=212)  \n means of an \ninvestigational- use-\nonly polymerase -\nchain -reaction \nassay (ThxID BRAF \nAssay, bioM\u00e9rieux) \nperformed at a \ncentral reference \nlaboratory.   \n \n \n \n \n \nOS \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nResponse rate  months); the \nhazard ratio for \ndisease \nprogression or \ndeath was 0.75 \n(95% CI, 0.57 to \n0.99; P = 0.03).  \n \nAt the time of the \ninterim survival \nanalysis, 40 \npatients (19%) in \nthe Dabrafenib \u2013\nTrametinib group \nand 55 patients \n(26%) in the \nDabrafeni b-only \ngroup had died \n(HR for death, \n0.63; 95% CI, 0.42 \nto 0.94; P = 0.02). \nAt 6 months, the \nOS rate was 93% in \nthe Dabrafenib \u2013\nTrametinib group \nand 85% in the \nDab-rafenib -only \ngroup. At the time \nof this report, \nneither group had \nreached a median  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 511 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nResponse duration  \n \n \n \n \n \n \n overall su rvival.  \n \nThe ORR as \nassessed by \ninvesti- gators was \n67% (95% CI, 60 -\n73) in the \nDabrafenib \u2013\nTrametinib group \nvs 51% (95% CI, 45 -\n58) in the \nDabrafenib -only \ngroup (P=0.002) In \nthe Dabrafenib \u2013\nTrametinib group, \n22 patients (10%) \nhad a complete \nresponse, and 118 \n(56%) had a partial \nresponse. In the \nDabrafenib -only \ngroup, 18 (9%) had \na complete \nresponse, and 90 \n(43%) had a partial \nresponse.  \n \nThe median \nduration of \nresponse was 9.2 \nmonths in the  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 512 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \n \n \n \n \n \n \n \nSafety  Dabrafenib \u2013\nTrametinib group \nand 10.2 months \nin the Dabrafenib -\nonly group  on the \nbasis of data that \nwere highly \ncensored because \nthe majority of \ninvestigator -\nassessed \nresponses (60%) \nwere still ongoing. \n \nRates of AEs were \nsimilar in the two \ngroups, although \nmore dose \nmodifications \noccurred in the \nDabrafenib \u2013\nTrametinib group. \nThe rate of \ncutaneous \nsquamous -cell \ncarcinoma was \nlower in the \nDabrafenib \u2013\nTrametinib group \nthan in the \nDabrafenib -only  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 513 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ngroup (2% vs. 9%), \nwhereas pyrexia \noccurred in more \npatients (51% vs. \n28%) and was more \noften severe (grade \n3, 6% vs. 2%) in the \nDabrafenib \u2013\nTrametinib group.   \nLong et al. 2015  To report the final \noverall survival \nanalysis for the \nrandomised, \ndouble -blind phase \n3 study of \nDabrafenib \ncombined with \nTrametinib \ncompared with \nDabrafenib \ncombined with \nplacebo in \npreviously \nuntreated patients \nwith BRAF \nVal600Glu/Lys \nmutation -positive \nmetastatic \nmelanoma, and \nprovide the latest Double -blinded, 2 -\narmed Phase III \nRCT \n \nGroup A:  \nDabrafenib 150mg \nbid po  \nTrametinib 2mg/d  \n(n=211)  \n \nGroup B:  \nDabrafenib 150mg \nbid po  \nPlacebo  \n(n=212)  Histologically \nconfirmed, \nunresectable stage \nIIIC or stage IV \nmetastatic  \nmelanoma with \nBRAF V600E or \nV600K mutations, \nas determined by \nmeans of an  \ninvestigational- use-\nonly polymerase -\nchain -reaction \nassay (ThxID BRAF \nAssay, bioM\u00e9rieux) \nperformed at a \ncentral reference \nlaboratory.  PFS (investigator -\nassessed)  \n \n \n \n \n \n \n \nOS \n \n \n \n \n \n \n \n \n \nResponse rate  \n 11.0 months for \nthe combin ation \n(95% CI: 8.0 -13.9) \nvs. 8.8 months for \nthe Dabrafenib -\nonly group (95% \nCI: 5.9 -9.3), \nHR=0.67 (0.53 -\n0.84),p=0.0004 \n \nMedian OS for the \nDabrafenib+Trame\ntinib group was  \n25.1 months (95% \nCI,: 19.2 \u2013NR)  vs. \n18.7 months (95% \nCI 15.2 \u201323.7); HR= \n0.71 (95% CI: \n0.55\u20130.92), \np=0.0107 \n Jaded -Score: 5  \n \nFunding:  \nGlaxoSmithKline  \n \nSame as previous \ntrial but with \nlonger follow up \nand overall survival \ndata 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 514 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfindings for \nprogression -free \nsurvival, response \nrate, duration of \nresponse, and \nsafety.   \n \n \n \n \nResponse duration  \n \n \n \n \nSafety  69% (95% CI: 62 -\n75) for the \nDabrafenib+Trame\ntinib group vs. 53% \n(95% CI: 46 -60), \np=0.014  \n \n12.9 months (95% \nCI: 9.4 -19.5) vs. \n10.6 months (95% \nCI: 9.1 -13.8)  \n \nTreatment -related \nAEs occurred in \n181 (87%) of 209 \npatients in the \nDabrafenib  and \nTrametinib group \nand 189 (90%) of \n211 patients in the \nDabrafenib only \ngroup; the most \ncommon was \npyrexia (108 \npatients, 52%) in \nthe Dabrafenib and \nTrametinib group, \nand hyperkeratosis \n(70 patients, 33%) \nin the Dabrafenib \nonly group. Grade  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 515 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n3 or 4 adver se \nevents occurred in \n67 (32%) patients \nin the Dabrafenib \nand Trametinib \ngroup and 66 \n(31%) patients in \nthe Dabrafenib \nonly group.  \nMcAr thur et al. \n2014  To present an \nupdate of safety \nand efficacy for the \nBRIM-3 study with \nextended follow -up \nfor the entire \npopulation, and \nalso analyse the \nefficacy and safety \nof Vemurafenib \nversus \nDacarbazine in \npatients with \nBRAFV600E and \nBRAFV600K \nmutatio n-positive \ndisease  Open -label, Phase \nIII RCT  \n \nGroup A: \nVemurafenib (960 \nmg bid po)  \n(n=337)  \n \nGroup B:  \nDacarbazine \n1000mg/m\u00b2 iv q21  \n(n=338)  Treatment -naive \nmetastatic \nmelanoma \n(unresectable \nstage IIIc or stage \nIV M1a, M1b, or \nM1c disease) with \ntumour tissue  \npositive for the \npresence of \nBRAFV600 \nmutations by the \ncobas test.  OS  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Median OS \ncensored at \ncrossover, was \n13.6 months (95% \nCI 12.0 \u201315.2) in \nthe Vemurafenib \ngroup versus 9.7 \nmonths (7.9 \u201312.8) \nin the Dacarbazi ne \ngroup; 12 month \noverall survival was \n56% (95% CI 50 \u2013\n61) for \nVemurafenib and \n44% (38 \u201351) for \nDacarbazine \ncensored at \ncrossover. HR for \ndeath was 0.70 \n(95% CI 0.57 \u20130.87; \np=0.0008).  An ITT Jaded -Score: 3  \n \nFunding:  \nF Hoffmann -La \nRoche -Genentech  \n \nUpdated data for \nthe BRIM3 trial  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 516 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \n \n \n \n \nPFS \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nProportion of \npatients with a \nconfirmed \nresponse (CR or \nPR). \n \n \n \n analysis of OS \nusing the observed \nsurvival times, \nwithout regard t o \ncrossover, resulted \nin an HR of 0.76 \n(95% CI 0.63 \u20130.93; \np=0.0068).  \n \nMedian PFS \ncensored at \ncrossover was also \nsignificantly longer \nin the Vemurafenib \ngroup than in the \nDacarbazine group \n(6.9 months [95% \nCI 6.1 \u20137.0] vs 1.6 \nmonths [1.6 \u20132.1]), \nrespectively; HR \n0.38, 95% CI 0.32 \u2013\n0.46; log -rank \np<0.0001 \n \nObjective \nresponses, \nconfirmed by an \nIR, were noted in \n57% of  patients \nreceiving \nVemurafenib and  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 517 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \n \n \n \n \n \n \n \nTime to response  \n \nDuration of \nresponse  \n \nTime to treatment \nfailure  \n \nPharmacokinetic \nprofile  \n \nTolerability and \nsafety  \n \n \n \n \n \n \n \n 9% of patients \ntreated with \nDacarbazine \nIndependently \nconfirmed CR were \nattained by 6% of \nthe patients in the \nVemurafenib group \nand 1% of patients \nin the Dacarbazine \ngroup.  \n \nNot reported  \n \nNot reported  \n \n \nNot reported  \n \n \nNot reported  \n \n \nMost common \ngrade 3/4 AEs of \ninterest in patients \ntreated with \nVemurafenib were \ncutaneous \nsquamous -cell \ncarcinomas,  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 518 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nValidation of the \ncobas test  increased liver \nfunction tests, \nkeratoacanthomas, \nrash, and \narthralgia. Grade 4 \nor worse adverse \nevents occurred in \n29 (8%) patients in \nthe Vemurafenib \ngroup (three [1%] \nincreased liver \nfunction test, one \n[<1%] neutropenia), \nand 32 (11%) \npatients in the \nDacarbazine group \n(nine [3%] were \nneutropenia). \nSeven (2%) patients \nin the Dacarbazine \ngroup and eight \n(2%) in the \nVemurafenib group \nhad grade 5 \nevents. \nAdditionally, eight \n(2%) patients in the \nVemurafenib group \nreported new \nprimary \nmelanomas.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 519 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n673 of the 675 \npatients (336 \npatients in the \nVemurafenib group \nand 337 in the \nDacarbazine \ngroup) to \ndifferentiate \nBRAFV600E and \nBRAFV600K \nmutations. Of \nthese 673 patients, \nSanger/454 \nsequencing could \nnot provide a valid \nresult for 14 \npatients. \nTherefore, 657 \n(98%) of 671 \npatients had \ntumours that were \ncobas -positive at \nscreening and for \nwhom Sanger 454 \nsequencing results \nwere available. Of \nthese 657 \ntumours, 598 \n(91%) carried the \nBRAFV600E  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 520 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmutation, 57 (9%) \nhad the \nBRAFV600K \nmutation  \nRobert et al. 2015  To evaluate the \neffect of \ncombination \ntherapy with \nDabrafenib plus \nTrametinib versus \nVemurafenib \nmonotherapy on \noverall survival in \npreviously \nuntreated patients \nwith unresectable \nstage IIIC or IV \nmelanoma with \nBRAF V600E or \nV600K mutations.  Open -label, Phase \nIII RCT  \n \nGroup A:  \nDabrafenib 150mg \nbid po  \nTrametinib 2mg/d  \n(n=211)  \n \nGroup B:  \nVemurafenib \n960mg/d bid po  Patients with \nmetastatic \nmelanoma with a \nBRAF V600 \nmutation. The \npresence of BRAF \nV600E or V600K \nmutations was \ncentrally \ndetermined with \nthe investigational \nuse of the THxID \nBRAF assay \n(bioM\u00e9rieux).  OS \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nPFS \n \n \n \n \n \n 100 patients (28%) \nin the \ncombination -\ntherapy group and \n122 (35%) in the \nVemurafenib group \nhad died (HR for \ndeath in the \ncombination -\ntherapy group, \n0.69; 95% CI, 0.53-\n0.89; P=0.005)  \nMedian OS was \n17.2 months for \npatients in the \nVemurafenib group \nand had not been \nreached for \npatients in the \ncombination group  \n \nMedian PFS was \nlonger in the \ncombination group \nthan in the \nVemurafenib group Jaded -Score: 3  \n \nFunding:  \nGlaxo -SmithKline  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 521 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \n \n \n \n \nORR \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDuration of \nresponse  \n \n \n \nSafety  (11.4 months vs. \n7.3 months; of \nresponse was 13.8 \nmonths (95% CI, \n11.0 to not \nreached) and 7.5 \nmonths (95% CI, \n7.3-9.3), \nrespectively.  \n \nThe response rate \nfor the BRAF V600E \nsubgrou p was \nsimilar to that in \nthe overall \npopulation in both \nstudy groups: 64% \nin the combination \ngroup and 52% in \nthe Vemurafenib \ngroup; in the BRAF \nV600K subgroup, \nthe response rates \nwere 65% and 44%, \nrespectively. \n \n13.8 months (95% \nCI: 11.0 \u2013NR) vs  \n7.5 months  (95% \nCI: 7.3 \u20139.3) \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 522 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nRates of severe \nadverse events and \nstudy -drug \ndiscontinuations \nwere similar in the \ntwo groups. \nCutaneous \nsquamous -cell \ncarcinoma and \nkeratoacanthoma \noccurred in 1% of \npatients in the \ncombination -\ntherapy group and \n18% of those in the \nVemurafenib \ngroup.  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 523 von 817 \n6.2.4.2.4.  Reviews  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAubin et al. 2013  To review the \navailable literature \non liver resection \nfor metastatic \nmelanoma in a \nsystematic manner, \nand to compare \noncological \noutcomes for \nsurgery with \nstandard therapy \nusing meta -\nanalytical \ntechniques.  Systemic review \nand meta -analysis  \n \nInitial literature \nsearch revealed \n423 potential \nreports  \nFinally 22 selected \nfor full review after \nchecking eligibility \ncriteria  579 patients who \nunderwent liver \nresection  Overall survival \n(OS) \n \n \n \n \nHazard ratios (HRs)  \n \n \n \n \n \n \n \n \n \nDisease -free \nsurvival (DFS)  Median OS: 14 -41 \nmonths  \n(R0, 22 \u201366months, \nR2, 10 \u201316months; \nR0 versus R1/R2: \nHR 0.52, 95% CI \n0.37 to 0.73). \nComparison of OS \nwith resection and \nnon-operative \nmanagement \nfavoured resection \n(HR 0.32, 95% CI \n0.22 to 0.46).  \n \nMedian DFS: 8 to \n23months  5 studies describe \na comparison \nbetween surgical \nexcision of liver \nmetastases and \nsystemic treatment \nof patients \nsuffering from \nhepatic \nmetastases.  \nOverall, there is a \ntrend to a \nfavourable \nprolongation in OS \nfor patients \nreceiving excision \nof liver lesions. \n \nOverall a valuable \nreview/meta -\nanalysis, however \u2013  \nas the authors \nadmit \u2013 with \nstudies of low \nquality involved. \n \n \n  2a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 524 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nBuder  at al. 2013  To review the \npresent status of \nsystemic treatment \nof metastatic uvea \nmelanoma and \nevaluate therapy \noutcome measured \nby overall response \nrate (ORR)  Systematic review  \n \nPubMed search \nwas performed for \n\u201cmetastatic\u201d [and] \n\u201cuveal\u201d [and] \n\u201cmelanoma\u201d as \nwell as for \n\u201cmelanoma\u201d [and] \n\u201ceye\u201d [and] \n\u201ctreatment\u201d for the \ntime period \nbetween 1980 and \nMay 2013. \u201cWeb of \nKnowledge\u201d and \ncongress abstract \nsearch via the \nASCO homepage \nwas per -formed. \nThe \nClinicalTrials.gov \nwebsite was \nsearched for terms \n\u201cmelanoma\u201d an d \n\u201ceye\u201d. Of 2017 \nreferences, 40 \nstudies were \nselected for final \nanalyses  841 patients out of \n40 studies  Overall response \nrate (ORR)  39/841 patients \nwith remission \n(overall response \nrate [ORR] 4.6%; \n95% confidence \nintervals [CI] 3.3 \u2013\n6.3%)  \n \nNo responses were  \nobserved in 22/40 \nstudies.  \n \nProgression -free \nsurvival ranged \nfrom 1.8 to 7.2, \nmedian overall \nsurvival from 5.2 \nto 19.0 months as \nreported in 21/40 \nand 26/40 studies, \nrespectively. \n \nBest responses \nwere seen for \nchemoimmunother\napy (ORR 10.3%; \n95% CI 4.8 \u201318.7%) \nthough mainly in \nfirst-line patients.  \n \nImmunotherapy Uvea melanoma \nonly. \nWell described, \nhowever due to \nlack of appropriate \nstudi es, no phase \nIII data included  2a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 525 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwith ipilimumab, \nantiangiogenetic \napproaches, and \nkinase inhibitors \nhave not yet \nproven to be \nsuperior to \nchemotherapy.  \nDequen et al. 2012  To perform a \nsystematic \nliterature review \nand network meta -\nanalysis to \ncompare overall \nsurvival with 3 \nmg/kg ipilimumab \nwith alternative \ntherapies in the \ntreatment of pre -\ntreated patients \nwith unresecta ble \nstage III or IV \nmelanoma.  Systematic review \nof randomized \ncontrolled trials  \nunresectable stage \nIII or IV melanoma,  \n \nSystematic \nliterature search \nperformed in \nMEDLINE, \nMEDLINE -In-Pro-\ncess, EMBASE, and \nthe Cochrane \nLibrary.  \n \nKey words and free \ntext wer e \ncombined to \ninclude the dis -\nease-specific \nsearch terms \u201cskin -\nneoplasms\u201d and 2739 patients from \n15 studies  Mean OS  Ipilimumab, at a \ndose of 3 mg/kg, \nwas associated \nwith a greater \nmean OS time \n(18.8 months; 95% \ncredible interval \n[CrI], 15.5 \u201323.0 \nmonths) than \nsingle -agent \nchemotherapy \n(12.3 months; 95% \nCrI, 6.3 \u201328.0 \nmonths), \nchemotherapy \ncombinations (12.2 \nmonths; 95% CrI, \n7.1\u201323.3 months), \nbiochemotherapies \n(11.9 months; 95% \nCrI, 7.0 \u201322.0 \nmonths), single -Statistically \nsophisticated \nreview with a \nBayesian network \nmeta -analysis \napproach. \nInterestingly, a \nparametric survival \ndistribution \n(Gompertz) was \nselected for \nanalysis. \n \nMeta-analyses \nmissed BRAF/MEK \ninhibitors. 1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 526 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n\u201cmelanoma\u201d; the \ndisease -staging \nterms \u201cmetastatic,\u201d \n\u201cadvanced,\u201d and \n\u201cstage III/3 or \nIV/4\u201d; and non -\nproprietary drug \nnames.  \n \n1,793 references \ndetected, 38 \nstudies finally \nincluded . During \nevaluation the \nnumber of studies \nhad to be reduced \nto 15 studies  agent \nimmunotherapy \n(11.1 months; 95% \nCrI, 8.5 \u201316.2 \nmonth s), and \nimmunotherapy \ncombinations (14.1 \nmonths; 95% CrI, \n9.0\u201323.8 months).  \nJiang et al. 2014  \n To \ncomprehensively \nanalyse the data \nfrom clinical RCTs \nto evaluate the \nefficacy and safety \nof DTIC alone \nversus DTIC \ncombined targeted \ntherapy in \ntreatment of \nmetastatic \nmelanoma.  Systematic review  \nand meta -analyses  \n \nThe Cochrane \nLibrary, MEDLINE, \nEBSCO, EMBASE, \nOvid databases \nand clinical trial \nwebsites from \n2003 to 2013 were \nscanned. The \nsearch strategy \nincluded the 2,221 patients \nincluded in 8 \nrandomized \ncontrolled trials  Overall response \n(CR+PR).  \n \n \n \n \n \n \n \n \n \n1-year survival  \n The overal l \nresponse in the \narm for DTIC \ncombined targeted \ntherapy was higher \nthan that in the \narm for DTIC alone \n(combined \nRR=1.60; 95% CI, \n1.27\u20132.01, Z=3.98)  \n \nThe 1 -year survival \nin the arm for DTIC Meta-analyses also \nfor adverse events  1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 527 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nkeyword \u2018\u2018DTIC\u2019\u2019 \ncombined with the \nMedical Subject \nHeadings (MeSH) \n\u2018\u2018metastatic \nmelanoma\u2019\u2019 and \n\u2018\u2018randomized \ncontrolled trials\u2019\u2019. \nChinese databases \nsuch as CNKI and \nCBMDisc using the \nabove search \nterms were used.  \n \n1,286 records \nidentified. 8 \nstudies included \nfor final \nevaluation.  \n \n \n \n \n \n \n \nAdverse event: \nNausea \n \n \n \n \n \n \n \nAdverse Event: \nVomiting  \n \n \n \n \n \n \n \nAdverse Event: \nFatigue  \n \n \n combined targeted \ntherapy was higher \nthan that in the \narm for DT IC alone \n(combined \nRR=1.34; 95% CI, \n1.20\u20131.49, Z=5.25, \nP<0.00001)  \n \nSignificant \ndifference between \nDTIC combined \ntargeted therapy \nand DTIC alone \n(combined \nRR=1.22, 95% CI: \n1.10\u20131.37, Z=3.64, \nP=0.0003)  \n \nsignificant \ndifference between \nDTIC combined \ntargeted therapy \nand DTIC alone \n(combined \nRR=1.73, 95% CI: \n1.41\u20132.12, Z=5.19, \nP<0.00001)  \n \nFailed to show a \nsignificant  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 528 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n \n \n \n \nAdverse Event: \nConstipation  \n \n \n \n \n \n \n \n \nAdverse Event: \nAnaemia  \n \n \n \n \n \n \n \nAdverse Event: \nNeutropenia  \n difference between \nDTIC combined \ntargeted therapy \nand DTIC alone \n(combined \nRR=1.09, 95% CI: \n0.96\u20131.24, Z=1.29, \nP=0.20)  \n  \nFailed to show a \nsignifica nt \ndifference between \nDTIC combined \ntargeted therapy \nand DTIC alone \n(combined \nRR=1.07, 95% CI: \n0.87\u20131.32, Z=0.67, \nP=0.51)  \n \nSignificant \ndifference between \nDTIC combined \ntargeted therapy \nand DTIC alone \n(combined \nRR=1.36, 95% CI: \n1.06\u20131.74, Z=2.39, \nP=0.02)  \n \nSignificant  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 529 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndifference between \nDTIC combined \ntargeted therapy \nand DTIC alone \n(combined \nRR=1.63, 95% CI: \n1.28\u20132.06, Z=4.03, \nP<0.0001)  \nJiang et al. 2013  To evaluate the \nefficacy and safety \nof temozolomide  \nalone and \ntemozolomide  -\nbased combination \nchemotherapy on \nmelanoma by \nusing meta -\nanalysis research \nmethodology  Systematic review \nand meta -analysis  \n \nSearch of the \nCochrane library, \nMEDLINE, EBSCO,  \nEMBASE, and Ovid \ndatabases as well \nas clinical trial \nwebsites with the  \nsearch term \n\u201ctemozolomide\u201d as \na keyword \ncombined with \n\u201cmelanoma\u201d and \n\u201crandomized \ncontrolled trials\u201d \nas medical subject \nheadings. Chinese \ndatabases such as \nCNKI and CBMDisc \nusing the above 703 patients in 5 \nRCTs  Overall response \n(CR+PR).  \n \n \n \n \n \n \n \n1-year survival  \n \n \n \n \n \n \nAdverse event: \nNausea+Vomiting  \n \n \n \n ORR in the TMZ -\nbased combination \ndrug therapy was \ngreater than that \nin TMZ alone \n(RR:1.44 [(95 % CI, \n1.06\u20131.95), \nZ=2.30, P=0.02]  \n \n1-year survival rate \nin the two groups \nwas not \nsignificantly \ndifferent (RR=1.13; \n95 % CI, 0.92 \u20131.40; \nP=0.87.  \n \nIncidence of \nnausea and \nvomiting between \nTMZ and \ncombination Meta-analyses also \nfor adverse events  1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 530 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsearch terms were \nused.  \n \n1,064 records \nidentified. 5 RCTs \nincluded for final \nevaluation.  \n \n \n \n \nAdverse Event: \nHeadache, Fatigue  \n \n \n \n \n \n \n \nAdverse Event: \nConstipation  \n \n \n \n \n \nAdverse Event: \nAnaemia, \nneutropenia, \nthrom bocytopenia  \n \n \n chemo -therapy not \nsignificantly \ndifferent [RR=1.16, \n(95 %CI, 0.90 \u2013\n1.48), Z=1.15, \nP=0.25>0.05].  \n \nNo significant \ndifference for the \nincidence of head -\nache and fatigue.  \nRR=0.53 (95% CI \n0.21\u20131.37) an d \nRR=0.77 (95% CI \n0.49\u20131.22).  \n \nNo difference for \nthe incidence of \nconstipation \nbetween the two \ngroups (RR= 1.05 \n[95% CI, 0.71 \u2013\n1.56]) \n \nNo a significant \ntoxicity between \nsingle -agent TMZ \nand combination \nchemotherapy.  \nRR: 1.24 (95% CI \n0.72\u20132.14) for  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 531 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nanaemia,  \nRR: 1.52 (95% CI \n0.53\u20134.34) for \nneutropenia  \nRR=0.98 (95% CI \n0.46\u20132.09) for \nthrombocytopenia.   \nMai et al. 2015  To establish the \noptimum treatment \nfor metastatic \nmelanoma, we did \na random -effects \nnetwork meta -\nanalysi s to \ncompare combined \nBRAF and MEK \ninhibition  Systemic review \nand meta -analysis  \n \nSearch of PubMed, \nthe Cochrane \nCollaboration \nCentral Register of \nControlled Clinical \nTrials, Cochrane \nSystematic \nReviews, and \nClinicalTrials. gov \nfor RCT without \nyear and lan guage \nrestrictions, using \nthe following \nalgorithm: \ncombined targeted \ntherapy AND \nmelanoma. After \nthe combinations \nof dabrafenib \u2013\ntrametinib or 5,976 patients \nrandomized to \nreceive two of the \nsix treatment \nstrategies in 16 \ndifferent trials  PFS \n \n \n \n \n \n \n \n \n \n \n \nOS  \n \n \n \n \n \n \n \n \n \n Combined BRAF -\nMEK inhibition \nimproved \nsignificant \nprolonged PFS, as \ncompared with \nBRAF inhibition \n(HR: 0.58, 95%CI: \n0.51-0.67, P < \n0.0001) or MEK \ninhibition alone \n(HR: 0.29, 95%CI: \n0.22-0.37, P < \n0.0001).  \n \nRanking \nprobabilities of \ntreatment from the \nnetwork meta -\nanalysis of OS \nindicated that, of \nthe 6 therapeutic \nstrategies, Statistically \nsophisticated \nreport using a \ncomprehensive \n(Bayesian) network \nmeta -analysis \napproach.  1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 532 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nvemurafenib \u2013\ncobimetinib have \nbeen identified, \nthe keywords of \nindividual \ninhibition of BRAF \n(dabrafenib, \nvemurafen ib, \nsorafenib) and MEK \n(trametinib, \ncobimetinib, \nselumetinib), trial \nand melanoma \nwere used to \nsearch relevant \nstudies  \n \n451 relevant \nrecords identified, \n16 eligible RCTs   \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nORR combined BRAF -\nMEK inhibition had \nthe highest. \nprobability of \nbeing the best \ntreatment arm for \nMM. Combined \nBRAF -MEK \ninhibition \nimproved \nsignificant \nprolonged OS \ncomparing with \nBRAF inhibition \n(HR: 0.67, 95%CI: \n0.56-0.81, P < \n0.0001) or MEK \ninhibition alone \n(HR: 0.48, 95%CI: \n0.36-0.65, P < \n0.0001).  \nSingle BRAF \ninhibition had a \nstatistically \nsignificantly longer \nin OS  than MEK \ninhibition alone \n(HR: 0.72, 95%CI: \n0.56-0.91, P = \n0.008), and \ncombined BRAF  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 533 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ninhibition and \nchemotherapy (HR: \n0.60, 95%CI: 0.47 -\n0.73, P < 0.0001).  \n \nCompared with \nchemotherapy, \ncombined BRAF -\nMEK inhibition \nimproved highest \nORR (OR: 29.46, \n95%CI: 2 0.04-\n43.57, P < 0.0001), \nfollowed by BRAF \ninhibition alone \n(OR: 14.65, 95%CI: \n10.49 -20.90, P < \n0.0001), and \ncombined MEK -\nchemotherapy (OR: \n2.18, 95%CI: 1.10 -\n4.23, P = 0.5982).  \n \nORR was superior \nin patients who \nreceived combined \nBRAF -MEK \ninhibition \ncompare d with \nthose who received \nBRAF inhibition  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 534 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(OR: 2.00, 95%CI: \n1.66-2.44, P < \n0.0001) or MEK \ninhibition alone \n(OR: 20.66, 95%CI: \n12.22 -35.47, P < \n0.0001).  \n \nThe single BRAF \ninhibition yielded \nbetter response \nrate than MEK \ninhibition alone \n(OR: 10.34, 95%CI: \n6.23-17.60, P < \n0.0001).  \nTeimouria et al. \n2013  To compare the \nefficacy and side \neffects of \ndacarbazine with \nthose of \ntemozolomide in \nthe treatment of \nmalignant \nmelanoma  Systemic review \nand meta -analysis  \nPubMed, Scopus, \nWeb of Science, \nand Cochrane \nCentral Register of \nControlled Trials \nwere searched. \nThe search terms \nwere \u2018dacarbazine\u2019 \nand \n\u2018temozolomide\u2019 \nand \u2018malignant \nmelanoma\u2019.  1,314 patients \nfrom 3 clinical \ntrials  Response to \ntreatment \n(CR/PR/SD)  \n CR \nRR=0.83 (95% CI= \n0.26\u20132.64), which \nwas nonsignificant \n(P=0.76).  \n \nPR: \nRR=1.35 (95% \nCI=0.95 \u20131.91), \nwhich was \nnonsignifi cant \n(P=0.1)  \n \nSD: Methodically \ncorrect meta -\nanalysis, but nly 3 \nstudies included . \nAlso analyses for \nadverse events \npresented.  1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 535 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n547 relevant \nrecords iden tified, \n3 eligible head -to-\nhead studies taken \nfor meta -analysis  RR=1.05 (95% \nCI=0.85 \u20131.3), \nwhich was \nnonsignificant \n(P=0.65) \n \nDisease control \nrate: \nRR=2.64 (95% \nCI=0.97 \u20131.36), \nwhich was \nnonsignificant \n(P=0.11).  \n \nAnaemia, neutron -\npenia, and \nthrombocytopenia:  \nRR (for all grades) \n= 1.14 (95% \nCI=0.57 \u20132.27), \n1.09 (95% \nCI=0.74 \u20131.60), and \n0.97 (95% \nCI=0.65 \u20131.46). All \nof which were \nnonsignificant.  \n \nThe summary of \nRR for anaemia, \nneutropenia, and \nthrombocytopenia  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 536 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(for grades 3 and \n4) was 1.8 (95% \nCI=0.9 \u20133.62), 0.97 \n(95% CI=0.48 \u2013\n1.97), and 1.44 \n(95% CI=0.9 \u20132.3). \nAll of which were \nnonsignificant.  \n \nThe summary of \nRR for \nlymphopenia (for \ngrades 3 and 4) of \ntemozolomide in \ncomparison with \nDTIC was 3.79 \n(95% CI=1.38 \u2013\n10.39), which was \nsignificant \n(P=0.01).  \n \n \n6.2.5.  Literatur  \nAgarwala SS, Glaspy J, O'Day SJ, et al. Results from a randomized phase III study comparing combined treatment with histamine  dihydrochloride plus interleukin -2 versus interleukin -2 \nalone in pat ients with metastatic melanoma. J Clin Oncol 2002;20:125- 133 \nAndtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015;33(25):2780 -2788.  \nAubin JM, Rekman J, Vandenbroucke -Menu F, et al. Systematic review and meta -analysis of liver resection for metastatic melanoma. Br J Surg. 2013;100(9):1138 -1147.  \nAvril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant  melanoma: a phase III study. J Clin Oncol 2004;22:1118- 1125  \nBafaloukos D, Tsoutsos D, Kalofonos H, et al. Temozolomide and cisplatin versus temozolomide in patients with advanced melano ma: a randomized phase II study of the Hellenic \nCooperative Oncology G roup. Ann Oncol 2005;16:950- 957 \nBedikian AY, DeConti RC, Conry R, et al. Phase 3 study of docosahexaenoic acid -paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol 2011;22:787 -\n793  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 537 von 817 \nBedikian AY, Millward M, Pehamberger H, et al. Bcl -2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J \nClin Oncol 2006;24:4738- 4745  \nBuder K, Gesierich A, Gelbrich G, Goebeler M. Systemic treatment of metastatic uveal melanoma : review of literature and future perspectives. Cancer Med. 2013;2(5):674 -686. \nChapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J M ed 2011;364:2507- 2516  \nChauvergne J, Bui NB, Cappelaere P, et al. Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin \nwith dacarbazine alone. Sem Hop 1982;58:2697- 2701  \nDanson S, Lorigan P, Arance A, et al. Randomized phase I I study of temozolomide given every 8 hours or daily with either interferon alfa -2b or thalidomide in metastatic malignant \nmelanoma. J Clin Oncol 2003;21:2551- 2557  \nDaponte A, Signoriello S, Maiorino L, et al. Phase III randomized study of fotemustine and d acarbazine versus dacarbazine with or without interferon -alpha in advanced malignant \nmelanoma. J Transl Med. 2013;11:38.  \nDequen P, Lorigan P, Jansen JP, van Baardewijk M, Ouwens MJ, Kotapati S. Systematic review and network meta- analysis of overall surviva l comparing 3 mg/kg ipilimumab with \nalternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. Oncologist. 2012;1 7(11):1376- 1385.  \nDummer R, Garbe C, Thompson JA, et al. Randomized dose -escalation study evalua ting peginterferon alfa -2a in patients with metastatic malignant melanoma. J Clin Oncol \n2006;24:1188- 1194  \nEisen T, Trefzer U, Hamilton A, et al. Results of a multicenter, randomized, double -blind phase 2/3 study of lenalidomide in the treatment of pretreat ed relapsed or refractory metastatic \nmalignant melanoma. Cancer 2010;116:146- 154 \nFalkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa -2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J C lin Oncol \n1991;9:1403- 1408  \nFalkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha -2b versus dacarbazine with tamoxifen versus dacarbazine with interferon \nalpha -2b and tamoxifen in patients with me tastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16:1743- 1751  \nFlaherty KT, Lee SJ, Zhao F, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic mel anoma. J Clin Oncol. 2013; 31(3):373- 379. \nFlaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF -mutated melanoma. N Engl J Med. 2012;367(2):107- 114. \nFlaherty KT, Robert C, Hersey P, et al.  Improved survival with MEK inhibition in BRAF -mutated melanoma . 2012;  N Engl J Med 367: 107- 114 \nGlaspy J, Atkins MB, Richards JM, et al. Results of a multicenter, randomized, double -blind, dose -evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant \nmelanoma. Cancer 2009;115:5228- 5236 \nHaus child A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo -controlled study of sorafenib in combination with carboplatin and paclitaxel as second -line \ntreatment in patients with unresectable stage III or stage IV melanoma. J Clin O ncol 2009;27:2823- 2830  \nHauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open -label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-\n365. \nHauschild A, Grob JJ, Demidov LV , et al. Dabrafe nib in BRAF -mutated metastatic melanoma: a multicentre, open -label, phase 3 randomised controlled trial. Lancet 2012; 380: 358- 365 \nHersey P, McLeod GR, Thomson DB. Treatment of advanced malignant melanoma with recombinant interferon alfa -2a in combination with DTIC: long -term follow -up of two phase II \nstudies. Br J Haematol 1991;79 Suppl 1:60- 66 \nHersey P, Sosman J, O'Day S, et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha( v)beta(3), + or - dacarbazine in patien ts with stage IV \nmetastatic melanoma. Cancer 2010;116:1526- 1534  \nHersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy -naive patients with advanced melanoma. Invest New \nDrugs 2011;29:489 -498 \nHodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711- 723 \nJiang G, Li RH, Sun C, Jia HY, Lei TC, Liu YQ. Efficacy and safety between temozolomide alone and temozolomi de-based double therapy for malignant melanoma: a meta- analysis. \nTumour Biol. 2014;35(1):315- 322. \nJiang G, Li RH, Sun C, Liu YQ, Zheng JN. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with mali gnant melanoma: a meta- analysis. PLoS One. \n2014;9(12):e111920.  \nJungnelius U, Ringborg U, Aamdal S, et al. Dacarbazine -vindesine versus dacarbazine -vindesine -cisplatin in disseminated malignant melanoma. A randomised phase III trial. Eur J Cancer \n1998;34:1368- 1374  \nKaufmann R, Spieth K, Lei ter U, et al. Temozolomide in combination with interferon -alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, \nphase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005;23:9001 -9007 \nKefford RF, Clingan PR, Brady B, et al. A randomized, double -blind, placebo -controlled study of high -dose bosentan in patients with stage IV metastatic melanoma receiving first -line \ndacarbazine chemotherapy. Mol Cancer 2010;9:69  \nKeilholz U, Goey SH, Pu nt CJ, et al. Interferon alfa -2a and interleukin -2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research \nand Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579- 2588  \nKim KB, Sos man JA, Fruehauf JP, et al. BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in P atients With \nPreviously Untreated Advanced Melanoma. J Clin Oncol 2012;30:34- 41 \nKirkwood JM, Bastholt L , Robert C, et al. Phase II, Open -Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced \nMelanoma. Clin Cancer Res 2012;18:555- 567  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 538 von 817 \nKirkwood JM, Lee S, Moschos SJ, et al. Immunogenicity and a ntitumor effects of vaccination with peptide vaccine+/ -granulocyte -monocyte colony -stimulating factor and/or IFN -alpha2b \nin advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009;15:1443- 1451  \nLarkin J, A scierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF -mutated melanoma. N Engl J Med. 2014;371(20):1867- 1876.  \nLarkin J, Chiarion- Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23- 34. \nLong GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J  Med. 2014;371(20):1877- 1888.  \nLong GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF -mutant melanoma: a multicentre, double -blind, phase 3 \nrandomised controlled trial. Lancet. 2015;386(9992):444- 451. \nMai R, Zhou S, Zhong W, et al. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta -analysis of randomized controlled \ntrials. Oncotarget. 2015.  \nMaio M, Grob JJ, Aamdal S, et al. Five -year survival rates for treatment -naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. \n2015;33(10):1191 -1196.  \nMaio M, Mackiewicz A, Testori A, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metasta tic melanoma. \nJournal of Clinical Onc ology 2010;28:1780- 1787  \nMcArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation -positive melanoma (BRIM -3): extended follow -up of a phase 3, \nrandomised, open -label study. Lancet Oncol. 2014;15(3) :323- 332. \nMcDermott D, Haanen J, Chen TT, Lorigan P, O'Day S. Efficacy and safety of ipilimumab in metastatic melanoma patients survivi ng more than 2 years following treatment in a phase III \ntrial (MDX010- 20). Ann Oncol. 2013;24(10):2694- 2698.  \nMcDermott DF , Sosman JA, Gonzalez R, et al. Double -blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report \nfrom the 11715 Study Group. J Clin Oncol 2008;26:2178- 2185  \nMiddleton M, Hauschild A, Thomson  D, et al. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interl eukin -2, interferon -\n{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Ann Oncol 2007; 18:1691- 1697  \nMiddleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of p atients with advanced metastatic malignant melanoma. J \nClin Oncol 2000;18:158- 166 \nO'Day S, Gonzalez R, Lawson D, et al . Phase II, randomized, controlled, double -blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic \nmelanoma. J Clin Oncol 2009;27:5452- 5458  \nO'Day S, Pavlick A, Loquai C, et al. A randomised, phase II study of inte tumumab, an anti -alpha(v) -integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 2011  \nO'Day SJ, Eggermont AM, Chiarion- Sileni V, et al. Final results of phase III SYMMETRY study: randomized, double -blind trial of elesclomol plus paclita xel versus paclitaxel alone as \ntreatment for chemotherapy -naive patients with advanced melanoma. J Clin Oncol. 2013;31(9):1211- 1218.  \nPatel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma : Final results of a randomised phase III study (EORTC \n18032). Eur J Cancer 2011;47:1476 -1483 \nPolyzos A, Legha SS, Burgess AM, et al. Phase II study of AMSA alone and in combination with DTIC in patients with metastatic  melanoma. Invest New Drugs 1988;6:57- 61 \nPresant CA, Bartolucci AA, Balch C, et al. A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma. Cancer \n1982;49:1355- 1357  \nRanson M, Hersey P, Thompson D, et al. Randomized trial of the combi nation of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients \nwith metastatic cutaneous melanoma. J Clin Oncol 2007;25:2540- 2545  \nReichle A, Vogt T, Coras B, et al. Targeted combined anti -inflammatory and angiostatic  therapy in advanced melanoma: a randomized phase II trial. Melanoma Res 2007;17:360- 364 \nRibas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard -of-care chemotherapy in patients with advanced melanom a. J Clin \nOncol. 2013;31(5):616- 622. \nRingborg U, Rudenstam CM, Hansson J, et al. Dacarbazine versus dacarbazine -vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor \nPharmacother 1989;6:285- 289 \nRobert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30 -39.Bedikian AY, Garbe C, \nConry R, Lebbe C, Grob JJ. Dacarbazine with or without oblimersen (a Bcl -2 antisense oligonucleotide) i n chemotherapy -naive patients with advanced melanoma and low -normal serum \nlactate dehydrogenase: 'The AGENDA trial'. Melanoma Res. 2014;24(3):237- 243. \nRobert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N En gl J Med. 2015;372(4):320- 330. \nRobert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521- 2532.  \nRobert C, Schadendorf D, Messina M, Hodi FS, O'Day S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially \nachieving disease control. Clin Cancer Res. 2013;19(8):2232- 2239.  \nRobert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastat ic melanoma. N Engl J Med 2011;364:2517- 2526  \nSchadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long -Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin \nOncol. 2015;33(17):1889- 1894.  \nSchadendorf D, Ugurel S, Schuler- Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide -pulsed dendritic cells (DC) in first- line treatment of patients with \nmetastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563- 570 \nSchwartzentruber DJ, Lawson DH, Richards JM, et al. Gp100 Peptide Vaccine and Interleukin -2 in Patients with Advanced Melanoma. N Engl J Med 2011;364:2119- 2127   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 539 von 817 \nSparano JA, Fisher RI, Sunderland M, et al. Randomized phas e III trial of treatment with high -dose interleukin -2 either alone or in combination with interferon alfa -2a in patients with \nadvanced melanoma. J Clin Oncol 1993;11:1969- 1977  \nTarhini AA, Millward M, Mainwaring P, et al. A phase 2, randomized study of SB -485232, rhIL -18, in patients with previously untreated metastatic melanoma. Cancer 2009;115:859- 868 \nTeimouri F, Nikfar S, Abdollahi M. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta -analysis consisting of \n1314 patients. Melanoma Res. 2013;23(5):381- 389.Agarwala SS, Ferri W, Gooding W, et al. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxife n in the \ntreatment of patients with metastatic melanoma. Cance r 1999;85:1979- 1984 \nThomson DB, Adena M, McLeod GR, et al. Interferon -alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a \nmulti -institutional Australian randomized trial. Melanoma Res  1993;3:133- 138 \nWeber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti -CTLA -4 treatment (CheckMate 037): a \nrandomised, controlled, open -label, phase 3 trial. Lancet Oncol. 2015;16(4):375- 384. \nWeber JS, Zarour H, Redman B, et al. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF -3512676 alone or with dacarbazine for patients with unresectable stage III and IV \nmelanoma. Cancer 2009;115:3944- 3954 \nYoung AM, Marsden J, Goodman A, et al. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon -alpha (IFN -alpha) in metastatic melanoma. Clin Oncol (R \nColl Radiol) 2001;13:458- 465  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 540 von 817 \n6.3. Frage V.4. Bio chemotherapie  - Adaptation  \nFrage V.4.  F\u00fchrt die Gabe von Biochemo therapien im metastasierten Stadium zu mehr objektiven Remissionen  / zu einer Verbesserung des \nGesamt\u00fcberlebens  ?  \n6.3.1.  Synopse Quellleitlinien  \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health  2005  LL Kanada  \nCancer Care O ntario 2007  \nF\u00fchrt die Gabe von \nBiochemo therapien im \nmetastasierten Stadium zu \nmehr objektiven \nRemissionen?  \n Ja \n \nInterferon -alpha und IL -2 \nverbe ssern Ansprechen von \nMonother apien aber nicht das \nGesamt\u00fcberl eben allein oder in \nKombination mit \nChemother apien. Ja \n \nDacarbazin plus Interferon \nalpha f\u00fchrt zu besserem \nAnsprechr aten, nicht zu einer \nVerl\u00e4ngerung des \nGesamt\u00fcbe rlebens.  \n  \n \nLeitlinie enth\u00e4lt keine \nEmpfe hlungen zu Therapien im \nfernmetastasierten Sta dium  Ja \nZugrunde li egende Evidenz  level of evidenz II  \n(4 Studien)  Evidenz Review, S.315  \n(1 Metaanalyse)   9 Studien zu \nBiochemotherapien  \n(Standardchemotherpie mit Il -2 \noder IFN)  \n7 Studien geben A nsprechraten \nan, 2 Studien mit verbessertem \nAnsprechen, 5 Studien kein \nUnterschied, gep oolt: besseres \nAnspr echen \nF\u00fchrt die Gabe von \nBiochemo therapien im \nmetastasierten Stadium zu Nein \n \nInterferon -alpha und IL -2 Nein \n \nDurch Verwendung einer - Nein \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 541 von 817 \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health  2005  LL Kanada \nCancer Care O ntario 2007  \neiner Verbesserung des \nGesamt\u00fcberlebens?  \n verbe ssern Ansprechen von \nMonother apien aber nicht das \nGesamt\u00fcberl eben allein oder in \nKombination mit \nChemother apien. Polychemotherapie wird das \nGesamt\u00fcbe rleben nicht \nverl\u00e4ngert  \n \nZugrunde li egende Evidenz  level of evidenz II  \n(4 Studien)  Evidenz Review, S.315  \n(1 Metaanalyse, 1 Review, 1 \nLeitlinie)  9 Studie n zu \nBiochemother apien \n(Standardchem otherapie mit Il -\n2 oder IFN).  \nKeine Studie zeigt ein \nverbessertes Gesam t\u00fcberleben  \n6.3.2.  Empfehlung,  Hintergrundstext und Literatur Kanadische Quell Leitlinie  \nQuellleitlinie: Biochemotherapy for the Treatment of Metastatic Ma lignant Melanoma: A Clinical Practice Guideline (Cancer Care Ontario) \n2007  \nQuestion: What is the role of biochemotherapy in the treatment of metastatic malignant melanoma? \nFor the purposes of this report, \"biochemotherapy\" is defined as a therapeutic regimen that includes, at a minimum, chemotherapy (either \nsingle agent or combination) and interleukin -2. Outcomes of interest include response rate, disease -free survival, overall survival, quality of life, \nand incidence of grade 3 and 4 toxicities.  \n \nRecommen dation  \nDue to the inconsistent results of the available studies with regard to benefit (response, time -to-progression, and survival) and consistently \nhigh toxicity rates, biochemotherapy is not recommended for the treatment of metastatic melanoma.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 542 von 817 \nKey Evid ence  \nNine randomized controlled trials of biochemotherapy for patients with metastatic malignant melanoma were eligible for inclus ion in this \nsystematic review of the evidence. Six randomized controlled trials compared chemotherapy alone to chemotherapy c ombined with interleukin -\n2 and interferon, two randomized trials compared a combination of chemotherapy and interferon with chemotherapy combined with  \ninterleukin -2 and interferon, and one trial compared inte rferon and interleukin -2 with versus without che motherapy.  \nSeven of the nine trials reporting on response rate outcomes provided statistical comparisons. Only two trials reported statistically significant \nresponse rates favouring treatment with biochemotherapy, while five trials failed to detect any significant differences. None of the nine trials \ndetected a statist ically significant survival improvement with biochemotherapy. \nWhen data were pooled, biochemotherapy was superior to chemotherapy in terms of better response (relative risk, 1.52; 95% con fidence \ninterval, 1.24 to 1.87; p<0.0001) and delayed progression at six months (relative risk, 0.85; 95% confidence interval, 0.75 t o 0.96; p=0.008) \nbut not decreased morta lity at 12 months (relative risk, 0.98; 95% confidence interval, 0.84 to 1.16; p=0.85).   \nBiochemotherapy is a toxic therapy, and patients are likely to e xperience serious hematologic, gastrointestinal, cutaneous, and constitutional \ntoxicities. In addition, there are risks of cardiovascular toxicities such as myocardial events and arrhyt hmias, hypotension, capillary leak \nsyndrome, hepatotoxicity, and renal toxicity. When conducted in the correct setting, grade 3 and 4 toxicities appear to be ma nageable, and \ntreatment -related death can be min imized.  \n \n \n \n \n \n \nLiteratur : \n4. Atkins MB, Lee S, Flahert y LE, Sosman JA, Sondak VK, Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with ci splatin, vinblastine, \ndacarbazine (CVD), IL -2 and interferon alpha- 2b (IFN) versus CVD alone in patients with metastatic melanoma ( E3695): An ECOG -coordinated intergroup trial [abstract]. Proc Am Soc Clin \nOncol 2003;22:A2847.  \n6. Atzpodien J, Neuber K, Kamanabrou D, et al. Combination chemotherapy with or without s.c. IL -2 and IFN -alpha: results of a prospectively randomized trial of the Cooperative \nAdvanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002;86:179- 184 \n5. Bajetta E, Del Vecchio M, Nova P, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin -2 \nand interferon -alpha2b in metastatic melanoma. Ann Oncol 2006;17:571- 577 \n8. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized tr ial. J Clin Oncol \n2002;20:2045- 2052   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 543 von 817 \n11. Hauschild A, Garbe C, Stolz W, et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre tri al of the \nDermatologic Cooperative Oncology Group (De COG). Br J Cancer 2001;84:1036- 1042  \n12. Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa -2a and interleukin- 2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for \nResearch and Treatment of Cancer Melanom a Cooperative Group. J Clin Oncol 1997;15:2579- 2588  \n10. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin, and interferon -alfa-2b with or without interleukin -2 in metastatic melanoma: a randomized phase III trial (18951) of the \nEuropean Organisati on for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005;23:6747 -6755 \n7. Ridolfi R, Chiarion -Sileni V, Guida M, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin -2, and interferon alpha- 2b in advanced melanoma outpatie nts: results from \nan Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002;20:1600- 1607  \n9. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chem otherapy with cisplatin, \ndacarbazine, and tamoxifen alone or in combination with interleukin -2 and interferon alfa- 2b. J Clin Oncol 1999;17:968- 975 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 544 von 817 \n6.4.  Frage V.5. Polychemotherapie \u2013 De novo Recherche  \nFrage V. 5. F\u00fchrt die Gabe von Polychemo therapien im meta stasierten Stadium zu mehr objektiven Remissionen  / zu einer Verbesserung des \nGesamt\u00fcberlebens als die Gabe von Dacarbazin?  \n6.4.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema  \nPopulation  Intervention  Comparison  Outcome  \nAdvanced melanoma patients stage \nIV, unresectable stage  III Polychemotherapy  DTIC Response, Overall Survival  \n \nSuchw\u00f6rter  \nStichwort  melanoma  review  Chemotherapy  Stage IV  \nStage 4  \nSynonyme     palliative  \nOber -/Unterbegriffe   Systemic thera py Salvage  \nmetastatic  \nMesh Term  melanoma  Review [Publication Type]  Drug Therapy   \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 545 von 817 \n6.4.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \nMedline  (melanoma[tiab] OR melanoma[MeSH]) AND  \n(review [ti] AND system*[ti]) AND (\u201csystemic therapy\u201d[tiab] OR \nchemotherapy[tiab] OR \"drug therapy\"[MeSH] OR m etastatic[tiab] OR \npalliative[tiab] OR disseminated[tiab] OR advanced[tiab] OR \"stage IV\"[tiab] \nOR \"stage 4\"[tiab] OR sal vage[tiab])  05.12.2011  27  \n(Auswahl 2 \nReviews)  \nUpdate Suche     \nMedline  s.o. 07.02.2012  28 (0 dazu)  \nCochrane Library  (melanoma and (r andom* or phase 3) and (systemic therapy or \nchemotherapy or  \nmetastatic or palliative or advanced or salvage)).ti,ab. and (review).ti.  07.02.2012 14  \n(Auswahl 3 \nReviews)  \n6.4.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  69 \nEinschlusskriterien  Systema tische Reviews zur medikament\u00f6se n Systemtherapie bei Melanompatienten im Stadium IV, nicht resektables St. III, die \nStudien zu Kombinationschemotherapien versus DTIC enthalten  \nAusschlusskriterien  Nicht systematische Reviews, RCTs, Kohortenstudien, Case Re ports,  Dosisfindungsstudie , Kolle ktive mit gemischten \nTumorentit \u00e4ten \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  5 \nAnzahl ausgew\u00e4hlter Volltexte  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 546 von 817 \n6.4.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nEigentler et al. \n2003 To investigate \nrates of response \nto var ious \ntreatment \nmodalities and the \noutcome for the \nmelanoma patients  Systematic Review  41 RCTs, p atients \nwith meta static \nmelanoma  \n7 RCTs \nPolychem otherapy \nvs. DTIC included  \nChiarion Sileni et al. \n2001 \nChapman et al. 1999 \nRingborg et al. 1989  \nLuikart et al. 1984  \nChauvergne et al. 1982  \nCarter et al. 1976 \nMoon et al. 1975   \n \n \n \n \nResponse Rate  \n \nOverall Survival DTIC vs. \nPolychem otherapy \n(without IFN), 7 \nRCTs  \n \nbenefit  \n \nNo difference  quality asses sment \nof studies reported  \nSearch terms and \ndatabases not \nmentioned  1a \nHuncharek et al. \n2001  To report the \nresults of a meta -\nanalysis comparing \nthe response rates \nof DTIC as single \nagent therapy for \nmetastatic \nmelanoma with \ncomb ination \nchemother apy Systematic Review  \n \nTreatment:  \nDTIC versus \nCombination \ntherapies  \n 20 RCTs, 3273 \npatients with \nmetastatic \nmelanoma  \n  \n \n \n \n \nResponse Rate  \n \n \nOverall Survival DTIC versus \nCombination \ntherapies (without \nIFN) 10 RCT\u00b4s  \n \nOR 1.33 (95% CI \n0.99-1.78) \n \nNo difference  Literature search \nreported  \nno quality \nassess ment of \nstudies 1a \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 547 von 817 \nAusgeschlossene Studien  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nGarbe et al. 2011  To present the \nsuccess of current \ntreatments and the \npromise  \nof those still in \nclinical \ndevelopment that \nmay yield  \nincrement al \nimprovements in \nthe treatment of \nadvanced, \nmetastatic \nmelanoma  Systematic Review  \n \nTreatment:  \nAdjuvant and \npallia tive \ntreatment \n RCTs Adjuvant and \npallia tive \ntreatment \n \nNo RCTs for \nPolychemotherapy \nvs. DTIC included    No RCTs for \nPolychemotherapy \nvs. DTI C included \n\uf0e0 study excluded   \nSasse et al. 2009  To compare the \neffects of \nchem otherapy \nalone versus \ncombined therapy \nwith chemoth erapy \nand \nimmun otherapy \n(chemoimmunoth e\nrapy) in people \nwith meta static \nmalignant \nmelanoma.  Systematic Review  \n \nTreatment:  \nChemot herapy \nversus \nChemoimmun other\napy \n 18 RCTs, 2625 \npatients with \nmeta static \nmelanoma  1 year Survival  \n \n \n \nResponse Rates  \n n.s. \nRR  1.06 (95% CI \n0.91 -1.24) p = \n0.48 \n \nsign. diffe rence \nin favor of \nchemoimmunother\napy  \nRR  1.40 (95% CI \n1.20 -1.63), p < \n0.0001  No RC Ts for \nPolychemotherapy \nvs. DTIC included \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 548 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nCrosby et al. 2009  To review the \nbenefits from the \nuse of systemic \ntherapies in \nmetastatic \ncutaneous \nmelanoma \ncompared to best \nsupportive \ncare/placebo, and \nto establish \nwhether a \n'standard' therapy \nexists which is \nsuperior to other \ntreatments  Systematic Review  \n \nTreatment:  \nSystemic therapies \nversus best \nsupportive \ncare/placebo  0 RCTs  Overall survival  \nMedian survival  \nProgression free \nsurvival  \n \n No RCTs were \nretrieved, so no \nanalysis of the \neffects of the \ninterventions \nwas carried out.  No RCTs for \nPolychemotherapy \nvs. DTIC included \n\uf0e0 study excluded   \n \n6.4.5.  Literatur  \nCarter RD, Krementz ET, Hill GJ,2nd, et al. DTIC (nsc -45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC -409962), C CNU (NSC -79037), vincristine (NSC -\n67574), and hydroxyurea (NSC -32065). Cancer Treat Rep 1976;60:601- 609 \nChapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol \n1999;17:2745- 2751  \nChauvergne J, Bui NB, Cappelaere P, et al. Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin \nwith dacarbazine alone. Sem Hop 19 82;58:2697- 2701  \nChiarion Sileni V, Nortilli R, Aversa SM, et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma p atients. \nMelanoma Res 2001;11:189- 196 \nCrosby T, Fish R, Coles B, e t al. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database of Systematic Reviews 2009;1  \nEigentler TK, Caroli UM, Radny P, et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials . Lancet Oncol 2003;4:748- 759 \nGarbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011;16:5 -24 \nHuncharek M, Caubet JF, McGarry R. Single -agent DTIC versus combination  chemotherapy with or without immunotherapy in metastatic melanoma: a meta -analysis of 3273 patients \nfrom 20 randomized trials. Melanoma Res 2001;11:75- 81 \nLuikart SD, Kennealey GT, Kirkwood JM. Randomized phase III trial of vinblastine, bleomycin, and cis -dichlorodiammine -platinum versus dacarbazine in malignant melanoma. J Clin \nOncol 1984;2:164- 168 \nMoon JH, Gailani S, Cooper MR, et al. Comparison of the combination of 1,3 -bis(2 -chloroethyl) -1-nitrosourea (BCNU) and vincristine with two dose schedules of 5 -(3,3-dimethyl -1-\ntriazino) imidazole 4 -carboxamide (DTIC) in the treatment of disseminated malignant melanoma. Cancer 1975;35:368- 371  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 549 von 817 \nRingborg U, Rudenstam CM, Hansson J, et al. Dacarbazine versus dacarbazine -vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor \nPharmacother 1989;6:285- 289 \nSasse AD, Sasse EC, Clark GOL, et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database of Systematic Reviews 2011;1  \n \n \n \n \n \n \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 550 von 817 \n6.5. Frage V.7. Le bermetastasen \u2013 De novo Recherche  \nFrage V.7.  Welche medikament\u00f6sen Ther apien k\u00f6nnen bei Lebermetastasierung empfohlen werden?  \n \n6.5.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients with liver \nmetastases Local therap ies, specific therapies  Standard chemotherapy  Response, Overall Survival  \n \nSuchw\u00f6rter  \nStichwort  melanoma  liver metast asis/metastases  treatment   chemoembolization, \nperfusion, TACE, \nimmunoembolization, IHP, \nHAI, resection, surgery, \n\u201eradiofrequency ablation \u201c, \nRFA, radioembolization, \nbrachytherapy  \nSynonyme   hepatic \nmetast asis/metastases  therapy   \nOber -/Unterbegriffe      \nMesh Term  melanoma      \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 551 von 817 \n \n6.5.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  (\u201cmelanoma\u201d[ tiab] OR \u201cmelanoma\u201d[MeSH]) AND ((liver[tiab] AND metastas*[tiab]) OR \n(hepatic[tiab] AND metastas*[tiab])) AND (treatment[tiab] OR therapy[tiab] OR \n\u201cchemoembolization\u201c[tiab] OR TACE[tiab] OR immunoembolization[tiab] OR IHP[tiab] OR \nHAI[tiab] OR perfusion[ti ab] OR resection[tiab] OR surgery[tiab] OR \u201cradiofrequency \nablation\u201d[tiab] OR RFA[tiab] OR radioembolization[tiab] OR brachytherapy[tiab])  18.01.11  722 \nEmbase  (melanoma and (liver or hepatic) and (treatment or therapy or chemoembolization or \nTACE or immun oembolization or IHP or HAI or perfusion or resection or  surgery or \nradiofrequency ablation or RFA or radioembolization or brachytherapy)). ti,ab.  11.05.11 1579 \nCochrane Library  (melanoma and (liver or hepatic) and (treatment or therapy or chemoembolizat ion or \nTACE or immunoembolization or IHP or HAI or perfusion or resection or  surgery or \nradiofrequency ablation or RFA or radioembolization or brachytherapy)). ti,ab.  21.07.11  35  \nUpdate Suche     \nMedline  s.o. 30.01.12  792 ( 3 dazu : \nHeusner  et al. \n2011 , Farolfi et al. \n2011 , Gonsalves  et \nal. 2011 ) \nEmbase  s.o. 23.01.12 1691 (0 dazu)  \nCochrane Library  s.o. 30.01.12  37 (0 dazu)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 552 von 817 \n \n6.5.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  2520  \nEinschlusskriterien  Studien zur medikament\u00f6sen Therapie von Lebermetas tasen bei Melanompatienten  \nMangels RCTs: Einschluss von Phase I/II Studien, Fallserien ab 10 Patienten  \nMangels ausreichender Daten zu Lebermetastasen kutaner Melanome, Einschluss von Studien mit Lebermetastasen \nuvealer Melanome  \nSprachen: e,dt  \nAusschlusskr iterien  Case Reports \nNicht systematische Reviews  \nStudien zu Lebermetastasen anderer Tumorentit\u00e4ten  \nAnzahl Volltexte  36 \nAusgeschlossene Studien  6 \nAusgew\u00e4hlte Studien  30 \nDie ausgew\u00e4hlten Arbeiten wurden wie folgt zusammengefasst:  \n- Resektion  \n- Isolierte hepa tische Perfusion (IHP)  \n- Hepatische arterielle Infusion (HAI)  \n- Hepatische arterielle Chemoembolisation (HACE) / Trans- arterielle Chemoembolisation (TACE)  \n- Radioembolisation (selektive interne Radio -Therapie \u2013 SIRT)  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 553 von 817 \n \n6.5.4.  Evidenztabelle  \n \nResektion  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nCaralt et al. 2010  To analyze the \noutcome of \npatients \nundergoing \nhepatic resection \nfor melanoma liver \nmeta stases.  Case Series  \n \nTreamtent:  \nLiver resection  14 patients  \nOcular melanoma \nn=6 \nCutaneous \nmelanoma n= 8  Recurrence  \n \n \n \nSurvival liver recu rrence \n46.2%  \nsystemic \nrecurrence 76.9%  \n1- and 3 -year \nsurvivals: 77 and \n49% Small series  4 \nFrenkel et al. 2009  To evaluate the \nposthepatectomy \nsurvival of uveal \nmelanoma patients \nwith liver \nmetasta ses. Retrospective \ncohort study  \n \nTreamtent:  \n\u2010 Liver resection  \n\u2010 No liver resection  74 uveal \nmelan oma patients \nwith m etastases  \n \noperated patients \nn=35  \nnon \u2010operated \npatients n=39  Survival  median survival \noperated patients: \n23 months (95% \nCI: 13.3 \u2013  41.3) \nnon \u2010operated \npatients:  \n6.8 (95% CI: 3.6 \u2013  \n12.5)  No cutaneous \nmelanoma patients \nRisk of selection \nbias Although \nsimilar \ndemographic and \nocular \nchara cteristics \nbetween the \ngroups are \nmentioned, no \nbaseline data are \npresented.  4* \n \nPoor \nqualitiy \ncohort \nstudy  \nMariani et al. 2009  To review the \nsurgical \nmana gement of Retrospective \nevaluation  \n 798 uveal \nmelan oma patients \nwith liver Survival  \n \n median overall   \npostoperative \nsurvival    No cutaneous   \nmelanoma patients   \nMultivariate 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 554 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nliver metastases \nfrom uveal \nmelanoma in a \nsingle institution \nwith regard to \nsurvival and the \ndetermin ation of \npredictive factors \nfor the o ptimal \nsurgical cand idate Treamtent:  \n\u2010 Surgery  \n metastase  \n \nsurgical resection  \nn= 255   \n \n \n \n \n \n \n \n \nPredictive factors  All patients n=255:   \n14 months  \nR0 resection n=76:   \n27 months  \nR1 rese ction n=22:   \n17 month  \nR2 resection   \nn=157: 11 months  \n \n4 variables \nindependently \ncorrelate   with \nprolonged survival:    \ninterval from \nprimary diagnosis \nto liver   \nmetastases >24 \nmonths  \ncompr ehensivenes\ns   of surgical \nresection   (R0)  \nnumber of \nmetastases \nresected (< or  =   \n4) \nabsence of \n\u0001ffect\u0001s   disease  analysis included    \nLack of control   \ngroup  \nWoon et al. 2008  To assess the \nsurvival of \nmelanoma patients Retrospective \nevaluation  \n 15 patients with \nhepatic melanoma \nmetastases, 9 Survival  Median survival for \nall patients: 7 \nmonths.  Small series  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 555 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwith hepa tic \nmetastases who \nunderwent surgery  Treatment:  \nLobectomy  \nCryoth erapy  patients suitable \nfor surgical  \n \u0001ffect\u0001s\u0001tion Curative su rgical \ngroup: 22 months  \npalliat ive group: 6 \nmonths.   \nHerman et al. 2007  To evaluate the \nexperience of liver \nresection for \npatients with \nmeta static \nmelanoma  Case Series  \n \nTreatment:  \nLiver resection  18 patients with \nmetastatic \nmelanoma, 10 \nwere o perated  \n \nOcular melanoma \nn=5 \nCutaneous \nmelanoma n=5 Survival  Overall median \nsurvival: 22 \nmonths  \n \nCutaneous \nmelanoma n=5 \n(Follow up 46 \nmonths):  \n3 dead, 1 alive, \ndisease free, 1 \nalive, recurrent \ndisease  Small series  4 \nPawlik et al. 2006  To evaluate the \nefficacy of hepatic \nresection in \npatients with \nmetas tatic ocular \nversus cut aneous \nmelanoma and to \nassess add itional \nfactors that may \naffect survival after \nresection of \nmelanoma \nmeta static to the Retrospective \nevaluation  \n \nTreatment:  \nLiver resection  40 patients with \nhepatic melanoma \nmetastasis \nunde rwent \nresection at 4 \nmajor \nhepatobiliary \ncenters  \n \nOcular m elanoma  \nn=16  \n \nCutaneous  \n \nRecurrence  \n \n \nMedian time to \nrecurrence  \n \n \nSurvival Cutaneous \nmelanoma N=24  \nTumor recurre nce \nn=18 (75.0%)  \n \nMedian time to \nrecurrence:  \n4.7 months  \n \nMedian Survival:  \n23.6 months  \n \n2\u2010year \u2010survival 17 of 24 patients \nwith cutaneous \nmelanoma received \nsystemic therapy  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 556 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nliver.  melanoma n=24  rate: 20.5%  \n \n5\u2010year \u2010survival \nrate: 0%  \nRose et al. 2001  To identify \npatients treated by \nsurgical resection \nfor meta static \nmelanoma to the \nliver and to \ndetermine if any \nfactors would be \nuseful for \nidentifying p atients \nwho should be \ntreated with \nsurgery  Retrospective \nevaluation  \n \nTreatment:  \nLiver resection  1750 patients with \nhepatic metastase s  \n \nsurgery n=34  \n \nextensive \nintraa bdominal \ndisease identified \nat exploratory \nceliotom y, no \nresection n=10  \n \ncurative resection \nn=18 (75%)  \n \npallia tive \ndebulking n=6 \n(25%)  median disease -\nfree survival (DFS)  \n \nOverall su rvival \n(OS) Median DFS  \n12 months  \n \nMedian OS 28 \nmonths  \n \n5\u2010year DFS and OS: \n12% and 29%.  \n \nMacroscopically, \ncomplete r esection \nof disease (P \n=.001) and \nhistolo gically \nnegative r esection \nmargins (P =.03) \nsignificantly \nimproved DFS by \nunivariate analysis  Uveal or cutaneous \norigin not \nmentioned  4 \nSalmon et al. 1998 To present the \npreliminary results \nof the therapeutic \napproach of \nlaparotomy with \nhepatic resection Prospective study  \n \nTreatment:  \nsurgical approach \nremov ing as much \nliver disease as 75 uveal \nmelanoma patients \nwith liver \nmetastases Survival Median overall \nsurvival \nall patients: 9 \nmonths.  \nSurgery plus \nchem otherapy No cutaneous \nmelanoma patients \nCombined \ntreatment  \nLack of control \ngroup  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 557 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(whene ver \npossible), \nimpla ntation of an \nintraa rterial \ncatheter and \nintraarterial \nchemoth erapy \n(IACH).  possible and \nintraarterial \nchemoth erapy for \n6 months   (n=61): 10 months  \ncurative resection \n(n=19): 22 months  \n \nIsolierte hepatische Perfusion (IHP)  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nHeusner et al. \n2011  To assess the \noverall survival \ntime of patients \nsuffering from \nmetastasized  \nuveal melanoma \nundergoing \nconventional \ntransa rterial \nhepatic \nchemope rfusion \nusing me lphalan  Case series  \n 61 uveal \nmelanoma patients \nwith liver \nmetastases  \n \nResponse  \n \n \n \nSurvival Response after \nfirst session \n(N=61) \nPR n=5 (8%)  \nSD n=29 (49%)  \nPD n=26 (43%)  \n \nMedian OS  \n10 months  Lack of control  \ngroup  \n 4 \nRizell et al. 2008  To analyze the \noutcome of three \ntreatment \nstrategies using Case series  \n \nTreatment:  \nIHP with 27 melanoma \npatients with live r \nmetastases \n Response  \n \n \n Response (N=27):  \nCR n=2  \nPR n=17  \nSD n=2  Lack of control  \ngroup  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 558 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nisolated \nhyperthermic liver \nperfusion (IHP) \nwith melphalan for \nliver metastases of \nmalignant \nmelanoma  modific ations \nduring 3 different \ntime p eriods (IHP I, \nIHP II and IHP III), \nin technique and \ntemperature \n(amount of \nmelph alan: 0.5, \n1.0 and 2 mg/kg \nbody weight in the \nperfusate; 41, 40 \nand 40\u00b0C)   Ocular melanoma  \nn=20  \nCutaneous \nmelanoma n=5  \nAnal melanoma \nn=2  \n \nMortality  \n \nSurvival Overall response \nrate 70%  \nPostoperative \nmortality n=6  \nMedian Survival: \n7.5 months (range \n0 \u2010 57), \npostopera tive \ndeaths excluded: \n12.6 months \n(range 2.5 \u201057 \nmonths)  \nAlexander et al. \n2003  To evaluate \nisolated hepatic \nperfusion (IHP) for \npatients with \nunresectable liver \nmetastases from \nocular mel anoma  Case series \n \nTreatment:  \n60-min \nhyperth ermic IHP \nusing 1.5 mg/kg \nof melphalan  29 patients with \nunresectable liver \nmetastases from \nocular melanoma  Response  \n \n \n \nProgression -free \nsurvival (PFS)  \n \nOverall Survival \n(OS) \n \n \nToxicity  Response (N=29)  \nCR n=3 (10%)  \nPR n=15 (52%)  \n \nMedian PFS: 8 \nmonths  \n \nmedia n OS: 12.1 \nmonths  \n \nGrade 3 or greater \nhepatic toxicity \n(reversible) n=19 \n(65%)  No cutaneous \nmelanoma patients  4 \n \nHepatische arterielle Infusion (HAI)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 559 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nFarolfi et al. 2011  To investigate \ndirect h epatic \nintra-arterial \nchemoth erapy of \nfotemustine or \ncarboplatin in \nmelanoma patients \nwith liver \nmetasta ses Case Series  \n \nTreatment:  \nHai, \nFotemustine, \nCarboplatin  23 melanoma \npatients with \nunresectable liver \nmetastases \n78% uvea \nmelan oma  Response  \n \n PR n=3 ( 16.7%)  \nSD n=4 (22.2%)  \nPD n=11 (61.1%)  - 4 \nMelichar et al. \n2009  To evaluate \nhepatic arterial \ninfusion of the \ncombination of \ncisplatin, \nvinblastine and \ndacarbazine in \npatients with liver \nmetastases of \nuveal melanoma.  Case Series  \n \nTreatment:  \nhepatic arterial \ninfusion (HAI) of \nthe combination of \ncisplatin, \nvinblastine and \ndacarbazine  \n 10 patients with \nhepatic metastases \nof uveal melan oma Response  \n \n \n \nSurvival Response (n=10)  \nPR n=2  \nSD n=4  \nPD n=4  \nMedian survival 16  \nmonths (range 5  \u2010  \n69) Small series  4 \nSiegel e t al. 2007  To compare the \neffectiveness of \nhepatic arterial \nFotemustine \ninfusion between \nliver m etastases \nfrom ocular and \ncutaneous \nmelanoma.  \n Retrospective \nevaluation  \n 36 patients with \nhepatic metastases \nfrom ocular or \ncutaneous \nmelanoma, 30 \npatients wer e \ntreated  \n \nOcular melanoma  \nn=18   \n \n \nResponse  \n \n \nSurvival \n \nToxicity  cutaneous \nmelan oma patients \n(N=12) \nPR n=4 (33%)  \nSD n=4 (33%)  \nPD n=4 (33%)  \nMedian survival: \n12 months.  \nToxicity (all \npatients N=30)  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 560 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nCutaneous \nmelanoma n=12  grade III \u2010IV throm -\nbocytop enia: 30% \ngrade III\u2010 IV \nneutropenia: 7% \nnausea/vomiting: \n17% (max. gr. I \u2010II) \nabdominal pain 7% \n(max. gr. I \u2010II) \nPeters et al. 2006  To investigate the \nuse of fot emustine \nvia direct intra -\narterial hepatic \n(i.a.h.) \nadministration in \npatients with uveal \nmelanoma \nmetastases Retrospective \nevaluation  \n \nTreatment: \nfotemustine, \nadmini stered intra -\narterially weekly \nfor a 4 -week \ninduction period, \nand then as a \nmaintenance \ntreatment every 3 \nweeks  101 uveal \nmelan omapatients \nfrom 7 centers \nwith liver \nmetastases Response  \n \n \n \n \nSurvival CR n=15 (15%)  \nPR n=21 (21%)  \nSD n=48 (48%)  \nPD n=17 (17%)  \n \nMedian overall \nsurvival: 15 \nmonths  \n(95% CI: 12.1 \u201017.6)  \n1\u2010year survival rate  \n67%, 3 \u2010 year \nsurvival rate 12%  No cutaneous  \nmelanoma patients  \n \n 4 \nAgarwala et al. \n2004  To evaluate the \naddition of \nembol ization to \nchemoth erapy and \nto dete rmine the \nrole of escalation \nof \nintrahepaticarterial Phase I/II trial  \n \nescalating doses \nofintrahepatic \nchemotherapywith\ncisplatin with \norwithout \npolyvinyls ponge 19 patients with \nocular melanoma \nand liver \nmetast ases Toxicity  \n \n \n \nResponse  Toxicity:  \nGrade 3 n=7  \nGrade 4 n=9  \n \nPR n=3 (16%)  \nSD n=13 (68%)  \nPD n=1 (5%)  \nNot evaluable n=2  No cutaneous \nmelanoma patients  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 561 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncisplatin dose, \neither alone or as \npart of \nchemoemboliz atio\nn. (PVS)  (11%)  \nBecker et al. 2002  To evaluate the \nactivity of \nseque ntial \nfotemustine, \ninterferon alpha, \nand i nterleukin 2 \nfor metastatic uvea \nmelanoma \npatien tsin a \nprospectiv ephase II \ntrial. Phase I/II study  \n \nTreatment:  \nFotemustine \n100mg/m\u00b2 via \nhepatic artery or \ni.v. fo llowed by s.c. \nIL\u20102 on day 31 and \ns.c. \ninterferonalpha o n \nday 36  48 pat ients with \nmetastatic ocular \nmelanoma  Response  \n \n \n \n \n \n \n \nSurvival \n CR n=1 (2%)  \nPR n=6 (12.5%)  \nSD n=18 (37.5%)  \n \nIntraarterial versus \ni.v. fotemustin  \nResponses \n21.7% vs 8%  \nOverall survival \n369 vs 349 days  No cutaneous \nmelanoma p atients  \nStudy stratifi ed \naccording to \npresence or \nabsence of \nextrahepatic \nmeta stases,resultin\ng in different \nprognos tic factors \nbetween th e \ngroups.  4 \nLeyvraz et al. 1997  To evaluate the \neffectiveness and \ntoxicity of hepatic \nintraarterial \nfotemustine when \nadministered \nthrough the \nhepatic arterial \nroute in the \ntreatment of liver \nmeta stases from \nocular melanoma  Phase II study  \n \nTreatment:  \n intraarterial \nfotemustine 100 \nmg/m2  \n(4 hour infusion)  31 patients with \nliver metastases \nfrom ocular \nmelanoma  Response  \n \n \n \n \n \n \n \n \nSuvival  \n Response liver \nmetastases (30 \npatients \nassess able) \nCR n=4 (13%)  \nPR n=8 (27%)  \nMinor Response  \nn=2 \nSD n=13  \nPD n=3  \nMedian overall \nsurvival 14 months  No cutaneous \nmelanoma patients  \n \nNo overall \nresponse  \ndata 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 562 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nKhayat et al. 1991  To evaluate \nhepatic intra -\narterial infusion \n(HIAI) of \nfotemustine  Phase II Study  \n \nTreatment:  \nintraarterial \nfotemustine 100 \nmg/m\u00b2 (4 hour \ninfusion)  17 patients with \nexclusive or \npredominant liver \nmetastases from \nmalignant \nmelanoma.  \n13 patients \nevaluable  Response  \n Hepatic Response  \n(N=13) \nCR n=2  \nPR n=6  \nMR n=1  \nSD n=3  \nPD n=1  \nOverall \nextrahepatic  \nresponse  \nrate 6/14 (42.8%)  Uveal or cu taneous \norigin not \nmentioned  \n 4 \nStorm et al. 1982  To evaluate \ncombined \ntreatment with \nintraarterial DTIC \ninfusion and \nlocalized \nhyperthermia of \npatients with \nadvanced liver \nmetastases Case Series  \n \nTreatment: IA -DTIC \nplus heat  10 melanoma \npatients with liver \nmetast ases \n \nOcular melanoma \nn=3 \nCutaneous \nmelanoma n=4  \nUnknown primary \nn=2 Response  \n \n \n \n \nSurvival Response  \nCR n=1  \nPR n=2  \nSD n=5  \nPD n=2  \nMedian survival \n8.5 \nmonths (range 3.5 \u2010 \n18) Small series  4 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 563 von 817 \n \nHepatische arterielle Chemoembolisation (HACE) / Trans -arterielle Chemoembolisation (TACE)  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAhrar et al. 2011 To evaluate the \nresponse rates and \nsurvival durations \nof patients with \nmetastatic \ncutaneous \nmelanomas who \nunderwent \nchemoembolizatio\nn. Retrosp ective \nevaluation  \n \nTreatment:  \nIntra \u2010arterial \nembo lic agent \nfollowed by \ncisplatin (100 \u2010  \n150mg)  42 patients with \ncutaneous \nmelan oma \nmetastatic to the \nliver \n \nextrahepatic \ndisease  \nn=36  \nno extrahepatic  \ndisease n=6  \nEvaluable n=36  Response  \n \n \n \n \n \nOverall Survival \n(OS) \n \nTime to \nprogression (TTP)  Response (N=36)  \nCR n=0  \nPR n=5 (13.9%)  \nMR n=9 (25%)  \nSD n=17 (47.2%)  \nPD n=5(13.9%)  \nMedian overall \nsurvival: 7.69 \nmonths  \nTTP of liver \ndisease: 6.01 \nmonths  Mulitvariate \nanalysis included  \nLack of control \ngroup  4 \nHuppert et al. \n2010  To evaluate \nresponse and \nsurviv al in patients \nwith liver \nmetastases from \nuveal melanoma \ntreated by \nchemoembolizatio\nn following an \ninvar iable \ntreatment pr otocol \nover a period of \nmore than 6 years.  Phase II Study  \n \nTreatment:  \nHepatic \ntransarter ial \nchemoemboliz atio\nn (TACE) \n100mg/m\u00b2 of \ncisplatine was \ncontinuously \ninfused by means \nof a power injector \npreceding \nembolization by \nmanual injection of 14 patients with \nhepatic metastases \nfrom uveal \nmelanoma  \n34 TACE\u00b4s were \nperformed  Response  \nTime to \nprogression  \nSurvival Response (N=14)  \nCR n=0  \nPR n=8 (57%)  \nSD n=4 (29%)  \nPD n=2(14%)  \n \nMedian time to  \nprogression 8.5  \nmonths (5 \u201035 \nmonths)  \nMedian survival:  \n14.5 months in  \nresponders versus  \n10 months in \nnonresponders  No cutaneous \nmelanoma patients  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 564 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npolyvinyl alcohol \nparticles  (p=0.18,  \nnot significant)  \nSchuster et al. \n2010  To report the \nexperience with \ntransa rterial \nchemoembol izatio\nn (TACE) in uveal \nmelanoma  patients \nwith pr etreated \nliver meta stases Case Series  \n \nTreatment:  \nfotemustine -based \nor cisplatin -based \nTACE after \ntreatment failure \nof systemic \ntherapy  25 uveal \nmelan oma patients \nwith liver \nmetast ases Toxicity  \n \n \n \n \nResponse  \n \n \n \n \n \nprogression \u2010free \nsurvival ( PFS) \n \nOverall survival \n(OS) Toxicity:  \nNo grade IV \ntoxicity or \ncatheterass ociated \ncomplic ations  \nResponse (N=25)  \nCR n=0  \nPR n=4 (16%)  \nSD n=14 (56%)  \nPD n=7 (28%)  \n \nPFS: 3 months \n(95% CI: 2 \u20104 \nmonths)  \n \nOS: 6 months (95%  \nCI: 5 \u20107 months)  No cutaneous \nmelanoma patie nts \n 4 \nYamamoto et al. \n2009  To retrospectively \nevaluate \nprognostic factors \nfor survival in \npatients with uveal \nmelanoma who \nreceived \nchemoembolizatio\nn (CE) with 1,3 -bis \n(2-chloroethyl) -1-Retrospective \nevaluation  \n(of patients treated \nwithin 2 different  \nPhase II studies)  \n \nTreatment:  \nChemoembolizatio\nn \nwith BCNU or with  53 patients with \nuveal mel anoma  \n \nCE n=19  \nIE n=34  Overall survival \n(OS)  \n \n \n \n \n \n \nProgre ssion-free \nsurvival (PFS)  Median OS  \nCE: 9.8 months  \nLow \u2010dose IE: 13.0 \nmonths  \nHigh \u2010dose IE: 20.4 \nmonths  \n \nMedian Liver PFS \nCE: 6.4 months  \nLow \u2010dose IE: 4.2 No cutaneous \nmelanoma patients  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 565 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nnitrosourea or \nimmunoemboliz ati\non (IE) with \ngranul ocyte-\nmacrophage \ncolony-stimulating \nfactor (GM -CSF) for \nhepatic m etastases  GM \u2010CSF months  \nHigh \u2010dose IE: 9.3 \nmonths  \nFiorentini et al. \n2009  To assess the \nsafety and efficacy \nof TACE with \nirinotecan as drug -\neluting beads  Phase II study  \n \nTreatment: TACE -\ncontaining beads \npreloaded with IRI \n(100 mg)  10 patients with \nliver m etastases \nfrom uveal \nmelanoma  Response  \n Partial response: \n10 patients  No cutaneous \nmelanoma patients  4 \nSharma et al. 2008  To present the \noutcomes with \nhepatic arterial \nchemoe mbolizatio\nn for m etastasis of \nstage 4 mel anoma  Retrospective \nevaluation  \n \nTreatmen t:  \nhepatic arterial \nchemoembolizatio\nn 20 patients with \nliver \u2010dominant \nmetastasis of \nocular or \ncutaneous \nmelan oma  \n \nOcular melan oma \nn=17  \nCutaneous \nmelanoma n=3  Response  \n \n \n \n \nOverall survival \n \n \n \n \nProgression \u2010free \nsurvival  Response  \nCR n=0  \nPR n=0  \nSD n=13 (65% ) \nPD n=7 (35%)  \nmedian overall \nsurvival:  \n271 days no \ndeaths within 30 \ndays of treatment  \nmedian \nprogression \u2010free \nsurvival:  \n185 days  Presence or \nabsence of \nextrah epatic \nmetastases not \nmentioned  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 566 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nVogl et al. 2006  To evaluate results \nin the palliative \ntreatme nt of \npatients with liver \nmetastases of \nuveal malignant \nmelan oma using \ntransa rterial \nchemoembol izatio\nn (TACE)  Case Series  \n \nTreatment:  \ntransarterial \nchemoembolizatio\nn (TACE) \nembolization \nsuspension: 10 \nmg/m\u00b2 Mitomy cin \nC, 10 ml Lipiodol, \nand an inje ction of  \n200-450 mg \nresor bable \nmicrospheres for \nvascular occl usion 12 patients with \nliver metastases of \nuveal malignant \nmelanoma  Side effects  \n \nResponse  \n \n \n \nSurvival no relevant side \neffects.  \nResponse  \nPR n=3  \nSD n=5  \nPD n=4  \nMean survival after \nfirst embolization \n19.5 months. \nLower survival \nrates for the \nprogressive group \n(16.5 months).  No cutaneous \nmelanoma patients  4 \nPatel et al. 2005  To evaluate \nchemoembolizatio\nn of the hepatic \nartery with BCNU \nfor metastatic \nuveal mel anoma  phase II study  \n \nTreatment: \nchemoembolizati o\nn of the hepatic \nartery with 1,3 -\nbis(2 -chloroethyl) -\n1-nitrosourea \n(BCNU) dissolved \nin eth iodized oil. \nGelatin sponge \nparticles were used \nas a tra nsiently \nocclusive agent. 30 patients with \nhepatic metastases \nfrom uveal \nmelanoma, 24 \npatients evaluable  respo nses in \nhepatic metastases  \n \n \n \nOverall survival \n Response (n=24)  \nCR n=1  \nPR n=4  \nSD n=13  \nPD n=6  \nMedian Survival \nITTP 5.2 months  \nCR+PR 21.9 \nmonths  \nSD 8.7 months  \nPD 3.3 month  No cutaneous \nmelanoma patients  4 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 567 von 817 \nRadioembolisation (selektive interne Radio -Therapie \u2013 SIRT)  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nGonsalves et al. \n2011  to assess the \nsafety and efficacy \nof \nradioembolization \nin the management \nof hepatic \nmetastasis of uveal \nmelanoma after \nfailure of \nimmunoembolizati\non or \nchemoemboliz atio\nn Retrospective \nevaluation  32 patients with \nhepatic metastases \nfrom uveal \nmelanoma  responses in \nhepatic metastases  \n \n \n \nMedian overall \nsurvival \n CR n=1  \nPR n=1  \nSD n=18  \nPD n=12  \n \n10 months  \nCR+PR+SD 14.7 \nmonths  \nPD 4.9 months  No cutaneous \nmelanoma patients  4 \nKennedy et al. \n2009  To evaluate \nYttrium-90 \nmicrosph eres \n(radioembol ization\n) delivered via the \nhepatic artery  Case Series  \n \nTreatment:  \nYttrium \u201090 \nmicrospheres \n(radioe mbolization\n) delivered via the \nhepatic a rtery 11 patients with \nliver metastases \nfrom uveal \nmelanoma  Toxicity  \nResponse  \nSurvival Toxicity:  \nGrade 3: n=1  \nResponse  \nCR n=1  \nPR n=6  \nSD n=1  \nPD n=1  \n1 year survival 80%  No cutaneous \nmelanoma pat ients 4 \n \n6.5.5.  Literatur  \n \nAgarwala SS, Panikkar R, Kirkwood JM. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplat in and chemoembolization with cisplatin and polyvinyl \nsponge in patients with ocular melanoma metastatic to th e liver. Melanoma Res 2004;14:217- 222 \nAhrar J, Gupta S, Ensor J, et al. Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cu taneous melanoma. Cancer \nInvest 2011;29:49- 55 \nAlexander HR, Jr, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma  metastatic to liver. Clin Cancer Res \n2003;9:6343- 6349   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 568 von 817 \nBecker JC, Terheyden P, Kampgen E, et al. Treatment of disseminated ocular m elanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002;87:840 -845 \nCantore M, Fiorentini G, Aitini E, et al. Intra- arterial hepatic carboplatin -based chemotherapy for ocular melanoma metastatic to the liver. Report of a p hase II study. Tumori 1994;80:37-\n39 \nCaralt M, Marti J, Cortes J, et al. Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. J Hepatobiliary Pancreat Sci 2010  \nEgerer G, Lehnert T, Max R, et al. Pilot study of hepati c intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single -center experience with seven \npatients. Int J Clin Oncol 2001;6:25- 28 \nFarolfi A, Ridolfi L, Guidoboni M, et al. Liver metastases from melanoma: hepatic intra -arteria l chemotherapy. A retrospective study. J Chemother 2011;23:300- 305 \nFiorentini G, Aliberti C, Del Conte A, et al. Intra- arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow -release irinotecan -eluting beads. Early \nresults of a phase II clinical study. In Vivo 2009;23:131- 137 \nFrenkel S, Nir I, Hendler K, et al. Long -term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 2009;93:1042- 1046  \nGonsalves CF, Eschelman DJ, Sullivan KL, et al . Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single -institution experience. AJR Am J Roentgenol \n2011;196:468- 473 \nHerman P, Machado MA, Montagnini AL, et al. Selected patients with metastatic melanoma may benefit from l iver resection. World J Surg 2007;31:171- 174 \nHeusner T -, Antoch G, Wittkowski -Sterczewski A, et al. Transarterial hepatic chemoperfusion of uveal melanoma metastases: Survival and response to treatment. RoFo Fortschritte auf \ndem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren 2011;183:1151- 1160  \nHuppert PE, Fierlbeck G, Pereira P, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanom a. Eur J Radiol 2010;74:e38- 44 \nKennedy AS, Nutting C, Jakobs T, et al. A first re port of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009;27:682- 690 \nKhayat D, Cour V, Bizzari JP, et al. Fotemustine (S 10036) in the intra -arterial treatment of liver metastasis from malignant melanoma. A phase II Study. Am J Clin Oncol 1991;14:400-\n404 Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997;15:2589- 2595  \nLeyvraz S, Zografos L, Bauer J, et al. Phase II study of hepatic intraarterial fotemustine in patients with hepatic metastases from uveal malignant melanoma: Preliminary results. Regional \nCancer Treatment 1992;5:ate of Pubaton: 1992  \nMariani P, Piperno -Neumann S, Servois V, et al. Surgical management of liver metastases from  uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol \n2009;35:1192- 1197  \nMelichar B, Dvorak J, Jandik P, et al. Intraarterial chemotherapy of malignant melanoma metastatic to the liver. Hepatogastroenterology 2001;48:1711- 1715  \nMelich ar B, Voboril Z, Lojik M, et al. Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbaz ine. \nHepatogastroenterology 2009;56:1157- 1162  \nNoter SL, Rothbarth J, Pijl ME, et al. Isolated hepa tic perfusion with high -dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res \n2004;14:67- 72 \nPatel K, Sullivan K, Berd D, et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: res ults of a phase II study. Melanoma Res 2005;15:297- 304 \nPawlik TM, Zorzi D, Abdalla EK, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease.  Ann Surg Oncol \n2006;13:712- 720 \nPeter s S, Voelter V, Zografos L, et al. Intra- arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol  2006;17:578-\n583 \nRizell M, Mattson J, Cahlin C, et al. Isolated hepatic perfusion for live r metastases of malignant melanoma. Melanoma Res 2008;18:120- 126 \nRose DM, Essner R, Hughes TM, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience.  Arch Surg \n2001;136:950- 955 \nSalmon RJ, Levy C, Plancher C, et al. Treatment of liver metastases from uveal melanoma by combined surgery -chemotherapy. Eur J Surg Oncol 1998;24:127- 130 \nSchuster R, Lindner M, Wacker F, et al. Transarterial chemoembolization of liver metastases from uveal  melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res \n2010;20:191- 196 \nSharma KV, Gould JE, Harbour JW, et al. Hepatic arterial chemoembolization for management of metastatic melanoma. AJR Am J Roentgenol 2008;190:99- 104 \nSiegel R, Hauschild A, Kettelhack C, et al. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocu lar melanoma. \nEur J Surg Oncol 2007;33:627- 632 \nStorm FK, Kaiser LR, Goodnight JE, et al. Thermoch emotherapy for melanoma metastases in liver. Cancer 1982;49:1243- 1248  \nvan Etten B, de Wilt JH, Brunstein F, et al. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases. Eur J Surg Oncol 2009;35:539-\n545 \nVogl T, Eichler K, Zangos S, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tum or control and survival. \nJ Cancer Res Clin Oncol 2007;133:177- 184 \nWoon WW, Haghighi KS, Zuckerm an RS, et al. Liver resection and cryotherapy for metastatic melanoma. Int Surg 2008;93:274 -277 \nYamamoto A, Chervoneva I, Sullivan KL, et al. High -dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology 2009;252:290- 298 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 569 von 817 \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 570 von 817 \n6.6. Frage V.8. L ebensqualit\u00e4t \u2013 De novo Recherche  \nFrage V.8.  Welche  medikament\u00f6sen Ther apieverfahren haben im metastasierten Stadium einen (positiven) Effekt auf die Lebensqualit\u00e4t? \n6.6.1.  PICO, Suchw\u00f6rter   \nPICO \u2013 Schema  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients, clinical stage III \nand IV  Systemic treatment  Observation, other systemic \ntreatments  Quality of life  \n \nSuchw\u00f6rter  \nStichwort  melanoma  Quality of life    \nSynonyme   Qol   \nMesh Term  melanoma  Quality of life    \n \n6.6.2.  Datenba nken, Suchstrategien, Trefferzahlen  \n6.6.2.1.  Prim\u00e4rrecherche 2012  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche      \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 571 von 817 \nDatenbank  Suchstrategie  Datum  Treffer \nMedline  (\u201cmelanoma\u201d[tiab] OR \u201cmelanoma\u201d[MeSH]) AND (\u201cQuality of \nlife\u201d OR \u201cQol\u201d OR \u201cQuality of life\u201d [Mesh])  24.02.11  399 \nUpdate Suche     \nMedline  s.o. 31.01.12  435 (3 dazu: Hofmann et al. 2011, Robinson et \nal. 2011, Ziefle et al. 2011, Bran dberg et al. \n2011)  \nCochrane Library  (melanoma and (\u201cquality of life\u201d or \u201cQoL\u201d)).ti,ab.  31.01.12  42 (0 dazu)  \nEmbase  (melanoma and (\u201cquality of life\u201d or \u201cQoL\u201d)). ti,ab.  24.01.12  497 (0 dazu)  \n6.6.2.2.  Aktualisierungsrecherche 2015  \nDatenbank  Suchstrategie  Datum  Treffer \nMedline  (((\u201cmelanoma\u201d[tiab] OR \u201cmelanoma\u201d[MeSH]) AND (\u201cQuality of \nlife\u201dOR \u201cQol\u201d OR \u201cQuality of life\u201d [Mesh]))) AND \n(\"2011.02.25\"[Date - Publication] : \"3000\" [Date - Publication])  16.09.2015  243 \nCochrane Library  (melanoma and (\u201cquality of life\u201d or \u201cQoL\u201d)).ti,ab.  16.09.2015  61 (0 dazu)  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 572 von 817 \n6.6.3.  Auswahlkriterien  \n6.6.3.1.  Prim\u00e4rrecherche 2012  \nAuswahl der Literatur  \nGesamttreffer  974 \nEinschlusskriterien  Studien / System. Review s zu Lebensqualit\u00e4t bei Melanompatienten unter Therapie  \nKlinische adjuvante und palliative Therapiestudien / system. Reviews zum Melanom, die Lebensqualit\u00e4t als prim\u00e4ren oder \nsekund\u00e4ren Endpunkt messen  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports  \nNicht systematische Reviews  \nKollektive mit gemischten Tumorentiti\u00e4ten  \nLebensqualit\u00e4t bei Melanompatienten nach/w\u00e4hrend chirurgischer Therapie  \nLebensqualit\u00e4t bei Melanompatienten ohne Therapie  \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  28 \nAnzahl ausgew\u00e4hlter Studien nach Handsuche (Durchsicht der Literaturlisten)  3 \nAnzahl der ausgeschlossenen Studien nach Sichtung der Volltexte  10 \nAnzahl ausgew\u00e4hlter Volltexte  21 \nDie ausgew\u00e4hlten Arbeiten wurden wie folgt zusammengefasst:  \n- Reviews zu QoL bei Mel anompatienten unter Therapie  \n- Adjuvante Therapienstudien die QoL als Endpunkt enthalten  \n- Palliative Therapienstudien die QoL als Endpunkt enthalten    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 573 von 817 \n6.6.3.2.  Aktualisierungsrecherche 2015  \nAuswahl der Literatur  \nGesamttreffer   304 \nEinschlusskriterien  System. Reviews  zu Lebensqualit\u00e4t bei Melanompatienten unter Therapie  \nKlinische palliative Phase III Therapiestudien / system. Reviews zum Melanom, die Lebensqualit\u00e4t als prim\u00e4ren oder sekund\u00e4ren  \nEndpunkt messen  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports \nNicht sys tematische Reviews  \nKollektive mit gemischten Tumorentiti\u00e4ten  \nLebensqualit\u00e4t bei Melanompatienten nach/w\u00e4hrend chirurgischer Therapie  \nLebensqualit\u00e4t bei Melanompatienten ohne Therapie  \nDie ausgew\u00e4hlten Arbeiten wurden wie folgt zusammengefasst:  \n\u2022 Reviews zu Q oL bei Melanompatienten unter Therapie  \n\u2022 Palliative Therapienstudien die QoL als Endpunkt enthalten   \nAnzahl ausgew\u00e4hlter Volltexte  5 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 574 von 817 \n6.6.4.  Evidenztabelle  \n6.6.4.1.  Prim\u00e4rrecherche 2012  \nReviews zu QoL bei Melanompatienten unter Therapie \nStudy  Aims  Design  Population  Outco mes Results  Comments  LoE \nCashin et al. 2008  To examine all of \nthe information \npublished so far on \nthe impact of \ninterventions on \nQoL, including all \navailable treatment \nstrategies or \nscreening \nprograms for MM  Systematic review  \n \nInclusion criteria: \nreports of original \nresearch related to \nQoL in MM and/or \neconomics  \nof MM  13 QoL studies  \n(5 economic \nstudies) \n QoL Instruments  \nMain QoL Results  \n(Interventions, \nClinical Outcome, \nAdverse Events)  \n QoL Instruments \nused:  \nEORTC, EORTC \nQLQ-36, QLQ C30, \nQWB-SA, Lin ear \nanalog self -\nassessment scale \nincluding the GLQ -\n8, GLQ -8, SF-36, \nRotterdam \nChecklist Symptom \nquesti onaire, QWB -\nSA \nQOL Results:  \nno significant \nimprovements in \nQoL for any \nalternative for \ntreating MM  Detailed \ndescription of \nstudies and r esults  1a \nCornish et al . 2009  To systematically \nreview the \navailable literature \non health -related \nquality of life \n(HRQOL) and Systematic review  \n \nInclusion criteria: \n(HR)QOL \nassess ment in \ncutaneous 13 selected st udies HRQOL in patients \nwith cutaneous \nmelanoma  - 20 different \ninstruments were \nused within the 13 \nstudies \n- 3 distinct periods \nof HRQOL impact: Results of QoL \nmeasurements \nwithin the studies \nare not pr esented  \nin detail . \n 1a-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 575 von 817 \nStudy  Aims  Design  Population  Outco mes Results  Comments  LoE \nmelanoma  melanoma  diagnosis, \ntreatment and \nfollow -up \n- systemic drugs \ndecreased \npatients\u00b4 HRQOL \nduring treatment.  Methodological \nquality of included \nstudies was \nmeasured by 14 \nnot val idated \ncriteria  \n \nAdjuvante Therapiestudien die QoL als Endpunkt enthalten  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nZiefle et al. 2011  To evaluate QoL  in \npatients with \nmelanoma using \nthe \nEuropean \nOrganiz ation for \nResearch and \nTreatment of  \nCancer Quality of \nLife Questionnaire \n(EORTC QLQ -C30) \nbefore and during \nthe first 12 months \nof adjuvant \ntreatment with IFN -\na-2a QoL evaluation \nwithin a phase III \ntrial \n \nQoL instrument:  \nEORTC QLQ -C30 \nTime points: \nbaseline, month 3, \n6 and 12  \n \nTreatment:  \nGroup 1: IFN -a-2a \n18 months  \nGroup 2: IFN -a-2a \n60 months  QoL Assessment  \n \nno. of forms \nreceived \n(expected)  \nBaseline  \nn=725 (850)  \n \nall timepoints  \nn=282 (850)  \n HRQOL at baseli ne \n \n \n \n \nHRQOL during \ntreatment  HRQoL co mpared \nwith the healthy \nreference \npopulation  \n \nsignificant \ndecrease of 9 of 15 \nQLQ-C30 sub scales  \npeaked at 3 \nmonths  \n \n \n No assessment of \nlong term QoL \nData (Group 2)  1b \nBrandbert et al. To compare QoL evaluation QoL Assessment  HRQOL during significant - 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 576 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n2011  health -related  \nquality  of life \n(HRQoL) and side -\neffects in p atients  \nwith high-risk \nmelanoma  \nparticipating in a \nrandomised  phase  \nIII trial of adjuvant  \ninterf eron alfa-2b within a phase III \ntrial \n \nQoL instrument:  \nEORTC QLQ -C30 \nTime points: \nbaseline, month 3, \n6 and 12  \n \nTreatment:  \nArm  A: \nObservation  \nArm B: 1 year \nintermediate Dose \nIFN-a-2b  \nArm C: 2 years \nintermediate Dose \nIFN-a-2b   \nno. of forms \nreceived > 80%  \n \nall timepoints  \nn=282 (850)  \n treatment \ncompared to \nbaseline \n \n \n \n \n \nHRQOL d ifferences \nbetween groups  \n intera ctions \nbetween \nrandomisation arm \nand time after \nrandom isation for \nalmost all EORTC \nQLQ-30 variables  \n \nArm A improved or \nremained at \nbaseline levels  \nARM B+C \nsignificant \nnegative impact on \nHRQoL of IFN \ntreatment.  \n \nthe impact were \nreversible when \ntreatment was \nstopped.  \nBottomley et al. \n2009  To examine the \nhealth -related \nquality of life \neffects of adjuvant \npegylated IFN -\nalpha -2b (PEG -IFN-\nalpha -2b) versus \nobservation in \npatients with stage QoL evalua tion \nwithin a phase III \ntrial \n \nQoL instrument:  \nEORTC QLQ -C30 \nTime points: \nbaseline, month 3, \n12, 24, 36, 48, 60.  QoL Assessment  \n \nno. of forms \nreceived \n(expected)  \nBaseline  \nGr. 1: n=521 (629)  \nGr. 2: n=520 (627)  \n HRQOL at month 3  PEG-IFN-alpha -2b \ntreatment arm:  \n-decreased global \nHRQOL at month 3 \n(-11.6 points; 99% \nCI, -8.2 to - 15.0) \nand year 2 ( -10.5 \npoints; 99% CI, -\n6.6 to - 14.4)  Analysis was \nrestricted to the \nfirst 3 years, as \nlimited data \nexisted at years  4 \nand 5.  \n \nConflict of interest \n5 of 18 authors 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 577 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nIII melanoma   \nTreatment:  \nGroup 1 \nobserv ation (n = \n629)  \nGroup 2 PEG -IFN-\nalpha -2b (n = 627)  36 months  \nGr. 1: n=158 (352)  \nGr. 2: n=134 (347)  \n \n60 months  \nGr. 1: n=10 (26)  \nGr. 2: n=9 (30)  \n \nof 1,256 patients \nwith stage III \nmelanoma  \n -statistically \nsignif icant \nimpaired (P< \n0.0001) at 3 \nmonths after \nbaseline: \nSocial functioning  \nRole functioning  \n(at other \ntimepoints no \nclinically \nmeaningful \ndifferences \nbetween both \ntreatment groups)  \n-statistically \nsignif icant \nimpaired (P<.0001) \nover time:  Appetite \nloss \nFatigue  received funding, \nhonoria or had \nconsultant/advisor\ny role (Schering \nPlough)  \nGarbe et al. 2008  To evaluate \nadjuvant Interferon \nalpha and DTIC  \nin terms of overall \nsurvival, \nrecurrence -free \nsurvival and \noccurrence of  \nadverse events. QoL Evaluation \nwithin a RCT  \n \nQoL Instrument:  \nEORTC QLQ -C30 \n \nTime points:  \nBaseline +  6 \nmonths  HRQOL assessment  \n  \nNo. of patients= \n238 (54%)  \n \n HRQOL at month 6  better outcome for \nthe general \ndime nsions of QoL  \nfor patients with \nadjuvant therapy  \nphysical \nfunctioning (Arm A \nvs. Arm C: p = \n0.007)  Baseline HRQOL \ndata not presented  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 578 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nHealth -related \nquality of life (QoL)  \nwas measured by a \nquestionnaire.  \nTreatment:  \nArm A: Interferon \nalpha (n=146)  \nArm B: Interferon \nplus Dacarbazine \n(n=148)  \nArm C: \nObserv ation (n= \n147) \n role functioning \n(Arm A vs.  Arm C: \np = 0.008)  \nemotional \nfunctio ning (Ar m A \nvs. Arm C: p = \n0.048)  \n \nmore drug -related \nsymptoms  \nfatigue symptom \nscale (Arm A vs. \nArm C: p = 0.036)  \nnausea and \nvomiting scale \n(Arm B vs. Arm C: \np = 0.037)  \nDixon et al. 2006  To evaluate data \non health -related \nquality of life \n(HRQoL) and costs \nof low -dose \nextended duration \nadjuvant \ninterf eron-alpha \ntherapy in the \ntreatment of \nmalignant \nmelanoma  \n QoL Evaluation \nwithin a RCT  \n \nQoL Instrument:  \nEORTC QLQ -C30 \n \nTime points:  \nBaseline, 3, 6, 12, \n24, 36, 48, 60 \nmonths  \n \nTreatment:  \nGroup 1: IFN low QoL assessment \n(%) \n \nGroup 1  \nn= 211 (68%)  \n \nGroup 2  \nn= 187 (56%)  \n \nof 674 melanoma \npatients (clinical \nstage not \nindicated)  HRQoL over time \nbetween groups  \n \n(Costs)  OBS group:  \nsignificantly be tter \nmean follow -up \nQoL on 5 of 6 \ndimensions of the \nfunctional scales: \nRF (role \nfunctioning), EF \n(emotional f.), CF \n(cognitive f.), SF \n(social f.) and QL  \nsignificantly better \nmean follow -up due to mis sing \ndata, follow -up \nQoL re sponses for \neach individual \nsubject were \nsummarised by \ntaking the ave rage \nof their follow -up \nQoL re sponses \nover time.  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 579 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndose, 60 months  \nGroup 2: \nObserv ation (OBS)   QoL symptom \nscores on 7 of 9 \ndime nsions: FA, \nNV, DY, AP, CO, DI \nand FI (after \nadjustment for \nbaseline QoL and \noverall survival \nstatus (dead or \ncensored)  \nLoquai et  al. 2011  To evaluate the \nimpact on quality \nof life (QOL) in \npatients treated \nwith once weekly \n2\u200a\u03bcg/kg PEG -IFN-\n\u03b12b and to \nexamine whether \nthere is a \ndifference in \npatients' and \nphysicians' \nperce ption of QOL  Retrospective \nevaluation  \n \nQoL Instrument:  \nEORTC Q LQ-C30 \n \nTime points:  \nBaseline, every 3 \nmonths  \n \nTreatment: 2 \u200a\u03bcg/kg \nPEG-IFN-\u03b12b  30 patients  \n QOL changes  \n \n \n \nPatients \nquestio nnaires \ncompared to \nphysician \nassess ment  impairment in \nmost QOL single \ndime nsions  \n \nQOL documented \nby physicians was \nsignificantly hig her \nthan QOL from the \npatients' \nquestio nnaires in \nall QOL \ndimens ions Small sample size  4 \nRatai et al. 2005 to evaluate the \nimpact of \ninterferon (IFN) \ntreatment on \npatients' quality of \nlife (QoL) after Comparative St udy \n \nQoL Instrument:  \nEORTC QLQ -C30  \n \nTime points:  220 patients  \nGroup 1 n=110  \nGroup 2 n=110  \n \n QoL The IFN -alpha -2b \ntreatment \nsignif icantly \naffected p atients' \nphysical co ndition, \nmental health, and Allocation to \ngroups not \nindicated Baseline \ndata not pr esented  \nTimepoints of \nassessment not 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 580 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nradical surgery of \ncutaneous \nmelanoma  Baseline und \nduring treatment  \n \nTreatment:  \nGroup 1: INF -\nalpha -2b \nGroup 2: \nObserv ation social life. In spite \nof se veral adverse \neffects, the \npatients a ssessed \ntheir QoL as good  indicated  \n \nTrask et al. 2004  To assess the the  \nlongitudinal cou rse \nof depression, \nfatigue, and QoL \nbefore and during \ninterf eron therapy  Observational \nstudy  \n \nQoL Instruments:  \n-BSI \n-FACT -BRM \n-RPFS \n-BDI \n \nTime points:  \nBaseline, 1, 2, 3, 6 \nmonths post \ntreatment  \n \nTreatment: high \ndose interf eron-\nalpha  16 pat ients \n Depression  \nQoL \nFatigue  \n 6-month post high -\ndose assessment: \nsignificantly \nincreased somatic \ncomplaints, \ndepre ssion, and \nfatigue, reductions \nin QoL in the areas \nof Physical Well-\nBeing, Func tional \nWell-Being, and \nAdditional \nSymptoms.  \nQoL did not \nimprove over the \ncourse of therapy  \n Small sample size  \ndata presented in \ndetail  \n 4 \nCohen et al. 2002  To prospectively \nassess QoL in \npatients with \nmalignant QoL Evaluation \nwithin a Phase Ib \nstudy  \n QoL assessment  \nBaseline n=29  \nWeek 3 n=28  \nFollow up n=27  Changes of PCS, \nMCS and IES over \ntime \n QoL remained \nstable during \ntreatment, no \nsignificant time Missing data at all \n3 timepoints. 2 of \n3 missing \nassessments at 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 581 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelan oma \nparticipating in a \nphase Ib \nimmun otherapy \ncancer cli nical trial \nof an autolo gous \ntumour -derived \nvaccine  QoL Instruments:  \n-SF-36 (RAND \nscoring method, 8 \nscales, range 0 \n(worst) to 100 \n(best). Physical \nComponent \nSummary (PCS) and \nMental Component \nSummary (MCS)  \nScores, computed \nby using items \nfrom the 8 \nsubscales  \n-Impact of Event \nScale (IES)  \n \nTime points:  \nbaseline, week 3 \nand follow -up  \n \nTreatment: vaccine   \nof 30 evaluable \npatients with stage \nIII or IV malignant \nmelan oma \n Association \nbetween IES, PCS \nand MCS Scores  \n \n effect for the PCS \nscore, MCS  \nscores or the IES \nscores  \n \nsignificant \nnegat ive \nassociation \nbetween IES sc ores \nat baseline and \nmental health \nscores at eac h time \npoint ( < 0.002 for \nall). \n follow up due to \nprogressive \ndisease.  \n \nMixed model \nregression \nanalyses, analyses \nusing the last \nobservation ca rried \nforward and \nanalyses using a \ncomplete case s \napproach were \nperformed.  \nBender et al. 2000  To describe short - \nand long -term \nchanges in \ncogn itive function \nand quality of life \nin patients with \nmelanoma \nreceiving Pilot Study  \n \nQoL instrument:  \nFACT -G scale  \nTime points: \nbaseline, 3, 6, 9, \n12 and 15 months  \n 18 melanoma \npatients (part of \nECOG EST 1690 \ntrial) \n \nbaseline  \nGroup A: n=6  \nGroup B: n=6  QoL \n(cognitive function)  significant \ndifference on the \nphysical wellbeing \ndime nsion of \nquality of life from \nT1 to T2 in Goup A  \nGroup A and B: \ntrend to Limitations: small \nsample size  \nBaseline \ncharact eristics \n(e.g. gender, age) \nare not pr esented  4 \nPoor \nquality \ncase \ncontrol \nstudy   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 582 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ninterferon (IFN) \nalpha -2b Treatment:  \nGroup A: high dose \nIFN a lpha-2b n=6, \nGroup B: low dose \nIFN a lpha-2b n=6, \nGroup C: control \ngroup n=6  Group C: n=6  \n \n15 months  \nGroup A: n=2  \nGroup B: n=3  \nGroup C: n=2  \n diminished overall \nquality of life  \n \nPalliative Therapiestudien die QoL als Endpunkt enthalten  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nRobinson et al. \n2012  To \ndeterminepatien t-\nreported signs, \nsymptoms, and \nfunctioning, \nHRQoL \nquestionnaire \npsychometrics, \nand treatment \nimpact on HRQoL  QoL Evaluation \nwithin a \nrandomized phase \nII study  \n \nQoL instrument:  \nMelanoma \nSubscale (MS) of \nthe Functional \nAssessment of \nCancer Therapy -\nMelanoma  \nBrief Pain Inventory \n(BPI) \n \nTreatment: DTIC + \nIntetumumab \nversus DTIC + \nPlacebo  QoL Assessment  \n \n127 patients  \n Baseline QoL  \n \n \n \n \nQoL at week 3  \n Baseline HRQoL \nscores differed \naccording to ECOG  \nperformance status  \n \ntrend for HRQoL  \nresponse in the  \ndacarbazine+  10 \nmg/kg \nintetumumab arm \nversus dacarbazine \n+ placebo:  \n \nMS 22 versus 10%,  \nBPI 23 versus 5%  no. of forms \nreceived not \nindicated  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 583 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nHofmann et al. \n2011  To compare best \nsupportive care \n(BSC) alone with \ncisplatin, vindesine \nand dacabazine -\nbased (CVD) \nchemotherapy and \nBSC in terms of \noverall survival, \ndisease control \nrate and quality of \nlife QoL Evaluation \nwithin a cohort \nstudy  \n \nQoL instrument:  \nEORTC QLQ -C30 \n \nTreatment:  \nArm A: BSC (n=34)  \nArm B: BSC+CVD \n(n=83) \n \n QoL Assessment  \n \nno. of forms \nreceived \n(expec ted) \nBaseline  \nn=83 (117)  \nArm A: 58.8%  \nArm B: 75.9%  \n  \n \nBaseline QoL  \n \n \n \n \nQoL at week 8  Arm A versus Arm \nB \n \nno significant \ndifferences  \nin the function and \nsymptom scales  \n \nincrease in \ndyspnoea and \nfatigue Arm B, not \nsignificant  \nreduction in the \nGlobal Health \nstatus in both \narms, not \nsignificant  Initial protocol: \nrandom \nassignment. Due \nto lack of patients \nconsent for \nrandomization the \nprotocol was \nchanged to \ntreatment \nassignment based \non patients choice  2b \nAvril et al. 2004  To compare \nfotemustine and \ndacarbazin e (DTIC) \nin terms of overall \nresponse rate \n(ORR) as primary \nend-point and \noverall survival, \nduration of \nresponses, time to \nprogression, time \nto occurrence of \nbrain metastases QoL Evaluation \nwithin a \nrandomized  phase \nIII study  \n \nQoL instrument:  \nEORTC QLQ -C30 \nTime points: \nbaseline and after \ninduction period  \n \nTreatment: \nFotemustine QoL assessment \nN=156  \nFotemustine group \nn=83 (of 112)  \nDTIC group n=73  \n(of 117)  \n \nof 229 Stage IV \nmelanoma patients  \n Quality  of life  \n \n(overall response \nrate, overall \nsurvival, duration \nof responses, time \nto progression, \ntime to occurrence \nof brain \nmetastases)  \n QoL: \nno statistically \nsignificant \ndifference between \ngroups.  \ngeneral tendency: \ndegradation for all \n(presented) \nfunctio nal and \nsymptom scales \nover time in both \ngroups.  \n QoL analysis only \navailable for \ninduction phase \ndue to high \nnumber of missing \nquestionnaires  \nData are presented \nfor 7 sca les only. \nMissing scales: \nEmotional \nfunctioning, \nCognitive \nfunctioning, 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 584 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(BM), and to assess \nsafety and quality \nof life  versus DTIC  \n disease \nprogression and \nperformance status \nwere the main \nfactors for QoL \nimpairment.  Dyspnoea, \nInsomnia, Appetite \nloss, Constipation , \nDiarrhoea, \nFinancial \ndifficulties  \nChiarion -Sileni et \nal. 2003  To analyse the \nhealth related \nquality of life \n(HRQOL) of \nadvanced \nmelanoma \npatients, in a \nrandomised trial \ncomparing bio -\nchemotherapy (bio -\nCT) versus \nchemotherapy (CT)  QoL Evaluation \nwithin a \nrandomized phase \nIII study  \n \nQoL Instrument:  \nRotterdam \nSymptom Checklist \n(RSCL)  \nTime points:  \nBaseline, Cycle 1, \n2, 3, 4, 5 and 6  \n \nTreatment:  \nCT: cisplatin and  \nDTIC alone  \nBio-CT: cisplatin, \nDTIC, IL -2 and IFN \na-2b Available QoL \nscores  \n \nBaseline n=140 (of \n178) \nCycle 6 n=16 (of \n57)  \n HRQOL difference  \nHRQOL at baseline \nas prognostic \nfactor  \n between treatment \narms over time:  \nstatistically \nsignificant \ndifference in the \noverall quality of \nlife score (P=0.03) , \ndecrease of 6.28 \npoints in the bio -\nCT arm  \nno significant \ndifference between \ntreamtents:  \nactivity level \n(P=0.20) \nphysical symptom \ndistress (P=0.08) \npsychological \ndistress (P=0.25) \n(values always \nslightly inferior in \nthe bio -CT arm)  \n \ndeterioration over  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 585 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntime:  \nbio-CT arm: \nsignificantly in all \ndomains (most \nimportant \nreduction in the \nactivity level)  \nCT arm: significant \nonly for the activity \nlevel and the \nphysical symptom \ndistress (P<0.001).  \n \nPrognostic Factors: \noverall quality of \nlife score, the \nphysical symptom  \ndistress score, and \nthe serum LDH \nlevel were \nconfirmed  \nas independent \nprognostic factors \nin in mulitvariate \nanalysis. \nKiebert et al. 2003  To report detailed \nHRQL results of a \nphase III clinical \ntrial comparing \ntemozolomide QoL Evaluation \nwithin a Phase III \nstudy  \n \nQoL Instrument:  Available HRQL \nscores  \nBaseline TMZ \nn=110  \nBaseline DTIC HRQL differences  \n-Between groups  \n-Over time  between groups:  \nbaseline: no \nsignificant  \ndifferences  \n12 weeks: TMZ At week 24 not \nenough data for \ninterpretations.  \nMore missing data \nin the DTIC group.  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 586 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(TMZ) to \ndacarbazine (DTIC) \nin patients with \nmetastatic \nmelanoma  EORTC QLQ -C-30 \n \nTime points:  \nbaseline, week 12, \n24 \nTreatment:  \nGroup 1 DTIC  \nGroup 2 \nTemozolo mide  n=110  \nWeek 12 TMZ n=50  \nWeek 12 DTIC \nn=31  \nWeek 24 TMZ n=22  \nWeek 24 DTIC n=8  \n(of 305 advanced \nmelanoma \npatients)  \n group significantly \nbetter physical \nfunctioning, less \nfatigue and sleep \ndisturbances, \ncognitive \nfunctioning \nequivalent, worse \non nausea and \nvomiting.  \n24 weeks: all \nsubscales \n(exception \ndiarrhea) better for \nTMZ patients  \n \nOver tim e: \nTMZ patients: \nclinically \nmeaningful \nimprovements in \nemotional \nfunctioning, \ncognitive \nfunctioning, and \nsleep disturbances \nat week 12. DTIC \npatients: poorer \nphysical \nfunctioning, \nimproved Limited external \nvalidity:  \nPrivilege of \nreceiving the new, \nmaybe \u201cbette r\u201d \ndrug in the TMZ \ngroup may \ninfluence the \nfunctioning scales \nmore than the \ndrug itself.  \np-values are only \nindicated for \nbaseline \ncharacteristics.  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 587 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nemotional well -\nbeing, and less \nnausea and \nvomiting, pain, \nappetite loss, and \ndiarrhea at week \n12. (not \nstatistically \nsignificant or \nconsidered \nclinically \nmeaningful)  \nYoung et al. 2001  To report the \nresults of DTIC \n+IFN-alpha in \npatients with \nmetastatic \nmelanom  QoL evalu ation \nwithin a phase III \nstudy  \n \nQoL instrument:  \nEORTC QLQ C30 \n(+3)  \nTime points: \nbaseline, at each \nvisit \n \nTreatment:  \nGroup 1 DTIC  \nGroup 2 DTIC + \nIFN-alpha  41 (of 57) \nadvanced \nmelanoma patients \ncompleted at least \n1 questionnaire  \n \nBaseline n=38  \nTimepoint of \ntumor assessment \nn=27  \n \n QoL \n-between groups  \n-over time  -no significant \ndifferences \nbetween the \ngroups, both at \nbaseline (z =70.82, \nP=0.41) and for the \nchange in scores \nover time (z = \n71.29, P=0.20)  \n-for both groups \nthe level of \nsymptoms \nworsened over \ntime,  but patients\u2019 \nfunctioning ability \nappeared to be \nstable  Limitations: \nmissing data  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 588 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nMiddleton et al. \n2000  To compare \ntemozolomide and \ndacarbazine (DTIC) \nin terms of overall \nsurvival, \nprogression -free \nsurvival (PFS), \nobjective response, \nand safety, and  to \nassess health -\nrelated quality of \nlife (QoL) and \npharmacokinetics \nof both drugs.  Randomized phase \nIII study  \n \nQoL Instrument:  \nEORTC QLQ -C30 \n \nTimepoints: \nbaseline, week 12  \n \nTreatment:  \nGroup 1 \nTemozolomide \n(TMZ)  \nGroup  2 DTIC  \n QoL Scores \navailable  \n \nBasel ine n=251  \nWeek 12  \nTMZ group n=51  \nDTIC group n=31  \n \nof 305 patients \nwith advanced \nmetastatic \nmelanoma  QoL (secondary \nobjective)  \n-Differences of \nScores at week 12 \nbetween groups  \n-Differences of \nmaintenance or \nimprovement of \nscores compared \nto baseline \nbetween  groups  \n \n(primary objective: \noverall survival, \nfurther secondary \nobjectives: PFS, \nResponse Rates, \nSafety)  TMZ group: \nsignificant better \nscores for physical \nfunctioning, \nfatigue, insomnia. \nSimilar results for \nresponder \nsubgroup analysis \nbetween groups.  \nTMZ group: \nsignificant more \npatients with \nmaintenance or \nimprovement of \nphysical and \ncognitive \nfunctioning  \n QoL data are not \nshown in detail  \nSample size seems \nto be too small for \nresponder \nsubgroup analysis \n(exact numbers \nnot indicated, DTIC \ngroup: QoL Scores \navailable n=31 of \n149, responders \nn=18 of 149)  1b \nSigurdardottier et \nal. 1996  to describe QoL of \npatients with \nadvanced \nmelanoma during \nchemotherapy and \nto compare the \nclinical outcome \nvariables and \npatients' self -\nassessed QoL  Longitudinal QoL \nstudy  \n \nQoL Instruments:  \n- EORTC QLQ -C36 \n- study -specific \nmelanoma module  \n- Hospital Anxiety \nand Depression \n(HAD) scale  \n \nTreatment: DTIC 95 patients with \nadvanced \nmelanoma  \n \n(73 patients of a \nrandomized \nclinical trial, 22 \nnon-randomized \npatients with \nchemotherapy)  QoL \n-score differences \nbetween baseline \nand week 9  \n - significant \ndeterioration in all \nQoL \nmeasurements, \nwith the exception \nof pain and \nemotional \nfunctioning at \nweek 9  No randomized \ndesign  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 589 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nplus vindesine with \nor without cisplatin  \nThomson et al. \n1993  To de scribe the \nprognostic \nassociations of QL \nscores obtained \nduring a \nmulticentre \nrandomised clinical \ntrial comparing \nDTIC plus \nrecombinant \ninterferon -alfa 2a \nversus DTIC alone \nfor patients with \nmetastatic \nmalignant \nmelanoma.  QoL assessment \nwithin a Phase III \nstudy  \n \nQoL instrument:  \nlinear analog self \nassessment (LASA) \nscales, GLQ -8 \nby physician: QL  \nIndex \nquestionnaire  \nTime points:  \nBaseline, week 12  \n \nTreatment:  \nGroup 1: DTIC  \nGroup 2 DTIC + \nIFN-alpha -2a 176 advanced \nmelanoma patients  \n \nNumber of QoL \ndata not indi cated  QoL \n(Response rate, \nResponse duration, \nTime to disease \nprogression, \nToxicity, Overall \nSurvival)  Quality of life was \nnot significantly \ndifferent in either \ngroup, except that \nfatigue, as \nmeasured at week \n12 by LASA scales, \nand activity, as \nmeasured by the \nfunctional living \nindex, were both \nimproved in the \ncombination  QoL data not \npresented in detail. \nNot clear, if score \nchanges between \nbaseline and week \n12 or if absolute \nscores at week 12 \nare compared \nbetween the \ngroups.  \nNumber of \nreceived \nquestionnaire s not \nmentioned.  2b poor \nquality  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 590 von 817 \n6.6.4.2.  Aktualisierungsrecherche 2015  \nPalliative Therapiestudien die QoL als Endpunkt enthalten  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nGrob et al. 2014  To compare the \nchange in QoL \nrelative to baseline \nin BRAF V600E \nmutation -positive \nadvanced and \nmetastatic \nmelanoma patients \nusing the EORTC -\nQLQ-C30 QoL evaluation \nwithin a phase III \ntrial \n \nQoL instrument:  \nEORTC QLQ -C30 \n \nTime points: \nbaseline, at week \n6, week 12, and \nweek 15 during \ntreatment, upon \nprogression , and 4 \nweeks after \nprogression was \nfirst determined. \n(before any study \ndrug was \nadministered)  \n \nTreatment:  \nGroup 1: \nDabrafenib \n150mg/bid po  \nGroup 2: DTIC \n1000mg/m2 iv q21  Dabrafenib, n=187  \nDTIC, n=63  \n \nAll required \nassessments  \n57 vs. 7 pts  \nNo baseline \nassessment  \n16 vs. 6 pts.  \n \nNo postbaseline \nassessments \n8 vs. 10 pts.  \n \nOne or two \nmissing \npostbaseline \nassessments \n96 vs. 33 pts  \n \nThree or more \nmissing \npostbaseline \nassessments \n10 vs. 7 pts  HRQOL at week 6  For DTIC, all \nfunctional \ndimensions except \nrole dimens ion \nworsened from \nbaseline at follow -\nup.  \nFor dabrafenib, all \nfunctionality \ndimensions \nremained stable \nrelative to baseline \nor improved at \nweek 6; In the \nDTIC arm, \nsymptom \ndimensions were \nunchanged or \nworsened from \nbaseline for all \nsymptoms except \npain (we ek 6), with \nthe greatest \nexacerbations \nobserved for \nfatigue and nausea \nand vomiting. \nMixed -model -BREAK -3 was not \npowered to find a \npre-specified \ndifference between \nthe two treatment \narms for any \nsymptom or \nfunctional \ndimension of QoL. \nQoL data  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 591 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nrepeated measures \nanalyses showed \nsignificant (P < \n0.05) and/or \nclinically \nmeaningful \nimprovements \nfrom baseline in \nfavour of \ndabrafenib for \nemotional and \nsocial functioning, \nnausea and \nvomiting, appetite \nloss, diarrhoea, \nfatigue, dyspnoea, \nand insomnia at \nweeks 6 and/or \n12. After crossing \nover to dabrafenib \nupon progression  \nHatswell et al. \n2014  To report and \ncompare pre - and \npost-progression \nhealth state \nutilities in \nadvanced \nmelanoma, when \ngenerated using \ndifferent methods -  QoL data extracted \nfrom the clinical \ndatabase of the \nphase III trial \nMDX010 -20 \n \nPatients were \nasked to complete \nboth the EORTC EORTC QLQ -C30  \nwas completed by \n616 patients \n(1,237 \nobservations)  \n \nSF-36 was \ncompleted by 599 \npatients (1,205 Analyses by \nprogression status \nand time to death \non the patient -level \ndata using \ngeneralised \nestimating \nequations fitted, \nand to analyse the Mean utility \nshowed a decrease \non disease \nprogression in \nboth the EORTC -8D \nand the SF -6D. \nWhilst higher \nutilities were \nobtained using the Not comparing \nQoL between \ntreatment groups \nbut between \nquestionnaires and \nmethods.  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 592 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nvia the EORTC \nQLQ-C30 and the \nSF-36 \n  \nTo explore the \nvalidity, in \nadvanced \nmelanoma, of \nprogression -based \nhealth -state utility \nmodelling \ncompared to \nmodelling based \nupon time to death \nhealth states.  QLQ-C30 and SF -\n36v2 \nquestionnaires on \nreceipt of the first \ndose of treatment, \nat the end of \ntreatment and 12 \nweeks after \ntreatment.  \n \nTreatment:  \n676 patients \nrandomized 3:1:1 \nto ipilimumab + \ngp100, ipilimumab \nonly, or gp100 \nonly.  observations).  predictive abilities \nof the two \napproaches.  EORTC -8D, the \nrelative decrease in \nutility on \nprogression was \nsimilar between \nmeasures. When \nanalysed by time \nto death, both \nEORTC -8D and SF -\n6D showed a large \ndecrease in utility \nin the 180 days \nprior to death. \nCompared to \nprogression status \nalone, the use of \ntime to death gave \nsimilar or better \nestimates of the \noriginal data when \nused to predict \npatient utility. \nIncluding both \nprogression status \nand time to death \nfurther improved \nmodel fit. Utilities \nseen in MDX010 -\n20 were also \nbroadly \ncomparable with  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 593 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nthose seen in the \nliterature.  \n \nRevicki et al. 2014  To analyse the \nHRQL outcomes \nduring the 12 \nweek treatment \ninduction period in \ncomparison to \nbaseline data of \nthe ipilimumab \nPhase III clinical \ntrial (MDX010 -20). QoL data from the \nphase III trial \nMDX010 -20 \n \nTreatment:  \n676 patients \nrandomized 3:1:1 \nto ipilimumab + \ngp100, ipilimumab \nonly, or gp100 \nonly. EORTC QLQ -C30 \ndata was available \nin 95% of the \npatients; Week 12 \nassessments were \navailable for 236 \n(62%), 85 (65%), \nand 80 (61%) of \nthe patients \ntreated with \nipilimumab plus \ngp100, ipilimumab \nalone, and gp100 \nalone, respectively.  QoL changes at \nweek 12 compared \nto baseline. In the ipilimumab \nplus gp100 and \nipilimumab alone \ngroups, mean \nchanges from \nbaseline to Week \n12 generally \nindicat ed \u201cno \nchange\u201d or \u201ca little\u201d \nimpairment across \nEORTC QLQ -C30 \nglobal health \nstatus, function, \nand symptom \nsubscales. \nSignificant \ndifferences in \nconstipation, \nfavouring \nipilimumab, were \nobserved (p<0.05). \nFor ipilimumab \nalone arm, \nsubscales with no \nor a litt le \nimpairment were \nphysical,  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 594 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nemotional, \ncognitive, social \nfunction, global \nhealth, nausea, \npain, dyspnoea, \nconstipation, and \ndiarrhoea \nsubscales. For the \ngp100 alone \ngroup, the \nobserved changes \nwere moderate to \nlarge for global \nhealth, role \nfunction, fatig ue, \nand for pain.  \nSchadendorf et al. \n2014  To evaluate the \nimpact of the \nMEKi, trametinib, \non patients\u2019 QOL \nversus \nchemotherapy.  \n QoL evaluation \nwithin a phase III \ntrial \n \nQoL instrument:  \nEORTC QLQ -C30 \n \nTreatment:  \nPatients \nrandomized 2:1 to \ntrametinib 2mg/d \npo or DTIC \n1000mg/m2 iv q21  EORTC QLQ -C30 \ndata was available \nin n=178 of the \npatients receiving \ntrametinib and \nn=95 of the \npatients receiving \nchemotherapy  QoL changes at \nweek 6 and 12 \ncompared to \nbaseline. In the primary \nefficacy population \nfrom base line to \nweeks 6 and 12, \npatients\u2019 global \nhealth status \nscores worsened \nby 4\u20135 points with \nchemotherapy but \nimproved by 2 \u20133 \npoints with \ntrametinib. Rapid \nand substantive \nreductions in QOL  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 595 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfunctionality (e.g. \nrole functioning, \n8\u201311 points at \nweeks 6 and 12) \nand symptom \nexacer -bation (e.g. \nfatigue, 4 \u20138 \npoints; nausea and \nvomiting, 5 points, \nboth at weeks 6 \nand 12) were \nobserved in \nchemotherapy -\ntreated patients.  \nIn contrast, \ntrametinib -treated \npatients reported \nsmall \nimprovements or \nslight worsening \nfrom basel ine at \nweek 12, \ndepending on the \nfunctional \ndimension and \nsymptom.  \nSchadendorf et al. \n2015  To compare the \neffect of \ndabrafenib plus \ntrametinib versus QoL evaluation \nwithin a phase III \ntrial \n EORTC QLQ -C30 \ndata was available \nin n=204 of the \npatients receiving QoL changes at \nweek 8, 16, 24, \n32, 40 and at time \npoint of Baseline scores \nacross both arms \nwere comparable \nfor all dimensions.  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 596 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndabrafenib alone \non HRQoL and \nsymptoms \n(improvement or \ndelay in \nworsening) in \npatients with BRAF \nV600E or V600K \nmutation -positive \nmetastatic \nmelanoma enrolled \nin the COMBI -d \ntrial. QoL instrument:  \nEORTC QLQ -C30 \n \nTreatment:  \nPatients \nrandomized 1:1 to \nreceive either a \ncombination of \noral dabrafenib \n(150 mg twice \ndaily) and oral \ntrametinib (2 mg \nonce daily) or a \ncombination of \noral dabrafenib \n(150 mg twice \ndaily) and placebo.  dabrafenib and \ntrametinib and \nn=202 of the \npatients \nDabrafenib and \nplacebo  at baseline \n>85% at week 40 \nand >70% at \ndisease \nprogression. \nMeasurement was \nperformed every 8 \nweeks.  progressive \ndisease compared \nto baseline. Global health \ndimension scores \nwere significantly \nbetter at weeks 8, \n16 and 24 for \npatients receiving \nthe combination \nduring treatment \nand at \nprogression. The \nmajority of \nfunctional \ndimension scores \n(physical, social, \nrole, emotional \nand c ognitive \nfunctioning) \ntrended in favour \nof the \ncombination. Pain \nscores were \nsignificantly \nimproved and \nclinically \nmeaningful (6 \u201313 \npoint difference) \nfor patients \nreceiving the \ncombination for all \nfollow -up \nassessments  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 597 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nversus those \nreceiving \ndabrafenib \nmonotherapy. For \nother symptom \ndimensions \n(nausea and \nvomiting, \ndiarrhoea, \ndyspnoea, and \nconstipation), \nscores trended in \nfavour of \ndabrafenib \nmonotherapy.  \n \n \nAusgeschlossene Studien  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAdamina et a l. \n2008  To assess the \nsafety and \nimmunogenicity of \nheterologous \nprime- boost \nimmunotherapy of \nmelanoma patients \nwith Influenza multi -centre  phase \nI/II open lab eled \nstudy  \n \nLQ instrument:  \nFACT -BRM 4 \nquestionna ire 20 resected AJCC \nstages IIb- IV \nmelanoma patients   QoL data are not \npresented  \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 598 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nvirosomes, and \nrecombinant \nVaccinia virus.  \nQuality of life will \nbe assessed with a \ndedicated FACT -\nBRM 4 \nquestio nnaire  \nBeguerie et al. \n2010  Tamoxifen vs. non -\ntamoxifen \ntreatment for \nadvanced \nmelanoma: a meta -\nanalys is metaanalysis  9 randomized \ncontrolled trials Secondary \noutcome quality of \nlife \n \n(Response, \nmortal ity,  toxicity, \ntreatment -related \nmortality)  None of the trials \nreported QoL  excluded   \nNoorda et al. 2007  To assess the long -\nterm health -\nrelated quality of \nlife (HRQL) of \nmelan oma \nsurvivors who had \nundergone isolated \nlimb perf usion (ILP) \nof the extrem ities, \nand to identify the \npatient- , tumour - \nand ILP -related \nfactors a ssociated Comparative St udy \n \nQoL Instr ument:  \nmailed \nquestio nnaire SF -\n36  \nTime point: after \nILP, at least 6 \nmonths disease \nfree \n \nComparison: \nnorm ative sample QoL assessment \nn=51 (89%) of  \n \n51 patients after \nisolated limb \nperfusion \nmedian follow up  \nafter ILP 14 years \n(range 3 -25 years)  SF-36 scores  SF-36 scores of the \npatient group were \nequal to or better \nthan that of the \ngeneral \npopulation, \nsignifican tly for \nbodily pain, \ngeneral health \nperceptions, and \nthe physical and \nmental health \ncomponent score s Assessment after \ntherapy, no \nbaseline data  \nStudy excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 599 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmost strongly with \nthe patients\u2019 self -\nreported HRQL.  of the Dutch \ngeneral pop ulation \nof SF-36 scores  \nPetrella et al. 2007  To determine the \nrole of single -agent \ninterleukin -2 in the \ntreatment of \nadults with \nmetastatic \nmelanoma. \nOutcomes: \nobjective and \ncomplete response \nrates, dur ation of \nrespons e, toxi city \nand quality of life systematic review  1 systematic \nreview, 5 RCTs, 12 \nPhase II trials, 1 \nQoL report    excluded  \n(only 1 QoL report)   \nQuirt et al. 2007  To examine the \nrole of \ntemozol omide in \npatients with \nmetastatic \nmelanoma  \nOutcomes: \nresponse rate, \nprogression -free \nsurvival, overall \nsurvi val, quality of \nlife, and adverse \neffects  systematic review  \n \n \n Two randomized \nphase III trials and \nthree randomized \nphase II trials  \n \n  only 2 studies with \nQoL data  excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 600 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSchallreuter et al. \n1991  A quite pr omising \nclinical trial was \nconducted using \nthe new \nnitroso urea \nfotemustine phase II study  19 patients   quality of life of \nthe patients during \nand after \nchemotherapy was \nnot severely \naffected  no QoL assessment \nstudy excluded   \nVerma et al. 2006  To examine t he \nrole of systemic \nadjuvant therapy \nin patients with \nhigh- risk, resected, \nprimary melan oma \nOutcomes: over all \nsurvival, dise ase-\nfree survival, \nadverse effects, \nand qu ality of life systematic review  37 randomized \ncontrolled trials, 2 \nmeta-analyses, \nand 1 sy stematic \nreview were \nidentified that \ninvestigated \ninterf eron, \nlevamisole, \nvaccine, or \nchem otherapy as \nadjuvant ther apy   only Q -TWiST data, \nno QoL data \npresented  \nstudy exluded   \nSigurda rdottier et \nal. 1993  To assiss the QoL \nof patients with \nmelanoma before  \nthe start of \ntreatment quality of life (QoL) \nstudy  \n \nQoL instruments: \n- EORTC QLQ -C36 \n- study -specific \nmelanoma (MM) \nmodule \n-Hospital Anxiety \nand Depres sion \n(HAD) scale  89 patients  Before treatment \nthe patients \nreported a \nrelatively low \nsymptom bu rden, \ngood physical and \nsocial functio ning, \nmoderate \npsychol ogical \ndistress and a high \noverall QoL r ating No assessment \nunder therapy  \nstudy excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 601 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nduring the past \nweek  \nCoates 1993  To measure \naspects of qu ality \nof life (QL) \nprospe ctively by \npatients using \nlinear analogue \nself assessment \n(LASA) sc ales \nincluding the GLQ -\n8 and by do ctors \nusing Spitzer's QL \nIndex within a \nclinical trial \ncompa ring \ndacarbazine (DTIC) \nplus recombinant \ninterf eron-alfa2a \n(IFN) versus DTIC \nalone  QoL evaluation \nwithin a phase III \nstudy  \n \nQoL instruments: \npatients: 5 linear \nanalog self \nasses sment (LASA) \nscales, GLQ -8 \nphysician: Spitzer's \nQL Index  \n \nTreatment:  \nDTIC plus \ninterf eron-alfa2a \nversus DTIC alone  Baseline QoL data \navailable of 152 \npatients  \n Prognostic value of \nQuality of Life \nScores a t Baseline  \n In univariate \nanalyses, Spitzer \nQL Index assessed \nby the doctor and \nLASA scores for \nphysical wellbeing \n(PWB), mood, pain, \nappetite, nausea \nand vo miting, GLQ -\n8 total and overall \nQL were significant \n(P < 0.01) \npredictors of \nsubsequent \nsurvival Only baseline QoL \ndata  \n \nStudy excluded   \nKilbridge et al. \n2002  To analyse quality -\nof-life-adjusted \nsurvival of the \nhigh- dose adjuvant \ninterferon alpha -\n2b regimen  A quality -of-life--\nadjusted survival \n(QAS) analysis \nanalysis of two \ncooper ative group \nphase III  trials, \nE1684 and E1690, \nwas pe rformed    E1684: increase in \nQAS for all sets of \npatient utilities, \nsignificant for 16%  \nE1690: increase in \nQAS 77%, decrease \n23%, not \nsignificant  Utility weights \nwere obtained in a \nseparate study of \n95 low -risk \nmelanoma pati ents \nand were \ncombined with \nsurvival and   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 602 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntoxicity data of \nE1684 and E1690  \n \nQoL data of the \ntrials are not \npresented  \n \nStudy excluded  \n6.6.5.  Literatur  \n \nAvril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated maligna nt melanoma: a phase III study. J Clin Oncol 2004;22:1118- 1125  \nBeguerie JR, Xingzhong J, Valdez RP. Tamoxifen vs. non- tamoxifen treatment for advanced melanoma: a meta- analysis. Int J Dermatol 2010;49:1194- 1202  \nBender CM, Yasko JM, Kirkwood JM, et al. Cogn itive function and quality of life in interferon therapy for melanoma. Clin Nurs Res 2000;9:352- 363 \nBottomley A, Coens C, Suciu S, et al. Adjuvant therapy with pegylated interferon alfa -2b versus observation in resected stage III melanoma: a phase III rand omized controlled trial of \nhealth -related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin  Oncol 2009;27:2916- 2923  \nBrandberg Y, Aamdal S, Bastholt L, et al. Health -related quality of life  in patients with high -risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate -dose \ninterferon alfa -2b. Eur J Cancer 2011  \nCashin RP, Lui P, Machado M, et al. Advanced cutaneous malignant melanoma: a systematic review of economic and  quality -of-life studies. Value Health 2008;11:259- 271 \nChiarion -Sileni V, Del Bianco P, De Salvo GL, et al. Quality of life evaluation in a randomised trial of chemotherapy versus bio -chemotherapy in advanced melanoma patients. Eur J Cancer \n2003;39:1577- 1585 \nCoates A, Thomson D, McLeod GR, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. \nEur J Cancer 1993;29A:1731- 1734  \nCohen L, Parker PA, Sterner J, et al.  Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumour -derived vaccine. Melanoma Res \n2002;12:505- 511 \nCornish D, Holterhues C, van de Poll -Franse LV, et al. A systematic review of health -related quality  of life in cutaneous melanoma. Ann Oncol 2009;20 Suppl 6:vi51- 8 \nDixon S, Walters SJ, Turner L, et al. Quality of life and cost -effectiveness of interferon -alpha in malignant melanoma: results from randomised trial. Br J Cancer 2006;94:492- 498 \nGarbe C, Rad ny P, Linse R, et al. Adjuvant low -dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective -randomized phase III DeCOG trial in \nmelanoma patients with regional lymph node metastasis. Ann Oncol 2008;19:1195- 1201  \nGrob JJ, Amonkar MM, Martin- Algarra S, et al. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality -of-life analyses of the BREAK -3 study comparing \ndabrafenib with dacarbazine. Ann Oncol. 2014;25(7):1428- 1436.  \nHatswell AJ, Pennin gton B, Pericleous L, Rowen D, Lebmeier M, Lee D. Patient -reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. \nHealth Qual Life Outcomes. 2014;12:140.  \nHofmann MA, Hauschild A, Mohr P, et al. Prospective e valuation of supportive care with or without CVD chemotherapy as a second -line treatment in advanced melanoma by patient's \nchoice: a multicentre Dermatologic Cooperative Oncology Group trial. Melanoma Res 2011;21:516 -523 \nKiebert GM, Jonas DL, Middleton MR.  Health -related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temo zolomide with \ndacarbazine. Cancer Invest 2003;21:821- 829 \nKilbridge KL, Cole BF, Kirkwood JM, et al. Quality -of-life-adjuste d survival analysis of high -dose adjuvant interferon alpha- 2b for high -risk melanoma patients using intergroup clinical \ntrial data. J Clin Oncol 2002;20:1311- 1318  \nLoquai C, Schmidtmann I, Beutel M, et al. Quality of life in melanoma patients during adjuvant treatment with pegylated interferon -alpha2b: patients' and doctors' views. Eur J Dermatol \n2011  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 603 von 817 \nMiddleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic m alignant melanoma. J \nClin Oncol 2000;18:158- 166 \nNoorda EM, van Kreij RH, Vrouenraets BC, et al. The health -related quality of life of long -term survivors of melanoma treated with isolated limb perfusion. Eur J Surg Oncol 2007;33:776-\n782 \nPetrella T, Quirt I , Verma S, et al. Single -agent interleukin -2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007;33:484 -496 \nQuirt I, Verma S, Petrella T, et al. Temozolomide for the treatment of metastatic melanoma: a systematic review. Onc ologist 2007;12:1114- 1123 \nRataj D, Jankowiak B, Krajewska- Kulak E, et al. Quality -of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients. Cancer Nurs 2005;28:172- 178 \nRevicki DA, van den Eertwegh AJ, Lorigan P, et a l. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual \nLife Outcomes. 2012;10:66.  \nRobinson DW,Jr, Cormier JN, Zhao N, et al. Health -related quality of life among patients wi th metastatic melanoma: results from an international phase 2 multicenter study. Melanoma \nRes 2012;22:54- 62 \nSchadendorf D, Amonkar MM, Milhem M, et al. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic mel anoma: quality -of-life \nanalyses of the METRIC study. Ann Oncol. 2014;25(3):700- 706. \nSchadendorf D, Amonkar MM, Stroyakovskiy D, et al. Health -related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus \ndabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015;51(7):833- 840.Adamina M, Weber WP, Rosenthal R, et al. Heterologous prime -boost \nimmunotherapy of melanoma patients with Influenza virosomes, and recombinant Vacci nia virus encoding 5 melanoma epitopes and 3 co -stimulatory molecules. A multi- centre phase \nI/II open labeled clinical trial. Contemp Clin Trials 2008;29:165- 181 \nSchallreuter KU, Wenzel E, Brassow FW, et al. Positive phase II study in the treatment of adva nced malignant melanoma with fotemustine. Cancer Chemother Pharmacol 1991;29:85 -87 \nSigurdardottir V, Bolund C, Brandberg Y, et al. The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Qual Life Res  \n1993;2:193- 203 \nSigurdardottir V, Bolund C, Sullivan M. Quality of life evaluation by the EORTC questionnaire technique in patients with gene ralized malignant melanoma on chemotherapy. Acta Oncol \n1996;35:149- 158 \nThomson DB, Adena M, McLeod GR, et al. Inter feron -alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a \nmulti -institutional Australian randomized trial. Melanoma Res 1993;3:133- 138 \nTrask PC, Paterson AG, Esper P, et al. Longitudi nal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psy chooncology \n2004;13:526- 536 \nVerma S, Quirt I, McCready D, et al. Systematic review of systemic adjuvant therapy for patients at hig h risk for recurrent melanoma. Cancer 2006;106:1431- 1442  \nYoung AM, Marsden J, Goodman A, et al. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon -alpha (IFN -alpha) in metastatic melanoma. Clin Oncol (R \nColl Radiol) 2001;13 :458- 465 \nZiefle S, Egberts F, Heinze S, et al. Health -related quality of life before and during adjuvant interferon -alpha treatment for patients with malignant melanoma (DeCOG -trial). J Immunother \n2011;34:403- 408 \n \n6.6.6.  \u00dcbersicht Frageb\u00f6gen  zur Erhebung der Lebensqualit\u00e4t \n \nEORTC QLQ- C30 ( Version 3.0 is currently the standard version of the QLQ -C30) \nThe QLQ -C30 is a questionnaire for patient self -completion, composed of multi -item and single scales. These include five functional scales \n(physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting and pain) and a global health status/QOL \nscale and six single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficu lties).  \n(http://groups.eortc.be/q ol/index.htm)  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 604 von 817 \nEORTC QLQ- C36  \nfirst generation core questionnaire. The 36 -item questionnaire was designed 1987 to be (1) cancer specific, (2) multidimensional in structure, \n(3) appropr iate for self -administration (i.e. brief and easy to complete), and (4) applicable across a range of cultural settings. \n(http://groups.eortc.be/qol/index.htm)  \n \nHADE  Scale  \nDimensionen: Angst, Depressivit\u00e4t; je 7 Items.  \n \nSF-36 (Short Form (36) Health Survey)  \nEntwickelt in den USA, Kurzform eines urspr\u00fcnglich aus 149 Items best ehenden Fragebogens, der in den 60er und 70er -Jahren entwickelt \nwurde.  \nDeutsche \u00dcbersetzung durch M. Bullinger, I. Kirchberger , Hogrefe Verlag, G\u00f6ttingen  \nKrankheits\u00fcbergreifendes Me\u00dfinstrument zur Erfassung der gesundheitsbezogenen Lebensqualit\u00e4t von Patie nten.  \n2 Bereiche: k\u00f6rperliche Gesundheit und psychische Gesundheit  \n8 Dimensionen: K\u00f6rperliche Funktionsf\u00e4higkeit, K\u00f6rperliche Rollenfunktion, K\u00f6rperliche Schmerzen, Allgemeine Gesundheitswahrn ehmung, \nVitalit\u00e4t, Soziale Funktionsf\u00e4higkeit, Emotionale Rolle nfunktion und Psychisches Wohlb efinden.  \n QWB-SA \nThe Quality of Well- Being Scale (QWB) has been used in numerous clinical trials and studies over the years to evaluate medical and surgical \ntherapies in conditions such as chronic obstructive pulmonary disea se, HIV, cystic fibrosis, diabetes mellitus, atrial fibrillation, lung \ntransplantation, arthritis, end stage renal disease, cancer, depression, and several other conditions. Further, the instrumen t has been used for \nhealth resource allocation modeling and served as the basis for an innovative experiment in the allocation of health care by the State of  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 605 von 817 \nOregon. Studies have also demonstrated that the QWB is respo nsive to clinical change derived from surgery or medical conditions such as \nrheumatoid arthritis, AIDS, and cystic fibrosis. \nThe self -administered form of the QWB (QWB -SA) was developed more recently. It has been shown to be highly correlated with the interviewer -\nadministered QWB and to retain its psychometric properties. The QWB -SA combines preference -weighted values for symptoms and functioning. \nSymptoms are assessed by questions that ask about the presence or absence of different symptoms or conditions. Functioning is  assessed by a \nseries of questions d esigned to record functional limitations over th e previous three days, within three separate domains (mobility, physical \nactivity, and social activity). The four domain scores are combined into a total score that provides a numerical point -in-time expression of well-\nbeing that ranges from zero (0) for d eath to one (1.0) for asymptomatic optimum functioning.  \nhttp://www.healthmeasurement.org/Measures.html  \n \nGLQ-8 \nTo measure quality of life in cancer patients receiving chemotherapy  \nNumber of items: 8 plus one optional write -in \nAdministration mode:  Self-admi nistered  \nAuthor: Coates Alan S  \nhttp://www.proqolid.org/instruments/glq_8_glq_8  \n LASA scale  \n5 linear analog self assessment (LASA) scales , measuring physical wellbeing, mood,  pain, nausea and vomiting and appetite  \nIES (Impact of Event Scale)  \na 15-item, sel f-report scale that assesses two  categories of cognitive responses to stressful events:  intrusion (intrusively experienced ideas, \nimages,  feelings or bad dreams) and avoidance (consciously  recognized avoidance of certain ideas, feelings or situations). The  scale was \noriginally developed to  assess cu rrent distress associated with a specific  trauma. Patients in the present study were asked to  rate the frequency  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 606 von 817 \nof intrusive thoughts and avoidance  behaviours in relation to their current health  status using a 4 -point scale (0, \u2018not at all\u2019; 1, \u2018rarely\u2019;  2, \n\u2018sometimes\u2019; 3, \u2018often\u2019), with higher scores representing  \nworse functioning. The IES total score  is the sum of the two subscale scores . \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 607 von 817 \n6.7. Frage V.9. Medikament\u00f6se Therapie Hirnmetastasen \u2013 De novo Recherche  \n6.7.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients with brain \nmetastases Systemic treatment  Observation, other systemic \ntreatments  Survival, progression free survival, \nQuality of Life  \n \nSuchw\u00f6rter  \nStichwort  melan oma Therapy  brain  Temo*, fotemustin  \nSynonyme   treatment  Cerebral, CNS   \nMesh Term      \n \n6.7.2.  Datenbanken, Suchstrategien, Trefferzahlen  \n6.7.2.1.  Prim\u00e4rrecherche 2012  \nDatenbank  Suchstrategie  Datum  Treffer \n1.Suche  \nMedline  (melanoma[tiab] OR melanoma[MeSH]) AND (treatme nt[tiab] OR therapy[tiab] OR 30.05.11  1553 (Auswahl 19)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 608 von 817 \nDatenbank  Suchstrategie  Datum  Treffer \ntherapy[MeSH] OR temo*[tiab] OR fotemustin[tiab]) AND (brain[tiab] OR cerebral[tiab] \nOR CNS[tiab] or Brain Neoplasms[MeSH])  \nEmbase  (melanoma and (treatment or therapy) and (brain or cerebral or CNS) ).ti,ab.  11.05.11  1247  \n(Dedubliziert : 346 , 0 dazu ) \nCochrane Library  (melanoma and (treatment or therapy) and (brain or cerebral or CNS)).ti,ab.  20.05.11 28 (Auswahl 3 Dubletten,  0 \ndazu)  \nUpdate Suche  \nMedline  s.o. 31.01.12  1625 (1 dazu , W eber et al. \n2011) \nEmbase  s.o. 23.01.12 1349 (1 dazu, Heller et al.  \n2011 -Abstr akt) \nCochrane Library  s.o. 31.01.12  31 (0 dazu)  \n \n6.7.2.2.  Aktualisierungsrecherche 2015  \nDatenbank  Suchstrategie  Datum  Treffer \nMedline  (melanoma[tiab] OR melanoma[MeSH]) AND (treatment[tiab] OR therap y[tiab] OR \ntherapy[MeSH] OR temo*[tiab] OR fotemustin[tiab]) AND (brain[tiab] OR cerebral[tiab] \nOR CNS[tiab] or Brain Neoplasms[MeSH])  15.10.2015  587 \nCochrane Library  (melanoma and (treatment or therapy) and (brain or cerebral or CNS)).ti,ab.  15.10.2015  45 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 609 von 817 \n6.7.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  3005  \nEinschlusskriterien  Systematische Reviews oder klinische Studien zur medikament\u00f6sen Therapie bei Melanompatienten mit Hirnmetastasen  \nRCT\u00b4s die Patienten mit Hirnmetastasen eingeschlossen haben  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports \nNicht systematische Reviews  \nKollektive mit gemischten Tumorentiti\u00e4ten  \nKombination mit Radiotherapie  \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  22 \nAnzahl ausgew\u00e4hlter Studien nach Handsuche (D urchsicht der Literaturlisten)  0 \nAnzahl der ausgeschlossenen Studien nach Sichtung der Volltexte  9 \nAnzahl ausgew\u00e4hlter Volltexte  13 (davon 1 Asco Abstract  \n \nAuswahl der Literatur  \nGesamttreffer  632 \nEinschlusskriterien  Systematische Reviews oder klinisch e Studien zur medikament\u00f6sen Therapie bei Melanompatienten mit Hirnmetastasen  \nRCT\u00b4s die Patienten mit Hirnmetastasen eingeschlossen haben  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 610 von 817 \nAuswahl der Literatur  \nNicht systematische Reviews  \nKollektive mit gemischten Tumorentiti\u00e4ten  \nKombination mit Radiotherapie  \nRCT\u00b4s, in denen Patienten mit Hirnmetastasen lediglich ein Subkollektiv waren  \n \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  133 \nAnzahl ausgew\u00e4hlter Volltexte  5 \n \n \n6.7.4.  Evidenztabelle  \n6.7.4.1.  Prim\u00e4rrecherche 2012  \nStudy  Aims  Design Population  Outcomes  Results  Comments  LoE \nHodi et al. 2010  To compare \nipilimumab, \nadmini stered with \nor without a \nglycoprotein 100 \n(gp100) pe ptide \nvaccine with gp100 \nalone in patients \nwith pr eviously \ntreated metastatic \nmelanoma  RCT \n \nTreatment:  \n \nGroup A  \nipilimumab plus \ngp100 (n=403)  \nGroup B \nipilimumab alone \n(n=137)  \nGroup C gp100 676 HLA -A*0201 -\npositive patients \nwith previously \ntreated \nunresect able stage \nIII or IV mel anoma  \n \n82 patients with \nbrain metastases  \n \n \n \n \nMedian Overall \nsurvival  \n \n \n \n All patients \n(ipilimumab \n+gp100 vs. \nipilimumab vs. \ngp100)  \n \n10.0 months vs. \n10.1 months vs. \n6.4 months, sign., \n(hazard ratio for \ndeath, 0.68; Outcomes of \npatients wit h brain \nmeta stases not \nreported \nseparately  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 611 von 817 \nStudy  Aims  Design Population  Outcomes  Results  Comments  LoE \nalone (n=136)  Overall Response \nRate \n p<0.001).  \n \n5.7% (n=23) vs. \n11% (n=15) vs. \n1.5% (n=2), sign., \np=0.04  \nAvril et al. 2004  To compare \nfotemustine and \ndacarbazine (DTIC) \nin in patients with \ndisseminated \ncutan eous \nmelanoma  RCT \n \nTreamtent:  \nArm A: \nFotemustine  \nArm B: DTIC  229 patients with \nmetastatic \nmelanoma  \n \n43 pati ents with \nbrain m etastases \n(Arm A n=22, Arm \nB n=21)   \n \n \n \n \nResponse  \n \n Patients with brain \nmetastases n=43  \nArm A Fotemustin \nvs. Arm B DTIC  \n \nCR n=0 versus n=0  \nPR n=1 versus n=1  \nSD not reported  \nPD not reported  \n Outcomes of \npatients with brain \nmeta stases not \nreported in detail.  \n \nAuthor contacted, \nno reply  4 \nWeber et al. 2011  To further evaluate \nthe efficacy and \nsafety of \nipilimumab at 10 \nmg/kg in \nmelanoma patients \nwith stable brain \nmetastases.  Retrospective \nanalysis of data \nfrom a phase II \nstudy  12 patients with  \nstable brain \nmeta stases  Response  \n \n \nSurvival PR n=2 of 12  \nSD n=3 of 12  \n \nMedian OS: 14 \nmonths  \n \nBoth patients with \na partial response \nand one with \nstable di sease \nwere alive at the \nlast follow -up, with \nsurvival time of Lack of control \ngroup  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 612 von 817 \nStudy  Aims  Design Population  Outcomes  Results  Comments  LoE \nmore than 4 years  \nAmaravadi et al. \n2009  To evaluate the \ncombination of the \noral alkylating \nagent \ntemozol omide and \nthe oral \nmultikinase \ninhib itor sorafenib \nin advanced \nmelanoma patients  Phase II study  \n \nTreatment:  \nSorafenib 400mg \ntwice daily  \n+ temozolomide  \n \n 167 patients with \nmetastatic \nmelanoma  \n \n53 patients with \nbrain m etastases \n(Arm D)  Response rates \n \n \n \n \n \n \n \n \n6-month PFS rate  \nMedian PFS  \nMedian OS  Evaluable patients \n(Arm D with brain \nmetastases) n=52  \n \nCR rate: 0%  \nPR rate: 15%  \nSD rate: 48%  \nPD rate: 37%  \n \n23% \n3.5 months  \n8 mo nths Response assessed \naccording RECIST \ncriteria, CT every 8 \nweeks  \n \nLack of control \ngroup  4 \nVestermark et al. \n2008  To evaluate single \nagent antitumour \nactivity and \ntoxic ity of \nThalidomide in a \nphase II se tting in \npatients with brain \nmetastases \nassociated with \nmeta static \nmelanoma  Phase II study  \n \nTreatment:  \nthalidomide  36 patients with \nbrain metastases CNS Response  \n \n \nCR+PR  \nSD \nPD \n \nMedian PFS  \nMedian OS  Evaluable patients: \nn=35  \n \nn=0 \nn=5 \nn=30  \n \n1.7 months  \n3.1 months  Response assessed \naccording RECIST \ncriteria, C T or MRI \nevery 3 months  \n \nLack of control \ngroup  4 \nLarkin et al. 2007  To assess the \nmaximum-\ntolerated dose \n(MTD), saf ety and Phase I/II study  \n \nTreatment:  \ntemozolom ide + 26 patients with \nbrain metastases CNS Response  \n \n \nCR+PR  Evaluable patients: \nn=20  \n \nn=0 Response assessed \naccording WHO \ncriteria, CT or MRI \nafter 3.+ 6. cycle 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 613 von 817 \nStudy  Aims  Design Population  Outcomes  Results  Comments  LoE \nefficacy of the \ncombination of \ntemozolomide and \nlomustine in \nmelanoma \nmeta static to the \nbrain  lomustine  SD \nPD \n \nMedian OS  n=10, 50%  \nn=10, 50%  \n \n2 months  (28days/cycle)  \n \nonly 10% of \npatients received \nmore than 2 cycles \nof therapy  \n \nLack of control \ngroup  \nSchade ndorf et al. \n2006  To test a dose -\nintensified regimen \nof temozolomide \nin mel anoma \npatients with brain \nmeta stases in a \nprospe ctive, open -\nlabel, multicentre \nphase II trial  Phase II study  \n \nTreatment:  \ntemoz olomide  \n \n 45 patients with \nasymptomatic \nbrain metastases CNS Response  \n \n \n \n \nCR \nPR \nSD \nPD \n \nMedian OS  Evaluable patients: \nn=40 (5 missing \npatients: no \nclinical r esponse)  \n \nn=0 \nn=2, 4.4%  \nn=5 \nn=33  \n \n4.1 months  Response assessed \naccording RECIST \ncriteria, CT or MRI, \nweek 8 and week \n20, responses \nwere confirmed 4 \nweeks later.  \n \nLack of control \ngroup  4 \nHwu et al. 2005  To examine the \nefficacy and safety \nof temozolomide \nplus thalidomide in \nchemother apy-\nnaive patients with \nbrain meta stases Phase II study  \n \nTreatment:  \ntemozolomide + \nthalidomide  26 patients with \nbrain metastases, \n16 with \nsymptoma tic brain \nmetastases CNS Response  \n \n \nCR \nPR \nSD \nPD \n \nMedian OS  Evaluable patients: \nn=14  \n \nn=2 \nn=1 \nn=7 \nn=4 \n \n5 months  Response assessed \naccording WHO \ncriteria, CT or MRI \nevery 8 weeks  \n \n11 patients did not \ncomplete first \ncycle  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 614 von 817 \nStudy  Aims  Design Population  Outcomes  Results  Comments  LoE \nLack of control \ngroup  \nBafaloukos et al. \n2004  To evaluate the \nefficacy and \ntoxicity of \ntemozol omide -\nbased \nchemotherapy in \npatients with \ncerebral \nmetastases from \nmelanoma.  Analyses of \npatients with b rain \nmeta stases within \n2 Phase II studies  \n \nTreatment:  \ntemozolomide + \ndocetaxel n=10, \ntemozol omide + \ncisplatin n=9,  \ntemozolomide \nalone n=6  25 patients with \nbrain metastases CNS Response  \n \n \nCR \nPR \nSD \nPD \n \nMedian OS  \n1-year survival rate  Evaluable patients: \nn=24  \n \nn=0 \nn=6 \nn=5 \nn=13  \n \n4.7 months  \n20.9%  \n Response assessed \naccording WHO \ncriteria, CT or MRI \nevery second cycle \n(28 days/cycle)  \n \nLack of control \ngroup  4 \nAgarwala et al. \n2004  To assess the \nsafety and efficacy \nof temozolomide \nin patients with \nbrain metastases \nfrom metastatic \nmelanoma  Phase II study  \n \nTreatment:  \ntemozolomide  \n \n 151 patients with \nbrain metastases \n \nn=117 no prior \nchemotherapy  \nn=34 prior \nchem otherapy  CNS Response  \n \n \nCR \nPR \nSD \nPD \n \n \nMedian OS  Evaluable patients: \nn=132  \n \nn=1 \nn=8 \nn=40  \nn=73  \n \nall patients \n(n=151)  \n3.2 months  \n Large study  \n \nResponse assessed \naccording WHO \ncriteria, \ngadolinium -\nenhanced MRI \nevery second cycle \n(28 days/cycle), \nresponses were \nconfirmed 4 weeks \nlater.  \n \nLack of control \ngroup  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 615 von 817 \nStudy  Aims  Design Population  Outcomes  Results  Comments  LoE \nChang et al. 1994  To investigate the \nsequential \nadmini stration of \ndacarb azine and \nfotemustine in the \ntreatment of \ncerebral \nmetastases from \nmalignant \nmelan oma Phase II study  \n \nTreatment:  \nDTIC + \nfotemustine  34 patients with \nbrain metastases Response  \n \n \nCR \nPR \nSD \n \n \n \n \n \nMedian OS  Evaluable patients: \nn=34  \n \nn=2  \nn=2 \nn=9 \n \nduration of \ncomplete \nresponse: 12, 36+ \nmonths  \n \n4.5 months  Tumour response \nwas defined \naccor ding to World \nHealth  \nOrganisation \ncriteria  \n \nLack of control \ngroup  4 \nJacquillat et al. \n1990  To investigate the \nactivity of \nfotemu stine \nagainst cerebral \nmetastases of  \ndisseminated \nmalignant \nmelan oma Phase II study  \n \nTreatment:  \nfotemustine  42 patients with \nbrain metastases \n  \n16 patients with \nonly brain \nmeta stases, 23 \npatients with  brain \n+  extracerebral \nmetastases Response  \n \n \nCR \nPR \nSD \nPD \n \nMedian OS  \n \n1-year survival  Evalu able patients: \nn=39  \n \nn=2 \nn=9 \nn=9 \nn=19  \n \n26 weeks (6 \nmonths)  \n21% Tumor assessment \naccording WHO \ncriteria  \n \nLack of control \ngroups 4 \nHeller et al. 2011  To report safety \nand efficacy  data \nof treatment with \nIpilimumab in \npatients with brain open-label study  \n \nTreatment:  \nipilimumab 3 or 10 \nmg/kg  165 with brain \nmetastases at \nbaseline  (of 869 \npatients)  Toxicity  \n \n \n \n drug-related \nserious adverse \nevents of any \ngrade : 26.1%  \n(similar rate to pts only asco abstra ct \navailable    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 616 von 817 \nStudy  Aims  Design Population  Outcomes  Results  Comments  LoE \nmeta stases   \n \n1 year survival  without brain \nmetastases)  \n20% \n \n6.7.4.2.  Aktualisierungsrecherche 2015  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAjithkumar et al. \n2015  To review the \npresent  \nunderstanding and \nevolving \nmultimodal \nmanagement of  \nmelanoma brain \nmetastases, and \nthe challenges of \nhow \nbest to integrate \nnew systemic \ntherapies  Systematic review  \n \nCategorized \naccording to \ntreatment modality  Patients suffering \nfrom brain \nmetastases of \nmelanoma  Not defined  \u201cFor patients with \nBRAF -mutant \nmelanoma,  \nBRAF -targeted \nagents could be \nused preferentia lly \nto \nradiotherapy while \nthe potential \nbenefi ts and risks \nof the  \ncombination of \nradiotherapy and \nimmunotherapy \nare \nstill being studied\u201c  Only descriptive \ninformation \nprovided  3a \nDummer et al. \n2013  To study the  \nsafety, tolerability \nand efficacy of \nVemuraf enib for Open -label, single -\narm, two -centre,  \nstudy designed  \n Patients with  \nBRAFV600 \nmutation -positive \nmetastatic Safety  \n \n \n 23 of 24 patients \nreported at least \none adverse event \n(AE). Grade 3  Funding:  \nRoche  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 617 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npatients with  \nadvanced \nmelanoma and \nsymptomatic brain \nmetastases Vemurafenib (960 \nmg bid)  \nn=24  \n melanoma with \nnon-resectable, \npreviously treate d \nbrain metastases.   \n \n \n \n \n \n \n \n \n \nBest overall \nresponse rate \n(BORR)  \n \n \n \n \n \n \n \n \nProgression -free \nsurvival (PFS)  \n \n \nOverall survival \n(OS) \n AEs were reported \nin 4 (17%; 95% \nconfidence inte rval \n[CI], 4.7 \u201337.4%) \npatients and \nincluded \ncutaneous \nsquamous cell \ncarcinoma in 4 \npatients  \n \nOverall partial \nresponse (PR) at \nboth intracranial \nand extracranial \nsites was  \nachieved in 10 of \n24 (42%; 95% CI, \n22.1\u201363.4) \nevaluable patients, \nwith stable disease  \nin nine  \n \nMedian PFS was \n3.9 (95% CI, 3.0 \u2013\n5.5) months  \n \nMedian OS was 5.3 \n(95% CI, 3.9 \u20136.6) \nmonths   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 618 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nGoyal et al. 2015  To review the \ncurrent evidence \nregarding the \ntreatment of \nmultiple brain \nmetastases from \nmelanoma.  Systematic review  \n 2006 pts. treated \nwith radiotherapy; \n642 treated with \nchemotherapy; \ndescription of non -\nRCTs for \nIpilimumab  Rate of Intracranial \nFailure, %  \n \n \nOverall Intracranial \nResponse Rate, %  \n \nMedian Overall \nSurvival, mo  \n \n \n \n \n \n \n \n \nProgression -Free \nSurvival or Median  \nTime to \nProgression  8-48% for SRS(+/ -\nWBRT), 29 -100% \nfor WBRT  \n \n7-47% for CTX  \n \n \n6.5-7.5m for \nWBRT,  \n5.7-15.2m for \nSRS(+/ -WBRT)  \n0-47monts for \nchemotherapy (+/ -\nWBRT/SRS)  \n4.7-21.3m for \nipilimumab (+/ -\nChemo/WBRT/SRS)  \n \n1.2-5m for \nchemotherapy (+/ -\nWBRT/SRS)  \n2.7m -9.5m fo r \nIpilimumab (+/ -\nChemo/WBRT/SRS)  \u201cAt this time, the \nstandard \nmanagement for \npatients with MBM \nfrom melanoma \nincludes SRS, \nWBRT, or a \ncombination of \nboth\u201c  2a \nLong et al. 2012  To confirm the \nactivity of \ndabrafenib in brain \nmetastases, we \nassessed \ndabrafenib  in Multicentre, open -\nlabel, phase 2 tr ial \nwith 2 cohorts:  \n \nCohort A  \nhad not received Patients with  \nBRAFV600 \nmutation -positive \nmetastatic \nmelanoma who \nhad or had not Overall intracranial \nresponse (CR or \nPR) \n \n \n Cohort A \n(Val600Glu -\nMutated)  \n29/74 pts. (39.2%, \n95% CI 2 8.0\u201351.2) \n(Val600Lys -Funding:  \nGSK 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 619 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npatients with \nVal600Glu or \nVal600Lys BRAF -\nmutant melanoma \nand at least one \nbrain metastasis \nwho were either \npreviously \nuntreated for brain \nmetastases or who \nhad progressive \nmetastases after \nprevious local \ntreatments.  previous local \ntreatment for brain \nmetastases  \n(n=89) \n \nCohort B  \nhad progressive  \nbrain metastases \nafter previous local \ntreatments  \n(n=83) \n \nPatients in both \ncohorts received \n150 mg oral \nDabrafenib twice a \nday \n received previous \nlocal treatment for \nbrain metastases  \n  \n \n \n \n \n \n \n \n \n \n \nSafety  \n Mutated)  \n1/15 pts. (6.7%, \n0.2\u201331.9)  \n \nCohort B  \n(Val600Glu -\nMutated)  \n20/65 pts. (30.8%, \n19.9-43.4)  \n(Val600Lys -\nMutated)  \n4/18 pts. (22.2%, \n6.4\u201347.6)  \n \nTreatment -related \nAEs of grade 3 or \nworse occurred in \n38 (22%) patients.  \nFour grade 4 \ntreatment -related  \nAEs occurred in \ncohort A. Two \ngrade 4 events \noccurred in cohort \nB. 51 (30%) \npatients had a \nserious adverse \nevent.  \nMargolin et al. To assess efficacy \nand safety of ipi -Open -label, phase \n2 trial with two Patients had to \nhave at least one Proportion of \npatients with 9/51 patients in \ncohort A  Funding:  \nBMS 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 620 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n2012  limumab \nspecifically in \npatients with \nmelanoma an d \nbrain  \nmetastases in a \nprospective clinical \ntrial parallel cohorts  \n \nCohort A  \nNeurologically \nasymptomatic; not \nreceiving \ncorticosteroid \ntreatment at study \nentry  \n(n=51) \n \nCohort B  \nsymptomatic; \nstable  \ndose of \ncorticosteroids \n(n=21) \n \nIpilimumab \n10mg/kg iv q21 \nfor four doses  measurable index \nbrain metastasis of \n0.5\u20133 cm in \ndiameter, or two \nmeasurable lesions \nlarger than 0.3 cm \nvisible on contrast \nMRI, or both.  disease control, \ndefined as CR,  \nPR, or stable \ndisease after 12 \nweeks  \n \n \n \n \nProportion of \npatients with an \nobjective response \n(CR/PR)  \n \n \n \nMedian PFS  \n \n \n \n \nOverall survival \n \n \n \n \nSafety & \nTolerability  exhibited disease \ncontrol (18%, 95% \nCI 8\u201331) \n \n1/21 patients in \ncohort B exhibited \ndisease control \n(5%, 0.1 \u201324). \n \nCohort A:  \nOR: 5/51 (10%, 3 \u2013\n21) \nCohort B:  \nOR: 1/21 (5%, 0.1 \u2013\n24) \n \nCohort A: 1.4 (1.2 \u2013\n2.6) months  \nCohort B: 1.2 (1.2 \u2013\n1.3) months  \n \nCohort A: 7.0 (95% \nCI 4.1 \u201310.8) \nmonths  \nCohort B: 3.7 (95%  \nCI 1.6 \u20137.3) months  \n \nMost common AEs \nin both cohorts:  \nFatigue, diarrhoea, \nnausea, headache,  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 621 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nrash, and pruritus. \nMost common \ngrade 3 events \noverall: diarrhoea, \nfatigue, \ndehydration, \nhyperglycaemia, \nand increased \nconcentrations of \nserum aspartate \naminotransf erase. \nOne patient in \neach \ncohort experienced \ngrade 4 confusion. \n3 patients in  \ncohort A had brain \noedema (one grade \n1 and two grade \n2). \nA man in cohort A \ndied for reasons \nrelated to  \nthe study drug 24 \ndays after his \nsecond dose of  \nipilimumab \nbecause of \ngang renous colitis, \ndespite  \ntreatment with  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 622 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncorticosteroids.  \n \n15 pts. in cohort A \ncompleted \ninduction. 28 pts. \nhad discontinued \ntreatment because \nof early \nprogression of \ndisease or death, \nfive requested  \ndiscontinuation \nwithout \ndocumented \nprogression, three \nhad adverse \nevents.  \n \n5 patients in \ncohort B \ncompleted \ninduction. 11 had \ndiscontinued \ntreatment because \nof disease \nprogression or \ndeath, 3 requested \ndiscontinuation, \nand 2 had AEs.  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 623 von 817 \n6.7.5.  Literatur  \n \nAjithkumar T, Parkinson C, Fife K, Corrie P, Jeffer ies S. Evolving treatment options for melanoma brain metastases. Lancet Oncol. 2015;16(13):e486 -497. \nAmaravadi RK, Schuchter LM, McDermott DF, et al. Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastase s. Clin Cancer Res \n2009;15:7711- 7718  \nAvril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22:1118- 1125  \nBafaloukos D, Tsoutsos D, Kalofonos H, et al.  Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Helleni c \nCooperative Oncology Group. Ann Oncol 2005;16:950- 957 \nChang J, Atkinson H, A'Hern R, et al. A phase II study of the sequential a dministration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant \nmelanoma. Eur J Cancer 1994;30A:2093- 2095  \nDummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF(V600) mutation -positive melanoma wit h symptomatic brain metastases: final results of an open -label \npilot study. Eur J Cancer. 2014;50(3):611- 621. \nGoyal S, Silk AW, Tian S, et al. Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. JAMA Oncol. 2015;1(5):668- 676. \nHeller KN, Pavlick A.C., Hodi F.S., et al. Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. Journal of  Clinical Oncology, 2011 \nASCO Annual Meeting Proceedings (Post -Meeting Edition). 2011;Vol 29:8581 \nHodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711- 723 \nHwu WJ, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005;103:2590- 2597  \nJacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with dissemina ted malignant \nmelanoma including patients with c erebral metastases. Cancer 1990;66:1873- 1878  \nLarkin JM, Hughes SA, Beirne DA, et al. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer 20 07;96:44 -48 \nLong GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF -mutant melanoma metastatic to the brain (BREAK -MB): a multicentre, open -label, phase 2 \ntrial. Lancet Oncol. 2012;13(11):1087- 1095.  \nMargolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients w ith melanoma and brain metastases: an open -label, phase 2 trial. Lancet Oncol. 2012;13(5):459- 465.Agarwala SS, \nKirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase I I study. J Clin Onco l 2004;22:2101- 2107  \nSchadendorf D, Hauschild A, Ugurel S, et al. Dose -intensified bi -weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II \nDeCOG/ADO study. Ann Oncol 2006;17:1592- 1597  \nVestermark LW, Larsen S , Lindelov B, et al. A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol 2008;47:1526 -1530  \nWeber JS, Amin A, Minor D, et al. Safety and clinical activity of ipilimumab in melanoma patients with brain metast ases: retrospective analysis of data from a phase 2 trial. Melanoma Res \n2011;21:530- 534  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 624 von 817 \n7. AG Radiotherapie  \n7.1. Frage VI.1. Radiotherapie Prim\u00e4rtumor  \nFrage VI.1. Hat eine Radiotherapie von inoperablen Prim\u00e4rtumoren oder eine postoperative Radiotherapie nach R1 o der R2 -Resektion von \nPrim\u00e4rtumoren bzw. bei Vorhandensein anderer Risikofaktoren (nicht einhaltbare Sicherheitsabst\u00e4nde) einen Einfluss auf das pr ogressionsfreie \n\u00dcberleben oder Gesamt\u00fcberl eben? \n7.1.1.  PICO, Suchw\u00f6rter  \nPICO - Schema  \nPopulation  Intervention  Compar ison Outcome  \nMelanoma patients with pr imary \ntumor, prior or after (partial) \nresection  radiotherapy  no radiotherapy  PFS, OS  \n \nSuchw\u00f6rter  \nStichwort  melanoma  radiotherapy  primary  margin  \nSynonyme   Radiation, irradiation    \nOber -/Unterbegriffe  Lentigo malign a, cutaneous, \nskin   Resection, R1, R2, inoperable, \nunresectable, adjuvant, \npostoperative  \nMesh Term  melanoma  radiotherapy, radiation    \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 625 von 817 \n7.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer  (Auswahl)  \n1. Suche     \nMedline (mela noma[tiab] OR melanoma[MeSH]) AND (radiotherapy[tiab] OR radiother apy[MeSH] \nOR radiation[tiab] OR radiation[MeSH]) AND (primary OR \"lentigo mali gna\" OR margin* \nOR resection OR R1 OR R2 OR inoperab* OR unresectab*) NOT (uvea*[ti] OR \nanorectal[ti] OR mucosal [ti]) 20.04.11 1836 (Auswahl 22 \nStudien)  \nMedline -Erweiterte \nSuchstr ategie  \n (melanoma[tiab] OR melanoma[MeSH]) AND (radiotherapy[tiab] OR radiother apy[MeSH] \nOR radiation[tiab] OR radiation[MeSH] OR irradiation) AND (skin OR cutan eous OR \nprimary OR \"lentig o maligna\" OR margin* OR resection OR R1 OR R2 OR postoperative \nOR inoperab* OR unresectab*) NOT (uvea*[ti] OR anorectal[ti] OR muco sal[ti])  16.05.11  5435 (Auswahl 8 \nStudien)  \nCochrane Library  (melanoma  and (radiotherapy  or radiation or irradiation) and (skin or cutaneous or \nprimary or \"lentigo maligna\" or margin* or resection or R1 or R2 or adjuvant or \npostoperative or inoperab* or unresectab*) not (uvea* or anorectal or mucosal)) .ti,ab.  20.04.11  42 (0)  \nEmbase  (melanoma  and (radiotherapy  or radiation or irradiation) and (skin or cutaneous or \nprimary or \"lentigo maligna\" or margin* or resection or R1 or R2 or adjuvant or \npostoperative or inoperab* or unresectab*) not (uvea* or anorectal or mucosal)) .ti,ab.  11.05.11  3272 (Auswahl 3 \nStudien)  \nUpdate Suche     \nMedline s.o. 31.01.12 5613 (1Studie dazu, \nHedblad et al. 2011) \nCochrane Library  s.o. 31.01.12 42 (0  dazu ) \nEmbase  s.o. 23.01.12  3475 (0  dazu ) \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 626 von 817 \n7.1.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  8721  \nEinschlusskriterien  Mangels RCT\u00b4s Einschluss v on Kohortenstudien und Fallserien ab 20 Patienten  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports  \nNicht systematische Reviews  \nKombinationstherapien  \nArbeiten zu RT von nicht invasiven Melanomen (Melanoma in situ/Lentigo maligna)  \nKollektive mit gemischten T umorentit\u00e4ten  \nArbeiten \u00e4lter als 1980  \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  34 \nAnzahl der ausgeschlossenen Studien nach Sichtung der Volltexte  19 \nAnzahl ausgew\u00e4hlter Volltexte  15 \n \n7.1.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nWasif et al. 2011  To study the \nsurgical \nmanag ement of \ndesmoplastic \nmelanoma (DM), \nidentify prognostic Retrospective \ncohort study  \n 1735 patients with \ndesmoplastic \nmelanoma  \n \n143 (8%) of \npatients i n the survival  adjuvant radiation \ntherapy: \nnegative impact on \nsurvival [HR 1.65 \n(95% CI 1.17 -2.31)]  Adverse impact of \nRT probably \nreflects selection \nbias 3b \n \nCohort \nstudy with \nimba lance \nof groups   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 627 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfactors, and impact \nof treatment \noptions  cohort r eceived \nadjuvant \nradioth erapy \nChen et al. 2008  To describe the \nclinicopathologic \nfeatures of  \ndesmoplastic \nneurotropic \nmelanoma (DNM), \nto update \noutcomes, and to \nexplore the role of \nadjuvant radi ation \ntreatment in the \nmanagement of \nthis entity  Retrospective \ncohort study  \n \nTreatment:  \nSurgery + different \nRT modalities and \nschedules  128 patients with \nDNM \n27 patients \nreceived \nradiotherapy after \nlocal excision  Local recurrence  \n \n \n \n \nPrognostic factors  RT group, N=27:  \nn=2 (7.4%)  \nSurgery only, \nN=101: n=6 (5.9%)  \n \nsignificant \npredi ctors of local \nrecurrence:  \n-a posi tive margin \n(P < .001)  \n-head and neck \nlocation (P = .03)  Imbalance of \ngroups: RT group \nincluded more \npatients with \nworse progno stic \nfactors (closer \nexicision margin, \nhigher t umor \nthicknes, more \nhead and neck \ntumors)  \n 3b \n \nCohort \nstudy with \nimba lance \nof gro ups \nHedblad et al. \n2011  To evaluate Grenz \nray treatment in a \nstructured way for \ntreatment of \nLentigo maligna \nmelanoma as an \nalternative to \nsurgery Retrospective \ncohort study  \n \nTreatment:  \nGrenz ray \ntreatment  593 patients with \nLentigo maligna or \nearly lentigo \nmaligna mel anoma  Complete \nclearance  88% Lack of control \ngroup  4 \nVongtama et al. \n2003  To address the role \nof radia tion \ntherapy in local \ncontrol of Retrospective \ncohort study  \n (1976 \u2013 1999)  \n 44 patients with \nDMM  \n14 patients with \npostoperative RT Local recurrence  \n \nLocal control in re \ncurrent DMM  Overall: n=21 \n(48%)  \n \nSurgery +RT (15 Possible selection \nbias, Imbalance of \ngroups, small \nsample size  4 \n \nCohort \nstudy with \nimba lance  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 628 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndesmoplastic \nmalignant \nmelanoma (DMM)  Treatment:  \nSurgery alone  \nSurgery + RT, \nmedian dose 50 Gy  after local \nrecurrence  \n1 patient with \npreoperative RT   \n \n \nDistant metastasis  pts) \nn=15  \nSurgery alone \n(7pts)  \nn=3 \nnonirradiated \npatients 35%  \nirradiated patients \n40% of groups \nand small \nsample \nsize \nFoote et al. 2008  To address the role \nof radiot herapy in \nthe local control of \ndesmoplastic \nmelanoma  Retrospective \nevaluation  \n \nTreatment:  \nSurgery + wide  \nfield radiotherapy \nwith a 3 - to 4-cm \nmargin  \n 24 patients with \nDM received \nsurgical excision \nas initial treatment \nfollowed by \npostoperative \nradiotherap y 3-year in -field \nrelapse -free \nsurvival  \n \n \n3-year relapse -free \nsurvival  \n \n \n3-year overall \nsurvival 91% (95%  \nconfidence interval \n68.1\u201397.6%) \n \n 86% (95% \nconfidence interval \n63.2\u201395.4%)  \n \n83% (95% \nconfidence interval \n54.9\u201394.3%).  Lack of control \ngroup  4 \nArora  et al. 2005  To determine local \nrecurrence rates \nfor patients with \ndesmoplastic \nmelanoma who \nunde rwent wide \nexcision alone  Retrospective \nevaluation  \n \nTreatment: surgery \nalone  \n 65 Patients with  \nDM received \nsurgi cal excision \nalone  \n \n Local recurrence \nrate n=2 ( 4% )  \nof 49 patients with \nminimum of 2 \nyears of follow -up Lack of control \ngroup  4 \nFarshad et al. To perform a Retrospective 150 patients with Local recurrence n=7 (7%)  Lack of control 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 629 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n2002  retrospective study \nof 150 patients \nwith le ntigo \nmaligna (LM) and \nlentigo maligna \nmelanoma  (LMM) \ntreated with \nradiotherapy using \nGrenz or  soft X -\nrays. evaluation  \n \nTreatment:  \nGrenzrays (12 kV)  \nX-rays (20 or 30 \nkV) \n \nLM: 10 -12 Gy x 10 \nfractions  \nLMM 7 -9 Gy x 6 \nfractions  LM or LMM  \ntreated at the skin \ncancer unit of the \nDepartment of  \nDermatology, \nUniversity of \nZurich \n(Switze rland)  \nbetween 1950 and \n2000   rate of 101 patients \nfollowed up for at \nleast 2 years  group  \nSchmid -Wendtner \net al. 2000  To present the \nresults of a \nfractionated \nradiation therapy \n(modified \nMiescher\u2019s \ntechnique) in 64 \npatients with LM or \nLMM treated \nbetween 1987 and \n1998.  Retrospective \nevaluation  \n \nTreatment:  \nsuperficial x -ray \nunit (Dermopan, \nSiemens, Erlangen, \nGermany)  \n100 Gy applied in \n10 fractions, safety \nmargin: 0.5 -  2.0 \ncm  64 patients  \nwith LM (n =4 2)  \nand LMM (n= 22)  Local recurrence \nrate LM n=0 (0%)  \nof 42 patients  \nLMM n=2 (9%)  \nof 22 patients  \n \nmedian fo llow up \n15 months  \n Lack of control \ngroup  4 \nStevens et al. \n2000  To assess local \nrecurrence and \nsurvival of patients \ntreated with \nsurgery and \npostoper ative Retrospective \nevaluation  \n \nTreatment:  \nTD 30 \u201336 grays \n(Gy), 5 \u20137 fractions, 174 Stage I \u2013III \nmelanoma patients \nreceived \npostoperative \nradiation the rapy \n Local recurrence \nrate  \n \n \n3-years metastasis \nfree survival  n=20 (11%) (Group \nA and B)  \n \n \n60% (Group A)  Lack of control \ngroup  \nNo baseline \nchara cteristics \npresented  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 630 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nhypofractionated \nradiation therapy  twice wee kly Group A n=32: \nprimary tumor site  \n(Group B n=142: \nlymph node \ninvolvement)  \nPanizzon et al. \n1999  To report radiation \ntreatment results \nof 129 patien ts \nwith the precursor \nlesion lentigo \nmaligna and 27 \npatients with \nlentigo maligna \nmelan oma Retrospective \nevaluation  \n \nTreatment:  \nRT alone  27 patients with \nlentigo maligna \nmelanoma  Complete response  n=25 (92.8%)  Lack of control \ngroup  \n 4 \nAng et al. 1994  To assess the \nefficacy and \ntoxicity of elective -\nadjunctive \nradiotherapy given \nin five 6 -Gy \nfractions to \npatients with \ncutaneous \nmelanoma of the \nhead and neck at \nhigh risk for l ocal-\nregional relapse  Retrospective \nevaluation  \n \nTreatment:  \n(most patients) \nelectrons, mostly \n9-12 MeV, 6 -Gy \ndose per fra ction, \ntwice a week, total \ndose 30Gy  \n 174 melanoma \npatients  \n \nGroup 1 (n=79) RT \nafter wide excision  \nGroup 2 (n=32) \nRT+limited neck \ndissection  \nGroup 3 (n=63) RT \nafter neck \n\u0001ecur\u0001ttion for \nnodal re lapse  \n 5-year local -\nregio nal control  \n \nSurvival \n \n \nPattern of failure \n(after median \nfollow-up of 35 \nmonths)  88% (all patients)  \n87% (Group 1)  \n \n47% (all patients)  \n62% (Group 1)  \n \nGroup 1  \nNED n=51  \nDermal r \u0001ecur. \nN=2 \nNodal relapse n=2  \nD+N n=1  \nDistant met. N=21  Lack of control \ngroup  \n 4 \nStorper et al. 1993  To elucidate the Retrospective 44 melanoma Survival  SE 19%  Imbalance of 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 631 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nefficacy of external \nbeam irradi ation in \nthe treatment of \nhead and neck \nmalignant \nmelanoma, in \ncompar ison with \nthe efficacy of \nsurgical exc ision \nand the efficacy of \nsurgical excision \ncombined with \nexternal beam \nirradiat ion evaluation  \n \nTreatment:  \n-surgery (SE), n=26 \n-primary external \nbeam irra diation \n(XRT), n=10 \n-adjuvant external \nbeam irra diation \n(SE+XRT), n=8 patients with \nrecurrent disease  \n \n XRT 20%  \nSE+XRT 37%  prognostic factors \nbetween groups  \nSite of RT not \nmentioned  \n \nPhipps et al. 1992  To examine  the \neffect of \nimmediat ely \npreoperative \nadjuvant \nradiotherapy in the \nsurgical treatment \nof primary \ncutaneous \nmalignant \nmelanoma  Retrospective \nevaluation  \n(1958 -1970)  \n \nTreatment:  \nAll patients: 400 \ncGy external beam \nradiotherapy, 52 \npatients add itional \nsingle -fraction \n2000 cG y \nSurgery within 24h  77 melanoma \npatients,  \nclinical Stage I  \n 5-years survival  \n10-year survival \nLocal recurrence  \n 68% \n57% \n14% \n \nFollow -up \nminimum 10 y ears Lack of control \ngroup  \nTumor thickness \nnot mentioned  4 \nElsmann et al. \n1991  To facilitate clinical \ndecisions the \nauthors report on Retrospective \nevaluation  \n(1974 -1989)  83 melanoma \npatients  \nLMM n=64  Local recurrence  \n \n n=1 (skin \nmetast asis) \nRT after total Lack of control \ngroup  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 632 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntheir results using \nsoft X -ray therapy \nof primary \nmelan omas  \nTreatment:  \nSoft X -ray 30 -\n100kV  \nTD 48 \u2013  105 Gy, \nfraction size 3.5 \u2013 \n7 Gy \n \nafter total excision \nn=23  \nafter partial \nexcision n=41  \nwithout prior \nexcision n=19  SSM n=8  \nNMM n=6  \nNot classified n=5  \n \npT1 n=17  \npT2 n=13  \npT3 n=19  \npT4 n=13  \npT classification \nnot available n=2  \nnot biopsied n=19   \n \n \n \n \n \n \nSurvival excision \n \nn=1 (recurrent \ntumor nodule)  \nRT without total \nexcision \n \n60%,  (melanoma \ndeaths 9.6%, other \ndiseases 30.1%)  \n \nFollow -up median \n42 months  \nHarwood et al. \n1983  To review the \nresults of radiation \ntreatment of 51 \npatients with LM \nand LMM.  Retrospective \nevaluation (1958 -\n1982)  \n \nTreatment:  \nLMM 125, 140 or \n175 KEV  28 patients with \nLentigo maligna \nmelanoma  Local recurrence or \nresidual tumor \nNo local recurrence  \nNot assessable  n=2 (7%)  \n \nn=23 (82%)  \nn=3 (11%)  Lack of control \ngroup  4 \nAusgeschlossene Studien  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nZygogianni et al. \n2011  To assess the \npotential impact of \nradiotherap y (RT) \non local control, \nquality of life and Review  Pubmed 1978 -  \n2010    Non systematic \nReview, excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 633 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \noverall survival  \nNewlin et al. 2005  To report our \nexperience with \nneurotropic \nmelanoma  Case Series  \n \nTreatment:  \nSurgery + x -rays (6 \nMV) \n 3 patients wi th \nneurotropic \nmelanoma  \nreceived RT after \nincomplete \nexcision (n=2) and \nadjuvant RT after \ncomplete excision \n(n=1)  Local control  1 patient: \nrecurrence in a \nregional lymph \nnode after 30 \nmonths  \n2 patients disease -\nfree (after 34 and \n14 months)  <20 patients, \nstudy excluded   \nCooper et al. 2001  To report our \ninitial results with \nelective radiation \ntherapy after \ndefinitive su rgery \nfor selected \npatients who have \nhigh- risk \nmalig nant \nmelanomas.  Retrospective \nevaluation  \n \nTreatment:  \nSurgery + 6Gy per \nfraction, 5 or 6 \nfractions 40 patients with \nhigh- risk \nmalig nant \nmelanomas  \n \n29 patients with \nrecurrent primary \nor regional disease  \n \n9 patients: close or \nmicroscopically \ninvolved su rgical \nmargins  5-year local -\nregional control \nrate \n \n 84% majority of \npatients received \nRT for r ecurrent \ndisease. Analyses \nwere per formed \ntogether for the \nvery heterogen ous \ngroup , \nstudy excluded  \n  \nSeegen schmiedt et \nal. 1999  To analyze \nrelevant endpoints \n(tumor response, \nlocal tumor \ncontrol, survi val) \nand to identify \nprognostic factors \nfor achieveme nt of Retrospective \nevaluation  \n \nTreatment:  \nlinac 6 \u201310 MV  \nphotons  \nor 4\u201318 MeV \nelectrons  2 917 melanoma \npatients  \n121 received RT, \nthereof  \n11 patients with \nrelapsed/residual \nMM (UICC IIB)  \n Response at 3 \nmonths  \n \nRecurrence rate  \n \nIn-field local \nrelapse  \n CR n=7 (64%)  \nPR n=4 (36%)  \n \nn=3 (27%)  \n \nn=2 (18%)  \n \nn=1 (9%)  <20 patients RT \nprimary tumor, \nstudy e xcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 634 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nthese endpoints in \nlong-term follow -\nup (FU)  Regional in -transit \nmetastases \n  \nof 11 patients \nTsang et al.  To report the \nexperience with \nradiotherapy for \nlentigo maligna  Retrospective \nevaluation  \n \n 54 patients with \nlentigo maligna    No patients with \nlentigo maligna \nmelanoma  \nstudy excluded  4 \nUmebay ashi et al \n1995  To answer whet her \nor not the proton \nbeam can pr ovide \nuseful trea tment \nfor cutaneous \nmelan oma Case series  \n \nTreatment:  \nproton beam, to tal \ndose of around \n100 Gy, \nfracti onated into \nsingle doses of \nappro ximately 10 \nGy 7 patients  \n \nwith 5 primary \nmelanomas and 3 \nmetastatic lymph \nnodes  Regression \nprimary melanoma  100%   n=1  \n90%     n=2  \n80%     n=1  \n85%     n= 1 <20 patients, \nstudy excluded   \nRounsaville et al. \n1988  Radiotherapy in \nthe management \nof cutaneous \nmelan oma: effect \nof time, dose, and \nfraction ation Review     Non systematic \nReview, excluded   \nVon Rottkay et  al. \n1987  Radiation therapy \nin malignant \nmelan oma using \naccel erated \nfractionation. \nRemission and Retrospective \nevaluation  \n(1982 -1985)  \n 14 patients at \ndifferent clinical \nstages    <20 patients, \ndiffer ent stages, \nstudy e xcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 635 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npreliminary results \nof local tumor \ncontrol  \nBlake et al. 1985  To report the  \nresults of \ntreatment of \nmalignant \nmelanoma by fast \nneutrons  Retrospective \nevaluation  \n \nTreatment:  \n156OcGy in 12 \nfractions (4 weeks) \nor 1395cGy in 6  \nfractions (2 weeks)  7 patients with \nprimary \nmelanomas \n \n(of 48 melanoma \npatients with 87 \ntumors)  \n Response  CR n=6 (86%) of 7 \nprimary \nmelanomas  <20 patients, \nstudy excluded   \nOvergaard et al. \n1980  Radiation \nTreatment of \nmalignant \nmelanoma  Retrospective \nevaluation (1970 -\n1980)  \n \nTreatment:  \nDifferent fractions \nand dose schedules  36 patients with  \n24 skin lesions and \n25 lymph node \nmetastases  Response  \nCR \nPR \nNo response  \nProgression  \n \n \n \nCR \nPR \nNo response  \nProgression  skin lesions n=24  \nn=7 \nn=10  \nn=6 \nn=1 \n \nlymph node \nmeta stases n=25  \nn=5 \nn=10  \nn=8 \nn=2 Baseline \ncharact eristics \nmissing  \nprimary \nmelanomas and \nskin metastases \nare not  \ndistinguished  \n \nstudy e xcluded   \nTonak et al. 1976  To present the \ntreatment results \nof 195 melanoma \npatients (clinical \nstages I and II)       published before \n1980, study \nexcluded   \nVon Lieven et al. To investigate the     published before   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 636 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n1976  correlation \nbetween the total \ndose needed for a \nlocal healing and \nthe p eriod of \ntreatment  1980, study \nexcluded  \nK\u00f6nig et al. 1970  Problems in the \nradiological \ntreatment of \nmalignant \nmelan omas of the \nskin. Report on \n136 patients \nfollowed -up over \nlong p eriod of time      published before \n1980, study \nexcluded   \nStein et al. 1965  The avoiding of a \ncombination -effect \nin combined \nsurgi cal-\nradiological \ntreatment of \nmalig nant skin \ntumors      published before \n1980, study \nexcluded   \nHellriegel et al. \n1963  To present \nradioth erapentic \nimprov ements and \nresults in \nmalignant \nmelan omas     published before \n1980, study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 637 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nWernsdoe rfer et al. \n1960  On the treatment \nand prophylaxis of \nmalignant \nmelan oma skin \ntumors      published before \n1980, study \nexcluded   \nSpoljar et al. 1959  The treatment of \nmalignant \nmelan oma     published before \n1980, study \nexcluded   \nNitter et al. 1956  The treatment of \nmalignant \nmelan oma with \nspecial reference \nto the possible \neffect of \nradiotherapy      published before \n1980, study \nexcluded   \nGreve et al. 195 2 Roentgen \nirradi ation of skin \ntumors      published before \n1980, study \nexcluded   \n7.1.5.  Literatur  \n \nAng KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994;30:795 -798 \nArora A, Lowe L, Su L, et al. Wide excision without radiation for desmoplastic melanoma. Cancer 2005;104:1462 -1467  \nBlake PR, Catterall M, Errington RD. Treatment of malignant melanoma by fast neutrons. Br J Surg 1985;72:517- 519 \nChen JY, Hruby G, Scolyer RA, e t al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 2008;113:2770- 2778 \nCooper JS, Chang WS, Oratz R, et al. Elective radiation therapy for high -risk malignant melanomas. Cancer J 2001;7:498- 502 \nElsmann HJ, Ernst K, Su ter L. Radiotherapy of primary human melanomas --experiences and suggestions. Strahlenther Onkol 1991;167:387- 391 \nFarshad A, Burg G, Panizzon R, et al. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X -\nrays. Br J Dermatol 2002;146:1042- 1046 \nFoote MC, Burmeister B, Burmeister E, et al. Desmoplastic melanoma: the role of radiotherapy in improving local control. ANZ J Surg 2008;78:273- 276 \nGREVE W. Roentgen irradiation o f skin tumors. Strahlentherapie 1952;89:401- 408 \nHarwood AR. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. Int J R adiat Oncol Biol Phys 1983;9:1019- 1021  \nHedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. J Am Acad Dermatol 2011  \nHELLRIEGEL W. Radiation therapy of primary and metastatic melanoma. Ann N Y Acad Sci 1963;100:131 -141  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 638 von 817 \nKoenig H. Problems in the radiological treatment of malignant melanomas of the skin. Report on 136 patients followed -up over long period of time. Z Arztl Fortbild (Jena) 1970;64:770-\n779 \nNewlin HE, Morris CG, Amdur RJ, et al. Neurotropic melanoma of the head and neck with clinical perineural invasion. Am J Clin Oncol 2005;28:399- 402 \nNitter L. The treatment of malignant melanoma with special reference to the possible effect of radiotherapy. 1956.  \nOvergaard J. Radiation treatment of malignant melanoma. Int J Radiat Oncol Biol Phys 1980;6:41 -44 \nPanizzon R.G. Radiotherapy of lentigo m aligna and lentigo maligna melanoma. 1999.  \nPhipps AR, Godfrey AM, Durrant KR, et al. The effect of immediately preoperative adjuvant radiotherapy in the surgical treatment of primary cutaneous malignant melanom a. Br J Plast \nSurg 1992;45:30- 33 \nRounsaville MC, Cantril ST, Fontanesi J, et al. Radiotherapy in the management of cutaneous melanoma: effect of time, dose, and fractionation. Front Radiat Ther Oncol 1988;2 2:62-78 \nSchmid -Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo mali gna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000;43:477- 482 \nSeegenschmiedt MH, Keilholz L, Altendorf -Hofmann A, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response an d long -\nterm outcome: a 20 -year experience. Int J Radiat Oncol Biol Phys 1999;44:607- 618 \nSpoljar M., Franicevic N., Kubovic M. The treatment of malignant melanoma. 1959.  \nStein G. The avoiding of a combination- effect in combined surgical -radiological treatm ent of malignant skin tumors. Strahlentherapie 1965;128:347- 350 \nStevens G, Thompson JF, Firth I, et al. Locally advanced melanoma: results of postoperative hypofractionated radiation therap y. Cancer 2000;88:88- 94 \nStorper IS, Lee SP, Abemayor E, et al. The role of radiation therapy in the treatment of head and neck cutaneous melanoma. Am J Otolaryngol 1993;14:426- 431 \nTonak J, Hermanek P, Hornstein OP, et al. Treatment of malignant melanoma (clinical stages I and II) (author's transl)]. Dtsch Med Wochenschr 1 976;101:435- 450 \nTsang RW, Liu FF, Wells W, et al. Lentigo maligna of the head and neck. Results of treatment by radiotherapy. Arch Dermatol 1994;130:1008- 1012 \nUmebayashi Y, Uyeno K, Tsujii H, et al. Proton radiotherapy for malignant melanoma of the skin. D ermatology 1995;190:210- 213 \nvon Lieven H, Skopal D. Radiosensitivity of malignant melanoma]. Strahlentherapie 1976;152:1 -4 \nvon Rottkay P. Radiation therapy in malignant melanoma using accelerated fractionation. Remission and preliminary results of local tu mor control. Strahlenther Onkol 1987;163:139-\n143 Vongtama R, Safa A, Gallardo D, et al. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck 2003;25:423 -428 \nWasif N, Gray RJ, Pockaj BA. Desmoplastic melanoma -  the step -child in the melanoma family? J Surg Oncol 2011;103:158- 162 \nWERNSDOERFER R. On the treatment and prophylaxis of malignant melanoma skin tumors. Strahlentherapie 1960;Suppl 46:43 -48 \nZygogianni A, Kyrgias G, Kouvaris J, et al. Melanoma: The Radiothera peutic Point of View; Review of the Current Literature. Rev Recent Clin Trials 2011  \n7.2. Frage VI.2. und VI.3. Radiotherapie Intransit - und Fernmetastasen  \nFrage VI.3. Welche Radiotherapie -Indikationen bestehen im Stadium der Fernmetastasierung?  \nFrage VI.2. Hat eine Radiotherapie von Satelliten - und In -transit -Metastasen einen Einfluss auf das Progressionsfreie \u00dcberl eben oder \nGesamt\u00fcberleben?  \n7.2.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema (Intransitmetastasen)  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients with s atellite or \nintransit metastases  radiotherapy  no radiotherapy  PFS, OS  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 639 von 817 \nSuchw\u00f6rter (Instransitmetastasen)  \nStichwort  Melanoma  radiotherapy  Satellite metastases  salvage  \nSynonyme   Radiation, irradiation  Satellite metastasis, In -transit \nmetastases, In -transi t \nmetastasis, Intransit \nmetastases, Intransit \nmetastasis   \nOber -/Unterbegriffe  cutaneous, skin, \nsubcutaneous   Local recurrence, \nLocoregional recu rrence, \nLocoregional spread, \nLocoregional metastases, \nLocoregional m etastasis, \nrelapse  relapse  \nMesh Term  melan oma radiotherapy, radiat ion Neoplasm Recurrence, Local   \n \nPICO \u2013 Schema (Fernmetastasen)  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients with di stant \nmetastases, Stage IV  radiotherapy  no radiotherapy  Lesion response, overall response, \nsurviv al, toxicity, qual ity of life  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 640 von 817 \n \nSuchw\u00f6rter (Fernmetastasen)  \nStichwort  melanoma  radiotherapy  Postoperative  \npalliative  metastases  \nSynonyme   Radiation, irradiation   Stage IV  \nOber -/Unterbegriffe  radiosurgery  \n  lung, pulmonal  \nbone  \nspinal cord  \nspine  \nliver, hepatic  \nvisceral \nskin, dermal  \nMesh Term  melanoma     \n \n7.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie (Instransitmetastasen)  Datum  Treffer \n1. Suche     \nMedline  (melanoma[tiab] OR melanoma[MeSH]) AND (radiotherapy[tiab] OR radiother apy[MeSH] OR \nradiation[tiab] OR radiation[MeSH]) AND (\"Satellite metastases\" OR \"Sa tellite metastasis\" OR \"In -\ntransit metastases\" OR \"In -transit metastasis\" OR \"Intransit metastases\" OR \"Intransit metastasis\" \nOR \"Local recurrence\" OR \"Locoregional recurrence \" OR \"Locoregional spread\" OR \"Locoregional \nmetastases\" OR \"Locoregional m etastasis\" OR \u201cNeoplasm Recurrence, Local\u201d[MeSH]) NOT (uvea*[ti] \nOR anorectal[ti] OR mucosal[ti])  14.04.11  477   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 641 von 817 \nDatenbank  Suchstrategie (Instransitmetastasen)  Datum  Treffer \nMedline \u2013 erweiterte \nSuchstr ategie  (melanoma[tiab] OR melanoma[MeSH])  AND (radiotherapy[tiab] OR radiother apy[MeSH] OR \nradiation[tiab] OR radiation[MeSH] OR irradiation) AND (skin OR cutaneous OR subcutaneous OR \n\"Satellite metastases\" OR \"S atellite metastasis\" OR \"In -transit metastases\" OR \"In -transit metastasis\" \nOR \"Intran sit metastases\" OR \"Intransit metastasis\" OR \"Local recurrence\" OR \"Locoregional \nrecurrence\" OR \"Locoregional spread\" OR \"Locoregional metastases\" OR \"Locoregional m etastasis\" \nOR \u201cNeoplasm Recurrence, Local\u201d[MeSH] OR salvage OR relapse) NOT (uvea*[ti] OR a norectal[ti] OR \nmucosal[ti])  04.07.11  4872  \nCochrane Library  (melanoma and (radiotherapy or radiation or irradiation) and (skin or cutaneous or su bcutaneous \nor Satellite metastases or Intransit metastases or Locoregional metastases or salvage or relapse or  \nrecurrence or locoregional spread)).ti,ab.  10.06.11  33  \nEmbase  (melanoma and (radiotherapy or radiation or irradiation) and (skin or cutaneous or su bcutaneous \nor Satellite metastases or Intransit metastases or Locoregional metastases or salvage or relaps e or \nrecurrence or locoregional spread)).ti,ab.  11.05.11  2710   \n \n \nUpdate Suche     \nMedline  s.o. 31.01.12  4980 (0 \ndazu)  \nCochrane Library  s.o. 31.01.12  33 (0 dazu)  \nEmbase  s.o. 23.01.12 2889 (0 \ndazu)  \nGesamttreffer   7902  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 642 von 817 \nDatenbank  Suchstrategie (Fernmeta stasen)  Datum  Treffer \n1. Suche     \nMedline (melanoma[tiab] OR melanoma[MeSH]) AND (radiotherapy[tiab] OR radiation[MeSH] OR \nradiosurgery[tiab] OR irradiation[tiab]) AND (postoperative[tiab] OR pallia tive[tiab] OR \nmetastas*[tiab] OR \"stage IV\"[tiab] OR lun g[tiab] OR pulmonal[tiab] OR bone[tiab] OR \"spinal \ncord\"[tiab] OR \"spine\"[tiab] OR liver[tiab] OR hepatic[tiab] OR visceral[tiab] OR skin[tiab] OR \ndermal[tiab])  16.05.11 3273  \nCochrane Library  (melanoma and (radiotherapy or radiation or irradiation or rad iosurgery) and (pos toperative or \npalliative or metastasases or \"stage IV\" or lung or  pulmonal or bone or \"spinal cord\" or \"spine\" or \nliver or hepatic or visceral or skin or dermal)).ti,ab.  19.05.11  28 \nEmbase  (melanoma and (radiotherapy or radiation or ir radiation or radiosurgery) and (pos toperative or \npalliative or metastasases or \"stage IV\" or lung or  pulmonal or bone or \"spinal cord\" or \"spine\" or \nliver or hepatic or visceral or skin or dermal)).ti,ab.  11.05.11  2915  \n \nUpdate Suche     \nMedline s.o. 31.01.12 3359 (0 \ndazu)  \nCochrane Library  s.o. 31.01.12  28 (0 dazu)  \nEmbase  s.o. 23.01.12  3032 (0 \ndazu) \nGesamttreffer   6419  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 643 von 817 \n7.2.3.  Auswahlkriterien  \nAuswahl der Literatur (Intransit - und Fernmetastasen)  \nGesamttreffer (Intransit - und Fernmetastasen)  14321  \nEinschlus skriterien  Arbeiten die d ie Radiotherapie  von Fern - und Intransit metastasen  bei Patienten mit metastasiertem M elanom beschreiben  \nMangels RCT\u00b4s Einschluss von Kohortenstudien und Fallserien ab 20 Patienten , bzw. ab 20 L\u00e4sionen (bei Angabe von \nl\u00e4sionsbezogen en Re sponsedaten)  \nSprachen: e,dt  \nAusschlusskriterien  ausschliesslich ZNS Metastasen (siehe Frage VI.4.)  \nKollektive mit gemischten Tumorentiti\u00e4ten  \nNicht systematischer Review  \nPublikation vor 1980  \nAnzahl ausgew\u00e4hlter Volltexte  23 \nBermerkungen:  \nDa zum Thema keine ranomisierten Studien existieren, wurden Fallberichte aufgenommen (Level 4). Kollektive mit ausschliesslicher ZNS Met astasierung wurden \nausgeschlossen.  Arbeiten mit historischen Verfahren (Bremer et al. 1999) wurden ausgeschlossen. Aufgrund der \u00dcbe rlappung der gefundenen Arbeiten aus \nbeiden Suchen wur den diese in einer gemeinsamen Evidenztabelle zusammengefasst  \n \n7.2.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nOvergaard et al. \n2009  \n \n(original \npublic ation 1996)  To investiga te the \nvalue of \nhyperthe rmia as an \nadjuvant to \nradiotherapy in RCT \n \nTreatment  \nRT vs \nRT+Hyperthermia 70 patients, 134 \nlesions, skin \nlesions: n=93   \n \n \n \nResponse  128 evaluable \ntumors, RT vs RT + \nHT \n \nCR: 35% vs 62% , Randomisation \nbased on lesions, \nnot on patients  \nResponse \nassess ment was 4 \n \n1b \n(question \nRT vs RT + \nHT)  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 644 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntreatment of \nmalignant \nmelanoma  (HT) \n \nRT; high voltage \nphotons or \nelectrons   \n \n \n \nOverall 5 -year \nSurvival Rate  \n sign.,  p=0.003  \nPR: 37% vs 27% \nn.s. \nNR: 28% vs 11% \nn.s. \n \n68 evaluable \npatients: 19%  not blinded  \nresponse was not \nanalyzed \nseparately for node \nand cutaneous \nlesions  \nRichtig et al. 2005  To evaluate t he \norgan -specific \nresponse rate, \nlocal response rate \nof each therape utic \nmeasure and \nsurvival of 68 \npatients with stage \nIV disease Retrospective \nevaluation  \n \nTreatment:  \nRT: TD 30 \u2013  50 Gy, \nfraction size 2 - 4 \nGy \nGama knife \nSurgery  \nLocal hyperthe rmia \nChemotherapy  68 patients with \nunresectable stage \nIV disease  \n \n46 treatment \nperiods \nradiother apy \n(total: 410 \ntreatment periods)  Respo nse  \n CR+PR (in regard  \nto treatment \nperiods):  \nTotal 12/46 (26%)  \nLymph N ode 3/9  \nBone 0/10  \nCutaneous / \nsubcutaneous 2/3  \nOther 2/3  \nBrain 5/21  No patient r elated \nresponse data \navailable 4 \nKirova et al. 1999  To assess the \nresponse rate and \nefficacy of \npallia tive radiation \ntherapy in patients \nwith m etastatic \nmelanoma  Retrospective \nevaluation  \n \nTreatment (most \npatients): TD 30 or \n20 Gy, fraction \nsize 3 or 4 Gy  28 patients, 35 \nsites,  \nbone and soft \ntissue metastases \nn=20,  \nbrain m etastases \nn=8  Response  \n Clinical response  \nbone metast ases \n67%  \n Response was \ndefined as relief of \nsymptoms  \nLack of response \nand survival data  4 \nSeege nschmiedt et \nal. 1999  To analyze \ndifferent endpoints Retrospective \nevaluation  121 patients of a \nmelanoma registry Response  \n Stage IV (n=53), at  \n3 months  Detailed analyses,  \nlarge cohort,  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 645 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nand prognostic \nfactors in patients \nwith locally \nadvanced, \nrecurrent or \nmetastatic \nmelanoma   \nTreatment: median \nTD 48 (range 20 -  \n66) Gy, fraction \nsize 2 \u20136 Gy with 2,917 \npatients  \n \nStage IV n=53 \n(distant LN, SK, ST \nmets n=7, visceral \norgan mets n=46)  \n  \n \n \n \n \n \n \n \n \n \n \nSuvival Rate (mean \nfollow up 7.8 \nyears)  CR n=9 (17%)  \nPR n=17 (32%)  \nNC n=12 (23%)  \nPD n=15(28%)  \n \nStage III (n= 57)  \nCR n=25 (44%)  \nPR n=19 (33%)  \nNC n=5 (9%)  \nPD n=8 (14%)  \n \nStage IV 6%  \nStage III 30%)  Results are \nreported \nsepara tely for \ndifferent stages, \nstage III i ncludes \nlymph node and \nintransit -\nmetastases \nresponse was not \nanalyzed \nseparately for node \nand cutaneous \nlesions  \nEngin et al. 1993  To present the \nexperience with \nhyperthermia \ncombined with \nradiation in \nadvanced \nmelan oma patients \nbetween 1980 -\n1988  Retrospective \nevaluation  \n \nTreatment:  \nRT mean TD 37 \n(range 13 -  66) Gy, \nmean fra ction size \n3.6 Gy (range 2 -  \n5.5) combined with \nhyperthermia  40 melanoma \npatients with 48 \nlesions, Stage IV \nlesions n=26  Response  Evaluable lesion s \n(n=33) \nCR n=12 (36%)  \nPR n=17 (52%)  \n WHO/UICC criteria \nwere used to \nassess tumor \nresponse  4 \nPyrh\u00f6nen et al. \n1992  To present 15 \npatients with \nhistolo gically \nproven recu rrent \nor metast atic Case Series  \n \nTreatment:  \nElectron beams at \nappropriate 15 melanoma \npatients, 89 \ntreated lesions  \nskin n=68 (76%)  \n transplanted skin Response  Evaluable lesions \n(n=89) \n \nCR n=61 (69%)  \nPR n=25 (28%)   4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 646 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncutaneous \nmelan omas treated \nwith large fractions \nbetween April \n1987  and May \n1991  energies (6 -15 \nMeV). A total dose \nof 40 Gy was given \nin 8 fra ctions \n(fraction size 5 Gy) \nover 23 days.  n=3 (3 % ) \n subcut aneous \nn=11 (12%)  \nlymph nodes n=7 \n(8%) No response n=3 \n(3%) \nHerbert et al. 1991  To evaluate the \nefficacy of \npallia tive radiation \ntherapy in the \ntreatment of spinal \ncord and  \ncauda equina \ncompression due \nto metastatic \nmalignant \nmelanoma  Retrospective \nevaluation  \n \nTreatment:  \nRT (all patients), \ndecompressive \nlaminectomy \n(n=11), st eroids \n(n=32) \n \nRT: cobalt -60, 6 or \n15 MV, median TD \n2850 cGy (range, \n500 to 4000 cGy), \nfraction size 200 -\n800 cGy 35 patients with \nspinal cord and \ncauda equina \ncompression, 38 \nsites treated  Response  \n \n \n \n \n \n \nMedian Overall \nSurvival (OS)  28 sites (in 26 \npatients) evalu able \n \nCR 11 sites (39%)  \nPR 13 sites (46%)  \nORR 24 sites (86%)  \n \nOS all patients: 11 \nweeks (range 4 \u2013 \n35 weeks)  multivariate \nanalysis performed \nbut not presented \nin detail, small \nsample size  \n 4 \nChadha et al. 1990 To evaluate the \nrole of \nbrach ytherapy in \nthe ma nagement \nof locally advanced \nmalignant \nmelan oma. Retrospective \nevaluation  \n(1979 -1986)  \n \nTreatment : \nbrachytherapy, \ntemporary and 33 melanoma \npatients with \nlocally advanced \ndisease \nwith/without nodal \ndisease or distant \nmetastases  \n \nLocal \ncontrol/Implant \nsite: \n \n 33 patients  \n \n80% at 6 months \n42% at 1 year  \n \nExtremity v s. \nIntrathoracic and Baseline \ncharact eristics are \nnot pr esented in \ndetail, clinical \nstages not \nindicated  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 647 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npermament \nimplants, different \ndoses   chest wall vs. \nGynecologic & \nintra-abdominal vs. \nHead and neck  \n \nn=13 of 14 vs. n=4 \nof 9 vs. n=3 of 7 \nvs. n=0 of 2  \nKonefal et al. 1988  To see if the use of \nlarger dose \nfractions increased \nthe rate of \npalliation of \nvisceral melan oma \nmetastases Retrospective \nevaluation  \n \nTreatment:  \nTD range <2000  -  \n5000 cGy, fra ction \nsize < 200 to  > \n600 63 patients, 89 \nvisceral m etastases \ntreated, 65 \nevalu able Response  40 of 65 lesions \n(62%)  \n19 of 28 bone \nmetastases (68%)  response was \ndefined as the \nsignif icant relief \nfrom symp toms for \nat least 2 months  4 \nRate et al. 1988  To present the \nexperience with \npalliative \nradioth erapy for \nmalignant \nmelanoma \nmetastatic to \nbrain,  to bone, or \nwith spinal cord \ncompre ssion. Retrospective \nevaluation  \n \nTreatment:  \nTD 1100 -  4000 \ncGy, fraction size \n115 cGy -  1100 \ncGy  26 patients with \n39 bone \nmetastases, 17 \npatients with \nspinal cord \ncompression  Response  Bone:  \n33 of 39 l esions \n(85%)  \nSpinal cord \ncompression:  \n(8/17) 47%  \nPartial palliation \n24% (4/17).  response was \ndefined as pain \nrelief  4 \nRounsaville et al. \n1988  To review the \nexperience of Retrospective \nevaluation  81 patients  \n29 patients (51 Response  Measurable tumor:  \nCR 4 of 51 sites Definition \nresponse in bone 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 648 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nthree San Francisco \nradiation oncology \ndepar tments   \nTreatment: TD \nrange 600  \u2013 7700 \ncGy, fra ction size \n180 - 1000  sites) with \nmeasu rable tumor \n(Lymph node, skin, \nliver, mucosa, \nspleen)  \n15 patients (28 \nsites) with bone \nmetastes  (8%) \nPR 22 of 51 sites \n(43%)  \nBone  metastases:  \n24 of 28 sites \n(86%)  metastases: \nmarked regression \nor elimination of \npain \nMameghan et al. \n1988  To assess the \nacute skin reaction \nafter treatment \nand to measure \nthe response of \nthe mel anoma  Case Series  \n \nTreatment:  \nRadiotherapy alone \n(15 lesions)  \nHeat therapy alone \n(6 lesions)  \nCombined \nradiation and heat \ntherapy (11 \nlesions)  12 melanoma \npatients with 32 \nlesions  \nsubcutaneous \ntissue n=26  \nLymph node n=5  \nCheek n=1  Response  All lesions (n=32)  \n \nCR n=14(44%) \nPR n=10(31%)  \nNo response \nn=2(6%) \nNot evaluable n=6 \n(19%)  \n \nLesions treated \nwith radiotherapy \nalone (n=15)  \nCR n=8  \nPR n=2  \nNo response n=1  \nNot evaluable n=4   4 \nKonefal et al. 1987  To retrospectively \nanalyze the results \nof 67 cutaneous or \nlymph node \nmeta static lesions, Retrospective \nevaluation  \n(1970 -1985)  \n \nTreatment:  35 melanoma \npatients with 67 \ncutaneous or \nlymph node \nmetastatic lesions, Response  \n All lesions (n=67)  \n \nOverall Tumor \nControl n=14  \nCR n=16  Overall tumor \ncontrol indicates \nthat lesions were \ncontrolled at the \ntime of patient\u00b4s 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 649 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfocusing on \ndoset ime \nfractionation and \ntumor respo nse TD 18 -66 Gy, \nfraction size 1.5 - \n8 Gy, i ntervals \ndaily to weekly  \n 30 cutaneous \nlesions  \n \n PR n=23  \nNo response n=28  \n \n death or at last \nfollow -up \nPR was defined as \n>50% reduction of \ntumor size \nOvergaard et al. \n1987  To present the \nexperience with \nhyperthermia and \nradiotherapy in \nmetastatic \nmelanoma patients  Retrospective \nevaluation  \n \nTreatment:  \n- Radiation alone \n(TD 15 -30 Gy) \nn=62 sites  \n- Simultaneous \nheat plus radiation \nn=26  \n- Sequential \nradiation plus heat \nn=27  \n- heat alone n=3  36 patients, many \npatients with \ndisseminated \ndisease,  \n118 lymph node \nand cutaneous \nmeta stases  \n Response  \n 102 lesions \nevalu able \nCR n=57 (56%)  \nPR n=32 (31%)  \nNR n=13 (13%)  Patient baseline \ncharacteristics are \nmissing , no \nresponse data \navailable for \ntumors treated \nwith radi ation \nalone.  \nPR was def ined as \n>50% redu ction of \ntumor size  4 \nOvergaard et al. \n1986  Some factors of \nimportance in the \nradiation trea tment \nof malignant \nmelanoma  Retrospective \nevaluation  \n \nTreatment:  \nTD median 40 Gy, \nrange 8 -77, \nfraction size \nmedian 5 Gy, \nrange 2 \u2013  11, \nnumber of 204 cutaneous or \nlymph node \nlesions in 114 \npatients with \nrecurrent or \nmeta static \nmelanoma, 45 \npatients with only \nlocal or regional \ndisease   \n \n \nLocal tumor \ncontrol  \n \n3 year survival  45 patients with \nregional disease  \n \nn=26 of 45 (58%)  \n \n56% Baseline \ncharact eristics are \nnot pr esented in \ndetail, clinical \nstages not \nindicated,  \nresponse for node \nand cutaneous \nlesions was not \nanalyzed 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 650 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfractions median \n10, range 1 -27. \n separately  \nBlake et al. 1985  Treatment of \nmalignant \nmelanoma by fast \nneutrons  Retrospective \nevaluation  \n \nTreatment:  \n75 MeV neutron \nbeam, TD 156O or \n1395 cGy in 12 or \n6 fractions  48 patients, 87 \nprimary, recurrent \nor metastatic \ntumors   \n \nResponse  \n \nRecurrence  \n \nComplications  All sites n= 87  \n \nCR n=62 (71%)  \n \nn=8 (9%)  \n \nn=19 (22%)  Baseline \ncharact eristics are \nnot pr esented in \ndetail, clinical \nstages not \nindicated,  \nresponse for \nprimary, recurrent \nor metastatic \nlesions was not \nanalyzed \nseparately  4 \nKhan et al. 1984  To evaluate th e \nresults of different \nmodes of \ntreatment the \nrecords of 182 \nmelanom pat ients, \nreferred to the \nRegional \nRadiother apy \nCentre, Newcastle \nupon Tyne \nbetween January \n1975 and \nDece mber 1980 Retrospective \nevaluation  \n \nTreatment:  \nexternal beam \nradiotherapy \n(collimated beam \nfrom cobalt -60 and \ncaesium -137 \ntelether apy units, \nor 100 -250 keV or \n4-8 MeV X -rays)  \ndifferent \nfraction ation 63 melanoma \npatients (42 Stage \n2, 21 Stage 3) with \n74 sites of dise ase \n(skin and lymph \nnodes, 58; bone, \n8; brain, 8) \n Response  \nDuration of \nremiss ion Overall response \nrate 73%  \nCR 47%  \nPR 26%  \n \nSites with skin and \nlymph node \nmeta stases (58):  \nCR 35 (60%)  \nPR 8 (14%)  \n \nBone metastases \n(8): \nCR 0  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 651 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nhave been \nreviewed regimes and tumor \ndoses  PR 6 (75%)  \n \nMedian duration of \nremission 7 \nmonths (range 1 -\n72) \nJohanson et al. \n1983  To report the the \nexperience of the \nPrincess Margaret \nHospital with large \ndose per fraction \n(800 rad) \nradioth erapy in the \ncurative and \npalliative treatment \nof nod ular \nmelanoma  Retrospective \nevaluation  \n(1975 -1980)  \n \nTreatment: TD \n2400 rad, fraction \nsize 800 rad, given \non day 0, day 7, \nand day 21  23 patients with \nrecurrent \nmelan oma  \n \nResponse  \n \n n= 23 patients  \n \nCR, no local \nrecurrence n=7  \nCR, local \nrecurrence n=2  \nPR n=5  \nSD n=3  \nno response n=6  \n clinical stages not \nindicated,  \nresponse was not \nanalyzed \nseparately  4 \nDoss et al. 1982  To review the \ninstitutional \nexperience  Retrospective \nevaluation  \n \nTreatment: TD \nrange 500 to \n<4500 cGy, \nfraction size 100 - \n1250  27 patients, 41 \nlesions  Response  CR 15/41 (37%)  \n \n Definition \ncomplete \nresponse: \ndisappearance of \nmeasurable \nlesions, symptoms \nceased within 2 \nmonths after RT  4 \nAdam et al. 1982 Response rate of \nmalignant \nmelan oma to large  22 patients, 24 \nsites, visceral sites \nn=2      \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 652 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfraction irradi ation \nKatz et al. 1981  To determine if \nresults in the \nirradiation of soft \ntissue, visceral, \nand bone \nmetastases were \ncomparable to \nthose previously \nreported in the \nliterature  Retrospective \nevaluation  \n \nTreatment: TD \nrange 1000 to \n6000 rad, fraction \nsize 200 \u2013  1000 \nrad 86 patients  \n \n16 patients with \nvisceral metastases \n(20 lesions)  \n \n32 patients with \nbone metastases \n(48 lesions)  \n \n8 patients with \nskin metastases \n(14 lesions)  Response  \n \n Visceral lesions  \n13 of 20 lesions \n(65%)  \nBone lesions  \n37 of 48 l esions \n(77%)  \n \n Definition \nresponse:  \nsubjective \ndecrease in bon e \npain, redu ction in \nsize to a d egree \nwhich signif icantly \nrelieved the local \ntumor -associated \nsymptoms  4 \nLobo et al. 1981  To evaluate the \nexperience in the \nradiotherapeutic \nmanagement of \npatients with \nmalignant \nmelanoma  Retrospective \nevaluation  \n \nTreatmen t:  \n(bone lesions) TD \nrange 2700 -3000 \nrad, fra ction size \n300 rad  45 patients, 69 \nlesions  \nBone n=22, lung \nn=3, liver n=3  \n Response  bone: 15 of 22 \n(68%)  \nlung: 1 of 3  \nliver 0 of 3  Response was \ndefined as \nimprov ement of \nsymptoms  \n 4 \nStrauss et al. 1981  To eval uate clinical \nresponses of \nmeta static \nmelanoma to four \nradiation  \ndose fractionation Retrospective \nevaluation  \n \nTreatment: fraction \nsize 180 rad to \n800 rad  48 patients, 83 \nsites Response  Soft tissue:29 of \n46 sites (63%)  \nBone: 7 of 9 sites  \n \n  Respons e was \ndefined as \nimprov ement of \nsymptoms  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 653 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nschemes.  \n7.2.5.  Literatur  \n \nAdam JS, Habeshaw T, Kirk J. Response rate of malignant melanoma to large fraction irradiation. Br J Radiol 1982;55:605- 607 \nBlake PR, Catterall M, Errington RD. Treatment of malignant melanoma by fast  neutrons. Br J Surg 1985;72:517- 519 \nChadha M, Hilaris B, Nori D, et al. Role of brachytherapy in malignant melanoma: a preliminary report. J Surg Oncol 1990;43:223 -227 \nDoss LL, Memula N. The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys 19 82;8:1131- 1134  \nEngin K, Tupchong L, Waterman FM, et al. Hyperthermia and radiation in advanced malignant melanoma. Int J Radiat Oncol Biol Phys 1993;25:87 -94 \nHerbert SH, Solin LJ, Rate WR, et al. The effect of palliative radiation therapy on epidural compr ession due to metastatic malignant melanoma. Cancer 1991;67:2472- 2476  \nJohanson CR, Harwood AR, Cummings BJ, et al. 0 -7-21 Radiotherapy in Nodular Melanoma. Cancer 1983;51:226- 232 \nKatz HR. The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. Int J Radiat Oncol Biol Phys 1981;7:907- 911 \nKhan MS, Ross WM. Management of malignant melanoma: a retrospective analysis of 182 patients. Clin Radiol 1984;35:151- 154 \nKirova YM, Chen J, Rabarijaona LI, et al. Radiotherapy as  palliative treatment for metastatic melanoma. Melanoma Res 1999;9:611- 613 \nKonefal JB, Emami B, Pilepich MV. Analysis of dose fractionation in the palliation of metastases from malignant melanoma. Cancer 1988;61:243- 246 \nKonefal JB, Emami B, Pilepich MV. Ma lignant melanoma: analysis of dose fractionation in radiation therapy. Radiology 1987;164:607- 610 \nLobo PA, Liebner EJ, Chao JJ, et al. Radiotherapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys 1981; 7:21- 26 \nMameghan H, Knittel T. Re sponse of melanoma to heat and radiation therapy --a review of the literature and experience from The Prince of Wales Hospital, Sydney. Med J Aust \n1988;149:474- 6, 478- 81 \nOvergaard J, Gonzalez Gonzalez D, Hulshof MC, et al. Hyperthermia as an adjuvant to rad iation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial \nby the European Society for Hyperthermic Oncology. 1996. Int J Hyperthermia 2009;25:323- 334 \nOvergaard J, Overgaard M. Hyperthermia as an adjuvant to radiotherapy i n the treatment of malignant melanoma. Int J Hyperthermia 1987;3:483- 501 \nOvergaard J, Overgaard M, Hansen PV, et al. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 1986;5:183 -192 \nPyrhonen SO, Kajanti MJ. The us e of large fractions in radiotherapy for malignant melanoma. Radiother Oncol 1992;24:195 -197 \nRate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Rad iat Oncol Biol Phys \n1988;15:859- 864 \nRichtig E, Ludwig R, Kerl H, et al. Organ - and treatment -specific local response rates to systemic and local treatment modalities in stage IV melanoma. Br J Dermatol 2005;153:925 -931 \nRounsaville MC, Cantril ST, Fontanesi  J, et al. Radiotherapy in the management of cutaneous melanoma: effect of time, dose, and fractionation. Front Radiat Ther Oncol 1988;22:62- 78 \nSeegenschmiedt MH, Keilholz L, Altendorf -Hofmann A, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long -\nterm outcome: a 20 -year experience. Int J Radiat Oncol Biol Phys 1999;44:607- 618 \nStrauss A, Dritschilo A, Nathanson L, et al. Radiation therapy of malignant melanomas: an evaluation of clinically used fractionation schemes. Cancer 1981;47:1262- 1266  \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 654 von 817 \n7.3. Frage VI.4. Radiotherapie und Chirurgie Hirnmetastasen  \nFrage VI.4. Wie ist der Einfluss unterschiedlicher Behandlungsmodalit\u00e4ten und deren Kombinationen (Operation, Ganzhirnbestrah lung, \nEinzeitbestrahlung) auf das Gesamt\u00fcberleben, die lokale Kontrolle, die intrakranielle Kontrolle, Verl\u00e4ngerung der symptomfreien Z eit und \nLebensqualit\u00e4t bei Patienten mit cerebralen Metastasen?  \n7.3.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients with cerebral \nmetastases Radiotherapy, surgery, stereotactic \nradiosurgery, combinations  no therapy  OS, local control, time without \nsymptoms, QoL  \n \nSuchw\u00f6rter  \nStichwort  Melanoma  radiotherapy  surgery  brain  \nSynonyme   Radiation, irradiation  resection, excision  Cerebral  \nCNS \nCentral Nervous System  \nOber -/Unterbegriffe   Stereotactic  \nradiosurgery    \nMesh Term  melanoma  radiotherapy, radiation    \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 655 von 817 \n7.3.2.  Datenbanken, Suchstrategien, Trefferzahlen  \n7.3.2.1.  Prim\u00e4rrecherche 2012  \nDatenbank  Suchstrategie  Datum  Treffer  \n1. Suche  \nMedline  (melanoma[tiab] OR melanoma[MeSH]) AND (radiotherapy[tiab] OR radiotherapy[MeSH] OR \nradiation[tiab] OR radiation[MeSH] OR \u201cIrradiation\u201d[tiab] OR Stereotatic[tiab] OR \nradiosurgery[tiab] OR surgery[tiab] OR resection[tiab] OR excision[tiab]) AND (brain[tiab] OR \ncerebral[tiab] OR CNS[tiab] OR \"Central Nervous System\"[tiab])  \n 19.09.11  874 (Auswahl \n64) \nCochrane Library  (melanoma and (radiotherapy or radiation or irradiation or stereotatic or radiosurgery or \nsurgery or resection o r excision) and (brain or cerebral or CNS)).ti,ab. 19.09.11  10 (Auswahl: \nMornex, \nDublette, \nzus\u00e4tzliche \nAuswahl 0)  \nEmbase  (melanoma and (radiotherapy or radiation or irradiation or stereotatic or radiosurgery or \nsurgery or resection or excision) and (brain  or cerebral or CNS)).ti,ab.  10.05.11 823 \n(zus\u00e4tzliche \nAuswahl 0)  \nUpdate Suche  \nMedline  s.o. 31.01.12  889 (0 dazu)  \nCochrane Library  s.o. 31.01.12 10 (0 dazu)  \nEmbase  s.o. 23.01.12  903 (0 dazu)  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 656 von 817 \n7.3.2.2.  Aktualisierungsrecherche 2015  \nDatenbank  Suchstrategie  Datum  Treffer  \nMedline  (((melanoma[tiab] OR melanoma[MeSH]) AND (radiotherapy[tiab] OR radiotherapy[MeSH] ORradiation[tiab] \nOR radiation[MeSH] OR \u201cIrradiation\u201d[tiab] OR Stereotatic[tiab] OR radiosurgery[tiab] OR surgery[tiab] OR \nresection[tiab] OR excision[tiab ]) AND (brain[tiab] OR cerebral[tiab] OR CNS[tiab] OR \"Central Nervous \nSystem\"[tiab]))) AND (\"2011.09.20\"[Date -  Publication] : \"2015.09.16\"[Date - Publication])  16.09.2015  246 \nCochrane \nLibrary  (melanoma and (radiotherapy or radiation or irradiation or s tereotatic or radiosurgery or surgery or \nresection or excision) and (brain or cerebral or CNS)).ti,ab. 16.09.2015  39 \n7.3.3.  Auswahlkriterien  \n7.3.3.1.  Prim\u00e4rrecherche 2012  \nAuswahl der Literatur  \nGesamttreffer  1802  \nEinschlusskriterien  Studien, die mind. einen der Paramete r Gesamt\u00fcberleben, lokale Kontrolle, symptomfreie Zeit oder Lebensqualit\u00e4t bei \nMelanompatienten nach Radiotherapie oder Operation von Hirnmetastasen beschreiben  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports \nNicht systematische Reviews  \nKollektive mit gem ischten Tumorentiti\u00e4ten  \nErweitertes \nAusschlusskriterium  Studien ohne Vergleichsgruppe  \nRetrospektive Kohortenstudie ohne Multivariatanalyse  \nPublikation vor 1980  \nAnzahl nach Abstractscreening, vorgesehen f\u00fcr Bewertung  64  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 657 von 817 \nAuswahl der Literatur  \nAnzahl der ausgeschlossenen Studie n nach Sichtung der Volltexte  57 \nAnzahl ausgew\u00e4hlter Volltexte  7 \n7.3.3.2.  Aktualisierungsrecherche 2015  \nAuswahl der Literatur  \nGesamttreffer  285 \nEinschlusskriterien  Studien, die mind. einen der Parameter Gesamt\u00fcberleben, lokale Kontrolle, symptomfreie Zeit oder Lebensqualit\u00e4t bei \nMelanompatienten nach Radiotherapie oder Operation von Hirnmetastasen beschreiben  \nRCTs  \nSystemische Reviews  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports  \nNicht systematische Reviews  \nKollektive mit gemischten Tumorentiti\u00e4ten  \nNon-RCTs  \nErweitertes \nAusschlusskriterium  Studien ohne Vergleichsgruppe  \nRetrospektive Kohortenstudie ohne Multivariatanalyse  \nPublikation vor 1980  \nAnzahl nach Abstractscreening, vorgesehen f\u00fcr Bewertung  64 \nAnzahl der ausgeschlossenen Studien nach Sichtung der Vollte xte 57 \nAnzahl ausgew\u00e4hlter Volltexte  3 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 658 von 817 \n7.3.4.  Evidenztabelle  \n7.3.4.1.  Prim\u00e4rrecherche 2012  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nEigentler et al. \n2011  To identify \nprognostic factors \nin patients with \nbrain metastases \n(BM) from \nmalignant \nmelanoma  Retrospective \nsurvival analysis  \n \nTreatment:  \nSRS + Surgery \n(n=122)  \nWBRT + \nChemotherapy \n(n=92) \n 692 patients  Median Survival  \n(from date of \ndiagnosis of brain \nmetastases)  \n Entire cohort \n(n=672)  \n5 months  \n \nSRS + Surgery vs.  \nWBRT + \nChemotherapy  \nSingle BM: \n9 vs. 6 months, \np=0.036  \n \n<3 BM:  \n6 vs. 7 months,  \np=0.448  \n \nmultivariate \nanalysis  \nindependent \nprognostic factors  \n- entire cohort: \nsingle vs. multiple \nBM,  HR 1.6, 95% \nCI 1.3 -2.7, \np=0.002  \n \nLDH not elevated \nvs. elevated, HR Retrospective \nstudy  \nlarge cohort  \nSRS vs. Surgery \nwas not compared  \n \nFunding: in part by \nan educational \ngrant from \nEssex/Schering -\nPlough. 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 659 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n1.6, 95% CI 1.1 -\n2.4, p=0.01 \n \n- Single B M: \nSRS or surgery vs. \nWBRT and/or \nchemotherapy, HR \n1.5, 95% CI 1.1-\n1.9, p=0.0061 \nStaudt et al. 2010  To identify \nprognostic factors \nin patients with \nbrain metastases \nfrom cutaneous \nmelanoma  Retrospective \nsurvival analysis  \n \nTreatment:  \nSurgery (n=63)  \nSRS (n=31) \nWBRT (n=122)  \nchemotherapy \n(n=28) \nno therapy (n=12)  265 patients  \n \n36.7% had local \ntreatment \n(neurosurgery or \nstere otactic \nradiosurgery (SRS)  Median Survival  \n(from date of \ndiagnosis of brain \nmetastases)  \n \n \n \n \n \n \n \n \n \n \n Entire cohort \n(n=265)  \n5 months, 95% CI \n4.3\u20135.7 months  \n \nsurgery vs. SRS vs. \nWBRT vs. \nchemotherapy vs. \nno therapy  \n9 vs. 9 vs. 4 vs. 3 \nvs. 1 month(s)  \n \nmultivar iate \nanalysis  \nindependent \nfavourable \nprognostic factors: \nLDH level, type of \ntherapy, number of \nbrain metastases, \npresence of bone Retrospective \nstudy  \ndetailed data, few \nmissing cases  \n \nfollow up time not \nmentioned (but at \ntime of analysis \nalready 253 \ndeaths)  \n \nFunding: not \nmentioned  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 660 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmetastasis  \nsurgery (n=63) vs. \nSRS (n=31):  \nHR 1.0, 95% CI 0.6 \n\u2013 1.8 \nRaizer et al. 2008 To gain a better \nunderstanding of \npatient and \ndisease \ncharacteristics that \nhave the greatest \nimpact on overall \nsurvival in \nmelanoma patients  \nwith brain \nmetastases Retrospective \nsurvival analysis  \n \nTreatment:  \nSurgery (n=126)  \nSRS (n=78) \nTemozolomide \n(n=113)  \nWBRT (n=190)  \n 355 patients  Median Survival  \n(from date of \ndiagnosis of brain \nmetastases)  \n \n \n \n \n \n \n \n \n Entire cohort \n(n=335)  \n5.2 months (range \n0.1 \u2013 155 months)  \n \nsurgery vs. SRS vs. \nTemozolomide vs. \nWBRT  \n \n9.3 vs. 10.0 vs. 7.9 \nvs. 6.1 months  \n \nmultivariate \nanalysis  \nsurgery: RR 0.56, \n95% CI 0.43 \u2013  0.75 \nSRS:  RR 0.69, 95% \nCI 0.50 \u2013  0.94 Retrospective \nstudy  \n \nMedian follow up \namong surviving \npatients 18 .4 \nmonths  \n \nFunding: Schering -\nPlough \nInternational 3b \nFife et al. 2004  To analyze \nprognostic factors, \neffects of \ntreatment, and \nsurvival for \npatients with Retrospective \nsurvival analysis  \n \nTreatment:  \nsurgery+RT \n(n=158)  1137 patients with \ncerebral \nmetastases; 686 \nwith therapy  Median survival \n(from date of \ndiagnosis of brain \nmetastases)  \n \n Entire cohort \n(n=1137)  \n4.1 months (range, \n0 to 17.2 years)  \n \nSurgery+RT vs. Retrospective \nstudy Large cohort  \nresults of \nunivariate analyses \nnot shown, only \n578 of 686 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 661 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncerebral \nmetastases from \nmelanoma.  surgery (n=47)  \nradiotherapy \n(n=236)  \nsupportive care \nalone (n=210)  \n  \n \n \n \n \n \n surgery vs. RT vs. \nsupp.care  \n \n8.9 vs. 8.7 vs. 3.4 \nvs. 2.1 months  \n \nmultivariate \nanalysis  \nPrognostic factors:  \nsurgical treatment \n(p<0.0001), no \nconcurrent \nextracerebral \nmetastases \n(p<0.0001), \nyounger age \n(p=0.0007), longer \ndisease -free \ninterval ( p=0.036)  patients included  \nmissing data not \nadressed  \n \nFunding:  \nSupported by the \nMelanoma \nFoundation of the \nUniversity of \nSydney and the \nMelanoma and \nSkin Cancer \nResearch Institute  \nMornex et al. 2003  To compare a \ncombined regimen \nof fotemustine \nplus whole brain \nirradiation with \nfotemustine alone  RCT \n \nTreatment:  \n \nGroup A: \nFotemustine (n = \n39) \n \nGroup B: \nfotemustine + \nWBRT (n = 37)  76 patients  \n   \n \n \nMedian survival \n \n \n \n \ncerebral response \nafter 7 weeks  \n Group A vs. B (ITT \npopulation)  \n \n86 days (2.8 \nmonths) vs. 105 \ndays (3.4 months) \nn.s.  \n \n5.1% (95% CI 1 \u2013\n17%) vs. 8.1% (95% \nCI 2\u201322%), p=0.60 Early termination \nof study, small \nsample size  \nIndependent tumor \nassessment  \n \nFunding: not \nmentioned  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 662 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n  \ncontrol rates \n(objective \nresponses + stable \ndisease) after 7 \nweeks  \n \ntime to cerebral \nprogression   \n23.1% (95% CI 10 \u2013\n36%) vs. 37.8% \n(95% CI 22 \u201354%), \np=0.16 \n \n \n49 days (1.6 \nmonths) vs. 80 \ndays (2.6 months), \np=0.030  \nWronski et al. \n2000  To review the \nsurgical \nexperience in a \nseries of patients \nwith brain \nmetastases from \nprimary melanoma  Retrospective \nsurvival analysis  \n \nTreatment:  \nSurgery alone \n(n=29) \n \nSurgery + WBRT \n(n=49) 91 patients  Median survival \nfollowing \ncraniotomy  \n \nsurvival rates  \n1 year  \n2 years  \n3 years  \n5 years  \n \n \n \n \n \n \n \n Entire cohort \n(n=91) \n6.7 months  \n \n \n \n36.3%  \n18.7%  \n13.2%  \n6.6% \n \nSurgery alone \n(n=29) vs. \nSurgery+WBRT \n(n=49) \n8.3 vs. 9.5 \nmonths, p = 0.67 \n \nmultivariate Retrospective \nstudy, small \nsample size,  \nresults of \nmultivariate \nanalyses not \npresented in detail  \n \nFunding: not \nmentioned  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 663 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nanalysis  \nnegative impact on \nsurvival: lack of \nresection of \nrecurrent b rain \ntumor (p =0.0003) \nand infratentorial \nlocation of brain \nmetastases (p = \n0.0013)  \nStevens et al. 1992  To analyze factors \naffectin g survival \nin 129 patients \nwith cerebral \nmetastases from \nmalignant \nmelanoma  Retrospective \nsurvival analysis  \n \nTreatment:  \nRadiotherapy \n(n=74) \nSurgery + \nRadiotherapy \n(n=45) 129 patients  Median survival \nafter detection of \ncerebral \nmetastases \n \n \n \n \n \n \n Entire coh ort \n(n=127) 5 months  \n \nRadiotherapy vs. \nSurgery + \nRadiotherapy  \n4 vs. 9 months \n(p<0.001) \n \nmultivariate \nanalysis  \nIndependently \nassociated with a \nprolonged survival: \nSurgery, p=0.004 Retrospective \nstudy,  \nmultivariate \nanalysis not \npresented in detail  \n \nFundin g: not \nmentioned  3b \n \nAusgeschlossene Studien  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 664 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nLonser et al. 2011  to determine the \neffectiveness of \nresection and the \neffects of \nimmunotherapy on \nbrain metastasis \nmanagement  Retrospective \nanalyses  \n \nTreatment:  \nSurgery, \nImmunotherapy, \nwhole brain \nradiation  41 patients   Duration of \nsurvival from \nbrain metastasis \ndiagnosis was not \nsignificantly \ndifferent between \npatients who \nreceived WBRT \n(mean 24.9 \nmonths) and those \nwho did not (mean \n23.3 months) (p > \n0.05)  Combination  with \nImmunotherapy \uf0e0 \nstudy excluded   \nSalvati et al. 2011  To report on 84 \npatients with \nsingle melanoma \nbrain metastasis \nsurgically treated \nfrom 1997 to 2007  Retrospective \nanalysis  \n \nTreatment:  \nSurgery  84 patients with \nsingle melanoma \nbrain metastasis 1-year survival \nrate \n \n2 years survival \nrate \n 52% (32 patients)  \n \n14% (12 patients)  Lack of \ncomparison group \n\uf0e0 study excluded   \nSkeie et al. 2011  To review a series \nof patients who \nunderwent Gamma \nKnife surgery (GKS)  Retrospective \nanalysis  \n \nTreatment:  \nGamma Knife  77 patients  with a \ntotal of 143 \nmetastases Growth control  \n \n \nmedian survival \nafter GKS  \n 59 of 70 (84.3%) \npatients  \n \n7 months (range 0 -\n73 months)  Lack of \ncomparison group \n\uf0e0 study excluded   \nRades et al. 2010  To investigate a \npotential benefit \nfrom escalation of Retrospective \nanalysis, Cohort \nstudy  51 patien ts \n \n  \n \n Standard vs. high \ndose \n Lack of \ncomparison group \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 665 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nthe whole -brain \nradiotherapy \n(WBRT) dose \nbeyond the \n\"standard\" \nregimen 30 Gy in \n10 fractions   \nTreatment:  \nWBRT  \n \n10x3 Gy (n = 33)  \n40 Gy/20 fractions \n(n = 11)  \n45 Gy/15 fractions \n(n = 7)  6 months survival \n(OS)  \n \n12 months OS  \n \n6 months local \n(intracerebral) \ncontrol (LC)  \n12 months LC  27% vs. 50%  \n(p = 0.009)  \n \n4% vs. 20%  \n \n23% vs. 50%  \n \n \n0% vs.13%.  \nRedmond et al. \n2008  To investigate \nwhich patient - or \ntreatment- specific \nfactors influence \nsurvival of patients \nwith melanoma \nbrain metastases Retrospective \nanalysis, Prognosis \nstudy  \n \nTreatment:  \nGKS 59 patients  Survival was \nsignificantly better \nin patients with \nsolitary metastasis \n(p = 0.04), lesions \nwithout evidence of \npre-GKS \nhemorrhage (p = \n0.004), and in \npatients with total \ntumor volume \ntreated < 4 cm(3) \n(p = 0.02)  Lack of \ncomparison group \n\uf0e0 study excluded   \nMathieu et al. \n2007  to assess clinical \noutcomes and \nidentify prog nostic \nfactors for survival \nand cerebral \ndisease control \nafter Gamma knife Retrospective \nanalysis, Prognosis \nstudy  \n \nTreatment:  \nGKS \n 244 patients  median survival  \n \nSustained local \ncontrol  5.3 months  \n \n86.2% of tumors  Lack of \ncomparison group \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 666 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nradiosurgery  \nHofmann et al. \n2007  To examine \nprognostic factors \nand the evaluation \nof different \ntreatment options  Retrospective \nsurvival analysis  \n \nTreatment:  \nSurgery (n=34)  \nSRS (n=43)  \nWBRT (n=33)  \ncorticosteroids \n(n=63)  \n \n 133 patients  Median Survival  \n(from date of \ndiagnosis of brain \nmetastases)  \n Entire cohort \n(n=133)  \n24 weeks (5.1 \nmonths) (range 1 \u2013\n196 weeks)  \n \nsurgery vs. SRS vs. \nWBRT vs. \ncorticosteroids:  \n57 vs. 40 vs. 24 vs. \n17 weeks  \n univariate analysis \nis missing, small \nsample size \uf0e0 \nstudy excluded   \nSamlowski et al. \n2007  To report a \nretrospective \nanalysis of our \ninstitutional \nexperience of \nmultimodality \ntreatment utilizing \nlinear accelerator \n(Linac) -based \nstereotactic \nradiosurgery (SRS)  Retrospective \nanalysis  \n \nTreatment:  \nstereotactic \nradiosurgery ( SRS) 44 patients  median survival \nwith brain \nmetastases \n \n \n \n1-year survival  \n2-year survival  \n \n \n \n \n 11.1 months (95% \nconfidence interval \n[CI]: 8.2 -14.9 \nmonths) from \ndiagnosis  \n47.7%  \n17.7%  \n \nAddition of WBRT \nto maintain control \nof brain \nmetastases in a \nsubset of  patients \ndid not improve \nsurvival  Lack of \ncomparison group \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 667 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nChristopoulou et \nal. 2006  To investigate the \neffect of gamma \nknife surgery on \nthe local control of \ncerebral \nmetastases from \nmelanoma and to \nassess survival  Retrospective \nanalysi s \n \nTreatment:  \nGKS 29 patients  local control  \n \n \n \n \n \n \n \n \nmedian survival \nfrom gamma knife \nsurgery  61.5% of 96 \nmetastases \nregressed by more \nthan 50% of the \npretreatment \nvolume, 25% \nregressing by more \nthan 90% and \n13.5% completely  \n5.7 months  Lack of \ncomparison g roup \n\uf0e0 study excluded   \nGaudy -Marqueste \neta l. 2006  To assess \nretrospectively a \nstrategy that uses \nGamma -Knife \nradiosurgery in the \nmanagement of \npatients with brain \nmetastases of \nmalignant \nmelanoma  Retrospective \nanalysis  \n \nTreatment:  \nGKS 106 patients , 221 \nbrain metastases Median survival \nfrom the time of \nGKR \n \nControl rate  \n \ncomplete response \npartial response  \nstabilization  5.09 months  \n \n \n \n83.7%  \n \n14% (14 BMs)  \n42% (41 BMs)  \n43% (43 BMs)  Lack of \ncomparison group \n\uf0e0 study excluded   \nKoc et al. 2005  To evaluate \nretrospectively the \neffectiveness of \nGamma Knife \nradiosurgery for \nintracranial \nmetastatic Retrospective \nanalysis  \n \nTreatment:  \nGKS \n 26  patients, 72 \nbrain metastases Overall median \nsurvival after G KS \n \n1-year survival  6 months  \n \n \n25% \n Lack of \ncomparison group \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 668 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma and to \nidentify prognostic \nfactors related to \nsurvival  \nMeier et al. 2004  to determine the \nfactors influencing \nsurvival in a \nretrospective \nreview of patients \nwith melanoma \nbrain metastases \nto permit more \nspecific \nrecommendations \nregarding therapy  Retrospective \nsurvival analysis  \n \nTreatment:  \nWBRT (n=54)  \nsurgery (n=37)  \nSRS (n=17)  \nchemotherapy \n(n=38)  100 patients  median overall \nsurvival  \n \n \n6-month survival  \n1-year survival  \n2-year survival  \n \n \n \n \n \n \n \n Entire cohort \n(n=100)  \n4.8 months  \n \n36% \n14% \n5% \n \nWBRT vs. surgery \nvs. radiosurgery \nvs. chemotherapy \nvs. temozolomide  \n \n5.5 vs. 10.6 vs. \n10.3 vs. 6.6 vs. \n10.1 months  < 20 patients in \none of the \ntreatment groups  \n\uf0e0 study excluded  \n \nOnly 63 patients \nincluded in \nmultivariate \nanalysis due to \nmissing data  \n \n  \nMorris et al. 2004  To determine the \noutcome of \npatients with \nmetastatic \nmalignant \nmelanoma (MMM) \ntreated with \npalliative whole \nbrain radiotherapy Retrospective \nanalysis  \n \nTreatment:  \nWBRT  \n 112 patients  median survival \nafter WBRT  51 days (range 3 -\n1386) Lack of \ncomparison group \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 669 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(WBRT)  \nRadbill et al. 2004  To identify \nassociated \nprognostic \nindicators for \npatients receiving \ngamma knife (GK) \nradiosurgery in the \ninitial treatment of  \nintracranial \nmelanoma \nmetastases Retrospective \nanalysis  \n \nTreatment:  \nGKS \n 51 patients, 188 \nbrain metastases median overall \nsurvival from time \nof GKS  26 weeks  \n \nSubgroup analysis: \n77 weeks for \npatients presenting \nwith a single \nlesion, compared \nwith 20 weeks for \npatients presenting \nwith multiple \nlesions (P = 0.003)  Lack of \ncomparison group \n\uf0e0 study excluded   \nStone et al. 2004  To evaluate overall \nsurvival in patients \nwith brain \nmetastases from \nmalignant \nmelanoma  Retrospective \nsurvival analysis  \n \nTreatment:  \nSRS+WBRT (n=8)  \nSurgery + WBRT \n(n=16)  \nWBRT (n=59)  91 patients  Overall Survival  A survival benefit \nof 7.3 months (p = \n0.05) was found to \nbe associated with \ngamma knife \nradiosurgery or \nsurgical excision \nplus radiation \ntherapy over \nradiation therapy \nalone after \ncontrolling for \ndifferences in age, \nnumber of brain \nlesions, a nd \npresence of \nsymptoms.  < 20 patients in \none of the \ntreatment groups  \n\uf0e0 study excluded  \n   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 670 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSelek et al. 2004  To report on the \noutcome of \npatients with \nmelanoma brain \nmetastases treated \nwith stereotactic \nradiosurgery (SRS)  Retrospective \nanalysis  \n \nTreatment:  \nSRS alone (61 \npatients), SRS + \nwhole -brain \nradiotherapy \n(WBRT) (12 \npatients), and \nsalvage SRS after \nWBRT (30 patients)  103 patients, 153 \nintracranial \nmelanoma \nmetastases 1-year local control \n(LC) for all patients \ntreated with SRS  49% < 20 patients in \none of the \ntreatment groups  \n\uf0e0 study excluded  \n  \nHerfarth et al. \n2003  Stereotactic \nradiosurgery is an \nalternative option \nto neurosurgical \nexcision in the \nmanagement of \npatients with brain \nmetastases. Retrospective \nanalysis  \n \n \nTreatment:  \nStereotactic \nradiosurg ery 64 patients, 122 \nbrain metastases  Median survival  \n \n1 year local control  10.6 months  \n \n81% Lack of \ncomparison group \n\uf0e0 study excluded   \nBuchsbaum et al. \n2002  To determine \nwhether various \ntherapies provided \nany benefit at all \nin a population of \npatients with brain \nmetastases from \nmelanoma  Retrospective \nanalysis  \n \nTreatment:  \nsurgical resection, \nWBRT, stereotactic \nradiosurgery, or \nWBRT combined \nwith local therapy  74 patients with \nbrain metastases median survival \nwas for all patients  5.5 months  \n \ncombined \ntreatment offered \nsignificantly better \nsurvival (P < \n0.0001; combined \nvs. other)  \n < 20 patients in \none of the \ntreatment groups  \n\uf0e0 study excluded  \n   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 671 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmedian survival \nwas 8.8 months \n(range, 1.8 -99.2 \nmonths) for the \ncombined therapy \ngroup, 4.8 months \n(range, 1.2 -27.8 \nmonths) for the \nlocal therapy alone \ngroup, 2.3 months \n(range , 0.2-9.6 \nmonths) for the \nWBRT alone group, \nand 1.1 months \n(0.1-3.0 months) \nfor the group that \nreceived no \ntherapy  \nGonzales -Martinez \net al. 2002  to evaluate \nretrospectively the \neffectiveness of \nstereotactic \nradiosurgery for \nintracranial \nmetastatic \nmelanoma and to \nidentify prognostic \nfactors  Retrospective \nanalysis  \n \nTreatment:  \nstereotactic radio \nsurgery  24 patients, 115 \nlesions  mean survival \nafter radiosurgery  5.5 months  \n \nno difference in \nterms of survival \nbetween patients \nwho underwent \nWBRT or \nchemotherapy and \nthose who did not  \n \nsignificant \ndifference (p < Lack of \ncomparison group \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 672 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n0.05) in mean \nsurvival was \nobserved between \npatients receiving \nimmunotherapy or \nthose with a \nKarnofsky \nPerformance Scale \n(KPS) score of \ngreater than 90  \nMingione et al. \n2002  To evaluate the \nusefulness and \nlimitations of \ngamma surgery in \nthe treatment of \nbrain metastases \nfrom melanoma.  Retrospective \nanalysis  \n \nTreatment:  \nGKS 45 patients, 92 \nbrain meta stases Follow -up imaging \nstudies available:  \n35 patients, 66 \nlesions  24% percent of the \nlesions \ndisappeared, 35% \nshrank, 23% \nremained \nunchanged, and \n18% increased in \nsize. Lack of \ncomparison group \n\uf0e0 study excluded   \nNoel et al. 2002  To evaluate the \nefficac y and \ntoxicity of \nstereotactic \nradiotherapy in the \ntreatment of brain \nmetastases of \nmelanoma.  Retrospective \nanalysis  \n \nTreatment:  \nstereotactic \nradiotherapy  25 patients, 61 \nmetastases Median survival   \n \noverall survival \nrates  \n3- month  \n6- month  \n12-month  \n \nProgression  \n \nlocal control rates  8 months  \n \n \n75 +/ - 9% \n53 +/ - 10% \n 29 +/ - 10% \n \nn=5 (9.8%)  \n \n \n95 +/ - 3% Lack of \ncomparison group \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 673 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n3- month  \n6- month  \n12-month  90 +/ - 5% \n84 +/ - 7% \nYu et al. 2002  To identify \nimportant \nprognostic factors \npredicti ve of \nsurvival and tumor \ncontrol in patients \nwith metastatic \nmelanoma to the \nbrain who \nunderwent gamma \nknife radiosurgery  Retrospective \nanalysis  \n \nTreatment:  \nGKS \n 122 patients, 332 \nintracranial \nmelanoma \nmetastases median overall \nsurvival from time \nof radio surgery  7.0 months  Lack of \ncomparison group \n\uf0e0 study excluded   \nZacest et al. 2002  to review the \noutcome of \npatients who \nunderwent surgery \nfor treatment of \ncerebral \nmetastatic \nmelanoma  Retrospective \nanalysis  \n \nTreatment:  \nsurgery  147 patients  median survival  \nfrom the time of \nsurgery  \n 8.5 months  \n \n \n \n Lack of \ncomparison group \n\uf0e0 study excluded   \nEllerhorst et al. \n2001  To obtain a \ndescription of the \npopulation offered \nWBRT  Retrospective \nanalysis  \n \nTreatment:  \nWBRT  87 patients  median survival  19 weeks  \n Lack of \ncompa rison group \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 674 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nKonstadoulakis et \nal. 2000  To evaluate the \nprognostic \nparameters and \ntreatment \nmodalities of \nmalignant \nmelanoma patients \nwith brain \nmetastases Retrospective \nanalysis  \n \nTreatment:  \nSurgery  \nsurgery + \nradiotherapy (n=2)  \nsurgery +  \nchemotherapy \n(n=17)  136 patients  1-year survival \nrate surgery  \n28.3%  \nradiotherapy \nand/or \nchemotherapy  \n6.67%  \nno treatment \n3.45%  \n (p=0.006)  Subgroups < 20 \npatients \uf0e0 study \nexcluded   \nLavine et al. 1999  To analyze the \neffectiveness of \nLeksell gamma \nunit thera py for \nmetastatic \nmelanoma to the \nbrain  Retrospective \nanalysis  \n \nTreatment:  \nGKS \n 45 patients, 59 \nLeksell gamma \nunit treatment \nsessions  Median overall \nsurvival from the \ntime of gamma \nknife treatment  \n \nimproved or stable \nneurological \nsymptomatology  \n \nlocal tum or control \nrate 8 months (range, \n1-20 months ) \n \n \n \n78% \n \n \n \n97% Lack of \ncomparison group \n\uf0e0 study excluded   \nFriehs et al. 1998  To determine the \neffectiveness of \ngamma knife \nradiosurgery in \npatients with \nmalignant \nmelanoma \nmetastases prospective \nmulticenter stu dy \n \nTreatment:  \nGKS 45 patients, 96 \nlesions  median overall \nsurvival  \n \ntumor control  4.2 months  \n \n \n86% of lesions  Lack of \ncomparison group \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 675 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSampson et al. \n1998  To identify \ndemographic \nfactors associated \nwith the \ndevelopment of \nclinically \nsignificant brain \nmetastases in 702 \nof these patients \nand to determine \nthe factors \ninfluencing the \nprognosis of this \npopulation to \npermit more \ninformed \nrecommendations \nregarding surgical \ntherapy  Retrospective \nsurvival analysis  \n \nTreatment:  \nSurgery (n=52)  \nSurgery+WBRT \n(n=87)  \nWBRT (n=180)  \nChemotherapy \n(n=205)  \nSymptomatic \ntreatment (n=178)  \n 702 patients  median overall \nsurvival  \n Entire cohort \n(n=702) 3.7 \nmonths  \n \nsurgery vs. \nsurgery+WBRT vs. \nWBRT vs. \nchemotherapy:  \n8.8 vs. 6.4 vs. 3.9 \nvs. 1.3 months  \n no multivaria te \nanalysis included \n\uf0e0 study excluded   \nFletcher et al. \n1998  To reviewe the \nresults of surgical \nresection  Retrospective \nanalysis  \n \nTreatment:  \nsurgery  77 patients, \ndifferent sites,  \nbrain n = 12    <20 patients with \nbrain metastases  \n\uf0e0 study excluded   \nGrob e t al. 1998  To evaluate the \neffectiveness of \nradiosurgery \nwithout whole \nbrain radiotherapy Retrospective \nanalysis  \n \nTreatment:  \nradiosurgery  35 patients  Median overall \nsurvival  \n \n \n 22 months \n(solitary brain \nmetastasis)  \n7.5 months ( single \nbrain metastasis + Lack of \ncomparison group \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 676 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nin the palliative \ntreatment of \nmelanoma brain \nmetastases  \n \n \nlocal control rate  \nat 3 months   metastases \nelsewhere)  \n4 months ( \nmultiple brain \nmetastases)  \n98.2% (55/56 \nmetastases)  \nMori et al. 1998  To evaluate result s \nafter stereotactic \nradiosurgery (SR) \nfor patients with \nmetastastic \nmelanoma to \nidentify patient \noutcomes and \nfactors for survival  Retrospective \nanalysis  \n \nTreatment:  \nSR alone n=9  \nSR+WBRT n=51  60, 118 melanoma \nbrain metastases Median survival \nafter SR  \n \nlocal control rate \nof evaluable \ntumors (n = 72)  \ndisappearance \nshrinkage  \nstable  7 months  \n \n \n90% \n \n \n11% \n44% \n35% < 20 patients in \none of the \ntreatment groups  \n\uf0e0 study excluded  \n  \nSeung et al. 1998  To evaluate the \nefficacy and \ntoxicity of gamma \nknife radiosurgery  \nin the treatment of \nmelanoma \nmetastases to the \nbrain  Retrospective \nanalysis  \n \nTreatment:  \nGKS  55 patients, 140 \nlesions  median overall \nsurvival  35 weeks  \n \n35 weeks for \npatients with \nsolitary metastases \nversus 33 weeks \nfor those with \nmultiple \nmetastases Lack of \ncomparison group \n\uf0e0 study excluded   \nGupta et al. 1997  To report the \nexperience of 31 \npatients who Retrospective \nanalysis  \n 31 patients median  overall \nsurvival  \n 4 months  \n \n < 20 patients in \none of the \ntreatment groups    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 677 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npresented with \ncerebral \nmetastasis of \ncutaneous \nmelanoma  \n \n Treatment:  \nSurgery (n=17)  \nSurgery + \nradiotherapy (n=6)    \uf0e0 study excluded  \n \nGieger et al. 1997  to determine the \nradiographic \nresponse of \nintracranial \nmetastatic \nmelanomas to SRS Retrospective \nanalysis  \n \nTreatment:  \nstereotactic \nradiosurgery  12 patients with \n21 intracranial \nmelanoma \nmetastases   Lack of \ncomparison group \n\uf0e0 study excluded   \nIsokangas et al. \n1996  To report the long -\nterm results of the \nirradiation of \nintracranial \nmalignant \nmelanoma  Retrospective \nanalysis  \n \nTreatment:  \nRadiotherapy  \nTD 40 Gy vs. \nnormalized TD at 3 \nGy (NTD3Gy) with \n30 Gy as cutpoints 60 patients  median survival  4.1 months  \n \nThose with higher \ntotal doses to the \ntumour area had \nsignificantly better \n(P = 0.0006) \nsurvival  Lack of \ncomparison group \n\uf0e0 study excluded   \nSkibber et al. 1996  To evaluate \npostoperative \nadjunctive cranial \nirradiation in 34 \npatients with \nsolitary brain Retrospective \nanalysis  \n \nTreatment:  \nSurgery alone \nn=12  34 patients, 34 \nbrain metastases  Overall survival \nwas significantly \nimproved in the 22 \npatients who \nreceived adjunctive \ncranial irradiation < 20 patients in \none of the \ntreatment groups  \n\uf0e0 study excluded  \n   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 678 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmetastases  Surgery + WBRT \nn=22  versus that in the \n12 patients who \nhad surgery alone  \nWillner et al. 1995  To show treatment \nresults and t o \ndefine prognostic \nsubgroups in \npatients \nundergoing \nradiotherapy for \nbrain metastases \nfrom malignant \nmelanoma  Retrospective \nanalysis  \n \nTreatment:  \nRadiotherapy  30 patients  \n Overall survival \nrate  \n6 months  \n1 year   \n39%  \n23% \n Lack of \ncomparison group \n\uf0e0 study excluded   \nSomaza et al. 1993  To determine local \ntumor control \nrates and survival \nof patients with \nmelanoma \nmetastases to the \nbrain  Retrospective \nanalysis  \n \nTreatment:  \nstereotactic \nradiosurgery + \nWBRT  23 patients, 32 \ntumors  median survival \nperiod after \ndiagnosis  \n \nlocal tumor control \nrate  9 months (range 3 \nto 38 months)  \n \n \n97% Lack of \ncomparison group \n\uf0e0 study excluded   \nDavey et al. 1991  To determine how \nmany patients \nmight be \ncandidates for \nradiosurgery, a \nretrospective \nanalysis of \ncomputed  41 patients    No survival + \nefficacy data \uf0e0 \nstudy excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 679 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntomographic bra in \nscans performed \non 41 patients with \ncerebral \nmetastases from \nmalignant \nmelanoma was \nundertaken  \nHagen et al. 1990  To report \ntreatment results \nof patients with \nbrain metastasis \nfrom melanoma  Retrospective \nanalysis  \n \nTreatment:  \nSurgery + \npostoperative \nradiation n=19  \n \nSurgery alone \nn=16  35 patients   Group A had a \nlonger interval to \nCNS relapse \ncompared with \ngroup B, but \nsurvival was \nsimilar. < 20 patients in \none of the \ntreatment groups  \n\uf0e0 study ex cluded  \n  \nOredsson et al. \n1990   Retrospective \nanalysis  \n \nTreatment:  \nSurgery  40 patients median survival  \n \n3-year survival  \n5-year survival  \n \nNeurological \nimprovement  \n \nsurgical mortality \nrate  8 months  \n \n25% \n15% \n \n25 patients \n \n \nless than 5%  \n \n Lack of \ncomparison group \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 680 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nQuality of life a s \njudged by \nKarnofsky index \nwas improved \nafter surgery and \nmaintained on an \nacceptable level for \nthe remaining time \nof survival  \nGuazzo et al. 1989   Retrospective \nanalysis  \n \nTreatment:  \nSurgery  31 patients Signific ant and life-\nthreatening \ncomplications  \n \nrelief of symptoms:  5 patients (17%)  \n \n \n \n64% had complete \nremission of \nsymptoms while a \nfurther 20% were \nsubstantially \nimproved  Lack of \ncomparison group \n\uf0e0 study excluded  \n  \nMendez et al. 1988   Retrospective \nanalysis  \n \nTreatment:  \nSurgery, \nRadiotherapy  55 patients with \nneurological signs \nand symptoms \nsecondary to \nmetastases to the \nbrain  6 month survival  58% if surgical \nexcision was \npossible  < 20 patients in \none of the \ntreatment groups  \n\uf0e0 study excluded  \n  \nRate et al. 1 988 To review the \nrecords of all \npatients receiving Retrospective \nanalysis  \n 77 patients with \nbrain metastases median survi val \nfrom the initiation \nof radiotherapy  14 week  Lack of \ncomparison group \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 681 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \npalliative \nradiotherapy for \nmalignant \nmelanoma \nmetastatic to \nbrain, to bone, or \nwith spinal cord \ncompression  Treatment:  \nRadiotherapy  \nRetsas et al. 1988   Retrospective \nanalysis  \n \nTreatment:  \nDifferent \ntreatments  100 patients  Median survival  2.5 months  Lack of \ncomparison group \n\uf0e0 study excluded   \nWornom et al. \n1986   Retrospective \nanalysis  \n \nTreatment:  \nsurgery  65 patients, 94 \nmetastatic lesions \n(brain, lung, \nabdomen, distant \nsubcutaneous \nsites, and distant \nlymph nodes)  Median survival \nafter excision of \nbrain metastases  \n \nRelief of symptoms  8 months  \n \n \n \n77% of brain \nmetastases Lack of \ncomparison group \n\uf0e0 study excluded   \nZiegler et al. 1986  To examine the \nrecords of 72 \npatients who \nreceived various \nregimens of \nradiotherapy for \ncerebral Retrospective \nanalysis  \n \nTreatment:  \nWBRT  \n300 cGy \n(conventional 72 patients  No difference in \nresponse could be \nattributed to dose \nschedules, either \noverall or in the \nsubgroups of \npatients who had Lack of \ncomparison \nbetween different \ntreatments \uf0e0 \nstudy excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 682 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmetastases from \nmalignant \nmelanoma  fractionation, CF) \nvs. 500 -600 cGy \n(high -dose-per-\nfraction, HDF) to a \ntotal of 3000 cGy  solitar y or multiple \nbrain metastases \nChoi et al. 1985   Retrospective \nanalysis  \n \nTreatment:  \nWBRT  \n \n 194 patients with \nintracranial \nmetastatic \nmelanoma    Lack of \ncomparison group \n\uf0e0 study excluded   \nStridsklev et al. \n1984  To analyze \npatients who \ncompleted whole -\nbrain irradiation \ntreatment for \nbrain metastases \nfrom malignant \nmelanoma  Retrospective \nanalysis  \n \nTreatment:  \nWBRT  39 patients  Median survival  \n \nclinical \nimprovement  \n \nobjective \nregression of th e \nbrain metastases  2 months  \n \nn=21 (53.8%)  \n \n \n6 of 15 evaluable \npatients (40%)  Lack of \ncomparison group \n\uf0e0 study excluded   \nMadajewicz et al. \n1984  To review 8 years \nof Roswell Park \nMemorial \nInstitute's (RPMI) \nexperience with the \nmanagement of \nmalignant \nmela noma CNS Retrospective \nanalysis  \n \nTreatment:  \n \nNone (n=15)  \nSteroids (n=17)  \nradiotherapy 125 patients with \nbrain metastases \n(73% multiple \nmetastases)  median survival  The median \nsurvival of the \nuntrea ted group of \npatients was 3 \nweeks as \ncompared with \nthat of 6 weeks for \nthe patients < 20 patients in \none of the \ntreatment groups, \nno multivariate \nanalysis \uf0e0 study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 683 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmetastases ( 1972 -\n1980)  (n=23)  \nsurgery (n=20)  \nchemotherapy  maintained on \nsteroids  \nonly, 9 weeks for \nthose who received \nradiotherapy, 11 \nweeks for the \npatients treated \nwith intraarterial \nchemotherapy, and \n26 weeks for the \npatients w ho \nunderwent \nsuccessful surgical \nexcision of a \nsolitary  \nlesion. \nByrne et al. 1983   Retrospective \nanalysis  \n \nTreatment:  \nGroup 1, multiple \nbrain metastases \ntreated with \nradiation therapy \n(RT) (n = 49)  \n \nGroup 2, single \nbrain metastasis \ntreated with RT (n \n= 17)  81 patients with \nbrain metastasis   \n \nMedian survival  Groups 1 vs 2 vs 3  \n \n11, 9 an d 41 \nweeks  No multivariate \nanalysis included \n\uf0e0 study excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 684 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nGroup 3, single \nbrain metastasis \ntreated with \nsurgery with or \nwithout RT (n = 9).  \nVlock et al. 1982  To examine the \nresults in 46 \npatients treated \nwith high - or low -\ndose fractions for \nintracranial \nmetastases Retrospective \nanalysis  \n \nTreatment:  \n26 patients \nreceived high -dose \nfraction therapy, \ngenerally 600 \nrad/fraction/week \nto 2400 --3600 rad; \n20 patients \nreceived low -dose \nfraction \nradiotherapy with \n125--400 \nrad/fraction daily  46 patients   \n \n \n \nMedian survival  \n \n \nImprovement  \n \nStability  \n \ndeterioration  high-dose fraction \ngroup vs. l ow-dose \nfraction group  \n \n3 months vs. 2 1/2 \nmonths  \n \n38 vs. 35%,  \n \n23 vs. 25%  \n \n38 vs. 40%  Lack of \ncomparison \nbetween different \ntreatments  \n \uf0e0 study excluded  \nKatz et al. 1981  To records of all \npatients who \nreceived \nradiotherapy for \nmelanoma \nmetastatic to br ain \n(63 patients  Retrospective \nanalysis  \n \nTreatment:  \ncorticosteroids, \nradiotherapy, \nsurgery (n=8)  63 patients Response  73% to \ncorticosteroids  \n42% to \nradiotherapy  \n < 20 patients in \none of the \ntreatment groups  \n\uf0e0 study excluded  \n   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 685 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nCarella et al. 1980  To dete rmine the \nresponse to whole \nbrain irradiation  Retrospective \nanalysis  \n \nTreatment:  \nWBRT  60 patients  Median survival  Study 1 patients \n10 weeks (range 1 -\n200) vs. Study II \npatients 14 weeks \n(range 1 -76) \n \nsignificant benefit \nfrom radiation \ntherapy in terms of \nsymptomatic and \nneurologic function \nimprovement. \nSymptomatic \nimprovement was \nobserved in 76%, \nwith 31% \ncompletely \nimproved  Lack of \ncomparison group \n\uf0e0 study excluded   \nCooper et al. 1980   Retrospective \nanalysis  \n \nTreatment:  \nWBRT  30 patients, 35 \ncourses   Marked \nimprovement in \nneurologic status \noccurred in \napproximately \n35%. Slight to \nmoderate \nimprovement was \nevident in an \nadditional 35%.  Lack of \ncomparison group \n\uf0e0 study excluded   \nHafstrom et al.  Retrospective 25 patients  median survival  5 months  Lack of   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 686 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n1980  analysis  \n \nTreatment:  \nSurgery  comparison group \n\uf0e0 study excluded  \nPennington  et al. \n1975   Retrospective \nanalysis  \n \nTreatment:  \n \nRadiotherapy, \nchemotherapy, \nsurgery and \nimmunotherapy  57 patients    Publication  <1980 \n\uf0e0 study excluded   \n \n7.3.4.2.  Aktualisierungsr echerche 2015  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nFogarty et al. 2015  To analyze the \ndistant intracranial \nfailure on magnetic \nresonance imaging \n(MRI) within twelve \nmonths of \nrandomization for \npts. receiving \nWBRT vs. \nobservation afte r Randomized \ncontrolled trial  \n \nTreatment:  \nWBRT with at least \n30Gy in 10 \nfractions  \n \nVs. \n 200 pts \nrandomized to \nWBRT or \nobservation  Proportion of \npatients with \ndistant intracranial \nfailure as \ndetermined by \nmagnet ic \nresonance imaging \n(MRI) assessment \nwithin twelve \nmonths of Only data quality \nof the first 100 pts \nreport ed so far.  Only data quality \nof the first 100 pts \nreported so far.  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 687 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nlocal treatment of \nbrain mets.  \n  Observation  randomization  \n \nTime to \nintracranial failure \n(local, distant and \noverall) as \ndetermined by MRI  \n \nQuality of life as \nmeasured by \nEORTC QLQ -C30 \nand BN -20 \n \nNeurocognitive \nfunction as \nmeasured by \nHopkins Verbal \nLearning Test, \nControlled Oral \nWord Association \nTest, Trail Making \nTest Part A & B, \nStroop - Colour \nand Word Test and \nDigit Span \n(Forwards and \nBackwards).  \n \nOverall survival  \n \nECOG Performance  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 688 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nstatus  \nGoyal et al. 2015  To review the \ncurrent evidence \nregarding the \ntreatment of \nmultiple brain \nmetastases from \nmelanoma.  Systematic review  \n 2006 pts. treated \nwith radiotherapy; \n642 treated  with \nchemotherapy; \ndescription of non -\nRCTs for \nIpilimumab  Rate of Intracranial \nFailure, %  \n \n \nOverall Intracranial \nResponse Rate, %  \n \nMedian Overall \nSurvival, mo  \n \n \n \n \n \n \n \n \nProgression -Free \nSurvival or Median  \nTime to \nProgression  8-48% for SRS(+/ -\nWBRT), 29 -100%  \nfor WBRT  \n \n7-47% for CTX  \n \n \n6.5-7.5m for \nWBRT,  \n5.7-15.2m for \nSRS(+/ -WBRT)  \n0-47monts for \nchemotherapy (+/ -\nWBRT/SRS)  \n4.7-21.3m for \nipilimumab (+/ -\nChemo/WBRT/SRS)  \n \n1.2-5m for \nchemotherapy (+/ -\nWBRT/SRS)  \n2.7m -9.5m for \nIpilimumab (+/ -\nChemo/WBRT/SRS)  \u201cAt this time , the \nstandard \nmanagement for \npatients with MBM \nfrom melanoma \nincludes SRS, \nWBRT, or a \ncombination of \nboth\u201c  1a \nHauswald et al. \n2013  To exploratory \ninvestigate the \ntreatment \nresponse to Randomized \ncontrolled trial  \n \nTreatment:  50 pts randomized \n1:1 to WBRT or \nWBHT+ integrated \nboost Toxicity (frequency \nand intensity \naccordi ng to \nCTCAE Ver. 4)  No results \npublished so far  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 689 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nconventional whole \nbrain radiotherapy \napplying 30 Gy in \n10 fractions v ersus \nwhole brain helical \ntomotherapy \napplying 30 Gy in \n10 fractions with \nan integrated \nboost of 50 Gy to \nthe brain \nmetastases as well \nas hippocampal -\nsparing in patients \nwith brain \nmetastases from \nmalignant \nmelanoma  WBRT 30 Gy in 10 \nfractions  \n \nVs. \n \nWBHT applying 30 \nGy in 10 fractions \nwith an integrated \nboost of 50 Gy to \nthe brain \nmetastases as well \nas hippocampal -\nsparing  every 2 months for \none year  \n \n \n7.3.5.  Literatur  \n \nBuchsbaum JC, Suh JH, Lee SY, et al. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from \nmalignant melanoma: a retrospective study. Cancer 2002;94:2265- 2272 \nByrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol 1983;1:313- 317 \nCarella RJ, Gelber R, Hendrickson F, et al. Value of radiation therapy in t he management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology \nGroup Brain Metastases Study I and II. Cancer 1980;45:679- 683 \nChoi KN, Withers HR, Rotman M. Intracranial metastases from melanoma. Clinical features and  treatment by accelerated fractionation. Cancer 1985;56:1 -9 \nChristopoulou A, Retsas S, Kingsley D, et al. Integration of gamma knife surgery in the management of cerebral metastases fro m melanoma. Melanoma Res 2006;16:51- 57 \nCooper JS, Carella R. Radiothera py of intracerebral metastatic malignant melanoma. Radiology 1980;134:735- 738 \nDavey P, O'Brien P. Disposition of cerebral metastases from malignant melanoma: implications for radiosurgery. Neurosurgery 1 991;28:8- 14; discussion 14- 5 \nEigentler TK, Figl A, Kr ex D, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patient s with brain metastases of \nmalignant melanoma. Cancer 2011;117:1697- 1703   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 690 von 817 \nEllerhorst J, Strom E, Nardone E, et al. Whole brain irrad iation for patients with metastatic melanoma: a review of 87 cases. Int J Radiat Oncol Biol Phys 2001;49:93 -97 \nFife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004;22:1293- 1300 \nFletcher WS, Pommier RF, Lum S, et al. Surgical treatment of metastatic melanoma. Am J Surg 1998;175:413- 417 \nFogarty GB, Hong A, Dolven -Jacobsen K, et al. First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases con firms high data quality. BMC Res \nNotes. 2015;8:192.  \nFriehs GM, Legat J, Zheng Z, et al. Outcomes in patients treated with gamma knife radiosurgery for brain metastases from malignant melanoma. Neurosurg Focus 1998;4:e1 \nGaudy -Marqueste C, Regis JM, Muraccio le X, et al. Gamma -Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole -\nbrain radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:809- 816 \nGieger M, Wu JK, Ling MN, et al. Response of intracr anial melanoma metastases to stereotactic radiosurgery. Radiat Oncol Investig 1997;5:72- 80 \nGonzalez- Martinez J, Hernandez L, Zamorano L, et al. Gamma knife radiosurgery for intracranial metastatic melanoma: a 6 -year experience. J Neurosurg 2002;97:494- 498 \nGoyal S, Silk AW, Tian S, et al. Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. JAMA Oncol. 2015;1(5):668- 676. \nGrob JJ, Regis J, Laurans R, et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancerologie Cutanee. Eur J Cancer 1998;34:1187- 1192  \nGuazzo EP, Atkinson RL, Weidmann M, et al. Management of solitary melanoma metastasis of the brain. Aust N Z J Surg 1989;59:321- 324 \nGupta G, Robertson AG, MacKie RM. Cerebral metastases of cutaneous melanoma. Br J Cancer 1997;76:256- 259 \nHafstrom L, Jonsson PE, Stromblad LG. Intracranial metastases of malignant melanoma treated by surgery. Cancer 1980;46:2088 -2090  \nHagen NA, Cirrincione C, Thaler HT, et al. The role of radiation therapy following re section of single brain metastasis from melanoma. Neurology 1990;40:158- 160 \nHauswald H, Habl G, Krug D, et al. Whole brain helical Tomotherapy with integrated boost for brain metastases in patients with malignant melanoma -a randomized trial. Radiat Oncol. \n2013;8:234.  \nHerfarth KK, Izwekowa O, Thilmann C, et al. Linac -based radiosurgery of cerebral melanoma metastases. Analysis of 122 metastases treated in 64 patients. Strahlenther Onkol \n2003;179:366- 371 \nHofmann MA, Coll SH, Kuchler I, et al. Prognostic facto rs and impact of treatment in melanoma brain metastases: better prognosis for women? Dermatology 2007;215:10 -16 \nIsokangas OP, Muhonen T, Kajanti M, et al. Radiation therapy of intracranial malignant melanoma. Radiother Oncol 1996;38:139 -144 \nKatz H.R. The r elative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the cent ral nervous system. 1981.  \nKoc M, McGregor J, Grecula J, et al. Gamma Knife radiosurgery for intracranial metastatic melanoma: an analysis of survival and prognostic factors. J Neurooncol 2005;71:307- 313 \nKonstadoulakis MM, Messaris E, Zografos G, et al. Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? J Neurosur g \nSci 2000;44:211- 8; discussion 219  \nLavine SD, Petrovich Z, Cohen- Gadol AA, et al. Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery 1999;44:5 9-64; \ndiscussion 64 -6 \nLonser RR, Song DK, Klappe r J, et al. Surgical management of melanoma brain metastases in patients treated with immunotherapy. J Neurosurg 2011;115:30- 36 \nMadajewicz S, Karakousis C, West CR, et al. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute exper ience. Cancer 1984;53:2550- 2552  \nMathieu D, Kondziolka D, Cooper PB, et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 2007;60:471- 81; discussion 481- 2 \nMeier S, Baumert BG, Maier T, et al. Survival and pr ognostic factors in patients with brain metastases from malignant melanoma. Onkologie 2004;27:145 -149 \nMendez IM, Del Maestro RF. Cerebral metastases from malignant melanoma. Can J Neurol Sci 1988;15:119 -123 \nMingione V, Oliveira M, Prasad D, et al. Gamma su rgery for melanoma metastases in the brain. J Neurosurg 2002;96:544- 551 \nMori Y, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radia t Oncol Biol Ph ys \n1998;42:581- 589 \nMornex F, Thomas L, Mohr P, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irrad iation versus fotemustine alone in cerebral metastases of \nmalignant melanoma. Melanoma Res 2003;13:97- 103 \nMorris  SL, Low SH, A'Hern RP, et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy for pati ents with metastatic malignant melanoma. Br J Cancer \n2004;91:829- 833 \nNoel G, Simon JM, Valery CA, et al. Linac radiosurgery for brain metastasis of melanoma. Stereotact Funct Neurosurg 2002;79:245- 255 \nOredsson S, Ingvar C, Stromblad LG, et al. Palliative surgery for brain metastases of malignant melanoma. Eur J Surg Oncol 1990;16:451- 456 \nPennington DG, Milton GW. Cerebral metastasis from melanoma. Aust N Z J Surg 1975;45:405- 409 \nRadbill AE, Fiveash JF, Falkenberg ET, et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer \n2004;101:825- 833 \nRades D, Heisterkamp  C, Huttenlocher S, et al. Dose escalation of whole -brain radiotherapy for brain metastases from melanoma. Int J Radiat Oncol Biol Phys 2010;77:537 -541 \nRaizer JJ, Hwu WJ, Panageas KS, et al. Brain and leptomeningeal metastases from cutaneous melanoma: surv ival outcomes based on clinical features. Neuro Oncol 2008;10:199- 207 \nRate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys \n1988;15:859- 864 \nRedmond AJ, Diluna ML, Hebert R, et al. Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumo ral hemorrhage on survival. J Neurosurg 2008;109 \nSuppl:99 -105 \nRetsas S, Gershuny AR. Central nervous system involvemen t in malignant melanoma. Cancer 1988;61:1926- 1934  \nSalvati M, Frati A, D'Elia A, et al. Single brain metastases from melanoma: remarks on a series of 84 patients. Neurosurg Rev 2011   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 691 von 817 \nSamlowski WE, Watson GA, Wang M, et al. Multimodality treatment of melanoma  brain metastases incorporating stereotactic radiosurgery (SRS). Cancer 2007;109:1855- 1862 \nSampson JH, Carter JH,Jr, Friedman AH, et al. Demographics, prognosis, and therapy in 702 patients with brain metastases from  malignant melanoma. J Neurosurg 1998;88:11- 20 \nSelek U, Chang EL, Hassenbusch SJ,3rd, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 2004; 59:1097-\n1106 \nSeung SK, Sneed PK, McDermott MW, et al. Gamma knife radiosurgery  for malignant melanoma brain metastases. Cancer J Sci Am 1998;4:103 -109 \nSkeie BS, Skeie GO, Enger PO, et al. Gamma knife surgery in brain melanomas: absence of extracranial metastases and tumor volume strongest indicators of prolonged  survival. World \nNeurosurg 2011;75:684- 91; discussion 598- 603 \nSkibber JM, Soong SJ, Austin L, et al. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 1996;3:118- 123 \nSomaza S, Kondziolka D, Lunsford LD, et al. Stereotactic rad iosurgery for cerebral metastatic melanoma. J Neurosurg 1993;79:661- 666 \nStaudt M, Lasithiotakis K, Leiter U, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010;102:1213 -1218  \nStevens G, Firth I, Coate s A. Cerebral metastases from malignant melanoma. Radiother Oncol 1992;23:185- 191 \nStone A, Cooper J, Koenig KL, et al. A comparison of survival rates for treatment of melanoma metastatic to the brain. Cancer  Invest 2004;22:492- 497 \nStridsklev IC, Hagen S, K lepp O. Radiation therapy for brain metastases from malignant melanoma. Acta Radiol Oncol 1984;23:231- 235 \nVlock DR, Kirkwood JM, Leutzinger C, et al. High -dose fraction radiation therapy for intracranial metastases of malignant melanoma: a comparison with low-dose fraction therapy. \nCancer 1982;49:2289- 2294  \nWillner J, Bohndorf W. CNS metastases in malignant melanomas. Strahlenther Onkol 1995;171:165 -173 \nWornom IL,3rd, Smith JW, Soong SJ, et al. Surgery as palliative treatment for distant metastases of melano ma. Ann Surg 1986;204:181- 185 \nWronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 2000;93:9- 18 \nYu C, Chen JC, Apuzzo ML, et al. Metastatic melanoma to the brain: prognostic factors aft er gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 2002;52:1277- 1287  \nZacest AC, Besser M, Stevens G, et al. Surgical management of cerebral metastases from melanoma: outcome in 147 patients trea ted at a single institution over two decades. J \nNeurosu rg 2002;96:552- 558 \nZiegler JC, Cooper JS. Brain metastases from malignant melanoma: conventional vs. high- dose-per-fraction radiotherapy. Int J Radiat Oncol Biol Phys 1986;12:1839- 1842  \n \n7.4. Frage VI.5. Adjuvante Radiotherapie Regionale Lymphknotenstation  \nFrage  VI.5. Beeinflusst eine adjuvante Radiotherapie der Lymphknotenstation das Gesamt\u00fcberleben und/oder die rezidivfreie Zeit von \nMelanompatienten?  \n7.4.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema  \nPopulation  Intervention  Comparison  Outcome  \nmelanoma patients after nodal \nsurge ry radiotherapy  no radiotherapy  Overall survival, progression free \nsurvival  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 692 von 817 \nSuchw\u00f6rter  \nStichwort  melanoma  adjuvant radiotherapy  postoperative  lymph node  \nlymph nodes \nSynonyme   radiation   nodal  \nOber -/Unterbegriffe      \nMesh Term  melanoma  adjuvant radi otherapy   lymphoid tissue  \n7.4.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  (\"melanoma\"[tiab] OR \"melanoma\"[MeSH]) AND (\"adjuvant radiotherapy\"[tiab] OR \n\"Radiation\"[tiab] OR \"postoperative\"[tiab] OR adj uvant radiotherapy[MeSH Terms]) AND (\"lymph \nnode\"[tiab] OR \"lymph nodes\"[tiab] OR \"nodal \"[tiab] OR \"lymphoid ti ssue\"[MeSH])  04.11.11  455 \nCochrane Library  (melanoma and (\"adjuvant radiotherapy\" or radiation) and lymph*).ti,ab  07.11.11  7 \nEmbase  (melanoma and (\"adjuvant radiotherapy\" or radiation) and lymph*).ti,ab  12.10. 10 475 \nUpdate Suche     \nMedline  s.o. 31.01.12  459 (0 dazu)  \nCochrane Library  s.o 31.01.12  7 (0 dazu)  \nEmbase  s.o. 23.01.12  590 (0 dazu)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 693 von 817 \n \n7.4.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttref fer 1056  \nEinschlusskriterien  Studien, die das Outcome (regionale Kontrollrate, Gesamt\u00fcberleben) einer adjuvanten Radiotherapie nach erfolgter \nLymphknotendissektion beschreiben  \nMangels RCT\u00b4s Einschluss von Kohortenstudien ab 20 Patienten  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports  \nNicht systematische Reviews  \nKollektive mit gemischten Tumorentit\u00e4ten  \nPublikationen vor 1980  \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  32 \nAnzahl ausgew\u00e4hlte Volltexte  11 \n7.4.4.  Evidenztabelle  \nStudy  Aims  Design  Popula tion Outcomes  Results  Comments  LoE \nBurmeister et al. \n2012  To compare \nadjuvant \nradiotherapy with \nobservation alone \nin patients at high Multicenter \nrandomized study  \n \nTreatment:  \nGroup A: surgery 250 patients after \nlymphadenectomy  \n  \n \n \nLymph node field \nrelapse  \n \n Surgery alone vs. \nSurgery + RT  \n \n34 patients vs. 20 \npatients r elapsed Jadad Score 3  \n \nLimitations: high \nnumber of \nineligible patients  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 694 von 817 \nStudy  Aims  Design  Popula tion Outcomes  Results  Comments  LoE \nrisk of lymph -node \nfield relapse who \nhad undergone \ntherapeutic \nlymphadenectomy \nfor metastatic \nmelanoma in \nregional lymph \nnodes  alone n=127  \n \nGroup B: surgery + \nRT (TD 48Gy, 20 \nfractions) after \nlymph adenectomy\n, n=123   \n \nRelapse -free \nsurvival  \n \n \n \nOverall s urvival (HR 0.56, 95% CI \n0.32 \u2013 0.98, \np=0.041)  \n \n73 vs. 70 events, \nn.s. \n(HR 0.91, 95% CI \n0.65 \u2013 1.26, \np=0.56)  \n \n47 vs. 59 deaths, \nn.s. \n(HR 1.37, 95% CI \n0.94 \u2013 2.01, \np=0.12)   \nFunding: National \nHealth and \nMedical Research \nCouncil of \nAustralia, Cancer \nAustralia, \nMelan oma Insitute \nAustra lia and the \nCancer Council of \nSouth Australia  \nGojkovic -Horvat et \nal. 2011  To determine the \nefficacy of and \ncriteria for \npostoper ative \nradiotherapy \n(PORT) in patients \nwith palpable \nmelanoma \nmetastases to the \ngroin  Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery \nalone, n=64  \n \nGroup B: surgery + \nRT (TD range 50 -  \n72 Gy, fraction \nsize 2 -  3 Gy) , 101 patients, 103 \nnodal dissections   \n \n \nRecurrence  \n \n \n \n \n \n \n2-year regional Surgery alone vs. \nSurgery + RT  \n \n14 of 66 \ndissections (21.2%; \n95% CI, 12.1 -\n33.0%) vs. 5 of 37 \n(13.5%; 95% CI, \n4.5-28.8%) \n(p=0.431) \n retrospective \nstudy, Imbalance \nof prognostic \nfactors b etween \nthe groups: worse \nprognostic factors \nin the su rgery + RT \ngroup  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 695 von 817 \nStudy  Aims  Design  Popula tion Outcomes  Results  Comments  LoE \nn=37  control rates  \n \n \n \n \n2 years overall \nsurvival  86% (95% CI, 76 -\n95%) and 91% (95% \nCI, 81 -100%),  \nrespectively \n(p=0.395) \n \n56% (95% CI, 44 -\n68%) vs. 56% (95% \nCI, 39 -72%), \n(p=0.813) \n \nBibault et al. 2011  To analyze the \noutcome after \nadjuvant radiation \ntherapy with \nstandard \nfractionation \nregimen in \nmetastatic lymph \nnodes (LN) from \ncutaneous \nmelan oma Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery \nalone, n=26  \n \nGroup B: surgery  \n+ RT (median TD \n50Gy, range 30 -70 \nGy, fraction size 2 \n- Gy), n=60 \n \n \n 86 patients with \nlymphadenectomy  \n \nIndications for \nradiation therapy: \n>/= 4 involved \nLNs, extr acapsular \nextension, LN size \n> 3 cm  \n \n  \n \n \nRegional control  \nOverall survival \n \n \n \n \n \n \n \n \n \n \n \n \n \n Surge ry alone vs. \nSurgery + RT  \n \nNo improvement of \nregional control \n(p=0.17) or overall \nsurvival (p=0.18)  \n \nSubgroup RT > 50 \nGy (n=30) vs. no \nRT (n=26):  \n \nbetter regional \ncontrol p=0.004, \nbetter survival \np=0.005  \ncontrol rates / \nregions: \nAxillary 90 vs. 70% retrospective \nstudy, Imbalance \nof groups: worse \nprognostic factors \nin the surgery + RT \ngroup (Ulceration, \nnumber of posi tive \nLN, extracapsular \nextension)  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 696 von 817 \nStudy  Aims  Design  Popula tion Outcomes  Results  Comments  LoE \n \n inguin al 80 vs. 72% \ncervical 85 vs. 50%  \n \nSubgroup \nextraca psular \nextension:  \nRT <50Gy vs. RT \n<50Gy  \n5 year regional \ncontrol 80 vs. 35%, \np=0.03 \nStrojan et al. 2010  \n To review \nexperiences in the \ntreatment of \nregionally \nadvanced \nmelanoma to the \nneck and/or \nparotid with \nadjuvant \nradioth erapy.  Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery \nalone, n=40  \n \nGroup B: surgery  \n+ RT (median \neqTD2 60 Gy, \nrange 47.8 \u201378.8, \nfraction size 5 Gy, \nrange 2 \u20136 Gy), \nn=43  83 patients after \nsurgery on \nmeta stases to the \nneck and/or \nparotid gland \nlymph  \nnodes, no distant \nmetastases \n  \n \n2-year regional \ncontrol rates  \n \n \n2-year distant  \nmetastasis -free \nsurvival rates  \n \n2-year survival \nrates (all deaths \nconsidered as \nevents)  Surgery alone vs. \nSurgery + RT  \n56% (CI 40 \u201372%) \nvs. 78% (CI 63 \u2013\n92%)  \n(p =0.015) \n \n55% (CI 40 \u201370%) \nvs. 40% (CI 25 \u2013\n56%), n.s.  \n \n51% (CI 36 \u201366%) \nvs. 58% (CI 42 \u2013\n73%), n.s.  \n \n retrospective \nstudy. Due to \nImbalance of \ngroups (irrad iated \npatients had more \nextensive surgery, \na significantly \nhigher m edian \nnumber of involved \nnodes, more \nfrequently \nextraca psular \ntumor extension, \nnonrad ical surgery, \nless systemic \nimmun otherapy \nwith in terferon) a \nrisk factor score \nwas used for 3b \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 697 von 817 \nStudy  Aims  Design  Popula tion Outcomes  Results  Comments  LoE \nretrospective \ngrouping of \npatients.  \nAgrawal et al. \n2009  To evaluate the \nimpact of adjuvant \nradiation therapy \n(RT) on regional \nrecurrence and \nsurvival after \ntherapeutic \nlymphad enectomy  Retrospective \ncohort stu dy \n \nTreatment:  \nGroup A: surgery \nalone, n=106  \n \nGroup B: surgery  \n+ RT (most \npatients: TD 30 Gy, \nfraction size 6 Gy, \n2.5 weeks), n=509  615 patients after \nlymphadenectomy \n(cervical, axillary, \ninguinal)  \n \n \n  \n \n \nRecurrence  \n(at a median \nfollow-up 60 \nmonths)  \n \n \n \n \n \n \n \n5-year regional \ncontrol rate  Surgery alone vs. \nSurgery + RT  \n \nRegional \nrecurrence: 43 of \n106 pts (40.6%) vs. \n52 of 509 pts \n(10.2%)  \n \ndistant recurrence: \n73.6% (78 of 106 \npts) vs. 55.4% (282 \nof 509 pts)  \n \nall sites 52 vs. \n87%, p<0.0001 \ncervical 43 vs. \n93%, p<0.0001 \naxillary 48 vs. 91%, \np<0.0001 \ninguinal 69 vs. \n69%, n.s.  \n \nmultivariate \nanalysis: DMFS and \nDSS both were \ninfluenced by the retrospective \nstudy, large series. \nP-values for \nrecurrence \nmissing. \ndata for overall \nsurvival not \ncompared between \ngroups \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 698 von 817 \nStudy  Aims  Design  Popula tion Outcomes  Results  Comments  LoE \nnumber of positive \nlymph nodes and \nthe number of \nlymph nodes \nremoved. In \naddition, DSS was \ninfluenced by \nprimary tumor \nthickne ss and the \nreceipt of adj uvant \nRT. \nThe most common \ncomplication  \nwas symptomatic \nlymphedema  \n \nHamming et al. \n2009  To examine the \neffect of adjuvant \nradiotherapy on \nregional control of \nmelanoma neck \nnode metastasis.  Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery \nalone, n=24  \n \nGroup B: surgery  \n+ RT (TD 24 - 36 \nGy, fraction size 6 \nGy) n=40  64 patients with \nnelanoma neck \nnode me tastasis  \n \n  \n \n \n2-year ipsilateral \nregional \nrecurrence rate  \n \n \n \n \n \n \n \n Surgery alone vs. \nSurgery + RT  \n \n46% vs. 18%, n.s. \n(p=0.16)  \n \nmultivariate \nanalysis: \nsignificant \nreduction of the RR \nrate aft er \ncorre ction for the \nnumber of involved \nnodes retrospective \nstudy, short \nmedian fo llow-up \n(2.5 years), small \nsample size, -\nImbalance of \nprognostic factors \nbetween the \ngroups 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 699 von 817 \nStudy  Aims  Design  Popula tion Outcomes  Results  Comments  LoE \n2-year disease -free \nsurvival (DFS)  \n \n \n2-year overall \nsurvival (OS).  (p=0.04)  \n \n29% vs. 18%, n.s. \n(p=0.30)  \n \n \n58% vs. 26%, n.s. \n(p=0.07)  \n \nMoncrieff e t al. \n2008  To examine the \neffectiveness of \nadjuvant \nradioth erapy in \ncontrolling \nregio nal disease in \nhigh-risk patients  Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery \nalone, n=587  \n \nGroup B: surgery  \n+ RT (median TD \n33 (range 30 -  60 \nGy, most patie nts: \nfraction size 5.5 \nGy, 2x/week) \nn=129  716 patients after \ncervical lymph \nnode surgery  \n  \n \n \n6 years regional \nrecurrence rate  \n \nOverall survival \n \n \n \n Surgery alone vs. \nSurgery + RT  \n \n6.1% vs. 10.1%, \nn.s. \n \n \nno benefit to \npatients with \nadjuvant \nradiotherapy  \n \nmultivariate \nanalysis: ulceration \nin the primary \ntumor: only \nsignificant \nindepe ndent \npredictor of \nregional \nrecurrence (p = retrospective \nstudy, large series, \nimba lance of \ngroups: the \nsurgery plus RT \ngroup includes \nsignificantly less \npatients with \nmicroscopic than \nmacro scopic \ndisease and \nsignificantly more \npatients with \nextensive surgery  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 700 von 817 \nStudy  Aims  Design  Popula tion Outcomes  Results  Comments  LoE \n0.005; hazard \nratio, 5.60; 95% \nconfidence \ninterval, 1.7 \u201318.4) \n \nnodal status, \nextracapsular \nspread and \nulcer ation of the \nprimary tumor: \nsignificant \nindependent \npredi ctors of \nsurvival (p = 0.001, \np = 0.014, and p = \n0.003)  \n \n \nFuhrmann et al. \n2001  To evaluate the \nusefulness of \nadjuvant \nradiotherapy \nfollowing resection \nof lymph node \nmetastases Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery \nalone, n=58  \n \nGroup B: surgery   \n+ RT (most \npatients TD 50 -65 \nGy, fra ction size 2 \n\u2013 3.8 Gy) n=58  116 patients, Stage \nIII after resection \nof lymph node \nmeta stases  \n  \n \n \nLocal r ecurrence \nrate \n \nOverall survival  \n \n(after a follow up \nof 12 -14 years)  Surgery alone vs. \nSurgery + RT  \n \n79% vs. 84%,  n.s. \n \n \n26% vs. 17% , n.s.  retrospective \nstudy, Imbalance \nof groups: pairs \nwere only matched \nfor gender and \nnumber of t umour -\nbearing lymph \nnodes. Group B \nincludes more \nhead and neck \nmelan omas and \nthicker tumours. 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 701 von 817 \nStudy  Aims  Design  Popula tion Outcomes  Results  Comments  LoE \nGroups were \ntreated in 2 \ndifferent german \ncentres using the \nsame fo llow up \nschedule.  \nmissing data, e.g. \nmedian follow up, \np-values  \n \nShen et al. 2000  To examine the \nincidence of \ncervical recurrence \namong patients \nwho did not \nreceive \npostoperative \nradioth erapy after \nsurgical \nmanagement of \nnodepos itive head \nand neck \nmelanoma  Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery \nalone, n=196  \n \nGroup B: surgery  \n+ RT (treatment \nSchedule not \nindicated) n=21  217 patients with  \nhead and neck \nmelanoma after \nregional lymph \nnode dissection  \n  \n \n \nCervical recurrence \nrate \n \n5 years overall \nsurvival \n5 years disease \nfree survival  \n Surgery alone vs. \nSurgery + RT  \n \n14% (25/183) vs. \n15% (2/13), n.s.  \n \n32% \n \n21% \n \nmulitvariate \nanalysis: \nextranodal \ndisease: only \nindependent \npredictor for \ncervical re currence  \n Baseline \ncharact eristics for \nthe su rgery+RT \ngroup were not \nindicated, no \nstatistical analyses \nfor this group due \nto small sample \nsize, retrospective \nstudy  3b \nO'Brien et al. 1997  To analyze the retrospective 143 patients after  Surgery alone vs. retrospective 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 702 von 817 \nStudy  Aims  Design  Popula tion Outcomes  Results  Comments  LoE \ninfluence of the \nnumber of positive \nnodes, \nextracaps ular \nspread, and the  \nuse of adjuvant \nradiotherapy on \nregional control \nand survival  cohort st udy \n \nTreatment:  \nGroup A: surgery \nalone, n=107 \n(sites)  \n \nGroup B: surgery  \n+ RT (TD 33 Gy, \nfraction size 5.5 \nGy, 3 weeks) n=45 \n(sites)  \n neck or parotid \ndissection, 152 \nlymphadenec tomy \nsites  \n \nLocal recurrence  \n \n \n \n5 years survival \n \n Surgery + RT  \n \n18.7% (20 of 107) \nvs. 6.5% (3 of 45), \np=0.055  \n \n35% vs. 40%, n.s.  \n study, imbalance \nof groups, difficult \nto compare data \nfor recurr ence with \nother studies as \nthey do not refer \nto patients but to \nirradiated sites.  \nCreagan et al. \n1978  To assess the role \nof postoperative \nradiation therapy \ndirected to the \nregional node area \nin patients \nunde rgoing \nlymphadenectomy \nfor metastatic \nmelanom a RCT \n \nTreatment:  \nGroup A: surgery \nalone, n=29  \n \nGroup B: surgery  \n+ RT (TD 5000 rad, \nfraction size 2500 \nrad) n=27  56 patients after \nlymphadenectomy  \n \n \n  \n \n \nTime to recurrence  \n \n \n \nSurvival \n Surgery alone vs. \nSurgery + RT  \n \n9 months vs. 20 \nmonths, n.s. \n(p=0.07)  \n \n22 months vs. 33 \nmonths, n.s. \n(p=0.09)  Limit ations:  \nrandomization \nscheme not \nappropriate (group \nassignment \npredict able), small \nsample size,  \nImbalance of \ngroups (more \nyounger patients \nand more patients \nwith only one \npositive node in \nthe RT group  \n 2b poor \nquality \nRCT  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 703 von 817 \n7.4.5.  Literatur  \n \nAgrawal S, Kane JM,3rd, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high -risk, lymph node -metastatic \nmelanoma. Cancer 2009;115:5836- 5844 \nBibault JE, D ewas S, Mirabel X, et al. Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiat Oncol 2011;6:12  \nCreagan ET, Cupps RE, Ivins JC, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, pros pective study. Cancer 1978;42:2206- 2210  \nBurmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph -node field relapse after therapeutic lymphadenectomy for  \nmelanoma: a randomised trial. Lance t Oncol  2012;  13: 589- 597 \nFuhrmann D, Lippold A, Borrosch F, et al. Should adjuvant radiotherapy be recommended following resection of regional lymph n ode metastases of malignant melanomas? Br J Dermatol \n2001;144:66- 70 \nGojkovic -Horvat A, Jancar B, Blas M, et al. Adjuvant Radiotherapy for Palpable Melanoma Metastases to the Groin: When to Irradiate? Int J Radiat Oncol Biol Phys 2011  \nHamming -Vrieze O, Balm AJ, Heemsbergen WD, et al. Regional control of melanoma neck node metastasis after selective neck dissec tion with or without adjuvant radiotherapy. Arch \nOtolaryngol Head Neck Surg 2009;135:795- 800 \nHenderson MA, Burmeister B, Thompson JF, et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patie nts after lymphadenectomy: Results of an intergroup \nrandomized trial (ANZMTG 01.02/TROG 02.01). J Clin Oncol (Meeting Abstracts) 2009;27:LBA9084  \nMoncrieff MD, Martin R, O'Brien CJ, et al. Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefi t for high -risk patients? Ann Surg \nOncol 2008;15:3022- 3027  \nO'Brien CJ, Petersen -Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 1997;19:589 -594 \nShen P, Wanek LA, Morton DL. Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas? Ann Surg Oncol 2000;7:554 -9; discussion 560 -1 \nStrojan P, Jancar B, Cemazar M, et al. Melanoma metastases to the neck nodes: role of adjuvant irradiation. Int J Radiat Oncol Biol Phys 2010;77:1039- 1045  \n \n  \n7.5. Frage VI.6. Fraktionierung  \nFrage VI.6. Hat das Fraktionierungsschema einen Einfluss auf die Effektivit\u00e4t der Radiotherapie bei Melanompatienten? \n7.5.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema  \nPopulation  Interven tion Comparison  Outcome  \nmelanoma patients  Radiotherapy high dose per fraction  Radiotherapy low dose per fraction  effectiveness  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 704 von 817 \nSuchw\u00f6rter  \nStichwort  Melanoma  radiotherapy  fraction   \nSynonyme   Radiation, irradiation  dose  \nOber -/Unterbegriffe      \nMesh  Term  melanoma  radiotherapy, radiat ion   \n \n7.5.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  ((melanoma[ti] OR melanoma[MeSH]) AND (radiotherapy[ti] OR radiotherapy[MeSH] OR \nradiation[MeSH] OR radiation[ ti] or irradiation[ti]) AND (fraction*[ti] OR dose[ti]))  14.07.1\n1 216 (Auswahl 9)  \nCochrane Library  (melanoma and (radiotherapy or radiation or irradiation) and fraction*).ti.  14.07.1\n1 3 (Overgaard, Chang, \nSause \u2013 alles Dubletten , \n0 dazu ) \nEmbase  (melanoma  and (radiotherapy or radiation or irradiation) and fraction*).ti.  11.05.1\n1 49 (Katz - Dublette)  \nUpdate Suche     \nMedline  s.o. 31.01.1\n2 221 (0 dazu)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 705 von 817 \nCochrane Library  s.o. 31.01.1\n2 3 (0 dazu)  \nEmbase  s.o. 23.01.1\n2 52 (0 dazu)  \n \n  \n7.5.3.  Auswahlkriterien  \nAuswahl  der Literatur  \nGesamttreffer  276 \nEinschlusskriterien  RCT\u00b4s  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports  \nNicht systematische Reviews  \nKombinationstherapien  \nKollektive mit gemischten Tumorentiti\u00e4ten  \nArbeiten \u00e4lter als 1980  \nAnzahl nach Abstractscreenin g, vorges ehen f\u00fcr Bewertung  9 \nAnzahl der ausgeschlossenen Studien nach Sichtung der Volltexte  7 \nAnzahl ausgew\u00e4hlter Volltexte  2 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 706 von 817 \n7.5.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSause et al. 1991  To evalu ate the \neffectiveness o f \nhigh dose per \nfraction irradi ation \nin the treatment of \nmelan oma RCT \n \nTreatment:  \n \nGroup A: 4 \nfractions, 8.0 Gy, \ndays 0, 7, 12 and \n21 \n \nGroup B: 20 \nfractions, 2.5 Gy, 5 \ndays a week  137 patients with \nskin, soft tissue \nand nodal lesions  \n \nGroup A n=67 \npatients  \n \n \nGroup B n=70 \npatients  Response  \n \n \n \n \n \n Group A vs. Group \nB: no significant \ndifferences  \n \nCR  24.2% vs. \n23.4%  \nPR   35.5% vs. \n34.4%  \nNC  33.9% vs. \n39.1%  \nPD   6.5% vs. 3.1%  \n Randomization \nscheme not \ndescribed  \nassessment not \nblinded  1b \nOvergaard et al. \n1985  To compare two \nhigh-dose per \nfraction radiation \nschedules in \nrecurrent or \nmetastatic \nmalignant \nmelanoma  RCT \n \nTreatment:  \n \nGroup A: 9 Gy X 3, \n2 fractions per \nweek  \n \nGroup B: 5 Gy X 8, \n2 fractions per \nweek  \n 14 patients, 35 \nskin and lymph \nnode metastases Respons e \n \n \n \n \n \n \n \n Group A vs. Group \nB: no significant \ndifferences  \n \nCR   n=11 (65%) vs. \nn=13 (72%)  \nPR    n=5 (29%) vs. \nn=5 (28%)  \nNC   n=1 (6%) vs. \nn=0 (0%)  Randomization \nscheme not \ndescribed, \nassessment not \nblinded, lesions \nnot patients were \nrandomized, very \nhetero geneous \npopul ation, small \nsample size  2b \nlow qual ity \nRCT \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 707 von 817 \n7.5.5.  Literatur  \nOvergaard J, von der Maase H, Overgaard M. A randomized study comparing two high -dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat \nOncol Bi ol Phys 1985;11:1837- 1839 \nSause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991;20:429- 432 \n \n  \n \n8. AG Nachsorge  \n \n8.1. Frage VII.3.  Selbstuntersuchung im Rahmen der Nachso rge - Adaptation  \nFrage VII.3.  Sollte die Selbstuntersuchung ein Bestandteil der Nachsorge sein?  \n \n8.1.1.  Synopse  (kurz)  \nThema/Fragestellung  LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care O ntario 2007  \n3. Sollte die \nSelbstuntersuchung ein \nBestandteil der Nachso rge \nsein? Notwendiger Bestandteil der \nNach sorge (C)  Bestandteil der Nachsorge f\u00fcr \njeden Patienten, leben slang; \nDurchf\u00fchrung von \nSchulungen zur \nSelbstunte rsuchung durch \n\u00c4rzte oder Pfl egekr\u00e4fte  LL Frankreich  \nFrench National Authority for \nHealth 2005  nur relevant f\u00fcr \nmedikament\u00f6se Therapien  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 708 von 817 \n8.1.2.  Empfehlung, Hintergrunds text und Literatur australischen und franz\u00f6sischen Quell -Leitlinie n \n LL Austr alien  \nNew Zealand Guideli nes Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 \nSchl\u00fcsselempfe hlungen  S. 122 \n \n1. Self -examination by patients is \nessential and they should be taught the \nprocess. Routine follow -up by the \npatient\u2019s preferred health p rofessional \nmay be appropriate to emphasise sun \nsmart behaviour and pe rform skin checks  \nGrade of Recommend ation: C  \n Empfehlungen zur Selbstunters uchung in \nder NICE Guideline b eziehen sich nur auf \nSCC und BCC, daher werden hier die \nAngaben aus dem Guideline  Evidence \nReview wiedergegeben:  \n \n S. 51 \n \nSuivi \nStade I AJCC  \nStandards  \n[\u2026] \n\u25a0 \u00e9ducation du patient \u00e0 \u2019aut od\u00e9pistage \nd\u2019un nouveau m\u00e9lanome et \u00e0 \nl\u2019autod\u00e9tection d\u2019une r \u00e9cidive.  \nNachsorge  \nStadium I nach AJCC  \nStandards  \n[\u2026] \n\u25a0 Anleitung des Patienten zur \nSelbstunt ersuchung auf ein neues \nMelanom und zur selbst\u00e4ndigen \nErkennung eines Rezidivs . \n \n \nStades IIA et IIB AJCC  \nStandards  \n[\u2026] \n\u25a0 \u00e9ducation du patient \u00e0 l\u2019autod\u00e9pistage \nd\u2019un nouveau m\u00e9l anome et \u00e0 \nl\u2019autod\u00e9tection d\u2019une r\u00e9cidive.  \nStadien IIA und IIB  \nStandards   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 709 von 817 \n LL Austr alien  \nNew Zealand Guideli nes Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 \n[\u2026] \n\u25a0 Anleitung des Patienten zur \nSelbstuntersuchung auf ein neues \nMelanom und zur selbst\u00e4ndigen \nErkennung eines Rezidivs . \n \nStades IIC et III AJCC  \nStandards  \n[\u2026] \n\u25a0 \u00e9ducation du patient \u00e0 l\u2019autod\u00e9pistage \nd\u2019un nouveau m\u00e9lanome et \u00e0 \nl\u2019autod\u00e9tection d\u2019une r \u00e9cidive.  \nStades IIC et III AJCC  \nStandards  \n[\u2026] \n\u25a0 Anleitung des Patienten zur \nSelbstuntersuchung auf ein neues \nMelanom und zur selbst\u00e4ndigen \nErkennung eines Rezidivs . \nHintergrundtexte  S. 121 \u2013 122  \n \n19.2 Undertaking follow -up \nCurrent guidelines world -wide do not \nspecify where routine follow -up should \ntake place or who should do it. [6,7] \nHowever, it is becoming a ccepted by \nmost [8 \u201310] but not all [11 \u201313] that \npatients themselves rather than doctors S. 370 (Guideline Evidence R eview)  \n \nPatient self examination  \n \nThe questions \nIn the follow -up of patients with skin \ncancer, what is the usefu lness of \neducation for self examin ation? \n S. 51  \n \nJUGEMENT ARGUMENT\u00c9 DES EXPERT S \n[\u2026] \nFace \u00e0 l\u2019ensemble de ces consid\u00e9r ations, \nil semble raisonnable d\u2019envisager une \nsurveillance min imale, \u00e0 savoir bas\u00e9e \nessentiellement sur l\u2019examen clinique et \nl\u2019\u00e9ducation du patient \u00e0 l\u2019autod\u00e9pistage.  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 710 von 817 \n LL Austr alien  \nNew Zealand Guideli nes Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 \nare likely to d etect their own recurrence.  \nThose studies reporting a h igh p atient-\ndetection rate attribute this to patients \nreceiving thorough explan ations of the \nsigns and symptoms of recurrences and \nnew primary melanomas. Despite such \nexplanations, it is obvious that the abil ity \nof individual patients to detect \nrecurrence varies. S ome can identify \nrecurrences that are not discernible to \ndoctors, while others can be u naware of a \nlarge tumour mass. The existence of \nthese latter patients perhaps explains the \nreticence of some centres to forego \nroutine follow -up. \nIn Australia, with its heightened \nawareness of the disease, up to 75% of \npatients detect their own recu rrences. \n[14] World -wide the mean percentage is \n62%. [1]  \nThe UK Medical Research Cou ncil has \ndesigned a \u2018framework for the design of \nan integrated follow -up program\u2019. [15] \nOne technique e mployed was to interview \npatients to determine their preferred \nfollow -up requirements. Most supported \nfollow -up by general practitioners, and \nfelt that the main purpose of follow -up \nwas reassu rance. However, there was The nature of the evidence  \nTwelve papers were identified \nrepre senting eleven studies (with one \nRCT reported at two stages of fol low-up) \nas follows:  \n\u2022 One RCT of good quality  \n\u2022 One systematic review of good quality  \n\u2022 One case control study of good quality  \n\u2022 Eight observational studies, four of \ngood qua lity, one of fair quality and  \nthree of poor quality  \nOnly one study originates from the UK. \nSeven studies are from the US, one study \nis from Australia and two studies are \nfrom Italy. Generalisabil ity to the UK is \ntherefore limited. \nSeven studies are of pati ents at risk of \nmelanoma based upon family hi story or \npresence of naevi. Three studies are of \nscreened pop ulations and two studies are \nof patients with proven melanoma.  \n \nSummary of the supporting evidence for \nthe recomme ndations  \n \nSelf examination (SE) versus ph ysician \nexamination  \nThere is consistent evidence that expert \nphysician e xamination has greater Pour les m\u00e9l anomes de stade I AJCC qui \npr\u00e9sentent globalement un faible r isque \nde r\u00e9cidive, l\u2019examen clinique annuel ou \nbiannuel aura pour objectif la d\u00e9tection \nd\u2019un \u00e9ventuel second m\u00e9lanome. Pour les \npatients de stades II et III AJCC, une \n\u00e9chographie ga nglionnaire de la zon e de \ndrainage peut \u00eatre envisag\u00e9e en option \n(accord d\u2019experts).  \nLes autres examens d\u2019imagerie (\u00e0 la \nrecherche de m\u00e9tastases \u00e0 distance) \nn\u2019ont pas apport\u00e9 la preuve qu\u2019ils \npouvaient influer sur la survie en partie \ndu fait de l\u2019absence de th \u00e9rapeutique \nefficace \u00e0 ce stade.  \nEn l\u2019absence d\u2019\u00e9tudes portant \nsp\u00e9cifiquement sur l\u2019int\u00e9r\u00eat de la \nsurvei llance et de son rythme, il n\u2019est pas \napparu possible de formuler des \nconclusions evidence -based \u00e0 partir de la \nlitt\u00e9rature. De ce fait, les \nrecommandations qui seront \u00e9 tablies  \nne pourront reposer que sur des a ccords \nd\u2019experts et seront le reflet d\u2019un \nconsensus pour un protocole de \nsurveillance minimum bas\u00e9 sur l\u2019examen \nclinique complet et l\u2019\u00e9ducation du patient \n\u00e0  \u2019aut od\u00e9pistage.  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 711 von 817 \n LL Austr alien  \nNew Zealand Guideli nes Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 \nconcern over trave lling times, costs, \nbrevity of consult ations, and poor \ncontinuity.  \nNearly all queried the experience and \nskill of the general practitio ners and said \ntraining would be vital, with rapid access \nto specialist advice if necessary. Total \nskin examination, instr uction in self -\nexamination and the provision of more \ninformation were seen as desirable at \nvisits to general practitioners. Other \nstudies assessing patients\u2019 opinions of \nthe value of follow -up [6,16] found that \nmost consi dered routine follow -up \nworthwhile,  with only a few conside ring \nthat it was not. While favouring follow -up, \nmore than half the patients in these \nstudies reported anxiety before each \nvisit. \n \nEvidence summary  \n \nThere is a consensus that the major ity of \npatients detect their own recurrence if \nthey have received a tho rough \nexplanation of the signs and symptoms \nof recu rrences and new primary \nmelanomas  \nLoE: IV  reliability than SE in detecting melanoma. \nSystematic review evidence suggests that \nmelanoma lesions detected by physicians \nare thinner than those detecte d by \npatients. Observational study ev idence  \nsuggests that detection by dermato logist \nis associated with earlier melanoma \ndiagnosis and that i nput by physicians is \nthe strongest single determinant of SE, \nalthough there is little evidence for \nimproved surviv al \narising from recurrences of melanoma \ndiagnosed by patients co mpared to \nrecurrences diagnosed by ho spital \ndoctors. The same level of  \nevidence suggests that SE based on naevi \ncount has poor concordance with \ndermatological assessment for risk of \nmelanoma a nd is not reliable. \n \nFactors affecting SE \nStudies have identified a number of \npatient characteristics and also events \nwhich are associated with SE. Systematic \nreview evidence suggests that elderly \nmen have lower rates of SE. There is \nobservatio nal study ev idence that factors \nassociated with greater likelihood of \npatients performing self skin CONFRONTATION  \nLes nouvelles donn\u00e9es iden tifi\u00e9es \nconvergent globalement avec les donn\u00e9es \npr\u00e9sent\u00e9es dans les documents initiaux \nde 1995 et 1998 et apportent de \nnouveaux \u00e9l\u00e9ments, notamment \nconcernant l\u2019\u00e9chographie ganglio nnaire \nqui peut \u00eatre propos\u00e9e pour le suivi des \npatients op\u00e9r\u00e9s de stades II  et III AJCC \n(option, accord d\u2019experts). L\u2019examen \nclinique co mplet et l\u2019\u00e9ducation \u00e0 \nl\u2019autod\u00e9pistage du patient restent le \nstandard.  \nLa fr\u00e9quence est \u00e0 adapter au stade du \npatient : une \u00e0 deux fois par an pour les \npatients atteints d\u2019un m\u00e9l anome de stade \nI et tous les 3 mois pour les autres \nstades.  \n \nS. 51 \n \nBEGR\u00dcNDETES URTEIL DER EXPERTEN  \n[\u2026] \nIm Angesicht dieser \u00dcberlegungen scheint \nes vern\u00fcnftig, eine minimale \n\u00dcberwachung in Erw\u00e4gung zu zi ehen, \ndas hei\u00dft im Prinzip basierend auf der \nklinischen Untersuchung u nd der \nAnleitung des Patienten zur  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 712 von 817 \n LL Austr alien  \nNew Zealand Guideli nes Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 \nReferences: 14 \u201316 \n \nSelf-examination may be co mbined, if \nappropriate, with routine follow -up by the \npatient\u2019s preferred health pr ofessional  \nLoE: IV  \nReferences: 14 \u201316 \n examin ation are: \n\u2022 skin awareness  \n\u2022 habitual sun protection  \n\u2022 previous benign skin b iopsy \n\u2022 family cancer history  \n\u2022 personal history of skin cancer \n\u2022 physician or nurse  exam ination or \nrecommendation  \n\u2022 help from a spouse (esp ecially wives \nassisting hu sbands)  \n\u2022 presence of a wall mirror  \n\u2022 age <50 years  \nThe same level of evidence su ggests that \nolder patients may be less likely to \nperform SE.  \n \nRates of SE  \nEstimates of rates of SE v ary widely within \nthe studies identified, according to \nfactors such as populations studied and \ndifferent definitions of SE or questions \nused by researchers to ascertain rates of \nSE. Subs equently, estimates of rates of SE \nfrom observ ational studies h ave range 9% \nto 87%. A rate of 71.6% for SE performed \nwithin the preceding year, was re ported \namongst first degree relatives of \nmelanoma p atients by Manne et al., \n(2004). Systematic review ev idence Selbstuntersuchung.   \nBei Melanomen im Stadium I nach AJCC, \ndie insgesamt ein geringes Rezidivrisiko \nhaben, wird die j\u00e4hrl iche oder \nzweij\u00e4hrliche klinische U ntersuchung die \nErkennung eines eventuellen zweiten \nMelanoms zum  Ziel haben. \nF\u00fcr Patienten in den Stadien II und III \nnach AJCC kann eine Lymphknoten -\nSonographie des Abflussgebi etes als \nOption ins Auge gefasst we rden \n(Expertenmeinung).  \nAndere bildgebende Verfahren (zur Suche \nnach Fernmetastasen) haben noch nicht \nden Be weis erbracht, dass sie das \n\u00dcberleben beeinflu ssen, zum Teil \naufgrund einer fehlen den effektiven \nTherapie in diesem Stadium.  \nDurch das Fehlen von Studien zum \nThema Nachsorge und Nachsorge -\nIntervalle scheint es nicht m\u00f6glich, aus \nder Literatur evidenzbasie rte \nSchlussfolgerungen zu ziehen.  \nDaher beruhen die gegebenen \nEmpfehlungen nur auf Expertenmeinung \nund spiegeln einen Konsensus f\u00fcr eine \nminimale Nachsorge basierend auf \nvollst\u00e4ndiger klinischer Unters uchung \nund Anleitung des Patienten zur  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 713 von 817 \n LL Austr alien  \nNew Zealand Guideli nes Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 \nsuggests that the effect of promoting SE \ncannot be disti nguished from that of \nroutine screening in patients seeing the \nphysician for unrelated reasons. RCT and \ncase control study evidence su ggests that \nrates of SE can be significantly improved \nthrough educational i nterventions.  \n \nRole of photography in SE  \nEvidence  from one RCT suggests that the \nuse of photography as an  \nadjunct to health education pr oduces no \nshort term (i.e. same day as intervention) \ndifference in compl iance above standard \neducation for SE  \nbut the same level of ev idence is \nsuggestive of a four mont h follow -up \nadvantage in terms of rate of SE through \nthe use of ph otographs.  \n \nBenefit of SE  \nCase control study evidence suggests \nthat SE is assoc iated with a marginally \nsignificant reduced risk of melanoma \nincidence: OR 0.66  \n[95% CI 0.44 -0.99] which is rep ortedly an \ninexpensive screening met hod. \nObservational study evidence su ggests \nthat female sex, high educational level Selbstuntersuch ung wider.  \n \nGEGEN\u00dcBERSTELLUNG  \nDie neuen Daten deuten in die glei che \nRichtung wie die Daten aus den ersten \nDokumenten von 1995 bis 1998 und \nbringen neue Elemente ein, vor allem \nbez\u00fcglich der Lymp hknoten -Sonographie, \ndie f\u00fcr die Nachsorge von operierten \nPatienten der Stadien II und III empfohlen \nwerden kann (Option, Expertenko nsens).  \nDie vollst\u00e4ndige klinische Unters uchung \nund die Anleitung zur \nSelbs tuntersuchung des Patienten bleiben \nStandard.  \nDie Nachsorgefrequenz ist an das \nStadium des Patienten anzupasse n: ein - \nbis zweimal f\u00fcr Patienten mit Melanom \nStadium I und alle 3 Mon ate f\u00fcr Patienten \nder anderen Stadien.    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 714 von 817 \n LL Austr alien  \nNew Zealand Guideli nes Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 \nand pe rformance of SE are associated \nwith thinner melan oma tumours.  \n\u2022 The prevalence study by Ai tken et al. \n(2004) found that 25.9% of ra ndomly \nselected adults reported whole body SE \nwithin the last 12 months and 1055 \n(33.9%) within the last 3 years and \nconcluded that input by physicians is the \nstron gest single determinant of SE.  \n\u2022 The case control study by Be rwick et al. \n(1996) found that SE was performed by \n15% of all subjects (p atients with \nmelanoma and population matched \ncontrols) and was associa ted with a \nmarginally significant  re duced risk of \nmelanoma in all su bjects: OR 0.66 [95% \nCI \n0.44-0.99].  \n\u2022 The qualitative study by Be rwick et a l. \n(2000) found that amongst a sample of \npatients with a hi story of melanoma and \nalso lower risk patients without a history \nof mel anoma, the rate of reported SE was \n32% at baseline, rising to 64% after an \neducational interve ntion (p = 0.03).  \n\u2022 The survey o f patients referred by their \nGPs to a pi gmented lesion clinic \nundertaken by Carli et al. (2002) found \npoor concor dance between SE and  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 715 von 817 \n LL Austr alien  \nNew Zealand Guideli nes Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 \ndermatological assessment for both \ncommon and atypical naevi and \nconcluded that SE of melanoma risk is \nnot rel iable. \n\u2022 The case series study by Carli et al. \n(2003) found that 40.6% of patients with \nmelanoma sampled self detec ted their \nmelanoma tumour. F emale sex (OR 0.70 \n[95% CI 0.50 -0.97]), high educational \nlevel (0.44  \n[95% CI 0.24 -0.79]) and perfo rmance of \nSE (0.65 [95% CI 0.45 -0.93]) were factors \nassociated with thinner tumours. 48% of \npatients performed SE, but only 20.4% \nregularly. \n\u2022 The systematic review by Helfan et al. \n(2001) found melanoma l esions detected \nby physicians to be thinner than those \ndetected by p atients.  \nElderly men had lower rates of SE and the \nauthors reco mmended that physicians \nperform skin examin ation in these \npatients. The authors r eported that the \neffect of promoting SE cannot be \ndistin guished from  \nthat of routine screening in p atients \nseeing the phys ician for unrelated \nreasons.  \n\u2022 The qualitative survey of first degree  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 716 von 817 \n LL Austr alien  \nNew Zealand Guideli nes Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 \nrelatives of patients with mela noma by \nManne et al. (2004) found the rate of SE \nin the last year to be 71.6%. SE correlated \nclosely with having received a clinical \nskin exa mination by a physician. \n\u2022 The case series study of patients with \nmetastatic mel anoma by Odili  \nand Evans (2001) found that 56% of cases \nof recurrent m elanoma were patient \ndetected and no si gnificant difference in \nsurvival between recu rrences diagnosed \nby SE and those di agnosed by hospital \ndoctor were found.  \n\u2022 The qualitative study by Ol iveria et al. \n(1999) found that amongst a sample of \nCaucasian people without melanoma, \nskin aw areness was a strong factor \nassociated with SE whereas older age and \nhigher education was asso ciated with a \ndecreased likelihood of perfor ming \nSE. \n\u2022 The RCT by Phelan et al. (2003) \ncompared nurse educ ation for SE and \nprovision of skin photographs with nurse \neducation and prov ision of standard \nbrochure in patients with 5 or more \ndysplastic na evi, wi th or without a history \nof melanoma. The mean group scores for \nknowledge,   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 717 von 817 \n LL Austr alien  \nNew Zealand Guideli nes Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 \nawareness and confidence increased in \nboth groups at imm ediate  \nfollow -up (p < 0.0001) but th ere were no \nsignificant diffe rences in scores  between \nthe photography group and the br ochure \ngroup.  \n\u2022 The RCT of patients at high risk for \nmelanoma based upon dy splastic naevi \nby Oliveria et al. (2004) pr ovided further \nfollow -up to the study by Phelan et al. \n(2003) and found that a teaching \nintervention with ph oto book \ndemonstrated a 51% i ncrease in 3 or \nmore reported examinations at 4 month \nfollow -up, co mpared to a 17.6% increase \nin the group which received teaching only \n[p = 0.001].  \n\u2022 The observational pilot study (as part \nof a subsequent trial) by Wei nstock et al. \n(2004) found the rate of SE  amongst \npatients attending for routine follow -up \nvisits to be between 12% and 38%. Help \nfrom a partner and presence of a wall \nmirror were associated with higher rates \nof SE whereas visual impairment was \nfound to be associated with lower rates \nof SE.  \nBemerkungen   Diese Leitlinie bezieht sich auf MM und Keine Literaturangaben zu Fragen der  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 718 von 817 \n LL Austr alien  \nNew Zealand Guideli nes Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 \nauf NMSC.  Selbstuntersuchung; Angaben sind daher \nnur ko nsensbasiert.  \n \n  \nLiteratur:  \n \nLL Austr alien New Zealand Guidelines Group 2008  \n7. Bain NS, Campbell NC, Ritchie LD, et al. Striking the right balance in colorectal cancer care --a qualitative study of rural and urban patients. Fam Pract 2002;19:369 -374 \n11. B asseres N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10 -year experience in a dermatology department \nin France. Dermatology 1995;191:199- 203 \n6. Baughan CA, Hall VL, Leppard BJ, e t al. Follow -up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) 1993;5:174- 180 \n16. Dancey A, Rayatt S, Courthold J, et al. Views of UK melanoma patients on routine follow -up care. Br J Plast Surg 2005;58:245- 250 \n1. Francken AB , Bastiaannet E, Hoekstra HJ. Follow -up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005;6:608- 621 \n14. Francken AB, Shaw HM, Accortt NA, et al. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence -based follow -up guidelines. Ann \nSurg Oncol 2007;14:1924- 1933  \n27. Garbe C, Paul A, Kohler -Spath H, et al. Prospective evaluation of a follow -up schedule in cutaneous melanoma patients: recommendations for an effective follow -up strategy. J C lin \nOncol 2003;21:520- 529 \n13. Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow -up in melanoma patients --monocenter evaluation of methods, costs and patient survival. Br J Cancer \n2002;87:151- 157 \n10. Jillela A, Mani S, Nair B, et al. The ro le for close follow -up of melanoma patients with AJCC stage I -III: a preli minary analysis. Proc Am Soc Clin Oncol 1995; 14:413  \n8. Kersey PA, Iscoe NA, Gapski JA, et al. The value of staging and serial follow -up investigations in patients with completely re sected, primary, cutaneous malignant melanoma. Br J Surg \n1985;72:614- 617 \n15. Murchie P, Hannaford PC, Wyke S, et al. Designing an integrated follow -up programme for people treated for cutaneous malignant melanoma: a practical application of the MRC \nframewo rk for the design and evaluation of complex interventions to improve health. Fam Pract 2007;24:283 -292 \n12. Poo -Hwu WJ, Ariyan S, Lamb L, et al. Follow -up recommendations for patients with American Joint Committee on Cancer Stages I -III malignant melanoma. Cancer 1999;86:2252- 2258  \n9. Ruark D, Shaw H, Ingvar C, et al. Who detects the primary recurrence in stage I cutaneous melanoma: patient or doctor? Mel anoma Res 1993; 3(Supplement 1):44.  \n \nLL GB NICE 2006  \nSiehe Evidence Table 5.3, S. 375 \u2013  379 des Guideline Evidence R eview \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 719 von 817 \n \n8.2. Frage VII.4., VII.5. und VII.6.  Nachsorge -Dauer und - Intervalle  \u2013 De-novo -Recherche  \nFrage VII.4.  Wie lange sollte die Nachsorge von Melanompatienten erfolgen?  \nFrage VII.5.  In welchen Intervallen sollte die Nachsorge erfolgen?  \nFrage VII.6.  Welche Untersuchungen sind im Rahmen der Nachsorge bei asymptomatischen Patienten indiziert?  \n8.2.1.  PICO, Suchw\u00f6rter  \n \nSuchw\u00f6rter  \nStichwort  melanoma  Surveillance  Relapse  \nSynonyme   Follow -up, After -care, aftercare, post -\noperative care  recurrence  \nOber -/Unterbegriffe, Mesh Term  S. Suchstrategie  (Kapitel 7.4.2. und Kapitel I.6.)  \n \n8.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  \"melanoma\"[tiab] AND (\"relapse\"[tiab] OR \"recurrence\"[tiab] OR \"surveillance\"[tiab] OR \n\u201cfollow -up\u201d[tiab] OR aftercare[tiab] OR \u201cafter -care\u201d[tiab] OR \u201cpost -operative care\u201d)  23.01.2012 7047  \nCochrane Library  (melanoma and (surveillance or \"follow up\")).ti.  23.01.2012  278  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 720 von 817 \nDatenbank  Suchstrategie  Datum  Treffer \nEmbase  (melanoma and (surveillance or \"follow up\")).ti.  23.01.2 012 443 \n2. Suche  s. \u201cEvidenztabelle I.6, I.7, I.8, VII.6\u201d , Kapitel I.6  \n3. Suche/Erg\u00e4nzungen  (\"second primary\"[title] AND melanoma) OR \"second melanoma\"[title] OR (\"multiple \nprimary\"[title] AND melanoma)  23.01.2012  186 \nBemerkungen: Datum der Erst -Recherc he (1. Suche) f\u00fcr Medline und Cochrane war der 21.12.2010 bzw. f\u00fcr die Erg\u00e4nzungs -Recherche (3. Suche) der \n08.06.2011. Die erste EMBASE -Recherche erfolgte am 11.05.2011. Eine let zte Update -Recherche (initiale Suche, Erg\u00e4nzungsrecherche) erfolgte am 23.01.2 012 \nf\u00fcr EMBASE, am 26.01.2012 f\u00fcr Medline bzw. am 19.01.2012 f\u00fcr Cochrane. In den Tabellen angegeben sind die Zahlen der letzten Update -Recherche. Die \nDaten f\u00fcr die zweite Suche f\u00fcr die Frage VII.6 en tnehmen Sie bitte der Tabelle \u201eI.6, I.7, I.8, VII.6\u201c  unter Kapitel I.6 . \n \n8.2.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  7954  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports, narrative Reviews, Bench Research  \nAnzahl nach Abstractscreening  163 (inkl. Dupl etten)  \nAnzahl ausgew\u00e4hlter Volltexte, vorgesehen f\u00fcr Bewertung  59 \nBemerkungen  \nZum Thema \u201cmultiple melanomas\u201d liegt ein Review von Francken et al. (2005) vor, das Studien bis Februar 2004 umfasst, das in diese Tabelle ebenfalls mit  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 721 von 817 \nAuswahl der Literatur  \naufgenommen wurde .  \n \nDie Tabelle enth\u00e4lt alle relevanten Rechercheergebnisse f\u00fcr die Fragen VII.4., VII.5., VII.6.  \nDie Literatur wurde entsprechend der Fragestellungen zugeteilt, s. hierf\u00fcr auch die \u00dcbersicht am Ende der Tabelle. Im Rahmen der AG -Treffen wurde durch die \nExperte n eine konsensbasierte Beantwortung der Frage VII.5 entschieden. Da diese Entscheidung nach erfolgter Literatursuche getroffe n wurde, sind die \nErgebnisse der Frage VII.5 in dieser Tabelle aufgef\u00fchrt. Auch die Nachsorgetabelle zu den verschiedenen Untersuch ungen und Intervallen zu den jeweiligen \nTumorstadien wurde konsensbasiert erstellt auf Basis der vorliegenden Literatur. Aufgrund der Studiendesigns und von thematis chen \u00dcberschneidungen ist \neine strikte Auftrennung der Literatur nach Fragestellung nicht m \u00f6glich. Aus diesem Grund wurde die Literatur, bei gleicher Suchstrategie, in dieser Tabelle \nzusammengefa\u00dft. Studien zu der Frage VII.6 zu der hier aufgef\u00fchrten Suchstrategie befinden sich in dieser Tabelle. Weitere St udien zu der Frage VII.6, die im \nRahmen  der 2. Literaturrecherche/Erg\u00e4nzungen (s.o.) identifiert wurden, sind in der Tabelle \u201eI.6, I.7, I.8, VII.6_kurz\u201centhalten.  \n \n8.2.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nLeiter et al. (2011)  To analyze stage - \nand time -\ndepend ent hazard \nrates (HR) and to \ndiscuss current \nsurveillance \nrecommendations.  Prognostic study  \n \n 33,384 patients \nwith CM stage I -III \n \n Overall survival  \n \nRelapse -free \nsurvival  \n \nHazard ratios (HRs) \nfor recurrences \nand secondary \nmelanoma  melanoma -specific \n5- and 10-year \nsurvival: 91.9% and \n87.2%, respectively  \n \nRecurrences \nrecorded in 4999 \npatients (15.3%; \nstage I, 7.1%; stage \nII, 32.5%; and stage \nIII, 51.0%) \n \nmedian RFS time: \n44 months  Very large and \nmulti -center \npatient cohort 1b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 722 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n10-year recurrence -\nfree survival was \n78.9% (95% \nconfidence interval \n73.1-90.5) ; in \nstage I, 89.0%; \nstage II,  \n56.9%; and stage \nIII, 36.0%.  \n \nHR for recurrent \nCM: \n- Stage IA: \nconstantly low \nlevel HR </= 1:125 \nper year  \n- stage IB: higher \nHRs >/= 1:40 for \nthe first 3 years \nand generally in \nstages II to III  \n \nFrom 3 years of \nfollow -up on ward, \nstage II and III CIs \noverlapped/ no \nsignificant \ndifferences for the \ndevelopment of \nrecurrences. After \n10 years of follow - \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 723 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nup HR of all 3 \nstages did not \ndiffer significantly. \n \nOf all patients 2.3% \ndeveloped \nsecondary \nmelanomas, with a \nconsistently low HR \n< 1:220 per year  \nVoit et al. (2001)  \n \n to evaluate \nwhether early \ndetection of \nmetastases \nimproves relapse -\nfree and overall  \nsurvival  Diagnostic study  \n \n 829 consecutive \nmacroscopically \ndisease -free \nmelanoma p atients  Sensitivity  \n \nSpecificity  \n \nPositive predictive \nvalue (PPV)  \n \nnegative  \npredictive value \n(NPV)  \n \nSurvival \n \nrelapse -free \nsurvival  \n \noverall survival \n2- and 4 -year \nsurvival rates  Physical \nexamination (PE): \nsensitivity 25.2%, \n(95% confidence \ninterval [CI]:  19.9 \u2013\n31.2%), PPV 57.5%, \n(95% CI: 47.5 \u2013 \n66.9%). specificity: \n98,4%, NPV 93.8%.  \n \nultrasound B -scans \n(UBS): sensitivity \n99.2%, 95% CI: \n97.3\u201399.6%, \nspecificity: 98.3%  \n(95% CI: 97.7 \u2013\n98.7%), PPV: 83.3% \n(95% CI: 78.5 \u2013 \n87.4%), NPV: 99.9% \n(95% CI: 99.6 \u2013No information \nabout the \nexaminer (blinded \nfor the results of \nthe oth er \nexamination?)  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 724 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n100.0%.  \n \nB-scan was highly  \nsuperior to \nphysical \nexamination  \n(P = 0.001).  \n \nOut of 242 proven \nmelanoma \nmetastases, 24.8% \nwere detected by \nboth methods \nsimultaneously. \n \nSurvival curbes: \nsee full -text \nFrancken et al. \n(2005)  To discuss \nfrequency and \nduration of follow -\nup, type of health \nprofessional \ninvolved, optimum \nintensity of routine \ninvestigation, and \npatients\u2019 \nsatisfaction with \nfollow -up. Systematic review \n(without meta -\nanalysi s) \n \n 72 articles \nincluded  \n \nGiven separately \nfor every included \nstudy (see original \narticle)  Various  first recurrence:  \n- 20\u201328% local or \nin-transit \nrecurrences  \n- 26\u201360% regional \nrecurrences  \n- 15\u201350% distant \nmetastases \n \nUltimately  \n- 3\u20135% local or in -\ntransit recurrence  \n- 5\u201313% regional Systematic \nliterature search, \nbut no meta -\nanalysis (no \nsummary of ef fect \nmeasures)  \n \n 2a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 725 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nnodes  \n- 3\u201310% distant \nmetastates  \n \n62% of patients \ndetected their first \nrecurrence \nthemselves  \n \nfrequency of late \nrecurrences \n(DFS>10 years) \nbetween 1% to 25%  \n \nIncidence of \nsubsequent PM: 2% \nto 7%  \n \nOptimum \nfrequency and \nlength of follow -up \nservices: no true \nevidence for \nfollow -up \nsurveillance in \nlocalised \nmelanoma \naccording to the \narticles In no study \nany benefit in DFS \nor OS associated  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 726 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwith follow -up \nsurveillance  \nPeric et al (2011 ) determine whether \nregular \nmeasurements of \nserum S100B are a \nuseful tool for \ndiscovering \npatients with CM \nmetastases and to \nevaluate the \ndiagnostic value of \nPET-CT during the \nfollow -up Diagnostic study  115 CM patients  \nincluded in regular \nfollow up  \n \n(82 patients with \nclinical signs of \ndisease \nprogression, 33 \n(28.7%) \nasymptomatic \npatients with two \nsubsequent \nelevated values of \nS100B)  Sensitivity  \n \nSpecificity  \n \nPPV \n \nNPV S100B: Sensitivity, \nspecificity, PPV and \nNPV 33.8%, 9 0.9%, \n96.0% and 17.5% \nrespectively in \npatients with \nclinical signs of \ndisease \nprogression. \n \nSensitivity and PPV \nof S100 in \nasymptomatic \npatients were \n100.0% and 69.7%.  \n \nPET-CT: \nsensitivity, \nspecificity, PPV and \nNPV of PET -CT for \nsymptomatic \npatients: 98.5% , \n90.9%, 98.5% and \n90.9%  \n \nsensitivity, \nspecificity, PPV and \nNPV of PET -CT for  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 727 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nasymptomatic \npatients: 100%, \n90.0%, 95.8% and \n100%  \nKruger et al. \n(2011 ) to demonstrate the \nhigh efficacy of \nultrasonography as \na noninvasive \ntechnique  \nfor early detection \nof lymph node \ninvolvement during  \nclinical follow -up, \nespecially in \npatients with \nsubclinical  \nmetastases.  Diagnostic study  433 melanoma \npatients with \nstage -dependent  \nfollow -up intervals \nof 3 to 12 months  \n Sensitivity  \n \nSpecificity  Sensitivity and \nspecificity of \ncombined clinical \nand sonographic \ninvestigations: \n0.9394 (95% \nconfidence \ninterval: 0.7977 \u2013\n0.9926)] and \n0.9808 (95% \nconfidence \ninterval: 0.9717 \u2013\n0.9875)] \nrespectively.  \n \ncombinatorial \napproach was \nsignificantly \nsuperior with \nregard to detection \nof metasta ses \ncompared with \nclinical \ninvestigations \nalone (P<0.0001)  \n Prospective design  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 728 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSignificant \ndifferences \nbetween clinical \nfollow -up and \nsonographically \nassisted follow -up \nfor stages I (P = \n0.0389), III( P = \n0.0101), and IV (P \n=0.0016).  \nTurner et al. \n(2011)  to relate the \nestimated delay in \ndiagnosis of \nrecurrence or SPM \nin patients with \nstage I or II \nmelanoma to the \nnumber of visits \nneeded by two \ndifferent \nmonitoring \nschedules. \nSecondarily, to \nestimate the effect \nof \nprognostic factors \non development of \nrecurrence or SPM  Prognostic study  2,998 consecutive  \npatients first \ndiagnosed with \nstage I or II \nmelanoma  Delay in diagnosis \nof recurrence  \n \npredictors of \ndeveloping new \nprimary  small difference in \nmodeled delay in \ndiagnosis (extra  \n44.9 and 9.6 \npatients per 1,000 \nfor recurrence and \nnew primary, \nrespectively, with \ndelay >2 months) \nusing a schedule \nthat requires far \nfewer visits (3,000 \nfewer visits per \n1,000 \npatients) than \nrecommended by \ncurrent guidelines.  \n \nAJCC substage= \npredictor of Big patient cohort  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 729 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nrecurrence  \n \nage and date  of \nprimary \ndiagnosis=predicto\nrs of \ndeveloping new \nprimary  \nAukema TS et al. \n(2010)  \n to assess the \nclinical relevance \nof increased S -\n100B during follow \nup of high- risk \nmelanoma patients \nand to determine \nthe value of \nsubsequent whole -\nbody PET/CT and \nbrain MRI.  Diagnostic study  \n \n 46 melanoma \npatients who were \nfound to have an \nelevated serum S -\n100B level during \nfollow -up  \n \n survival  \n \nAccuracy  \n \nSensitivity  \n \nSpecificity  \n \nnegative predictive \nvalue (NPV)  \n \npositive predictive \nvalue (PPV)  \n \nFalse-positives (FP)  \n \nFalse negatives \n(FN) Median of the \nelevated S -100B \nserum levels \nduring follow -up: \n0.14 \u00b5g/L, range \n0.10\u20131.33 \u00b5g/L.  \n \nPET/CT:  \nhypermetabolic  \nlesions in 27 of 46 \npatients (59%).  \nFN: n=0  \nFP: n=4  \nby median follow -\nup of 1 year  \nsensitivity: 10 0% \nspecificity: 83%  \naccuracy: 91%  \nPPV: 85%  \nNPV: 100%.  \n \nMRI: sensitivity of MRI \nnot determined \nbecause of the low \nincidence of brain \nmetastases.  \n \nSmall population  \n \n \n \n 2b \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 730 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nBrain metastases in \n1 patient (2%).  \nNPV: 100%  \nspecificity: 100%  \n \nPPV of an elevated \nserum S -100B: 50% \n(S-100B level>0.10 \n\u00b5g/L).  \n \nOf the 23 patients \nwith a true positive \nPET/CT scan, 6 \n(26%) recei ved \nsurgical treatment \nwith curative \nintent; 17 (74%) \nreceived palliative \ntreatment or \nsupportive care.  \n \n2-year-survival: \n51.9% in patients  \nwith a positive \nPET/CT compared \nwith 100% in the  \npatients with \nnormal PET/CT \nfindings (P=0.002).  \nBrown RE et al. to determine the Diagnostic study  1,235 patients  Sensitivity  210 patients post hoc analysis 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 731 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(2010)  \n clinical efficacy of \nroutine CXR for  \nrecurrence \nsurveillance in \nmelanoma.   \n with invasiv e \ncutaneous \nmelanoma \u22651.0 \nmm in Breslow  \nthickness and \nwithout clinical \nevidence of \nregional or distant \nmetastases  \n  \nSpecificity  \n \nPPV \n \nNPV (17.0%) had a \nrecurrence: local or \nin-transit in 36,2%, \ndistant (nonlung) \nmetastases in \n35,2%, lung -only \nmetastases in \n13,3%.  \n \n99% (n = 4,180) of \nCXR were read as \neither \u2018\u2018normal\u2019\u2019 or \nfalsely positive \n(FP). 0.9%(n = 38) \nof all CXR obtained \nwere true positives \n(TP).  \n \nSensitivity and \nspecificity: 7.7% \nand 96.5%, \nrespectively. on data from a \nprospective, \nrandomized, \nmultiinstitutional \nstudy on \nmelanoma (Sunbelt \nMelanoma Trial)  \n \nno information \nabout reference \nstandard  \n \nHohnheiser et al. \n(2010)  to identify factors \nthat influence time \nto recurrence and \nsurvival after the \nfirst rec urrence \nwith a special \ninterest in late \nrecurrences.  Prognostic study  \n \n 2487 patients with \nthe first \nmanifestation of a \ncutaneous \nmalignant \nmelanoma  Overall survival  \n \nTime to first \nrecurrence  \n \nPrognostic factors  Significant \nindependent \nprognostic factcors \nfor survival (Cox \nregression \nanalysis):  \n- patient\u2019s age  \n- sex Retrospective \nreview (prospective \ndatabase)  \n \nLarge patient \ncohort  \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 732 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n- tumor \nlocalization,  \n- pT \n- pN.  \n \nmedian time to \nfirst recurrence: 24 \nmonths.  \n \n5-recurrence -rate: \n81.6%  \n \nlate recurrences -\nrate (>10 -years): \n6.5% \n \nindependent \nfactors for time to \nrecurrence. (C ox \nregression \nanalysis)  \n- age at primary  \n- treatment  \n- pT \n- pN  \n- type of \nrecurrence were \nfound to be  \n \nindependent factor \ninfluencing survival  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 733 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nafter a first \nrecurrence:  \n - type of \nrecurrence  \n \n(advanced age at \ndiagnosis of \nrecurrence male \nsex  \nmarginally \nsignificant)  \nLeiter et al. ( 2010)  To investigate \nwhether detection \nin an early phase is \nassociated with \nprolonged survival \nand whether the \nobserved longer \nsurvival times are a \nmere co nsequence \nof detection at an \nearlier time point \n(lead time bias). Prognostic study  \n \n 1969 patients with \nmelanoma stage I \u2013  \nIII, recurrences in \n112 patients  disease -specific \nmortality  \n \nOverall survival \n(OS) \n \nSurvival after \nrecurrence (SAR)  \n \nAdjusted surviv al \ntime by using \nsjourn time  disease -specific \nmortality: 69.6% \n(n=78).  \n \nOverall 10 -year \nsurvival rate: 36.1%  \n10-year SAR \nsurvival rate: 25.4%  \n \n10-year OS \nprobability for \ndetection in early \nphase: 42.6% for \nearly phase vs. \n25.6% for \nadvanced phase  \n (P = 0. 012) \n \nAdjustment for Adjustment for \nimportant \nconfounding factor  \n \nEstimated sojourn \ntime (no evidence \nbase available)  \n \nMissing data in 10 \nof 112 patients for \nCox proportional \nhazard model  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 734 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nlead time:  \n10-year OS \nprobability: 40.5% \n(95 CI: 27.4, 53.6) \nfor early phase \nrecurrences \nvs.25.6% (95% CI: \n12.5, 38.7) for \nadvanced phase \nmetastases \n(P=0.021)  \n \nindependent \nprognostic factors \n(multivariate \nanalysis):  \n- detection of ear ly \nphase metastases  \n(P = 0.022)  \n- stage at primary \ndiagnosis (P \n<0.0001)  \nRueth et al . (2010)  To examine \nwhether  \nconditional survival \n(CS) is more \naccurate in \npredicting  \nlongterm \nmelanoma survival. Prognostic study  8647 T2 -T4 \npatients patients \nwho underwent \nsurgical treatment \nfor melanoma  \n \n cancer -specific \nsurvival  \n \n10-year-survival \nrate At diagnosis:  \n10-year survival \nrates:  \nlow-risk: 79.6%  \nhigh-risk: 41.2% \nP<0.001  \n \ninitial predictors of Very large patient \ncohort \n \nOnly available \nstudy which gives \ndata for this \noutcome \n(conditional 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 735 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsurvival: age, \ngender, location, \nulceration  \n \nOn CS analysis:  \n- survival \ndifferences  \nuntil 8 years after \ntreatment  \n- 10-year survival \nrates:  \nlow-risk :95.4%  \nhigh-risk: 91.7%  \nP = 0.51  \n \nOn Multivariate \nanalysis: age, \ngender, location, \nulceration: no \nlonger predictive \nafter 8 years  survival)  \n \nCS is a function of \nthe traditional \nsurvival estimates, \nadjusted to reflect \nthe probability  \nof survival \nconditioned on \nliving to a certain \npoint in follow -up \n \nthe low -risk \ncategory: T2 \u2013T3, \nN0 \n \nhigh-risk category \nT4N0 or T2 -4N1-3 \nMurchie et al. \n(2010)  to evaluate the \neffects of GP -led \nmelanoma follow -\nup on patient \nsatisfaction, in \ncomparison to \nhospital -led follow -\nup, follow -up \nguideline RCT \n \n 142 melanoma \npatients free of \nrecurrent disease  Patient satisfaction \nmeasured by \nquestionnaire  \n \nAdherence to \nguidelines  \n \nHealth status \nmeasured by SF -36  cluster -adjusted \nmean summary \nsatisfaction score: \n- at baseline no \nsignificant \ndifferenc e between \ngroups  \n- at follow -up \nsignificantly lower Reliable \nrandomization \ndesign; blinding \nnot possible  \n \nStudy took place in \nScotland; \ntransferability to \nGerman health 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 736 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncompliance, \nanxiety and \ndepression, as well \nas health status.   \nAnxiety and \ndepression \nmeasured by the \nHospital Anxiety \nand Depression \nScale HADS  in the intervention \ngroup 26.4 (95% \nCI: 24.9 \u2013 \n27.9) vs 33.5 (95% \nCI: 32.5 \u201334.4),  \n \nAdherence o \nguidelines: \n- in the year before \nthe study: 84,9% in \nthe intervention \ngroup and 85.4% \nof the control \ngroup  \n- At follow -up: \n98.1% in the \nintervention group \nand 80.9% of the \ncontrol group  \n \nSF-36 scores and \nHADS score:  \nno statistically \nsignificant \ndifferences \nbetween groups at \neither baseline or \nfollow -up.  care system?  \nMorton RL et al. \n(2009)  to evaluate the \naccuracy of Diagnostic study  \n 108 patients  AJCC  \nstage IIIA/B (N1a, sensitivity  \n CXR: sensitivity, \n48%; 95% Not all patients \nreceive verification 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 737 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n detecting \nasymptomatic \npulmonary \nmetastases by \nsurveillance chest \nX-rays (CXRs) in \nmelanoma patients \nwith a positive SNB   N2a) disease  specificity  \n \ntime to diagnosis  \n \nsurvival  confidence interval \n[95% CI], .27 \u2013.68) \nspecificity, 78%; \n95% CI, .77 \u2013.79 \n \nAdditional \nmetastatic disease \nwas apparent in \n18% of CXR -\ndetected versus \n76% of non -CXR-\ndetected patients \n(p<0.05)  \n \nmedian time to \ndiagnosis of \npulmonary \nmetastases: 24 \nmonths (95% CI, \n12\u201341) vs. 16 \nmonths (95% CI, \n10\u201330, p = 0.30 \nlog rank).  \nmedian survival of \n42 months (95% CI, \n24\u201384)vs. 36 \nmonths (95% CI, \n18\u201346, p = 0.53 \nlog rank)  using a reference \nstandard (only \npatients with \npositive CXR)  \nTarhini AA et al. To asses the effect Progostic study  Sera from 670 Overall survival median OS time: Patien ts were 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 738 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(2009)  of elevated serum \nS100B level at \nbaseline and \nduring therap y.  patients with high \nrisk melanoma \n(\u2265stage IIB disease) \nbanked at baseline \nand 3 additional \ntime points were \ntested for S100B  \n \n (OS) \n \nRFS 7.2 years (95% CI, \n6.0 years to not \nreached). RFS ti me: \n3.1 years (95% CI, \n2.4 to 3.7 years).  \n \nMultivariate \nanalysis was \nperformed \nadjusting for \nsignificant \nprognostic factors \n(ulceration and \nlymph node status) \nand treatment. \nBaseline S100B was \na significant \nprognostic factor \nfor survival (HR = \n1.39; 95% CI , 1.01 \nto 1.92; P = 0.043) \n \nS100B values \nmeasured at later \ntime points over 1 \nyear were also \ndemonstrated to \nbe significant \nprognostic factors \nfor RFS and OS. \nLower S100B included in an \nintergroup trial \nE1694 was a \nrandomized \ncomparison of  \nheGM2ganglioside \nvaccine (GMK) \nversus HDI that \naccrued 880 \npatients.  \n \nNo information \nabout staging   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 739 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nvalues at baseline \nand during follow -\nup were associated \nwith longer \nsurvival.  \nLeiter  et al. (2009)  To develop an \nefficient and cost -\neffective \nsurveillanc e \nstrategies, \ndependent on \ntumor stage  Economic study  \n \n Same cohort as \nLeiter et al. (2010) \nand Garbe et al. \n(2003)  \n \n1969 patients  Total costs  \n \nCosts per \nrecurrence \ndetection  Total costs for \nroutine melanoma \nfollow -up during \nthis 2 -year period: \n236.30\u20acpatient.  \n \nCosts for follow -up \nexaminations in: \n- stage I: \n307914\u20ac/887261  \n- stage II: \n62673\u20ac/252292$  \n- stage III: \n89651\u20ac/352214$)  \n \ncosts for the \ndetection of one \nrecurrence for \nphysical \nexamination and \nLN sonography:  \n- stage \n14289\u20ac/4391$ \nand \n18035\u20ac/131423$  Retrospective \nanalysis of \nprospective study \ndata \n \nFor detailed tables \nof costs, see \noriginal publication  \n \nThe calculation of \ncosts was based on \nthe 2004 GO\u00c4 \n(Germany) and on \nthe 2004 Medicare \nfee reimbursement \nschedule (USA)  \n \n. 2b   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 740 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n- stage II: \n500\u20ac/512$ and \n1333\u20ac/9712$  \n- stage III: \n168\u20ac/171$ and \n1250\u20ac /9112$, \nrespectively. \n \nCost for CR to \ndetectof one 1 \nrecurrence: \n- stage I: \n22886\u20ac/20 512$)  \n(stage II an d III: see \nfull-text) \n \nTotal costs \namounted to \n990.8\u20ac/2208$ per \npatient (stage I) \nand up to 1841\u20ac/  \n4009$ per patient \n(stage III)  \nEgberts et al. \n(2009 ) \n to investigate \nwhether a serial \nanalysis of protein \nS-100B in serum \nwith a \nluminescence \nimmunoassay Diagnostic study  97 patients with \nstage II/III disease \ntreated within \nprospective \nrandomized trials  Sensitivity  \n \nSpecificity  \n \nPPV sensitivity to \ndetect metastasis:  \nS-100B: 36.5% vs.  \nLDH: 17,3%,  \n(P=0.006).  \n \nsensitivity in Treatment bias: \nPatients were \ntreated with \ndifferent adjuvant \ntherapies  \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 741 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncompared with \nroutine LDH \nassessment could \nbe of value as an \nindicator of \nmelanoma \nprogression  patients \nprogressing to \nstage  \nIV: S-100B: 53.8% \nvs. LDH: 23.1% \n(P=0.008)  \n \nSpecificity 98% for \nboth S -100B and \nLDH \n \nPPV: S -100B% 73% \nvs. LDH: 64%  \nMoore  Dalal et al. \n(2008)  to determine the \neffect of the \nmethod of \ndetection of initial \nrecurrences and  \ntiming of visit on \npost-recurrence \nsurvival in patients  \nundergoing SLN \nbiopsy  Prognostic study  198 Clinical stage \nI/II patients who \ndeveloped \nrecurre nce after \nSLNB and who were \nevaluable for \nlongterm follow -up  Method of \nrecurrence \ndetection  \n \nPrognistic factors \nof survival  \n Median follow -up \nafter first \nrecurrence: 17 \nmonths.  \n \nSelf-detection of \nrecurrences in 55% \nof patients, 78% \nwere seen earlier \nthan their \nscheduled visit.  \n \nSelf-detected \nphysical \ndiseases:  \n-24% in -transit  \n-23% nodal   2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 742 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nPhysician detection \nin 45%, in 46% by a \nscheduled \nradiographic test \n(CXR  \n16%; CT 29%; PET \n1%). \n \nmethod of \ndetection \nsignificantly \npredicted post -\nrecurrence survival \n(p<0.05)  \n \nMultivariate \nanalysis adjusted \nfor worst site of \nrecurrence, \nmethod of \ndetection remained \nsignificantly \nassociated with \npost-recurrence \nsurvival (P = 0.02) \nTiming of visit did \nnot affect survival  \nHengge et al. \n(2007)  to analyze the \nfollow -up of  Economic analysis  \n 526 melanoma \npatients stage I -III Recurrence  \n Detection of 57 \nrecurrences in Retrospective data  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 743 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma patients \nunder clinical and \neconomic aspects \non an as -treated \nbasis based on \ncurrent \nrecommendations \nof the AJCC/UICC \n2002 and the \nGerman \nDermatologic \nSociety.  Method of \nexaminatio n \n \nDirect medical \ncosts per \nmetastasis  \n \nQALYs  stages I -III (5-year \nfollow -up period), \n61% detected by \nphysician and 39 % \nby patients. \nDetection of 25 \nSPM. \n \nThe total costs for \nmelanoma follow -\nup in stages I \u2013III \nfor the 5 -year term \nat the tertiary care \nuniversity center \naccounted for \n725,095 \u20ac \n($870,114)  \n- Clinical \nexaminations \nrepresented \n21,437 \u20ac \n($145,724)  \n- technical \nexaminations \naccounted for \n286,656 \u20ac \n($343,987)  \nlaboratory costs \ntotaled 317,002 \u20ac  \n($380,402) \nrespectively  Patients kept only \nabout 75% of \nfollow -up \nappointments (real \ncosts possibly even \nhigher)  \n \nCosts were \ncalculated \naccording to \nstandardized \naverage fees (GO\u00c4 \n2004)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 744 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nFerrone et al. \n(2005)  To determine the \nincidence of \nmultiple primary \nmelanomas (MPM) \nfrom a prospective, \nsingle -institution, \nmultidisciplinary \ndatabase, and to \ndescribe the \nclinical and \npathological \ncharacteristics and \nrisk factors specific \nto these patients.  Prognostic study  \n \n 4484 patients \ndiagnosed with a \nfirst PM, 385 h ad \n>=PM  Incidence of MPM  \n \nRisk factors for \nMPM For 74% of \npatients, the initial \nmelanoma was the \nthickest tumor.  \n \nestimated \ncumulative 5 -year \nrisk of: \n- a SPM for the \nwhole cohort: \n11.4%, with 5,5% \noccurring within \nthe 1st year  \n- a MPM for \npatients with a \npositive family \nhistory or \ndysplastic nevi: \n19.1% and 23.7%, \nrespectively.  \n- a third PM  \nfrom the date of \nthe SPM: 30.9%, \nwith  \n15.6% occurring \nwithin the 1st year  Retrospective \ndesign (prospective \ndatabase)  2b \nMachet et al. \n(2005)  \n to study the value \nof adding \nultrasound lymph \nnode examination Diagnostic study  373 patients \nenrolled in a \nfollow -up protocol  Sensitivity  \n \nspecificity  Sensitivity of \nclinical \nexamination and \nultrasound  No information \nabout design \n(prospective/retros\npective)  2b \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 745 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(7.5 MHz) to the \nroutine clinical \nexamination \nrecommended by \nFrench guidelines \nin melanoma \nfollow -up. Examination: \n71,4% [95% \nconfidence interval \n(CI) 55.4 \u201384.3] and \n92.9 \n(95% CI 80.5 \u201398.5), \nrespectively. \nP=0.02). Specificity \nof clinical \nexamination and \nultrasound \nexamination: \n99.6% (95% CI \n99.2\u201399.8) and \n97.8% (95% CI  \n97.0\u201398.4), \nrespectively. \nGoggins et Tsao \n(2003)  To examine how \nthe risk of a SPM \ntumor varied with \ntime from \ndiagnosis of CM \nand examined the \npatient -specific \nfactors that modify \na CM patient\u2019s risk \nof developing a \nsecond primary \ntumor.  Prognostic study  \n \n 61,245 melanoma \npatients, of whom \n2.32% developed \n>=1 additional \nprimary CM  Incidence of \nadditional primary \nCM \n \nRisk factors  >/= 1 additional \nCM in 2.32% of the \n61,245 patients \nduring follow -up, \nca. 22% of these \npatients had 2 \nsynchronous \nprimary CMs.  \n \nHRs correspond to \nmean rates of \n271.3, 227.8, \n229.3 and 224.4 Retrospective \ndesign  \n \nLarge patient \ncohort \n \nFor cumulative risk \nand monthly \nhazard diagrams \nsee original article  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 746 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncases per 100,000 \nper year from 1 \u20134 \nyears, for 5 \u201310 \nyears, 10 \u201315 years, \nand 15 \u201320 years \nafter diagnosis, \nrespectively. \n \npresence of 1st CM \non th e face, neck, \nand trunk \uf0e0 \nincreased risk for \n2nd CM (in both \nunivariate and \nmultivariate \nmodels):  \n \nstage IV disease \uf0e0  \nlower risk of 2nd \nCM \nGarbe  et al. (2003)  To prospectively \nexamine and \nevaluate the \nresults of follow -up \nprocedures in a \nlarge cohort of \ncutaneous \nmelanoma \npatients.  Prospective cohort \nstudy  \n 2,008 patients with \nstage I -IV \n Recurrence \ndetection  \n \nTime to detection \nof recurrence  \n \nModes of detection  Detection of \nrecurrences: \n- in 71% on \nscheduled follow -\nup examinations  \n- in 17% by \npatients \nthemselves, in 13% \nof these \nrecurrences Descriptive study  \n \nStandardized \nfollow -up \nprocedures \n \nDetailed \ndescription of \nprocedures and of \nfollow -up of study 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 747 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndiagnosis was \nestablished during \nsubsequent regular \nfollow -up \nexaminations  \n- in 12% by \nphysicians not \nparticipating in the \nmelanoma follow -\nup schedule  \n \nIn 2,3% of patients, \nSPM were \nidentified. \n \nModes of \ndetection: see full -\ntext drop-outs \n \nData about yield of \ndifferent imaging \nmethods vs. \nphysical \nexamination not \nlisted here (see \noriginal article)  \nManola et al. \n(2000)  To identify factors \nthat are prognostic \nfor survival in \npatients with \nmetastatic \nmelanoma treated \nin eight Eastern \nCooperati ve \nOncology Group \n(ECOG)  \ntrials conducted \nover the past 25 Prognostic study  See fulltext  Survival  \n \nRelative risks  Median survival: \n6.4 months (95% \nconfidence \ninterval, 6.1 to 6.9 \nmonths.) F  \n \nfactors conferring \nthe greatest \nincreased risk of \ndeath:  \n- number of  \nmetastatic sites  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 748 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nyears.  (RR = 1.12)  \n- ECOG \nperformance status \n>= 1 (RR = 1.49)  \n- metastatic  \ndisease in the GIT \n(RR = 1.49), liver \n(RR = 1.44), pleura \n(RR = 1.35), or \nlung (RR = 1.19).  \n \nPrior \nimmunotherapy \n(RR = 0.84) and \nfemale sex (RR = \n0.87)were \nassociated with \nprolonged survival. \n \nresponse to \nprotocol treatment \n(RR = 0.57) was a \nsignificant \nprognostic factor:  \n \nPrognostic for \npoorer survival:  \n- increased number  \nof sites of \nmetastasis (RR = \n1.30)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 749 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n- abnormal LDH \n(RR = 1.89)  \n- abnormal alkaline \nphospha tase (RR = \n1.76)  \n- abnormal \nplatelets (RR = \n1.63)  \n- GI metastases (RR \n5 1.66)  \nSchlagenhauff et \nal. (2000)  To evaluate the \nsignificance of \nserum protein \nS100 in  \nscreening for \nmetastases during \nregular follow -up \nexaminations of \npatients with \nmalignant \nmelanoma.  Diagnostic study  \n \n 411 melanoma \npatients with PM \nwith a tumour \nthickness >= 1.5 \nmm  \n \n(237 patients stage \nII, 148 patients \nstage III, 26 stage \nIV) \n \n Sensitivity  \n \nSpecificity  \n \nFalse -negatives \n(FN) \nTrue-negative (TN)  \nTrue-positives (TP)  \nFalse -positi ves (FP)  \n \n \nPositive predictive \nvalue (PPV)  \n \nNegative predictive \nvalue (NPV)  \n \nefficiency of \nprotein S100 as a \ndiagnostic test  Serum protein \nS100 cut -off value \nat 0.13 \u00b5g/l:   \nFN: n=28  \nTN: n=355  \nTP: n=13  \nFP: n=15  \nPPV: 46  \nNPV: 93  \nTest efficiency (< \n2): 1.39. The \nprotein S100 \nvalues of the \nmetastasis group \nwere significantly  \nhigher (P \n=0.0.001).  \n \nS100:  \nsensitivity: 0.32, Interval between \nrelapse and serum \nanalysis of S100: \nup to 2 months \n(clinical situation \nmay change during \nthis interval)  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 750 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nspecificity: 0.96  \n \ncut-off value of \n0.08 \u00b5g/l \n(outcomes for this \ncut-off: see full -\ntext):lower \nspecificity, PPV and \ntest efficiency  \nsensitivit y: 41%  \nBrobeil et al. \n(1997)  To determine the \nimpact of an \nintensive follow -up \nprotocol on the \nstage of disease at \ndiagnosis of \nsubsequent \nprimary \nmelanomas.  Prevalence study  \n \n 101 patients with \nSPM (67 with \nsynchronous and \n44 with \nmetachronous \nSPM) Incidence of MPM  \n \nTumor thickness in \nprimary and \nsecondary lesions  Of 2,600 patients: \n4.3% of patients \nwith SPM  \n \nmean tumor \nthickness: 1,72 \nmm for PM vs. \n0.58 mm for SPM  \n \nmean thickness of \nmetachronous \nmelanoma: 2.27 \n(range 0.18 -10.2) \nmm for PM vs. \n0,90 (range 0.11 -\n2.58) mm for SPM  \n \ninitial primary \nmelanomas tended \nto be thicker (by an Retrospective \ndesign  \n \nPredominantly \nmale patients  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 751 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \naverage of 3.8 mm, \np = 0.008).  \nBasseres et al. \n(1995)  To assess the cost -\neffectiveness of \nsurveillance in \nstage I melanoma.  Prevalence study  528 patients with \nmelanoma stage I \nand Clark\u2019s level II \nor higher (214 \nmales, 314 \nfemales)  Time to relapse  115/52 8 patients \nhad relapses.  \n \nThe rate of relapse \nand the mean time \nbetween initial \nresection and \nrelapse: 9.6% and \n37 months for \nmelanoma < 1.5 \nmm, 34% and 24 \nmonths for \nmelanoma of 1.5 \nto 3 mm, 47.7% \nand 17 months for \nmelanoma > 3 mm.  \n \nTime between \nrelapse  and last \nfollow -up \nexamination: \u2264 2 \nmonths in 9% of \ncases, \u2264 3 months \nin 23% and \u2264  4 \nmonths in 34%.  Retrospective \ndesign  \n \nFor cost analysis \nsee full text of \npaper  2b \nDe Giorgi et al. \n(2010)  To identify main \nrisk factors Prognostic study  \n 40 patients with \nMPM  Thickness of SPM  \n Overall mean \nthickness of Retrospective \ndesign  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 752 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nassociated with \nMPM and to \ninvestigate the \nassociation \nbetween regular \nfollow up and \ntumour thickness \nof a SPM   Odds ratio of \nhaving MPM  \n \n melanoma: 0.517 \nmm for first \nmelanoma and \n0.64 mm for SPM \n(P = 0.1 2).  \n \nSignificant \ndifference in mean \ntumour thickness \nin patients not \nattending follow up \nvs. patients \nadhered to follow \nup (1.22 mm vs. \n0,36 mm)  \n \nOR of having a \ndiagnosis of MPM \nin comparison with \nSPM: \n- female 1.94 (vs. \nmale)  \n- >/= 1 atypical \nnevi 4.18  \n- positive family \nhistory 2.18   \nSmall patient \nsample with \nsecondary \nmelanoma  \nBower et al. (2010)  To determine the \noutcome and \nincidence of \nmultiple primary  Prognostic factors  41 melanoma \npatients with \nmultiple melanoma \nand no evidence of Diseas e-free-\nsurvival  \n \noverall survival  Thickness of \nsubsequent vs. \nprimary \nmelanomas: Posthoc analysis  \nfrom a multi -\ninstitutional \nprospective 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 753 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma (MPM) \nand other cancer \ntypes among \npatients with \nmelanoma. The \nrisk for secondary \nnonmelnoma \nmalignancies was \nalso assessed.  distant metastasis \nand no palpable \nnodal metastasis.  \n \n(Patients with \nsynchronous \nlesions not \nincluded)  median 0,32 mm \nversus 1,50mm, \np<0,0001)  \n \nMultivariant \nanalysis: age \n(p=0,028), \nlymphovascular \ninvasion (p=0,010) \nand SSM subtype \nof the original \nmelanoma \n(p=0,024) were \nassociated with \nMPM.  \n \nPatients with MPM \nvs. patients with \nsingle primary \nmelanoma:  \n- 5-year-DFS:  \n88,7 vs. 81.3%, \np=0,380  \n- 5-years -OS \n95,3 vs. 80%, p= \n0,005 \n \ndetection of \nsecondary \nmelanomas within \nthe first year in randomized trial  \n \nLoss-to-follow -ups \nnot commented  \n \nPatients with \nmelanoma <1mm \nexcluded  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 754 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n29,3% of patients, \ndetection of \nsubsequent  \nmelanoma within \n60 days in 9,8 % \nafter primary \nmelanoma.  \n \nMedian time to \ndevelopment of \nsecond primary: 29 \nmonths. \nNonmelanoma \nmalignancies in \n6,1% of patients  \nFusi et al. (1993)  To determine \nwhether there are \nsignificant trends \nin the prognostic \nfactors or in the \ntiming and sites of \nrecurrence.  Prognostic study  \n \n 250 patients with \nrecurrent \nmalignant \nmelanoma  Time to recurrence  \n \nSites of recurrence  \n \nSurvival Sites of first \nrecurrence: 52% \nregional nodes, \n17% local \nrecurrences, 8% in -\ntransit metastases,  \n23% to a distant \norgan.  \n \nDiagnosis of \nrecurrences: 67% \nwithin 24 months, \n81% within 36 \nmonths  \n Retrospective \ndesign  \n \nPopulation not \ndescribed in detail  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 755 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSurviva l after the \ndiagnosis of \nrecurrence was \nindependent of:  \n- thickness of the \nprimary tumor \n- duration of DFI  \n(local, in -transit or \nregional nodal)  \n \ndiagnosis of \ndistant organ \nmetastasis: shorter \nsurvival  \n \nlocal recurrence, \nin-transit \nmetastasis, and \nregiona l nodal \nmetassis: \ncomparable \nsurvivals  \nRomano et al. \n(2010)  implications for \nfollow -up \nguidelines  Prognostic study  \n \n 340 patients AJCC \nstage III who \nrecurred  Relapse -free \nsurvival  \n \nOverall survival  \n \nMode of relapse \ndetection  \n 5-year RFS for \nstage IIIA, IIIB, and \nIIIIC patients was \n63%, 32%, and \n11%, respectively  \n \nSite of first relapse: \n- local/in -transit Retrospective \ndesign  \n \nestimated site -\nspecific risk of first \nrelaps e for each \nsubstage  \n 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 756 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n5-year survivals  28% \n- regional nodal \n21% \n- systemic 51%  \n \n1st relapses  \ndetected by patient \nor family, \nphysician, or by \nscreening \nradiologic tests in \n47%, 21%,  \nand 32% of \npatients, \nrespectively.  \n \nFactors associated \nfor better OS \n(multivariate \nanalysis):   \n- younger age  \n- 1st relapse being \nlocal/in -transit or \nnodal, \nasymptomatic, or \nresectable.  \n \nestimated 5 -year \nsurvivals for stages \nIIIA, IIIB, and IIIC \nfrom time of 1st  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 757 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nrelapse: 20%, 20%, \nand, 11%, \nrespectively. \nSurvival curves \nshowed a plateau \nat around 50 \nmonths in all \nsubstages.  \nStucky et al. (2010)  Understanding the \nrisk factors for \nlocal and in -transit \nrecurrences \n(LR/ITR) may help \nfacilitate methods \nof prevention, early \ndetection, and \ntreatment.  Prognostic study  \n 255 patients \ntreated with \nsurgical rese ction \nof a single \nmelanoma and \nwith at least 18 \nmonths of follow -\nup  \n \n(26 patients with \nLR/ITR)  Time to recurrence  \n \nSite of recurrence  average time to \nLR/ITR: 16.2 \nmonths (range, \n4.2\u2013 \n82.4 mo).  \n \nWithin 12 months \nof follow -up:LR/ITR \nin 53% of the \npatients  \n \nwithin 18 months \nof follow up:  78% \nof recurrences  \n \npatients with \nLR/ITR (n=26):  \n- 3% local \nrecurrences  \n- 5% in transit \nrecurrence  \n- 2% both LR/ITR  Retrospective \ndesign  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 758 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n- 56% concurrent \nregional LN \nmetastases.  \n \nLR/ITR was \nassociated with: \n- older age  \n- thicker original \ntumo r \n- presence of \nangiolymphatic \ninvasion in the \noriginal melanoma  \nMeyers et al. \n(2009)  To determine the \nimpact of routine \nimaging on the \nmethod of \ndetection of first \nrecurrence in \npatients with stage \nII and sentinel \nlymph node \u2013\npositive stage III \nmelanoma.  Prognostic study  \n \n 118 patients with \nstage II or III  \n  Mode of recurrence \ndetection  \n \nTime to recurrence  \n \nOverall survival \n \nCosts  Median time to \nrecurrence: 14 \nmonths (range, 2 \u2013\n88 months)  \n \nTypes of \nrecurrence: 9% \nlocal, 40% in \ntransit, 16% \nregional lymph \nnode basin, 35% \ndistant  \n \nMode of detection:  \n- self-detection in \n37% asymptomatic \npatients  Retrospective \nanalysis of \nprospective \ndatabase  \n \nSmall patient \ncohort 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 759 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n- 30% of patients \nwith symptoms \nthat led to \ndetection of \nrecurrence  \n- in 23% by \nphysician during \nroutine follow -up \nexamination  \n- in 7% by ro utine \nfollow -up imaging  \n- in 3% by high LDH \nvalues  \n \nMedian survival \nafter recurrence: \n22 months \n(locoregional \ndisease) vs. 7 \nmonths (distant \ndisease)  \n \nno difference in \nsurvival among \nsymptomatic vs. \nasymptomatic \npatients  \n \nno significant \ndifference in \nsurvival between a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 760 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nself-detected \nrecurrence and \nrecurrence \ndetected by either \na physician or by \nroutine diagnostic \nscans.  \nFrancken et al. \n(2008)  To calculate \nrecurrence rates \nand establis h \nprognostic factors \nfor recurrence to \nhelp redesign a \nfollow -up schedule.  Prognostic study  \n \n. 4726 patients with \na single invasive \nprimary cutaneous \nmelanoma and \nstage I or II disease  Recurrence rate  \n \nDisease -free \nsurvival  \n \nDisease -specific \nsurvival  Recurrence \noccurred in 18.9% \n(895 of 4748) of \npatients overall, \n5.2% (95 of 1822)  \nof those with stage \nIA disease, 18.4% \n(264 of 1436) with \nIB, 28.7% (215 of \n750) with IIA,  \n40.6% (213 of 524) \nwith IIB and 44.3% \n(86 of 194) with IIC \ndisease. Overall, \nthe median \ndisease -free \nsurvival time was \n2.6 years, but \nthere were marked \ndifferences \nbetween AJCC \nsubgroups.  \nPrimary tumour Retrospective \ndesign  \n \nPart of the cohort \nvery old (sta rting \n1959)  \n \nFor Kaplan -Meier \ncurves for time to \nfirst recurrence see \noriginal article  \n \nTime between \nrelapse and last \nfollow -up not \nmeasured  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 761 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nthickness, \nulceration and \ntumour mitotic \nrate were \nimportant \npredictors of \nrecurrence. \nKhan et al. (2006)  \n To help develop \nparameters for \nfuture trials, \ntreatment history \nand  Prognostic study  212 patients with \npathologically \nproven stage IV \nmelanoma  \n \n survival  median survival of \nstage M1c: 6.0 \nmonths. Survival \nwas longer for \nstage M1a and \nM1b and shorter in \nolder patients. No \nsignificant \ndifferences were \nfound in survival \nbased on gender.  \n \nPatien ts with a \nnormal LDH level \nsurvived almost \ntwice as long \n(median survival, \n12.0 months, [95% \nCI 8.85 \u201315.15]) \ncompared to those \nwith an elevated \nLDH level (median \nsurvival 6.0  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 762 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmonths, [95% CI \n3.51\u20138.49]); these \nwere significantly \ndifferent by the \nlog-rank t est (\u03c72 = \n5.88, P = .0154).  \nMartenson ED et al. \n(2001)  \n \n To evaluate \nwhether S -100B \nprotein in serum is \nan independent \nprognostic marker \nin malignant  \nmelanoma.  Prognostic study  \n \n \n 1,007 consecutive \npatients for \nscheduled follow -\nup visits.  \n \n(876 stage I, 35  \nstage II, 96 stage \nIII) \n \n Disease -specific \nsurvival  \n The mean serum \nconcentration of S -\n100B protein was \nsignificantly \nrelated to clinical \nstage  \n \nsignificant \ndifferences in \ndisease -specific \nsurvival for \npatients with S -\n100B values > and \n< 0.10 mg/L, bo th \nwhen analyzed in \nthe whole group of \npatients and in the \nsubset of patients \nwith metastatic \ndisease (clinical \nstages II to III)  \n \nSignificantly lower \nlevels in patients in Follow -up \ndiagnost ic \nprocedures not \nstated in article  \n \nStudy included in \nMocellin et al. \n2008  \n \nThe three -stage \nsystem for \nclassification of \nmalignant \nmelanoma  2b- \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 763 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwhom the \nmetastases had \nbeen resected \ncompared  \nwith patients with \nsubcutaneous \nand/or LN \nmetastases \n(P=0,004)  or \ndisseminated  \nmetastases (P < \n0,001).  \n \nmultivariant \nanalysis: In clinical \nstages II and III, \nthe S -100B protein \nlevel in serum was \nthe strongest \nindependent \nprognostic factor \nfor melanoma \nsurvival (P<0,001) \nMruck  et al. \n(1999)  \n To investigate the \npredictive value of \nthe protein S100 \nas a tumor marker \nin the post -surgical \nfollow -up staging \nof patients with Diagnostic study  50 patients  \n Sensitivity  \n \nSpecificity  \n \nPredictive values  FDG-PET: \nSensitivity=100%, \nspecificity=95%  \n \nConventional \nimaging: \nSensitivity=9 2%, Selection criteria \nnot described  \n \nNo information \nabout time interval \nbetween blood \nsample and 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 764 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nhigh risk \nmelanomas (Clark \nlevels IV/V, \nthickness>0,75 \nmm) specificity=82%  \n \nS100 :  \nCut-off-levels were \n0,1\u00b5g/l and \n0,2\u00b5g/l:  \nSensitivity=85%, \nspecificity=55% \nwhen measured by \nRIA, \nSensitivity=77%, \nspecificity=61% \nwhen measured by \nLIA \n \nNPV=91% (RIA) and \n88% (LIA)  \nPPV=39% (RIA), 40% \n(LIA) \n \nAt a cut -off level of \n4,0\u00b5g/l, TK \nshowed a \nsensitivity of 70% \nand a specificity of \n41%. imaging \nprocedures \n \nSmall patients \ncohort \nPoo-Hwu et al. \n(1999)  To evaluate the \nfollow -up pr otocol \ninstituted in 1987 \nat the Yale Retrospective \nprognostic study  \n \n 373 patients \nfollowed according \nto the protocol \nschedule.  Recurrence -free \ninterval  \n \nOverall survival median time \ninterval to \nrecurrence: \n- stage I:22.0 Detailed follow -up \nprocedure given  \n \nRetrospective 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 765 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nMelanoma Unit to \nimprove upon the \ndetection of \ndisease recurrence \nin patients with \nAmerican Joint \nCommittee on \nCancer Stage I -III \ncutaneous \nmelanoma.  AJCC Stage I -III \n  \nModes of detection  (range, 2.0 \u201360.5) \nmonths  \n- stage II 13.2 \n(range, 2.4 \u201371.0) \nmonths  \n- stage III: 10.6 \n(range, 2.3 \u201353.8) \nmonths  \n \n51% locoregional \nrecurrences \ndetected by \npatients,  \n64% distant \nmetastases \ndetected by \nphysicians  \n \nphysician -detected \nrecurrences: \n- 57% by history or \nphysical \nexamination  \n- 18% by abnormal \nchest X -ray \n- 23% by CT scan \nor MRI  \n- 2% by elevated \nLDH \n \nmedian survivals: design   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 766 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n34 months for \nlocoregional vs. 13 \nmonths for distant \nrecurrences  \n \nAll 19 patients with \nMPM were \nidentified by \nphysician -\nperformed physical \nexamination.  \nvon Schoultz et al.  \n(1996)  \n To asses the \npotential \nprognostic value of \nserum \nconcentrations of \nS-100\u00df  Serum levels of S -\n100\u00df protein were \nmeasured in a \nconsecutive series \nof 643 patients \nwith cutaneous \nmalignant \nmelanoma during \n08/1990 -10/1992 \n \n 643 patients in \ntotal \n553 p atients: stage \nI \n(with/without \nsatelilites within 5 \ncm), 24 patients: \nstage II (in -transit \nmetastases and/or \nregional lymph \nnode metastases), \n66 patients: stage \nIII (distant \nmetastases)  \n \n Overall survival  Significant \ncorrelateion of \nserum \nconcentrations of  \nS-100\u00df to clinical \nstages. They were \nsignificant higher \nin men than in \nwomen (p<0,001).  \n \nAssociation \nbetween OS rate \nwith serum levels \nof S-100. \n \nobserved/expected \ndeath ratio was \nmarkely increased \nwith increasing No information \nabout number of \nblood samples \ntaken  \n \nPoor inf ormation \nabout population  \n \nNo information \nabout study design \n(prospective/ \nretrospective?)  \n \nDisease \nclassification \ndifferent from \nAJCC was used  \n \nstudy included in 2b-   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 767 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nlevels of S -100\u00df \n(P<0,001). A \nfivefold increase in \nrelative hazard was \nindicated by a \nvalue of S -100\u00df \n>0,6\u00b5g/l (P<0,001) \nand when its cut -\noff level was used \nS100\u00df had \nadditional \nprognostic value \nindependent of \nclinical stage \n(P<0,001).  Mocellin et al. \n2008  \nKaufmann , Crone -\nM\u00fcnzbrock (1992)  To evaluate the \nvalue of CT and U S \nin detecting \nabdominal \nmetastases.  Diagnostic study  \n 849 patients with \nmalignant \nmelanoma  \n \n \n \n \n Sensitivity  \n \nspecificity  Interval between \ntherapy of primary \nmelanoma and \ndiagnostis of \nreccurence: 2,5 \nyears  \n \nUS: sensitivity; \n53%, specificity; \n98% \n \nCT sens itivity 85%, \nspecificity 94%  Selection criteria \nnot described  \n \nNo information \nabout time interval \nbetween \nultrasound and CT  2b- \nKelly et al. (1985)  To develop Prognostic study  295 patients with disease -free independent Incomplete patient 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 768 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nguidelines for the \nfollow -up of \npatients with \nprimary cutaneous \nmelanoma   \n \n \n \n \n \n  metastatic \nmalignant \nmelanoma(clinical \nStage I).  interval  \n \npredictors of \ndisease -free \ninterval  \n \nrecurrence rate  significant \npredictor of DFI: \ntumor thickness (p \n= 0.0015)  \n(not significant: \nsex, age, elective \nregional LN -\ndissection, tumor \nlocation)  \n \ndiminution of \nDFIfrom 3.97 years \n(< 1.0 mm) to 1.10 \nyears (> 5.0 mm) is \nevident with \nincreasing \nthickness. \n \nAssociation \nbetween increased \nrisk of recurrence \nand increases in \ntumor thickness \n>1.5 mm in the \nfirst 4 ye ars \n(greatest increase \nin risk is in the 1st \nyear)  records (of 295 \npatients, only 177 \nwere included in \nmultivariate \nanalysis)  \n \nFor details of \nsurvival and \nrecurrence \nstatistics, see \noriginal article  \nAlvarado  et al. \n(2011)  to asses s the \nfrequency of the Prevalence study  \n 146 patients with \nprimary melanoma incidence rate of \nmetastases Recurrences in 75% \nof patients  Limitation of study \nand bias not 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 769 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n pelvic metastases \nin patients with \nprimary melanoma \nin the head and \nneck to identify \nevidence \nsupporting the  \nuse of pelvic CT \nscans in this group \nof patients.   \n who had adequate \nfollow -up \nevaluation for at \nleast 5 years. \n \n(109: stage I or II \ndisease, 33: \npatients stage III, \n4: stage IV)  \n \n  \nSurvival  \n \nTime to recurrence  \n \n  \nmedian time to the \nfirst recurrence: 13 \nmonths.  \n \nMedian duration of \nthe OS: 3.8 years.  \n \nMedian duration of \nthe OS for the 110 \npatients with \nrecurrences: 2.3 \nyears. \n \n48% of patients \nhad remained alive \n>4 years from the  \ntime of the first \ndiagnosis of \nmelanoma, \ndevelopement of \nmetastases in 56% \nof patients, \ndevelopement of \npelvic metastases \nin 7% of patients  \n \nmost common \nsites of first \nrecurrence: lymph \nnodes (n=41, 37%), descr ibed \n \nPatients with \nmucosal melanoma \nincluded   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 770 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsatellite soft tissue \n(n=41, 37%), chest \n(n=33, 30%), \nabdomen (n=13, \n15%), and the brain \n(n=7, 6%).  \nDeRose et al. \n(2011)  \n to determine the \nutility and cost \neffectiveness of \nradiological \nrestaging of \npatients with stage \nIIB\u2013IIIC melanoma \nat the 3 -year \nfollow -up time \npoint  Economic and \nprevalence study  210 patients with \nstage IIB \u2013IIIC \nmelanoma  Recurrence rate  \n \nTime to recurrence  \n \nTP \n \nFP \n \ncosts per diagnosis  Recurrences in 55% \nof patients, in 69% \nwith disease \nsymptoms  \n \n88% recurrences \nbefore 3 years \n(median time to \nrecurrence 12 \nmonths,  \n95% confidence \ninterv al: 10 \u201316 \nmonths)  \n \n25 head CTs, 27 \nhead MRIs, 52 \ntorso CTs were \nperformed. In \ntotal: 3 FP and 2 TP  \n \nTotal cost per \ndiagnosis:$312 \n990.  Reference standard \nnot described  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 771 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nHansel et al. \n(2009)  To analyse the \nfrequency of late \nrecurrent MM in \nsouth -easter n \nGermany  Prevalence study  \n \n 1881 patients in \nstage I or II (AJCC) \nwith a follow -up of \n> or = 10 years  \n \n \n(1 uveal \nmelanoma, \nexcluded)  Overall survival  \n \nRelapse -free \nsurvival  20 patients with \nlate recurrence of \nmelanoma . largest \nperiod from \ndiagnosis of PM  to \nrecurrence: 25.1 \nyears, median 13.9  \n \nLoco-regional \nmetastases in \n63.2%, distant \nmetastases in 42%, \ndeaths in 75%  \n \nAll but one of the \nsurvivors had in -\ntransit metastases \nonly (n=3).  \n \nOS: between 10.9 \nand 35.7 years \n(median 14.7).  \n \nStatistical variate  \nanalysis failed to \nidentify possible \nfactors \nsignificantly \nassociated with \nlate recurrence  Conclusion about \ninfrequence of late \nrecurrence can be \ndrawn, but \nstatistical \nconclusions inside \nthis small cohort \nare not valid \nbecause of small \npatient sample  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 772 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nEinwachter -\nThompson, MacK ie \n(2008)  To review patients \nwith invasive \nmelanoma thinner \nthan 0.5 mm \nfollowed for at \nleast 5 years to \nprovide an \nevidence base for \nconsidering \nmodification of \nguidelines. cohort study  \n 430 patients with \ninvasive melanoma \n< 0.5 mm Deaths  \n \nInterval between \ntwo primaries  19% deaths from \nmelanoma in the \nwhole group.  \n \n11 patients \ndeveloped \nsimultaneous or \nsubsequent \nprimary melanoma \n(3 simultaneously, \n5 within 36 \nmonths, 1 between \n3-5 years, 2 \nbetween 69 and 73 \nmonths after the \nfirst diagnosis.)  Data on thin \nmelanomas only  \n \nRetrospective \ndesign  \n \nIn some cases \npathological review \nshowed melanoma \n> 0.5 mm at \ndiagnosis  or some \npatients developed \nthicker SPM  3b \nFrancken AB et al. \n(2008)  To asses the \nfrequency of \npatient detection \nof both first \nprimary \nmelanomas (FPMs) \nand second \nprimary melanoms \n(SPMs)  Prevalance study  112 patients with \nrecently diagnosed \nSPM  \n \n FPM and SPM -\ndetection rate  Patients deteced \n59% of the FPMs \nvs. 46% of the \nSPMs themselves  \n \nsignificant \npredictors for a \npatient-de-tected \nFPM: \n- females gende  \n- greater Breslow \ntumour thickness  \n- younger age  \n(OR 4,9; 3,2 and Only patients with \nSPMs were \ninterviewed  \n \n(both in situ and \ninvasive \nmelanomas were \nincluded.)  \n \nExcluded were \npatients who had \nmultiple primary \nmelanomas or who \ndeveloped a 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 773 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n0,9 respectively).  \n \npredicting factors \nfor the patient \ndetection of a SPM:  \n- greater tumour \nthickness  \n- ready visibility of \nthe lesion to the \npatient  \n(OR 1,9 and 3,6 \nrespectively)  recurrence earlier \nthan the SPM \n(amongst others)  \nFrancken et al. \n(2007)  In this prospective \nstudy the \nfrequency of \ndetection of first \nmelanoma \nrecurrence (FMR) \nby patient or \ndoctor was \nanalyzed  Prevalence study  \n \n 211 patients with a \nfirst melanoma \nrecurrence (FMR) \nwere interviewed  Median time to \ndetecti on of an \nFMR \n \nSites of recurrence  \n \nModes of detection  \n \nMean survival median time to \ndetection of FMR: \n28 months (range, \n2\u2013322) \n \nSymptoms present \nin 74%, in 39% FMR \ndetected as a \nconsequence of \nsymptoms.  \n \nin 56 patients \nFMRs detection \nwas at a follow -up \nvisit: \n- 63% by physical \nexamination  \n- 14 % by chest x -risk of bias (in \ngroup B, only \npatients  with \nunambiguous \ninformation in \npatients records \nwere included)  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 774 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nray  \n- 11% by LN \nultrasound  \n \nDetection of FMR:  \n- in 154 patients by \npatient, partner, or \nrelative  \n- in 57 patients by \na doctor  \n \nmean survival time: \n23.8 months.  \nZogakis et al. \n(2007)  To estimate \nsurvival and time \nto first recurrence \nin patients with \nnegative sentinel \nnodes.  Prevalence study  \n \n 773 melanoma \npatients with \ntumor -negative \nSLNs  Overal l survival  \n \nDisease -free \nsurvival  \n \nTime to first \nrecurrence  Recurrence in 8,9 \n% of patients with  \ntumor -negative \nSLNs \n \n1-year, 3 -year, and \n5-year DFS rates: \n98%, 91%, and \n88%, respectively.  \n \n1-year, 3 -year, and \n5-year OS rates: \n99.7%, 96%, and \n92.7%, \nrespectively. \n \nSignificant Subgroup of \nsentinel -node-\nnegative patients  \n \nRetrospective \ndesign  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 775 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndifferences in \nsurvival between \npatients with \nlocal/in -transit and \nnodal vs. distant \nfirst recurrence  \n \nNo significant \ndifference in time \nto the development \nof local/in -transit \nvs. nodal vs.distant \nrecurrence  \nBeyeler M et al. \n(2006)  \n To compare  \nthe efficacy of \nimaging \ntechniques and \nserum S100 in  \nthe early detection \nof melanoma \nprogression  Diagnostic study  127 patients  Sensitivity  \n \nMode of detection  In 5.5% of patients, \nS100 was the  \nfirst indicator of \ndisease \nprogression. \n \n40.2% of relapses \nnoted by the \npatients \nthemselves,  \n27.6% diagnosed \nby a doctor. \nImaging \nprocedures lead to \ndetection of \nmelanoma \nrecurrence in Population not \ndescribed.  \n \nSmall patient \nnumber in every \nstage  \n \nspecificity not \ngiven  \n \nNo information \nabout time interval \nbetween imaging \nprocedures and \nblood samples.  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 776 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n26.8%. (US in 6 \npatients, PET scan \nin 12 patien ts, \nCT scan in 13 \npatients, PET -CT in \n3 patients, chest x -\nray in 0 patients)  \n \nS100 sensitivity: \n37%. \nDiFronzo et al. \n(2001) To investigate \nwhether routine \nreassessment and \ncareful education \nof postoperative \npatients would \nfacilitate earlier \ndiagnosis of a \nsubsequent second \nprimary melanoma, \nas reflected by \nreduced thickness \nof that lesion . cohort study  3310 patients with \nprimary melanoma \nAJCC stage I/II \n \n Rate of patients \nwho developed \nSPM 114 patients with \nAJCC Stage I or II \nmelanoma \ndeveloped a SPM  \n \nAJCC stages of \nSPM: \n- lower in 48%  \n- same -stage in \n50% \n \nmean tumor \nthickness for PM: \n1.32 +- 1.02 mm, \nfor SPM: 0.63 + - \n0.52 mm  \n \nlevel of invasion of \nSPM vs. PM  \n- decreased in 60% Standard follow -up \nprocedure is \ndefined  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 777 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n- remained the \nsame in 27%  \n- increased in 13% \nof patients.  \n \nsignificant \ndifferences in \nstage, tumor \nthickness, and \nlevel of invasion \nbetween PM and \nSPM (paired t te st) \nDicker et al. (1999)  To address the \nfollowing \nquestions: (i) what \nis the overall risk \nof recurrence? (ii) \nWhen do \nrecurrences occur? \n(iii) How are they \ndetected? (iv) What \nis the risk of \nrecurrence from \nmelanomas which \nappeared to be \nconfined to the \nepidermis when \nthey were excised? \n(v) How are second \nprimary Prevalence study  \n \n 1568 patients with \nstage I m elanoma  \n \n Risk of recurrence  \n \nFirst site and \ndetection of \nrecurrences  \n \nChanges in \nbehaviour (see full \ntext) Overall 19% \ndeveloped \nrecurrences  \n \n79% of recurrences \noccurred during \nthe first 3 years. \n<8% after the 10 -\nyear interval. \n \npatients detected \ntheir recurrences \nmore often than  \ndoctors at follow -\nup clinics  \n \nThe first site of \nrecurrence was:  Large patient \ncohort \n \nNo standardized \nfollow -up protocol  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 778 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanomas \ndetected? (vi) Do \npatients alter their \nbehaviour after \nattending a \nmelanoma follow -\nup clinic?  - local 17%  \n- in transit 6%  \n- local nodes 56%  \n- distal 22%  \nJohnson et al. \n(1998)  To characterize the \nsubgroup of \npatients with \nmultiple \nmelanomas.  cohort study  \n \n 60 with with \nmultiple primary \nmelanomas, and  Time to diagnosis \nof second \nmelanoma  \n \nTumor thickness of \nsecond melanoma  In 30% MPM were \ndiagnosed \nconcurrently within \n1 month, in 63% > \n1 month apart,  and \nin 7% concurrently \nand subsequently \n(>2 primaries).  \n \nmedian time \ninterval between \nsubsequent \ndiagnoses of 2nd \nPM: 63 months \n(range 2 -456) \n \nin patients with > 2 \nPM: median time \ninterval between \nsubsequent \nlesions: 42 months \n(range 2 -456).  \n Retro spective \ndesign  \n \nSmall patient \ncohort 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 779 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAppearance of \nsubsequent \nprimary  \n- 42% within 3 \nyears  \n- 17% between 3 -7 \nyears  \n- 42%> 7 years  \n- 19% > 10 years  \n- 6% > 15 years  \nAfter initial \ndiagnosis  \n  \nmean tumor \nthickness from the \n1st primary lesion \nto the subsequent \nlesion(s) decreased \nfrom 0.98 to 0.90 \nmm. \nSylaidis  et al. \n(1997)  To investigate the \nincidence of \nrecurrence in thick \n(> 4 mm) localized \nmelanoma to draw \nconclusions about \nduration and \nfrequency of \nfollow -up. cohort study  \n \n 244 patients  \n(176 patients had \ntheir first \nrecurrence \nbetween years 1 \nand 10 \npostoperatively)  Overall survival (= \ndisease specific \nsurvival in this \nstudy)  \n \nSurvival after first \nrecurrence  5-year survival: \n45% (95% CI 39%, \n51%)  \n \n10-year survival: \n37% (95% CI: 31%, \n43%).  \n \n- 42 patients wi th \nlocal recurrences: Retrospective \ndesign  \n \nPatient cohorts \nonly includes \npatients with \nmelanoma > 4 mm \nthickness  \n \nNo attempts to 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 780 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n5-year survival rate \nof 26% (95% CI: \n13%, 39%).  \n- 93 with regional \nrecurrences: 5 -year \nsurvival rate of 18% \n(95% CI: 10%, 26%).  \n- 41 with distant \nmetastases: 5 -year \nsurvival rate of 5% \n(95% CI: 0%, 11%).  recover patients \nlost to follow up  \n \nPatients who died \nof other diseases \nwere excluded  \nMartini et al. \n(1994)  To establish a \nfollow -up guide for \ncutaneous \nmelanoma.  Prevalen ce study  \n 840 stage I \ncutaneous \nmelanoma patients  \n \n(recurrence in 202 \npatients)  Time to first \nrecurrence  \n \nPathway of first \nrecurrence  Mean time to first \nrecurrence: 22.27 \nmonths (median \n13.5 months).  \n \n45.54% of relapses \noccurred during \nthe 1st year, \n79.21 % during the \nfirst 3 years, 89.6% \nin the first 4 years \nand 94.55% in the \nfirst 5 years. \n \nRecurrences \nsignificantly earlier \n(mean 18.18 \nmonths, median \n10.5 months) in Retrospective \ndesign with \nincomplete \npatients records \n(only 675 of 840 \npatients \n\u201chistologically \nevaluable\u201d).  \n \nPatient cohort \ncontains melanoma \nin situ (105 lesions \nnot invasive).  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 781 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmales than in \nfemales (mean \n26.78 months, \nmedian 17.5 \nmonths).  \n \nPathway of first \nrecurrenc e: \n81.19%: lymphatic  \n17.33%:hematic  \n1,48%: unknown \nBaughan et al. \n(1993 ) To assess the \nobjective value of \nfollow -up in \ndiagnosing and \ntreating tumour \nrelapse and its \nsubjective value as \nperceived by \npatients.  cohort study  \n \n 339 melanoma \npatients (65 \npatients developed \nrecurrences)  Time to relapse  \n \n5-year-survival  \n \nQuestionnai re \nresults (subjective \nvalue of follow -up \nto patients)  82% of first \nrelapses occurred \nwithin 3 years and \nnone has yet been \nseen after 7 years. \n \nActuarial 5 -year-\nsurvival (doctor -\ndiagnosed vs. \npatient -diagnosed \nrecurrences): 18 \nvs. 20 % (P>0,8)  \n \nFor time to  first \nrelapses over year \nof follow -up, see \nfig. 1 in original \narticle.  Retrospective \ndesign  \n \nNo standard \nfollow -up protocol  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 782 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nKang et al. (1992)  To examine the \nnatural history and \nimpact of regular \nfollow -up \nevaluation of \nmultiple primary \ncutaneous \nmelanoma  cohort study  \n \n 41 patients with \nmultiple cutaneous \nmelanoma  Interval between \nmelanoma \ndiagnoses \n \nTumor thickness  \n \n In 39% the MPM \nwere diagnosed \nconcurrently (vs. \n61% subsequently).  \n \nSignificant \ndecrease in \nBreslow\u2019s thickness \nfrom the 1st PM \n(1.21 \u00b1 0.28 mm) \nto the second (0.51 \n\u00b1 0.08 mm) \n(P<0.05) \n \nmedian time \ninterval between \nsequential \nmelanomas: 36 \nmonths (range 2 -\n372) Retrospective \ndesign  \n \nSmall patient \ncohort 3b \nBrandt et al. (1990)  To investigate the  \nprognostic value of \nseveral factors on \ncancer-specific \nsurvival and \ncancerspecific \ndisease -free \nsurvival, from time \nof excision on, by \nperforming life -Prevalance study  \n \n 231 patients who \nunderwent local \nexcision  \nas the single \ntreatment of \nmelanoma with a \nthickness  \nof <= 1.5 mm.  Cancer -specific \nsurvival (CSS)  \n \ncancer -specific \ndisease -free \nsurvival  During follow -up: - \n14/206 patients \ndied. \u2013 (6 patients \nas a result of the \ndisease, 8 from \nother causes)  \n \nRecurrence in11 \npatients:  \n- 4 local Retrospective \ndesign  \n \nNo standard \ntherapy and follow -\nup protoco l  \n \nDifferent excision \nmargins have been \nused 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 783 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntable analysis on \n206 evaluable \npatients.  recurrences  \n- 4 LN me tastases \n- 3 distant disease.  \n \n- Actuarial 5 -year \nCSS: 96.1%  \n- 10-year \nCSS:92.3%  \n- 15-year CSS: \n92.3%.  \n \ncancer -specific DFS \nafter 5 years: \n95.2%, after 10 \nyears: 86.9%, after \n15 years: 86.9%.  \nMcCarthy et al. \n(1988)  To re -examine \nfollow -up regimens \nand provide follow -\nup guidelines \ntailored to the risk \nof the individual \npatient.  Prevalence study  \n \n 886 melanoma \npatients with \nevidence of \nrecurrent disease  Recurrence rate  \n \nSite of first \nrecurrence  \n \nTime to first \nrecurrence  Time to first \nrecurrence \ndepended upon:  \n- thickness of the \ntumor  \n- whether ELND \nwas performed or \nnot  \n \nTimes to \nrecurrence for 50% \nrespectively 95% of \nthe recurrent \npatients in mo nths:  Retrospective \ndesign  \n \nDifferent follow -up \nschedules over \ntime \n \nLarge patient \ncohort 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 784 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n- 32 months and \n134 months for \n0.1 \u2013 0.7 mm \ntumor thickness  \n- 25 months and \n116 months for \n0.8 \u2013 1.5 mm \ntumor thickness \nwithout ELND  \n- 36 months and \n145 months for \n0.8 \u2013 1.5 mm \ntumor thickness \nwith ELND  \n- 16 months and \n108 months for \n1.6 \u2013 3.0 mm \ntumor thickness \nwithout ELND,  \n- 20 months and \n112 months for \n1.6 \u2013 3.0 mm \ntumor thickness \nwith ELND  \n- 12 months and \n60 months for > \n3.0 mm tumor \nthickness without \nELND  \n- 19 months and \n60 months for >  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 785 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n3.0 mm tumor \nthickness with \nELND  \nBuljan M et al. \n(2010)  To analyse the \nclinical, \nhistopathological \nand \nepidemiological \ncharacteristics of \n36 patients, with \nmultiple primary \nmelanomas (MPM)  cohort study  \n \n \n 36 patients (3,6%) \nwere diagnosed \nwith MPM.  \n \n28 patients: 2 \nprimary melanoma  \n6 had 3 melanoma \nand 2 had 4 \nmelanomas.  Time interval \nbetween first and \nsubsequent \nmelanoma  Diagnosis was \nestablished \nsynchronously in \n11 patients  \n \nin the the other \npatients time \ninterval between \nPM and SPM varied \nfrom 1 month to \n16 years, average \ntime interval : 41 \nmonths.  Retrospective \ndesign  \n \nSmall population  \n \nNo data \nconcerning \nexamination \nintervals of follow -\nup 3b- \nMcMeniman et al. \n(2010)  To define the risk \nfactors for multiple \nprimary melanoma  \n(MPM).  Prognostic factors  \n \n 58 patients with \nmore than one \nprimary were \ninterviewed via \ntelephone  \n \n Rate of patients \nwho developed \nMPM \n \nAge at diagnosis  \n \nTumor thickness  \n \nRisk factors  50% of patients \nhad their first \nmelanoma between \n40\u201359 years of \nage. \n \n68% had the same \nor a less invasive \nlevel of melanoma \non their \nsubsequent \nlesion/s.  \n Data incomplete or \ninaccurate on \nmany patients  \n \nRisk of recall bias  \n \nSmall patient \ncohort 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 786 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nWith subsequent \nmelanomas a \ngreater proportion \nwere found by the \ndermatologist.  \n \nRisk factors: see \nfull-text  \nZissimopoulos et \nal. (2009)  \n \n To evaluate 111In -\nO Scintiscan in \nmalignant \nmelanoma for the \ndetection of \nrecurrence and \nmetastatic disease, \nafter clinical and \nhistological \ndiagnosis and \ninitial surgery \ntreatment and \nduring 3 years of \nfollow -up. Diagnostic study  35 patients with \nmalignant \nmelanoma  \n \n20 female, 15 \nmale, mean age \n46\u00b17, range 32 -51 \nyears  \n \nTreatments in \nsome patients: \nInterferon alpha, \nIL-2 Positive - rate During 3 years of \nthe follow -up \nperiod, 26/35 of \nthe patien ts \nhad clinical \nrecurrence. \n \n(17 patients: \nregional lymph \nnode metastases, 9 \ndistal metastases)  \n \nIn 111In -O \nScintiscan  \n20/26 patients had \npositive scans with \n56 lesions, 6 had \nnegative scans. CT \nimages showed \nonly 31 lesions. Selection criteria \nnot given  \n \nSmall sample size  \n \nNo information \nabout false \npositives and false \nnegatives.  \n \nPositive CT: only \nnumber of \nmetastases is given \nbut not number of \npatients  \n \nNo information \nabout interval \nbetween CT and \n111In -O Scintiscan  \n \nNo information 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 787 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nabout results of \nother  staging \nmodalities  \nSolivetti FM et al.  \n(2006)  to assess the \npotential of \nultrasonography \n(US) in the \ndetection of in -\ntransit or satellite \nmetastases.  Diagnostic study  600 patients who \nhad thick \nmelanoma  \n(>1 mm) and who \nwere clinically free \nof in-trans it or \nsatellite melanoma \nmetastases during \nfollow -up.  \n \n Number of \ndetected \nmetastases \n \nUS features of in -\ntransit metastases  US suspicion of in -\ntransit or satellite  \nmetastases in 63 \npatients. A total of \n95 lesions were \nidentified. Lesion \ndiameter ranged \nfrom 4 mm to \n17mm (mean \ndiameter 8 mm). \nFour of 95 lesions \nhad a diameter >1 \ncm; most (82 \ncases) had \ndiameters of 6 \u20138 \nmm. \n \nNo false positive or \nfalse negative US  \n \nUS features: see \nfull-text  4 \nDancey et  al. \n(2004)  to assess patient \nopinions on follow -\nup. \n cohort study  231 melanoma \npatients and 50 \nGPs who filled out \na questionnaire  Patients` opinion \non follow -up \n \nGP satisfaction  98% found the \nclinics to be u seful \n \n22,5% felt it was  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 788 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nto ascertain \nwhether GPS would \nbe willing to follow \nmelanoma patients \nup in a primary \ncare setting   \n \n difficult to attend \nthe clinic  \n \n53% expressed  \nsome degree of \nanxiety at \nattending the \noutpatient \ndepartment  \n \n12%: recurrence, \n52% of them \ndetected it \nthemselves  \n \n60% of patients \nwould be happy to \nconsider routine \nfollow -up with th eir \nGP \n \n70% of local GPs \nwould be unhappy \nto monitor their \npatients.  \nJohnson et al. \n(1999)  to determine the \nvalue of follow -up \nin two subgroups \nof patients with a \nthin melanoma less Prevalence study  \n \n 306 patients: 178 \nwith a melanoma < \n0.76 mm (group 1) \nand 128 with a \nmelanoma of 0.76 Recurrence rate  Recurrences in 4 \npatients (2.2%) in \ngroup 1 and 16 \n(12.5%) in group 2  \n Standardized \nfollow -up \nprocedure  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 789 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nthan 0.76 mm and \n0.76\u2013 1.5 mm \nthick. \u2013 1.5 mm (group 2)  \n \n group 1:  \nall patients \npresented with \nuntreatable, \nwidespread \nmetastatic dis ease, \ndetected by a \nclinician in the \nfollow -up clinic.  \n \ngroup 2: 1: local \nrecurrence, 1 in -\ntransit recurrence, \n3 subcutaneous \nrecurrence, 7 nodal \nmetastases and 4 \npatients distant \nmetastases. In \n13/16 patients, \nrecurrence was \ndetected by \nclinician in the \nfollow -up clinic.  \nMooney et al. \n(1998)  To asses the \nimpact on survival \nby components of \na surveillance \nprogram (physical \nexamination, blood \ntests, and chest Prognostic study  \n 1004 patients AJCC \nStage I or II  \n \n \n Method of \ndetection  \n \nSurvival \n \n5-, 10- and 15 -year \nsurvival  Physical \nexamination \ndetected 72% \nconstitutional \nsymptoms \nindicated 17% and \nchest radiograph Retrospective \ndesign  \n \nNo information \nabout \nverification/referen\nce test  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 790 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nradiograph) used \nto detect \nrecurrences in \npatients with \ncutaneou s \nmelanoma  revealed 11% of \nrecurrences. Blood \ntests did not  \npredict any \nrecurrence. 9/17 \npatients with \nrecurrences \ndetected by chest \nradiograph alone  \nunderwent curative \nsurgical resection. \nThese patients had \na statistically \nsignificant \nprolonged survival \ncompared to those \nsurgical candidates \nwho did no t \nundergo resection. \nNo statistically \nsignificant \ndifference in OS \nbetween patients \nwith \nasymptomatic \npulmonary \nrecurrences and \nthose with \nsymptomatic \npulmonary \nmetastases  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 791 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nThe 5 -year, 10 -\nyear, and 15 -year \nOSrates, with their \nassociated 95% CI, \nfor patient s who \nremained disease \nfree: 92%\u00b12%, 85% \n\u00b13%, and 77% \u00b14%, \nrespectively. The \nrates for patients \nwith recurrences \nare 46% \u00b1 8%, 17% \n\u00b1 6%, and 14% \u00b1 \n6%, respectively.  \nMooney et al. \n(1997)  To assess costs \nand potential \nbenefits of an \nintensive chest X -\nray (CXR) screening \nprogram to detect \nasymptomatic \npulmonary \nmetastases in \npatients with \nintermediate -\nthickness, local, \ncutaneous \nmelanoma.  Economical study  \n \n A hypothetical \ncohort of pati ents \ndiagnosed in 1996 \nwith intermediate -\nthickness, local, \ncutaneous \nmelanoma. \nIntermediate \nthickness \nmelanoma was \ndefined as \u2265 (AJCC) \nStage I -  \nclassification pT2  Potential savings in \nyears of life from \nsurgical resection \nof lung metastases \nin quality -adjusted \nand non- quality \nadjusted life years \n(QALY AND \nNQALY), \nundiscounted and \ndiscounted  \n \nCost-effectiveness \nratio (C/E) of CXR \nscreening  For the base case, \ncost of screening \nper NQALY was \n$150,000 and was \n$165,000 for QALY \nin 1996 dollars \nusing \nundiscounte d \nhealth benefits. \nScreening \naccounted for \napproximately 80% \nof program costs \nand treatment \naccounted for 20%. No level of \nevidence was \nassigned because \nof unique study \ndesign and \nhypothetical cohort \nof patients    \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 792 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAnnual cost -\neffectiveness ratios \nwere lowest in \nYears 3 \u201310 of \nscreening. The \ntotal cost of a 20 -\nyear screening \nprogram for \npatients diagnosed \nin 1996 was \nestimated to be \nbetween $27 \u2013$32 \nmillion. \n \n8.2.5.  Literatur  \nLiteratur:  Zuteilung zur \nFragestellung:  \nVII.4 VII.5 VII.6 \nAlvarado et al. (2011)  x x x \nBasseres et al. (1995 ) x x x \nBaughan et al. (1993 ) x x  \nBeyeler et al. (2006 )   x  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 793 von 817 \nLiteratur:  Zuteilung zur \nFragestellung:  \nVII.4 VII.5 VII.6 \nBower et al. (2010)  x x  \nBrandt et al. (1990 ) x   \nBrobeil et al. (1997 ) x x  \nBrown et al. (2010 )   x \nBuljan et al. (2010 ) x x  \nDancey et al. (2004 ) x x  \nDe Giorgi et  al. (2010)  x x  \nDeRose et al. (2011 ) x x x \nDicker et al. (1999)  x x  \nDiFronzo et al. (200 1) x x  \nEgberts et al. (2009)   x \nEinwachter -Thompson, MacKie (2008 ) x x  \nFerrone et al. (2005)  x x  \nFrancken et al. (2008)      \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 794 von 817 \nLiteratur:  Zuteilung zur \nFragestellung:  \nVII.4 VII.5 VII.6 \nFrancken et al. (2005)  x x  \nFrancken et al. (2007 ) x x x \nFusi et al. (1993)  x x  \nGarbe et al. (2003)  x x x \nGoggins et Tsao (2003)  x x  \nHansel et al. (2009)  x x  \nHengge et al. (2007 ) x x x \nHohnheiser et al. (2010)  x x  \nJohnson et al. (1998)  x x  \nJohnson et al. (1999)  x x x \nKang et al. (1992)  x x  \nKr\u00fcger et al. (2011)    x \nKaufmann, Crone -M\u00fcnzbrock (1992)   x x \nLeiter et al. (2009 )     \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 795 von 817 \nLiteratur:  Zuteilung zur \nFragestellung:  \nVII.4 VII.5 VII.6 \nLeiter  et al. (2010)  x x  \nLeiter  et al. (2011)  x x  \nMachet et al. (2005)    x \nManola et al (2000)  x  x \nMartenson et al. (2001)     \nMartini e t al. (1994)  x x  \nMcCarthy et al. (1988)  x x  \nMcMeniman et al. (2010)  x x  \nMeyers et al. (2009) x x x \nMooney et al. (1997)     \nMooney et al. (1998)   x x x \nMoore Dalal et al. (2008 ) x x x \nMorton RL et al. (2009 )  x x \nMruck S et al. (1999 )   x  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 796 von 817 \nLiteratur:  Zuteilung zur \nFragestellung:  \nVII.4 VII.5 VII.6 \nMurchi e et al. (2010) x x  \nPeric et al (2011 )   x \nPoo-Hwu et al. (1999 ) x x  \nRueth et al. (2010 )  x  \nSchlagenhauff  et al. (2000)    x \nSolivetti et al.  (2006)    x \nStucky et al. (2010) x x  \nSylaidis et al. (1997)  x x  \nTarhini AA et al. (2009)   x  x \nTurner et al. (2011)  x x  \nVoit et al. (2001)    x \nvon Schoultz et al. (1996)    x \nZissimopoulos et al. (2009 )   x \nZogakis et al. (2007)  x x  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 797 von 817 \n \nAlvarado GC, Papadopoulos NE, Hwu W -, et al. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res 2011;21:127-\n130 \nAukema TS, Olmos RA, Korse CM, et al. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S -100B level during follow -up. Ann Surg Oncol 2010;17:1657-\n1661 \nBasseres  N, Grob JJ, Richard MA, et al. Cost -effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10 -year experience in a dermatology department in \nFrance. Dermatology 1995;191:199 -203 \nBaughan CA, Hall VL, Leppard BJ, et al. Foll ow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) 1993;5:174- 180 \nBeyeler M, Waldispuhl S, Strobel K, et al. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein. Dermatology 2 006;213:187- 191 \nBower MR, Scoggins CR, Martin RC,2nd, et al. Second primary melanomas: incidence and outcome. Am Surg 2010;76:675- 681 \nBrandt SE, Welvaart K, Hermans J. Is long -term follow -up justified after excision of a thin melanoma (less than or equal t o 1.5 mm)? A retrospective analysis of 206 patients. J Surg Oncol \n1990;43:157- 160 \nBrobeil A, Rapaport D, Wells K, et al. Multiple primary melanomas: implications for screening and follow -up programs for melanoma. Ann Surg Oncol 1997;4:19- 23 \nBrown RE, Strom berg AJ, Hagendoorn LJ, et al. Surveillance after surgical treatment of melanoma: futility of routine chest radiography. Surgery 2010;148:711 -6; discussion 716- 7 \nBuljan M, Situm M, Bolanca Z, et al. Multiple primary melanoma: epidemiological and prognostic  implications; analysis of 36 cases. Coll Antropol 2010;34 Suppl 2:131- 134 \nDancey A, Rayatt S, Courthold J, et al. Views of UK melanoma patients on routine follow -up care. Br J Plast Surg 2005;58:245- 250 \nde Giorgi V, Rossari S, Papi F, et al. Multiple prim ary melanoma: the impact of atypical naevi and follow up. Br J Dermatol 2010;163:1319- 1322  \nDeRose ER, Pleet A, Wang W, et al. Utility of 3 -year torso computed tomography and head imaging in asymptomatic patients with high -risk melanoma. Melanoma Res 2011;21:364- 369 \nDicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanoma follow -up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol \n1999;140:249- 254 \nDiFronzo LA, Wanek LA, Morton DL. Earlier diagnosis of second p rimary melanoma confirms the benefits of patient education and routine postoperative follow -up. Cancer \n2001;91:1520- 1524  \nEgberts F, Hitschler WN, Weichenthal M, et al. Prospective monitoring of adjuvant treatment in high -risk melanoma patients: lactate dehydrogenase and protein S -100B as indicators of \nrelapse. Melanoma Res 2009;19:31- 35 \nEinwachter -Thompson J, MacKie RM. An evidence base for reconsidering current follow -up guidelines for patients with cutaneous melanoma less than 0.5 mm thick at diagnosis. B r J \nDermatol 2008;159:337 -341 \nFerrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005;294:1647 -1654  \nFrancken AB, Accortt NA, Shaw HM, et al. Follow -up schedules after treatment  for malignant melanoma. Br J Surg 2008;95:1401- 1407  \nFrancken AB, Bastiaannet E, Hoekstra HJ. Follow -up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005;6:608- 621 \nFrancken AB, Shaw HM, Accortt NA, et al. Detection of first relapse i n cutaneous melanoma patients: implications for the formulation of evidence -based follow -up guidelines. Ann Surg \nOncol 2007;14:1924- 1933  \nFrancken AB, Shaw HM, Thompson JF. Detection of second primary cutaneous melanomas. Eur J Surg Oncol 2008;34:587- 592 \nFusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993;91:94- 98 \nGarbe C, Paul A, Kohler -Spath H, et al. Prospective evaluation of a follow -up schedule in cutaneo us melanoma patients: recommendations for an effective follow -up strategy. J Clin Oncol \n2003;21:520- 529 \nGoggins WB, Tsao H. A population -based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003;97:639 -643 \nHansel G, Schonlebe J, Haroske G, et al. Late recurrence (10 years or more) of malignant melanoma in south -east Germany (Saxony). A single -centre analysis of 1881 patients with a \nfollow -up of 10 years or more. J Eur Acad Dermatol Venereol 2010;24:833- 836 \nHengge UR, Wallerand A, Stutzki A, et al. Cost -effectiveness of reduced follow -up in malignant melanoma. J Dtsch Dermatol Ges 2007;5:898- 907 \nHohnheiser AM, Gefeller O, Gohl J, et al. Malignant Melanoma of the Skin: Long -term Follow -up and Time to First Rec urrence. World J Surg 2010  \nJohnson RC, Fenn NJ, Horgan K, et al. Follow -up of patients with a thin melanoma. Br J Surg 1999;86:619 -621 \nJohnson TM, Hamilton T, Lowe L. Multiple primary melanomas. J Am Acad Dermatol 1998;39:422- 427 \nKang S, Barnhill RL, Mihm MC,Jr, et al. Multiple primary cutaneous melanomas. Cancer 1992;70:1911- 1916  \nKaufmann PM, Crone -Munzebrock W. Tumor follow -up using sonography and computed tomography in the abdominal region of patients with malignant melanoma]. Aktuelle Radiol \n1992;2:81- 85 \nKelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow -up after treatment of a primary malignant melanoma. J Am Acad Dermatol 1985;13:756 -760 \nKhan MA, Andrews S, Ismail -Khan R, et al. Overall and progression -free survival in metastatic  melanoma: analysis of a single -institution database. Cancer Control 2006;13:211- 217 \nKruger U, Kretschmer L, Thoms KM, et al. Lymph node ultrasound during melanoma follow -up significantly improves metastasis detection compared with clinical examination alo ne: a \nstudy on 433 patients. Melanoma Res 2011;21:457- 463 \nLeiter U, Buettner PG, Eigentler TK, et al. Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? Melanoma Res \n2010;20:240- 246 \nLeiter U, Marghoob AA, Lasithiotakis K, et al. Costs of the detection of metastases and follow -up examinations in cutaneous melanoma. Melanoma Res 2009;19:50- 57  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 798 von 817 \nLeiter U, Buettner PG, Eigentler TK, et al. Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma \nRegistry. J Am Acad Dermatol 2011  \nMachet L, Nemeth -Normand F, Giraudeau B, et al. Is ultrasound lymph node examination superior to clinical examination in melanoma follow -up? A monocentre cohort study of 373 \npatients. Br J Dermatol 2005;152:66- 70 \nManola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18:3782- 3793  \nMartens on ED, Hansson LO, Nilsson B, et al. Serum S -100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001;19:824- 831 \nMartini L, Brandani P, Chiarugi C, et al. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow -up schedule. Tumori 1994;80:188- 197 \nMcCarthy WH, Shaw HM, Thompson JF, et al. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guide lines for follow -up study. Surg Gynecol Obstet \n1988;166:497- 502 \nMcMeniman E, De'Ambrosis  K, De'Ambrosis B. Risk factors in a cohort of patients with multiple primary melanoma. Australas J Dermatol 2010;51:254 -257 \nMeyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the ut ility of follow -up staging. Ann Surg Oncol 2009;16:941-\n947 \nMooney MM, Kulas M, McKinley B, et al. Impact on survival by method of recurrence detection in stage I and II cutaneous melan oma. Ann Surg Oncol 1998;5:54- 63 \nMooney MM, Mettlin C, Michalek AM, et a l. Life -long screening of patients with intermediate -thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost -\neffectiveness analysis. Cancer 1997;80:1052- 1064  \nMoore Dalal K, Zhou Q, Panageas KS, et al. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol 2008;15:2206- 2214  \nMorton RL, Craig JC, Thompson JF. The role of surveillance chest X -rays in the follow -up of high -risk melanoma patients. Ann Sur g Oncol 2009;16:571- 577 \nMruck S, Baum RP, Rinne D, et al. Diagnostic accuracy and predictive value of the tumor- associated antigen S100 in malignant melanomas: validation by whole body FDG -PET and \nconventional diagnostics. Anticancer Res 1999;19:2685- 2690  \nMurchie P, Nicolson MC, Hannaford PC, et al. Patient satisfaction with GP -led melanoma follow -up: a randomised controlled trial. Br J Cancer 2010;102:1447- 1455  \nPeric B, Zagar I, Novakovic S, et al. Role of serum S100B and PET -CT in follow -up of patients wi th cutaneous melanoma. BMC Cancer 2011;11 \nPoo-Hwu WJ, Ariyan S, Lamb L, et al. Follow -up recommendations for patients with American Joint Committee on Cancer Stages I -III malignant melanoma. Cancer 1999;86:2252- 2258 \nRomano E, Scordo M, Dusza SW, et al. Sit e and timing of first relapse in stage III melanoma patients: implications for follow -up guidelines. J Clin Oncol 2010;28:3042- 3047  \nRueth NM, Groth SS, Tuttle TM, et al. Conditional survival after surgical treatment of melanoma: an analysis of the Surveill ance, Epidemiology, and End Results database. Ann Surg Oncol \n2010;17:1662- 1668  \nSchlagenhauff B, Schittek B, Ellwanger U, et al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of m elanoma \nrecurrence? Melanoma Res 2000;10:451- 459 \nSolivetti FM, Di Luca Sidozzi A, Pirozzi G, et al. Sonographic evaluation of clinically occult in -transit and satellite metastases from cutaneous malignant melanoma. Radiol Med \n2006;111:702- 708 \nStucky CC, Gray RJ, Dueck AC, et al. Risk factors associated with local and in -transit recurrence of cutaneous melanoma. Am J Surg 2010;200:770- 775 \nSylaidis P, Gordon D, Rigby H, et al. Follow -up requirements for thick cutaneous melanoma. Br J Plast Surg 1997;50:349- 353 \nTarhini AA, Stuckert J, Lee S, et al. Prognostic significance of serum S100B protein in high -risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin \nOncol 2009;27:38- 44 \nTurner RM, Bell KJ, Morton RL, et al. Optimizing the frequency of follow -up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol 2011;29:4641- 4646  \nVoit C, Mayer T, Kron M, et al. Efficacy of ultrasound B -scan compared with physical examination in follow- up of melanoma patients. Cancer 2001;91:2409- 2416  \nvon Schoultz E, Hansson LO, Djureen E, et al. Prognostic value of serum analyses of S -100 beta protein in malignant melanoma. Melanoma Res 1996;6:133- 137 \nZissimopoulos A, Karpouzis A, Kouskoukis C. Indium -111 pentetreotide scin tigraphy and CT scans after 3 years in the follow -up of patients with malignant melanoma. Hellenic Journal \nof Nuclear Medicine 2009;12:142- 145197  \nZogakis TG, Essner R, Wang HJ, et al. Natural history of melanoma in 773 patients with tumor -negative sentinel  lymph nodes. Ann Surg Oncol 2007;14:1604- 1611  \n \n  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 799 von 817 \n9. AG Begleittherapie  \n9.1. Frage VIII.1. Misteltherapie  \nFrage VIII.1. Beeinflusst eine Misteltherapie das Gesamt\u00fcberleben und/oder die rezidivfreie Zeit von Melanompatienten? \n9.1.1.  PICO, Suchw\u00f6rter  \nPICO - Schema  \nPopul ation  Intervention  Comparison  Outcome  \nMelanoma patients  Mistletoe  Observation  Overall survival, progression free \nsurvival  \n \nSuchw\u00f6rter  \nStichwort  melanoma  mistletoe  primary   \nSynonyme      \nOber -/Unterbegriffe Skin cancer  Viscum album    \nMesh Term  melanom a mistletoe    \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 800 von 817 \n9.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  (\u201cmelanoma\u201d OR \u201cmelanoma\u201d[MeSH Terms] OR \u201cskin cancer\u201d) AND (\u201cmistletoe\u201d OR \u201cviscum \nalbum\u201d OR \u201cmistletoe\u201d[MeSH Terms])  28.09.10 41 \nCoch rane Library  (melanoma and (mistletoe or viscum album)).ti,ab.  28.09.10  2 \nEmbase  (melanoma and (mistletoe or viscum album)).ti,ab.  12.10.10  47 \n    \nUpdate Suche     \nMedline  s.o. 26.01.12  42 \nCochrane Library  s.o. 26.01.12  2  \nEmbase  s.o. 23.01.12  53  \n \n9.1.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  97 \nEinschlusskriterien  Klinische Studien zur Misteltherapie bei Melanomapatienten, alle Stadien  \nVergleichsarm: Beobachtung oder Standardtherapie , Sprachen: e,dt   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 801 von 817 \nAuswahl der Literatur  \nAusschlusskriterien  Studien oder Reviews  mit Einschluss anderer/gemischter Tumorentit\u00e4ten  \nCase Reports , Experimentelle Arbeiten  \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  3 \nAnzahl ausgew\u00e4hlter Studien durch Handsuche (Durchsicht der Referenzlisten der ausgew\u00e4hlten Arbeiten)  3 \nAusgeschlossene Studien (mangelhafte methodische Qualit\u00e4t)  3 \nBer\u00fccksichtigte Studien  3 \n9.1.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nKleeberg et al. \n2003  \n \nFinal re sults of the \nEORTC 18871/DKG \n80-1 randomised \nphase III trial:rIF N- \na2b versus rIFN -g \nversus ISCADOR \nM1 versus \nobserv ation after \nsurgery in \nmelanoma patients \nwith either high -\nrisk primary To clarify whether \nclaims of the \nefficacy of Iscador \nM were justified  Prospectiv e, \nrandomised phase \nIII adjuvant trial  803 pts: 423 pts \nwere ra ndomized \nin the EORTC \n18871 3 -arm trial, \n407 pts in the \nDKG-80-1 4-arm \ntrial (102 pts in the \ncontrol arm, 101 \npts in the rIFN -\nalpha arm, 102 in \nthe rIFN -gamma \narm and 102 in \nIscador -M arm).  \nThus 204 pts were \nused to a ssess the  \n \n \nDisease free \nInterval rate (DFI)  \n \nOverall Survival \n(OS) \n  Iscador M1 versus \ncontrol  \n \nHR 1.32 (0.93, \n1.87)  \n \n \nHR 1.21 (0.84, \n1.75)  \n \n \nThe data su pport, \nbut do not provide \nsignificant proof of \nearlier wa rnings The trials were \nstopped after \nreaching the \nplanned sample \nsize for the IFN -\nquestion and after \nhaving the r esults \nof an interim \nevaluation showed \nan appro ximately \n10% lower 2 -year \nDFI rate in the \nIscador arm \ncompared with the \ncontrol group.  1b \n \nIndivi dual \nRCT  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 802 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(thickness >3 mm) \nor regional lymph \nnode m etastasis  value of Iscador: \n102 co ntrols vs. \n102 pts in the \nIscador group.  \n \nStage IIb: 48%/49%  \nStage III: 52%/51%  \n \nBaseline \ncharact eristics \nwere well b alanced  about a p otential \nnegative effect of \nmistletoe extracts \nin melanoma \npatients, since the \nobserv ations did \nnot reach \nsignificance.  Fund ing: \nIn part by grant \nDKG 80 -1 \nAugustin et al. \n2005  \n \nSafety and Efficacy \nof the Long -term \nAdjuvant \nTreatment of \nPrimary \nInterm ediate - to \nHigh-Risk \nMalignant \nMelanoma \n(UICC/AJCC Stage \nII and III) with a \nStandardized \nFermented \nEuropean Mi steltoe \n(Viscum album L.) \nExtract To evaluate the \ntherapeutic safety \nand efficacy of \nFermented \nEuropean Misteltoe \nExtract (FME)  Mulicenter, \ncomparative, \nepidemi ological \ncohort study  686 Patients, 329 \ntreated with FME \nvs. 357 controls \nfrom 35 centers;  \n \nUICC /AJCC tumor \nstage (II/III) %  \n91,5/8,5 vs \n95.0/5.0  \n \nTreatment group:  \n83,3% patients \nreceived FME P  \n16,7% received \nFME M, Q or others  \n \nmedian duration of \ntherapy: 30 \nmonths  Prim. endpoint  \nTumor -related \nsurvival \nSec. endpoint  \nOverall Survival \nDisease -free-\nsurvival \nBrain metastasis -\nfree survival  Significant \nreduction of \ntumor -related \nmortality hazard in \nthe FME group  \nTumor -related \nmortality rate 8,9% \nFME group vs. \n10,7% control \ngroup  \nAdjusted hazard \nratios (FME vs. \ncontrol): \nHR Tumor -related \nsurvival = 0,41 \nHR Overall survival \n= 0,64 \nHR Disease -free \nSurvival = 0,73 Limits:  \nNot randomized \ndesign  \nThus, baseline \ncharacteristics \nwere well ba lanced  \nPotential biases \nwere well \naddressed by \nusing a \nstandardized \nparallel goups \nstudy design, \nindependent \nauditing of data \nquality, \nmultivariate \nadjusted en dpoint \ncriteria for 2b \n \nIndividual \nCohort \nStudy   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 803 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nHR Brain \nmetast asis-free \nsurvival = 0,33 potential \nconfounders and \nother measures.  \nFunding:  \nThe study was \nsupported by an \neducational grant \nof the Research \nInstitute Hiscia, \nArlesheim \n(Switze rland) \n(Iscad or) \nAlbarr\u00e1n Weick, M. \n1998  \n \nRetrospe ktive Fall-\nKontroll -Studie \nzum Stellenwert \nder adjuvanten \nTherapie des \nmalignen \nMelanoms mit \nIscador P.c.Hg.  To evaluate the \nimpact of adjuvant \nIscador on \nprogre ssion free \nsurvival and \nOvera ll Survival Matched pairs (1:3) \nretrospective \ncohort study  Of 1288 \ndocumented \nmelan oma patients \nof the University \nHospita lFreiburg, \n458 patients \nreceived I scador. \n273 of this \npatients were \nevaluated in the \nstudy  \n \nControl group:  \n819 of more than \n25 000 mela noma \npatients within the \nGerman Central \nMalignant Progression free \nsurvival  \nOverall Survival No significant \ndifferences \nbetween the \ngroups regarding \noverall su rvival \n(p=0,9669) and \nprogression free \nsurvival (p=0,5746)  \n \nIscador treatment \nhad no d etrimental \neffect on overall \nsurvival  Study is well \nreported  \nInvasionlevel was \nnot well balanced \nbetween the \ngroups (more Level \nIV and III in control \ngroup)  \nLimits:  \nRetrospective \ndesign, Iscador \npreparation was \nnot standardized  \nFunding:  \nnot reporte d \nInaugural \nDissert ation 2b \n \nIndividual \nCohort \nStudy   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 804 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nMelanoma \nRegistry.  \n \nAusgeschlossene Studien  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nStumpf et al. 2003  \n \nRetrospective \nStudy of Melanoma \nPatients Treated \nwith Mistletoe \nExtracts  to analyze  \nsurvival time  and \nsurvi val rate of all \npatients with \nmalignant  \nmelanoma who \nhad been \ncounseled at the \nTumoramb ulanz \nHerdecke  Retrospective \nStudy  284 melanoma \npatients of the \nTumorambulanz \nHerdecke were \nincluded,  \n94 patients with \nsufficent data were \nanalysed, 66 of \nthis patients \nreceived mistle toe \ntreatment.  \nThis 66 patients \nwere compared \nwith patient data \nfrom the literature Survival \ntime \nSurvival \nrate \n Survival time and \nsurvival rate were \ncomparable to \ncontrols of \nliterature  Poor quality \uf0e0 \nstudy excluded  \n \nLimits: \nretrospective \ndesign, \nheterogen eous \npatient collective: \npatients with and \nwithout \nmeta stases, \nclinical stage was \nnot indicated, \nCompar ison with \nliterature data \nbased on clark \nlevel \nDifferent \ntreatment \nregimens (Iscador \nM, Iscador P and \nothers) \nFunding:  4 \n \npoor quality \ncohort study   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 805 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nThe stu dy was \npartially initiated \nand fi nanced by \nHelixor GmbH&Co  \nGrossarth -Maticek \net al. 2007  \n \nEfficacy and Safety \nof the Long -term \nTreatment of \nMelanoma with a \nMistletoe \nPreparation \n(Iscador) To investigate if \nthe long -term \napplic ation of the \nmistletoe \nprepar ation \nIscador show any \neffect in \nprospe ctive \ncontrolled  \nstudies on survival, \ntumor progression, \nand psychosomatic \nself-regulation of \npatients with  \nmelanoma  Study 1: \nRand omised \nmatched -pair \nstudy (22 pairs)  \n \nStudy 2: Non -\nrandomi sed \nmatched -pair \nstudy (32 pairs)  Study population \nconsisted of 1499 \nmelanoma patients \nof different \ngerman centres  \n \nMelanoma patients \nwithout \nmetasta ses, \nreceiving \nconventional \ntherapies were \nmatched to \nmelanoma patients \nwith same \nchara cteristics to \nreceiv e \nadditio nally \nIscador  \n Overall \nsurvival  \nProgression \nfree \nsurvival  \nSelf \nregulation  Overall survival:  \nNo difference \nbetween Iscador \nand control group  \n \nSignificant better \nprogression free \nsurvival in Iscador \ngroup:  \nHR, 95% C I \nStudy 1:  \nHR 0,49 (0,32, \n0,75)  \nStudy 2:  \nHR 0,72 (0,54, \n0,97)  \n \nSelf regulation:  \nSignificant better \nself regulation \nafter Iscador \ntherapy p=0,0048  Poor quality \uf0e0 \nstudy excluded  \n \nRecruitment period \nwas between 1973 \nand 1988  \nTwo studies were \nanalysed \nseperately but \nwere reported \ntogether  \nLimits  \nSmall sample size  \nQuestionable \nmethod of \nrandomis ation \n(two slips of paper \nwith the names of \ntwo p atients were \ndrawn of a hat)  \nkaplan meier \ncurves available of \noverall su rvival \n(n.s.) but not of \nprogression free \nsurvival 4 \n \npoor quality \ncohort study   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 806 von 817 \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(signi ficant)  \nFunding:  \nNo sta tement \nincluded  \nAffiliation of \nCorresponding \nauthor: Institut \nHiscia, CH -\nArlesheim (Is cador)  \nSchuppli R. 1990  \n \nAdjuvant \ntreatment of \nmalignant \nmelanoma with \nIscador P c Hg.]  To assess the \ntherapeutic effect \nof Iscador plus Hg \non overall survival  Controlled study  \n High risk \nmelanoma patients  \n \n114 patients \ntreated with BCG \nalone  \n84 patients treated \nwith BCG and \nIscador P c Hg  Overall \nsurvival  Risk factor \nSurvival  \nIscador group: 3,4  \nContol group: 2,3  Poor quality \uf0e0 \nstudy excluded  \nThe study was \nconducted at the \nDepartment of \nDermatology, \nUniversitiy B asel, \n1981 -1988  \nLimits: \nStudy reporting of \nlow quality  \nNo baseline \ncharachteristics, \n(groups balanced?)  \nStatistical methods \nwere not reported  \nFunding:  \nNo statement \nincluded  4 \n \npoor qua lity \ncohort study   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 807 von 817 \n9.1.5.  Literatur  \nAlbarranweick M. Retrospektive Fall -Kontroll -Studie zum Stellenwert  der adjuvanten Therapie des malignen Melanoms mit Iscador P.c.Hg. 1998  \nAugustin M, Bock PR, Hanisch J, et al. Safety and efficacy of the long -term adjuvant tr eatment of primary intermediate - to high -risk malignant melanoma (UICC/AJCC stage II and III) with \na standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and S witzerland. \nArzneimittelforschung 2005;55:38- 49 \nGrossarth -Maticek R, Ziegler R. Efficacy and safety of the long -term treatment of melanoma with a mistletoe preparation (Iscador). Schweizerische Zeitschrift fur GanzheitsMedizin 2007  \nKleeberg UR, Suciu S, Br ocker EB, et al. Final results of the EORTC 18871/DKG 80- 1 randomised phase III trial. rIFN -alpha2b versus rIFN -gamma versus ISCADOR M versus observation \nafter surgery in melanoma patients with either high -risk primary (thickness >3 mm) or regional lymph n ode metastasis. Eur J Cancer 2004;40:390- 402 \nSchuppli R. Die adjuvante Behandlung des malignen Melanoms mit Iscador\u00ae c.Hg. Krebs und Alternativmedizin 1990  \nStumpf C, Rosenberger A, Rieger S, et al. Retrospective study of malignant melanoma patients treated  with mistletoe extracts. Forsch Komplementarmed Klass Naturheilkd \n2003;10:248- 255  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 808 von 817 \n \n10. AG Versorgungsqualit\u00e4t und Qualit\u00e4tsindikatoren  \n10.1.  Frage IX.1.  Klinische Studien - Adaptation  \nFrage IX.1.  Welchen Patienten sollte eine Teilnehme an klinischen Studien empfoh len werden?  \nDie Frage wurde letztendlich Konsens -basiert beantwortet  \n10.1.1.  Synopse Quellleitlinien (kurz)  \nThema/Fragestellung  LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care O ntario \n2007  \n1. Sollte Patienten die \nTeilnahme an klinischen \nStudien em pfohlen werden?  Teilnahme an Studien sollte \nPatienten ab St. I nach \nResektion des Prim\u00e4rtumors \nangeboten we rden (B);  \nPatienten sollten dar\u00fcber \ninformiert we rden, dass sie \nvon der Teilna hme an einer \nStudie wahrscheinlich ke ine \nNachteile zu e rwarten haben \n(A)  Teilnahme an St udien sollte \nallen Patienten erm\u00f6glicht \nwerden, auch unter 19 -\nj\u00e4hrigen; kein Beweis f\u00fcr Vor - \noder Nachteile f\u00fcr den \nPatienten durch \nStudienteilnahme  Keine E rw\u00e4hnung  Nur relevant f\u00fcr \nmedikament\u00f6se Therapien  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 809 von 817 \n10.1.2.  Empfehlung, Hintergrundstext und Literatur australischen und franz\u00f6sischen Quell -Leitlinien  \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National \nAuthority for Health \n2005)  LL Kanada  \nCancer Care O ntario 2007  \nSchl\u00fcsselempfe hlungen  S. 128  \n \nPatients can be informed that \nthey are unlikely to be \ndisadvantaged by participation \nin an RCT.  \n \nGrade of Recommendation: A   Keine Erw\u00e4hnung  Systemic Adjuvant Therapy for \nPatien ts at High Risk for  \nRecurrent Melanoma: Upda ted \nGuideline Recommend ations \n2009  \n \nS. 2 \nRecommendations  \nPatients with high -risk \nmelanoma should be \nencouraged to participate in \nappropriate clin ical trials \nexploring novel therape utics, \ngiven that at most a sma ll OS \nbenefit exists with currently \navailable thera pies.  \n \n \nHintergrundtexte  S. 127  \n \n20. Clinical Trials  \nThe clinical trial is an \ninstrument designed to assess \nthe effectiv eness of potentially \nnew or altered interventions Patient -centered care  \n \nC. Evidence  \n \nS. 41 \n \nClinical trials  Keine Erw\u00e4hnung  Keine Erw\u00e4hnung   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 810 von 817 \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National \nAuthority for Health \n2005)  LL Kanada  \nCancer Care O ntario 2007  \nthat involve a wide range of \nclinical a ctivity. \nTrials frequently involve drug \ntherapy, but may address new \ndevices, surgical procedures, \ntreatment by external \ninstrumentation (e.g. \nradiotherapy), or psychosocial \naspects of cli nical \nmanagement. [1] \nCommonly, the study question \nis whether a new treatment is \nbetter than the old one. It is \ncustomary to compare each \nnew treatment group with a \ncontrol group, the members of \nwhich must be offered \ntreatment matching the best \nstandard cu rrently available for \ntheir consideration b efore \njoining the t rial. [1]  \nThe randomised clinical trial \n(RCT), which involves random \nallocation of patients to their \ntreatment or control group, is \nbecoming the \u2018gold sta ndard\u2019 \nfor assessment of new \nmanagement processes.  One high -quality systematic \nreview investigated patien t \noutcomes r elated to mortality \nand mo rbidity among \nparticipants and \nnonpartic ipants in clinical trials. \nRCTs of different speciali ties \nwere included, but the largest \nproportion was of patients with \ncancer. The review found little \nevidence for better outcomes \nthrough pa rticipation in trials \naside from those ari sing from \nthe effects of the trea tments \ncompared, or differences \nbetween participants and non -\nparticipants.  \nThe same review found no \nevidence of greater risk arising \nfrom trial pa rticipation. \nA previo us, poorer -quality \nsystematic review than the one \ncited above examined evidence \nfor better patient outcomes \nthrough RCT participation. The \nmajority of RCTs were of \npatients with cancer. The \nreview concluded that it is  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 811 von 817 \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National \nAuthority for Health \n2005)  LL Kanada  \nCancer Care O ntario 2007  \nClinical trials involve significant \nfunding and req uire the \ninformed consent from patients \nand frequently, the involvement \nof a number of centres and \nhealth pr ofessionals to obtain \nan appropriate number of \nsubjects to ensure sound \nstatistical power. \nThe conduct of trials by \ncooperative groups of trialists \nis the most likely way to \nadvance evidence -based \nmedicine through well -designed \nprotocols and rigorous \nevaluation. [2]  \nHowever, in our community \nsome people are concerned \nabout RCTs, believing that \npatients involved in such trials \nmay be at risk from fa ctors that \nwould not occur in treatment \noutside a trial. On the other \nhand, others see participation \nin an RCT as being of benefit to \nthe trial subject and probably \nan optimal way of receiving the \nbest contemp orary care and likely that clinical trials have a \npositive, rather than a negative, \neffect on survival and morbidity \noutcomes, with benefits arising \nfrom the use of trial protocols.  \nOne literature review found that \nchildren and adolescents with \nmelanoma are not entered into \nclinical trials. Retrospective \nstudies have found that \nadole scents with cancer are not \nas likely to be entered into \nclinical trials as children and \nadults. \nAn audit of skin cancer MDT \nactivity undertaken in the South \nWest of England found that \nmany trusts did not have \nsufficient infrastruc ture to \nensure that patients are o ffered \ntrial entry.  \nAn audit of implementation of \nrecommendations made in the \nCalman \u2013Hine Report (1995) \nunde rtaken by the Commission \nfor Health I mprovement (CHI) \nand the Audit Commission in \n2001 found that only a small  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 812 von 817 \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National \nAuthority for Health \n2005)  LL Kanada  \nCancer Care O ntario 2007  \nclinical oversight.  \nA recent Cochra ne Review \nassessed the effect of \nparticip ation in RCTs (\u2018trial \neffects\u2019) i ndependent both of \nthe effects of the clinical \ntreatments being co mpared \n(\u2018treatment effects\u2019) and any \ndifferences between p atients \nwho participated in RCTs and \nthose who did not. [3 ]  \nThe outcome of this review led \nits authors to conclude that \nthere is no greater risk from \nparticipating in RCTs than there \nis from being treated outside \nan RCT. The authors considered \nthat the belief or asse rtion that \nresults of RCTs cannot be \napplied t o usual practice is \nchallenged by the review. [2] \nThis outcome would appear to \nprovide a sound basis for \nclinicians to offer participation \nin RCTs to their p atients.  \nAny uncertainty about the \neffects of treatment can best be \nresolved through a randomised proportion of patients with \ncancer are involved in clinical \ntrials. Trial participation was \nless lik ely in settings outside of \nlarge cancer ce ntres.  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 813 von 817 \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National \nAuthority for Health \n2005)  LL Kanada  \nCancer Care O ntario 2007  \ntrial as long as the eligibility \ncriteria for the trial match the \npatient popul ation seen in \nusual practice, or the trial \ntreatment is a pplied only to \npatients who match the \neligibility criteria. [4]  \n \nEvidence summary  \nOutcomes for patients who \npartic ipate i n RCTs on average \ndo not differ from those of \npatients who receive similar \ntreatments and do not \npartic ipate in a trial. \nLoE: I  \nReference: [2]  \n    \nLiteratur:  \n \nLL Austr alien New Zealand Guidelines Group 2008  \n4. Kunz R, V ist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev 2007;(2):MR 000012  \n3. Optimising Cancer Care in Australia. 1 \u2013122. 2002. Melbourne. Available from <http:/www.cosa.org.au/documents/optim_Cance r_Care_final.pdf>. Clinical Oncology Society of Australia, The Cancer \nCouncil Australia and The National Cancer Control Initiative.  \n1. The Cancer Council Victoria. About Clinical Trials. Available from <http:www.cancervic.org.au/browse.asp?ContainerID=abou t_clinical_trials> accessed 1 September 2007  \n2. Vist GE, Hagen KB, Devereaux PJ, et al. Outcomes of patients who participate in randomised controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane \nDatab ase Syst Rev 2007;(2):MR000009 \n \nLL GB NICE 2006  \n1. Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a \"trial effect\". J Clin Epidemiol 2001;54:217 -224 \n2. Peppercorn JM, Weeks JC, Cook EF, et al. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004;363:263- 270  \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 814 von 817 \n3. Poirier V, Wright S, Lucke T, Verne J, Sandhu J, De Berker D, et al. Auditing current Skin Ca ncer Multi -disciplinary Team (MDT) practices against the Manual of Cancer Se rvices Standards in the South West \nRegion.  \n4.  Vist GE, Hagen KB, Devereaux PJ, et al.  Systematic review to determine whether participation in a trial influences outcome. BMJ 2005;330:1175 \n \n \n \n \n11. Abk\u00fcrzungsverzeichnis  \n \nAUC    area under curve  \nBCG    Bacille Calmette Guerin  \nBM    brain metastases \nBT    Breslow Thickness  \nCD    conventional diagnostics  \nCI    confidence interval  \nCLND     Complete lymph node dissection   \nCM    cutaneous mela noma   \nCR    Complete Response  \nCR    conventional radiography  \nCS    conditional survival \nCSP    conventional screening proc edures  \nCT    chemotherapy  \nCWS, P3     cell wall skeleton and purified trehalose dimycolate  \nCXR    Chest X -ray CXR  \nDFI    disease -free interval  \nDFS    disease - free su rvival  \nDM    distant metastases  \nDMFD     distant metastasis -free survival  \nDMFI     distant metastasis -free interval  \nDMFS     distant metastasis -free survival  \nDMM     desmoplastic malignant melanoma  \nDNCB     Dinitrochlorobenz ene \nDNM    desmoplastic neurotropic melanoma  \nDPCP     Diphencyprone   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 815 von 817 \nDSS    disease -specific survival  \nDTIC    dacarbazine  \nELND     \u00b4elective lymph node di ssection`  \nFAS    full analyses set  \nFMR    first mel anoma recurrence  \nFN     false negative  \nFP    false po sitives  \nGIT    gastrointestinal tract  \nGKS     Gamma Knife surgery  \nGy    Gray \nHACE     Hepatic artery chemoembolization  \nHAI    Hepatic artery infusion  \nHDI    high dose interferon  \nHR    Hazard ratio  \nHRQL     health related quality of life  \nIDI    intermediate  dose interferon  \nIES    Impact of Event Scale  \nIFN    Interferon \nIHP    Isolated hepatic perfusion  \nIl-2    Interleukin 2  \nIL-BCG    intralesionally - bacillus Calmette Guerin  \nILP    isolated limb perfusion  \nincl.    including  \nITT    Intent To Treat  \nLDI    low dose interferon  \nLM    lentigo maligna  \nLMM    lentigo maligna melanoma  \nLN    lymph node(s)  \nMCS    Mental Component Summary  \nMER    methanol extraction residue of bacillus Calmette -Guerin  \nMets    metastases \nMM    malignant melanoma  \nMPM    multiple primary  melanomas  \nMPV-BCG   multiple puncture vaccination -  bacillus Calmette Guerin   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 816 von 817 \nMUP    melanoma with unknown primary  \nMV    Megavolt  \nn.r.    not reported  \nn.s.    not significant  \nNC    no change  \nNED    no evidence of disease  \nNMM     nodular malignant melanoma  \nNR    not reached  \nOBS    observation  \nOR    Odds ratio  \nOS    Overall survival \nPCS    Physical Component Summary  \nPD    Progressive Disease  \nPDS    power Doppler sonography  \nPE    physical eexamination  \nPM     primary melanoma  \nPP    Per protocol  \nPR    Partial R esponse  \nPV-10    10% w/v Rose Bengal in saline  \nRCT    randomized controlled trial \nRECIST     Response Evaluation Criteria in Solid Tumors  \nRFS    Relapse -free su rvival, Recurrence free survival  \nrIFN-beta   recombinant interferon beta  \nRR    Relapse Rate  \nRR    relative risk  \nRSCL      Rotterdam Symptom Checklist  \nRT    radiotherapy  \ns.c.    subcutaneous  \nSD    Stable Disease  \nSIRT    selektive interne Radio -Therapie  \nSLN    senitinel lymph node  \nSLNB     sentinel -lymph node biopsy  \nSM    second melanoma  \nSPM    second p rimary melanoma   \n \n\u00a9 Leitlinienprogramm Onkologie | S3 LL Melanom -Evidenztabellen  | Version 2.0. Juli  2016  Seite 817 von 817 \nSRS    stereotactic radiosurgery  \nSSM    superficial spreading melanoma  \nST    soft tissue  \nTACE     Trans -arterial chemoembolization  \nTD    Total dose  \nTLND     therape utic lymph \u2013 node -dissection  \nTMZ    temozolomide  \nTN    true negatives  \nTP    true positives  \nUICC    Union International Contre Cancer  \nUS    ultrasound  \nWBRT     whole brain radiation therapy  \nWHO     World Health Organisation  \nVs.    versus  \nWb    whole body  \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}